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Cytochrome P450s are highly polymorphic enzymes responsible for the Phase I metabolism of over 80% 
of pharmaceutical drugs.  Polymorphic variation can result in altered drug efficacy as well as adverse 
drug reactions so the lack of understanding of the effects of single amino acid substitutions on 
cytochrome P450 drug metabolism is a major problem for drug development. 
 
In order to begin to address this problem, this thesis describes an in silico analysis of over 300 non-
synonymous single nucleotide polymorphisms found across nine of the major human drug metabolising 
cytochrome P450 isoforms. Information from functional studies - in which regions of the cytochrome 
P450 structure important for substrate recognition, substrate and product access and egress and interaction 
with the cytochrome P450 reductase were delineated - was combined with in silico calculations on the 
effect of mutations on protein stability in order to establish the likely causes of altered drug metabolism 
observed for cytochrome P450 variants in functional assays carried out to date. This study revealed that 
75% of all cytochrome P450 mutations showing altered activity in vitro are either predicted to be 
damaging to protein structure or are found within regions predicted to be important for catalytic activity. 
Furthermore, this study showed that 70% of the mutations that showed similar activity to the wild-type 
enzyme in in vitro studies lie outside of functional regions important for catalytic activity and are 
predicted to have no effect on protein stability. Based on these results, a cytochrome P450 polymorphic 
variant map was created that should find utility in predicting the functional effect of uncharacterised 
variants on drug metabolism.  
 
To further test the accuracy of the in silico predictions, in vitro assays were performed on a panel of 
CYP3A4 and CYP2C9 variants heterogeneously expressed in E.coli.  All mutations predicted to alter 
protein function by stabilising or destabilising the apo-protein structure in silico were found to 
significantly alter the thermostability of the holo-protein in solution. Thermostability assays also suggest 
that other mutations may affect stability by disrupting haem binding, changing protein conformation or 
altering oligomer formation.  
 
 The utility of a fluorescence-based functional P450 protein microarray platform, previously developed in 
our laboratory, for generating kinetic data for multiple CYP450 variants in parallel was also examined. 
Since the microarray platform in its current stage of development was found to be unsuitable for this 
purpose, kinetic data for the full panel of CYP3A4 and CYP2C9 variants was generated using solution 
phase assays, revealing several variants with altered catalytic turnover and/or binding affinity for 
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1.1 Nature’s outstanding chemists  
 
Found across all lineages of life, from bacteria to humans, Cytochrome P450 (CYP450) enzymes 
are arguably nature’s most versatile catalysts, participating in key biosynthetic pathways and 
metabolising many diverse endogenous and exogenous substrates [1]. Their role in the synthesis 
of sterols, a key constituent of the plasma membrane, enabled the evolution of eukaryote 
organisms and their contribution to the synthesis of novel chemical compounds, exemplified by 
the on-going “chemical warfare” between plants and animals, has supported the diversification 
of eukaryotes [2]. In humans, CYP450s play a central role in steroid, fatty acid and xenobiotic 
metabolism.  
 
First identified in 1962 and named for the unique absorbance soret peak observed at 450 nm for 
the carbon monoxide bound species [3-5], this superfamily of haem-thiolate mixed 
monooxygenases has been the subject of extensive research for over half a century. Research 
areas are vast and include the use of CYP450s in environmental bioremediation and as 
biocatalyst for a variety of biotechnology application including drug and antibiotic synthesis [6]; 
however, the majority of CYP450 research has focussed on their role in human drug metabolism. 
Amongst others, these enzymes are notorious in the pharmaceutical industry as they are often 
implicated in adverse drug reactions and therefore play a vital role in the drug development 
process [7].  
1.2 Evolution of Cytochrome P450s 
 
Not surprisingly, CYP450s are among the most rapidly evolving genes, consistent with 
organisms’ need to metabolise new chemical toxins in an ever changing environment [8].  
Functional diversity can be generated through a variety of genetic mechanisms, the most widely 
recognised being gene duplication [9]. Although CYP450s are most well-known for xenobiotic 
metabolism, cytochrome P450s are an ancient superfamily and it is likely that this function arose 
as an extension of their primary role in the metabolism of endogenous substrates [8].  Co-
evolution between animals and plants is likely to have driven the evolution of CYP450s 
detoxifying function: as plants evolved CYP450s producing toxins that made them less desirable 
food sources, animals required new CYP450s capable of metabolising these new toxins [10].  
 




1.3 Cytochrome P450 nomenclature 
 
The cytochrome P450 superfamily consists of mainly microsomal and mitochondrial haem-
thiolate proteins that catalyse oxidation, peroxidation or reduction reactions. There are now over  
21 000 named CYP450 sequences found in animals, plants, fungi, protozoa, bacteria, archaea 
and more recently even viruses [11].  The number of genes per organism is highly variable and 
multiple cytochrome P450 genes can be expressed simultaneously.   
 
The P450 Nomenclature Committee is responsible for the naming of CYP450 genes (Figure 1.1) 
and CYP450 genes are assigned into families and sub-families using a standard nomenclature 
system based on sequence identity, phylogenetic association and gene organisation [12]. The 
same nomenclature is used for DNA, mRNA and protein sequences; however the gene name is 
italicised while the mRNA and protein sequence names are shown in plain font. Defective genes 
that do not produce functional proteins, referred to as pseudogenes, are designated with an 
additional letter “P” at the end of the gene name e.g. CYP1A8P.   
  
 
Figure 1.1 Naming CYP450 genes  
 
In general a CYP family is made up of sequences with amino acid sequence identities greater 
than 40% and a subfamily with amino acid sequence identities of greater than 55%; sequences 
that are more than 97% identical are considered as alleles of the same gene unless there is 
sufficient evidence suggesting otherwise.  Alleles are indicated by a star followed by a number 
according to the order in which they were identified. Sub-alleles with genetic variation in the 
non-coding regions of the genes are designated with an additional letter (e.g. CYP2C9*1C has 
the same coding sequence as the wild-type protein but has a mutation in the non-coding region of 
the gene.)  




As CYP450s are ubiquitous, many more sequences will be identified as more organisms are 
sequenced. Blocks of numbers for CYP450 families have therefore been reserved for new 
families, allocated along taxonomic lines (rather than the phylogenetic relatedness); for example 
CYP1- CYP49 and CYP301-CYP499 are for CYP450 families found in animals.  
1.4 Cytochrome P450 Chemistry  
 
The primary role of CYP450 enzymes is to activate inert C-H bonds in organic molecules, 
creating functional groups suitable for conjugation to facilitate biotransformation. In general 
CYP450s achieved this by activating molecular oxygen, which in turn yields a highly reactive 
iron-oxo species that can attack the unreactive chemical sites, introducing a hydroxyl group into 
the molecule [8]. In xenobiotic metabolism this serves to convert unreactive lipophilic substrates 
into more reactive hydrophilic products, facilitated the elimination of these foreign compounds 
from the body.  The haem group, bound within the hydrophobic centre of the protein and co-
ordinated to a conserved cysteine residue, serves as the catalytic centre and consists of a large 
heterocyclic aromatic ring made up of four pyrrole rings linked together by methane bridges, 
collectively known as a porphryrin ring (Figure 1.2).  The porphryrin ring has an iron atom in the 
centre that is responsible for the redox chemistry, cycling between the ferrous and ferric 




Figure 1.2  Chemical structure of the haem group coordinated to a catalytic cysteine residue.  




The CYP450-catalysed hydroxylation reactions can be represented by the following equation 
 
RH + O2 + 2e- + 2H+
                         ROH + H2O 
 
where RH is the substrate and ROH is the product. A redox partner protein, cytochrome P450 
reductase (CPR) in the case of microsomal CYP450s, transfers two electrons sequentially from 
the electron donor NAD(P)H to the haem iron during the catalytic cycle: 
 
NADPH                 NADP+ + 2e- + H+ 
 
Other enzymes such as flavin-dependent monooxygenases and non-haem iron oxygenases can 
catalyse similar oxidation reactions. It is however CYP450s remarkable versatility in terms of 
substrate and reaction type, combined with their elegant ability to catalyse region- and stereo-
selective oxidations, that makes them so important in physiology as well as attractive for 
biotechnological applications [13, 14]. While the above equation gives the stoichiometry of the 
reaction, elucidation of CYP450 catalytic cycle is required to understand the mechanistic details 
of the reaction.  
1.4.1 The Catalytic Cycle  
 
There has been much work, speculation and debate over the past 50 years surrounding the 
precise nature of the highly reactive intermediates responsible for the demanding chemistry 
catalysed by CYP450 enzymes. Spectroscopic techniques together with quantum and molecular 
mechanics approaches have given useful insight into the nature of the reactive intermediates 
[15]. The most highly sought after reactive intermediate in the CYP450 catalytic cycle, 
Compound I, was physically observed in 2006 [16] and in 2010 its capture and spectroscopic and 
kinetic characterization was finally reported [17].    
 
Figure 1.3 depicts the catalytic cycle for CYP450-catalysed hydroxylations as it is currently 
understood [18, 19]. The cycle begins with the CYP450 in the low spin ferric (Fe3+) state, with a 
water molecule bound to the 6th axial position of the haem iron (1). Substrate binding causes 







Figure 1.3 The catalytic cycle for CYP450-catalysed 
hydroxylations. 




molecule accompanied by a high spin shift (2). The substrate bound complex has a greater 
reduction potential and thus can now accept the first electron from its NAD(P)H dependent 
redox partner leading to a ferrous (Fe2+) substrate-bound species (3). The ferrous haem iron then 
binds dioxygen, forming a ferric superoxide complex (also referred to as an oxy-haem complex) 
(4). This complex accepts the second electron from its redox partner and is reduced to a ferric 
peroxo species (5). This species is then protonated at the distal oxygen generating a ferric 
hydroperoxo species (6), which is a highly reactive intermediate referred to as Compound 0 
(P450-0). Compound 0 can be artificially generated from the substrate bound ferric form of the 
enzyme (2) via the peroxide shunt pathway using a strong oxidising agent such as peroxide, 
circumventing the need for an electron donor to complete substrate metabolism. A second 
protonation at the distal oxygen cleaves the O-O bond yielding an iron(IV)-oxo radical species 
known as Compound I and a water molecule (7).  Compound I then abstracts a hydrogen atom 
from the substrate yielding Compound II and a substrate radical (8). This is followed by a rapid 
rearrangement of the hydroxyl to the substrate radical to yield a hydroxylated product and a 
ferric enzyme (9). The product then leaves the active site and a water molecule coordinates the 
6th axial position of the haem iron again leading to a resting ferric enzyme ready to start a new 
cycle (1).  The capture and characterisation of Compound I in 2010 was significant in confirming 
the “rebound mechanism” and the key role of compound II in C-H bond activation [17, 18].  
1.4.2 Spectral properties  
 
 The haem group is a strong chromophore and consequently spectroscopic methods are very 
useful for studying CYP450s.  Carbon monoxide (CO) coordinates strongly to the reduced 
(ferrous) iron of haem proteins and typically gives an absorption peak at 420 nm, as observed for 
proteins such as myoglobin [8]. CYP450 proteins were first identified as “novel microsomal 
carbon monoxide-binding pigments” in 1958 [20] and later named cytochrome P450s [3-5] 
owing to the unique absorption spectrum of the ferrous carbon monoxide-bound form, with a 
absorption maximum at 450 nm caused by the presence of the deprotonated sulphur on the 
cysteine axial ligand. When solubilised from microsomal membranes the CYP450 is relatively 
unstable and if this cysteine residue is protonated or replaced by a neighbouring amino acid such 
as a histidine the absorption maximum shifts to 420 nm [21]. This denatured or inactive form of 
the haem bound CYP450 is typically referred to as P420.   
 




The spin state of the haem iron is the fundamental property affecting the haem spectrum. 
Cytochrome P450s exist as a mixture of low spin and high spin forms corresponding to the S = 
1/2 and S = 5/2 spin states of the haem iron both in the presence and absence of substrates [22]. 
 
The spin state and hence the absorption peak of the ferric CYP450 is influenced by the ligation 
state of the haem iron. In the low spin state the haem iron is hexacoordinated and gives rise to an 
absorption peak at ~ 417 nm. In this substrate-free low spin state water usually serves as the 6th 
distal ligand. Removal of the distal ligand leads to a high spin pentacoordinate state with an 
absorption peak at ~ 390 nm. In the hexacoordinated species the iron atom sits within the haem 
plane while in the pentacoordinated species the iron atom sits about 0.5 Å out of plane.  
 
Substrate binding can be measured by monitoring the difference spectrum between the bound 
and unbound protein. In the absence of substrate the low spin state is dominant [22]. A type I 
difference spectrum, with a peak at 385-390nm and a trough at 420 nm, is observed when 
substrate binding displaces the distal water molecule causing a shift in the equilibrium towards 
the high spin state accompanied by an increase in redox potential facilitating reduction of the 
ferric iron by the redox partner [8]. In contrast, a type II difference spectrum, with a peak at 425-
435nm and a trough at 390-405nm, is observed when a substrate (or inhibitor) coordinates to the 
iron more strongly than the water molecule it displaced. This binding spectrum is typical of 
molecules containing nitrogen heterocycles, where a lone pair of electrons is free to coordinate to 
the iron (e.g. nicotine).  While substrate binding usually causes a spectral shift, there are 
instances where substrates bind within the active site without affecting the spin state of the haem 
iron [19]; this occurs when substrates bind at a periphery site or in an orientation that does not 
displace the distal water molecule.  
 
The ferrous CYP450, with or without substrate, exists almost exclusively in the high spin state.  
Other factors such as temperature [22], ionic strength [23] and hydrostatic pressure [24] also 
affect the spin-state equilibrium and therefore serve as useful methods for studying CYP450s.  
1.4.3 CYP450-catalysed reactions 
 
CYP450 catalyse the metabolism of an enormous number and diverse range of substrates; 
however most CYP450 oxidation reactions can be broadly categorised as hydroxylations, 




epoxidations or heteroatom oxidations  [8] (Figure 1.4). CYP450s also show reduction activity 
under anaerobic conditions; reductions by the ferrous CYP450 complex frequently lead to the 
formation of harmful free radicals [25]. 
 
 
Figure 1.4 Common cytochrome P450-catalysed reactions. A) Hydroxylation, B) Epoxidation and C) Heteroatom 
oxidation reactions. The site of oxidation is indicated in yellow.  






The hydroxylation of carbon atoms in aliphatic and polycyclic aromatic hydrocarbons is by far 
the most common and best understood CYP450-catalysed reaction and is central to CYP450-
mediated drug metabolism [8] (Figure 1.4 A).  The site of oxygen insertion is determined by the 
energy required to break the C-H bond as well as steric effects and the position of the substrate 
within the active site [26].  Tertiary C-H bonds are easier to break than primary C-H bonds and 
as a result hydroxylation of tertiary Carbons is far more common than hydroxylation of terminal 
methyl groups.  However if the C-H bond is weakened by an adjacent heteroatom or halogen 
then hydroxylation is highly favoured, as seen for a methyl group attached to an aromatic ring. 
Hydroxylation of a carbon adjacent to a heteratom such as oxygen, nitrogen or sulphur leads to 
heteroatom dealkylation. Harmful reactive metabolites capable of acetylating proteins can 
however be produced if hydroxylation occurs at a carbon atom attached to more than one 
halogen atom [8, 27]. Bio-activation of thiophenes and sulphur containing polycyclic aromatic 
rings can also have toxicological implications, due to the formation of reactive metabolites 
capable of forming DNA abducts [8]. 
Epoxidation  
 
CYP450 are capable of oxidising olefins to their corresponding epoxides (Figure 1.4 B). 
CYP450-mediated epoxidations of some endogenous substrates are important for the synthesis of 
physiologically important molecules such as arachidonic acid. However epoxidation of foreign 
compounds can also lead to toxic, mutagenic and teragenic metabolites [28].  Aberrant 
epoxidation reactions can also lead to mechanism-based inactivation on the CYP450 enzyme 
caused by a terminal olefin carbon associating with a pyrrole nitrogen on the CYP450 haem 
group [8].   
Heteroatom oxidations 
 
Cytochromes P450s can also oxidise heteroatoms within a substrate; oxidation of heteroatoms 
relies on the availability of lone electron pairs to which oxygen can be transferred. More 
electronegative atoms, such as oxygen, are less susceptible to oxidation while heteroatoms such 
as nitrogen and sulfur are readily oxidised to N-oxide and sulfoxide metabolites (Figure 1.4 C). 




While these categories give a simplified overview of the main CYP450-catalysed reaction-types, 
CYP450s catalyse many variations of these reactions as well as many other more complex and 
unusual reactions. Guengerich and Munro recently reviewed unusual CYP450 reactions, 
illustrating the incredible diversity and versatility of these enzymes [29].  
1.5 Cytochrome P450 structure 
1.5.1 The highly conserved CYP450 fold 
 
Camphor-metabolising CYP101 (P450cam) from Pseudomonas putida was the first CYP450 to 
have its crystal structure solved [30] and extensive studies on this enzyme, combined with other 
subsequently solved bacterial CYP450 structures, provided the initial framework for our 
understanding of structure-function relationships in CYP450 enzymes. Today there are over 500 
CYP450 structures in the Protein Data Bank (PDB), including nearly 100 mammalian structures 
[31]. As predicted by Hasemann and co-workers [32], despite very low sequence identities (even 
below 20%), the CYP450 fold is highly conserved across prokaryote and eukaryote structures. 
CYP450s have a globular three-dimensional fold typically made up of 4 to 5 β-sheets and 
thirteen α-helices surrounding a large buried hydrophobic active site (Figure 1.5). The protein 
comprises a relatively flexible domain on the distal side of the protein, primarily responsible for 
substrate recognition and binding; a more rigid haem binding core; and a domain with 
intermediate flexibility on the proximal side of the protein that provides a binding site for the 
redox partner- responsible for transferring electrons to the haem iron during the catalytic cycle- 
in close proximately to the catalytic centre [33].  The haem binding regions are generally 
conserved between CYP450s while the substrate recognition regions are more variable [34]. 
There are a number of key conserved features found in all CYP450s, namely the I-helix catalytic 
groove, the K-helix core stabilising motif, the meander region and the Cys-pocket. 
 
The I-helix catalytic groove is the conserved consensus motif (G/A)GX(D/E)T, located in the 
middle of the I-helix [30]. This region plays an important role in proton transport [35, 36] and is 
responsible for the formation of the oxygen binding pocket [37]. The K-helix core stabilising 
motif is the invariant EXXR motif within the K-helix that interacts with the meander region [32]. 
The meander is found between the K’-helix and the L-helix and is highly conserved in structure 
despite the lack of any secondary structure formation. The absolutely conserved Asp and Arg 




residues in the core stabilising motif interact with an Arg/His residue in the meander region, 
forming a set of salt bridges known as the ERR triad. The Cys-pocket refers to the sequence 
motif FXXGXXXCXG that forms a β-bulge around the absolutely conserved catalytic Cys 
residue that coordinates to the haem iron.   
 
 
Figure 1.5 The CYP450 three dimensional structure 
The CYP450 structure is shown in grey (CYP3A4, PDB structure 1TQN), is shown in grey with the haem group in 
black. Secondary structure elements, α-helices and β-strands are labelled using the nomenclature of Poulos et al 
[37]. Panel A, B and C show a side view, distal view and proximal view respectively. The I-helix is shown in red, 
the B-C loop in black and the F-G loop in green to aid orientation. The positions of conserve regions are indicated as 
follows: the halting signal (yellow); the proline-rich motif (magenta); the I-helix catalytic groove (blue); the core 
stabilising motif consisting of the meander stabilised by the ERR triad (orange); the cys-pocket (cyan).  




1.5.2 Membrane binding 
 
Whilst all prokaryotic CYP450s are soluble and located in the cytosol, CYP450s in eukaryotes 
are almost exclusively membrane bound, embedded in either the endoplasmic reticulum or the 
mitochondria membrane. Consequently eukaryote CYP450s have an additional membrane 
anchoring region that is absent in the soluble bacterial CYP450s.  
 
CYP450s embedded in the endoplasmic reticulum, referred to as microsomal CYP450s, are the 
most common CYP450s in mammals and are found predominantly in the liver, the primary site 
of xenobiotic metabolism. The hydrophobic signal-anchor sequence is a 20 to 25 amino acids 
stretch near the N-terminus that is embedded in the membrane. It is usually preceded by an 
acidic amino acid residue that targets the protein to the endoplasmic reticulum [38]. The signal-
anchor sequence is flanked on the C-terminal end by a series of basic residues referred to as the 
halting-signal that ensure the protein is orientated correctly in the membrane [38]. The halting-
signal is followed by a proline rich motif, PPGPXPXPXXGN, which is important for protein 
folding rather than catalytic activity [39-41].   
 
Determining the structure of membrane bound proteins in notoriously difficult; the full-length 
CYP450 is highly unstable when removed from its native membrane environment and 
consequently the N-terminal membrane binding region is truncated in CYP450 crystal structures 
and in many cases mutations are introduced to enhance the protein solubility [42].  As a result, 
the position of CYP450s in the membrane and the effect of the membrane on protein 
conformation, flexibility and substrate access remain largely unexplained. Experimental studies 
indicate that the membrane anchor domain forms a single transmembrane helix and that 
hydrophobic regions within the CYP450 fold are also embedded within the membrane [43-45]. 
Residues interacting with the membrane have been identified by site-specific antibody [46, 47], 
fluorescence quenching [48] and atomic force microscopy [49] experiments.  Studies using 
molecular dynamics to model the orientation of microsomal human CYP2C9 within the 
membrane have revealed that the F-G loop region is partially buried and that the membrane 
stabilises an open tunnel leading to the buried active site that is likely to facilitate the access of 
liposoluble substrates via the membrane; the water soluble products are thought to egress 
through another tunnel pointing towards the water phase [50, 51] (Figure 1.6). The orientation of 
CYP2C9 in these models is also predicted to be favourable for electron transport from the redox 




partner protein (NADPH dependent cytochrome P450 reductase (CPR)) and these models are 
largely consistent with data from experimental studies.  
 
 
Figure 1.6 This diagram shows CYP450 and CPR embedded in a membrane. The CYP450 anchor region and part of 
the catalytic domain are buried in the membrane and the CYP450 is orientated in a way that would allow CPR to 
bind to the proximal face of the protein, facilitating electron transport to the haem iron. The hydrophobic substrate 
(S) accumulates in the membrane and enters the CYP450 active site (AS) via an access channel (ACh). It is oxidised 
to a more hydrophilic product (P); the product then leaves the active site via an egress channel (ECh) and enters the 
cytosol. This figure is from Berka et al, 2011 [50]. 
 
Recently, solid-state nuclear magnetic resonance (NMR) was used to determine a high-resolution 
structure of microsomal rabbit CYP2B4 embedded in an artificial membrane of temperature 
resistant bicelles [52]. This NMR model revealed a helical transmembrane region tilted at ~17° 
from the lipid bilayer normal. This study did not however give insight into associations between 
the catalytic domain and the bilayer or conformational changes associated with membrane 
binding as the experiment was set up to selectively detect signal from the rigid N-terminal 
transmembrane region and did not provide details on the catalytic domain; instead the N-terminal 
truncated CYP2B4 crystal structure was used to model the catalytic domain.   
1.5.3 Substrate access and recognition regions 
 
The substrate binding regions are found on the distal side of the protein and correspond to the 
less conserved or more variable regions of the protein. There are 6 recognised substrate 
recognition sites called named SRS 1 to 6 [53].  The variable regions of the protein that make up 
these SRS regions include helices A, B, B’, F and G and adjacent loops: the B-C loop forms SRS 
1; the F and G helices and the F-G loop forms a lid over the active site cavity forming part of a 
substrate access channel and SRS2 and SRS3; the loop region N-terminal of strand 1 of β-sheet 3 
lines the active site and forms SRS5; and the loop region (or β-turn) between strands 1 and 2 in 




β-sheet 5 protrudes into the active site forming SRS6 [34].  The centre of the I-helix, which is the 
only highly conserved substrate recognition region in CYP450s, makes up SRS4.  
   
While some CYP450s are remarkably substrate specific, metabolising only a small set of very 
similar molecules, other CYP450s, particularly those responsible for drug metabolism, have 
broad substrate specificities metabolising a vast range of molecules with very different 
geometries and chemical properties. Although substrate specificity is generally thought of as a 
property inherently linked to the amino acid composition and geometry of the active site [33], 
structures of mammalian CYP450 reveal a large active site capable of binding more than one 
substrate or inhibitor molecule at once [54-57].  Additionally  there are structures with a single 
substrate molecule bound in a non-productive position within the active site [58, 59] further 
suggesting that substrate binding does not conform to the traditional “lock and key” model, but is 
rather a multi-step process involving a flexible active site. CYP450s ability to adopt different 
structural conformations enables an individual CYP450 to accommodate molecules of different 
shapes and sizes and as a result, static structures of the active site provide limited insights into 
substrate specificity [33].  There are two schools of thought pertaining to conformational 
changes and substrate binding: 1) “induced-fit” where the substrate binding regions adjust their 
shape to accommodate a substrate and 2) “conformation selection” where the enzyme pre-exists 
in multiple conformations. Atypical kinetics has repeatedly been observed for a number of 
CYP450 isoform and there is an on-going debate as to whether it is a result of multiple 
molecules binding to the enzyme and/or the presence of kinetically distinct conformers [60-63], 
but either way it can likely be attributed to the high flexibility of the active site.   
 
The role of CYP450 flexibility in substrate access and binding has been examined in numerous 
studies. Temperature β factors from crystallographic data have been used to infer regions of 
flexibility in CYP450 structures [42]. Comparing multiple crystal structure of the same or related 
proteins can also provide useful information on the flexibility of CYP450s [54, 64-66]. Lee et al 
compared 30 structures of bacterial P450cam bound to range of different substrates; this study 
revealed three distinct conformational clusters that could be attributed to the multi-step closure 
of the enzyme around the substrate that proceeds through a well-defined intermediate [65].  
There are now a number of tools available for rapidly comparing large numbers of crystal 
structures enabling the inference of  protein dynamics from large ensembles of static structures 
(e.g. ProDy [67], Polyphony (Pitt, unpublished) and as more mammalian CYP450 structures are 




solved these approaches will become increasingly useful for studying CYP450 flexibility. 
Spectroscopic methods such as NMR [68-71], mass spectrometry [72, 73], high pressure 
absorption spectroscopy [74-77] and Raman spectroscopy [76, 78, 79] as well as molecular 
dynamic simulations [51, 76, 80] have been used extensively to study the role of CYP450 
flexibility in substrate access and binding.  
 
Classical molecular dynamics simulations typically use a crystal structure as a starting point. To 
prepare the structure for modelling in solution, hydrogen atoms are added, unresolved (missing) 
regions are modelled, protonation states of titratable amino acids are defined and the structure is 
subjected to energy minimisation using empirical force fields. MD simulations normally attempt 
to mimic physiological or in vitro conditions using explicit solvent, counterions and a defined 
temperature and pressure (1 atm). Classical modular dynamics simulations typically generate a 
series of conformations over a timescale of tens-of-nanoseconds, with femtosecond resolution.  
Large conformational changes cannot normally be detected using classical MD due to the limited 
timescales; consequently a number other MD techniques have been developed to observed larger 
motions including simulations at elevated temperature, replica exchange MD and adaptive 
acceleration MD. In addition MD techniques such as steered MD [81] and random expulsion MD 
[82] have been developed that simulate molecules exiting the active site to gain insight into 
substrate access and product egress routes. MD simulations for CYP450s are not straight forward 
due to the redox and spin states exhibited by the haem bound cofactor that cannot easily be 
represented by classical force field models. This has posed a challenge for modelling CYP450s 
and much work has gone into developing appropriate force field parameters, both for the 
pentacoordinate [83-85] and hexacoordinate haem states [76, 80, 86].  
 
The most flexible parts of the protein are typically in loop regions located on the distal side of 
the protein, which is relatively flexible compared to the haem core. This is fitting since the haem 
core ensures the high regio- and stereo-specificity of metabolism while the flexible distal regions 
responsible for substrate recognition allow for broad substrate specificity [33, 42]. Not 
surprisingly, the broader a CYP450s substrate specificity, the more flexible the distal regions 
[76, 80]. MD simulations performed by Hendrychova et al on human CYP2A6, CYP2C9, 
CYP2D6 and CYP3A4 and rabbit CYP2B4 in the absence of substrate showed that the active 
site volumes fluctuate by more than 50%, predominantly due to the movement of main chains 
with only a small number of side chains moving independently during the simulation [87]. These 




simulations also show that the bottle necks of CYP450 access/egress channels fluctuate around 
1.5 Å suggesting that these channels never fully open in the absence of substrate but rather that 
substrates induce conformational changes as they move along a pathway into the active site.  
Hydration of the active site also differed between isoforms; CYP2E1 was the least hydrated, 
consistent with its preference for hydrophobic substrates.  
 
Human CYP3A4, the most abundant CYP450 in the human liver, has the broadest substrate 
specificity and is responsible for the metabolism of around 50% of all drugs. It is the most 
flexible CYP450 [76, 80] and substrate binding to CYP3A4 has been extensively studied yet is 
still poorly understood. Sevrioukova et al recently reviewed the latest insights into CYP3A4s 
molecular mechanism [88]. In short, based on extensive studies using a range of techniques, it is 
now believed that substrates are not fixed in one position and may dissociate and rebind at 
different stages in catalysis. Following this, the binding affinity and metabolism of one substrate 
can be affected by another molecule (either the same or different) present in the active site. 
Substrate binding is thus viewed as a multistep process with substrates potentially binding at a 
periphery site, important for substrate recognition, before moving into the active site. Zharkova 
et al have identified subfamily specific patterns of residues located at the entrance of the binding 
site of drug metabolising CYP450 and suggest that these residues form a periphery binding 
responsible for substrate recognition [89].  
1.6 Cytochrome P450’s redox partners  
 
During the catalytic cycle CYP450s source electrons from their redox partners via NAD(P)H to 
drive catalysis: small soluble iron-sulfur proteins such as adrenodoxin and putidaredoxin, 
generally serve as redox partners for bacterial and mitochrondria CYP450s, while the membrane 
bound NADPH dependant Cytochrome P450 reductase (CPR) serves as a redox partner for 
microsomal CYP450s [90]. CPR is co-immobilised with CYP450s in the endoplasmic reticulum 
membrane and is responsible for electron transfer to all known microsomal CYP450s.  
 
CPR is made up of four domains: the FMN-binding, connecting, FAD-binding and NADPH-
binding domains [91] (Figure 1.7). NADPH binds to the NADPH binding domain of CPR and 
transfers electrons to the flavin adenine dinucleotide (FAD) bound to the adjacent FAD-binding 
domain; FAD then transfers the electrons to the flavin mononucleotide (FMN) bound to the 




FMN-binding domain and finally the elections are transferred sequentially from FMN to the 
haem iron of a substrate-bound CYP450. The connecting domain orientates the other two 
domains, bringing the flavins together for electron transfer. The flexible hinge region enables the 
FMN-binding domain to re-orientate itself so that the region containing the bound FMN can 
interact with the CYP450.   
  
Figure 1.7 Structure of microsomal NADPH cytochrome P450 reductase (PDB code 1AMO). The NADPH- and 
FAD-binding domains are shown in blue, the connecting domain in grey and the FMN-binding domain in green. 
The bound co-factors are shown as sticks with NADP+ in orange, FAD in red and FMN in yellow. The missing 
hinge region connecting the FMN domain to the connecting domain is indicated by a dotted line.  
 
The interaction between CPR and CYP450 is transient and unstable, with Kd ~ 0.05 μM [92].  A 
number of studies have contributed to elucidating the CYP450-CPR interface and have identified 
clusters of basic residues on the proximal surface of CYP450s that interact with exposed acidic 
clusters on the CPR FMN domain surface [93-98]. The bacterial redox system cytochrome P450-
BM-3 - a 119kDa self-sufficient enzyme from Bacillus megaterium - consists of a CYP450 haem 
domain linked to a FMN/FAD-containing CYP450 reductase domain via a single polypeptide 
chain, closely resembling a “fused” mammalian CYP450 redox system [90, 99]. The structure of 
P450-BM3 has been used as a template to model the interaction between a microsomal CYP2B4 
and CPR, confirming previously identified interfacial residues and identifying additional ionic-
charge clusters that mediate the interaction [98].   




In 1992, Voznesensky and Schenkman reported that increased ionic strength increased the rate of 
first electron transfer to CYP2B4; this appeared inconsistent with reports suggesting that charged 
pairing stabilises the CPR-CYP450 complex [100]. Davydov et al however later clarified this 
apparent discrepancy by showing that while the affinity of the complex decreased with increased 
ionic strength, consistent with charge pairing, there was an increase in the rate of electron 
transfer through the complexes that were formed, leading to overall elevation of CYP2B4 
reduction [96], as was observed by Voznesensky and Schenkman. 
 
Early studies suggested that hydrophobic interactions involving the hydrophobic N-terminal 
peptides are also important for complex formation and showed that the N-terminal truncated 
CPR was incapable of transferring electrons to the CYP450 [101]. Subsequent studies using 
truncated CPR and CYP2E1 reconstituted with phospholipids, however, showed that removal of 
the N-terminal did not prevent CPR-CYP450 complex formation, CYP450 reduction or affect 
the systems sensitivity to changes in ionic strength [102]. Overall the picture that emerges is that 
due to the transient, weak nature of the interaction, CYP450 and CPR need to be co-immobilised 
for efficient CYP450 activity in order to increase the probability of a productive electron transfer 
encounter occurring at the appropriate points in the CYP450 catalytic cycle. CPR mediated 
CYP450 activity of recombinant proteins is only observed in solution in the presence of a 
phospholipid component or when very high protein concentrations are used (> 4µM) [103].  
 
Phospholipids make up a large part of the microsomal membrane, acting as a matrix for the 
interaction between CPR and CYP450. The phospholipid composition can affect CPR-CYP450 
interactions and electron transport [104-107] and can also act as effector molecules, modulating 
CYP450 activity directly [104].  
1.7 Membrane organisation of multiple CYP450s and CPR  
 
CYP450 and CPR, in the presence of phospholipids, form the primary components of the 
microsomal CYP450 monooxygenase system [108], however other proteins including 
cytochrome b5 and NADH-cytochrome b5 also interact with the system and can affect CYP450 
activity. Although CPR and CYP450 form a 1:1 complex [92, 109], CYP450 levels exceed CPR 
levels by 10 to 20 fold, depending on their induction status [110]. Thus there is competition 
between CYP450s for CPR binding and isoforms with higher binding affinity for CPR could out-




compete isoforms with lower affinity. This suggests that other mechanisms must be in place to 
ensure low affinity isoforms are not rendered inactive as a result [111]. There is now substantial 
evidence suggesting that both homomeric and heteromeric CYP450-CYP450 interactions within 
membranes play a complex yet important role in modulating drug metabolism, both by affecting 
interactions with CPR as well as directly impacting CYP450 function [111, 112].  
 
Early on it was postulated that several CYP450 molecules cluster around each reductase 
molecule and that lateral motion is required for some CYP450 molecules to interact with a 
reductase molecule [113].  Rotational diffusion studies in both microsomes and reconstituted 
systems have shown that a proportion of the CYP450 protein is immobile [114-116] as a result 
of CYP450 aggregation and that increased lipid content increases the protein mobility. In 
addition, CPR-CYP450 complex formation disrupts CYP450 aggregates and increases protein 
mobility [115, 117].  
 
Both full length CYP450 proteins and N-terminal truncated CYP450 proteins tend to aggregate 
in solution to varying degrees, depending on the construct. Studies show that CYP2B4 exists as 
hexamers in solution [118-120] and CYP1A2 is reported to exist as hexamers or heptamers [119, 
121, 122] or as a mixture of tetramers and 40-mers [123].  More recent studies have identified 
multiple, kinetically distinct CYP3A4 and CYP2B6 conformers in solution that are believed to 
be a result of CYP450 oligomers [124-128].   
 
Reed et al recently reviewed the effects of heteromeric CYP450-CYP450 complex formation on 
CYP450 function [112].  Based on experimental evidence from studies that compare substrate 
metabolism by an individual CYP450 with substrate metabolism by a mixture of different 
CYP450 isoforms, they describe three interaction models: 1) Simple competition between two 
CYP450s for CPR binding. In this model the CYP450s have different binding affinities for CPR 
but there are no interactions between the different CYP450 that have a functional effect e.g. 
[129-131]. 2) Formation of a CYP450-CYP450 complex that affects reductase binding. For 
example Backes and co-workers showed that CYP1A2 and CYP2B4 form a ternary complex in 
both reconstituted systems and microsomes and that the CYP1A2 in complex with CYP2B4 has 
a higher affinity for the reductase than CYP1A2 alone [132, 133]. 3) CYP450:CYP450 
complexes that alter the rate of catalysis. There is plenty of evidence suggesting that CYP450-
CYP450 interactions can directly alter the rate of substrate turnover, with the presence of one 




isoform inducing or inhibiting the activity of another isoform [134-139]. As with homo-
oligomers, hetero-oligomer formation is likely to affect the conformational flexibility of 
individual CYP450 molecules within the oligomer, in turn affecting catalytic activity in a 
substrate specific manner. Apart from evidence from functional assays, there is also direct 
physical experimental evidence from cross-linking, fluorescent studies, fluorescence resonance 
energy transfer (FRET) and mutagenesis experiments for the formation of specific homomeric 
and heteromeric CYP450-CYP450 complexes in the membrane [112].  
 
In summary, CYP450 exists in multienzyme complexes involving specific and nonspecific 
interactions that modulate CYP450 metabolism.  Currently, however, little is known about the 
cellular conditions that control complex formation, the regions of the protein important for 
specific CYP450-CYP450 interactions or the mechanistic effects of these interactions [112].  
1.8 Factors regulating CYP450 expression and function 
 
Cytochrome P450 regulation occurs predominantly at the transcriptional level and CYP450 
expression can be induced by both endogenous and exogenous compounds. Expression levels 
vary according to tissue-type, developmental stage, age, sex and disease state and while the liver 
is the primary site of drug metabolism, many CYP450s are also expressed in other tissue types 
such as intestine, skin, brain, lung and placenta, with endocrine factors (steroids) being largely 
responsible for the tissue-specific and sex-specific expression of CYP450s.  
 
The expression of many drug metabolising enzymes is regulated by transcription factors that are 
activated by exogenous compounds.  The aromatic hydrocarbon receptor (AhR) protein is a well-
known example: when a polycyclic aromatic hydrocarbon ligand binds to AhR, its chaperones 
dissociate and it translocates to the nucleus, dimerising with the AhR nuclear translocator and 
leading to increased transcription of CYP450 genes [140]. Consequently, CYP450 expression is 
generally increased rapidly in response to the presence of xenobiotics, enabling their efficient 
breakdown.  
  




1.9 Cytochrome P450s in human drug metabolism 
1.9.1 Overview of drug metabolism  
 
Xenobiotic metabolism refers to the metabolic pathways that modify the chemical structure of 
foreign compounds, including drugs and toxins, usually converting lipid-soluble substances to 
more water-soluble products that can readily be excreted.  While this process generally serves to 
detoxify foreign compounds, it can also lead to the formation of reactive intermediates that can 
exhibit toxic effects. In some cases, drugs are deliberately administrated as inactive prodrugs that 
are activated by enzymatic modification.  
 
Physical barriers and drug transport proteins such as P-glycoprotein serve as the body’s first line 
of defence against foreign compounds. The cell membrane acts as a hydrophobic permeability 
barrier and, while useful polar molecules enter the cell through selective transport proteins, the 
hydrophobic nature of the membrane prevents unwanted hydrophilic molecules from entering the 
cell. Thus hydrophilic drugs can only enter a cell if they are recognised by a transport protein 
[141]. In contrast hydrophobic compounds can readily diffuse across the cell membrane and 
consequently most clinical drugs are lipophilic and need to be metabolised before they can be 
excreted.  
 
P-glycoprotein is an ATP-dependent efflux pump with broad substrate specificity that pumps 
foreign compounds out of cells. P-glycoproteins are expressed predominately in tissues with 
excretory functions, as well as in important tissue-blood barriers. In the gastrointestinal tract it 
reduces drug absorption by transporting passively absorbed drugs back into the lumen; in liver 
cells and the proximal tubular of the kidney it pumps drugs into the bile ducts and urine-
conducting ducts respectively; and in the blood–brain barrier it prevents the accumulation of 
harmful substances in the brain [142]. Drug transport proteins thus in some ways improve the 
efficacy of drug metabolism by preventing the cellular drug metabolising enzymes being 
overwhelmed with high drug concentrations [143].  
 
Drug metabolism can be divided into 3 phases [144]: Phase I) reactive or polar groups are 
introduced into the substrate, providing sites for conjugation;  Phase II) polar species such as 
glutathione, sulphate, acetate or glucuronic acid are conjugated to the reactive metabolites - these 




anionic groups prepare the molecule for active transport out of the cell; Phase III) conjugates 
may be metabolised further and are excreted into the extracellular media via a variety of efflux 
pumps belonging to the multidrug resistance protein family that recognise the anionic groups on 
the conjugates [145]. Cytochrome P450s, flavin monooxygenases, dehydrogenases and esterases 
are responsible for phase I metabolism, while sulfotransferases, UDP‐glucuronosyl transferases, 
N‐acetyltransferases, glutathione S‐transferases and methyltransferases are the main enzymes 
responsible for phase II metabolism [146].  
1.9.2 Human CYP450 drug metabolising enzymes 
 
In humans there are 57 functional CYP450 genes and 58 pseudogenes, divided into 18 families 
and 44 subfamilies [12]. While the CYP450s in most families are primarily involved in 
biosynthesis and metabolism of endogenous compounds, CYP450s in families 1-3 are 
responsible for the phase I metabolism of 70-80% of all pharmaceutical drugs, as well as the 
detoxification of many other xenobiotic compounds that enter the body [147]. Figure 1.8 shows 
the proportion of pharmaceutical drugs metabolised by each of the major human drug 
metabolising isoforms found in the liver. CYP450s expressed in extra-hepatic tissues only play a 
minor role in the total drug clearance, however they are very important for the localised 
metabolism of drugs in peripheral tissues and can contribute significantly to localised drug 
efficacy, detoxification and adverse effects [148]. The major human drug metabolising enzymes 








Figure 1.8 The proportion of pharmaceutical drugs 
metabolised by the major human drug metabolising 
CYP450 enzymes in the liver: CYP1A2 (5%), 
CYP2A6 (2%), CYP2B6 (2-4%), CYP2C8 (1%), 
CYP2C9 (10%), CYP2C19 (5%), CYP2D6 (20-
30%), CYP2E1 (2-4%) and CYP3A4 (40-45%) [149]. 
 




Table 1.1 The major human hepatic drug metabolising CYP450s 
CYP450 Main role in xenobiotic metabolism Substrate specificity  
1A2 Drugs, carcinogens & oestrogens Planar, aromatic, polyaromatic and heterocyclic amides 
and amines 
 
2A6 Drugs, carcinogens & nicotine Non-polar low MW molecules- usually with 2 
hydrogen bond acceptors (Including ketones and 
nitroamines) 
 
2B6 Drugs & environmental chemicals Neutral or weakly basic, mainly lipophilic non-planar 
molecules with 1 or 2 hydrogen bond acceptors 
(including anaesthetics, herbicides and insecticides)  
 
2C8 Some drugs Large and weakly acidic molecules (including  
antimalarials and antidiabetics) 
 
2C9 Drugs Weakly acidic molecules with a hydrogen bond 
acceptor (including most NSAIDs) 
 
2C19 Drugs Neutral or weakly basic molecules or amides with 2 or 
3 hydrogen bond acceptors (including most proton 
pump inhibitors (PPIs)) 
 
2D6 Drugs Basic molecules with a basic nitrogen 4-7 Å from the 
site of metabolism (includes plant alkaloids and 
antidepressants) 
 
2E1 Carcinogens, solvents, few drugs Small neutral, hydrophilic planar molecules as well as 
long chain fatty acids (includes aliphatic alcohols and 
halogenated alkanes) 
 
3A4 Drugs & carcinogens Very board - Large lipophilic molecules with very 
diverse structures (includes > 50% of clinical drugs) 
   
Table adapted from [147, 150] 
 
 






There are three functional genes in the CYP1 family: CYP1A1, CYP1A2 and CYP1B1. While 
CYP1A2 is constitutively expressed at high levels in the liver, representing 4-16% of the total 
CYP450 liver content [147], CYP1A1 and CYP1B1 are primarily expressed extra-hepatically 
[151-156].  CYP1 expression is primarily regulated by AhR that upon activation by polycyclic 
aromatic hydrocarbons binds to enhancer elements flanking the CYP1A1, CYP1A2 and 
CYP1B1 genes, driving transcription [157].  
 
CYP1 enzymes show overlapping catalytic activities, oxidising many polycyclic aromatic 
hydrocarbons and other aromatic compounds.  CYP1A1 and CYP1A2 have a sequence identity 
of over 70% but still show distinct substrate preferences: CYP1A1 prefers planar aromatic 
hydrocarbons while CYP1A2 prefers aromatic amines and heterocyclic compounds [147]. 
Endogenous substrates for CYP1 enzymes include oestrogens, retinoic acid, arachidonic acid, 
melatonin, prostaglandins and uroporphyrinogen [158].  
 
The CYP1 proteins are notorious for their role in bioactivating carcinogens including 
benzo(a)pyrene, arylarenes, nitroarenes, arylamines found in charred food, cigarette smoke and 
products from industrial combustion [8, 147]. The resultant highly reactive metabolites are 




CYP1A2 also plays an important role in the hepatic metabolism of numerous pharmaceutical 
drugs including analgesics, antipyretics, cardiovascular drugs, antipsychotics, antidepressants 
and anti-inflammatory drugs [147]. CYP1A2 is subject to reversible and irreversible inhibition 
by a number of drugs, natural substances and other compounds that bind within the active site of 
the enzyme [159]; as a result, drug treatments involving CYP1A2 substrates are sensitive to 
drug-drug interactions that can lead to adverse drug effects in patients. α-Naphthoflavone and 
fluvoxamine are two of the most potent and well known CYP1A2 inhibitors [160-162] but other 
CYP1A2 inhibitors include oral contraceptives, cimetidine and furafylline [147]. In addition to 
this, exposure to CYP1A2 inducers can lead to increased CYP1A2 expression and increased 
drug clearance, resulting in reduced drug efficacy or toxicity in the case of pro-drugs.   





A crystal structure of CYP1A2 with inhibitor α-naphthoflavone bound in the active site reveals a 
compact, relatively narrow and planar active site that is highly suited to the shape and size of its 
substrates [163]. The shape of the active site is similar to that observed in the more recently 
solved CYP1B1 [164] and CYP1A1 [165] crystal structures but is distinct from the active site 
architecture observed in drug metabolising CYP2 and CYP3 structures.  
CYP2 family  
 
The CYP2 family consists of 16 functional genes (CYP2A6, CYP2A7, CYP2A13, CYP2B6, 
CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2F1, CYP2J2, CYP2R1, 
CYP2S1, CYP2U1 and CYP2W1), divided into 13 subfamilies [12]. Isoforms CYP2A6, 
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP2E1 are most important in terms of 
hepatic clinical drug metabolism, while the other members are predominately expressed in extra-
hepatic tissues, often in a sex-specific manner, and are primarily involved in the metabolism of 




CYP2A6 is mainly expressed in the liver, making up ~4% of the total hepatic CYP450 content 
[166, 167].  Data suggests that the constitutive androstane receptor (CAR), pregnane X receptor 
(PXR) and glucocorticoid receptor (GR) are involved in CYP2A6 regulation, however regulation 
of CYP2A6 expression is still relatively poorly understood [168]. CYP2A6 has a preference for 
low molecular weight, non-planar molecules, usually with 2 hydrogen bond acceptors [147]. 
CYP2A6 crystal structures show a relatively small, compact, hydrophobic active site [169]. 
Active site residue Asn297 serves as a hydrogen bond donor playing an important role in the 
positioning of substrates for regio-selective oxidation.  
 
CYP2A6 oxidises several endogenous compounds including steroids, retinoic acid and bilirubin 
[168, 170] as well as numerous xenobiotics including pharmaceutical drugs, carcinogens, 
constituents of tobacco smoke and environmental toxins. CYP2A6 is responsible for the 7-
hydroxylation of coumarin, the C-oxidation of nicotine and the 3-hydroxylation of cotinine in the 
liver. It is also the main isoform responsible for the bioactivation of the cancer prodrug tegafur 




[171] and the metabolism of aromatase inhibitor letrozole to its inactive carbinol metabolite 
[172]. CYP2A6 inhibitors include the selective competitive inhibitors pilocarpine and 
tranylcypromine and mechanism based inhibitors selegiline, methoxsalen, (R)-(+) menthofuran 




CYP2B6 is a minor hepatic P450 making up ~2 – 5% of the total hepatic CYP450 content. 
Expression levels vary greatly both between individual and within individuals at different time 
points and inter-individual variation of up to 300 fold has been reported [147]. The major 
regulators of CYP2B6 gene expression are nuclear receptors CAR via a phenobarbital-response 
enhancer module [173] and PXR via a distal xenobiotics-response enhancer module within the 
CYP2B6 promoter [174].  These receptors act as xenobiotic sensors and compounds such as 
barbiturates, rifampicin, hyperforin and other CYP2B6 substrates act as ligands for these 
receptors, inducing CYP2B6 transcription [147].  
 
CYP2B6 substrates tend to be neutral or slightly basic and are typically lipophilic non-planar 
molecules. Crystal structures of CYP2B6 bound to various ligands [56, 175-177] reveal that the 
enzyme can adopt very different conformations. Conformational changes of several flexible 
regions in the protein drastically alter the shape of the active site, enabling the enzyme to 
efficiently bind and metabolise molecules of different shapes and sizes without disrupting the 
overall CYP450 fold [178].  
 
CYP2B6 metabolises pharmaceutical drugs, pesticides and other environmental chemicals and 
pollutants [8, 179]. CYP2B6 is generally thought to play a supportive role in drug metabolism 
but is dominant in the metabolism of a number of drugs including cyclophosphamide, efavirenz, 
artemisinin, ketamine and methodone [180]. CYP2B6 also N-demethylates the recreational drug 
“ecstasy” leading to the formation of reactive metabolites that are potentially neurotoxic [181].  
 
CYP2C8, CYP2C9, CYP2C19  
 
CYP2C8, CYP2C9 and CYP2C19 make up ~20% of the hepatic CYP450 content [8]: CYP2C9 
is the most abundant, followed by CYP2C8 and CYP2C19 which have expression levels ~2 and 




~10 fold lower than CYP2C9 respectively [147, 182]. CYP2C enzymes are also expressed in 
extra-hepatic tissue such as the heart [183] and small intestine [184, 185]. CYP2C genes are 
regulated by PXR/CAR, GR and vitamin D receptor pathways via response elements in their 
promoter regions and are induced to varying degrees by xenobiotics [186].  
 
Despite having an amino acid sequence identity > 80% they each have distinct substrate 
specificity and play unique roles in drug metabolism. CYP2C8 prefers large, weakly acidic 
molecules whilst CYP2C9 substrates are also generally weakly acid molecules and usually have 
a hydrogen bond acceptor; in contrast CYP2C19 usually binds neutral or weakly basic molecules 
or amides with 2 or 3 hydrogen bond acceptors [147].  Comparison of the available crystal 
structures of the three enzymes reveals that CYP2C8 has the largest active site [187]. While the 
backbone of CYP2C8 is most similar to CYP2C19, the size of their active sites differs 
substantially as they are lined by different amino acid side chains. The active sites of CYP2C9 
and CYP2C19 are much more similar, apart from the distal B-C loop region which adopts 
different conformation in the two structures and it has been suggested that sequence differences 
within and adjacent to the B-C loop affect conformational flexibility and substrate specificity. A 
crystal structure of CYP2C8 with two molecules of 9-cis retinoic acid bound in the active site 
demonstrates conclusively that more than one substrate molecule can bind simultaneously within 
its active site [55].   
 
CYP2C enzymes have a number of endogenous substrates, including arachidonic acid and some 
steroids [8, 147]. CYP2C9 contributes most significantly to drug metabolism in humans, 
metabolising most non-steroidal anti-inflammatory drugs, the anticoagulant warfarin, the 
anticonvulsants phenytoin and valproic acid, antidiabetics like tolbutamide and glibenclamide 
and many other drugs.  CYP2C8 shows some overlap in substrate specificity with CYP2C9, as 
well as distinct catalytic activities. CYP2C8 is the main enzyme responsible for the metabolism 
of anticancer drug paclitaxel, antidiabetics rosiglitazone and pioglitazone and the antimalarial 
drug amodiaquine and also plays a major role in the metabolism of other antimalarial drugs 
including chloroquine and dapsone. CYP2C19 is the isoform primarily responsible for the 
metabolism of anticonvulsant mephenytoin, proton pump inhibitors such as omeprazole, the 
anticoagulant prodrug clopidogrel, the antimalarial drug proguanil as well as a number of 
antidepressants [8, 147].    
 






CYP2D6 makes up about 2% of the total hepatic CYP450 content [166], and is also expressed at 
low levels in the brain and the small intestine [185, 188]. CYP2D6 is typically considered a non-
inducible gene [189, 190] and as a result its transcriptional regulation is poorly understood. 
Studies however suggest that hepatocyte nuclear factor 4 alpha (HNF4α) and antagonist COUP 
Transcription Factor 1 (COUP-TF-1) play a role in regulating CYP2D6 expression via the 
positive DR-1 element [191] and rifampicin has been shown to induce CYP2D6 in vivo [192].  
CYP2D6 down regulation has also been observed in response to nitric oxide produced during 
inflammation [193]. 
 
Typically CYP2D6 substrates contain a basic nitrogen, 4 to 7 Å from the site of metabolism, and 
a planar aromatic ring.  Crystal structures of CYP2D6 show that the active site adopts different 
conformations in the presence and absence of ligands [194, 195].  In a prinomastat bound 
CYP2D6 structure, the active site adopts a closed conformation and its shape closely conforms to 
the shape of the bound substrate [194]. The thioridazine bound structure adopts a substantially 
different conformation, accommodating two substrate molecules in its active site (to be 
published, PDB code 3TBG).   This structural flexibility is likely to contribute to the catalytic 
versatility of the CYP2D6 enzyme. Phe120 within the B-C loop controls the orientation of the 
substrates aromatic ring with respect to the haem and mutations at this position can affect the 
enantioselectivity of oxidation [194, 196].   
 
CYP2D6 O-demethylates endogenous substrate 5-methoxytryptamine back to serotonin and as 
well as two related 5-methoxyindolethylamines derived form 5-hydroxytryptamine [197, 198]. 
CYP2D6 also metabolises a surprising large number of drugs considering its relatively low 
expression levels in the liver, metabolising over 20% of all clinically used drugs [149] including 
antidepressants, antipsychotics, antiarrhythmics, narcotic analgesics, opioid analgesics, β-
blockers and anti-cancer drugs [147]. Highly selective drugs used for CYP2D6 phenotyping 
include debrisoquine, dextromethorphan, metoprolol, sparteine, and tramadol [199].  CYP2D6 is 
highly prone to inhibition as many molecules that are not necessarily substrates bind with high 
affinity to its active site and as a result drug treatments involving CYP2D6 substrates are 
particularly sensitive to drug-drug interactions [147].  
 






CYP2E1 is expressed at high levels in the liver, making up on average ~7% of the hepatic 
CYP450 content [166]. It is also expressed at low levels in range of other tissues including the 
brain, lung, testis, ovaries and cardiac tissue. Expression levels in the liver are subject to high 
variability [200-202] and CYP2E1 is inducible by hormones as well as by many of its substrates 
via complex regulatory mechanisms. Transcript levels do not tend to correlate with protein 
expression levels and pre-translational, translational and post-translational mechanisms appear to 
play a significant role in regulating CYP2E1, including both mRNA and protein stabilising 
mechanisms [203, 204]. CYP2E1 substrates are generally small, planar molecules including 
organic solvents and low molecular weight xenobiotics [147]. Consistent with its preference for 
small substrates, the CYP2E1 active site is the smallest of the human drug metabolising 
isoforms. CYP2E1 however also metabolises much larger endogenous C9–C20 fatty acid 
signalling molecules.  Fatty acid bound crystal structures reveal that the rotation of a single 
phenylalanine side chain merges the active site with an adjacent void forming part of the 
substrate access channel, significantly increasing the size of the active site and thereby allowing 
it to accommodate long chain fatty acid molecules [205]. This is consistent with molecular 
dynamic studies which reveal that the volume of the CYP2E1 active site fluctuates between 220 
and 1310 Å during simulation due to the motion of side chains acting as gates to two adjacent 
cavities [87].  
 
CYP2E1 metabolises solvents such as ethanol and acetone, as well as many industrial and 
environmental toxins including carcinogens [206, 207]. CYP2E1 is particularly prone to the 
production of reactive oxygen species caused by the uncoupling of oxygen consumption with 
NADPH [208]. This, as well as CYP2E1 tendency to metabolise xenobiotics into reactive 
metabolites, has implemented CYP2E1 in liver damage.  CYP2E1 plays a role in the metabolism 
of a few clinically important drugs including chlorzoxazone, paracetamol, enflurane and general 
anesthetics such as halothane and sevoflurane [147].  
CYP3 family  
 
The CYP3 family consists of functional genes CYP3A4, CYP3A5, CYP3A7 and CYP3A43. The 
substrate specificities of these proteins overlap but they show different tissue expression patterns 




[209]. CYP3A4 is the most abundant CYP450 isoform in the liver. Expression levels vary more 
than 100 fold between individuals and CYP3A4 can make up as much as 60% of the hepatic 
CYP450 content [210, 211], but averages are between 14-24% [147]. It is also expressed in the 
small intestine where it is the dominant CYP450 involved in first-phase metabolism of orally 
administrated drugs. In contrast CYP3A5 is only expressed in the liver in ~20% of individuals 
but is the dominant CYP3 isoform in several extra-hepatic tissues [147, 209]. CYP3A5 and 
CYP3A4 have an amino acid identity of over 85% and metabolise many of the same substrates, 
but CYP3A5 is generally more limited in its metabolic capabilities and catalyses reactions at a 
slower rate [212, 213]. CYP3A7 is the dominant CYP3 isoform in fetal liver [214, 215] and it is 
estimated that only ~20% of adult livers express active CYP3A7 [209]. CYP3A43 is expressed 
at low levels in the liver but at relatively high levels in the prostate and testis, where it is thought 
to play a role in steroid metabolism [209]; little is known about its substrate specificity but it is 
not expected to contribute significantly to human drug metabolism.  
 
CYP3A protein expression is highly inducible by wide range of xenobiotics and endogenous 
molecules, with multiple signalling pathways regulating CYP3A genes. The major cis-acting 
modules responsible for inducible transcriptional regulation include the proximal PXR 
responsive element prPXRE, the distal xenobiotic-responsive enhancer module XREM, and the 
constitutive liver enhancer module CLEM4 [147]. Nuclear receptors proteins involved in 
CYP3A transcription regulation include xenobiotic sensors PXR  and CAR [216], GR [217], the 
bile acid receptor FXR [218], the oxysterole receptor LXR [219], the vitamin D receptor [220] 
and the lipid regulator PPARα [221, 222]. Inducers of CYP3A4/5 expression include 




CYP3A4 is the most important CYP450 isoform with regard to human drug metabolism. It 
preferentially binds large, lipophilic molecules of very diverse shapes, sizes and chemical 
properties but also metabolises many smaller molecules [147]. Crystal structures reveal that 
CYP3A4 has a large active site capable of adopting markedly different conformations and 
binding multiple drug molecules simultaneously [54, 57, 58, 223-227].  Molecular dynamic 
studies predict that CYP3A4 is the most flexible of all CYP450s, consistent with its ability to 
metabolise the largest and most diverse range of substrates [76, 80].  




CYP3A4 substrates include drugs, carcinogens, macrocyclic natural products and endogenous 
steroids such as testosterone progesterone and androstenedione. CYP3A4 plays a major role in 
metabolism of about 30% of clinically used drugs but metabolises well over half of drugs to 
some degree [147]. Drugs metabolised by CYP3A4 include macrolide antibiotics (e.g. 
erythromycin), anti-arrhythmics (e.g. quinidine), HIV-antiretrovirals (e.g. ritonavir), calcium 
array blockers (e.g.  nifedipine) and immunosuppressants (e.g. cyclosporine) [8].  While several 
probe drugs (e.g. midazolam, erythromycin and dextromethorphan) are used for CYP3A4 
phenotyping, allosteric regulation and overlapping substrate binding regions result in poor 
correlation between data for different substrates [228-230]. 
1.9.3 CYP450 drug-drug interactions 
 
Co-administration of drugs can results in CYP450 drug-drug interactions that reduce drug 
efficacy and/or cause severe side effects for patients.  As discussed above, many drugs act as 
CYP450 inducers or inhibitors. In addition, more than one drug may compete for metabolism by 
the same CYP450 isoform or bind simultaneously to the enzyme leading to altered rates of 
metabolism or even altered metabolite formation, the net result being substantial changes in drug 
exposure.   It therefore follows that the safety and efficacy profile of a drug may be drastically 
affected by the presence of other drugs or xenobiotics, which is particularly problematic for 
drugs with narrow therapeutic windows [231].  
 
There are numerous examples of CYP450 related drug-drug interactions that have serious 
clinical implications. For example, the co-administration of the antihistamine prodrug 
terfenadine with antimicrobial agents such as ketoconazole [232, 233] or macrolide antibiotics 
such as erythromycin [234] leads to a type of cardiac dysrhythmia known as ‘torsades de 
pointes’. Terfenadine is a potassium channel blocker and is cardiotoxic at high doses – normally 
it is rapidly metabolised to non-toxic metabolites by CYP3A4 and as a result plasma levels of 
terfenadine are very low. The co-administration of CYP3A4 inhibitors however greatly reduces 
CYP3A4 mediated metabolism leading to high plasma levels of terfenadine that in turn disrupts 
the heart’s electrical cycle by causing prolonged QT intervals.  Terfenadine was used by over 
100 million patients prior to 1990 [235] but was later superseded by fexofenadine, the non-
cardiotoxic active metabolite of terfenadine [236], due to these health risks.   
 




A problem particularly pertinent to health care in Africa is the concurrent treatment of 
Tuberculosis (TB) and human immunodeficiency virus (HIV) [237]. TB and HIV co-infection is 
very common and co-administration of anti-tuberculosis and antiretroviral drugs has become the 
standard care for patients.  Rifamycin antibiotics such as rifampin are an essential part of 
multidrug regimens for TB treatment, but they are strong inducers of drug transporters, CYP450s 
and Phase II drug metabolising enzymes and therefore greatly reduce the plasma concentrations 
of co-administrated antiretrovirals (e.g. nevirapine) that are metabolised by these enzymes, 
potentially compromising HIV treatment [238-241].  
 
To further complicate drug treatment, unregulated and non-prescribed herbal remedies, 
traditional medicines and even foodstuffs (e.g. St John’s wort, the African potato, ginseng, garlic 
and grapefruit) can alter CYP450 metabolism and cause severe drug-drug interactions when 
ingested with prescription drugs [242]. For example, the African potato is widely used in Africa 
for the treatment of HIV, yet compounds in the African potato can inhibit CYP3A4 activity by 
up to 90% so if this traditional remedy is used together with prescription drugs that are CYP3A4 
substrates, those drugs may accumulate to toxic levels in the body [243].  
 
In addition to small molecule drugs, therapeutic proteins such as cytokines used in cancer 
treatment (or proteins that modulate cytokine activity such as monoclonal antibodies) can also 
cause drug-drug interactions by influencing the expression of CYP450 enzymes and drug 
transporters proteins [244]. 
1.9.4 CYP450 pharmacogenetics: inter-individual differences in drug response 
 
As a consequence of both intrinsic and extrinsic factors, drug response - both in terms of drug 
efficacy and the occurrence and severity of side effects - can differ dramatically from one patient 
to another [245].  Differences in drug response can often be attributed to differences in CYP450 
mediated drug metabolism, which is highly variable between patients. Although non-genetic 
factors such as age, sex, diet, disease state and co-administration of drugs affects CYP450 
expression and function, genetic variation underlies many of the inter-individual differences in 
drug metabolism and associated adverse drug reactions [147]. 
 




While CYP450s have very broad and often overlapping substrate specificities, many drugs are 
only or mainly metabolised by one CYP450 isoform and as a result changes in the expression or 
function of even a single isoform can significantly alter the pharmacokinetic profile of a drug. If 
a drug is metabolised too fast, the bioavailability may be too low making the drug ineffective; on 
the contrary, if the drug is metabolised too slowly, drug levels may be too high for too long 
causing toxicity (in the case of a prodrug, where the CYP450 metabolism activates the drug, the 
opposite is true).  Differences in the nature and relative quantities of reactive metabolites formed 
can also lead to varied side effects.  
 
CYP450 drug metabolising enzymes are highly polymorphic in the population and the 
occurrence and frequency of variant alleles varies between ethnic groups. Variant alleles include 
deletions, insertions, copy number variants and single nucleotide polymorphisms (SNPs) both in 
the coding and non-coding regions of the genes. This variation can lead to aberrant splicing, 
frameshifts, premature termination of translation, can affect transcription, alter protein 
expression levels or influence protein function. Consequently, aberrant CYP450 alleles can 
diminish, enhance or alter CYP450-mediated drug metabolism. Table 1.2 gives examples of 
major aberrant CYP450 alleles that influence clinical drug metabolism and patient outcomes - 
the global minor allele frequency and frequency within different ethnic groups is also shown for 
each allele.     
 
The terms “extensive metaboliser”, “poor metaboliser”, “intermediate metaboliser” and “ultra‐
rapid metaboliser” are commonly used to describe the pharmacokinetic phenotype associated 
with CYP450 genotypes [149]. Extensive metabolisers have two normal functional alleles and 
most recommended drug doses assume patients are extensive metaboliser. Poor metabolisers are 
homozygous for a non-functional allele or compound heterozygous for two different non-
functional alleles and therefore lack active enzyme. As a result, poor metabolisers show low drug 
clearance, which can lead to toxicity and adverse drug reactions due to prolonged drug exposure 
or alternatively they do not benefit from prodrugs that are activated by that particular CYP450. 
Intermediate metabolisers are heterozygous for a non-functional allele or homozygous for two 
partially functioning alleles and can also experience reduced drug clearance, but to a lesser 
degree than poor metabolisers. Intermediate metabolisers are also more susceptible to developing 
a poor metaboliser phenotype in response to drug inhibition or environmental factors.   
Ultrarapid metabolisers have an increased number of functional gene copies and as a result have 




an increased rate of drug clearance, reducing drug efficacy; conversely rapid activation of 
prodrugs by ultrarapid metabolisers can lead to toxicity.  
 
These phenotype-genotype associations are of course greatly over-simplified and do not hold 
true for all drugs or in all patients, since polymorphisms can have substrate specific effects and 
genetic variation in drug transporters, drug receptors, other drug metabolising enzymes and the 
drug target itself may also have functional implications that make it difficult to predict the 
clinical outcome [246, 247].  
 
Owing to CYP1A, CYP1B and CYP2E1 proteins’ role in the activation and clearance of 
carcinogens and the metabolism of signalling molecules, genetic variation in these enzymes has 
been studies extensively as risk factors for cancer development and several variants have been 
identified that increase patient’s susceptibility to certain cancers (examples in Table 1.2).   
 
CYP2A6 enzymes are highly polymorphic and ~ 9 % of Caucasians, ~22 % of Africans and 50% 
of Asians are estimated to have low-activity or loss-of-function alleles [248]. Patients that are 
homozygous or compound heterozygous for these defective alleles are poor metabolisers of 
nicotine, which may influence smoking behaviour and susceptibility to certain cancer. These 
CYP2A6 polymorphisms also influence the metabolism of some pharmaceutical drugs such as 
the anticancer prodrug tegafur.  
 
Polymorphic variation in CYP2B6, CYP2C9, CYP2C19 and CYP2D6 has been implicated 
widely in altered drug response and adverse reactions (Table 1.2). Alleles causing changes in 
expression as well as altered protein function have been identified that lead to both poor and 
ultrarapid metaboliser phenotypes, with serious implications for patients on certain drug 
treatments. CYP2D6 polymorphic variation has the highest clinical impact since environmental 
and non-genetic factors have comparably little influence on CYP2D6 expression and many null 
alleles as well as alleles with several fold amplifications exist [147].  
 
In contrast, CYP3A4 polymorphic variation is generally thought to have less significant clinical 
impact as there are no null alleles and, while variants in the coding region can affect protein 
function, they occur at low frequencies of less than 5% heterozygous with the wild-type allele, 
limiting their effect on drug clearance [249]. In addition CYP3A4 is a highly inducible enzyme 




and expression levels vary greatly within and between patients in response to non-genetic 
factors. Importantly however single amino acid substitutions in CYP3A4 can affect the 
regioselectivity of oxidation [250-252]; consequently CYP3A4 polymorphic variation should not 
in fact be ignored since mutations could lead to the formation of toxic metabolites and may have 





Table 1.2  Examples of the major aberrant CYP450 alleles that influence clinical drug metabolism and patient outcomes 




Allele Frequencies  Functional effect Clinical consequence References 
CYP1A2*1C −3860G>A Promoter 18.8 %  
(26–40% Africans, African  
Americans; 21–27 % Asians, Pacific; 
1-8 % Caucasians; 20–30 Hispanic) 
 
Decreased inducibility (smokers) May influence susceptibility to 
certain cancers; decreased caffeine 
3-demethylation in Japanese 
smokers  
[253] 
CYP1A2*1F −163C>A Intron 1 35 % (A>C)  
(note C is the reference allele even 
though A is more common) 
Increased inducibility (smokers 
and coffee consumers) 
Increased susceptibility to cancer; 
increased metabolism of 
olanzapine; increase susceptibility 
to myocardial infarction 
[254-260]  
CYP2A6*2 1799T>A L160H 1.3 %  
(0–1 % African, African American; 0–
2.5 % Asian; 4-10% Caucasian) 
No activity Decreased nicotine metabolism; 
increased risk of tobacco-related 
lung cancer; influence on smoking 
behaviour and nicotine dependence; 
decreased activation and clearance 





Recombination Gene deletion (1–2 % African American; 5–24 % 
Asian; 1–4% Caucasian) 
Null alleles 
CYP2A6*7 6558T>C I471T 4 % 
(0 % African, African American; 6 -
13% Asian; 0 % Caucasian) 
 
Decrease activity (Substrate 
specific in vitro) 
CYP2A6*9 48T>G Promoter, TATA-
box 
13 % 
(4–2 % African, African American; 
16–27 % Asian;  4–5 % Caucasian) 
 Decreased activity 
CYP2A6*10 1412T>C; 
1454G>T 
I471T; R485L  Decreased activity (essentially 
inactive towards nicotine in vivo) 
CYP2A6*17 5065G>A V365M 2.5 %  (4 – 50% African, African 
American; 0 % Asian; 0-2% Cauc.)  
Decreased activity (substrate 





CYP2B6*4 18053A>G K262R 2-6 % 
(0% African, African American; 5-12 
% Asian; 4 % Caucasian) 
Increased activity (substrate 
specific effects in vitro) 
Increased drug clearance 




Q172H; K262R 27 % 
(33-50 % African, African American;  
21 % Asian; 14-27  % Caucasian; 62% 
Pacific)  
Decreased expression in the liver 
(substrate specific effects in 
vitro) 
Decreased drug clearance leading to 
adverse reactions (efavirenz, 
nevirapine, S-methadone) 
[266-272] 
CYP2C9*2 3608C>T R144C 6.9 % 
(0-2 % African, African American; 0–
2 % Asian, Pacific; 10-17 % 
Caucasian; 6.5 % Hispanic) 
Decreased activity Decreased drug clearance and 
increased risk of adverse drug 
reactions (Anticoagulants warfarin, 
acenocoumarol and 
phenprocoumone; sulfonylurea 
hypoglycemic drugs; NSAIDS) 
[273-280]  
CYP2C9*3 42614A>C I359L 4.3 % 
(0-1% African , African; 2 – 6 % 
Asian; 6% Caucasian) 
Decreased activity 
CYP2C19*2 19154G>A Splicing defect 20 % 
(10- 17 % African, African American; 
22-32 % Asian, Pacific; 6-15 % 
Caucasian; 15 % Hispanic) 
 
Null allele Decreased clearance of PPIs leading 
to increased efficacy in 
Helicobacter pylori eradication 
therapy; decrease  clearance  and 
increased risk of adverse drug 
reactions for antidepressants 
(amitriptypine, citalopram, 
clomipramine, moclobemide), 
antimalarials (proguanil) and 
antifungals (voriconazole); 
decreased activation of prodrug 
clopidogrel  resulting in decreased 
anticoagulation effect and increased 
risk of cardiovascular events. 
[281-295] 
CYP2C19*3 17948G>A W212X 1.4 % 
(0-1 % African, Caucasian, Hispanic; 






CYP2C19*17 −806C>T Promoter 15 % 
(15–27 African, African American; 0-2 
% Asian; 21-25 % Caucasian) 
Increased expression Increased clearance of PPIs leading 
to decreased efficacy; increased 
activation of prodrug clopidogrel 
leading to increased risk of bleeding 
[282, 283, 296, 
297]  
CYP2D6*3 2549delA Frameshift gMAF 0.009 
~0.01 all ethnicities 
Null allele Decreased clearance of many 
antiarrhythmics, antidepressants and 
antipsychotics leading to increased 
risk of adverse drug reactions; 
decreased activation of opioids 
(codeine, dihydrocodeine, 
oxycodone, tramadol) leading to 
decreased analgesic effect; 
decreased activation and efficacy of 
tamoxifen. 
[298-302] 
CYP2D6*4 Recombination Deletion 3-6 % all 
ethnicities 
Null allele 
CYP2D6*6 1707delT Frameshift ~1% all ethnicities Null allele 
CYP2D6*10 100C>T P34S 26 % 
(8-12% African, African American; 
40-70 % Asian; 2 % Caucasian) 
Decreased expression & activity 
CYP2D6*17 1023C>T T107I R296C 5 %  (for 1023C>T) 
(14-24 % African; 0 % Asian, 
Caucasian) 
Decreased expression & activity 
CYP2D6*41 2988G>A Splicing defect 5.5 % 
(1-6 % African, Asian, Pacific, 
Hispanic; 9 % Caucasian)  
Decreased expression & activity 
CYP2D6*Nxn Recombination Copy number 
variations 
Up to 30 % African, African 
American; 1-9 % Caucasian 
Increased expression & activity Increased activation of opioid 
prodrugs leading to toxicity  
[303-305] 
CYP3A4*22 15389 C>T Intron 6 2.1 % 
(4.3 % African American; 4.3 % 
Asian; 2.5-8% Caucasian) 
Decreased expression & activity Decreased metabolism of statins 
(decreased clearance of simvastatin 
leading to increased lipid-lowering 
response); decreased dose 
requirements of calcineurin 
inhibitors (tacrolimus) for stable 
renal transplant patients   
[306-308] 





Polymorphisms affecting protein function 
 
Table 1.3 shows the number of distinct star-alleles with variant amino acid sequence or with 
proven functional affects for each of the major human drug metabolising isoforms ([309]; 
accessed 20 Jan 2014)). Many SNPs code for amino acid changes that occur in different 
combinations and in addition to these SNPs, haplotype variants and SNPs not yet assigned to a 
particular allele also exist. A list of the single amino acid substitutions resulting from 
polymorphic variation for each isoform can be found in Appendix B Table B1-B9.  
 
Table 1.3  The number of distinct star-alleles for each of the major human drug metabolising isoforms  











While in vivo data provides useful information on the clinical phenotype associated with a 
particular allele, results are often contradictory due to other compounding genetic and non-
genetic factors [147]. The presence of multiple SNPs in a single allele can also make it difficult 
to understand the contribution of each individual SNP to an altered phenotype and hence the 
molecular mechanisms underlying the changes in CYP450 drug metabolism are poorly 
understood based on clinical studies alone.  
 
Recombinant expression systems for individual CYP450 enzymes have enabled site-directed 
mutagenesis studies to investigate the effect of SNPs on protein structure and function in 
controlled systems.  In vitro studies have shown that single amino acid substitutions can affect 
the binding affinity of substrates, alter the turnover rates of oxidation by as much as 1000 fold, or 
even change the enantioselectivity or regioselectivity of oxidation [149, 252, 310-312].  





by directly affecting substrate binding, or by altering interactions with protein partners.  The 
effect of SNPs can also be substrate specific, affecting the metabolism of some substrates but not 
others [313-317]. For example, Ariyoshi et al found that allele CYP2A6*7, coding for the 
mutation I471T, lacked nicotine C-oxidase activity yet coumarin-7 hydroxylase activity was 
conserved. Similarly, Wang et al found that CYP2C19 E122A showed comparable S-
mephenytoin 4-hydroxylation activity to the wild-type but significantly decreased omeprazole 
5’-hydroxylase activity. Furthermore, single amino acid substitutions can affect CYP450 
inhibition in an inhibitor dependant manner. Additionally the presence of more than one 
mutation does not necessarily have an additive effect since two mutations that show no effect on 
protein function in isolation may significantly disrupt protein function when they occur in 
combination; alternatively instability as a result of one mutation may be counter-balanced by 
another mutation. A screening platform has been used recently to assay 18 CYP2C19 variants 
against 10 different drugs [315]; however few such studies have been reported to date and as a 
result, the effect of non-synonymous mutations on drug metabolism remains poorly understood 
experimentally for all except a limited set of mutations and substrates. 
1.9.5 CYP450s and drug development  
 
The pharmaceutical industry is facing unprecedented financial challenges as despite escalating 
costs, research and development (R&D) productivity has been declining [318, 319]. Drug failure 
rates are high with only 8% of drugs entering clinical trials eventually making it to market [320]. 
The average drug takes over 10 years to reach the shelf [320] and costs ~$ 1.8 billion to develop 
- most of which represents the cumulative costs of failed drug initiatives [318].  Problems with 
drug efficacy, toxicology and safety are the leading causes of attrition in drug discovery.  In 
addition, drugs are only effective in ~40% of patients to whom they are prescribed [321] and 
even after gaining FDA-approval, around 4% of approved drugs are later withdrawn due to 
unexpected side effects [320].   This highlights the need for new approaches to drug discovery 
and improved methods of testing the efficacy and safety of drugs prior clinical trials.  
 
CYP450s are notorious in the pharmaceutical industry as they are regularly responsible for 
adverse drug reactions, poor drug efficacy and the failure of drugs in late stages of clinical trials.  






The drug discovery process typically begins with target identification followed by drug 
screening to identify promising lead compounds. Computational tools are used to predict the 
absorption, distribution, metabolism, and excretion (ADME) and toxicity of lead compounds 
based on their chemical structure and properties [322, 323].  These in silico studies are followed 
by preclinical testing to identify the primary drug elimination pathways. Key preclinical studies 
include in vitro kinetic studies using hepatocytes, liver microsomes and recombinant CYP450s to 
determine which CYP450 isoforms are responsible for metabolising the drug and to investigate 
enzyme induction and inhibition that could lead to drug-drug interactions [324]. In addition, 
genotoxicity and cytotoxicity studies are carried out on the parent compound and its metabolites 
to test for reactivity that may lead to adverse side effects. After rigorous preclinical testing, 
successful drug candidates are tested in vivo using animal models (usually in mice, rats, dogs or 
other primates) and finally, once a drug meets all the safety requirements, it enters clinical trials 
in humans.  
 
Clinical trials can be divided into three phases [325]: Phase I trials are used to determine 
tolerable drug doses based on pharmacokinetic parameters as well as drug safety in 20 to 80 
healthy volunteers. In Phase II trials the dosing regimen is verified and adverse reactions are 
monitored at higher dosages over longer periods in a larger group of individuals (several 
hundred) with the target disease.   Phase III trials serves as a final test for safety and efficacy. 
These trials are performed in much larger groups of people (several thousand) and are 
randomised, including both disease and control groups. 
1.9.6 The shift towards personalised medicine 
 
Treatment prescriptions and dosage guidelines have traditionally been based on the general or 
average population rather than an individual or a particular ethnic group. Pharmacogenetic 
studies are now however showing an increasing number of genetic markers that can consistently 
be used to predict adverse drug reactions and drug efficacy. As this information is used more 
effectively, the medical profession seems set to be revolutionised as it begins to move away from 
a “one drug fits all” approach to drug treatments tailored for the individual.  While the 
incorporation of this valuable genetic information into clinical practice has initially been slow 
[326], substantial progress developing standardised clinical pharmacogenetic guidelines for 





Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Pharmacogenetics 
Working Group of the Royal Dutch Pharmacists Association [327-329]. These guidelines are 
now freely available online [330]. In a list of over 500 well-known pharmacogenetic associations 
compiled by the CPIC, CYP450 genes are implicated in over 50% of cases [331]. In addition, 
CYP450 genotype-phenotype associations are mentioned in 56 of the 91 FDA-approved drug 
labels containing pharmacogenomic information [332]. The high prevalence of CYP450 genes in 
these lists further emphasises the clinical relevance of CYP450 polymorphic variation. Several 
clinically relevant genetic tests for CYP2C9, CYP2C19 and CYP2D6 genotyping now exist 
including Roche AmpliChip CYP450 Test, DMET Plus (Affymetrix, Inc); VeraCode ADME 
Core Panel (Illumina, Inc) and TaqMan Drug Metabolism Genotyping Assay Sets (Applied 
Biosystems, Inc) [333].     
 
The anticoagulant drug warfarin is a well-known example of a drug with established genetic 
biomarkers that can guide dosing and help prevent adverse drug reactions and poor efficacy. 
Warfarin is the most commonly prescribed anticoagulant for the treatment and prevention of 
thrombotic disorders in the world [334] but it has a very narrow therapeutic window and 
consequences of over- or under-dosing can be devastating [335-337].  There is substantial inter-
individual variation in patient responses to warfarin and consequently dosage adjustments have 
to be made frequently. Numerous genetic factors as well as clinical factors such as age, weight, 
smoking status and co-administration of other medications influence a patient response [275].  
Polymorphisms in the CYP2C9 and VKORC1 genes have been identified as genetic markers 
affecting warfarin dosage requirements.  S-warfarin, the most potent enantiomer, is primarily 
metabolised by CYP2C9 and CYP2C9*2 and CYP2C9*3 alleles encoding CYP2C9 proteins with 
R144C and I359L mutations respectively have been associated with poor warfarin clearance. 
Poor metabolisers are at risk of bleeding complications due to prolonged drug exposure and 
require lower warfarin doses; the mechanistic basis for this is that warfarin reduces blood-
clotting by binding to the vitamin K reductase protein, thereby inhibiting the formation of 
vitamin-K-dependent clotting factors. Common SNPs in the non-coding region of the VKORC1 
gene can increase or decrease the expression levels of the vitamin K reductase protein and 
consequently affect a patient’s sensitivity to warfarin.  This pharmacogenetic information has 
been incorporated into the FDA-approved drug label under the “Dosage and Administration” and 
“Clinical Pharmacology” sections (Figure 1.9).  Genotyping prior to use is not yet mandatory 





treatment would prevent 85 000 serious bleeding events and 17 000 strokes and reduce 
healthcare expenditure by over $1 billion annually [338].  
 
 
Figure 1.9 Extracts from the prescription information for warfarin sold under the brand name Coumadin. A) From 
Dosage and Administration section. B) From Clinical Pharmacology section.  
 
Although clinical pharmacogenetics guidelines are being established and used in clinical practice 
for a range of drugs, genetic testing prior to drug administration is not yet a routine procedure. In 





response since to date the effect of CYP450 polymorphism on drug metabolism has only been 
determined for a relatively small number of SNPs and potential drugs.  Thus CYP450 
pharmacogenetic information is far from complete and the full benefit of the existing information 
is yet to be realised.  
1.9.7 In silico approaches for predicting the effects of SNPs on protein function.  
 
There are a number of in silico tools which aim in general to predict the effect of single point 
mutations on protein stability, based on methods such as physical effective energy functions 
[339-341], empirical potential energy functions [342, 343], statistical potential energy functions 
[344-346] and machine learning [347-350]. Of these, physical potential energy functions are 
likely to be the most accurate but are generally computationally expensive and time consuming 
whilst machine learning methods and empirical potential energy functions use experimental data 
to fit their function and generally suffer from over fitting the function to the training data set. In 
addition, although a large number of mutations do result in loss of protein function due to effects 
on protein stability, a significant number also affect functional sites directly [351].   
 
A number of in silico tools are available that aim to rapidly distinguish between disease 
associated mutations and benign mutations based on the residues position relative to functional 
sites, protein stability calculations or a combination of both. These tools include SIFT [352, 
353], SNAP [354], FoldX [355], SDM [356-358], PolyPhen [359], I-mutant [360] amongst many 
others. However, whilst a few of these tools have been used to predict the effect of SNPs on 
CYP450 function [361], none of them are specifically tailored for CYP450 enzymes and 
consequently, if taken into account at all, functional site predictions are by no means 
comprehensive and the predicted effects of mutations on functional sites are only qualitative.  
Quantitatively predicting the effect of mutations on ligand and co-factor binding is still a huge 
challenge for computational biology as accurate calculations are very computationally intensive, 
limiting their use for large interactions surfaces or large numbers of mutations.  
1.9.8 In vitro methods for testing CYP450 drug metabolism 
 
Apart from the ethical issues surrounding animal testing, animal studies are also expensive and 





humans, animals have different CY450 isoforms with different expression levels and catalytic 
properties, limiting their applicability to human drug metabolism. As a consequence, accurate in 
vitro human drug metabolism models for testing drugs prior to clinical trials would add 
substantial value. Current in vitro methods for measuring CYP450 drug metabolism include liver 
slices, primary hepatocytes, transformed cell lines, microsomes and recombinant enzymes [362, 
363]. In vitro screening techniques to monitor CYP450 substrate turnover include radiometric, 
fluorogenic and chromatography/mass spectrometry based activity assays [364-366]. A number 
of mathematical models have been developed to extrapolate in vivo CYP450 activity from in 
vitro assays: this is simplest for more complex systems that more closely mimic the liver 
environment, such as liver slices and hepatocytes [367], but strategies for reconstructing the 
relative contribution of individual CYP450 isoform based on recombinant proteins assays have 
also been developed [368].  While these in vitro–in vivo extrapolation techniques are limited, 
they are likely to become more reliable as the quality of in vivo and pharmacokinetic data 
improves. Despite the challenges, in vitro assays are already very useful for predicting CYP450 
drug metabolism and clinical important drug-drug interactions [369] .   
Liver slices, primary hepatocytes and transformed cell lines 
 
Liver slices and primary hepatocytes most closely resemble the in vivo system and contain the 
full complement of CYP450s and other drug metabolising enzymes within their cellular 
environments. Access to high quality human liver samples is however limiting and viability is 
poor because samples deteriorate rapidly. In addition cells can be damaged during high precision 
tissue slicing or hepatocyte extraction whilst liver samples also vary due to inter-individual 
differences between donors e.g. age, sex, disease state and genetic variation. Thus, while liver 
slices may be useful for studying inter-individual variations, sample sizes are normally too small 
to be of statistical significance and poor reproducibility complicates routine testing. Hepatocytes 
are however particularly good models for predicting enzyme induction as well as liver toxicity 
[363].  
 
Primary hepatocytes can be cultured up to a few passages, but CYP450 expression tends to 
decline in an isoform specific manner [370]. Various culturing techniques have been explored to 
preserve hepatocyte activity during prolonged culturing, including: co-culturing hepatocytes with 





producing cells such as fibroblasts [372, 373]; the use of culturing matrices such as hydrogels 
that attempt to mimic the extra-cellular environment [374]; and the addition of hormones, 
specific nutrients, and inducers to the culture medium [362]. However, concerns remain about 
the effect of such methods on data interpretation [362].  
 
A number of transformed human liver cell lines exist, such as HepG2 and BC2 but, while they 
are more stable, they are less reliable than primary hepatocyte cultures, generally showing low or 
partial CYP450 expression with expression patterns that do not closely resemble those in the 
liver [362].  
 
While whole cell systems provide a more “in vivo-like” environment for the CYP450s, 
quantifying the contribution of individual CYP450 isoforms to drug metabolism is more difficult 
in samples containing multiple CYP450 isoforms. Isoform specific probes can give information 
on individual CYP450s activity but, due to overlapping specificities between isoforms, many 
probes have low specificity making accurate metabolic profiling challenging [375]. Determining 
the effect of polymorphic variation on drug metabolism is also difficult due to the confounding 
effects of other isoforms and other inter-individual differences; in addition, availability of liver 
samples expressing low frequency alleles is limiting.  
“Organs on a chip” technologies 
 
More recent advances in microfluidics and tissue engineering technologies have led to the 
development of highly miniaturized “organ on a chip” tissue models [376]. A number of these 
3D systems attempt to mimic the liver environment using co-cultured hepatocytes [377, 378]. 
The fluid channels in the microfluidic systems enable the tightly controlled flow of medium 
creating organ-like perfusion. In vitro microfluidic chips for monitoring drug metabolism have 
also been developed using cell free systems, subcellular fractions (microsomes), cell lines and 
intact tissue [379].  Despite promising progress in this field however, these systems are not yet 









Microsomes are vesicle like fractions of the endoplasmic reticulum formed during tissue 
homogenisation and can be prepared by differential centrifugation [380]. Human liver 
microsomes are the most common source of CYP450s for in vitro metabolism studies. The 
proportion of membrane bound proteins in microsomes is representative of the proportions found 
in the liver, however drug transport is not taken into account and many phase II drug 
metabolising enzymes are missing from these preparations [362]. While microsomes are useful 
for CYP450 activity assays, they are not suitable for induction studies as the required protein 
expression systems are no longer intact.   Microsomes are now commercially available together 
with prior characterisation of the CYP450 activity and variability between preparations is 
reduced by creating microsome pools which are representative of a particular group of people 
rather than just one individual. In addition, microsomes generally show higher activity than 
hepatocytes or liver slices as the CYP450 content is enriched and there is less competition with 
other enzymes.  
Recombinant enzymes  
 
While recombinant CYP450 expression systems do not accurately mimic the in vivo 
environment, they are the most useful tool for studying the activity of individual CYP450 
isoforms in isolation [363]. As opposed to trying to understand drug metabolism in a complex 
system like the liver, recombinant enzymes provide a way to deconvolute the system and 
determine the role of individual enzymes in the metabolism of a given drug.  What is more, this 
renewable enzyme source enables the production of high purity proteins in high quantity suitable 
for biophysical studies (e.g. X-ray crystallography and spectroscopic studies) and site-directed 
mutagenesis enables structure-function studies. This is particularly useful for determining the 
effect of non-synonymous mutations on protein stability and/or function and such information 
can be used both to rationalise in vivo data and to guide further clinical studies.   
 
Recombinant CYP450 have been expressed in a variety of different host cells including bacteria, 
yeast, insect and mammalian cells and whole cells (transgenic cell lines), microsomal 
preparations (referred to as supersomes or baculosomes when expression is baculovirus 





Despite these advances however, the pharmaceutical industry remains in need of cost-effective, 
high-throughput methods suitable for screening large numbers of drugs candidates against wild-
type CYP450 enzymes as well as against all clinically relevant polymorphic forms.  Typically 
high-throughput CYP450 screens are very expensive and not widely accessible, requiring large 
quantities of protein and banks of automated liquid chromatography/mass spectroscopy (LC/MS) 
machines for metabolite detection [321]. While there have been several attempts to create 
miniaturised high-throughput CYP450 assays that do not rely on large quantities of protein or 
LC/MS technology (e.g. [381, 382] ), miniaturising CYP450 assays is fraught with challenges 
and these approaches only work on a limited scale. As such, there is still much scope for the 
development of high-throughput assays for monitoring CYP450 activity and screening for P450-
mediated drug-drug interactions.  
1.10 Objectives  
 
The  effect  of  non-synonymous  single  nucleotide  polymorphisms  on  cytochrome  P450  drug  
metabolism  is currently  poorly  understood  due  to  the  large  number  of  polymorphisms  and  
the  diversity  of  potential substrates. The pharmaceutical industry is thus in need of new reliable 
in silico and in vitro approaches to predict the metabolism of drug candidates in individual 
patients at early stages of drug development.    
 
A reliable in silico approach for predicting CYP450 variants with altered function would serve as 
a useful tool for prioritising variants for in vitro study as well as for rationalising in vitro and 
clinical data.  Furthermore a reliable cost-effective high-throughput platform for monitoring 
CYP450 activity enabling the rapid screening of selected variants in parallel for altered drug 
metabolism, inhibition and drug-drug interactions would provide valuable data for preclinical 
drug development and for guiding pharmacogenetic studies carried out in clinical trials. These 
are therefore the broad aims and objectives addressed in this thesis.  
 
The subsequent chapters of this thesis thus describe: 
 
1) The relationship between structure and function in human CYP450 and the delineation of 





2) An in silico approach for predicting the effect of mutations on CYP450 stability and 
function and guiding the selection of variants for in vitro testing. 
3) The in vitro thermostability and kinetic parameters of a panel of CYP3A4 and CYP2C9 
variants. 
4) The utility of a high-throughput CYP450 protein microarray platform for rapidly 





 Substrate recognition sites Chapter 2
in mammalian CYP450s 






Xenobiotic metabolising CYP450s are often termed “promiscuous” as individual isoforms can 
metabolise compounds with very different shapes, sizes and chemical properties. This broad 
substrate specificity allows relatively few enzyme catalysts to handle a large range of foreign 
compounds. While there is some overlap between isoforms, the substrate specificities, even 
between CYP450s with over 95% sequence identity, are distinguishable. For example, both 
CYP2C4 and CYP2C5 catalyse the 21‐hydroxylation of progesterone, but the binding affinity of 
progesterone is 10-fold greater for CYP2C4 than for CYP2C5, despite a >95% sequence identity 
between these two enzymes [383]. This difference in binding affinity is caused by a single amino 
acid difference within a substrate binding region.  Amino acid differences within substrate 
binding regions can also result in differences in the regioselectivity of metabolism as seen for the 
metabolism of aflatoxin B1 by human CYP3A4 and CYP3A5, where 3α‐hydroxylation by 
CYP3A4 leads to detoxification of aflatoxin B1 but exo‐8,9‐oxidation by CYP3A5 leads to the 
formation of a genotoxin [384]. Determining the regions of the enzyme responsible for this vast 
catalytic diversity, yet distinct substrate specificity, displayed by CYP450s is crucial for 
predicting the effects of polymorphic variation on drug metabolism.   
 
In 1992, Gotoh et al described the first substrate recognition site map for mammalian 
cytochrome P450s by inferring substrate interacting residues from the only substrate bound 
CYP450 crystal structure available at the time [53]. Using the crystal structure of Pseudomonas 
putida P450 101A (P450cam) in complex with a camphor molecule, Gotoh manually identified 
all residues lying within 10 Å of the oxygen atom of the bound camphor molecule as putative 
substrate recognition sites (SRS). SRS regions were then inferred in CYP2 enzymes by group to 
group alignment of mammalian CYP2 sequences with P450cam and other bacterial CYP450 
sequences. From this work six putative SRS regions were identified (Figure 2.1). 
 
By interchanging or mutating residues within SRS regions or studying chimeras of closely 
related CYP450s, experimental studies have validated Gotoh’s SRS map, showing that residues 
within these SRS regions are indeed important for substrate binding and specificity in 
mammalian CYP450s [385-392]. There are however other experimental studies suggesting that 
residues lying outside of Gotoh’s SRS map are also important for substrate binding in 
mammalian CYP450s [385, 393, 394].  







Figure 2.1 Gotoh’s original substrate recognition site map 
Structure of bacterial cytochrome P450cam bound to a camphor molecule (red sticks), PDB code 2CPP.  The SRS 
regions delimited by Gotoh are coloured as follows: SRS1, cyan; SRS2, green, SRS3, yellow; SRS4, orange; SRS5, 
magenta; SRS6, blue. Residues that Gotoh found to be within 10Å of the camphor molecule are shown as red lines. 
The haem co-factor is shown in black.  
 
A large number of mammalian CYP450 structures in complex with substrates or inhibitors have 
been deposited in the RCSB Protein Data Base since Gotoh published the first CYP450 SRS map 
in 1991, providing direct evidence for specific protein-ligand contacts; most of these are of 
human CYP450s. There are also several structures of the same enzyme in complex with different 
ligands for a number of isoforms. For example, CYP3A4 complexes are now available for 
progesterone, metyraprone [58], erythromycin, ketoconazole [54], bromoergocryptine [227], 
ritonavir [224] and 8 different ritonavir analogues [57, 225, 226].     
 
Furthermore, compared to Gotoh in 1992, we now have access to bioinformatic tools that rapidly 
and accurately determine protein-ligand interactions in protein complexes (e.g. LIGPLOT [395] 
and Zamora’s molecular interaction fields [396]) as well as databases dedicated to storing and 
comparing these protein-ligand interactions (e.g. CREDO [397, 398] and PLI [399]).  
Furthermore, docking and molecular dynamic tools can today be used in combination with site of 




metabolism predictions [400, 401] to predict the binding modes of substrates for which there is 
presently no structural data available.  
 
Using a combination of new mammalian CYP450 structural data and in silico docking 
experiments this Chapter defines and describes an expanded and more complete mammalian 
CYP450 SRS map. This Chapter includes work done in collaboration with Prof Yap Chun Wei 
from the Department of Pharmacy at the University of Singapore that was published in Current 
Drug Metabolism in 2011 ([402], full manuscript appended at the end of Thesis). New insights 
into substrate recognition sites based on substrate/inhibitor mammalian CYP450 crystal 
structures published after the manuscript was completed are also described. My contribution to 
the experimental work described in this Chapter included identification of protein-ligand 
interactions in crystal structures of CYP450 complexes, delimitation of the “X-ray structures 
SRS map” and “periphery site map” as well as the analysis of new structures published after the 
manuscript was complete. The docking experiments were performed by Lim Yen Ching and Yap 
Chun Wei and analysis of the docking results and generation of the “Docking CYP450 SRS 
map” was done by Alexander Zawaira from the Blackburn Laboratory.   




2.2 Results       
 






Figure 2.2  Structural alignment showing the contact residues and SRS maps for the major human drug metabolising 
CYP450 isoforms.   Ligand contact residues in CYP450-ligand complexes available in 2011 delimited by LIGPLOT 
are highlighted in red. Contacts from new CYP450-ligand complexes published after 2011 are shown in yellow. 
Residues making contact with a substrate/inhibitor molecule bound at a periphery site are highlighted in magenta. 
Gotoh’s SRS map is boxed in green, the X-ray structures SRS map in red and the docking SRS map in blue. The 
new proposed SRS 4’a region is boxed in yellow and periphery site regions (PS1 and PS2) are boxed in magenta. 
The demarcated SRS regions are mapped from the sequence alignment to the structural alignment based on 
CYP3A4 structure (1TQN) - boundaries of SRS regions will vary slightly for some isoforms depending on whether 
a sequence or structural alignment is used.  
2.2.1 The X-ray structures CYP450 SRS map 
 
Mammalian CYP450 crystal structures in complex with substrate or inhibitor molecules provide 
direct evidence for substrate binding residues. The 43 inhibitor or substrate bound mammalian 
structures available in 2011 were therefore used to delimit the new SRS map based on X-ray 
structures as follows. The majority of substrate/inhibitor molecules in these structures are bound 
at the catalytic site with either a known or predicted site of metabolism or a lone pair of electrons 
within 5 Å of the haem iron. Residues making contact with a molecule bound to a catalytic site 
were determine by LIGPLOT [395] and mapped onto a sequence alignment of mammalian 
CYP450s (Appendix A, Figure A1). Assuming that residues at the equivalent positions in each 
isoforms may also be substrate contact residues, the positions of interacting residues were 
inferred onto the other aligned structures and boundaries of SRS regions were delimited 3 
residues on either side of identified contact residues. Figure 2.2 shows the contact residues 
identified within the major human CYP450 drug metabolising isoforms mapped onto a structural 
alignment and highlighted in red. The “X-ray structure SRS map” determined from the full 
mammalian CYP450 alignment is boxed in red and, for comparison, Gotoh’s original SRS map 




is boxed in green. The new map can be seen to incorporate Gotoh’s map as a subset, but it has 
further revealed, amongst other things, two new SRS regions near the N-terminal of the enzyme, 
SRS1’a and SRS1’b. All SRS regions have been extended in the new map, particularly SRS2 
now incorporating a large section of the F-G loop with only a few residues separating it from 
SRS3.  
 
Given that it is known that CYP450s metabolise a diverse range of substrates and that isoforms 
responsible for drug metabolism have broad substrate specificities, it seems obvious that the 
ligands bound within these crystal structures only represent a small percentage of possible 
CYP450 ligands. The principal component analysis (PCA) plot shown in Figure 2.3 was 
generated using PubChem fingerprints as chemical descriptors to compare the distribution of 
ligands from CYP450-ligand complexes with “total known” human CYP450 substrates in 
chemical space. While the ligands used to delimit the X-ray structures SRS map fall within all 
four quadrants of the PCA plot, is its clear that the coverage of the “total known” CYP450 
substrate chemical space is low.  
 
Figure 2.3 PCA plot showing the chemical diversity of CYP450 ligands used to delineate the X-ray structures SRS 
map.  The plot shows the distribution of known CYP450 substrates in chemical space using PubChem fingerprints. 
Green triangles represent “all known” CYP450 substrates and red triangles represent the ligands used to delineate 
the X-ray structures SRS map. This PCA analysis was carried out by Prof Wei’s group, University of Singapore.  




2.2.2 The Docking CYP450 SRS map 
 
In order to address the limited coverage of total known CYP450 substrate space in the PDB, a 
“docking CYP450 SRS map” was therefore determined by docking 868 known substrates into 10 
mammalian isoforms and identifying residues making contact with the docked substrates.  
Collaborators Lin Yen Chen and Yap Chun Wei carried out docking experiments at the 
University of Singapore using AutoDock Vina software. The Singapore group used a -
1kcal/mole binding affinity cut-off and a 5Å distance cut-off between the site of metabolism and 
the haem iron for docked complexes in an attempt to include as many substrates-enzyme 
complexes as possible without including too many incorrect poses. Table 2.1 shows the number 
of substrates used to generate the docking SRS map for each isoform.  The majority of known 
substrates were successfully docked into the corresponding isoform within the cut-off criteria 
giving a very high coverage of the “known” CYP450 substrate chemical space for these 
isoforms.  
 
Table 2.1 The number of known substrates docked into each CYP450 isoforms to generate SRS map 
CYP450 No. of known substrates 
No. of substrates used to 
generate docking SRS map 
% of known substrates 
used to generate SRS map 
1A2 65 61 94 
46A1 11 11 100 
2A6 33 26 79 
2B4 12 12 100 
2C5 5 5 100 
2C8 28 27 96 
2C9 156 152 97 
2D6 212 186 88 
2R1 2 2 100 
3A4 401 386 96 
 
Using the curated docking poses, contact residues, determined by LIGPLOT, were, thereafter, 
mapped onto a sequence alignment of the CYP450 isoforms used for the docking experiments 
(Appendix A, Figure A2; this map was generated by a post-doctoral fellow from the Blackburn 
group, Dr Alexander Zawaira). The docking SRS map delimited from these contacts is boxed in 
blue in Figure 2.2. Interestingly, this map closely resembles the X-ray SRS map, the most 




notable difference being the merging of SRS2 and SRS3, which suggests that the F-G loop is 
also important for substrate binding in mammalian CYP450s.    
2.2.3 Insights from new crystal structures of mammalian CYP450 complexes 
 
Since the publication of the x-ray and docking SRS maps in 2011, the number of mammalian 
CYP450 crystal structure complexes available in the PDB has more than doubled enabling 
verification of aspects of the docking SRS map. Crystal structure complexes are now also 
available for the following human isoforms: CYP2C19, CYP2D6, CYP1A1, CYP11B2, 
CYP7A1, CYP17A1 and CYP1B1. New ligand contact residues identified for the human 
CYP450s in the structural alignment in Figure 2.2 are highlighted in yellow. Notable, all new 
contacts for these isoforms, except for one, fall within the X-ray structures SRS map. In 
particular, new contact residues within the newly delimited SRS1’a and SRS1’b confirm the role 
of these new regions in substrate binding whilst CYP3A4 Tyr 53 - which falls on the boundary 
of SRS1’a, outside of the X-ray SRS structures map but within the docking SRS map - provides 
physical evidence for the extension of SRS1a’ region.   
 
Other new mammalian structures were also examined for new binding modes that might lead to 
the identification of new or extended X-ray SRS regions or confirm the extended regions in the 
docking SRS map. For example, the crystal structure of human CYP7A1 bound to cholest-4-en-
3-one (Figure 2.4) and 7-ketocholesterol (PDB codes 3SN5 and 3V8D respectively) revealed a 
new substrate binding mode with a contact residue falling outside both the X-ray SRS map and 
the docking SRS map. Contact residues Phe 129 and Ile 125 in Figure 2.4 lie within the newly 
delimited SRS1’c region, SRS1’c was defined based on contact residues identified in CYP2B4 
(Appendix A, Figure A1), thus demonstrating that SRS1’c is used by at least one other isoform.  
Arg 260 however falls between SRS3 and SRS4 (Figure 2.4), in a region that has not previously 
been identified as a SRS region in crystal structures or docking studies; this new putative SRS 
region, labelled SRS4’a, has been mapped onto the alignment in Figure 2.2.  
 
Notably though, all other new mammalian structures showed similar binding modes to those 
previously observed with contact residues falling within the delimited SRS regions, thus serving 
broadly to substantiate the x-ray and docking SRS maps.  
 






Figure 2.4 Structure of CYP7A1 in complex with cholest-4-en-3-one showing a new substrate binding site. Residues 
in red make contact with cholest-4-en-one (yellow) and fall within Gotoh’s SRS map. Residues labelled and 
coloured in blue make contact with the substrate but fall outside Gotoh’s SRS map. F129 and I125 fall within 
SRS1c’ in the X-ray SRS map whereas R260 lies between SRS3 and SRS4.  
2.2.4 Mammalian CYP450 periphery sites 
 
There is a large amount of evidence, including crystallographic data, showing that multiple 
substrate/inhibitor molecules can bind within the active site. Binding of addition molecules 
within the active site can affect the enzyme conformation and substrate binding affinity and may 
result in atypical kinetic profiles commonly observed for drug metabolising CYP450 isoforms 
[61]. In addition, substrate binding has been described as a multistep process and residues on the 
periphery of the catalytic binding site are thought to form an initial binding site important for 
substrate specificity in some isoforms [88, 89].  Consequently, residues making up periphery 
sites within the active site are likely to play a role in substrate recognition and mutations at these 
positions may lead to altered drug metabolism.   
 
Binding of substrates to periphery sites were not considered in the docking studies described 
above as there is no way to determine categorically which docking solutions are correct. By 
contrast, crystal structures with multiple ligands bound to the active site provide useful insight 
into the residues important for the binding of multiple molecules. In this analysis, only ligands 
bound within the active site or in cavities clearly linked to the active site in crystal structures 
were considered; molecules bound at separate sites on the surface or at dimer interfaces were not 




considered. For example, Figure 2.5 shows two retinoic acid molecules bound to the active site 
of CYP2C8: one bound to the catalytic site and one bound to a periphery site.  
 
 
Figure 2.5 Cross section through the cavities within the structure of CYP2C8, PDB code 2NNH, showing two 
molecules of retinoic acid bound to the active site. The molecule bound at the catalytic site is shown in yellow and 
the molecule bound at the periphery site, shaded in purple, is shown in orange. The haem group is shown in red.  
 
Residues making contact with ligands bound at a periphery site, and which were not previously 
identified as ligand contacts, are highlighted in purple in Figure 2.2. Interestingly, the majority of 
the periphery site contact residues identified by this approach fall within the delimited SRS 
regions. However a new periphery site region lying outside the main SRS regions was identified 
in the crystal structure of human CYP2B6 in complex with two amlodipine molecules, with one 
bound to the haem iron and one extending from the active site into the substrate access tunnel 
(Figure 2.6 A); here, Glu 387 and Phe 389 within strand 2 of β-sheet 3, between SRS5 and 
SRS6, interact with the second amlodipine molecule via hydrophobic interactions. This region 
has been designated periphery site 2 (PS2) and is boxed in purple in the alignment in Figure 2.2. 
 
Periphery site contacts at structurally equivalent positions to CYP2B6 Glu 387 were also found 
to be present in CYP2B4 in complex with two amlodipine molecules and in human CYP8A1 
with minoxidil bound at the catalytic site and β-octylglucoside bound at a periphery site (Figure 
2.6 B and C).   
 





Figure 2.6 A) Structure of CYP2B6 bound to two amlodipine molecules, PDB code 3UA5. B) Structure of CYP2B4 
bound to two amlodipine molecules, PDB code 3TMZ. C) Structure of CYP8A1 bound to the inhibitor minoxidil, 
PDB code 3B6H. Residues making contact with the molecule in yellow bound at the catalytic site are shown in red 
and residues in contact with the molecule in orange bound at the periphery site are shown in magenta. The amino 
acids labelled and coloured in blue form part of the secondary periphery site but fall outside of previously delimited 
SRS regions. D) A portion from a structural alignment of CYP2B6, CYP2B4 and CYP8A1 showing the position of 
these periphery site contact residues falling within strand 2 of β-sheet 3 in between SRS 5 and 6.  
 
The structure of CYP2B4 in complex with three molecules of the antifungal drug bifonazole - 
one at the catalytic site and the other two at periphery sites on opposite ends of the active site 
cavity - also revealed two additional contact residues at positions lying outside the SRS map 
(Figure 2.7): Gln 45 lies on the boarder SRS1’a in the X-ray SRS map while Phe 184 lies at the 
end of α-helix between SRS1’c and SRS2; this region has been designated periphery site1 (PS1) 
in the alignment in Figure 2.2.  A surface rendering of the CYP2B4 structure shows it to be in an 




unusually wide-open conformation; despite this and the binding of two drug molecules at 
periphery sites over 10 Å apart, however, all other ligand contact residues fall within the main 
SRS map.  
 
 
Figure 2.7 Structure of rabbit CYP2B4 in complex with three bifonazole molecules (antifungal drug), PDB code 
2BDM. A)  The bifonazole molecule bound at the catalytic site is shown in yellow and bifonazole molecules bound 
at periphery sites are shown in orange. Periphery site contact residues lying within the X-ray structures SRS map are 
shown in magenta while contact residues Q45 and F184, lying outside the SRS regions, are labelled and coloured in 
blue. B) Surface view of the CYP2B4 complex showing the unusual open conformation. 
 
 




2.2.5 Structural analysis of the newly-delimited SRS regions based on the X-ray 
structures and docking SRS maps 
 
A structural analysis of each of the new SRS regions was carried out to determine whether they 
are truly new separate SRS regions or whether they are merely extensions of existing SRS 
regions.  
SRS1’a, SRS1’b and SRS1’c 
 
Figure 2.8 shows the relationship between SRS1’a, SRS1’b, SRS1 and SRS1’c. SRS1’a and 
SRS1’b are separated by residues that are removed from the active site cavity and shielded from 
the active site by other parts of the protein suggesting that SRS1’a and SRS1’b are distinct SRS 
regions.  
 
In contrast, the region between SRS1 and SRS1’c is not shielded from the active site. A surface 
rendering of the active site cavity shows that Trp126, which lies 3 position from SRS1 and 3 
positions from SRS1’c, forms part of the active site cavity and could therefore also interact with 
a bound substrate.  
 
To test the possibility that this region could make contact with the substrates bound to the active 
site, additional docking studies were performed by the Singapore group using CYP2B4 structure 
2BDM, where the CYP450 shows an unusual open conformation. Nine of the 12 compounds 
docked into the active site of the CYP2B4 structure made contact with residues in the region 
between SRS1 and SRS1’c. Following this it seems clear that SRS1’c should be merged with 
SRS1 into one continuous SRS region.  
 





Figure 2.8 The relationship between SRS1’a, SRS1’b, SRS1 and SRS1’c. 
A) The structure of CYP3A4, PDB code 2V0M  is shown in grey with SRS1’a residues in green, SRS1’b residues in 
yellow, SRS1 residues in orange and SRS1’c residues in red. The residues that lie between SRS1’a and SRS1’b and 
between SRS1 and SRS1’c are shown in black. B) A surface rendering of the active site cavity showing that residue 
Trp126 between SRS1 (orange) and SRS1’c (red) forms part of the wall of the active site cavity indicating that 
SRS1’c is likely to be an extension of SRS1 rather than a new separate SRS region.  
 
Merging of SRS2 and SRS3 
 
The F, G, F’ and G’ helices and interlinking loop regions make up SRS2 and SRS3. According 
to the structural alignment in Figure 2.2 there are four to five residues separating SRS1 and 
SRS2 in the X-ray structures SRS map. The merging of these two regions in the docking map 
was due to ligands contacts Tyr 225 and His 230 identified in CYP2C9 docking complexes 
(Figure 2.9). Tyr 225 made contact with vardenafil and His 230 made contact with glibenclamide 
and vardenafil when these ligands were docked into CYP2C9 structure 1R9O. In CYP2C9 




structures 1OG2 and 1OG5, the region between SRS2 and SRS3 is a helical structure bent away 
from the active site; in contrast this region is a more disordered loop region position closer to the 
active site in structure 1R9O. A comparison of CYP450 crystal structures shows that the F-G 
loop is very flexible and can take on different conformations; it is therefore likely that the region 
between SRS2 and SRS3 does indeed play a role in substrate binding as suggested by the 





Figure 2.9 Relationship between SRS2, SRS3 and the active site cavity in three different CYP2C9 crystal structures. 
The SRS2 and SRS3 regions of PDB structures 1OG2, 1OG5 and 1R9O, shown in yellow, green and blue 
respectively, were aligned in PyMol. The region separating SRS2 and SRS3 and His 230 is shown in red. Substrate 
contact residues Tyr 225 and His 230 identified in the docking studies and responsible for the merging of SRS2 & 3 
are shown as sticks. A surface rendering of the cavities in the enzyme shows that residues Tyr 225 and His 230 form 
part the active site cavity. A) A side view of the F-G loop. B) A top view of the F-G loop.  
SRS4’a 
 
SRS4’a was delimited as a result of a ligand contact within α-helix H that occurred in crystal 
structures of the human Cholesterol 7 alpha-hydroxylase CYP7A1, however there were no ligand 
contacts in this region in any of the other mammalian crystal structures or docking complexes. 
Interestingly, CYP7A1 ligand complexes adopt different conformations to the structures of other 
drug metabolising CYP450 isoforms observed to date, with the I and H helices bent upwards to 
accommodate the ligand (Figure 2.10). As crystal structures represent a single snap shot in time, 
it is difficult to predict whether other isoforms are able to adopt a similar conformation to bind 
ligands in a similar orientation; it is therefore difficult to predict whether SRS4’a is also used for 
substrate binding in other isoforms or whether it is unique to CYP7A1.    





Figure 2.10 Alignment of SRS4’a in CYP7A1 with CYP2C9, CYP2D6 and CYP3A4 structures. The H and I helices 
of each structures were aligned in PyMOL based on the position of their haem groups. CYP7A1 (PDB code 3SN5, 
grey) is shown in complex with ligand cholest-4-en-3-one (yellow). CYP7A1 ligand contact Arg 260, responsible 
for the identification of SRS4’a, is labelled and shown as a stick model. The SRS4’a region is shown in red in 
CYP7A1 and orange in CYP2C9 (PDB code 1OG5, blue), CYP2D6 (PDB code 2FDQ, cyan) and CYP3A4 (PDB 
code 1TQN, light pink).   
Final Combined SRS map  
 
Based on the structural analysis described above, the combined SRS map is made up of seven 
distinct regions: SRS1’a, SRS1’b, SRS1, SRS(2,3), SRS4, SRS5 and SRS6 (Figure 2.11).  
SRS4’a is still considered a putative SRS region since it has only been identified in a single 
isoform that adopts an unusual conformation.  
The combined SRS map covers ~33% of the CYP450 protein sequence.  It is important to note 
however that many of the residues within these regions point away from the active site and are 
unlikely to make direct contact with substrates. Of the residues falling within SRS regions in 
CYP2C9, 55 % have side chains pointing away from the active site in the CYP2C9 crystal 
structure 1OG2. (Figure 2.11). These residues have not however been excluded from the SRS 
regions due to the dynamic nature of protein structures as well as differences in side chain 
positions that may exist between isoforms.  





Figure 2.11 The final combined SRS map  
Regions of the CYP2C9 sequence that fall within the final SRS regions 1’a to 6 are shown in panels [A] to [F]. SRS 
zones are boxed and labelled in red and secondary structures are shown below the sequence: black rectangular boxes 
represent α-helices and black arrows represent β-sheets. Based on visual inspection of the CYP2C9 1OG2 structure, 
SRS residues with side chains facing towards the active site are shown in bold face while those pointing away are 
shown in plain font. Numbering of sequence positions in according to the CYP2C9 UniProt sequence  P11712. 






The work described in this Chapter has resulted in the generation of a new extended mammalian 
CYP450 substrate recognition map based on protein-ligand contacts delimited in mammalian 
CYP450 crystal structures and CYP450 docking studies. While the new map includes all regions 
of the SRS map described by Gotoh in 1991, it is based on a much larger experimental data set 
and exhibits a number of new features, covering a substantially larger region of the CYP450 
sequence. As such this new map represents a significant advance over the largely speculative 
predictions of Gotoh that were extrapolated from the very limited experimental data set available 
in 1991.  
 
The new map, based on a combination of the maps derived from crystal structures and docking 
complexes, cover 33% of the CYP450 sequence, compared to Gotoh’s map covering only 16%. 
The following new and extended features account for this two-fold increase in sequence 
coverage: (1) Two new regions, SRS1’a and SRS1’b, appear before SRS1 in the new map. (2) 
SRS1 is extended by ~20 residues. (3) Extension of SRS2 and SRS3 in the new map results in 
the co-joining of these two regions to form the newly designated SRS(2,3), which is ~ 3 times 
the size of Gotoh’s original SRS2 and SRS3.  (4) SRS4 has an N-terminal extension of ~7 
residues. (5) SRS5 is extended by ~3 residues. (5) SRS6 is extended by ~ 9 residues. A new 
putative SRS region between SRS(2,3) and SRS4 has also been identified and designated 
SRS4’a. This later region resulted from a single ligand contact observed in CYP7A1 crystal 
structures and consists of 7 residues which would effectively add an additional 1.5% sequence 
coverage to the SRS map.  
 
Despite the large sequence coverage of the new map, a number of key residue positions were 
found to interact with the majority of bound substrates: this is particularly apparent in the 
docking SRS map where many of the residues contacting more than 80% of docked substrates 
for different isoforms occur at the same position in the alignment (Appendix A, Figure A2).  
Mutations at these key residue positions are therefore likely to affect the binding of a broad 
range of CYP450 substrates for a given isoform.  
 




Two periphery site ligand contact regions, responsible for the binding of multiple ligands within 
the active site were also identified in crystal structure complexes. PS1 lies just N-terminal of 
SRS2 and PS2 lies C-terminal of SRS5. All other periphery site contacts fell on the boundaries 
of, or within, SRS regions.  
 
While we can be confident of the ligand poses observed in crystal structures, docking algorithms 
are not very good at accurately predicting binding energies; furthermore, docking molecules into 
large flexible CYP450 sites is particularly challenging. This raises concerns that incorrect 
docking modes may lead to the incorrect assignment of ligand contact residues and an 
overestimation of the sequence coverage of the SRS map. The X-ray structures SRS map and the 
docking SRS map were however found to be very similar, despite the large increase in the range 
and diverse of chemical structures included in the docking complexes; importantly, the new 
SRS1’a, SRS1’b  and SRS1’c (SRS1’c was combined with SRS1 following a structural analysis 
of the two regions and further docking studies) appeared in both maps, effectively cross-
validating the data generated by the two approaches. The main additional insight gained from the 
docking study was the co-joining of SRS2 and SRS3, still separated by ~5 residues in the X-ray 
structures map. This suggests that a relatively small number of ligands sample most regions of 
the SRS map.  
 
Looked at from a different perspective, the lack of new contact residues identified in the docking 
studies may be a result of docking ligands into static structures, thereby limiting protein 
conformations to those observed in crystal structures. Since the new combined SRS map lines 
the majority of the active site cavity observed in crystal structures, the CYP450 would need to 
adopt a different conformation for new contacts to be identified. As an example of this, the 
CYP7A1 structure in complex with cholest-4-en-3-one (Figure 2.4) reveals a new CYP450 
conformation and binding mode that led to the identification of a new SRS region.  Despite the 
wealth of CYP450 structure data available, it is still therefore conceivable that we have not 
observed all possible CYP450s ligand-binding conformations, particularly with regard to ligands 









Table 2.2 Examples of “non-Gotoh-SRS” residues affecting substrate binding in mammalian CYP450 
enzymes. 
CYP450 Residues Position relative to SRS map Activity affected Reference 









N-term of SRS1 
 








     







     
CYP2B1 Ser407 Asn417 
Ala419 





     
CYP2B5 His120 
Pro221 
C-term of SRS1 








N-term of SRS1 





     
CYP2C19 Pro220 
Thr221 














The information in this table was collated by Dr Zawaira 
 
Despite these caveats, the new SRS map and periphery site maps offer a more comprehensive 
overview of substrate binding than Gotoh’s original map and, moreover, they are much more 
extensively rooted on experimental data sets, so they should aid in predicting the effects of 
mutations on substrate binding. Importantly, the new map is able to explain the substrate specific 
effects observed for a significant number of “non-Gotoh-SRS” residues in the literature (Table 
2.2), including:   
 




1) A study by Ibeanu et al showed that CYP2C19 residues Pro 220 and Thr 221were important 
determinants of omeprazole hydroxylase activity [385]. These residues lie within the F-G loop 
and SRS(2,3), in the region co-joining Gotoh’s SRS2 and SRS3. SRS(2,3) acts as a “lid” over 
the active site cavity and is comprised of the F and G helix connected by the F-G loop.  The F-G 
loop is much longer in mammalian CYP450s than in bacterial CYP450s (more than 2 times the 
length) and is highly flexible, adopting very different conformations in different structures of the 
same isoform. In some structures this region is comprised of two short F’ and G’ helixes (e.g. 
CYP2C9 structure 1OG2) while in other structures it is a disordered loop region (e.g. CYP2C9 
1R9O). The F-G loop regions forms part of many of the major substrate access channels (see 
Chapter 3) and when the enzyme is in a closed conformation comes in close proximity with the 
active site, thus playing an important role in substrate recognition in mammalian CYP450s. 
 
 2) He et al showed that CYP2B5 residue Pro 221, another non-Gotoh-SRS residue position in 
the F-G loop and SRS(2,3), plays a role in progesterone hydroxylase activity [393].   
 
3) Hu et al also identified CYP2B5 “non-Gotoh-SRS” residue His 120 as an important 
determinant of progesterone hydroxylase activity; this residue falls within the extended SRS1 
region in the new map. 
 
4) Yun et al identified rabbit CYP1A2 residues 67-78 (L(S)QQYGDVLQIR) and rat CYP1A2 
residues 175-184 (FQELMAARVGR) as substrate recognition regions using mechanism-based 
inactivators. Rabbit CYP1A2 residues 76-78 (QIR) fall within the newly designated SRS1’b, 
which is consistent with these experimental results. Rat CYP1A2 residues 175 to 184 lie between 
SRS1 and SRS(2,3); however, while there is no crystal structure for rat CYP1A2, the 
homologous residues in a human CYP1A2 structure occur at the surface of the enzyme, far away 
from the active site (Figure 2.12). It appears that these residues were probably mis-identified, 
perhaps as a result of the reactive product diffusing away from the active site before reacting and 
thus binding randomly to a good nucleophile rather than to residues in close proximity to its 
binding site.   
 
5) Separate studies identified canine CYP3A12 residue Thr 187 and rat CYP2C11 residues Phe 
187 and Val 4 as important residues for steroid hydroxylation [386, 394]. CYP3A12 Thr 187 and 
CYP2C11 Phe 187 are not homologous residues, aligning with CYP3A4 residues Thr187 and 




Phe189 respectively, however they both lie upstream of SRS(2,3) in the newly delimited 
periphery site 1 (PS1) region.  This supports the proposition that these periphery site regions are 
important for catalytic activity and substrate recognition. The closely related human CYP3A4 
and CYP2C9 enzymes both display atypical kinetics for some substrates and are able to bind 
multiple substrates within the active site [61]. Following this, it is plausible that CYP3A12 
residue Thr 187 and CYP2C11 residue Phe 187 residues affect the binding of a second steroid 
molecule within the active site.  CYP2C11 Val 4 falls within the N-terminal hydrophobic 
membrane-binding domain and does not form part of the catalytic domain so mutations at this 
position must influence the catalytic activity indirectly through another mechanism.  
 
 
Figure 2.12 Structure of human CYP1A2 showing the position of residues 176-185 (LQELMAGPGH) in red. These 
residues are homologous to rat CYP1A2 residues 175-184 (FQELMAARVGR) which were shown to be important 
for substrate recognition, however they are far removed from the active site.  
 
“Non-Gotoh-SRS” CYP2B1 residues Leu 58, Ser 407, Asn 417 and Ala 419 identified as 
residues important for catalytic activity [404, 405] fall outside the new SRS map. Leu 58 falls 
four residues downstream of SRS1’a in the multiple sequence alignment but there is no crystal 
structure of CYP2B1 available yet so it is not possible to tell if this residue would fall within the 
same structural environment as SRS1’a in a structural alignment.  Von Weymer et al showed 
that the substitution of CYP2B1 residues Ser 407, Asn 417 and Ala 419 to equivalent residues in 
CYP2B2 prevented inactivation by two mechanism-based inhibitors. These residues occur 
between SRS5 and SRS6; Ser 407 lies just before the conserved meander region important for 




enzyme stability and Asn 417 and Ala 419 are part of the haem binding region. It is therefore 
possible that the experimental observations are a result of secondary effects on catalysis such 
altered enzyme stability and conformation or changes to the haem environment.  
 
Overall it is encouraging that the new SRS and periphery site maps are able to explain seven of 
the twelve examples of “non-Gotoh-SRS” residues or sequences affecting substrate recognition 
found in the literature, exemplifying the predictive power of the new maps.   
 







Ligand bound CYP450 structures were retrieved from the RCSB Protein Data Bank (PDB) [31]. 
Structures deposited in the PDB before 2011 were as follows: CYP1A2 (Homo sapiens): 
2HI4.CYP2A6 (Homo sapiens): 3EBS, 1Z11, 2FDU, 2FDV, 2FDW and 2FDY. CYP2A13 
(Homo sapiens): 2P85. CYP2B4 (Oryctolagus cuniculus): 2Q6N, 2BDM, 1SUO, 3KW4 and 
3ME6. CYP2B6 (Homo sapiens): 3IBD. CYP2C5 (Oryctolagus cuniculus): 1N6B and 1NR6. 
CYP2C8 (Homo sapiens): 2NNJ, 2NNI, 2NNH and 2VN0. CYP2C9 (Homo sapiens): 1OG5 
and 1R9O. CYP2E1 (Homo sapiens): 3GPH, 3KOH, 3LC4, 3E4E and 3E6I. CYP2R1 (Homo 
sapiens): 3C6G, 3DL9 and 3CZH. CYP3A4 (Homo sapiens): 1W0F, 1W0G, 2J0D, 2V0M and 
3NXU. CYP46A1 (Homo sapiens): 2Q9F, 3MDM, 3MDR, 3MDT and 3MDV. CYP19A1 
(Homo sapiens): 3EQM. CYP8A1 (Homo sapiens): 3B6H. CYP11A1 (Homo sapiens): 3NA0. 
 
Structures deposited in the PDB between Jan 2011 and April 2014 (“New structures”) were as 
follows: CYP1A1 (Homo sapiens): 4I8V. CYP1B1 (Homo sapiens): 3PM0. CYP2A6 (Homo 
sapiens): 3T3R, 4EJJ. CYP2A13 (Homo sapiens): 4EJG, 4EJH, 4EJI, 3T3S. CYP2B4 
(Oryctolagus cuniculus): 4JLT, 4H1N, 3UAS, 3TMZ, 3TK3, 3R1A, 3R1B. CYP2B6 (Homo 
sapiens): 3UA5, 4I91, 3Q0A, 3QU8. CYP2C19 (Homo sapiens): 4GQS. CYP2D6 (Homo 
sapiens): 3QM4, 3TDA, 3TBG. CYP2E1 (Homo sapiens): 3T3Z. CYP3A4 (Homo sapiens): 
4K9T, 4K9U, 4K9V, 4K9X, 4K9W, 3TJS, 4I4G, 4I4H, 3UA1. CYP7A1 (Homo sapiens): 
3V8D, 3SN5. CYP11A1 (Homo sapiens): 3N9Y. CYP11A1 (Bos taurus): 3MZS. CYP11B2 
(Homo sapiens): 4DVQ, 4FDH, 3N9Z, 3NA1. CYP17A1 (Homo sapiens): 3RUK, 3SWZ. 
CYP19A1 (Homo sapiens): 4KQ8, 4GL5, 4GL7, 3S79, 3S7S.  CYP46A1 (Homo sapiens): 
4J14, 4FIA, 4ENH.  
 
All CYP450 structural images in this Chapter and throughout this Thesis were generated using 
PyMOL [406]  
 
 




2.4.2 Identifying Protein-ligand interactions in crystal structures of CYP450 complexes 
 
Both LIGPLOT [395] and Zamora’s identifies Zamora’s molecular interaction fields (MIFs) 
[396] were tested as methods to identify residues interacting with ligands in crystal structures. 
LIGPLOT identifies hydrophobic interactions and hydrogen bonding between amino acids and 
the specified ligand while Zamora’s method calculates the interaction energies between the 
amino acids and the ligand. Identical residues were identified using LIGPLOT (in default mode) 
and Zamora’s MIFs (interacting residues with MIF-calculated interaction energies ≤ 1 kcal/mol). 
Following this, for simplicity only LIGPLOT was used (in default mode) to identify residues 
interacting with bound ligands in all CYP450 complexes deposited in the PDB before 2011 and 
CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 complexes deposited 
between Jan 2011 and April 2014.  All other new mammalian structures were aligned in PyMOL 
and examined for new/unusual ligand binding poses, making use of regions that fall outside of 
the previously defined X-ray structures SRS map. Contact residues for structures showing 
unusual binding poses were subsequently identified using LIGPLOT.   
 
Substrate/inhibitor molecules were considered to be bound to the catalytic site only if there was a 
known or predicted site of metabolism (determined by Dr Zawaira using the program MetaSite 
[401]) or, in the case of an inhibitor, a lone pare of electrons within 5 Å of the haem iron. Using 
these criteria, substrate/inhibitor molecules bound within the active site but not at the catalytic 
site were identified as molecules bound to a periphery site and interactions with these ligands 
were delimited as periphery site contact residues rather than catalytic site contact residues. 
CYP450 structures in complex with the following ligands fell into the “periphery site category”:  
(CYP2B4, 2BDM, TM1 502 and TM1 503); (CYP2B6, 3UA5, OX6 502); (CYP2C8, 2NNH, 
REA 1502); (CYP2D6, 3TBG, RTZ 1 and 2); (CYP3A4, 2V0M, KLN 1501); (CYP3A4, 3K9T, 
1RD 602); (CYP3A4, 4K9U, 5AW 503); (CYP8A1, 3B6H, BOG 701). Ligands bound to the 
surface of the CYP450 substrates or sites completely separate from the main active site cavity 
were not consider as periphery sites. Surface renderings of the cavities within the structure were 
visualised in PyMOL to determine whether sites fell within the active site cavity. 
 
 




2.4.3 PCA of the chemical diversity of CYP450 substrates using PubChem fingerprints 
 
The principal component analysis of CYP450 substrates chemical descriptors was carried out by 
collaborators Lim Yen Ching and Yap Chun Wei as follows.  A list of known substrates for 
CYP1A2, CYP2A6, CYP2B4, CYP2C5, CYP2C8, CYP2C9, CYP2D6, CYP2R1, CYP3A4 and 
CYP46A1 was compiled from primary literature, Micromedex, Protein Data Bank and other 
online databases and resources [31, 407-417]. Chemical structures for these substrates were 
obtained from PubChem database and were processed using Pipeline Pilot Student Edition v6.1.5 
Standardize Molecule, Strip Salts, and “Add Hydrogens” modules [418]. PubChem fingerprints 
[419] for each substrate were computed using PaDELDescriptor v2.4 [420], and a Principal 
component analysis (PCA) was performed using SIMCA-P+ v12.0.1 [421] to show the 
distribution of substrates in X-ray CYP450 complexes in the chemical space of “all known 
substrates”.  
2.4.4 Sequence and structural alignments 
 
Sequences with the following accession numbers were retrieved from the UniProt Data Base and 
aligned using ClustalW (default parameters) [422]: CYP1A2, P05177 (Homo sapiens); CYP2A6, 
P11509 (Homo sapiens); CYP2A13, Q16696 (Homo sapiens); CYP2B4, P00178 (Oryctolagus 
cuniculus); CYP2B6, P20813 (Homo sapiens); CYP2C5, P00179 (Oryctolagus cuniculus); 
CYP2C8, P10632 (Homo sapiens); CYP2C9, P11712 (Homo sapiens); CYP2E1, P05181 (Homo 
sapiens); CYP2R1, Q6VVX0 (Homo sapiens); CYP3A4, P08684 (Homo sapiens); CYP46A1, 
Q9Y6A2 (Homo sapiens); CYP19A1, P11511 (Homo sapiens); CYP8A1, Q16647 (Homo 
sapiens) and CYP11A1, P05108 (Homo sapiens). 
 
A multiple CYP450 structural alignment was generated including one representative structure for 
each isoform using the program Baton (D.Burke, unpublished data and [423]). The PDB codes 
for representative structures were as follows CYP1A2, 2HI4; CYP2A6, 2FDV; CYP2B6, 3IBD; 
CYP2C8, 1PQ2; CYP2C9, 1R9O; CYP2C19, 4GQS; CYP2E1, 3E4E; CYP2D6, 2F9Q; 
CYP3A4, 1TQN. 
 




2.4.5 Delimiting the X-ray structures SRS map 
 
The ligand contact residues identified in X-ray crystal structures of mammalian CYP450s 
deposited in the PDB before 2011 were annotated on the multiple sequence alignment of 
mammalian CYP450 to generate an SRS map. All residues at equivalent positions (i.e. 
evolutionarily equivalent residues) in other isoforms in the sequence alignment were assumed to 
be contact residues. SRS regions were delimited as blocks of contact residues within three amino 
acid positions of each other. SRS boundaries were delimited three residues on either side of the 
outer most contacts in each block. The use of three amino acids is arbitrary but is consistent with 
the way Gotoh defined the boundaries of the first CYP450 SRS map [53].  
 
Following this, the structural alignment of the major human drug metabolising isoforms was also 
annotated with contact residues and the X-ray SRS map based on the boundaries of the SRS map 
delimited in the sequence alignment for CYP3A4.  Boundaries for other isoforms may differ 
slightly between the sequence and structural alignments but as the SRS regions include 3 
residues on either side of the outer most contact residues, all contact residues still fall within the 
map.  The structural alignment was also annotated with new ligand contacts identified in new 
crystal structures, new SRS regions and periphery site contacts.  
2.4.6 Delimiting the Docking SRS CYP450 map based on docking complexes 
 
Docking studies were carried out by collaborators Lim Yen Ching and Yap Chun Wei as 
follows. CYP450 structures CYP1A2 (2HI4), CYP2A6 (1Z10), CYP2B4 (2Q6N & 2BDM), 
CYP2C5 (1NR6), CYP2C8 (2VN0), CYP2C9 (1R9O), CYP2D6 (2F9Q), CYP2R1 (3CZH), 
CYP3A4 (2V0M) and CYP46A1 (2Q9F) were retrieved from the RCSB Protein Data Base and 
prepared for docking using AutoDock Vina [424]. Structure preparation included (1) the removal 
of multiple protein chains, water molecules, buffer molecules and ligands from the pdb file, (2) 
the addition of hydrogen atoms and (3) conversion to pdbqt format using AutoDock tools [425].   
 
The test whether the docking system, Auto Dock Vina, was suitable for docking substrates into 
the active sites of the CYP450s in question in default mode, substrates present in X-ray CYP450 
structures were re-docked into the protein structure. The position of the ligand in the docking 
complex was compared to the ligand position in the crystal structure. RMSD values, representing 




the difference between docking complexes and crystal structure complexes, in the re-docking 
tests were ≤ 2 Å. This indicated that AutoDock Vina under default parameters was suitable for 
docking substrates into CYP450 proteins.  
 
Following this, PaDEL-AD v1.7 [426] was used to automate the docking of the 868 known 
substrates into the relevant CYP450 structures and the identification of LIGPLOT contacts in the 
docked complexes.  A maximum of 9 docking modes were generated per substrate giving 
approximately 7000 docking modes in total. Several of the resultant CYP450:substrate 
complexes were randomly selected and visually inspected for quality control purposes. The 
docking modes of some substrates with high binding energies were also visualised to check for 
errors. LIGPLOT contacts for docking poses with a ligand binding free energy of less than -1 
kcal/mol and atoms within 5 Å of the haem iron were used to generate the Docking SRS map as 
described for the X-ray structures SRS map (the docking SRS map was generated by Dr 
Zawaira). The 5 Å distance cut-off is a commonly accepted upper limit for the distance between 
the haem iron and a site of metabolism. A -1 kcal/mol cut-off was chosen to include as many 
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The dynamic motions of CYP450 enzymes controlling the access and egress of molecules into 
and out of the active site are still poorly understood. Most CYP450 crystal structures show the 
protein in a “closed” conformation with no access routes large enough to allow a water molecule 
to pass from the bulk solvent into the active site.  Isolation of the active site from the bulk 
solvent is a requirement for catalysis as it prevents uncoupling of the reaction yet substrate and 
solvent access channels must by necessity exist. There are however also “open” crystal structures 
with pathways wide enough to allow molecules at most the size of water molecules (2.8 Å in 
diameter) to enter the active site [427]. “Wide-open” conformations with tunnels wide enough to 
accommodate molecules the size of a typical substrate have only been observed in a few cases 
(e.g. CYP55A1 structure 1ROM  [428] and CYP450BM-3 structure 2HPD [429]). The inference 
from the structural data is therefore that CYP450s must undergo considerable conformational 
changes to allow substrate/products and water molecules in and out of the active site.  Factors 
such as pathway width and curvature, as well as the properties of residues lining the pathway 
may selectively control the access of molecules into the enzyme’s active site [430].  Gora et al 
recently reviewed general structural mechanisms controlling the passage of small molecules 
including substrates, products, ions and solvent molecules, into and out of proteins. These 
mechanisms, referred to as gates, are dynamic systems made of individual residues, loops or 
secondary structure elements or entire domains that can reversibly switch between an open and 
closed conformation, thereby controlling pathways within enzymes.   
 
A number of in silico approaches, including thermal motion pathway analysis [431], adiabatic 
mapping [81], molecular dynamics [80, 87, 431-436] and computational geometry tools [66, 
437-440] have been used to gain insight into CYP450 flexibility and tunnel-gating. These 
independent methods are in general agreement and several pathways found in distinct parts of 
the CYP450 fold have been identified as putative substrate access and solvent tunnels. 
 
Thermal motion pathway (TMP) analysis of crystallographic temperature factors was the first 
systematic method used to predict putative substrate tunnels in closed structures [431]. Putative 
tunnels were identified by linking chains of residues with elevated temperature factors, 
corresponding to regions of high flexibility, from the active site to the enzyme surface.    
 




Standard molecular dynamics approaches should in principle allow the visualisation of the 
opening and closing motions of tunnels. In practice, however the time scales on which ligand 
binding/unbinding occur are much longer than are computationally realistic to simulate for a 
large protein. Sampling techniques such as steered molecular dynamics (SMD) [81] and random 
expulsion molecular dynamics (REMD) [82] attempt to solve this problem. In SMD a force is 
applied to pull a ligand from the active site to the exterior of the protein along a tunnel and a 
rupture force is calculated; this information has been used to complement energy profiles 
obtained from adiabatic mapping, giving insight into the probability of a ligand passing through 
a given passage [432]. REMD reduces the timescales of spontaneous substrate exit by applying 
an artificial force to the substrate in a random direction in addition to the standard molecular 
mechanics force field.  
 
Pathways accessible to spherical probes the size of water molecules identified using REMD 
closely corresponded to those identified by TMP [434], revealing three main exit routes (pw1, 
pw2 and pw3) defined by the secondary structures surrounding their point of exit. Pw2 was 
further subdivided into 5 subclasses (pw2a-e), which all share proximity with the B-C loop/B’ 
helix, on the basis of REMD ligand egress trajectories [433]. In addition two other small 
channels referred to as the “solvent channel” (tunnel S) and the “water channel” (tunnel W) have 
been identified [427, 441, 442]. Tunnel S is thought to convey and control the access of protons 
to the active site, however substrates and other molecules may also use this channel to access and 
exit the active site [427].  Tunnel W acts as an aqueduct for water molecules to access and exit 
the active site during the catalytic cycle and is controlled at least in part by the binding of CPR to 
the proximal face of the CYP450 [442]. A description of each REMD derived tunnel is given in 
Table 3.1 [66, 427] and the exit point of each tunnel is illustrated in Figure 3.1.  This 
nomenclature is now commonly used to describe the position of tunnels in CYP450 enzymes. 
 
Gating residues have been identified for some of these pathways using molecular dynamics 
approaches. The tunnel-closing interactions identified are generally present in the start 
configuration of the simulation and only break when the ligand escapes from the protein [433, 
434]. A study by Fishelovitch et al, analysing substrate tunnels in CYP3A4 using SMD, revealed 
that л-stacked phenylalanine residues were the main residues responsible for gating pw2a, 2b, 
2c, 2e and pw3 [434]. This study also found that some residues gate more than one pathway and 
that, in some instances, the identification of gating residues was substrate dependant. Another 




study by Schleinkofer et al identified a gating residue pair for rabbit CYP2C5 pw2c tunnel using 
REMD simulations with progesterone and 21-hydroxyprogesterone as substrates [433].   
 
Figure 3.1 Positions of REMD tunnel egress points projected onto the CYP450 fold. 
CYP3A4 structure 1TQN is shown with helical regions in red, β-sheets in yellow and loop regions in green. 
Secondary structure elements are labelled using the nomenclature of Poulos et al [37]. The position of pw2d is not 
clearly visible from this angle as it egresses between the N-terminus and the A’ and A helices.  
 
Table 3.1 CYP450 pathways identified in REMD studies 
Pathway  Description 
pw1  Passes under the helix I, exiting the protein between the C/C’ and H or L helices close 
to the G-H loop and β-sheet 2. 
pw2a Exits between the F–G loop, B–C loop/B’ helix/BB’ loop and β-sheet 1. 
pw2b Exits between the B/B’ loop and the β-sheet 1and β-sheet 3 
pw2c Exits between the G and I helices and the B’ helix/B–C loop 
pw2d Exits between the N-terminus and the A’ and A helices 
pw2e Exits through the B–C loop 
pw3 Exits between the F and G helices or at the EF loop 
S Exits between the F, E and I helices and the β-sheet 5 
W Exits at the base of the B–C loop near the 
C-terminus of the  B helix 




In 2006 Cojocaru et al used CAVER, a computational geometry tool designed to rapidly identify 
pathways from protein clefts to the protein surface in static or dynamic structures [437], to 
determine the distribution and pattern of tunnels in static CYP450 structures [66]. The tunnels 
identified using this approach largely corresponded to those identified in REMD simulations and 
hence it is possible to assign CAVER tunnels to REMD tunnels using the standard nomenclature. 
In addition to previously delimited REMD tunnels, two new pathways (pw4 and pw5) were 
identified as well as two new subclasses of pw2 (pw2f and pw2ac). Pw4 exits the protein through 
the F-G loop while, pw5 exits between the K and K’ helices. Pw2ac exits between the top of the 
B-C loop (or B’ helix) and the G helix, between pw2c and pw2a/pw2b. Pw2f could be 
considered a variant of pw2a, exiting between the F’ helix/F-G loop and β-sheet 5.  
 
This Chapter describes the use of differential tunnel-opening patterns observed in static human 
CYP450 crystal structures to identify gating residue and tunnel-closing interactions for REMD 
equivalent pathways. The computational geometry tool, CAVER, was used to identify open 
tunnels in all available CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 and CYP3A4 crystal 
structures. Based on the assumptions that amino acid side chain motions are the main mechanism 
controlling the opening and closing of ligand access tunnels, “tunnel-closed” structures were 
aligned with “tunnel-open” structures to identify side chains obstructing the pathway of interest. 
Following this, the intra-protein interactions made with these gating residues that are responsible 
for tunnel closure were identified.   
 
A large portion of the work described in this Chapter was done in collaboration with a post-
doctoral fellow in the Blackburn laboratory, Dr Alexander Zawaira, and was published in the 
Journal of Structural Biology in 2011 ([443], full manuscript appended at the end of Thesis). My 
contribution to the experimental work in this publication included the following: determination 
of the optimal gauge width cut-off for tunnel identification using CAVER; tunnel calculations 
and assignment as well as the identification of gating models in a large portion of the structures 
analysed; calculation of the average rate of evolution of tunnel-intersecting residues in CYP2 
isoforms.  I have subsequently updated and expanded the work independently to include gating 
mechanisms identified in two addition CYP450 isoforms (CYP2B6 and CYP2D6) as well as to 
incorporate further insights from new structural data.   






CAVER uses the Dijkstra algorithm (a graph search algorithm designed to find the shortest path 
from a specified point to all other points within a graph simultaneously), to calculate the shortest 
low-cost path from a user defined starting point within the structure to the bulk solvent. CAVER 
returns a list of possible routes out of the molecule, giving greatest priority to routes with the 
widest bottleneck (gorge width) irrespective of the length of the tunnel. There are no or very few 
tunnels wide enough for typical substrates or water molecules to pass through (radius > 2.8 Å) in 
most CYP450 crystal structures. Tunnel-opening resulting from the disruption of tunnel-gating 
interactions is likely to lead to larger conformational changes, allowing molecules in and out of 
the protein.  Similarity to REMD tunnels was thus an important criterion for identifying open 
tunnels and the subsequent delimitation of gating models. Based on this criterion, a gorge width 
cut-off suitable for identifying differential tunnel-opening patterns in CYP450 structures, while 
restricting calculated tunnels to REMD equivalent tunnels as far as possible, was required to 
distinguish open tunnels from closed tunnels.  
 
A suitable cut-off was chosen based on a preliminary thresholding exercise aimed at finding an 
optimal balance between the number of tunnel-open/tunnel-closed structure pairs and the 
resemblance of CAVER calculated tunnels to REMD tunnels. At gorge width cut-offs < 0.7 Å 
there were no differential tunnel-opening patterns as all REMD tunnels were open with over 35 
tunnels calculated per structure. At gorge width cut-offs > 2.5 Å there were no open tunnels apart 
from artefacts arising from missing regions within crystal structures.   At gorge width cut-offs < 
1 Å, the majority of calculated tunnels did not match REMD tunnels. A gorge width cut-off of 
1.4 Å (~ half a water molecule) gave the best balance between tunnel similarity and differential 
tunnel-opening in most CYP450 isoforms and was therefore used throughout the rest of this 
study.  
 
The CAVER algorithm divides the 3-dimensional protein space into a grid and calculates a 
convex envelope around the protein. Grid points lying on the envelope are possible tunnel exit 
point. If several of these possible exit points fall within the region of a REMD tunnel exit, 
several variants of the same REMD tunnel may be calculated by CAVER [66]. All tunnel 
variants were recorded but in principle, only one of these tunnels need be considered. The tunnel 




that most closely resembled the REMD tunnel with the widest gorge width was used to identify 
gating residues.  
 
Tunnel-gating residues where identified by aligning structures with differential tunnel-opening 
patterns and manually identifying residue side chains obstructing the tunnels in the tunnel-closed 
structures.  Where possible structures of the same isoform were aligned, enabling the 
delimitation of two-state gating models made up of a tunnel-intersecting residue and its 
interacting partners. Protein interaction calculator [444] was used to identify tunnel-closing 
interactions defined as intra-protein interactions involving the tunnel-intersecting residue that are 
present in the tunnel-closed structure but absent in the tunnel-open structure. 
 
In the cases where a tunnel showed no differential tunnel-opening patterns between structures of 
the same isoform, tunnel-intersecting residues were identified by aligning structures of different 
isoforms.  Only singlet gating models could be delimited in these cases because tunnel-closing 
interactions exclusive to the tunnel-closed structure could not be identified in cases where the 
protein sequences differed between open and closed structures.   
3.2.1 Differential tunnel-opening patterns and gating models in CYP2A6 structures 
 
Table 3.2 shows the distribution of open tunnels in CYP2A6 crystal structures.  CAVER was 
used to identify two open tunnels in CYP2A6: the water channel (tunnel W), open in 6 out of 8 
CYP2A6 structures, and a previously undefined tunnel open in all 10 structures. This new tunnel 
was named pw6 in keeping with the naming convention of Cojocaru et al [66]. Pw6, starting at 
the haem iron, initially follows a similar path to pw1 passing under the I helix but unlike pw1, 
exits on the opposite side of the C helix, between the C helix and the N-terminus of the L helix, 
near the C-D loop (Figure 3.2). Gating models for pw6 were not delimited here as REMD 
simulations have not confirmed the use of this tunnel.   





Figure 3.2 CYP2A6 structure 3T3R showing CAVER calculated tunnel pw6 with a gorge width of 1.56 Å.  
Table 3.2 CAVER-calculated tunnels in CYP2A6 crystal structures 
PDB Tunnel No. pw2a pw2b pw2c pw2e pw3 S W pw2ac pw6 Width(Å) 
1Z10 1         × 1.54 
 2       ×   1.51 
1Z11 1         × 1.50 
 2       ×   1.48 
2FDU 1       ×   1.56 
 2         × 1.52 
2FDV 1       ×   1.55 
 2         × 1.53 
 3       ×   1.43 
2FDW 1         × 1.57 
 2       ×   1.45 
2FDY 1         × 1.47 
 
2PG5 1         × 1.49 
 2       ×   1.48 
 3         × 1.42 
3T3R 1         × 1.56 
 2       ×   1.47 
4EJJ 1         × 1.49 
 
3T3Q 1         × 1.50 
 2       ×   1.47 
Note:  pw2ac and pw6 (in italics) have only been identified in static structures and have not yet been confirmed as 
REMD tunnels. 




Singlet gating models in CYP2A6 
 
In an attempt to identify a two-state gating model for tunnel W, tunnel-open structure 2FDV was 
aligned to tunnel-closed structure 2FDY. Lys 125 was identified as a tunnel-intersecting residue. 
The only difference in intra-protein interactions involving Lys 125 in the tunnel-open and tunnel-
closed structures was the Lys 125- Glu 96 interaction present exclusively in the tunnel-open 
structure (Figure 3.3). Due to the lack of a tunnel-closing interaction, the gating of tunnel W can 




Figure 3.3 CYP2A6 structure 2FDV (green) with open tunnel W (grey) aligned to tunnel-closed structure 2FDY 
(red) showing tunnel-intersecting residue K125. The interaction between K125 and E96 keeps the tunnel open in 
structure 2FDV (tunnel-opening interaction).  
 
Singlet gating models were also identified for pw2a, pw2c, pw2e and tunnel S by aligning 
CYP2A6 structures to open tunnels observed in CYP2C8 structures (Table 3.3).   Figure 3.4 
shows CYP2A6 residues, Gln 104, Phe 107, Phe 118, Leu 370 and Phe 480 intersecting pw2e.    
 
Singlet gating models were not delimited for pw2b and pw3 as backbone regions of CYP2B6 








Table 3.3 Singlet gating models in CYP2A6 
Gated tunnel Structures: open/closed Tunnel-intersecting residues 
W 2FDV(CYP2A6)/2FDY(CYP2A6) Lys 125a 
   
pw2a 2NNH(CYP2C8)/2FDV(CYP2A6) Phe 480 
   
pw2c 2NNH(CYP2C8)/2FDV(CYP2A6) Phe 107, Phe 111, Phe 118, Gln 242, Glu 245, Met 293 
   
Pw2e 2NNH(CYP2C8)/2FDV(CYP2A6) Gln 104, Phe 107, Phe 118, Leu 370, Phe 480 
   
S 2NNH(CYP2C8)/2FDV(CYP2A6) Phe 107, Phe 111, Phe 118, Met 205, Leu 241 
   





Figure 3.4 CYP2C8 structure 2NNH (green) with open tunnel pw2e (grey) aligned to all 10 CYP2A6 structures 








3.2.2 Differential tunnel-opening patterns and gating models in CYP2B6 structures 
 
Table 3.4 shows the distribution of open tunnels in CYP2B6 crystal structures. Differential 
tunnel-opening patterns were observed for REMD tunnels pw2a, pw2b and tunnel S as well as 
the newly assigned tunnel pw6. 
 
Table 3.4 CAVER-calculated tunnels in CYP2B6 crystal structures 
PDB Tunnel No. pw2a pw2b pw2c pw2e pw3 S W pw2ac pw6 Width(Å) 
3IBD 1         × 2.11 
 2a  ×*        1.53 
3UA5 1 ×         2.24 
 2      ×    2.16 
4I91 1         × 1.41 
            
3QOA 1         × 1.40 
 
3QU8 none           
            
Note:  pw2ac and pw6 (in italics) have only been identified in static structures and have not yet been confirmed as 
REMD tunnels. 
* indicates tunnel may be an artefact of regions missing from the crystal structure.  
a  Missing Glu218 atoms in the crystal structure render pw2b open in 3IBD 
Two- state gating models in CYP2B6 
 
Table 3.5 shows the two-state tunnel-gating models identified in CYP2B6.  The side chain of 
Leu 51 intersects pw2a in all the tunnel-closed structures. Leu 51 interacts hydrophobically with 
Leu 219 and Met 365 and forms a side chain-main chain interaction with Gln 215 in the tunnel-
closed structures. Gln 215 forms part of a small section of the F-G loop backbone that obstructs 
pw2a. The side chain of adjacent residue Leu216 also intersects pw2a, interacting 
hydrophobically with Leu 219 and Leu 43.  These tunnel-closing interactions are all absent in the 










Table 3.5 Two-state gating models in CYP2B6 
Gated tunnel Structures: open/closed Tunnel-closing interaction 
pw2a 3UA5/(3IBD, 4I91, 3QOA, 3QU8)  Leu 51-Leu 219 hydrophobic 
  Leu 51-Met 365 hydrophobic  
  Leu 51-Gln 215 side chain-main chain H-bond 
  Leu 216-Leu 219 hydrophobic 
  Leu 216-Leu 43 hydrophobic 
    
S 3UA5/(4I91, 3QOA, 3QU8)a Phe 206-Leu 363 hydrophobic 
  Phe 206-Ile 480 hydrophobic 
Tunnel-intersecting residues are shown in bold face 
a Tunnel S is also closed in 3IBD however the side chain of F206 does not intersect S in this structure. Residues 
Ser107, Glu474 and Ile480 appear to restrict tunnel S in this case. 
 
Phe 206 gates tunnel S in CYP2B6, intersecting tunnel S in 3 of the 4 tunnel-closed structures 
and making hydrophobic tunnel-closing interactions with Leu 363 and Ile 480 (Figure 3.5).  
Tunnel S is also closed in structure 3IBD but is not intersected by Phe 206; rather it appears to be 
restricted by Ser 107, Glu 474 and Ile 480. 
 
A two-state gating model was not identified for pw2b because the open tunnel in 3IBD is an 
artefact of the missing side chain atoms of Glu 218.  It does however indicate that Glu 218 may 
play a role in pw2b gating in CYP2B6.  
 
 
Figure 3.5 Gating model for tunnel S in CYP2B6.  
CYP2B6 structure 3UA5 (green) with open tunnel S (grey) aligned to closed structures 4I91, 3QOA and 3QU8 (red) 
in PyMOL. F206 obstructs tunnel S in closed structures 4I91, 3QOA and 3QU8 forming hydrophobic interactions 
with L363 and I480.  




Singlet gating models in CYP2B6 
 
Table 3.6 shows the CYP2B6 singlet gating models identified for pw2b, pw2c, pw2e and tunnel 
W by aligning CYP2B6 structures to tunnel-open structures from other isoforms.  
 
Table 3.6 Singlet gating models in CYP2B6 
Gated tunnel Structures: open/closed Gating residue 
pw2b 1TQN(CYP3A4)/3QOA(CYP2B6) Glu 218 
   
pw2c 2NNH(CYP2C8)/3QOA(CYP2B6) Phe 108, Leu 290 
   
pw2e 2NNH(CYP2C8)/3QOA(CYP2B6) Ile 101, Val 104, Phe 115 
   
W 2FDV(CYP2A6)/3QOA(CYP2B6) Trp 121 
 
 
Pw2b tunnel-intersecting residue Glu 218 was identified by aligning CYP2B6 structures to 
CYP3A4 structure 1TQN, as speculated above.  Pw2b gating residues could not be identified 
when CYP2B6 structures were aligned to tunnel-open structures from more closely related 
CYP2C8 and CYP2C9 isoforms as the B-C loop backbone intersected pw2b in all these 
structural alignments.  
 
Tunnel-intersecting residues were not identified for CYP2B6 pw3 as the G helix backbone 
obstructs pw3 in structural alignments with CYP3A4 tunnel-open structure 2V0M.   
3.2.3 Differential tunnel-opening patterns and gating models in CYP2C8 structures 
 
Table 3.7 shows the distribution of open tunnels in CYP2C8 crystal structures. Differential 
tunnel-opening patterns were observed for REMD tunnels pw2a, pw2c, pw2e and tunnel S as 
well as the newly assigned tunnel pw6. Pw2b was open in all structures while pw3 and tunnel W 








Table 3.7 CAVER-calculated tunnels in CYP2C8 crystal structures 
PDB Tunnel No. pw2a pw2b pw2c pw2e pw3 S W pw2ac pw6 Width(Å) 
1PQ2 1  ×        2.05 
 2  ×        1.55 
 3 ×         1.40 
2NNH 1  ×        2.46 
 2   ×       1.70 
 3    ×      1.53 
 4a          1.50 
 5      ×    1.44 
2NNI 1  ×        2.34 
 2      ×    1.55 
 3   ×       1.50 
 4         × 1.42 
 5         × 1.42 
 6         × 1.42 
2NNJ 1  ×        2.28 
 2      ×    1.53 
 3   ×       1.50 
 4         × 1.49 
2VN0 1  ×        2.15 
 2    ×      1.60 
 3         × 1.55 
 4         × 1.44 
Note:  pw2ac and pw6 (in italics) have only been identified in static structures and have not yet been confirmed as 
REMD tunnels. 
a Cojocaru et al identified a tunnel in the same position in P450cam using CAVER and assigned it pw5 however, it 
has not yet been observed in REMD simulations.  
Two-state gating models in CYP2C8 
 
Table 3.8 shows the two-state gating models identified for tunnels pw2a, pw2c, pw2e and tunnel 
S in CYP2C8 structures. Ile 476 intersects pw2a in all tunnel-closed CYP2C9 structures with the 
exception of 2NNJ, which is intersected by Ile 50. Ile 476 gates pw2a in the tunnel-closed 
structure 2NNH by forming a network of hydrophobic interactions with Val 362, Pro 367 and 
Met 388 that are absent in the tunnel-open structure 1PQ2.  Ile 476 also intersects pw2a in 
tunnel-closed structures 2NNI and 2VN0 but only the Ile 476 – Pro 367 hydrophobic tunnel-




closing interaction is present in 2NNI, 2VN0 and 2NNH suggesting that it is the primary tunnel-
closing interaction.  
 
 
Table 3.8 Two-state gating models in CYP2C8 
Gated tunnel Structures: open/closed Tunnel closing interaction 
pw2a 1PQ2/2NNH Ile 476-Val 362 hydrophobic 
  Ile 476-Pro 367 hydrophobic 
  Ile 476-Met 388 hydrophobic 
    
pw2c 2NNH/1PQ2 
 
Arg 241-Glu 285 ionic  
pw2e 2NNH/1PQ2 
 
Asn 99-Ser 114 
 
side chain-main chain H-bond 
S 2NNI/(1PQ2, 2VN0a ) Lys 199 – Phe 168 hydrophobic 
Tunnel-intersecting residues are shown in bold face.  
a Tunnel-closing interaction Lys199-Phe168 is present in tunnel-closed structure 2VN0 shown in italics however the 
tunnel-intersecting residue Lys199 does not intersect the tunnel in this structure.  
 
Pw2c is gated by the Arg 241-Glu 285 ionic interaction in CYP2C8 structure 1PQ2 (Figure 3.6 
A) reducing the size of the gorge width from 1.7 Å/1.5 Å (observed in the tunnel-open 
structures) to 0.9 Å. This ionic interaction is absent in tunnel-open structures 2NNH, 2NNI and 
2NNJ.  Note that this ionic interaction is not observed in tunnel-closed structure 2VN0, however 
while pw2c is classified as closed in this structure, it has a larger gorge width than 1PQ2 (1.24 Å 
compared with 0.9 Å). Pw2c 2VN0 may therefore represent an intermediate between the tunnel-
open and tunnel-closed states.  
 
Arg 99 – Ser 114 side chain-main chain interaction, present in all three of the CYP2C8 tunnel-
closed structures, gates pw2e. In these structures, the side chain of Arg 99 is orientated towards 
the centre of the B-C loop, intersecting tunnel pw2e, whereas in the tunnel-closed structures the 
Arg side chain is orientated away from pw2e and does not interact with Ser 114 (Figure 3.6 B).  
 






Figure 3.6. Gating model for pw2c and pw2e in CYP2C8.  
A) CYP2C8 structure 2NNH, 2NNI and 2NNJ (green) with open tunnel pw2c (grey) aligned with tunnel-closed 
structures 1PQ2 and 2VN0 (red) in PyMOL. The side chain of R241 intersects tunnel pw2c in structure 1PQ2 and 
forms an ionic interaction with D285, reducing the gorge width of pw2c to 0.9 Å. The side chain of R241 in 2VN0 
also intersects pw2c but to a lesser degree reducing the gorge width to 1.24 Å. B) CYP2C8 structures 2NNH and 
2VN0 (green) with open pw2e were aligned with tunnel-closed structures 2NNI, 2NNJ and 1PQ2 (red) in PyMOL. 
The side chain of R99 forms a hydrogen bond with the main chain of S114 closing pw2e in all three closed 
structures. This R99-S114 interaction is absent in both open structures.  
 
Figure 3.7 shows tunnel S gated by tunnel-intersecting residue Lys199. This residue interacts 
with Phe 169 in the tunnel-closed CYP2C8 structure 1PQ2 but not in the tunnel-open structure. 
Although Lys 199 does not intersect tunnel S in the other tunnel-closed structure 2VN0 the Lys 
199 – Phe 169 hydrophobic tunnel-closing interaction is also present in this structure.  
 
 
Figure 3.7 CYP2C8 structure 2NNI (green) with open tunnel S (grey) aligned to tunnel-closed structure 1PQ2 (red). 
The side chain of Lys 199 intersects tunnel S forming a hydrophobic interaction with Phe 169.  
 




Singlet gating models in CYP2C8 
 
Table 3.9 shows the CYP2C8 singlet gating models identified for pw3 and tunnel W by aligning 
CYP2C8 structures to tunnel-open structures from other isoforms. Gating residues could not be 
identified for pw2b, as pw2b was open with a gorge width > 2 Å in all CYP2C8 structures.  
 
Table 3.9 Singlet gating models in CYP2C8 
Gated tunnel Structures: open/closed Gating residue 
pw3 2V0M (CYP3A4)/2NNH(CYP2C8) Ile 207, Leu 208, Thr 229, Val 233 
   
W 2FDV(CYP2A6)/2NNH(CYP2C8) Trp 120, Arg 125  
   
 
3.2.4 Differential tunnel-opening patterns and gating models in CYP2C9 structures 
 
Table 3.10 shows the distribution of open-tunnels in CYP2C9 crystal structures. Differential 
tunnel-opening patterns were observed for REMD tunnels pw2c and pw2e as well as CAVER 
calculated tunnel pw2ac and the newly assigned tunnel pw6. Pw2a and pw2b were closed in all 
CYP2C9 structures and the tunnel S was open in all structures. 
 
Table 3.10 CAVER-calculated tunnels in CYP2C9 crystal structures 
PDB Tunnel No. pw2a pw2b pw2c pw2e pw3 S W pw2ac pw6 Width(Å) 
1OG2 1      ×    1.75 
 2   ×       1.52 
1OG5 1      ×    1.78 
 2   ×       1.55 
 3         × 1.45 
1R9O 1      ×    2.21 
 2        ×  1.93 
 3    ×      1.88 
 4        ×  1.68 
 5    ×      1.48 
Note:  pw2ac and pw6 (in italics) have only been identified in static structures and have not yet been confirmed as 
REMD tunnels. 
 




Two-state gating models in CYP2C9  
 
Differential tunnel-opening patterns in CYP2C9 static crystal structures revealed two-state 
gating models for REMD tunnels pw2c and pw2e (Table 3.11). Arg 108 gates pw2c, forming an 
ionic interaction with Asp 293 and main chain-main chain interactions with Phe 110 and Gly 111 
(Figure 3.8 A).  Phe 110 is also involved in gating pw2e; Phe 110 and Ile 99 interact 
hydrophobically, intersecting pw2e in the tunnel-closed structures (Figure 3.8 b).  Other 
interactions responsible for pw2e tunnel closure are hydrophobic interactions Phe 110-Phe 114, 
Ile 99-Ala 103 and Ile 99-Phe 114.  
 
Table 3.11 Two-state gating models in CYP2C9 
Gated tunnel Structures: open/closed Tunnel closing interaction 
pw2c (1OG5, 1OG2)/1R9O Arg 108-Asp 293 ionic 
  Arg 108-Phe 110 main chain-main chain H-bond 
  Arg 108-Gly 111 main chain-main chain H-bond 
pw2e 1R9O/(1OG5, 1OG2) Phe 110-Ile 99 hydrophobic 
  Phe110–Phe 114 hydrophobic  
  Ile 99–Ala 103 hydrophobic 
  Ile 99–Phe 114 hydrophobic 
Tunnel-intersecting residues are shown in boldface. 
 
 
Figure 3.8 Gating model for pw2c and pw2e in CYP2C9.  
A) CYP2C9 structures 1OG2 and 1OG5 (green) with open tunnel pw2c (grey) aligned to tunnel-closed structure 
1R90 (red) in PyMOL. The side chain of R108 intersects tunnel pw2c in 1R9O forming an ionic interaction with 
D293 and main chain-main chain hydrogen bonds with F110 and G111; these interactions are only present in the 
tunnel-closed structure. B) CYP2C9 structure 1R9O (green) with open pw2e aligned to tunnel-closed structures 
1OG2 and 1OG5 (red) in PyMOL. The side chain of residues F110 and I99 insect tunnel pw2e in both of the tunnel-
closed structures and form the following hydrophobic tunnel closing interactions that are absent in 1R9O: F110-I99; 
F110-F114; I99-A103; I99-F114.  




Singlet gating models in CYP2C9  
 
Table 3.12 shows the CYP2C9 singlet gating models identified for pw2a, pw2b, pw3 and W by 
aligning CYP2C9 structures to tunnel-open structures from other isoforms. Gating residues could 
not be identified for tunnel S in CYP2C9 static structures as this tunnel was open in all three 
structures. 
 
Table 3.12 Singlet gating models in CYP2C9 
Gated tunnel Structures: open/closed Gating residue 
pw2a 1PQ2(CYP2C8)/1OG5(CYP2C9) Phe 476 
   
pw2b 1PQ2(CYP2C8)/1OG5(CYP2C9) Phe 100, Lys 72 
   
pw3 2V0M(CYP3A4)/1OG5(CYP2C9) Ile 207, Leu 208, Thr 229 
 2V0M(CYP3A4)/1R90(CYP2C9) Tyr 225 
   
W 2FDV(CYP2A6)/1OG5(CYP2C9) Trp 120 
3.2.5 Differential tunnel-opening patterns and gating models in CYP2D6 structures 
 
Table 3.13 CAVER-calculated tunnels in CYP2D6 crystal structures 
PDB Tunnel No. pw2a pw2b pw2c pw2e pw3 S W pw2ac pw6 Width(Å) 
3QM4 1  ×        1.45 
            
2F9Q 1      ×    2.25 
            
3TDAa 1  ×        1.49 
 2 ×         1.49 
 3b ×         1.49 
3TBG 1b ×         2.13 
 2  ×        2.13 
 3      ×    2.01 
 4 ×         1.90 
 5      ×    1.85 
 6    ×      1.44 
a Three tunnels branch from one tunnel and therefore have an identical minimum gorge width  
b Variant of pw2a displaced closer to the solvent channel than the canonical pw2a.  




Table 3.13 shows the distribution of open tunnels in CYP2D6 crystal structures. Differential 
tunnel-opening patterns were observed for REMD tunnels pw2a, pw2b, pw2e and tunnel S.   
Two- state gating models in CYP2D6 
 
Two-state gating models were delimited for tunnels pw2a, pw2e and tunnel S (Table 3.14). 
While there is one CYP2D6 structure where pw2b is closed, a portion of the F-G loop backbone 
rather than an amino acid side chains obstructs this tunnel and hence a gating model based on the 
movement of side chains could not be delimited. 
 
Table 3.14 Two-state gating models in CYP2D6 
Gated tunnel Structures: open/closed Tunnel closing interaction 
pw2a 3TBG/3QM4 Phe 219- Phe 51 hydrophobic (aromatic) 
  Phe 219-Gln 52 main chain-main chain H-bond 
  Phe 219- Leu 46 hydrophobic 
  Phe 51-Gly 218 main chain-main chain H-bond 
  Phe 51-Thr 54 main chain-main chain H-bond 
    
pw2e 3TBG/(3QM4, 3TDA) Phe 483-Phe120 hydrophobic (aromatic) 
  Phe 483-Val 374 hydrophobic 
    
S 3TBG/(3QM4, 3TDA) Gln 210-Asp 179 side chain-side chain H-bond 
Tunnel-intersecting residues are shown in bold face 
 
All four pw2a tunnels observed in CYP2D6 structures vary in position, with tunnel 1 in 3TBG 
and tunnel 3 in 3TDA (Table 3.13) positioned closer to tunnel S than the canonical pw2a 
identified by REMD. Tunnel 4 in 3TBG was used to identify pw2a tunnel-intersecting residues 
since it is the tunnel with the widest gorge width that most closely resembles the canonical pw2a 
tunnel. The side chains of Phe 219 and Phe 51 in the tunnel-closed structure 3QM4 intersect this 
tunnel (Figure 3.9). Table 3.14 lists the tunnel-closing interactions made by these residues. The 
F-G loop of tunnel-closed structure 2F9Q adopts a substantially different conformation to 3TBG 
and 3QM4, with the F-G loop backbone passing through the middle of pw2a. Residues 42 to 51 
are also missing in this structure and thus this tunnel-closed structure was not used to identify 
pw2a gating residues.  
 






Figure 3.9 Gating model for pw2a in CYP2D6.  
CYP2D6 structure 3TBG (green) with open tunnel pw2a (grey) was aligned with tunnel-closed structure 3QM4 
(red) in PyMOL. The side chain of F219 and F51 as well as the main chain of L46 intersects the tunnel in 3QM4. 
F219 forms hydrophobic interactions with F51 and L46 and a main chain-side chain interaction with Q52 in the 
tunnel-closed structure 3QM4 but not in the tunnel-open structure 3TBG.  F51 also forms a side chain-main chain 
hydrogen bond with T54 and a main chain-main chain bond with Q52 that are not present in the tunnel-open 
structure.   
 
Phe 483 gates pw2e in tunnel-closed structures 3QM4 and 3TDA (Figure 3.10 A). Tunnel-
closing interactions F483-V374 and F483-F120 were present in both 3QM4 and 3TDA. A 
different gating model is however observed for the third tunnel-closed structure 2F9Q (Figure 
3.10 B), this gating model was however not considered due to the V374M mutations in this 
structure, which appears to alter the enzyme conformation. M374 interacts with F220 which, in 
contrast to F220 that faces away from the active site in the other three CYP2D6 structures, is 
orientated towards the active site due to a conformational change in the F-G loop region. This 
structure illustrates how a single amino acid substitution can affect enzyme conformation and 
tunnel gating. 
 
The three solvent tunnels that are observed in CYP2D6 structures (one in 2F9Q and two in 
3TBG) are not equivalent. Tunnel number 5 in 3TBG, with a gorge width of 1.8 Å (Table 3.13) 
most closely resembles the canonical tunnel S delimited in REMD studies and was used to 
determine tunnel-gating residues. The side chain of Gln 210 forms a hydrogen bond with the side 
chain of Asp 179, closing tunnel S in structures 3QM4 and 3TDA (Figure 3.11). 
 





Figure 3.10 Gating model for pw2e in CYP2D6.  
A) CYP2D6 structure 3TBG (green) with open tunnel pw2e (grey) aligned to tunnel-closed structures 3QM4 and 
3TDA (red) in PyMOL. F483 interacts with F120 and V374 via hydrophobic interactions to close pw2e. F483 does 
not interact with F120 and V374 in the tunnel-open structure. B) Tunnel-closed structure 2F9Q (orange) with 




Figure 3.11 Gating model for tunnel S in CYP2D6. CYP2D6 structure 3TBG (green) with open tunnel S (tunnel 
number 5 in Table 3.13) aligned to tunnel-closed structures 3QM4 and 3TDA (red) in PyMOL. The side chain of 
Q210 forms a hydrogen bond with the side chain of D179, closing tunnel S in structures 3QM4 and 3TDA.  
Singlet gating models in CYP2D6 
 




Table 3.15 shows the CYP2D6 singlet gating models identified for pw2c and tunnel W. Gating 
residues could not be identified for pw3 as the protein backbone of tunnel-closed structures 
obstructs this tunnel.    
 
Table 3.15 Singlet gating models in CYP2D6 
Gated tunnel Structures: open/closed Gating residue 
pw2c 1OG5(CYP2C9)/2F9Q(CYP2D6) Leu 110, Leu 213, Glu 216 
   
W 2V0M(CYP3A4)/2F9Q(CYP2D6) Trp 128, Arg 133 
 2V0M(CYP3A4)/3TBG(CYP2D6) Trp 128, Arg 129 
3.2.6 Differential tunnel-opening patterns and gating models in CYP3A4 structures 
 
Table 3.16 shows the distribution of open tunnels in CYP3A4 crystal structures. Differential 
tunnel-opening patterns were observed for REMD tunnels pw2a, pw2b, pw3 and tunnel S.  Pw2c 
and tunnel W is closed in all structures while pw2e is open in all structures.   
 
Table 3.16 CAVER-calculated tunnels in CYP3A4 crystal structures 
PDB Tunnel No. pw2a pw2b pw2c pw2e pw3 S W pw2ac pw6 Width(Å) 
1TQN 1  ×        2.33 
 2    ×      1.86 
 3      ×    1.43 
 4      ×    1.43 
1W0F 1  ×        2.21 
 2    ×      1.87 
1W0G 1  ×        2.31 
 2    ×      1.90 
2J0D 1a ×*         3.29 
 2b          3.23 
 3  ×        2.40 
 4 ×         2.24 
 5 b          2.12 
 6      ×*    1.73 
 7    ×      1.69 
2V0M 1  ×        2.41 
 2 ×         1.56 
 3    ×      1.55 




 4     ×     1.53 
 5 ×         1.50 
3NXU 1  ×        2.09 
 2    ×      1.83 
4K9T 1 ×         2.36 
 2    ×      1.49 
 3 ×         1.43 
4K9U 1c          3.92 
 2d          2.46 
 3  ×        2.16 
 4    ×      1.69 
 5     ×     1.42 
 6e      ×*    1.41 
4K9V 1  ×        2.31 
 2    ×      1.84 
4K9X 1f          2.39 
 2  ×        2.16 
 3    ×      1.62 
 4 f          1.51 
4K9W 1  ×        2.13 
 2    ×      1.68 
3TJS 1g          2.45 
 2  ×        2.23 
 3h      ×*    1.89 
 4    ×      1.56 
4I3Q 1  ×        2.09 
 2      ×    1.98 
 3    ×      1.81 
 4      ×    1.59 
4I4G 1  ×        1.96 
 2    ×      1.68 
4I4H 1  ×        2.17 
 2    ×      1.83 
 3  ×        1.66 
3UA1 1  ×        2.35 
 2    ×      1.89 
* indicates tunnel may be an artefact of regions missing from the crystal structure.  
a This tunnel is probably an artefact of the gap created by missing residues 214-218 in 2J0D. It lies in close proximity to 
canonical pw2a however, others have assigned it as pw2f.  
b This tunnel is probably an artefact of the gap created by missing residues 214-218 in 2J0D. It falls between canonical tunnel S 
and pw2a. 




c This tunnel is probably an artefact of the gap created by missing residues 210-215 in 4K9U and it is not clear whether the 
tunnel would pass through the F-G loop (pw3) or in the region of tunnel S.  
d This tunnel is probably an artefact of the gap created by missing residues 210-215 in 24K9U. It falls between canonical tunnel 
S and pw2a  
e This is probably an artefact of the gap created by missing residues 210-215 in 4K9U. 
f This is probably an artefact of the gap created by missing residues 212-214 in 4K9X. It falls between canonical tunnel S and 
pw2a. 
g This is probably an artefact of the gap created by missing residues 212-218 in 3TJS. It falls between canonical tunnel S and 
pw2a 
h This is probably an artefact of the gap created by missing residues 212-218 in 3TJS 
Two-state gating models in CYP3A4 
 
Differential tunnel-opening patterns in CYP3A4 static crystal structures revealed two-state 
gating models for tunnels pw2a, pw2b, pw3 and tunnel S (Table 3.17). 
 
A network of aromatic interactions gate pw2a in CYP3A4. Phe 215, a residue within the F-G 
loop region, is the main gating residue, intersecting pw2a in all the tunnel-closed CYP3A4 
structures (except for 4K9U and 3TJS where a region of the protein containing this residue is 
missing from the crystal structure).  CYP3A4 structures can be clustered into 3 groups based on 
the position of Phe 215 side chain (Figure 3.12): 1) Tunnel-open structures where the side chain 
faces away from pw2a and the active-site cavity towards the bulk solvent. 2) Tunnel-closed 
structures where Phe 215 interacts with Phe 57 and Phe 53, with its side chain partially 
intersecting pw2a. 3) Tunnel-closed structures where Phe 215 lies in the middle of pw2a, closing 
the tunnel completely, with its side chain pointing towards the active site forming hydrophobic 
interactions with Phe 57, Phe108 and Phe 220. These three clusters provide a visual model for 
the closing of pw2a where Phe 215 makes a series of aromatic contacts, first interacting with Phe 
57 and Phe 53 in the intermediate state, followed by interactions with Phe 108 and Phe 220, 
closing the tunnel further.  The Phe 215 – Phe 57 interactions appears to be the most vital for 
tunnel-closing and is present in both the intermediate and final closed states.   
 
Pw2b is open in 15 out of the 16 CYP3A4 crystal structures. In the closed structure, 4K9T, F108 
is flipped around with the side chain intersecting pw2b instead of falling within the centre of the 
B-C loop bordering pw2e (Figure 3.13).  F108 forms tunnel-closing interactions with I223 and 
R106.  F108 also interacts with F220 but an aromatic interaction between F108 and F220 is also 
present in the tunnel-open structure so by our definition it is not a tunnel-closing interaction. It is 
however in a different position and orientation in the tunnel-closed structure so it is likely to 
break and then reform on tunnel-closure.  





Table 3.17 Two-state gating models in CYP3A4 
Gated tunnel Structures: open/closed Tunnel closing interaction 
pw2a 2V0M/(1TQN, 1W0F, 1W0G, 3NXU, 
4K9V, 4K9X, 4K9W, 4I3Q, 4I4G, 
3UA1) 
 
Phe 215-Phe57 hydrophobic (aromatic) 
 2V0M/(4K9X, 4K9W, 4I4G, 3NXU) Phe 215-Tyr 53 hydrophobic (aromatic) 
    
 2V0M/(1TQN, 1W0F, 1W0G, 4K9V,  
4I3Q, 3UA1) 




    
    
pw2b 1TQN/4K9T Phe 108-I223 hydrophobic 
  Phe 108-R106 cation-pi 
    
    
pw3  (model 1) 2V0M/(1TQN, 1W0F, 1W0G, 4K9V, 
4I3Q, 3UA1, 4K9T) 
Phe 213-Phe 304 
Phe 213 –Phe 108 








    
 2V0M/(1TQN, 1W0F, 1W0G, 4K9V, 
4I3Q, 3UA1) 
Phe 304-Phe 241 hydrophobic (aromatic) 
 
    
pw3 (model 2) 2V0M/(4K9W, 4I4G, 3NXU, 4I4H) Leu 211- Phe220 hydrophobic 
    
    
S  1TQN/(1W0F, 4I4G, 4K9T, 4I4H, 
2V0M) 
Arg 212-Asp 214 main chain-main chain H-bond 
(and ionic in some structures) 
 1TQN/(1W0F, 1W0G, 3UA1, 4I4H)  Arg 212-Glu 308 side chain-side chain and ionic 
 1TQN/1W0G Arg 212-Leu 483 main chain-side chain H-bond 
 1TQN/3UA1 Arg 212-Ile 369 main chain-side chain H-bond 
    
 1TQN/(2V0M, 4K9W, 4I4G, 3NXU) Leu 482-Leu 211 hydrophobic 
 1TQN/(2V0M, 4K9W, 3NXU) Leu 482-Phe 304 hydrophobic 
 1TQN/(2V0M, 4K9X, 4K9T) Leu 482-Ile 369 hydrophobic 
    
  1TQN/(3NXU, 4I4G, 4K9X) Gln 484-Glu 308) side chain-side chain H-bond 
Tunnel-intersecting residues are shown in bold face. Structures where the tunnel-closing interactions is present but 
the intersecting residue indicated in bold does not intersect the base of tunnel S (i.e. it is not the main residue 
responsible for tunnel-closure) are shown in italics.  





Figure 3.12 Gating model for tunnel pw2a in CYP3A4 
CYP3A4 structures cluster into 3 groups based on the position of F215. A representative structure from each cluster 
is shown here: 1) 2V0M (green) with open tunnel pw2a aligned to tunnel-closed structures 2) 4K9X (orange) and 3) 
1TQN (red). F215 forms tunnel-closing interactions with F57 and F53 in structures in cluster 2 (4K9X, 4K9W, 
3NXU and 4I4G) and tunnel-closing interactions with F57, F108 and F220 in structures in cluster 3 (1TQN, 1W0F, 
1W0G, 4K9V, 4I3Q, 3UA1) that are absent in the tunnel-open structures (cluster 1).  
 
 
Figure 3.13 Tunnel gating model for pw2b in CYP3A4 
CYP3A4 tunnel-open structures (1TQN, 1W0F, 1W0G, 2J0D, 2V0M, 3NXU, 4K9U, 4K9V, 4K9X, 4K9W, 3TJS, 
4I3Q, 4I4G, 4I4H and 3UA1) (green) with open tunnel pw2b aligned to tunnel-closed structure 4K9T (red) in 
PyMOL. The side chain of F108 intersects pw2b in the tunnel-closed structure with tunnel-closing interactions 
F108-I223 and F108-R106. In the tunnel-open structures, F108 is flipped around facing towards pw2e instead of 
pw2a and does not make contact with R106 or I223. 
Tunnel pw3 is open in 2 (2V0M and 4K9U) of the 16 CYP3A4 structures. While the main part 
of the tunnel is similar in the two tunnel-open structures, the exit points vary considerably. Pw3 




is shorter in 2V0M and exits the molecule by a more direct route between the loop region 
flanked by helix F and helix F’ and the loop region flanked by helix G and helix G’. Pw3 bends 
over helix I in 4K9U exiting between the N-terminal of helix F, the C-terminal of helix G and the 
E-F loop region. Structure 4K9U has a missing region between helix F and F’, which boarders 
the tunnel so only pw3 in 2V0M was used to identify gating residues in the tunnel-closed 
CYP3A4 structures. Structures 2J0D, 4K9X, 3TJS also have regions missing that border pw3 so 
they were excluded from the analysis. In four of the eleven tunnel-closed CYP3A4 structures 
included in the analysis, L211 intersects pw3; in six of the structures, F213 and F304 intersect 
pw3 and in the remaining structure, F213 but not F304 intersects pw3. According to the 
definition of open/closed tunnels and gating residues used in this study, there are at least two 
different gating models for pw3. The tunnel-closing interactions making up each of these models 
are shown in Table 3.17 and illustrated in Figure 3.14 A and B.  
 
CAVER identified a total of 4 open solvent tunnels that are not artefacts of missing residues in 
CYP3A4 structures. Two of these solvent tunnels are present in 1TQN and are essentially the 
same tunnel branching into two near the surface due the CAVER algorithms use of grid points 
(Figure 3.15).  The other two solvent tunnels were identified in 4I3Q and are variants of the 
canonical tunnel S. Since the solvent tunnels in 1TQN most closely resemble the canonical 
tunnel S identified in REMD analysis, they were used to identify gating residues – many of the 
gating residues identified however also intersect the solvent tunnels in 4I3Q.  
 
Tunnel-intersecting residues responsible for tunnel S closure were identified on the basis that 
they intersected both the open solvent tunnels in 1TQN, i.e. intersect the tunnel in the base 
region rather than the branch region, thereby closing both tunnels.  Tunnel-closed CYP3A4 
structures 2J0D, 4K9U and 3TJS have missing residues in the solvent tunnel region so they were 
excluded from the analysis.    
 
Arg 212, Leu 482 or Gln 484 or a combination of these residues intersect the solvent tunnel in 
the tunnel-closed CYP3A4 structures (Figure 3.16). There were no tunnel-closing interactions 
common to all tunnel-closed CYP3A4 structures and tunnel-intersecting residues make several 
different interactions that result in tunnel closure. These interactions are listed in Table 3.17.  
 






Figure 3.14 Gating models for pw3 in CYPA4 
CYP3A4 structure 2V0M (green) with open tunnel pw3 (grey) aligned to tunnel-closed structure 1TQN (red) in (A), 
illustrating pw3 gating model 1, and aligned to 4I4H (red) in (B) illustrating pw3 gating model 2. Residues involved 
in tunnel-closing interactions are indicated are labelled. (A) F213 and F304 intersect tunnel pw3 in structure 1TQN 
and are involved in the following tunnel-closing interactions that are absent in the tunnel-open structure: F213-F304, 
F213-F108, F213-F215, F213-V240, F213-F241, F304-F241. F213 also interacts with F220 however this 
interactions is also present in the tunnel-open structure. (B) L211 intersects tunnel pw3 in structure 4I4H and is 
involved in the following tunnel-closing interactions that are absent in the open structure: L211-L210, L211-F220 
and L211-F241. L211-F220 is however the only tunnel-closing interaction present in all four tunnel-closed 
structures where pw3 is gated by L211. F213 and F304 are not involved in the gating of pw3 in this structure but 
their positions are also labelled for comparison.  





Figure 3.15 Solvent tunnels calculated by CAVER in CYP3A4 structure 1TQN.  
Solvent tunnels calculated by CAVER are shown in green and blue (tunnels 3 and 4 in Table 3.16 respectively) both 
with a gorge width of 1.43 Å. The tunnels are identical at the base branching into the surface of the molecule. The 
branches are not separated by the protein structure.  
 
Figure 3.16 Examples of tunnel S intersecting residues in CYP3A4 structures 
CYP3A4 structure 1TQN (green) with open tunnel S (grey) was aligned to tunnel-closed structures 1W0F (red) with 
tunnel-intersecting residue R212, 2V0M (blue) with tunnel-intersecting residue L484 and 3NXU (orange) with 
tunnel-intersecting residue Q484. The figure shows a cross-section through the base of the branched tunnel S.  




Singlet gating models in CYP3A4 
 
Table 3.18 shows the CYP3A4 singlet gating models identified for pw2c and tunnel W.  Gating 
residues were not delimited for pw2e as this tunnel was open in all 16 CYP3A4 crystal 
structures.  
 
Table 3.18 Singlet gating models in CYP3A4 
Gated tunnel Structures: open/closed Gating residue 
pw2c 1OG5(CYP2C9)/1TQN(CYP3A4) Phe 113, Met 114, Arg 212, Phe 213, Phe 304, Phe 241 
   
W 2FDV(CYP2A6)/1TQN(CYP3A4) Trp 126, Lys 127 
   
3.2.7 Analysis of gating models 
 
An annotated sequence alignment shows the relative positions of gating residues making up the 
singlet and two-state gating models in isoforms CYP2A6, CYP2B6, CYP2C8, CYP2C9, 
CYP2D6 and CYP3A4 (Figure 3.17). 
 
Tunnel-intersecting residues identified in each of the six CYP450 isoforms were classified 
according to their side chain chemical types (Table 3.19).  ‘Hydrophobic aromatic’ was the most 
common side chain chemical type observed in tunnel gating, making up the highest percentage 
of tunnel-gating residues in all isoforms except CYP2B6 and CYP2C8. Only 10% of CYP2C8 
gating residues have aromatic side chains, with the majority having polar or charged side chains.  
In contrast, half CYP2B6 gating residues are ‘hydrophobic aliphatic’ and only 10 % have polar 
or charged side chains.  
 









Figure 3.17 Multiple sequence alignment of human CYP450 isoforms showing residues forming part of tunnel 
gating models. Sequences were retrieved from the UniProt Data Base. Tunnel-intersecting residues are shown in 
bold while their interacting partners are shown in plain font. Residues are colour coded according to the tunnel they 
gate: pw2a (yellow), pw2b (blue), pw2c (green), pw2e (purple), pw3 (red), tunnel S (cyan), tunnel W (grey). 
Residues that gate multiple tunnels are boxed according to the colours of the addition tunnels they gate.   
 
Table 3.19 A summary of the distribution of tunnel-intersecting residue side chain chemical types 
Isoform Total Hydrophobic aromatic  Polar/Charged Hydrophobic aliphatic  
CYP2A6 18 10 (55.5 %) 4 (22.2 %) 4 (22.2 %) 
CYP2B6 10 4 (40.0 %) 1 (10.0 %) 5 (50.0 %) 
CYP2C8 10 1 (10.0 %) 5 (50.0 %) 4 (40.0 %) 
CYP2C9 11 5 (45.5 %) 3 (27.3 %) 3 (27.3 %) 
CYP2D6 10 4 (40.0 %) 4 (40.0 %) 2 (20.0 %) 
CYP3A4 16 9 (56.3 %)  4 (25.0 %) 3 (18.8 %) 
Total 75 33 (44.0 %) 21 (28.0%) 21 (28.0 %) 
Note: If a residue intersected two different tunnels it the same isoform it was counted twice. The chemical-type with 
the highest percentage of intersecting residues for each isoform is shown in bold.  
 
The different usage of side chain chemical types in tunnel gating within the CYP2 family, 
particularly between CYP2C8 and CYP2C9 that have high sequence similarity, suggests that the 
evolution rates may be high for tunnel gating residues. To test this hypothesis, the rate of 
evolution of each sequence positions in the CYP2 family was determined using rate4site 
software as described in the Methods section. Table 3.20 shows the average relative rate of 
evolution of tunnel-intersecting residues positions for each isoform. Calculated rates of evolution 
were normalised so that the average rate of evolution of all the positions in the sequence was 
zero and the standard deviation was one. Negative scores therefore represent positions that are 
more conserved than average and positive scores indicated positions that are less conserved than 




average. The average rate of evolution of tunnel-gating positions in all isoforms was found to be 
significantly higher than the average rate of evolution of the entire sequence.  
 
Table 3.20 Average rate of evolution of tunnel-intersecting residues in CYP2 isoforms 
Isoform 




CYP2A6 1.1402 0.00006 
CYP2B6 0.9881 0.00104 
CYP2C8 0.9740 0.00123 
CYP2C9 1.4125 0.00000 
CYP2D6 0.7668 0.00850 
The average rate of evolution of the entire sequence is zero and the standard deviation is 1. The null hypothesis that 
the average rate of evolution of the entire sequence is the same as the average rate of tunnel-intersecting residues 
was rejected for the alternative hypothesis that the average rate of evolution of the tunnel-intersecting residues is 
higher than the average rate of evolution of the entire sequence for all isoforms at the 5% level.  






Based on the assumptions that amino acid side chains play a critical role in tunnel gating and that 
CAVER calculated tunnels are sufficiently similar to canonical REMD tunnels, gating models 
for a total of 34 CYP450 tunnels in six of the major human drug metabolising isoforms were 
identified using in silico tools.   
 
Using a 1.4 Å gorge width cut-off, 75% of the open tunnels identified by CAVER were assigned 
to REMD tunnels.  The assignment of CAVER tunnels to REMD tunnels, pw2b, pw2c, pw2e 
and tunnel W was straightforward. There were however cases where the assignment of pw2a and 
tunnel S was less clear as a number of tunnel variants were calculated for these tunnels, some 
falling midway between pw2a and tunnel S.  Of the remaining CAVER tunnels that did not 
match REMD tunnels, two thirds were assigned to the newly defined tunnel pw6, however there 
are no REMD studies to date confirming that substrate molecules use this pathway so gating 
models were not delimited for this tunnel. There were no CAVER tunnels with a gorge width 
greater than 1.4 Å that resembled the REMD tunnels pw1 or pw2d in the crystal structures 
analysed in this study.  
 
It was not possible to identify gating models for all REMD equivalent tunnels calculated by 
CAVER. Neither two-state nor singlet gating models could be delimited for tunnels that were 
open in all structures of a given isoform, as was the case for CYP2C8 pw2b, CYP2C9 tunnel S, 
CYP2D6 pw2b and CYP3A4 pw2e. In other cases, gating models could not be identified 
because the protein backbone intersected the tunnel of interest substantially in tunnel-closed 
structures, as was the case for CYP2A6 pw2b, CYP2A6 pw3 CYP2B6 pw3 and CYP2D6 pw3.  
 
Gora et al recently reviewed different gating mechanisms in enzymes, classifying them into six 
groups based on their structure: 1) “wing” gates controlled by the rotation of a single side chain; 
2) “swinging doors” controlled by the rotation of the side chains of two residues distant in 
sequence, 3) “aperture” gates controlled by the backbone motion of 3-4 residues, distant in 
sequence, resulting in tunnel constriction; 4) “drawbridges” or 5) “double drawbridges” 
controlled by the movement of one or two fragments consisting of 3-20 residues neighbouring in 




sequence and 5) “shell” gates based on the movement of entire domains separated by a hinge 
region [430].  
The approach used in this study is most suited to identifying “wings” and “swinging” doors, with 
the majority of gating models identified here falling into the “wings” category, typified by the 
gating models observed for CYP3A4 pw2a and pw2b (Figure 3.12 and Figure 3.13).  Aperture 
gating models were however also observed since, although backbone motions control these 
gates, the movement of the backbone results in side chains moving closer together and 
intersecting the tunnel rather than intersection by the backbone itself. Gating models for 
CYP2D6 pw2a and pw2e (Figure 3.9 and Figure 3.10 A) provide good examples of aperture 
gates as the side chains of the tunnel-intersecting residues move closer together in the closed 
structure without changing orientation i.e. the tunnel appears to constrict rather than close due to 
the swinging motion of the side chains. In cases where backbone regions of the protein intersect 
the tunnel, it is difficult to predict the gating mechanism as larger conformational changes in the 
protein structure occur that may involve aperture or drawbridge gating mechanisms. 
 
Table 3.21 Human CYP450 gating models identified in molecular dynamics studies  
Tunnel Gating residues Products used in SMD simulations 
CYP3A4 pw2a F57-F215 temazepan and testosterone-6OH 
CYP3A4 pw2b F108-F220 temazepan and testosterone-6OH 
CYP3A4 pw2c F108-F241 temazepan and testosterone-6OH 
CYP3A4 pw2e F108-F220 temazepan 
 R105-S119 testosterone-6OH 
CYP3A4 pw3 F213-F241 temazepan 
 F213-V240 testosterone-6OH 
CYP3A4 S R212-L482 temazepan and testosterone-6OH 
Interactions that appear in the two-state gating models in this Chapter, matched to the same tunnel, are underlined 
and in bold. Residue that appear in two-state or singlet gating models, matched to the same tunnel but not 
necessarily the same interaction partner, are shown in bold.  
 
CYP3A4 is the only human CYP450 isoform for which gating models have been identified in 
molecular studies to date.  Table 3.21 gives a list of these gating models, identified by 
Fishelovitch et al using steered molecular dynamic simulations [434].  Here, three of the same 
gating interactions in CYP3A4 were identified and matched to the same tunnel as Fishelovitch et 
al. Notably, the CYP3A4 pw2b F108-F220 interaction was identified as an interaction that 
would break and reform in a new position/orientation during tunnel closure, but because it was 




present in both the tunnel-closed and tunnel-open structures it was not included as a tunnel-
closing interaction. Table 3.21 also shows that 62.5% (10/16) of the residues that appear in the 
molecular dynamics gating models also appear in the gating models delimited in this Chapter, 
matched to the same tunnel. As noted above, gating models for CYP3A4 pw2e could not be 
delimited using the approach followed here; if we exclude pw2e literature gating residues from 
the calculation, this study identified 10/12 (83%) gating residues previously reported for studies 
using molecular dynamics simulations; this indicates that a large proportion of gating residues 
identified in molecular dynamic studies can also be identified in static crystal structure using the 
far simpler approach described here.  
 
While molecular dynamic studies generally identify one interacting partner per gating residue, 
the present work regularly identified multiple tunnel-closing interacting partners for each tunnel-
intersecting residue.  This suggests that either molecular dynamic studies are more proficient at 
identifying a smaller number of true gating interactions or, perhaps more likely, that gating 
mechanisms are more complex than previously thought. Coordinated motion of side chains 
within aromatic residue clusters of gating residues (e.g. Figure 3.18) may provide one such more 
complex mechanism for coordinating the opening and closing of different tunnels. 
 
 
Figure 3.18 Aromatic cluster of gating residues found in CYP3A4. CYP3A4 structure 1TQN is shown in blue with 
the haem group in black and aromatic residues appearing in two-state and singlet gating models in this work shown 
in red.  
 




An annotated sequence alignment of the CYP450 isoforms used in this study shows that gating 
residues regularly fall at evolutionarily equivalent positions in different isoforms, yet despite 
this, the amino acid types at these positions, even in closely related isoforms, often differ. The 
rates of evolution of gating residue positions compared to the average rate of evolution of the 
entire sequence within the CYP2 family suggests that gating residues are subject to fast 
evolutionary dynamics. Ligand tunnels can play a role in substrate specificity and the varied 
amino acid types used in tunnel gating in different isoforms seems likely play an important role 
in selective substrate entry.  Tunnel gates can be found at any position along the tunnel but are 
most regularly found at the entrance to the tunnel, at the bottleneck of the tunnel (narrowest 
point) or near the end of the tunnel at the entrance to the active site cavity [430].  The fact that 
different viable tunnel gating combinations may evolve at any position along the tunnel may 
explain the fast evolutionary dynamics observed for gating residues.  
 
The gating of tunnel W by the highly conserved tryptophan residues, present in all isoforms 
except CYP2A6, is the most conserved gating model observed here.  Controlling the flow of 
water molecules in and out of the active site is vital for the CYP450 catalytic cycle. Molecular 
dynamic studies using CYP3A4 have also found that Arg 375, another highly conserved residue, 
is important for the CPR mediated control of tunnel W [442]. This further suggests that in 
contrast to the gating of tunnels used by substrate molecules, water channel gating is conserved 
across isoforms.  
 
In conclusion, the results presented here suggest that a simple and rapid approach using static 
crystal structures and a combination of tools such as CAVER and Protein Interaction Calculator 
provides a comprehensive alternative to complex molecular dynamic studies for identify gating 
models for substrate access and egress pathways. This work reports the largest set of gating 
models for CYP450 tunnels to date, identifying 49 tunnel-closing interactions (two-state gating 
models) and an additional 54 tunnel-intersecting residues (singlet gating models) thereby adding 
valuable insight into CYP450 tunnel gating and setting a benchmark for future molecular 
dynamic studies.  
 
 





3.4.1 Structures  
 
Structures were retrieved from the RCSB Protein Data Bank [31] as follows. CYP2A6: 1Z10, 
1Z11, 2FDU, 2FDV, 2FDV, 2FDW, 2FDX, 2FDY, 2PG5, 3T3R, 4EJJ, 3T3Q. CYP2B6: 3IBD, 
3UA5, 4I41, 3QOA, 3QU8.  CYP2C8: 1PQ2, 2NNH, 2NNI, 2NNJ, 2VN0. CYP2C9: 1OG2, 
1OG2, 1R90. CYP2D6: 3QM4, 2F9Q, 3TDA, 3TBG. CYP3A4: 1TQN, 1W0F, 1W0G, 2J0D, 
2V0M, 3NXU, 4K9T, 4K9U, 4K9V, 4K9X, 4K9W, 3TJS, 4I3Q, 4I4G, 4I4H, 3UA1.  
3.4.2 Tunnel identification using CAVER 
 
Tunnels were identified in each CYP450 structure using the computational geometry tool 
CAVER [437]. The haem iron coordinates were read in from the PDB file and used as the 
starting point for tunnel searches and water and ligand molecules and hydrogen atoms were not 
taken into account.   CAVER returns a ranked list of possible routes out of the molecule giving 
greatest priority to routes with the widest gorge width irrespective of the length of the tunnel. In 
cases where two tunnels have identical gorge widths the shorter tunnel is prioritised.  
Determining the gorge width cut-off 
 
A preliminary study was carried out to determine 1) the variation in the number of tunnel-
open/tunnel-closed structure pairs with changes in gorge width cut-off and 2) the resemblance of 
CAVER calculated tunnels to REMD tunnels with changes in gorge width cut-off.  The number 
of tunnel/open tunnel-closed pairs for each isoform was recorded as the gorge width cut-off was 
increased from 0.7 Å to 3.3 Å in 0.1 Å increments and tunnels resembling REMD tunnels were 
assigned to determine the verisimilitude of the accepted tunnels at each gorge width cut-off.  
 
Based on this preliminary study a gorge width cut-off of 1.4 Å was chosen as it gave the best 
balance between the verisimilitude of calculated tunnels and the number of tunnel-open/tunnel-
closed structure pairs for REMD equivalent tunnels. Tunnels with a gorge width cut-off > 1.4 Å 
were therefore assigned as open tunnels and where possible were assigned to REMD tunnels in 
accordance with the standard nomenclature [66, 427].  




3.4.3 Delimiting two-state gating models 
 
Two-state gating models were identified using structures from the same isoform showing 
differential tunnel-opening patterns. Tunnel-open and tunnel-closed structure pairs were 
identified for a given tunnel and a given isoform and aligned in PyMOL with the tunnel of 
interest in the open structure displayed. Amino acid side chains from the tunnel-closed structure 
that intersect the tunnel of interest in the tunnel-open structure were manually delimited by 
searching along the length of the tunnel.  In cases where there was more than one tunnel-closed 
structure for a given isoform and tunnel, all tunnel-closed structures were aligned to the open 
structure to determine if the same tunnel-intersecting residues were responsible for tunnel 
closure in all structures. In cases were a large portion of the protein backbone intersected a 
tunnel, gating residues were not identified.  
 
Residues that directly interact with the tunnel-intersecting residues were identified separately for 
the tunnel-open and tunnel-closed structures using Protein Interaction Calculator [444]. 
Hydrophobic, aromatic, main chain-main chain, main chain-side chain, side chain-side chain, 
ionic and cation-pi intra-protein interactions were identified using default parameters. 
Interactions with the tunnel-intersecting residue present in the tunnel-closed structure but absent 
in the tunnel-open structure are assigned as tunnel-closing interactions while those present in the 
tunnel-open structure but absent in the tunnel-closed structure are assigned as tunnel-opening 
interactions. Interactions present in both structures were omitted from the two-state gating 
models.  
3.4.4 Delimiting singlet gating models 
 
In cases where all a given tunnel was closed in all structures of a given isoform singlet gating 
models were identified by aligning the tunnel-closed structures to a tunnel-open structure of a 
different isoform. As for two-state gating models, residues from the tunnel-closed structures 
intersecting the tunnel of interest in the tunnel-open structure were manually delimited. Tunnel-
closing interactions cannot be determined in these cases as there is no simple way of identifying 
interactions that occur exclusively in the tunnel-closed structure when the protein sequences 
differ between structures.  




3.4.5 Analysis of gating models 
Sequence alignment 
 
Sequences with the following accession numbers were retrieved from the UniProt Data Base and 
aligned using ClustalW (default parameters) [422]:  CYP2A6, P11509 (Homo sapiens); 
CYP2B6, P20813 (Homo sapiens); CYP2C8, P10632 (Homo sapiens); CYP2C9, P11712 (Homo 
sapiens); CYP2D6, P10635; CYP3A4, P08684 (Homo sapiens). Residues in two-state and 
singlet gating models were highlighted on the alignment according to the tunnel they gated with 
tunnel-intersecting residues in bold and interacting residues in plain font.  
Distribution of amino acid side chain types 
 
Tunnel-intersecting residues were classified as hydrophobic aromatic (Phe, Trp, Tyr), 
polar/charged (Arg, Lys, Glu, Asp, Thr, Gln, Asn, Ser, His, Cys) or hydrophobic aliphatic (Leu, 
Ile, Val, Met, Pro) according to side chain chemical type. The propensity of side chain chemical 
types responsible for tunnel gating in each isoform was determined by calculating the percentage 
of tunnel-intersecting residues falling into each group. If the same residue acted as a gating 
residue for two different tunnels it was counted twice.  
Evolutionary dynamics of gating residues in CYP2 family 
 
The following CYP2 sequences were aligned using ClustalW (default parameters) [422]: 
CYP2A6, P11509 (Homo sapiens); CYP2B6, P20813 (Homo sapiens); CYP2C8, P10632 (Homo 
sapiens); CYP2C9, P11712 (Homo sapiens) and CYP2D6, P10635. PROML (Protein Maximum 
Likelihood program) in the PHYLIP suit of programs (version 3.695, default parameters, [445]) 
was used to generate a phylogenetic tree using the ClustalW alignment in PHYLIP format as 
input.  Rate4site (version 2.01 for Windows, default parameters, [446]) was then used to 
calculate the relative rate of evolution of each sequence position in the CYP2 alignment; the 
ClustalW alignment and phylogenetic tree were used as input.  The rates were normalised so that 
the average rate of evolution of all positions in the sequence was zero and the standard deviation 
was one. The average rate of tunnel-intersecting sequence positions for each isoform was 
calculated and a one-tailed student t-test was performed in Excel to determine if the rate of 




evolution of tunnel-gating residues in each isoform was significantly higher than the average rate 
of evolution of the entire sequence.                                                         




 In silico analysis of the Chapter 4
effect of polymorphic variation on 
protein stability and function 






The sheer number of non-synonymous CYP450 polymorphisms, combined with the observed 
substrate specific phenotypic effects and the many diverse potential drugs, highlights the need 
for improved in silico prediction tools for determining the effects of single amino acid 
substitutions in CYP450 enzymes on drug metabolism. Changes in the amino acid sequence of 
CYP450s can directly affect structural stability, haem binding, substrate access and recognition, 
as well as interactions with CPR.  
 
Chapters 2 and 3 described the delimitation of substrate recognition sites and tunnel gating 
residues. In addition to these functional studies, a number of other studies from the Blackburn 
group and elsewhere have contributed to elucidating the CYP450-CPR interface and have 
identified clusters of basic residues on the proximal surface of CYP450s that interact with 
exposed acidic clusters on the CPR FMN domain surface [93-98].   
 
In order to then analyse the impact of polymorphic variation on enzyme stability and function in 
human CYP450 drug metabolising enzymes, representative in silico modelling tools were used 
to predict the qualitative effect of mutations on protein stability; the resulting data was combined 
with previous in silico analyses of conserved structural features, SRS regions, CPR contacts and 
tunnel gating residues to create a unified CYP450 SNP map, which was used to correlate the 
location of individual mutations with their experimentally observed impact on CYP450 function. 
This work described in this Chapter was published in Current Drug Metabolism in 2013 ([447], 
full manuscript appended at the end of Thesis).  
 
 






This study focused on a set of 9 human CYP450 isoforms responsible for the majority of known 
drug metabolism: CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, 
CYP2E1 and CYP3A4. An in silico structural analysis of 348 non-synonymous single nucleotide 
polymorphisms found across these isoforms was carried out to determine the effects of mutations 
on enzyme stability and function. 
4.2.1 Experimental Data 
 
 
Figure 4.1 SNPs categorised according to available experimental data. 
 
In order to enable the correlation of stability prediction data for individual CYP450 SNPs with 
known effects on function, experimental data was first extracted and compiled from the 
literature. Experimental activity data was available for 38% of the SNPs analysed in this study 
(Figure 4.1); these data are collated in Appendix B, Tables B1-B9. Analysis of the data set 
showed that 17% of these SNPs were categorised as inactive, 34% of SNPs led to decreased 
activity and 11% displayed substrate specific effects on activity. It must be noted though that 
only a small percentage of SNPs have been tested on more than one substrate in the same in vitro 
experiment, so it is possible that some SNPs that currently fall within the neutral or decreased 
activity category, based on available data, would show substrate specific effects if tested on a 




broader range of different substrates. CYP3A4 L293P and CYP2C9 R150H were the only SNPs 
reported to give increased activity in vitro. The remaining 37% of SNPs tested showed no 
significant effect on enzyme expression or activity.  
 
The number of SNPs per isoform, classified into 6 categories on the basis of available 
experimental data, is shown in Table 4.1. To date, CYP2B6 and CYP2C19 polymorphic variants 
have been the most thoroughly characterised, the largest contribution for CYP2B6 variant data 
coming from a study by Watanabe et al, who investigated the effect of 26 variant CYP2B6 
alleles, expressed in COS-7 cells, on 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) and selegiline 
metabolism [448].  There is in vitro data for 24 out of the 39 CYP2C19 SNPs and 20 of these 
were tested by Wang et al who reported expression levels, P420:P450 holoprotein levels and 
kinetic data for 3 different substrates and 10 inhibitors using high through-put activity assays 
[315, 316].  The functional data available for individual CYP2D6 SNPs is the most incomplete 
and as a result, only 12% of the SNPs found in CYP2D6 could be classified.  CYP2D6 shows the 
highest levels of polymorphic variation and although there is a large amount of clinical data 
available, as well as data from several in vitro studies, most CYP2D6 alleles contain multiple 
SNPs in the coding and/or non-coding regions of the gene, which makes it difficult to determine 
the contribution of individual mutations to the observed phenotype.  
 
Table 4.1 Summary of SNP classification based on available experimental data for each of the 9 major drug 
metabolising CYP450 isoforms  
Experimental Data 1A2 2A6 2B6 2C8 2C9 2C19 2D6 2E1 3A4 Total 
inactive 4 3 7 1 2 2 2 0 2 23 
decreased activity  3 5 3 5 12 9 1 1 6 45 
substrate specific 3 3 2 0 0 2 4 0 0 14 
increased activity  0 0 0 0 1 0 0 0 1 2 
neutral 4 4 9 5 9 9 3 2 4 49 
unknown 24 26 10 8 21 17 71 15 23 215 
Total SNPs  38 41 31 19 45 39 81 18 36 348 
Table shows the number of SNPs classified into each of the 6 categories based on experimental data as described in 
Methods, Section 4.4.3.  
4.2.2 The CYP450 SNP map 
 
In order to visualise the positions of individual CYP450 SNPs relative to key structural and 
functional regions of the enzymes, a multiple structural alignment, generated based on a 
representative structure for each of the nine isoforms analysed in this study, is shown in Figure 




4.2. This alignment has been annotated with structural features using the program JOY [449].  
  
 





Figure 4.2  The CYP450 SNP map consists of a multiple structural alignment, generated based on a representative 
structure for each of the 9 drug metabolising CYP450 isoforms.  
 
The alignment is annotated with the following structural features according to the JOY format: Solvent 
inaccessible/buried residues (upper case), Solvent accessible (lower case), Positive Φ (italics),  Hydrogen bond to 




main chain amide (bold), Hydrogen bond to main chain carbonyl (underlined), α-helix (red), β-sheet (blue), 310-helix 
(dark red).  
 
Secondary structures are named according to the nomenclature of Poulos et al [37]. The positions of conserved 
motifs are also indicated below the alignment.   
 
Functional regions as described in Methods are indicated as follows: SRS regions (boxed in grey), haem contacts 
(shaded in green), CPR contacts (shaded in yellow- light yellow for residues within 6Å of interface and bright 
yellow for charge cluster residues), gating residues (boxed in blue) and aqueduct gating residues (boxed in dashed-
blue). 
 
The positions of known SNPs are highlighted according to their classifications based on experimental data available 
in the literature. Inactive (red), decreased activity (orange), substrate specific (magenta), increased activity (bright 
green), neutral (blue) and unknown (grey). If more than one SNP can occur at the same residue position then the 
position is highlighted according to the SNP that shows the most drastic effect on enzyme function.  
 
Secondary structure assignment and regions important for the enzymes’ structural integrity and 
function are also indicated, as described in Methods. The positions of SNPs are highlighted 
according to their assignment based on available experimental data. The alignment does not give 
information on the mutant residue type, but this information can be found in Appendix B, Tables 
B1-B9. If more than one SNP occurs at the same position, the wild-type residue is highlighted 
according to the mutant residue type that has the greatest known effect on enzyme function.   
 
Approximately half of SNPs analysed fell within ordered secondary structure regions (helices A-
L or β-sheets 1-5), while the other half occurred in loop/disordered regions.  Ordered helices and 
β-strands make up about 50% of the CYP450 structure, indicating that the SNPs are evenly 
spread across the protein structure (Table 4.2).  A visual representation of the positions of 
CYP3A4 SNPs relative to secondary structure elements, conserved motifs and functional regions 
within the 3-D protein structure is shown in Figure 4.3.  
 
 
Table 4.2 Distribution of SNPs across secondary structure regions 
Secondary 
structure 1A2 2A6 2B6 2C8 2C9 2C19 2D6 2E1 3A4 Total 
ordered 16 22 11 9 25 19 41 14 23 180 (52%) 
loop/disordered 22 19 20 10 20 20 40 4 13 168 (48%) 
Total SNPs 38 41 31 19 45 39 81 18 36 348 









Figure 4.3 CYP3A4 Structural overview 
CYP3A4, PDB structure 1TQN, is shown in grey with the haem group in black. Secondary structure elements, α-
helices and β-strands are labelled using the nomenclature of Poulos and co-workers [37]. Positions of polymorphic 
variants found in CYP3A4 are indicated in red. (A) Distal face view showing the position of the halting signal 
(yellow), the proline-rich motif (magenta), the I-helix catalytic groove (blue), the core stabilising motif, the meander 
stabilised by the ERR triad (orange) and the cys-pocket (cyan). (B) Side view showing the position of the SRS 
regions (cyan), the gating residues (magenta), the haem contacts (green) and the CPR interface (yellow) on the 
proximal face of the protein.     
4.2.3 Effect of SNPs on protein stability 
 
Site Directed Mutator (SDM) [356], a statistical potential energy function first developed by 
Topham et al [344], was used as a representative in silico tool to predict the effect of each 
individual CYP450 SNP on protein stability as described in detail in Methods, section 4.4.7 and 
4.4.8. SDM uses environment-specific substitution frequencies within homologous protein 
families to calculate a stability score. The environment specific substitution tables (ESSTs) 
provide information on the amino acids local structural environment and the probability of it 
being substituted by another amino acid. The algorithm uses these ESSTs to calculate a stability 
score, which predicts the difference in free energy between a wild-type and mutant protein, by 
analogy to a reversible folding-unfolding thermodynamic cycle. Based on this pseudo ΔΔG 
stability score, SDM classifies mutations as stabilising, destabilising or neutral.  
 
Table 4.3 gives SDM results for three CYP2C9 SNPs, providing an example of a mutation 
predicted to be neutral, a mutation predicted to be damaging due to stabilising effects, and a 
mutation predicted to be damaging due to destabilising effects; SDM results for the full data set 
can be found in Appendix B, Table B1–B9. Tables in Appendix B include pseudo ΔΔG scores - 
together with predicted effect on stability – and structural information, including the relative  




solvent accessibility (RSA) of the wild-type and mutant residue as well as the secondary 
structure location and the functional region within which the mutation falls and a summary of 
any available experimental in vitro data for each of the 348 CYP450 SNPs in the data set.  
 
Table 4.3 SDM results for three different CYP2C9 SNPs  
CYP2C9 SNP L208V Q214L L413P 
Secondary Structure α-helix F α-helix F’ (F-G loop) between 310 helix & helix L 
Relative solvent accessibility of WT residue 51.6 % 6.6 % 2.6 % 
Relative solvent accessibility of mutant residue 47.9 % 14.9 % 7.2 % 
pseudo ΔΔG scores (kcal.mol-1) - 0.6  3.2 - 4.1 
SDM Prediction Neutral Damaging - stabilising Damaging- destabilising 
 
 
SDM predicted 28% to be damaging mutations that are likely to result in a functionally impaired 
enzyme (Figure 4.4). The majority of these mutations are predicted as damaging due to 
destabilising effects (-∆∆G scores) however 6% of the SNPs are predicted as damaging due to a 
stabilising effect (+∆∆G scores); the literature rationalisation on positive ∆∆G scores as 
damaging is based on the premise that mutations that are highly stabilising may reduce 
conformational flexibility that is important for function [450-453]. 64% of the SNPs were 
predicted to be neutral by SDM. SDM could not be used to predict the effect of the remaining 
8% of the SNPs on stability as these mutations lie within the N-terminal domain, which is 
truncated or disordered in crystal structures. These mutations were however considered to be 
neutral since they are unlikely to affect the stability of the catalytic domain and since in vitro 
studies have shown that the N-terminal membrane anchor region is not important for enzyme 
activity [454]. A summary of the SDM predictions for SNPs in each isoform is shown in Table 
4.4.  
 





Figure 4.4 Proportion of SNPs predicted to be damaging to protein structure 
 
Table 4.4 Summary of SDM predictions 
Effect of SNPs on stability 1A2 2A6 2B6 2C8 2C9 2C19 2D6 2E1 3A4 Total 
Neutral 27 28 19 12 26 28 50 15 19 224 
damaging – destabilising 7 4 5 6 14 7 20 2 12 77 
damaging – stabilising 1 6 2 0 1 1 5 1 4 21 
No prediction 3 3 5 1 4 3 6 0 1 26 
Total  38 41 31 19 45 39 81 18 36 348 
Table shows the number of SNPs in each isoform predicted to be neutral (-2 < ∆∆G < 2 kcal.mol-1), damaging due 
to destabilising effects (∆∆G < -2 kcal.mol-1) and damaging due to stabilising effects (∆∆G < 2 kcal.mol-1) as well as 
the number of SNPs in each isoform for which a prediction could not be obtained.  
 
4.2.4 Correlation between stability predictions and experimental data 
 
Table 4.5 lists the SNPs that could be classified based on experimental data, together with their 
secondary structure and functional region location, their predicted effect on protein stability, and 








Table 4.5  Structural information and protein stability predictions for SNPs that could be classified according 
to their effect on enzyme activity based on experimental data collected from the literature. 













P42R loop btwn N-term & helix A proline rich motif -0.3 neutral inactive 
T83M B-sheet12 SRS1'b 0.1 neutral neutral 
E168Q α-helix D undefined 0.0 neutral decreased activity 
F186L loop btwn Helix D & E undefined -1.0 neutral decreased activity 
S212C loop btwn helix E & F undefined -1.9 neutral decreased activity 
G299A B-sheet 2 undefined -5.2 damaging neutral 
D348N α-helix J undefined 0.8 neutral substrate specific 
R377Q α-helix K ERR triad/core stabilising motif -1.1 neutral inactive 
I386F loop btwn helix K & B-sheet 31 haem contact/SRS5 0.1 neutral substrate specific 
C406Y B-sheet 32 undefined 0.0 neutral substrate specific 
R431W 310 helix ERR triad/meander 2.3 damaging inactive 
T438I loop btwn  310 helix & helix L undefined -0.8 neutral neutral 
R456H loop btwn  310 helix & helix L 
Cys pocket/haem contact/CPR 
contact (charge cluster residue) 
-1.5 neutral inactive 
Q478H end of helix L undefined 0.3 neutral neutral 
CYP2A6 
V110L  α-helix B' SRS1 0.3 neutral decreased activity 
R128Q  α-helix C haem contact/CPR contact -0.9 neutral inactive 
L160H  α-helix D undefined -1.9 neutral inactive 
K194E loop btwn helix E & F undefined -0.4 neutral neutral 
R203S α-helix F SRS(2,3) -1.2 neutral neutral 
R203C α-helix F SRS(2,3) -7.2 damaging decreased activity 
S224P α-helix G' SRS(2,3) 1.6 neutral decreased activity 
V365M loop btwn helix K & B-sheet 31 SRS5 1.5 neutral substrate specific 
Y392F B-sheet 32 undefined 1.3 neutral substrate specific 
E419D loop btwn B-sheet 32 & helix K' undefined 0.2 neutral neutral 
N438Y loop btwn  310 helix & helix L Cys-pocket/CPR contact 2.1 damaging decreased activity 
I471T btwn B-sheet 51 & 52 SRS6 -2.3 damaging substrate specific 
K476R btwn B-sheet 51 & 52 SRS6 1.3 neutral decreased activity 
G479V btwn B-sheet 51 & 52 SRS6 2.1 damaging inactive 
R485L btwn B-sheet 51 & 52 SRS6 1.3 neutral neutral 
CYP2B6 
R22C Truncated N-terminal halting signal n/a n/a neutral 
T26S Truncated N-terminal undefined n/a n/a neutral 
D28G Truncated N-terminal undefined n/a n/a neutral 
R29T Truncated N-terminal halting signal n/a n/a neutral 




M46V loop btwn N-term & helix A SRS1'a -1.8 neutral inactive 
G99E B-C loop SRS1 -1.0 neutral inactive 
K139E loop btwn helix C & D undefined 0.6 neutral inactive 
R140Q loop btwn helix C & D undefined 0.4 neutral decreased activity 
T168I start of helix E undefined 3.4 damaging decreased activity 
Q172H α-helix E undefined 2.4 damaging neutral 
M198T α-helix E SRS(2, 3) -2.7 damaging substrate specific 
S259R loop btwn helix G & H undefined 0.0 neutral neutral 
K262R loop btwn helix G & H undefined -0.4 neutral substrate specific 
I328T α-helix J undefined -3.9 damaging inactive 
R336C loop btwn helix J & J’ undefined -3.0 damaging decreased activity 
I391N loop btwn B-sheet 32& helix K’ undefined -4.6 damaging inactive 
P428T loop btwn 3 10 helix & helix L haem contact -1.2 neutral inactive 
M459V  Β-sheet 51 undefined -0.5 neutral neutral 
G476D loop bwn  Β-sheet 51 & 52 SRS6 0.5 neutral inactive 
Q485L loop bwn  Β-sheet 51 & 52 undefined -1.7 neutral neutral 
R487C  Start of Β-sheet 52 undefined -3.6 damaging neutral 
CYP2C8 
R139K loop btwn helix C & D undefined -1.4 neutral neutral 
G171S α-helix E undefined 1.5 neutral neutral 
R186G loop btwn helix E & F undefined -4.6 damaging inactive 
I223M F-G loop SRS(2,3) 0.2 neutral neutral 
A238P α-helix G SRS(2,3) -2.2 damaging decreased activity 
K247R α-helix G undefined 0.5 neutral neutral 
I264M α-helix H undefined -0.4 neutral decreased activity  
I269F α-helix H undefined 0.2 neutral decreased activity 
K383N loop btwn B-sheet 42 & 32 CPR contact -1.1 neutral neutral 
K399R loop btwn helix K' & 310 helix undefined -0.4 neutral decreased activity 
P404A loop btwn helix K' & 310 helix meander 1.2 neutral decreased activity 
CYP2C9 
L19I truncated N-terminal signal-anchor sequence n/a n/a neutral 
L90P loop btwn helix B & C CPR contact -2.5 damaging  decreased activity 
R125H α-helix C CPR contact/SRS1 -0.6 neutral decreased activity 
T130R α-helix C SRS1 -2.1 damaging decreased activity 
R132Q loop btwn helix C & D 
CPR contact (charge cluster 
residue)/SRS2 
-0.2 neutral decreased activity 
R144C α-helix D undefined -11.5 damaging decreased activity 
R150H α-helix D undefined -0.6 neutral increased activity 
R150L α-helix D undefined -0.2 neutral neutral 
Q214L α-helix F' (F-G loop) SRS(2,3) 3.2 damaging  decreased activity 
H251R α-helix G undefined -0.1 neutral neutral 
E272G α-helix H undefined -4.0 damaging neutral  
P279T loop btwn helix H & I undefined 1.1 neutral  neutral 
T299A centre of α-helix I catalytic groove/SRS4 1.9 neutral  decreased activity 
R335Q loop btwn helix J & J' undefined -0.3 neutral neutral 




R335W loop btwn helix J & J' undefined -2.2 damaging decreased activity 
E354K α-helix K ERR triad / core stabilizing motif -4.0 damaging inactive 
I359L end α-helix K SRS5 0.2 neutral decreased activity 
I359T end α-helix K SRS-5 -3.9 damaging decreased activity 
D360E loop btwn helix K & B-sheet 31 SRS-5 -1.3 neutral decreased activity 
P382S loop btwn B-sheet 42 & 32 SRS5 -0.9 neutral neutral 
D397A loop btwn helix K’ & 310 helix undefined 1.2 neutral inactive 
Q454H α-helix L undefined 1.4 neutral neutral 
A477T loop btwn B-sheet 51 & 52 SRS-6 0.6 neutral decreased activity 
P489S end of B-sheet 52 undefined 1.7 neutral neutral 
CYP2C19 
L17P truncated N-terminal signal-anchor sequence n/a n/a neutral 
I19L truncated N-terminal signal-anchor sequence n/a n/a neutral 
S51G α-helix A SRS1'a -2.0 neutral decreased activity 
M74T B-sheet 12 SRS1'b -2.7 damaging neutral 
E92D loop btwn helix B & B' CPR contact/SRS1 0.0 neutral substrate specific 
W120R α-helix C haem contact/SRS1 -2.7 damaging decreased activity 
E122A α-helix C SRS1 1.4 neutral substrate specific 
R132Q loop btwn helix C & D 
CPR contact (charge cluster 
residue)/SRS1  
0.4 neutral inactive 
R144H α-helix D undefined 0.2 neutral decreased activity 
R150H α-helix D undefined -0.6 neutral neutral 
A161P loop btwn helix D & E undefined -10.5 damaging decreased activity 
F168L  α-helix E undefined 1.0 neutral neutral 
W212C α-helix F' SRS(2,3) -2.1 damaging decreased activity 
P227L F-G loop SRS(2,3) 0.6 neutral decreased activity 
D256N loop btwn helix G & H undefined -0.3 neutral decreased activity 
R329H α-helix J undefined -0.6 neutral neutral 
I331V1 
(WT 1.B) 
loop btwn helix J & J' undefined -0.4 neutral neutral 
D360N loop btwn helix K & B-sheet 31 SRS5 1.5 neutral decreased activity  
V394M  α-helix K' undefined -0.1 neutral neutral 
R410C 3 10 helix meander -0.3 neutral neutral 
R433W loop btwn 3 10 helix & helix L 
Cys-pocket/haem contact/CPR 
contact (charge cluster residue) 
0.4 neutral inactive 
R442C α-helix L 
CPR contact  (charge cluster 
residue) 
-10.0 damaging decreased activity 
CYP2D6 
A90V α-helix B undefined -0.2 neutral neutral 
T107I α-helix B' SRS1 4.2 damaging substrate specific 
E156A α-helix D undefined 0.42 neutral decreased activity 
R296C α-helix I SRS1 -8.8 damaging neutral 
I297L α-helix I SRS1 0.2 neutral substrate specific 
H324P loop btwn helix H & I undefined -4.6 damaging inactive 
I369T loop btwn helix K & B-sheet 31 Haem contact/SRS5 -3.2 damaging substrate specific 




E410K loop btwn α-helix K’ & 310 helix undefined 0.4 neutral substrate specific 
R441C loop btwn 310 helix & helix L 
Cys-pocket/haem contact/CPR 
contact (charge cluster residue) 
-10.4 damaging inactive 
S486T Β-sheet 52 SRS6 0.7 neutral neutral 
CYP2E1 
R76H B-sheet 12 SRS1'b 0.8 neutral decreased activity 
V179I α-helix E undefined -0.1 neutral neutral 
V389I Β-sheet 32 undefined -0.3 neutral neutral 
CYP3A4 
G56D btwn N-term & α-helix A SRS1'a -2.3 damaging  decreased activity 
R130Q α-helix D haem contact/CPR contact/SRS1 -1.4 neutral inactive 
V170I loop btwn helix D & E undefined -0.3 neutral neutral 
D174H α-helix E undefined 0.2 neutral neutral 
T185S α-helix E undefined -1.4 neutral decreased activity 
F189S loop btwn helix E & F undefined -5.2 damaging decreased activity 
S222P α-helix F' SRS(2,3) -0.9 neutral decreased activity 
L293P Start of Helix I start of SRS4 -0.5 neutral increased activity 
T363M α-helix K core-stabilising motif 2.1 damaging decreased activity 
L373F start of  B-sheet 31 haem contact/SRS5 0.0 neutral decreased activity 
P416L start of 310 helix meander 3.9 damaging inactive 
M445T start of α-helix L CPR contact -2.6 damaging neutral 
P467S loop btwn B-sheet 51 & 52 undefined -1.4 neutral neutral 
 
 
The correlation between SDM results and experimental data is shown in Figure 4.5, from which 
it can be seen that of the 38 CYP450 SNPs for which there was experimental data and which 
were predicted to be damaging by SDM, 31 showed altered activity in the experimental data, 
giving a positive predictor value (PPV) (i.e. the percentage of test positives that are true 
positives) of 82% for SDM.  Conversely, of the 84 SNPs in the data set that showed altered 
activity experimentally, SDM predicted that 31 would be damaging, meaning that, used on its 
own, SDM has a sensitivity (i.e. the percentage of correctly classified true positives) of 37% in 
analysis of CYP450 SNPs.  Finally, of the 42 SNPs classified as neutral based on experimental 
data and which could be analysed by SDM, 35 were predicted to have no significant effect on 
protein stability, meaning that used on its own, SDM has a specificity (i.e. the percentage of 
correctly classified true negatives) of 83% in analysis of CYP450 SNPs. 
 





Figure 4.5 Correlation between SDM stability predictions and experimental data.  
 
The y-axis shows the percentages of SNPs predicted to be damaging to protein structure (red columns), those 
predicted to be neutral (blue columns) and those that fell within truncated regions of the structure that could not be 
analysed by SDM (grey columns) for (A) each experimentally classified group and (B) for a combination of all 
groups showing altered enzyme function vs. those classified as neutral, as shown along the x-axis.  The numbers of 
SNPs accounting for these percentages are shown within the columns.  
 
4.2.5 Effect of SNPs on function 
 
According to the analysis performed here, 54% of the CYP450 sequence space forms part of one 
or more functional regions (Figure 4.2 & Figure 4.6): The seven conserved motifs cover ~13% of 
the CYP450 sequence space; just over 5% of CYP450 residues form haem contacts; ~8% form 
the CPR interface; & SRS’s are the largest functional regions, covering one third of the sequence 
space (Chapter 2).  Gating residues have additionally been identified in six of the nine isoforms 
(Chapter 3) and currently make up an average of 2% of the CYP450 sequence. 
 
Figure 4.6 also shows the percentage of SNPs falling within each functional region. Based on the 
percentage sequence space covered by each functional region, SNPs were found to be evenly 
spread throughout all functional regions, including the conserved motifs, with 52% of SNPs 
falling within one or more defined regions and the other 48% falling within undefined functional 
regions. A breakdown of the number of SNPs falling within each functional region for each 
isoform is given in Table 4.6. 
 





Figure 4.6 Percentage of SNPs falling within each functional region and the percentage sequence space covered by 
each functional region, illustrating that SNPs are spread evenly across functional regions.  
 
Table 4.6 Summary of SNPs locations within functional regions for each isoform 
The numbers in this table represent the number of SNPs falling within each functional region for each isoform. Note 
that because functional regions overlap many SNPs fall within more than one functional region. 
4.2.6 Correlation between functional region analysis and experimental data 
 
The correlation between the functional region location of SNPs and experimental data is shown 
in Figure 4.7, from which it can be seen that of the 64 CYP450 SNPs for which there is 
experimental data and which fall in functional regions important for catalytic activity (and which 
are therefore potentially damaging), 53 showed altered activity in the experimental data, giving a 
Functional Region 1A2 2A6 2B6 2C8 2C9 2C19 2D6 2E1 3A4 Total 
undefined 22 17 20 12 21 19 31 8 18 168 
SNPs in functional 
region 16 24 11 7 24 20 50 10 18 180 
conserved motifs 9 6 4 2 6 6 15 0 5 53 
haem contacts 3 3 2 1 1 3 9 3 4 29 
CPR contacts 3 4 0 1 5 8 9 3 5 38 
SRS regions 7 17 7 4 18 13 30 8 11 114 
gating residues 0 1 0 0 1 0 3 0 1 6 




positive predictor value (PPV) of 83% for this functional region analysis.  Conversely, of the 84 
SNPs in the data set that showed altered activity experimentally, 53 fall in functional regions 
important for catalytic activity (and are therefore potentially damaging), giving a sensitivity of 
63%.  Finally, of the 49 SNPs classified as neutral based on experimental data, 38 were found to 
fall within undefined regions or regions that are not important for catalytic activity (and are 
therefore less likely to be damaging), giving a specificity of 78%. 
 
 
Figure 4.7 Correlation between functional analysis and experimental data 
The y-axis shows the percentages of SNPs falling within functional regions important for catalytic activity (purple) 
vs. those falling within undefined functional regions or regions that do not affect catalytic activity (grey) for (A) 
each experimentally classified group and for (B) a combination of all groups showing altered enzyme function vs. 
those classified as neutral, as shown along the x-axis.  The numbers of SNPs accounting for these percentages are 
shown within the columns. Note that functional regions important for catalytic activity include all defined regions 
excluding the N-terminal signal- anchor motif and halting signal. 
 
Table 4.7 shows the number of SNPs occurring in each functional region, broken down 
according to their experimentally determined effect on function. Where a SNP occurred in more 
than one region, it was assigned to the functional region that corresponds best with the observed 
experimental data. For example, if a mutation occurred at the position of a haem contact and it 
fell within a SRS region, but the experimental data shows that no holoprotein could be detected 
for this variant, then this SNP was assigned to the haem contact region instead of the SRS region.  
If it was unclear which functional region best fitted the data then the SNP was assigned to both 
regions, thus explaining the differences in the absolute numbers in Figure 4.7 and Table 4.7. The 
numbers in brackets indicate the number of these SNPs predicted to be damaging by SDM.  
 




Five SNPs within the N-terminal signal anchor sequence and halting signal have been 
functionally characterised in vitro and all of them were classified as neutral according to 
experimental data. N-terminal regions play a role in membrane binding but mutations in these 
regions are not expected to have an effect on protein folding or catalytic activity.  The majority 
of the other neutral SNPs (67%) occurred within undefined regions, while 16% occurred within 
SRS regions.  
 
Of the 13 mutations falling within the other conserved motifs - namely the proline rich motif, the 
I-helix catalytic groove, the Cys-pocket, the core stabilising motif and the meander region – 12 
resulted in an inactive protein or a protein with decreased activity. Three of these inactive SNPs 
fell within the ERR triad. 
   
Approximately 82% of SNPs falling within SRS regions had some effect on protein function, 
with the majority causing decreased activity. Experimental data showed that 31 SNPs falling 
within undefined functional regions had an effect on enzyme activity, of which 10 were 
predicted to be damaging by SDM.   
 
Table 4.7 Correlation between experimental data and functional region localisation of SNPs 







signal anchor sequence 0 (0) 0 (0) 0 (0) 0 (0) 3 (n/a) 
halting signal 0 (0) 0 (0) 0 (0) 0 (0) 2 (n/a) 
proline rich motif 1 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
I-helix catalytic groove 0 (0) 1 (0) 0 (0) 0 (0) 0 (0) 
cys-pocket 3 (1) 1 (1) 0 (0) 0 (0) 0 (0) 
core stabilizing motif  2 (1) 1 (1) 0 (0) 0 (0) 0 (0) 
meander 2 (2) 1 (0)  0 (0) 0 (0) 1 (0) 
ERR-Triad 3 (2)  0 (0) 0 (0) 0 (0) 0 (0) 
haem contact 6 (1) 2 (1) 0 (0) 0 (0) 0 (0) 
CPR contact 1 (0)  5 (3) 0 (0) 0 (0) 2 (1) 
SRS 5 (1) 23 (8) 9 (4) 0 (0) 8 (2) 
gating residue 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 








4.2.7 Combining stability predictions and functional region analysis 
 
The correlation between the experimental data and the combined SDM stability and functional 
analysis predictions is shown in Figure 4.8, from which it can be seen that of the 78 CYP450 
SNPs for which there is experimental data and which fall in functional regions important for 
catalytic activity and/or are predicted to be damaging by SDM, 63 showed altered activity in the 
experimental data, giving a positive predictor value of 81% for this combined analysis. 
Conversely, of the 84 SNPs in the data set that showed altered activity experimentally, 63 fall in 
functional regions important for catalytic activity and/or are predicted to be damaging by SDM, 
giving a sensitivity of 75% for this combined analysis.  Finally, of the 49 SNPs classified as 
neutral based on experimental data, 34 were found to fall within undefined regions or regions 
that are not important for catalytic activity and are predicted to have no effect on stability, giving 
a specificity of 69% for this combined analysis. 
 
 
Figure 4.8  Correlation between experimental data and the combined SDM stability and functional analysis 
predictions.  
 
The y-axis shows the percentage of SNPs found in functional regions important for catalytic activity or predicted by 
SDM to be damaging to the structure vs. those found in undefined functional region and predicted to have no effect 
on stability (A) for each experimentally classified group and (B) for combination of all groups showing altered 
enzyme function vs. those classified as neutral. The numbers of SNPs accounting for these percentages are shown 
within the columns. Note that functional regions important for catalytic activity include all defined regions 
excluding the N-terminal signal- anchor motif and halting signal. 






Previous functional studies have delineated regions of the cytochrome P450 structure important 
for substrate recognition (Chapter 2), substrate and product access and egress from the active site 
(Chapter 3) and interaction with the cytochrome P450 reductase [98]. In this Chapter, this 
functional information has been combined with in silico calculations on the effect of 
polymorphic variations in the major human drug metabolising CYP450 enzymes on protein 
stability. These results were compared to experimental data in order to establish the likely causes 
of altered drug metabolism observed for cytochrome P450 variants in functional assays to date. 
In the process, a cytochrome P450 polymorphic variant map was created (Figure 4.2), which 
gives an overview of the location of known CYP450 polymorphic variation in relation to 
important structural and functional regions, whilst detailed SNP tables (Appendix B, Tables B1-
B9) provide information on the structural environments of each variant residue, the predicted 
effect of the mutation on protein stability and a summary of the available in vitro data for each 
SNP.  
 
A number of in silico tools are available that aim to distinguish between disease associated 
mutations and benign mutations based on the residues position relative to functional sites, 
protein stability calculations or a combination of both.  Using the tools PolyPhen [359] and SIFT 
[353, 455], Wang et al previously predicted that 39-43% of the human CYP450 SNPs they 
analysed would have an impact on protein function [361] and correlation with known 
experimental data suggested a PPV of 70%.  Other CYP450 studies have used a combination of 
docking and molecular dynamics to assess changes to the binding pocket and ligand interactions 
for small sets of SNPs [456-458].  However, whilst tools such as PolyPhen take the positions of 
some functional sites into account, quantitatively predicting the effect of mutations on ligand and 
co-factor binding is still a huge challenge for computational biology as accurate calculations are 
very computationally intensive, limiting their use for large interaction surfaces.  
 
The aim the work described in this Chapter was to break down the analysis of possible functional 
effects of SNPs into different components in order to distinguish between mutations affecting 
stability and those lying within functional regions of the enzyme, as well as to more precisely 
predict the molecular mechanisms underlying changes in enzyme activity caused by different 




CYP450 SNPs.  Site Directed Mutator (SDM) was therefore chosen as a representative tool to 
predict the effect of mutations on the stability of the apoprotein, enabling the differentiation 
between mutations affecting the inherent stability of the protein fold as opposed to those at 
functional sites important for haem or substrate binding. SDM - which is a statistical potential 
energy function - provides a quick, high throughput method for calculating the effect of single 
point mutations on protein stability and performs favourably compared to a number of other 
published methods [357]. SDM is not based on prior knowledge of the mutant’s thermodynamic 
measurements and has been found to demonstrate better sensitivity in predicting stabilizing 
mutations than other methods [356].  Importantly, for the purpose of this study, SDM focuses 
solely on predicting the energetic effects of mutations on protein stability (∆∆G), ignoring 
effects on functional regions such a ligand contacts.  Interestingly, when SDM was used in 
isolation here, a PPV of 82% was observed, apparently immediately exceeding the performance 
of PolyPhen or SIFT for CYP450 enzymes.  
 
While it may have been interesting in principle to compare results from other tools that 
specifically predict effects of SNPs on protein stability, many of these tools have previously been 
compared extensively in other studies and have been found to be comparable [356, 357]; 
furthermore, the shortage of quantitative experimental data on the effect of SNPs on CYP450 
protein stability would make it difficult to be sure which tool was the most accurate for a given 
mutation in any such comparative study. It therefore seemed unlikely that a comparative study of 
in silico tools would add much value to the analysis.  Related to this point, although initially 
specific ΔΔG values were calculated for each SNP using SDM, this data was subsequently only 
used in a qualitative manner, serving to ameliorate any deficiency in the absolute accuracy of 
individual SDM-computed ΔΔG values across the large panel of variants.  
 
Reliable in silico prediction of the effect of SNP variants on CYP450 protein function remains a 
challenging endeavour today.  In this Chapter, using a representative, computationally-light in 
silico tool in isolation to predict the effects of individual SNPs on the stability of the CYP450 
apoproteins, an encouraging specificity of 83% and a positive predictor value of 82% was 
obtained when predictions were compared to available experimental activity data, but a 
sensitivity of only 37% was found for CYP450 SNPs (Figure 4.5, Table 4.8), suggesting that 
altered CYP450 activity is only partially explained by changes in protein stability. This is in 
agreement with studies by Blundell et al who have shown that although changes in protein 




stability can be relatively accurately predicted in silico, these predictions alone are in general not 
sufficient to enable accurate large-scale classification of benign and disruptive single amino acid 
substitutions [356, 357, 459].  However, by combining the SDM predictions on effect of each 
SNP on protein stability with an analysis of whether or not the relevant SNP fell within a known 
functional region important for catalysis, the sensitivity of the predictions was significantly 
improved to 75%, and very good positive predictor and specificity values were still retained 
(Table 4.8).  In more detail, the combined ‘SDM plus functional region analysis’ approach 
enabled us to account for 87% of the SNPs that result in very low or inactive enzyme activity; 
76% of the SNPs that result in decreased activity and 64% of the SNPs that result in substrate 
specific affects in vitro (Figure 4.8).   
 
Table 4.8 Summary performance of SDM and functional region analysis on CYP450 SNPs 
 Sensitivity (%) Specificity (%) PPV (%) 
SDM alone 37 83 82 
Functional region analysis alone 63 78 83 
SDM plus functional region analysis 75 69 81 
 
By way of illustration of the approach used in this study, CYP2C19*5, corresponding to the 
single amino acid substitution R433W, has been identified as a defective allele that contributes to 
the s-mephenytoin poor metaboliser phenotype in Caucasian and Oriental populations [460]. In 
vitro functional assays have shown that expression levels in yeast are similar to the wild-type but 
that P450 holoprotein is not detected [315]. Figure 4.9 shows a model of the CYP2C19 
polymorphic variant R433W aligned to the wild-type structure. Arg 443 is a buried residue with 
a relative solvent accessibility of 5.3%.  When this residue is mutated to a tryptophan, the side 
chain volume increases by 54.4 Å3 while the relative solvent accessibility changes from 2% to 
17%. The ∆∆G SDM score for this mutation is 0.4 kcal.mol-1, which indicates that this mutation 
is neutral and does not have a significant effect on the stability of the apoprotein. However, Arg 
433 is part of the Cys-pocket, or β-bulge, which is a highly conserved region important for haem 
binding. Based on the protein-ligand interaction data for CYP2C19, Arg 433 is a haem contact 
residue that interacts through its 5-guanidino group with the haem propionate via a salt bridge. 
Mutating this residue to a tryptophan disrupts this interaction and the increase in volume and the 
position of the side chain may plausibly result in a steric clash between tryptophan and the haem 
group, providing a possible explanation for the lack of holoprotein observed in vitro.  
Importantly, if the functional region and stability analyses had not been segregated, this level of 
mechanistic interpretation would not have been possible. 






Figure 4.9  CYP2C19 R433W model aligned to the wild-type structure 
The CYP2C19 R433W model (red) generated by ANDANTE is aligned to the wild-type CYP2C19 pdb structure 
4GQS (grey). Wild-type residue Arg 433 is shown interacting with the haem group. 
 
Although the alignment in Figure 4.2 has been annotated with the known CYP450 functional 
regions, CYP450 function is by no means completely understood. Information about residues 
important for conformational change, oligomerisation and interactions with effector molecules is 
still limited. Investigating further mutations that show altered in vitro activity but do not affect 
protein stability and lie outside known functional regions may shed light on hinge regions and 
peripheral or allosteric binding sites important for conformational change and substrate access in 
CYP450s.  In this context, it is interesting that the analyses carried out here reveal that 5 out of 
the 14 SNPs that show altered substrate specific in vitro activity, together with one SNP that 
showed increased in vitro activity, lie within currently undefined functional regions of CYP450 
structure (Table 4.6).  For example, CYP2C19 variant D256N shows similar expression and 
holoprotein levels to the wild-type enzyme but shows substrate specific changes in Km and 
reduced Vmax [461]. Asp 256 lies in the loop region between helices G and H (Figure 4.10) and 
this G/H loop has shown high conformation variability in molecular dynamics studies on 
mammalian CYP450 structures [76, 80] so Asp 256 may therefore form part of a hinge region 
important for conformational changes within the enzyme.  While the putative periphery site 
regions and SRS 4’a region identified in Chapter 2 were not included as functional regions in 




this study, it is interesting to note that of the 5 SNPs that show altered substrate specific in vitro 
activity but which do not affect protein stability and which lie outside known functional regions, 
2 fall within PS2 (CYP1A2 C406Y and CYP2A6 Y392F align with CYP2B6 E387 and F389 
that made contact with amlodipine molecules bound at periphery sites within the active site – 
Chapter 2, Figure 2.6) and 1 falls within the putative SRS 4’a region (CYP2B6 K262R).  
Furthermore, one of the SNPs that showed deceased in vitro activity and does not affect protein 
stability falls within putative SRS4’a.  
 
A significant limitation in the analysis carried out here on damaging SNPs is the quality, 
availability and variability of experimental data found in the literature.  In particular, 
heterogonous expression system, total protein quantification, methods for generating kinetic 
data, as well as kinetic models for data analysis, vary between studies and can all profoundly 
influence results, as recently reviewed by Hiratsuka [462].  For example, most CYP450 substrate 
turnover is still analysed today using Michaelis-Menten kinetics, yet it is well documented that 
some CYP450 isoforms such as CYP3A4 show atypical kinetics due to multiple binding sites, 
substrate inhibition, allosteric regulation or multiple active forms of the enzyme.  Depending on 
the model to which the experimental data was fitted, substantially different kinetic parameters 
might be reported for any given system, complicating quantitative comparisons between 
different studies on mammalian CYP450 SNPs.  
 
Figure 4.10 CYP2C19 D256N model aligned to the wild-type structure  
The CYP2C19 D256N model (red) generated by ANDANTE is aligned to the wild-type CYP2C19 pdb structure 
4GQS (grey). Asp256 and Asn256 are shown as sticks.  
The sum of the defined functional regions drawn together in the CYP450 SNP map (Figure 4.2) 
make up over half of the protein, whilst the substrate recognition regions cover ~33% of the 




sequence space, reflecting the broad substrate specificities of mammalian CYP450s.  It is 
important to recognise therefore that not all mutations in these functional regions will affect 
enzyme activity for all possible substrates. It is also important to note that certain residues within 
SRS regions have side chains facing away from the active site (see for example Chapter 2, 
Figure 2.11); some of these residues make contact with the substrate via main chain interactions 
rather than side chain interactions and mutation of such residues might directly affect ligand 
interactions (and hence enzyme function) as a result either of altered positioning of main chain 
atoms relative to the bound ligand within the active site, or alternatively by directly affecting 
protein stability. In other instances, such residues with side chains facing away from the active 
site do not obviously make main chain contacts to the ligand; here mutational effects on enzyme 
function are more likely to be manifested through either direct effects on protein stability or 
through co-operative conformational changes that indirectly perturb the active site. By way of 
example of this latter type, CYP2A6 variant R203S, lying within the F helix and SRS(2,3), 
shows similar activity to the wild-type enzyme in in vitro studies; the side chain of Arg 203 faces 
away from the active site (Figure 4.11) and SDM predicts that mutation of Arginine 203 to 
Serine will not be damaging, consistent with experimental data.  By contrast, variant R203C does 
show reduced activity in vitro; this mutation is predicted to be highly destabilising by SDM and 
is likely to affect substrate binding by disrupting the F helix.  
 
It could be argued that residues in SRS regions that make neither side chain nor main chain 
contacts to the ligand in known CYP450 structures should be excluded from the annotated 
functional regions in the CYP450 SNP Map. However, as further CYP450 structures are 
determined, the precise positioning of equivalent residues relative to bound ligands may change, 
arguing for their retention as part of the SRS regions at this point; indeed there are already 
examples of SRS residues that face towards the active site in one structure and away from the 
active site in other structures as a result of conformational changes, particularly in regions that 
can convert between ordered helices and disordered loop regions such as the F-G loop and B-C 
loop (e.g. in CYP2C9 structures 1OG2 and 1OG5 the F-G loop and B-C loop are predominantly 
helices but in the 1R9O structure these regions are disordered loops ). In addition, mutations can 
also change the conformation of a protein and as  a result the orientation of SRS residue side 
chains, as seen for the V374M mutation in the CYP2D6 structure 2F9Q (Chapter 3, Figure 3.10 
B). 
 




Inclusion of SDM data in the CYP450 SNP map has proved useful in extending predictions of 
the likely consequence of mutation on CYP450 function, including for those variants that fall 
within known functional regions. Importantly, most SNPs analysed in this study have only been 
tested to date for one or a small subset of substrates, so it is plausible that more SNPs lying 
within SRS regions will show altered metabolism or substrate specific effects when tested on a 
larger panel of drugs.  The work described in this Chapter therefore provides a useful 
rationalisation of CYP450 structure-function relationships by combining both in silico and 
experimental data into a unified CYP450 SNP Map that has surprisingly good predictive 
capability (judged by the sensitivity and specificity data presented here) and which should 




Figure 4.11  CYP2A6 model showing the position of R203. 
 
CYP2A6, PDB structure 1Z10 chain A , is shown in grey, the haem group in red and a coumarin substrate molecule 
bound within the active site shown in green. R203 is shown in blue. 





4.4.1 Non-synonymous single nucleotide polymorphisms  
 
Non-synonymous single nucleotide polymorphisms (SNPs) were sourced from the Human 
Cytochrome P450 Allele Nomenclature Committee home page ([309]; accessed 10 Oct 2012) 
and NCBI dbSNP [463] for isoforms CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, 
CYP2C19, CYP2D6, CYP2E1 and CYP3A4. 
 
4.4.2 Experimental Data Collection 
 
Available experimental data on protein expression, holoprotein levels, enzyme activity and 
kinetics (Km, Vmax and Vmax/Km) was extracted from the literature and tabulated for each SNP 
(Appendix B, Table B1-B9).  Due to the wide range of data types and the great diversity in 
methodology all data was expressed as a fraction (variant data/ wild-type data) measured in the 
same experiment. If the difference between wild-type and variant data was reported to be 
statistically significant, it is indicated in Tables B1-B9 with an asterisks (some studies provide 
quantitative data without statistical evidence). If no quantitative data was available then data was 
expressed qualitatively as similar to wild-type “similar”, significantly lower than wild-type 
“decreased”, significantly higher than wild-type “increased” or not detectable “ND”. All in vivo 
data was recorded qualitatively. If more than one non-synonymous SNP coexist in one allele and 
have therefore been tested as a double or triple mutant (as is common for CYP2D6), data was 
included only if it is clear which SNP is dominant in the resulting phenotype.  
4.4.3 Classifying SNPs based on Experimental data 
 
After careful analysis of all available data, SNPs were classified into six groups based primarily 
on the in vitro experimental evidence. In vivo data was however, considered if it was the only 
data available.  “Inactive” refers to mutations that resulted in protein/holoprotein levels that are 
not detectable or activity that is less than 2% of wild-type activity for all expression systems and 
substrates tested. “Decreased activity” refers to SNPs that resulted in significantly decreased 
expression levels, haem incorporation or altered kinetic parameters, leading to impaired enzyme 
function.  “Increased activity” refers to mutants that show significant increases in activity. 




“Substrate specific” refers to mutants that show more than 50% difference in mutant/wild-type 
activity ratios for different substrates. “Neutral” refers to mutants that show similar holoprotein 
levels and activity to that of the wild-type enzyme. “Unknown” refers to SNPs that have not yet 
been tested in vitro or for which the experimental data is inadequate or contradictory.  
4.4.4 Crystal Structures 
 
Structures of human CYP450 proteins and rat CYP2B4 were retrieved from the RCSB Protein 
Data Bank [31]. The PDB codes for the structures used in this study are as follows. CYP1A2: 
2HI4. CYP2A6: 1Z10, 1Z11, 2FDU, 2FDV, 2FDW, 2FDY, 2PG5, 2PG6, 2PG7, 3EBS. 
CYP2B6: 3IBD. CYP2C8: 1PQ2, 2NNH, 2NNI, 2NNJ, 2VN0. CYP2C9: 1OG2, 1OG5, 1R9O. 
CYP2C19: 4GQS. CYP2D6: 2F9Q. CYP2E1: 3E6I, 3E4E, 3GPH, 3KOH, 3LC4. CYP3A4: 
1TQN, 1W0E, 1W0F, 1W0G, 2J0D, 2V0M, 3NXU.  CYP2B4 (rat):2BDM. Only chain A was 
used for structures that have more than one CYP450 chain in the asymmetric unit.   
 
4.4.5 Generating an annotated structural alignment 
 
A multiple CYP450 structural alignment was generated including one representative structure for 
each isoform using the program Baton (D.Burke, unpublished data and [423]). The PDB codes 
for representative structures were as follows CYP1A2: 2HI4, CYP2A6: 2FDV,  CYP2B6: 3IBD,  
CYP2C8: 1PQ2,  CYP2C9: 1R9O, CYP2C19: 4GQS, CYP2E1: 3E4E, CYP2D6: 2F9Q, 
CYP3A4: 1TQN. 
 
The program JOY [449] was used to annotate the protein sequence alignment with 3D structural 
features.  Here is a brief description of the structural features represented by JOY. 
 
Solvent accessibility is measured using the program PSA which implements the algorithm 
developed by Lee and Richards (1971). A relative solvent accessibility (RSA) is calculated by 
comparing an extended conformation of a residue to the residue conformation in question. The 
default cut-off setting of 7% RSA was used. This classifies residues with less than 7% RSA as 
inaccessible and residues of >7% as accessible. In the Joy format, buried residues are displayed 
in upper case and accessible residues in lower case. 
 




Secondary structure assignment is calculated using the program SSTRUC (D.K.Smith, 
unpublished). In the JOY format, residues forming α, 310 and π helices, and β strands are 
displayed in different colours. The default consensus secondary structure definition was used 
which means a consensus secondary structure is assigned, underneath the alignment, if more than 
70% of the residues at that position are in a particular conformational state. α-helices A – L and 
β-sheets 1-5 are labelled below the alignment according to CYP450 nomenclature of Poulos and 
co-workers [37]. 
 
Main chain dihedral angles are also calculated by SSTRUC. Residues with a positive main chain 
φ angle are shown in italics. 
 
Hydrogen bonding within a structure is calculated using the program HBOND (J.Overington, 
unpublished), which calculates the associated energy and angles for interactions between heavy 
atom donor and acceptor pairs. JOY uses a lenient distant cut-off of 3.5Å for hydrogen bonds. 
The hydrogen bond data is split into three classes: 1) side chain to main chain amide; 2) side 
chain to main chain carbonyl; 3) side chain to other side chain.  Residues whose side chain is 
bonded to a main chain amide are denoted in bold face. Residues that are underlined indicate that 
their side chain is hydrogen bonded to a main chain carbonyl. Residues whose side chain is 
hydrogen bonded to another side chain are not displayed in the JOY format used here. 
4.4.6 Defining CYP450 functional regions 
 
The structural alignment was further annotated with known functional regions. If residues did 
not fall within any of these regions then their functional region was classified as undefined. 
Functional regions can overlap so one residue may fall within more than one functional region.  
The definitions of functional regions are as follows. 
Conserved motifs 
 
The hydrophobic signal-anchor sequence and the halting-signal are usually truncated in crystal 
structures and therefore do not appear in the structural alignment. The proline rich motif (N-
terminal sequence motif PPGPXPXPXXGN),  the I-helix catalytic groove  (conserved consensus 
motif (G/A)GX(D/E)T), the K-helix core stabilising motif  (invariant EXXR motif within the K-




helix) and meander, and the Cys-pocket (sequence motif FXXGXXXCXG containing the 





Haem-residue interactions were identified using the protein-ligand interaction database CREDO 
[397]. CREDO assigns each contact residues to an interaction type based on the geometry and 
distance thresholds using criteria adapted from Marcou and Rognan [464]. Residues interacting 
with the haem group were identified in all the available PDB structures for each isoform, 
combined and mapped onto the representative structure in the sequence alignment. This was 
done to account for any differences in the haem binding regions for structures of the same 
isoform due to conformational changes. 
SRS regions 
 
SRS regions were assigned based on the SRS map delimited in Chapter 2. 
Cytochrome P450 reductase (CPR) contacts 
 
CPR contacts were assigned based on the recent model for interactions between CYP2B4 and 
FMN domain of rat CYP450 reductase [98]. This model was built using the bacterial redox 
complex structure (CYP102: 1BVY, chain A) as a template and was used to identify the key 
residues involved in ionic interactions at the interface. All CYP2B4–P450-oxidoreductase 
interfacial residues calculated from the 1BVY.pdb-derived structural model at 6Å distance cut-
off were mapped onto the human CYP450 representative structures via structural alignment. 
Residues forming part of ionic charge clusters where further categorised as ionic charge cluster 
residues to distinguish them from the other CPR contact residues at the interface. 
Gating residues 
  
Gating residues were assigned as follows: 1) Residues involved in the putative gating models 
identified in Chapter 3 were assigned as gating residues (CYP2A6: Q104, F107, F111, F118, 
K125, M205, L241, Q242, E245, M293, L370, F480; CYP2B6: L43, L51, I101, V104, F108, 
F115,  W121, F206, Q215, L216, E218, L219, L290, L363, M365, I480;  CYP2C8: N99, S114, 




W120, R125, F168, K199, I207, L208, T229, V233, R241, E285, V362, P367, M388, I476; 
CYP2C9: K72, I99, F100, A103, R108, F110, G111, F114, W120, I207, L208, Y225, T229, 
D293, F476; CYP2D6: L46, F51, Q52, T54, L110, F120, W128, R129, R133, D179, Q210, 
L213, E216, G218, F219, V374, F483,  CYP3A4: Y53, F57, R106, F108, F113, M114, W126, 
K127, L211, R212, F213, D214, F215, F220, I223, V240, F241, F304, E308, I369, L482, L483, 
Q484.). 2) Gating residues identified in the literature using steered molecular dynamics 
simulations [434] (CYP3A4: F57, R105, F108, S119, I120, R212, F213, F215, F220, V240, 
F241, L482.). 3) Residues involved in an aqueduct gating mechanism regulated by binding of the 
CYP450 reductase identified using solvent explicit molecular dynamics [442]. (CYP3A4: R375)  
As R375 is highly conserved in CYP450 is has been suggested that this could be a general 
aqueduct gating mechanism. All residues at this position in the alignment have been defined as 
aqueduct gating residues. (CYP1A2: H388, CYP2A6: R372, CYP2B6: H369, CYP2C8: H368, 
CYP2C9: H368, CYP2C19: H368, CYP2D6: H376, CYP2E1: H370, CYP3A4: R375)     
4.4.7 Comparative modeling of polymorphisms using ANDANTE 
 
Polymorphisms were modelled using ANDANTE, a program that makes use of environmental 
substitution tables (ESSTs) to reduce the side chain rotamer search space during comparative 
modeling of single amino acid mutations [465].  A Python script was written to run ANDANTE 
in batch mode. Mutant structures were generated for each SNP using all the available PDB 
crystal structures for the respective isoform. ANDANTE was run using the default parameters 
and the “- local” option which attempts to minimise all rotamer clashes in the local area that 
result from the mutation. Note that ANDANTE does not take co-factors or ligands into account 
when modeling side chain positions. All mutant structures for each SNP were visualised and 
compared to the original template crystal structures using PyMOL [406]. 
4.4.8 Predicting the effect of polymorphisms on protein stability using SDM 
 
SDM input: SDM requires a wild-type and mutant structure (which has only one single amino 
acid substitution) in PDB format as input. The mutant structures built using ANDANTE, 
together with their template structures, were used as input for the mutant and wild-type structures 
respectively.  
 




SDM output:  SDM output gives details of the local structural environment of the wild-type and 
mutant residue which includes secondary structure prediction and percentage solvent 
accessibility. SDM also outputs a pseudo ΔΔG score or stability score and a prediction of disease 
association. Negative scores suggest that the mutation is destabilising and positive scores 
indicate a stabilising effect. A cut-off of 2 kcal.mol-1 had previously been used to indicate that a 
mutation is damaging to the protein structure. Both stabilising and destabilising mutations that 
reach this cut-off were therefore categorised as damaging mutations whilst mutation with scores 
between -2 and 2 kcal.mol-1 are classified as neutral. It must be noted that like ANDANTE, SDM 
does not consider co-factors or ligands when calculating solvent accessibility or stability scores. 
 
SDM was run on all ANDANTE derived mutant structures. If ANDANTE generated more than 
one structure for the same SNP, an average SDM score and standard deviation were calculated. 
In subsequent analysis, the output from SDM was used in a qualitative manner, mutations were 
described as damaging or neutral and no further specific use of the absolute numerical SDM 



















 Cloning and Expression of Chapter 5
CYP450 proteins






Heterogeneously expressed recombinant CYP450 proteins are useful for studying CYP450 
function in simplified in vitro systems. The ease of site directed mutagenesis in these systems 
enables the study of non-synonymous mutation - this is particularly useful for low frequency 
alleles where clinical samples are limited. The first heterologous mammalian CYP450 was 
expressed in 1991 in E.coli [466]; recombinant CYP450s are now routinely expressed in 
bacteria, yeast, insect and mammalian cells.  
 
E.coli expression of recombinant proteins is in general fast, easy and inexpensive, producing 
relatively high yields of protein compared with other expression systems. Expression of 
mammalian CYP450s in E.coli is, however, challenging due to hydrophobic membrane binding 
regions, differences in codon usage between E.coli and mammalian cells and problems with 
protein folding in the absence of endogenous chaperones [454]. Post-translational modification 
of recombinant proteins seldom occurs in E.coli, but this does not generally pose a problem for 
recombinant CYP450 expression as haem incorporation is the only post-translational 
modification thought to be important for catalytic activity and occurs in E.coli, provided the 
protein folds correctly [467]. Co-expression of molecular chaperones can improve protein 
folding [468]. 
 
N-terminal sequence alterations within the hydrophobic membrane-binding region are normally 
required for adequate recombinant expression in E.coli due to the lack of 5’ features necessary 
for high protein expression in bacteria and to differences in codon usage between bacteria and 
mammals.  These alterations are not thought to affect enzyme activity because the N-terminal 
region does not play a role in catalysis [469, 470] and, where tested, heterologously expressed 
CYP450 proteins show comparable activity to native proteins purified from liver samples [471, 
472]. The N-terminal membrane-binding region, however, does influence sub-cellular 
localisation and CYP450s can be designed to localise in the inner membrane, cytoplasm or 
periplasm; to aggregate into inclusion bodies; or to be secreted into the extra cellular medium. 
CYP450s are however most commonly localised in the cytoplasm with the N-terminal anchor 
embedded in the plasma membrane [454]. Truncating the N-terminal anchor region can increase 
expression and solubility and simplify purification although some truncated isoforms still 




associate with the membrane via peripheral membrane interaction; these interactions can be 
disrupted with high salt buffers or detergents post cell lysis.  
 
Strategies to combine heterologously expressed CPR and CYP450 redox partners to reconstitute 
the full active monooxygenase system include the following: 1) combining enzymes after 
expression and purification; 2) co-expressing enzymes in the same host cell using two different 
vectors; 3) co-expressing proteins using a bicistronic vector or a dual promoter vector; 4) 
expressing CPR and CYP450 as a single fused polypeptide.  
 
The aim of this Chapter was to generate a panel of CYP3A4 and CYP2C9 variants for in vitro 
characterisation and kinetic assays. A heterologous expression system enabling easy site-directed 
mutagenesis, time and cost effective protein expression and simple protein purification was 
required. Previous in vitro studies on CYP3A4 wild-type protein in the Blackburn laboratory 
provided the ground work for this study and a suitable CYP450 and CPR expression system was 
already established [473]. The DH5α E.coli strain, commonly used for CYP450 expression, was 
used for CYP3A4 and CPR expression and offered the advantage of high insert stability and 
good plasma yield and quality.  Various full length and truncated CYP3A4 and CPR constructs, 
with tags on either the N-terminus or the C-terminus, were tested for expression and activity. N-
terminal truncated CYP3A4 and CPR protein constructs with C-terminal tags were found to give 
the highest levels of active protein. 
 
The BCCP-tag, an 83 amino acid biotin carboxyl carrier protein domain from the E.coli acetyl-
coenzyme A carboxylase, is a compact structure dominated by β-strands (Figure 5.1) that is 
recognised and biotinylated at a specific lysine residue by the host cell’s native biotin ligase 
[474]. The biotin molecule can then act as a point of attachment for the protein, binding 
specifically to streptavidin. The BCCP tag was thus included in the CYP450 and CPR constructs 
to allow orientated immobilisation of proteins to derivatised microarray surfaces via the high 
affinity streptavidin-biotin interaction. The BCCP tag has also previously been reported to 
improve folding and soluble expression and can additionally serve as a useful protein-folding 
marker: presuming the fusion protein folds co-translationally, if the N-terminal domain mis-
folds, this will cause aberrant exposure of hydrophobic regions which will either disrupt the 
correct folding of the BCCP-tag or drive aggregation, thus by either route preventing 
biotinylation [475].  




The polyhistidine-tag (His-tag), a protein motif consisting of 6 histidine residues, was fused to 
the C-terminus of the BCCP-tag via a glycine‐serine linker (G-S linker). It was included to allow 
easy purification as it binds reversibly to Ni2+, allowing one-step non-denaturing purification via 
Ni2+- affinity chromatography.  
 
 
Figure 5.1  Structure of the biotinylated biotin carboxyl carrier protein domain from the E.coli acetyl-coenzyme A 
carboxylase (BCCP tag). The protein, PDB structure 1BDO, is shown in grey and the biotin molecule attached to the 
side chain of Lysine 122 is shown in green.  
 
Using this CYP450 expression system, the objectives of this Chapter were as follows: 
 
1. Select a panel of CYP3A4 and CYP2C9 polymorphic variants for study 
2. Generate expression vectors for each variant via site-directed mutagenesis 
3. Express and purify proteins 
4. Quantify CYP450 holoprotein levels   




5.2 Results  
5.2.1 Generating CYP3A4 and CYP2C9 variant constructs 
Selecting polymorphic variants for testing 
 
To test the effect of clinically relevant mutations on CYP450 stability and structure in vitro, 
eight CYP3A4 and seven CYP2C9 polymorphic variants were selected for expression in E.coli 
(Figure 5.2). The selected variants included mutations predicted from the work described in 
Chapter 4 to be neutral, stabilising or destabilising, falling within both functional and undefined 
regions of the protein structure (Table 5.1). There are reports in the literature showing altered 





























Figure 5.2 CYP3A4 and CYP2C9 
structures showing the positions of amino 
acid substitutions in polymorphic variants 
selected for study. (A) CYP3A4, PDB 
structure 1TQN, and (B) CYP2C9, PDB 
structure 1OG2, are shown in grey with 
haem groups in black.  The positions of 
mutations are labelled and indicated in red.   




Table 5.1.  Summary of information from in silico analysis and classifications based on experimental data for 
selected CYP450 variants. 
P450 variant Functional region 
location* 
Predicted effect on 
protein stability† 
Classification based on experimental data from 
literatureΨ 
CYP3A4    
   G56D SRS1'a destabilising decreased activity 
   K96E CPR contact neutral unknown 
   P218R SRS(2,3) neutral unknown 
   S222P SRS(2,3) neutral decreased activity 
   I223R SRS(2,3) destabilising unknown 
   L293P Start of SRS 4 neutral increased activity 
   L373F haem contact/SRS5 neutral decreased activity 
   M445T CPR contact destabilising neutral 
CYP2C9    
   V76M undefined neutral unknown 
   R132Q CPR contact/SRS2  neutral decreased activity – decreased CPR affinity 
   R150H undefined neutral increased activity - increased CPR affinity 
   Q214L SRS(2,3) stabilising decreased activity 
   P279T undefined neutral similar 
   I359L SRS5 neutral decreased activity 
   I359T SRS5 destabilising decreased activity 
 
*Functional region location based on CYP450 SNP map (see Chapter 4, Figure 4.2) 
† Based on Site Directed Mutator (SDM) scores: destabilising, ∆∆G < -2.0 kcal.mol -1; neutral, -2.0 < ∆∆G < 2.0 
kcal.mol-1; destabilising ∆∆G > 2.0 kcal.mol-1 
Ψ  Variants were classified based on in vitro data as follows:  “Inactive” -  undetectable protein/holoprotein levels or  
activity <  2% of wild-type for all expression systems and substrates tested; “Decreased activity”- decreased 
expression levels, holoprotein levels or activity compared to wild-type; “Increased activity” –  increased activity 
compared to wild-type; “Neutral” -  similar holoprotein levels and activity to wild-type enzyme; “Unknown”- 
absent, inadequate or contradictory experimental data. 
 
Recombinant CYP3A4, CYP2C9 and CPR wild-type constructs 
 
Figure 5.3 A shows the plasmid expression vector pBJW102.2 used for cloning and expressing 
CYP450 proteins and CPR. This vector has a T5 promoter under the control of two lac-operator 
sequences allowing tightly regulated, graded, high‐level protein production that can be induced 
with isopropyl‐β‐D-thiogalactopyranoside (IPTG). The lac repressor protein, coded for by the lac 
I gene, controls the basal activity of the lac-promotor; the β‐lactamase coding sequence confers 
ampicillin resistance. The translated recombinant proteins have a BCCP-tag (~9 kDa) and a 
His6-tag fused to the C-terminus of the CYP450 or CPR proteins by G-S linkers (Figure 5.3 B). 
The BCCP-tag is quantitatively biotinylated by endogenous biotin ligase following the addition 
of free biotin to the E.coli cultures. CYP3A4, CYP2C9 and CPR were all expressed as N-
terminal truncated proteins and the truncated sequences are shown in Figure 5.4.  
 







Figure 5.3  (A) Plasmid map of pBJW102.2 vector used for expressing CYP3A4, CYP2C9 and CPR proteins. The 
red arrow indicates the position of the CYP3A4, CYP2C9 or CPR gene inserted into the pBJW102.2 backbone for 
expression. The size of each of the resulting expression vectors is shown in the centre of the map. (B) A schematic 
representation of the recombinant protein constructs expressed using the pBJW102.2 plasmid show in A. The N-
terminal truncated proteins are fused to a BCCP-tag followed by a polyhistidine-tag on the C-terminus.  The length 
and size of the full recombinant protein constructs are given for CYP3A4, CYP2C9 and CPR.  
 
Mutations corresponding to the selected variants were introduced into the CYP3A4 and CYP2C9 
genes within the pBJW102.2 vector using inverse PCR, as described in Methods. DNA 
sequences for pBJW102.2 + CYP3A4 wild-type, pBJW102.2 + CYP2C9 wild-type and 
pBJW102.2 + CPR together with the translated protein sequences are given in Appendix C. The 




point mutations introduced by inverse PCR and the resulting amino acid substitutions are also 











5.2.2 Protein expression and purification 
 
All CYP3A4 and CYP2C9 wild-type and variant proteins were successfully expressed in E.coli 
DH5α.  Soluble crude lysates were extracted and separated for visualization by electrophoresis 
on denaturing polyacrylamide gels (Figure 5.5 A & B). The recombinant Proteins expressed at 
low levels and bands of the correct size were not clearly visible on stained protein gels, but all 
variant proteins were detected by western blot analysis using both streptavidin-horseradish 
peroxidase (strep-HRP) (Figure 5.5 C & D) and anti-6xHistidine horseradish peroxidase (anti-
His HRP) (Figure 5.5  E & F) indicating that both the biotinylated BCCP-tag and the His-tag 
were present.  
 
All of CYP3A4 and CYP2C9 proteins showed some degree of proteolysis in western blots. A 
greater degree of proteolysis was visible for the CYP3A4 samples, which showed multiple bands 
in the 35 - 50 kDa and the 10 - 20 kDa regions. CYP2C9 proteins generally showed fewer and 
less distinct bands in these regions. The bands at 18 kDa, only visible in the Strep-HRP blots, 
correspond to the native biotinylated E.coli protein [476].  
 
Recombinant proteins were partially purified using Ni-TED His-tag purification columns in the 
presence of 20% glycerol; crude lysates were kept on ice and all purifications were carried out 
on the same day as cell lysis. Partially purified samples were immediately concentrated and 
 
CYP3A4  MALTA MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGN---- 
 
CYP2C9   MALTAMDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI--- 
 
CPR    MALTAMGDSHVDTSSTVSEAVAEEVSLFSMTDMILFSLIVGLLTYWFLFRKKKEEV----  
 
 
Figure 5.4 N-terminal truncated sequences for CYP3A4, CYP2C9 and CPR recombinant proteins. Boxes indicate 








buffer exchanged into a buffer suitable for protein storage to minimize protein unfolding and 
degradation. Figure 5.5 G & H show denaturing protein gels for partially purified CYP3A4 and 
CYP2C9 samples, respectively.  The bands around 65 kDa, indicated by an arrow, correspond to 
the CYP450 proteins. Another dominant band appears at 40 kDa but, whilst there were bands at 
40 kDa in western blot analysis of purified protein (data not shown) those bands were 
comparatively fainter relative to the 65 kDa band than the dominant band seen in Figure 5.5 G & 
H, indicating that the band at 40 kDa is likely to be a contaminating E.coli protein that co-
migrates with the degradation products. After partial purification, the CYP3A4 proteins again 
show varying degrees of degradation while CYP2C9 proteins appear to be less susceptible to 
degradation. 
 
Figure 5.6 shows protein gel and western blot analysis of CPR protein samples. Panel A shows a 
denaturing protein gel of CYP3A4 crude lysate and partially purified protein for easy 
comparison. A strong band at the expected molecular weight for CPR was present in the crude 
lysate and partially purified protein and is visible in western blots detected with both anti- His 
HRP and strep-HRP (Figure 5.6 B, C and D). Once again, there was a strong band at 40 kDa in 
the partially purified samples, which is not visible in the western blots, confirming the presence 
of a co-purifying E.coli protein. Increasing imidazole concentrations were included in the wash 
buffer in an attempt to reduce the levels of contaminating proteins in the partially purified 
protein samples; however, this did not substantially improve the purity but did reduce the protein 
yield (data not shown).   
 








Figure 5.5  SDS-PAGE and western blots analysis of recombinant CYP3A4 and CYP2C9 wild-type and variant 
proteins. (A) and (B)  show SDS-PAGE of soluble crude lysates containing CYP3A4 and CYP2C9 proteins 
respectively. ~10 µg of protein lysate was loaded per lane.  (C) and (D) show western blots of soluble crude lysates  
containing CYP3A4 and CYP2C9 proteins detected with strep-HRP and  (E) and (F) show western blots detected 
with anti-His HRP antibody. 5 µg of protein lysate was loaded per lane for western blot analysis. (G) and (H) show 
SDS-PAGE analysis for partially purified CYP3A4 and CYP2C9 proteins, respectively. Lanes containing molecular 
weight markers are indicated by “M” and labelled in kDa. An arrow indicates CYP450 proteins at expected 
molecular weights.  
 
 
Figure 5.6  SDS-PAGE and western blot analysis of recombinant CPR protein.  SDS-PAGE analysis of soluble 
crude lysate (lane 1) and partially purified protein (lane 2) for (A) CYP3A4 wild-type protein preparations (included 
for comparison) and (B) CPR protein preparations. (C) and (D) show western blots of soluble crude lysates 
containing CPR proteins detected with anti-His HRP antibody and Strep-HRP, respectively. Lanes containing 
molecular weight markers are indicated by “M” and labelled in kDa. 
Specific protein quantification 
 
The holoprotein content in crude lysates and partially purified samples was determined using 
carbon monoxide (CO) P450 spectral assays [5, 477]. This assay distinguishes between two 
forms of the holoprotein: the correctly folded P450 form and the inactive P420 form. The 
reduced ferrous from of the haem ion binds CO, yielding an absorption peak at 450nm, provided 
the haem group is correctly incorporated into the CYP450 (Figure 5.7). The inactive form (P420) 
has an absorption maximum at 420 nm and forms due to disruptions to the haem environment.  
 
 
Figure 5.7  Schematic showing the reduction of ferric haem ion to ferrous ion in the presence of a reducing agent, 
followed by the co-ordination of CO at the axial position leading to an absorption peak at 450nm. 
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Figure 5.8 shows the ferrous CO vs. ferrous difference spectra for CYP3A4 and CYP2C9 wild-
type and variant partially purified protein samples. The P450 content, P420 content and P420 to 
P450 ratio was calculated from these spectra (Figure 5.9).  
 
The CYP3A4 protein samples all contained P450 and P420 protein at varying levels. All 
CYP3A4 variants showed elevated P420 to P450 ratios compared with the wild-type protein. 
G56D and L373F variants had the lowest P450 content – only 12% and 4% of wild-type - and 
the highest P420 to P450 ratios, suggesting that these mutations decrease protein stability and/or 
haem incorporation. While reducing the expression temperature from 30 °C to 25 °C for G56D 
and L373F variants reduced the P420 to P450 ratio, total P450 yield was also lower (data not 
shown).   
CYP2C9 wild-type and variant protein samples showed only the P450 form of the protein and 
the P450 content was generally higher than for CYP3A4 protein samples. The V76M variant had 
the lowest P450 content of the CYP2C9 variants (20% of wild-type).  
Figure 5.8 Ferrous CO vs. ferrous difference spectra 
for (A) CYP3A4 and (B) CYP2C9 wild-type and 
variant partially purified protein samples. Wavelength 
is shown on the x-axis and difference in absorbance is 
shown on the y-axis.  





Figure 5.9  P450 and P420 protein content in CYP3A4 and CYP2C9 partially purified protein samples measured by 
CO P450 spectral assays. (A) nmols P450 and P420 per mg of total protein for CYP3A4 wild-type and variant 
samples. (B) P420:P450 ratios for CYP3A4 wild-type and variant samples. (C) nmols P450 per mg of total protein 
for CYP2C9 wild-type and variant samples. Note: P420 protein was not detected in any of the CYP2C9 protein 
preparations.  




Table 5.2 Protein enrichment table for CYP3A4 recombinant proteins expressed in E.coli 























WT 560 0.17 6.3  3.2 2.8 0.6 16 9 
G56D 448 0.02 0.5  2.5 0.3 0.1 18 10 
K96E 592 0.25 9.8  2.5 3.0 0.5 12 5 
P218R 528 0.14 4.7  1.7 2.7 0.3 20 6 
S222P 416 0.1 2.8  2.0 1.5 0.2 15 7 
I223R 320 0.08 1.7  2.9 1.5 0.3 19 17 
L293P 480 0.1 3.2  2.2 2.0 0.3 20 9 
L373F 384 0.002 0.1  2.4 0.1 0.02 60 37 
M445T 544 0.11 4.0  3.6 1.4 0.3 13 8 
 
* Total protein extracted from 1 litre E.coli culture (protein expressed for 18 h at 30°C). Ψ Specific P450 protein 
content measured by carbon monoxide P450 spectral assays. † Total protein recovered from a 1 litre E.coli culture 
(protein expressed for 18 h at 30°C) after His-tag purification.  
  
Table 5.3 Protein enrichment table for CYP2C9 recombinant proteins expressed in E.coli 












Protein† (mg)  
Specific  
P450 protein 








WT 368 0.34 7.9 5.6 4.0 1.4 12 18 
V76M 432 0.06 1.6 4.4 0.8 0.2 14 15 
R132Q 384 0.42 10.2 8.0 4.3 2.2 10 21 
R150H 496 0.32 10.0 9.5 3.3 2.0 10 20 
Q214L 352 0.24 5.3 5.4 2.8 1.0 12 18 
P297T 464 0.40 11.6 8.7 3.8 2.1 9 18 
I359L 272 0.21 3.5 9.0 2.7 1.5 13 44 
I359T 416 0.31 8.1 15.0 2.7 2.5 9 31 
 
* Total protein extracted from 1 litre E.coli culture (protein expressed for 18 h at 30°C). Ψ Specific P450 protein 
content measured by carbon monoxide P450 spectral assays. † Total protein recovered from a 1 litre E.coli culture 
(protein expressed for 18 h at 30°C) after His-tag purification.  
 
Purification enriched the P450 content relative to total protein by 12 to 20 fold in all CYP3A4 
protein samples apart from variant L373F, which was enriched 60 fold (Table 5.2). The total 
P450 protein recovered after His-tag purification was between 5 and 17 % for all CYP3A4 




proteins except for L373F, which showed a 37% recovery. P420 was similarly enriched in these 
samples as His-tag purification does not selectively purify P450 from P420.  
 
Purification enriched the P450 content in CYP2C9 protein samples by 9 to 14 fold and the 
recovery after purification was between 15 and 44 % (Table 5.3). The yield of CYP2C9 P450 
protein was generally higher than the yield of CYP3A4 P450 protein, particularly after 
purification. CYP3A4 wild-type total P450 yield per litre of culture was 20% less than CYP2C9 
before purification (6.3 vs 7.9 mg) and 60% less than CYP2C9 after purification (0.6 vs 1.4 mg) 
indicating that more CYP3A4 P450 protein is lost during the purification process, potentially 
through conversion to apoprotein  or P420.  
 
His-tag purification of CPR from crude lysate gave a total protein yield of ~ 1.5 mg per litre of 
E.coli culture. Based on a protein gel, which indicated that CPR made up ~50 % of the protein in 
the partially purified CPR protein sample, the CPR concentration after His-tag purification was  
~  6 nmol per mg of partially purified protein and the total CPR yield was ~ 9nmol per litre of 










Recombinant P450 holoprotein was successfully expressed and purified for all the CYP3A4 and 
CYP2C9 variant proteins cloned in E.coli; however, expression levels varied and the ratio of 
active to inactive protein differed between isoforms as well as variant and wild-type proteins.   
 
Protein yield before purification was ~ 95 nmol P450 per litre culture for CYP3A4 wild-type and 
125 nmol P450 per litre of culture for CYP2C9 wild-type protein. Other studies have obtained 
expression levels of 370 nmol per litre culture for CYP3A4 [478] and 9-19 nmol per litre culture 
for CYP2C9 [471] in DH5α where proteins were expressed with modified N-terminal domains 
as opposed to truncated ones.  
 
The differences between expression levels and protein recovery observed between isoforms and 
variant proteins may result from varied translational efficiencies, differences in protein targeting 
or varying levels of haem incorporation. Previously, western blot analysis showed that while 
truncating the N-terminal membrane-binding domain of CYP3A4 increases soluble protein 
expression, a large portion of the protein still expresses in the insoluble fraction [473]. Protein in 
the insoluble fraction may result from aberrant mis-folded protein that aggregates into inclusion 
bodies or from proteins associated with the membrane. CYP450s can associate with the 
membrane through peripheral or ionic interactions in the absence of the membrane-binding 
domain. Here, detergents were added to cell lysates to disrupt these interactions as previous work 
showed that the addition of detergents increased the levels of the CYP3A4 in the soluble fraction 
[473]. It is notable in this regard that the data shown in Table 5.2 and Table 5.3 reflects CYP450 
concentrations determined by CO P450 spectral assays in which any apoprotein - whether mis-
folded or not - would be invisible.  
 
The other likely explanation for differences in P450 yields between proteins is that while 
proteins may initially express as active P450, more inherently unstable isoforms or variants may 
destabilise during cell lysis and purification, converting into P420 or losing their haem group 
altogether. This would be consistent with the observation that the difference in CYP3A4 wild-
type and CYP2C9 wild-type P450 yields is greater in partially purified samples than in the crude 
lysates and that P420 was detected in CYP3A4 samples but not in CYP2C9 samples.  
 




While the BCCP tag can act as a folding marker (the BCCP domain is only biotinylated if it 
folds correctly and it is only likely to fold correctly if the N-terminal protein folds correctly), 
folded apoprotein and protein that initially folds correctly and subsequently unfolds or converts 
to P420 will be biotinylated but inactive. This may be problematic for downstream assays, as the 
P450 active form is unlikely to bind preferentially to a Ni2+ or streptavidin surface, making it 
difficult to separate the active and inactive CYP450 protein. 
 
The bands observed at the molecular weight corresponding to CYP450 proteins (~65 kDa) on the 
denaturing protein gels represent all forms of the CYP450 protein present: P450, P420 and 
apoprotein. While CO P450 spectral assays only quantify CYP450 holoprotein, this data 
combined with a rough estimate of total CYP450 from protein gels suggests that CYP3A4 wild-
type protein in partially purified protein samples is made up of ~ 25 % apoprotein, < 5% P420 
and ~ 70% P450 and that CYP2C9 wild-type protein in partially purified protein samples is 
made up of ~ 50% apoprotein, no P420 and ~ 50% P450.    
 
All the CYP3A4 variants showed a somewhat higher P420 to P450 ratio than the wild-type 
protein after purification, but the differences were most striking for variants G56D and L373F. 
These variants also showed lower levels of total CYP3A4 in protein gels. Single point mutations 
can affect the solubility of a protein on overexpression and a study by Idicula-Thomas et al 
showed a positive correlation between thermostability and solubility of heterologous proteins 
expressed in E.coli in general [479]. Here, G56D was predicted to destabilise protein structure 
(Table 5.1), and while L373F is not predicted to be destabilising, Leu 373 is a haem contact 
residue so it is not surprising that this mutation alters the haem environment, leading to an 
increase in P420 levels.  
 
P420 was not detected in any of the CYP2C9 protein samples, suggesting that CYP2C9 is more 
stable than CYP3A4. Specific P450 protein levels in partially purified samples ranged between 
65 and 110 % of wild-type levels for all CYP2C9 variants except for V76M, which showed 
much lower P450 levels.  
 
While His-tag purification enriched P450 proteins adequately for downstream applications, a 
large amount of P450 protein was lost during purification and the purity of samples was low. 
Larger purification tags such as glutathione S-transferase (GST) and maltose binding protein 




(MBP) are known to give better protein yields but for the purposes of this work the His-tag was 
chosen as it is much smaller and therefore less likely to affect CYP450 conformation and 
function downstream [480].   
 
Other affinity resins for His-tag protein purification were previously tested in the Blackburn 
laboratory in an attempt to improve the yield and purity of CYP450 samples. In a comparison 
between the cobalt-based resin TALON and the nickel-based resins HisLink, Ni-IDA and Ni-
TED, Ni-TED gave the best balance between yield and purity [473]. In other work, MagReSyn 
NTA (ReSyn Biosciences, South Africa) gave much better purity than Ni-TED resin, but only 
the inactive P420 form was detected in those purified samples (personal communication, 
Omesan Nair). MagReSyn NTA beads also resulted in inactive protein when they were used to 
purify the haem enzyme catalase (personal communication, Andrew Nel), perhaps suggesting 
that the magnetic centres or the polyethylene imine coating of these beads interact with haem 
groups, dislodging or altering their position in the active sites. 
 
While other purification methods in conjunction with nickel affinity chromatography could be 
used to improve purity, additional purification steps would be time consuming, decrease yield 
and potentially increase the ratio of P420 to P450.  E.coli does not have any native CYP450 
genes so it seemed unlikely that contaminating proteins would interfere with downstream assays; 
as such, efforts to further purify each of the 17 CYP450 proteins were not pursued.   
 
In conclusion, while further optimisation may improve expression, purification and total P450 
yields, P450 protein was obtained for all CYP3A4 and CYP2C9 variants selected for in vitro 
studies and levels were deemed suitable for downstream assays.  It is clear from the results in 
this Chapter that single amino acid substitutions affect soluble expression levels and haem 
incorporation. P420:P450 ratios immediately suggest that some mutations have a substantial 
effect on the stability of the holoprotein structure in vitro. The effect of mutations on protein 
stability will be tested and discussed in the next Chapter.  
 
  





5.4.1 Recombinant cloning of CYP3A4, CYP2C9 and CPR constructs 
Original parent vectors 
 
N-terminal truncated CYP3A4 and CYP2C9 constructs (both cloned into pBJW102.2 parent 
vectors) and a full length CPR construct (cloned into pMD004 vector) were a gift from 
Procognia Ltd, Maidenhead, UK.  The N-terminal truncated version of CPR was then cloned into 
pBJW102.2 by a former post-doctoral fellow in our laboratory, Dr Siddharth Sharma.  
pBJW102.2 + CYP3A4, pBJW102.2 + CYP2C9 and pBJW102.2 + CPR vector sequences can be 
found in Appendix C. The pBJW102.2 vector was originally created by cloning the BCCP 
domain of the E. coli AccB enzyme (amino acids 74 ‐ 156)  and a glycine‐serine linker sequence 
in frame, 3’ to the His-6 tag of the commercially available pQE-80L E.coli expression vector 
(Qiagen, USA).  
 
The translated CYP3A4 protein has a 24 amino acid deletion at the N-terminus and shows 
mutations V175I and V253I when compared to human CYP3A4 UniProt sequence P08684. 
These mutations have not previously been characterised as polymorphisms and are not predicted 
to have an effect on protein stability. V175I does not fall within a functional region and although 
V253I is the last residue of SRS (2, 3) it faces away from the active site and is not expected to 
affect enzyme function. For the purposes of this study, this sequence is considered the wild-type 
sequence. The translated CYP2C9 protein has a 28 amino acid deletion at the N-terminus and 
contains no mutations when compared to human CYP2C9 UniProt sequence P11712. The 
translated CPR protein has a 43 amino acid N-terminal deletion and has one mutation, V226L, 
when compared to the human CPR UniProt sequence P16435.  This mutation is on the opposite 
side of the protein to the NADPH, FAD and FMN binding pockets and is not expected to affect 
protein function. CYP3A4, CYP2C9 and CPR recombinant protein sequences can be found in 
Appendix C.  
Inverse PCR to introduce single point mutations into CYP3A4 and CYP2C9 genes 
 
Inverse PCR, using the pBJW102.2 + CYP3A4 vector or the pBJW102.2 + CYP2C9 vector as a 
template, was used to generate variant expression vectors. Primers were designed using Vector 




NTI Advance 11.0 (Invitrogen, USA) and synthesized in 5’phosphorylated form by Inqaba 
Biotechnical Industries, South Africa or by Integrated DNA Technologies, USA. (Table 5.4) 
 
Table 5.4 Primers used to introduced single point mutations into CYP3A4 and CYP2C9 genes within the 
pBJW102.2 vector by inverse PCR 
Mutation Change Forward Primer (5'-3') Reverse Primer (5'-3') TA (°C) 
3A4         
G56D 224 G>A ACTTTTGTATGTTTGACATGGAATG* CCTTATGGTAGGACAAAATATTTCC* 51 
K96E 343 A>G GAAGAATGTTATTCTGTCTTCAC CACTAGCACTGTTTTGATCATGTC 54 
P218R 710 C >G GATTCTTTCTCTCAATAACAGTCT* GATCCAAAAAATCAAATCTTAAAAG* 47 
S222P 721 T>C CCAATAACAGTCTTTCCATTCCTC* GAGAAAGAATGGATCCAAAAAATC* 51 
I223R 725 T>G GAACAGTCTTTCCATTCCTCATC TTGAGAGAAAGAATGGATCCAAA 54 
L293P 935 T>C CGGAGCTCGTGGCCCAATCAATTA GATCGGACAGAGCTTTGTGGGACT 62 
L373F 1174 C>T TTTGAGAGGGTCTGCAAAAAAGATG* TCTCATAGCAATTGGGAATAATCTG* 55 
M445T 1391 T>C CGAGGTTTGCTCTCATGAACATG TGCCAATGCAGTTTCTGGGTCCAC 70 
2C9         
V76M 271 G>A ATGCTGCATGGATATGAAGCAGTG       CACTATGGGTTTCAGGCCAAAATA 57 
R132Q 440 G>A AGAATTTTGGGATGGGGAAGAGG GCAGCGTCATGAGGGAGAAACG 62 
R150H 494 G>A ACTGCCTTGTGGAGGAGTTGAGA GGGCTTCCTCTTGAACACGGTC 62 
Q214L 686 A>T TGATCTGCAATAATTTTTCTCCTA          GGATCCAGGGGCTGCTCAAAAT 57 
P279T 880 C>A ACATCTGAATTTACTATTGAAAGC TTGGTTGTGCTTTTCCTTCTCCA 57 
I359L 1120 A>C CTTGACCTTCTCCCCACCAGCCT GTATCTCTGGACCTCGTGCACCA 64 
I359T 1121 T>C CTGACCTTCTCCCCACCAGCCT TGTATCTCTGGACCTCGTGCACC 64 
* indicates primers synthesized by Integrated DNA Technologies; all other primers were synthesized by Inqaba 
Biotechnical Industries.  All primers were 5’phosphorylated. Annealing temperatures (TA) used for each set of 
primers are shown in the last column.  
 
DNA amplification was performed using the KAPA HiFi PCR Kit (Kapa Biosystems, South 
Africa). The reaction set up and PCR cycling protocol used are shown in Table 5.5 and Table 5.6 
respectively. A negative control containing no template DNA was included. After PCR 
optimization (25 µl reactions) and product verification by electrophoresis, bulk PCRs (2 × 50 µl 
for each variant) were performed.   
 





Table 5.5 PCR reaction setup 
Component Final concentration 
KAPA HiFi Buffer  1X (includes 2 mM MgCl2) 
dNTP Mix 0.3 mM 
Forward Primer 0.3 mM 
Reverse Primer 0.3 mM 
Template DNA 50 ng per 50 µl reaction 
KAPA HiFi DNA Polymerase 1U per 50 µl reaction 
PCR-grade water make up to total volume 
 
Table 5.6 PCR cycling protocol                      
Step Temperature Duration Cycles 
Initial denaturation 95°C 4 min 1 
Denaturation 98°C 20 sec 
25 Annealing (TA) See Table 5.4 15 sec 
Extension 72°C 3.5 min 
Final extension 72°C 5 min 1 
Agarose gel electrophoresis  
 
The linear PCR products were verified electrophoretically on 1% agarose gels. Agarose gels 
were prepared by melting agarose (w/v) in Tris Acetate-EDTA buffer (TAE: 40 mM Tris base, 
20 mM acetic acid, 1 mM EDTA, pH 8.0), adding 1:10 000 SYBR® Green (Life Technologies) 
to melted agarose for DNA visualisation, pouring it into a gel mould and allowing it to set. 1 × 
TAE was used as the running buffer and PCR products were mixed with 1 × DNA loading dye 
(Fermentas) and loaded into the gel wells. Mass RulerTM DNA ladder (Fermentas) was also 
loaded to estimate the size of the products and the original DNA templates were loaded as 
controls. Electrophoresis was carried out at 120V for ~40 min and the gels were viewed using 
the SynGene ChemiGenius Bio Imaging System (Synoptics Ltd, UK) and the SynGene 
GeneSnap software version 7.07.01 was used to acquire and process the gel images.  
DNA-cleanup and Dpn1 digestion 
 




The bulk PCR products were purified using GeneJET PCR Purification Kit (Fermentas) and 
treated with FastDigest Dpn1 (Fermentas) to restrict the parental template DNA, according to 
manufacturer’s instructions. The PCR products were then separated by electrophoresis on a 0.8% 
agarose gel as described above. The target PCR bands were excised from the gel under 
Ultraviolet (UV) illumination with a sterile scalpel.  The PCR products were then purified from 
the gel using the GeneJET Gel Extraction Kit (Fermentas) according to manufacturer’s 
instructions. This was done to remove any non-specific PCR products from the sample. The 
purified DNA samples were quantified using the NanoDrop ND-100 spectrophotometer 
(NanoDrop Technologies, USA) 
DNA ligation 
 
The ends of the PCR product contained the 5’phospho group from the original primers, aiding 
the blunt end ligation of the linear DNA back into a circular plasmid form. DNA products were 
ligated using T4 DNA ligase (Fermentas) according to manufacturer’s instructions for self-
circularisation of blunt ended linear DNA.  
Competent cell preparation 
 
The rubidium chloride method was used to prepare competent DH5α cells. 5ml of Luria Broth 
(LB) was inoculated with freshly plated DH5α cells and incubated overnight at 37°C with 
shaking. The 5ml culture was then used to inoculate a 500ml culture and incubated at 37°C with 
shaking until OD600~0.5. The culture was cooled on ice for 15min and cells were pelleted by 
centrifugation for 10min at 4500 rpm, 4°C. The cell pellets were resuspended in 30ml TfbI (100 
mM RbCl, 50 mM MnCl2, 30 mM KOAc, 10 mM CaCl2, 15%(v/v) glycerol, pH5.8), left on ice 
for 30min and cells were again pelleted by centrifugation for 5min at 4000 rpm, 4°C. The cell 
pellet was resuspended in 6ml TfbII (10 mM MOPS, 75 mM CaCl2, 10 mM RbCl and 15% (v/v) 
glycerol, pH 6.5) on ice and stored in aliquots at -80°C. 
DNA transformations  
 
DH5α competent cells were thawed on ice for 10min. 10 µl of each ligation reaction (~10ng 
DNA) was added to a separate tube containing 100 µl of competent cells. An extra tube of 
competent cell, serving as a negative control, was included to which no DNA was added. Tubes 




were swirled gently to mix and placed on ice for 30 min. The cells were heat shocked in a water 
bath set at 42°C for 90 s and then cooled instantly on ice for 2 min. 900 µl of LB, pre-warmed at 
37°C, was added to each tube and tubes were incubated at 37°C for 2 h with gentle shaking. 20 
µl of each transformation mix was plated onto separate Luria Agar plates supplemented with 
100µg/ml ampicillin (LB-Amp agar plates) and plates were incubated at 37°C overnight. No 
colonies - or very few - grew on the negative control plates, while a large number of colonies 
formed on the sample plates, indicating that plasmid DNA containing the ampicillin resistant 
gene was successfully incorporated.  
Plasmid DNA extraction for DNA sequencing  
 
3 to 5 individual colonies were selected from each plate and used to inoculate 5ml LB 
supplemented with 100µg/ml ampicillin (LB-Amp) and incubated for 12-16 h at 37°C with 
shaking. Cells were harvested from 2 ml of the 5 ml cultures by centrifugation at 14000rpm for 
10min. Plasmid DNA was isolated from these cells using GeneJET Plasmid Miniprep Kit 
(Fermentas) according to manufacturer’s instructions, quantified by Nano Drop and sent for 
sequencing to confirm that point mutations were correctly incorporated.  
Sequencing  
 
Sequencing was carried out by Inqaba Biotechnical Industries or the Central DNA Sequencing 
Facility at the University of Stellenbosch using the dye terminator method. At least one correct 
clone was obtained for each variant.  
Glycerol stocks 
 
Sequence verified plasmid DNA was then used to transform DH5α cells to ampicillin resistance 
and recombinant colonies where grown in 5ml LB-Amp cultures as before. Glycerol stocks were 
prepared by diluting cultures 1:2 with 30% glycerol and aliquots were stored at -80°C for future 
use.  




5.4.2 Protein Expression and Enrichment 
 
CYP3A4, CYP2C9 and CPR protein expression 
 
Glycerol stock were streaked out onto LB –Amp agar plates and incubated at 37°C overnight. 
Single colonies were inoculated into 5-10ml LB-Amp starter cultures and incubated at 37°C with 
shaking overnight. 5ml of each starter culture was then added to 500 ml of Terrific Broth (12g 
yeast extract powder, 6 g Tryptone powder, 0.4% glycerol in 89 mM potassium phosphate buffer 
pH 7.4) supplemented with trace elements (Final concentration: 250µM FeCl3, 24µM ZnCl3, 
21µM CoCl2, 21µM Na2MoO4, 0.15µM CaCl2, 20µM H3BO3, 10µM CuCl2, 0.03% HCl), 1 mM 
thiamine and 100µg/ml ampicillin. Two 500 ml cultures (total of 1 litre) were grown per protein. 
The 500 ml cultures were incubated at 37°C with shaking at 160 rpm until the cell density 
reached OD600 0.4 - 0.6 (~4 h). 0.042g (0.5 mM) of δ-aminolevulinic acid (Sigma-Aldrich, 
Germany) was then added to CYP3A4 and CYP2C9 cultures to facilitate haem synthesis and 
cultures were incubated at 30°C with shaking at 160 rpm for a further 30 min. Protein expression 
was induced with 1 mM IPTG (Melford, UK) and 50 µM Biotin (Sigma-Aldrich, USA) was 
added to facilitate biotinylation of the BCCP-tag. Expression was carried out at 30°C with 
shaking at 120 rpm for ~18 h. Cells were harvested by centrifugation at 6000 rpm at 4°C for 15 
min. Pellets from the two 500 ml cultures were washed in 1 x phosphate-buffer saline (PBS 
pH7.4, Sigma-Aldrich, Germany), combined, centrifuged as before and stored at -20°C.    
Protein extraction 
 
Cell pellets were thawed on ice and 14 ml of lysis buffer (20 mM phosphate buffer, pH 7.4; 20% 
glycerol (v/v); 10 mM β‐mercaptoethanol) was used to resuspend a cell pellet harvested from 1 
litre of culture giving a total volume of ~20 ml. Following this, 1.5 mg/ml lysozyme (Fluka, 
Belgium), 80 U/ml DNase I (Roche, Germany), 0.5 mM CaCl2 and 2.5 mM MgCl2 was added 
and the cell suspension was left on ice with gentle shaking for 30min. The following detergents 
were then added to disrupt aggregates and solubilise membranes: 0.15% IgePal CA‐630, 0.5% 
CHAPS and 0.1% Triton X-100 (Sigma-Aldrich, USA). The suspension was left on ice with 
gentle shaking for a further 30 min. Crude soluble lysate was then separated from the cell debris 
by centrifugation at 10 000 ×g at 4° C for 30 min.  






His-tag purification was carried out on the same day as protein extraction using Protino Ni-TED 
packet columns (Macherey-Nagel, Germany), according to manufacturer’s instructions. These 
columns are packed with dry silica based resin that is pre-charged with Ni2+ ions. The Ni2+ ions 
are chelated to the resin by TED-pentadentate metal chelator which coordinates 5 of the 6 
coordination sites on nickel. This leaves one site open to bind the polyhistidine tag on the 
recombinant protein, allowing purification. The polyhistidine- tagged proteins were eluted from 
the column with a buffer containing 300 mM imidazole. Imidazole, which has a high affinity for 
Ni2+, displaces the protein from the nickel coordination site, allowing rapid elution of the protein 
of interest. The eluted samples were concentrated to < 700 µl using Amicon Ultra 15 ml 
centrifugal filters (10K MWCO; Merk Millipore Ltd, Ireland) by centrifugation at 4000 ×g at 
4°C for ~ 45min. Protein samples were then buffer exchanged from the Ni-TED elution buffer 
into P450 storage buffer (20 mM potassium phosphate, pH 7.4; 20% glycerol (v/v); 0.2 mM 
EDTA; 1 mM DTT) using Zeba desalting columns (7K MWCO; Pierce, USA) according to 
manufacturer’s instructions and aliquots were stored at -20°C. CYP3A4, CYP2C9 and CPR 
proteins stored in this way retained activity for over 8 months.  
Total protein quantification 
 
Total protein was quantified by Bradford assay [481] using the Bio-Rad Protein Assay Dye 
Reagent (Bio-Rad, USA) according to manufacturer’s instructions. Crude lysates were quantified 
using the standard assay and partially purified samples were quantified using the microassay. 
Standard curves were generated using bovine serum albumin (BSA, Roche, Germany). Protein 
concentrations were measured in triplicate in a 96 well plate format using a Bio-Rad iMark 
microplate reader.  
Gel electrophoresis  
 
Protein samples were visualised using sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Samples were suspended in 1× sample application buffer (12 mM 
Tris-HCl pH 6.8, 1% (v/v) β-mercaptoethanol, 0.4% (w/v) SDS, 5% glycerol, 0.02% (w/v) 
bromophenol blue) with vortexing and then boiled at 95°C for 5 min. The samples were then 




loaded onto a two phase polyacrylamide gel immersed in 1x running buffer (2.5 mM Tris base, 
0.19 M glycine, 0.1% (w/v) SDS, pH 8.3). The polyacrylamide gel generally consisted of a 10% 
separating gel (10% (w/v) acrylamide/bis-acrylamide; 375 mM Tris-HCl, pH 8.8; 0.1% SDS; 
0.03% (w/v) ammonium persulfate; 0.1% (v/v) TEMED) overlaid with stacking gel (4% (w/v) 
acrylamide/bis-acrylamide; 125 mM Tris-HCl, pH 6.8; 0.1% SDS; 0.03% (w/v) ammonium 
persulfate; 0.3% (v/v) TEMED) to insure even migration of the protein. A prestained protein 
ladder (either PageRuler or PageRuler Plus from Fermentas) was also loaded onto the gel to 
estimate the size of the protein bands. Samples were separated by electrophoresis at 120 V for ~1 
h using the Bio-Rad Mini Format 1-D Electrophoresis Systems (Bio-Rad, USA). The gel was 
immersed in Coomassie blue staining solution (0.05% (w/v) Coomassie brilliant blue, 50% (v/v) 
methanol, 7% (v/v) acetic acid) overnight followed by destaining (5% (v/v) methanol, 7% (v/v) 
acetic acid) or stained using Acqua Stain (Acquascience, UK) according to manufacturer’s 
instructions. 
Western Blot analysis 
 
Protein samples were separated by SDS-PAGE as described above, followed by electroblotting 
at 100 volts for 1 h onto a BioTrace NT nitrocellulose blotting membrane (Pall Corporation, 
Mexico) using a wet blotting system (Bio-Rad, USA) and 1X transfer buffer (30 mM Tris, 0.19 
M glycine, 20% (v/v) isopropanol). The membrane was immersed in Ponceau S reversible stain 
(Sigma Aldrich) to check protein transfer was successful and was then blocked in 5% fat free 
milk powder (w/v) in 1 x TBS-Tween (0.1 % Tween (v/v); 50 mM Tris base, pH7.5; 0.15 M 
NaCl) for 1 hour to prevent non-specific binding of the antibody to the membrane. The 
membrane was then probed with 1:2000 Streptavidin Peroxidase labelled conjugate (strep-HRP)  
(Kirkegaard and Perry Laboratories, USA) or 1:15 000 Anti-His HRP conjugated (Sigma-
Aldrich) in 5% fat free milk powder (w/v) overnight at 4°C with gentle shaking. After three 5 
min washes in 1x TBS-Tween, the SuperSignal® West Pico Chemiluminescent Substrate 
(Thermo Scientific, USA) was used for the detection of HRP according to manufacturer’s 
instructions. The membrane was subsequently visualised using the SynGene ChemiGenius Bio 
Imaging System (Synoptics Ltd, UK) or exposed to X-ray film that was then developed. 
 




5.4.3 Specific protein quantification: Carbon monoxide P450 spectral Assays 
 
CYP450 protein samples were diluted in P450 storage buffer as shown in Table 5.7 and divided 
into two 1 ml plastic cuvettes (one reference and one sample cuvette).  The cuvettes were placed 
into a Varian Cary 50 UV Visible spectrophotometer (Varian, Australia) and a baseline reading 
between 400 and 500 nm was recorded. Carbon monoxide (Speciality Gases, SA) was bubbled 
into the bottom of the sample cuvette (~60 bubbles at a rate of 1 bubble per second). A small 
spatula tip (~1 mg) of sodium dithionite (Na2S2O4, Sigma-Aldrich, Germany) was added to each 
cuvette. Cuvettes were covered with parafilm and inverted several times to dissolve the sodium 
dithionite.  The cuvettes were then placed back inside the spectrophotometer and spectra 












Readings from the final spectra were used to calculate the amount of P450 and P420 protein 
present in the sample using the following equations: 
 
 [(∆A450 - ∆A420) observed  –  (∆A450 - ∆A420) baseline]/0.091 = nmol P450 per ml                  [4.1] 
 
  
[(∆A420 - ∆A490) observed  – (∆A420 - ∆A490) theoretical  –  [(∆A420 - ∆A490) baseline]/0.110  =  
 nmol of P420 per ml                                                                                                               [4.2] 
 
 
where  (∆A420 - ∆A490) theoretical  = (nmol P450 per ml from equation [4.1] ) × (- 0.041)          [4.3] 
Protein sample Total protein concentration 
CYP3A4 crude lysates ~ 10 mg/ml 
CYP2C9 crude lysates ~ 5 mg/ml 
CYP3A4 partially purified samples 1 mg/ml 
CYP2C9 partially purified samples 1 mg/ml 
























 Testing the effect of Chapter 6
polymorphic variation on the 
thermostability of CYP450 proteins 






The folded structure of a protein is stabilised by an intricate network of weak interactions and 
changes to this interaction network can lead to conformational changes and altered protein 
stability.  Protein stability can also be altered by chemical changes affecting covalent bonds 
within the protein structure [482]. While covalent changes are usually irreversible, the folded 
(native) and unfolded (denatured) state of a protein are in constant equilibrium due to the flexible 
and dynamic nature of proteins. In general, for wild-type proteins under physiological 
conditions, the folded state is much more stable than the less ordered unfolded state so proteins 
quickly resume their native structures making this dynamic equilibrium of little consequence to 
the function of proteins [483].  Changes in the protein environment as well as mutations can 
however shift the equilibrium towards the unfolded state. Combinatorial mutagenesis on 
thermostable CYP-119 protein revealed that salt bridges, charge-charge interactions, aromatic 
stacking and side chain volume of hydrophobic residues contribute to enhanced thermostability 
in the CYP450s [484].  
 
Mutations are generally thought to affect the equilibrium between the folded and unfolded states 
of proteins by changing the free energy of the folded state. The unfolded or denatured state is 
typically however not a random coil but rather a poorly defined partially folded structure. As a 
result, the effects of a mutation on the stability of the denatured protein can also shift the 
equilibrium [483].  Consequently, a mutation increasing the conformational entropy of the 
unfolded state by destabilising the partially folded state can stabilise the native protein. While we 
can attempt to predict and rationalise the effects of mutations on the folded protein by analysing 
crystal structures, effects on the undefined denatured state are far more difficult to comprehend. 
 
The conformational stability of a protein can be determined by calculating the equilibrium 
constant and free energy change for the conversion between the folded and unfolded states under 
a chosen condition [482]. Changes to the protein environment such as increased temperature, 
high salt concentrations, chemical denaturants, changes in pH and increased hydrostatic pressure 
can be used to drive protein unfolding by shifting the equilibrium towards the unfolded state.  
Techniques used to monitor protein unfolding include UV difference spectroscopy, circular 
dichroism, fluorescent-based assays, activity measurements, optical rotatory dispersion and 
nuclear magnetic resonance (NMR) [482].   





Protein unfolding curves, comprising of pre-transition, transition and post-transition phases, can 
be generated by monitoring changes to the protein state as the severity of the denaturing 
condition is increased.  It is essential that the unfolding reaction is reversible and reaches 
equilibrium for accurate thermodynamic measurements.  
 
Choosing denaturation conditions and a monitoring technique depends largely on the equipment 
and quantity of protein available, as well as the structural information required. Fluorescent 
assays generally require less protein than other methods, however pre- and post-transition 
baselines are steep and highly sensitive to temperature, making fluorescence inappropriate for 
monitoring thermal unfolding [482]. While NMR requires large amounts of pure protein, it 
yields a much greater level of structural detail than other techniques. Circular dichroism 
monitors changes to secondary structures within the protein, while UV difference spectroscopy 
gives information on the environments of aromatic residues, giving insight into changes in 
tertiary structure [482].  
 
CO P450 spectral assays offer a convenient method for monitoring changes between the 
correctly folded active state of the protein (P450) and the inactive state (P420). The switch 
between the P450 and P420 is caused by alterations to the cysteine co-ordinated haem 
environment. The P420 form still has a haem group attached within the hydrophobic cavity and 
it is generally accepted that the cysteine thiolate coordinated to the haem iron at the proximal 
position is either protonated, resulting in a weak thiol ligand [485-487] or replaced by another 
amino acid [21, 488]. The P420 form is not a uniform, well define-structure but appears to differ 
structurally under different denaturing conditions and between isoforms [489-492].  Several 
studies have suggested that the axial cysteine ligand is replaced by a histidine residue also 
located within the β-bulge or within the haem environment, however not all isoforms have a 
histidine residue in close proximity to the haem group. Lu et al showed that the thermal 
denatured CO bound ferrous CYP2C8 P420 has a protonated cysteine thiolate co-ordinating the 
haem iron and that the P450 state could not be regenerated by reducing the temperature [492]; 
this is in agreement with other studies showing that the thermal inactivation of CYP450s is 
irreversible [493, 494].  
 




The aim of the work described in this Chapter was to determine the effect of polymorphic 
variation on CYP450 stability for the panel of CYP3A4 and CYP2C9 variant proteins that were 
cloned, expressed and purified as described in Chapter 5.  Thermodynamic protein unfolding 
curves could not be accurately used to test the thermostability of the CYP450 due to the 
irreversible nature of the thermally induced P450 to P420 conversion. Generating unfolding 
curves using other denaturing conditions that show reversible denaturation, such as hydrostatic 
pressure, requires specialised equipment not available locally and can be protein intensive. 
However, since the goal here was to determine the relative stability of the variant proteins 
compared to the wild-type, it was deemed that reversible unfolding curves were not necessary. 
CO P450 spectral thermostability assays were therefore carried out at one constant temperature 
and the decrease in P450 was monitored over time to determine the half-life of each protein.   
 
 






To test the thermostability of the 17 CYP3A4 and CYP2C9 proteins produced in Chapter 5, CO 
P450 difference spectra were used to measure the decrease in P450 content at an elevated 
temperature as a function of time. When the CYP450 protein samples were incubated at an 
elevated temperature, the peak began to shift from 450 nm to 420 nm indicating the irreversible 
thermal conversion of active P450 into inactive P420 (Figure 6.1).  Assays were performed using 
partially purified recombinant CYP3A4 and CYP2C9 proteins, previously expressed in E.coli 
(Chapter 5). Different temperatures were tested to ensure the decrease in P450 could be 
monitored at a constant temperature over a 30 minute period: 34 °C was chosen for CYP3A4 




Figure 6.1 Ferrous CO vs. ferrous difference spectra for CYP23A4 wild-type thermostability assay. The difference 
spectra show a decrease in P450 and an increase in P420 with time. Assay was carried out at 34 °C and absorbance 
spectra were measured every 4 min are shown here.  
 
CYP3A4 and CYP2C9 wild-type protein samples both showed an exponential decrease in P450 
content, although the graphs did not tend to zero, suggesting either the presence of a stable P450 
sub-population or background signal. When the temperature was elevated further, up to ~60°C, 
in both cases the peak at 450 nm disappeared rapidly followed by a decrease in P420 until no 




peaks were visible (data not shown). This data implies that the asymptote - or ‘plateau’ - was 
probably a result of a more stable P450 sub-population rather than background signal.  
6.2.1 Comparing the thermostability of CYP3A4 polymorphic variants 
 
Figure 6.2 shows the results from the CYP3A4 thermostability assays. Both a one phase and two 
phase exponential decay model was fitted to the data sets using Graph-Pad Prism software.  
While the one phase model fitted all the data reasonably well provided the plateau was not 
constrained to zero, the two phase model was the preferred fit for wild-type and variants K96E, 
S222P, I223R and L293P. The more complex two phase model gave rate constants with very 
large confidence intervals that were often inconsistent between replicates. All data sets were 
therefore analysed using the one phase model, assuming that the contribution of the slower phase 
to the decrease in P450 content is very small due to the fact that it appears to have a much longer 
half-life than the fast phase, resulting in a graph that appears to reach a plateau.   
 
To determine the effect of polymorphic variation on CYP3A4 stability, the effect of mutations 
on the half-life of the unstable sub-population and the effect of mutations on the plateau - the 
proportion of P450 making up the stable sub-population – were considered. The wild-type 
protein had a half-life of 6.3 minutes at 34°C and reached a plateau with 29 % P450 remaining, 
indicating that approximately one third of the P450 was in the more stable form.   
 
The most notable differences in stability compared to wild-type were observed for variants 
G56D, L373F, P218R, S222P and M445T (Figure 6.2). G56D and L373F plateaued at ~ zero, 
indicating that these mutations abolish the stable P450 sub-population. They also had the lowest 
half-lives of all the variants, ~ 3 and 2 minutes respectively. P218R, S222P and M445T also had 
a very significant effect on the plateau, with only 7-8 % of P450 making up the stable sub-
population; however, they only a moderate effect on the half-life (15 – 30% decrease) of the 
unstable sub-population. 
 
I223R and K96E mutation had much smaller effects on stability while L293P showed no 
significant differences compared to wild-type (Figure 6.2). 





Figure 6.2 Thermostability of CYP3A4 polymorphic variants at 34°C.  A) Graphs showing the decrease in P450 
content at 34 °C over 30 minutes. A one phase exponential decay model was fitted to the data using non-linear 
regression as described in Methods. B) Comparison of % P450 remaining when the graph reached a plateau for each 
variant. C) Comparison of the half-life of each variant at 34 °C.  Error bars represent the standard deviation of three 
replicates. Student t-test was used to determine values significantly different from wild-type: * P < 0.05, ** P < 
0.01, *** P < 0.005. 




6.2.2 Comparing the thermostability of CYP2C9 polymorphic variants 
 
 
Figure 6.3 Thermostability of CYP2C9 polymorphic variants at 48°C.  A) Graphs showing the decrease in P450 
content at 48°C over 30 minutes. A one phase exponential decay model was fitted to the data using non-linear 
regression as described in Methods. B) Comparison of % P450 remaining when the graph reaches a plateau for each 
variant. C) Comparison of the half-life of each variant at 48 °C. Error bars represent the standard deviation of three 
replicates. Student t-test was used to determine values significantly different from wild-type: * P < 0.05, ** P < 
0.01, *** P < 0.005.  




Figure 6.3 shows the results from the CYP2C9 thermostability assays. The one phase 
exponential decay model was the preferred model for all the CYP2C9 proteins.  The wild-type 
protein had a half-life of 11.5 min at 48°C and the graph reached a plateau with 35% P450 
remaining.   
 
P279T had a half-life of 15.3 minutes (33% higher than wild-type) and I359L had a half-life of 
7.5 minutes (35% lower than wild-type); however, differences in the half-lives were not 
significantly different for any of the CYP2C9 variants compared to wild-type.  
 
Q214L, V76M, I359L and I359T did however have a significant effect on the plateau. Q214L 
had a higher proportion of P450 making up the stable sub-population compared to the wild-type 
protein, plateauing with 44% P450 remaining. V76M, I359L and I359T all had adverse effects 
on the stable P450 populations, with graphs plateauing at 15 %, 10 % and 3 % P450 remaining 
respectively.  
 
R132Q and P279T had particularly large standard deviations, with one of the three replicates in 
each case giving curves with much lower plateau’s than the other two replicates, making it 
difficult to determine whether these mutations have an effect on the stable P450 population.  





Thermostability of wild-type CYP3A4 and CYP2C9 proteins 
 
CYP2C9 proteins were much more stable than CYP3A4 proteins, to the extent that CYP3A4 had 
a shorter half-life at 34°C than CYP2C9 had at 48°C. The observed differences in stability are 
consistent with the differences in expression levels and P450:P420 ratios determined in Chapter 
5, where total P450 yield for CYP3A4 wild-type was 20% lower than CYP2C9 wild-type prior 
to His-tag purification and 60% lower after purification. Notably, the P420 form of the protein 
was not detected in any of the CYP2C9 partially purified samples, while the P420 form was 
present in all CYP3A4 samples. Proteins are often observed to be more stable in crude lysates 
than in partly purified protein preparations and can denature during purification. In this work, 
and important observation is that expression was carried out at 30°C for both CYP3A4 and 
CYP2C9 proteins, but this temperature is only 4°C lower than that subsequently used for the 
CYP3A4 thermostability assays, possibly explaining why a portion of the CYP3A4 protein was 
in the P420 form even before purification.  This suggests that a lower expression temperature 
might improve P450:P420 ratios for CYP3A4 proteins; however, while expression of CYP3A4 
proteins at lower temperatures did moderately improve P450:P420 ratios, this was at the cost of 
overall P450 yield.  
 
Exponential decay curves for both CYP3A4 and CYP2C9 indicated energetically distinct P450 
sub-populations that did not interconvert between each other during the course of the assay. In 
support of this idea, previous published studies examining the binding kinetics of CO to 
CYP3A4 using flash photolysis have argued that there are two kinetically distinct pools of P450, 
both in the membrane and in solution [128, 495, 496].    
 
Other studies have also observed conformational heterogeneity for CYP2B4 [497, 498] and 
CYP3A4 proteins [124] using hydrostatic pressure spectroscopy. Elevated pressure typically 
causes a high-spin to low-spin shift of the haem iron [499-502], followed by the conversion of 
P450 to P420; these two pressure-induced processes can occur one after the other [503] or within 
overlapping pressure ranges [498, 502, 504]. Davydov et al observed that only 65 to 70% of CO 
bound ferrous CYP2B4 in solution was susceptible to a pressure-induced P450 to P420 transition 
in the absence of detergents, however all P450 could be converted to P420 in the presence of 




detergent indicating that the observed heterogeneity may be a result of oligomer formation [497].  
Similar heterogeneity was also seen for ferric CYP2B4 and CYP2B4 within proteoliposomal 
membranes [498].  
 
In another study it was shown that 70% of CYP3A4 in solution and 50% in microsomes was 
susceptible to substrate-induced spin shifts and rapid, reversible pressure-induced P450 to P420 
conversions [124].  The other fraction of the protein however remained predominately in the 
low-spin state. In solution, this remaining fraction was subject to slow, irreversible inactivation 
at high pressures indicating that the pressure induced P450 to P420 conversion of CYP3A4 was 
biphasic consisting of a fast reversible phase and a slow irreversible phase. In microsomes 
however only the fast reversible phase was observed. A pressure induce high-spin to low-spin 
shift was also detected in solution phase but not in microsomes, suggesting that the high-spin 
state is stabilised by interactions with other proteins and lipids within the membrane.  
Stabilisation of the high-spin state is thought to reflect decreased water accessibility of the haem 
[77].   
 
Similarly to CYP2B4, the addition of detergents known to break up oligomers has been reported 
to reduce the heterogeneity of CYP3A4 observed in solution. This led the authors to suggest that 
the 1:2 conformer distribution in solution is a result of hexameric organisation, where 2 subunits 
have a different orientation to the other four. Interestingly both CYP2B4 and CYP1A2 have been 
shown to exist as hexamers in solution [119-121, 505]. 
 
In this Chapter, similar conformational heterogeneity for both CYP3A4 and CYP2C9 in solution 
was observed; only 65 – 70% of the P450 was susceptible to rapid heat-induced P450 to P420 
conversion at a constant elevated temperature while the remaining fraction was much more 
stable, consistent with the literature. As suggested by Davydov et al, this 1:2 conformer ratio 
may indicate the formation of hexamers in solution for both CYP2C9 and CYP3A4, but gel 
filtration experiments and further thermostability assays done in the presence of detergents 








Effect of mutations on thermostability 
 
A number of the single amino acid substitutions studied here affected the proportion of protein 
that was sensitive to the rapid heat-induced P450 to P420 conversion and/or affected the half-life 
of this conversion. Table 6.1 provides a summary of the results, comparing the predicted effects 
of mutations on the stability of the apo monomeric P450 structure (as determined in silico by 
SDM in Chapter 4) with the effect of mutations on the thermostability of the P450 proteins 
determined in solution in this Chapter.   
 
Table 6.1  Predicted effects of mutations on protein stability versus experimentally determined effects on 
protein stability.  
CYP450 
variant 
% RSA Ψ of 
wild-type residue 
Predicted effect on stability 
by SDM† 
Experimentally determined effect 
on thermostability  
CYP3A4    
   G56D 13.4 destabilising decrease 
   K96E 60.7 neutral none* 
   P218R 85.8 neutral decrease 
   S222P 52.1 neutral decrease 
   I223R 0.0 destabilising decrease 
   L293P 54.1 neutral none 
   L373F 13.5 neutral decrease  
   M445T 39.6 destabilising decrease  
CYP2C9    
   V76M 0.1 neutral decrease 
   R132Q 63.2   neutral none 
   R150H 68.3   neutral none 
   Q214L 6.6 stabilising increase 
   P279T 90.2 neutral none 
   I359L 1.7 neutral decrease 
   I359T 1.7 destabilising decrease 
 
Ψ RSA refers to the relative solvent accessibility as calculated by (Site Directed Mutator) SDM . 
† Based on SDM scores: destabilising , ∆∆G < -2.0 kcal.mol -1; neutral, -2.0 < ∆∆G < 2.0 kcal.mol-1; stabilising 
∆∆G > 2.0 kcal.mol-1 
* K96E showed a small decrease in half-life however this may have been accounted for by the small (although 
insignificant) increase in the plateau and was therefore not classified as a destabilising mutation.  
 
Not surprisingly mutations in close proximity to the haem binding region, such as L373F (haem 
contact) and M445T (predicted to be destabilising by SDM) in CYP3A4, appear to destabilise 
the haem significantly in both conformers, increasing the proportion of protein sensitive to rapid 




heat-induced conversion to P420 and decreasing the half-life of this conversion. The most 
significant effect was observed for L373F, which is in direct contact with the haem (Figure 6.4): 
the slow phase was abolished completely and monophasic conversion to P420 occurred at a 
much more rapid rate. CYP3A4 mutation G56D had a similar effect to the L373F mutation; 
while Gly 56 is not in close proximity to the haem binding region, it was predicted to be a 
destabilising mutation by SDM.   
 
 
Figure 6.4 CYP3A4 L373F model aligned to the wild-type structure 
The CYP3A4 L373F model (red) generated by ANDANTE aligned to the wild-type CYP3A4 pdb structure 1TQN 
(grey) with wild-type residue Leu373 and variant residue Phe373 shown in bold. The haem group, which interacts 
with the residue 373, is shown in yellow 
                                         
For reasons less immediately apparent, P218R and S222P had a significant effect on the 
thermostability of CYP3A4;  P218R and S222P were both predicted to be neutral by SDM and 
fall within the flexible F-G loop, well away from the haem binding region. However, it is 
interesting to note that the F-G loop has been implemented in the dimerization of mammalian 
P450s, both in solution and membranes [506, 507]. In membrane bound P450s this loop lies in 
close proximity to the membrane or is partially embedded within the membrane.  Furthermore, 
CYP2B4 crystallises as a dimer along a two-fold symmetrical axis, made up of two open 
structures with the extended F-G loop from one molecule fitting into the open cleft of the second 
molecule (Figure 6.5 A) [506].   Close hydrophobic contacts between residues 213-230 and the 
binding partner were observed, whilst H226 co-ordinated to the haem iron, providing a spectral 
reporter for dimerization in solution. H226-Fe CYP2B4 dimers were also detected in solution 
and dimerization could be reversed to form catalytically active monomers.   
 




The F-G loop also forms part of the dimer interface in CYP2C8 crystal structures [508] (Figure 
6.5 B) and cross-linking experiments confirmed that this region also forms part of the dimer 
interface between CYP2C8 protein partners in membranes [509].  
 
CYP3A4 mutations P218R, S222P and I223R and CYP2C9 mutation Q214L fall within the 
flexible F-G loop. While the quaternary structure of CYP3A4 in solution is unknown, based on 
evidence from other isoforms, it seems reasonable to speculate that if CYP3A4 is forming 




Figure 6.5 CYP450 dimerization observed in crystal structures. A) CYP2B4 crystal structure, PDB code 1PO5, 
rendered using PyMOL showing dimerization of two P450s in an open conformation related by two-fold symmetry. 
One molecule (blue) interacts with a second molecule (grey) by coordination of H226 to the haem iron and close 
hydrophobic interaction between residues 213-230 shown in purple and the open cleft of the binding partner. B) 
CYP2C8 crystal structure, PDB code 1PQ2, rendered using PyMOL showing dimerization of two asymmetric 
CYP2C8 molecules via the F-G loop (green). Residues making the closest contact between molecules are shown in 
purple and the two palmitic acid molecules bound at the interface of the dimer are shown in yellow. The orientation 
of the dimer is compatible with membrane binding as the N-terminals of both molecule lie on the same side of the 
dimer.   
 
The dominant effect of P218R and S222P mutations on thermostability is a shift in towards the 
unstable, heat sensitive conformer, which could be attributed to the disruption of oligomer 
formation.  I223R causes a significant (P < 0.05) but more moderate shift towards the unstable 
conformer and a moderate decrease in the half-life of the fast phase. Unlike Pro218 and Ser222, 
which are both solvent exposed residues with side chains orientated towards the bulk solvent, Ile 
223 is buried (Table 6.1) indicating that it is unlikely to interact with other CYP3A4 molecules 




directly without a substantial change in protein conformation (Figure 6.6). I223R is however 
predicted to be damaging to protein structure by SDM so the observed effects on thermostability 
may be as a result of destabilisation of the secondary/tertiary structure rather than a direct effect 
on the quaternary structure.   
 
CYP2C9 variant Q214L, a buried residue within the F’ helix, was the only variant predicted to 
be stabilising by SDM and the only variant that showed a significant increase in thermostability, 
showing a significant increase in the proportion of stable conformer in solution, but no 
significant difference in the half-life of the fast phase.   
 
 
Figure 6.6 CYP3A4, PDB structure 1TQN rendered using PyMOL, illustrating the surface accessibility of residues 
P218 (red), S222 (blue) and I223 (yellow) within the F’ helix.  P218 and S222 side chains form part of the surface of 
the molecule whereas I223 is buried beneath the surface.  
 
I359L and I359T mutations in CYP2C9 decrease the proportion of protein making up the stable 
P450 sub-population. Ile358 is the last residue of α-helix K and is buried within the hydrophobic 
core of the protein.  SDM correctly predicts that a mutation to threonine at this position will 
destabilise the protein fold but incorrectly predicts the effect of the conserved mutation to 
leucine; while isoleucine and leucine are both hydrophobic residues with the same volume and 
similar properties, the subtle differences between these residues at this position appear to have a 
significant effect on the conformation of the CYP2C9 fold.  
 
CYP2C9 variant V76M also showed significantly less P450 in the stable sub-population than 
observed for the wild-type protein but was not predicted to be a destabilising mutation by SDM.  
V76 is a buried residue within strand 2 of β-sheet 1 and does not fall within any know functional 
region of the protein.  





In conclusion, 10 out of the 15 variants proteins tested had significantly altered thermostability 
compared to the corresponding wild-type protein. The results suggest that the observed effects of 
mutations on protein thermostability in solution may result from changes in the haem binding 
environment, alterations in oligomer formation or destabilisation of the protein fold. Based on 
these in vitro results, in silico predictions by SDM had a specificity of 100% (5/5) and a 
sensitivity of 50% (5/10).  SDM’s low sensitivity is expected since effects on haem binding and 
quaternary structure are not accounted for by SDM:  of the 5 false negatives, as predicted by 
SDM, one (L373F) is a haem contact and two may alter oligomer formation (P218R, S222P); the 
other two variants were either incorrectly predicted by SDM or have long range effects on 
oligomer formation, P450 conformation or haem binding, without significantly disrupting the 
stability of the protein fold.  
 
Based on the evidence, it seems reasonable to speculate that CYP3A4 adopts a hexameric 
structure in solution, in which two monomers are intertwined, as seen for the CYP2B4 crystal 
structure where the F-G loop from one monomer fits into the active site of the other monomer, 
by inference producing a more stable P450 form that can be disrupted by mutations in the F-G 
loop. In support of this hypothesis, kinetic data for CYP3A4 described in Chapter 7 suggests that 
two kinetically distinct CYP3A4 conformers exist in solution.  
 
If oligomer formation does indeed play a key role in CYP450 regulation in membranes [111, 
112], the effect of mutations on P450:P450 interactions may be an important consideration when 
determining the effect of polymorphic variation on drug metabolism, but accounting for such 
quaternary effects of polymorphic variation is beyond the scope of this work.   
 





6.4.1 Thermostability assays  
 
Partially purified CYP450 protein samples were diluted in P450 storage buffer to a concentration 
of ~ 1 µM P450, estimated based on CO P450 spectral assays performed on similar protein 
preparations (Section 5.4.3). 250 µl of the diluted sample was place into 2 quartz cuvettes: one 
reference and one sample cuvette (quartz cuvettes, holding smaller volumes, were used instead 
of 1 ml plastic cuvettes used previously in order to save on protein sample).  The cuvettes were 
placed into a Varian Cary 50 UV Visible spectrophotometer and a baseline reading between 400 
and 500 nm was recorded. CO was bubbled into the bottom of the sample cuvette (~30 bubbles 
at a rate of 1 bubble per second). A small spatula tip (< 1 mg) of sodium dithionite was added to 
each cuvette. Cuvettes were covered with parafilm and inverted several times to dissolve the 
sodium dithionite and incubated at room temperature for 5 min to allow time for the P450 peak 
to reach a maximum prior to starting the thermostability assay. The cuvettes were then placed 
back into the spectrophotometer maintained at a constant temperature of 34°C or 48°C by 
circulating water from a heated water bath through the cell holder. Several readings were taken 
over the first 30 seconds to ensure the P450 peak had stopped increasing and to allow time for 
the cuvette to equilibrate to the new temperature.  The reading with the highest P450 peak was 
taken as time zero and following this readings were taken at 2 minute intervals for 30 minutes. 
Assays were carried out in triplicate. The amount of P450 in each sample at each time point was 
calculated using the equations described in Section 5.4.3.  
6.4.2 Data analysis 
 
Time vs. % P450 remaining was plotted for each replicate. The % remaining P450 was 
calculated by comparing the concentration of P450 in the sample at each time point to the initial 
P450 concentration at time zero.  Readings on the spectrophotometer had to be taken manually at 
each time point so time points varied slightly between replicates. Figure 6.2 A and Figure 6.3 A 
shows average time vs. average % P450 remaining for visualisation purposes,  however average 
plateau’s,  half-lives and standard deviations were calculated by fitting a curve through each 
replicate data set separately to account for differences in time points.  Whether the data was 




averaged prior to curve fitting or afterwards however made no significant difference to the 
results.  
Graph-Pad Prism software (San Diego, USA) was used to fit both one phase (equation 6.1) and 
two phase (equation 6.2) exponential decay models to the data sets using non-linear regression. 
The plateau was constrained to values greater than zero.  A comparison of the two models was 
performed in Prism using the F-test. The model that fitted better to 2 or more of the 3 replicate 
data sets was considered the preferred model for the given variant protein. Reported parameters 
are however all based on the one phase model.  
 
𝑌 = (𝑌0 − 𝑃𝑙𝑎𝑡𝑒𝑎𝑢)𝑒
−𝐾𝑥 + 𝑃𝑙𝑎𝑡𝑒𝑎𝑢                                                     [6.1] 
 
Where Y0 is the Y value when X (time) is zero (i.e. 100% P450), Plateau is the Y value at 
infinite X (time), K is the rate constant (min -1) and half-life = ln(2)/K. 
 
𝑌 = 𝑃𝑙𝑎𝑡𝑒𝑎𝑢 +  𝑆𝑝𝑎𝑛𝐹𝑎𝑠𝑡∗𝑒−𝐾𝑓𝑎𝑠𝑡
∗𝑋 + 𝑆𝑝𝑎𝑛𝑆𝑙𝑜𝑤∗𝑒−𝐾𝑠𝑙𝑜𝑤
∗𝑋     [6.2]  
 
Where SpanFast + SpanSlow + Plateau = Y0, Kfast and Kslow are the two rate constants (min-1), 
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In vitro CYP450 kinetic data has long been used to predict in vivo CYP450 drug metabolism as 
well as drug-drug interactions.  Many CYP450 kinetic profiles show hyperbolic saturation 
kinetics in vitro and classic Michaelis-Menten kinetics can be used to determine kinetic 
parameters. With an increase in available in vitro data, it is however becoming evident that 
atypical kinetic profiles observed for CYP450s, first thought to be an exception to rule, may in 
fact be the norm for many CYP450 isoforms.  These unusual kinetics have most commonly been 
associated with CYP3A4, but have also been reported for CYPs 1A2, 2B4, 2B6, 2C8, 2C9, 2D6, 
2E1 and 3A5 [61, 63]. CYP450 atypical kinetics are substrate dependant, with different 
substrates potentially showing different kinetic profiles when metabolised by the same CYP450 
isoform. Michaelis-Menten models are therefore often erroneously forced though data sets that 
are actually atypical, or the data sets are simply truncated removing the atypical portion of the 
curve (usually occurring at high substrate concentrations) in both cases leading to inaccurate 
estimations of Vmax and Km.  The correlation between atypical in vitro kinetic data and in vivo 
data is still poorly understood [510], however the allosteric effects causing atypical kinetic 
profiles may play an important role in regulation of substrate metabolism in vivo. Even if the 
atypical kinetics observed for a substrate is an artefact of the in vitro system and does not occur 
in vivo, it will affect the scaling of data to an in vitro system and therefore should not be ignored 
[510, 511].  
 
A number of theories, with supporting experimental evidence and kinetic models, attempt to 
explain the atypical kinetic profiles observed for these enzymes. These include multiple 
substrate/effector binding sites [61, 512, 513], multiple kinetically distinct enzyme 
conformations [62] and CYP450-CYP450 allosteric interactions [112]. While each theory may 
explain some individual data sets, the combined evidence suggest that in reality a combination of 
all these factors may be at play [60].  
Multiple binding sites 
 
The failure of substrates to conform to Michaelis-Menten kinetics and the lack of mutually 
competitive inhibition between substrates metabolised by the same enzyme first indicated the 




possibility of several distinct binding sites within the CYP450 active site. This was later 
supported by crystallographic data giving direct evidence of more than one substrate molecule 
bound within the active site e.g. PDB structure 2V0M shows two molecules of ketoconazole 
bound within the active site of CYP3A4.  Evidence from mutagenesis studies [251, 514], spectral 
binding studies [515, 516], studies using FRET and Job’s titration to determine the stoichiometry 
of the CYP450−substrate complexes [517], as well as studies using fluorescent probes, also 
support the presence of multiple binding sites 
 
The binding of a second molecule within the active site may result in steric hindrance or a 
conformational change that leads to a change in the binding affinity or the rate of turnover of the 
first substrate, thereby either activating or partially or fully inhibiting substrate turnover.   Two 
molecules bound in two distinct positions, both with access to the reactive oxygen (Figure 7.1 A) 
or able to attain a productive orientation (Figure 7.1 B) with distinct binding constants and 
oxidation rates, may compete for the reactive oxygen when bound simultaneously leading to 
partial substrate inhibition [61, 518]. Furthermore, different binding orientations/sites can also 
yield different products, as seen for the oxidation of triazolam to both 1’-hydroxytriazolam and 




Figure 7.1  A) Two substrates bound at separate sites, competing for the reactive oxygen. Figure adapted from [518]. 
B) Two substrates bound at separate sites,  both able to attain a productive orientation. Figure adapted from [518]. 
                                          
Effector binding sites have also been implicated in CYP450 kinetics, where a molecule other 
than the substrate binds to the enzyme, altering its activity by changing the enzyme 
conformation, sterically hindering the bound substrate or by altering the haem environment.  
This can lead to unexpected drug-drug interactions and an atypical kinetic profile.  





A number of generic models have been developed to take into account the possibility of multiple 
substrate binding sites, as well as the presence of effector sites [519-521]. While these models 
account for many possible scenarios, they still make assumptions about the nature by which the 
binding sites interact and, even so, lead to complex kinetic equations with many unknown 
variables making the calculation of kinetic parameters by curve fitting very difficult if not 
impossible for many data sets.  
Kinetically distinct CYP450 conformers 
 
As discussed in more detail previously in Chapter 6, multiple conformations of the enzyme can 
exist in solution. Instead of two binding sites with different kinetic properties accounting for the 
atypical kinetic profiles, it is plausible that two enzyme conformers, each with different binding 
affinities and rate constants, account for the atypical behaviour observed. Although considering 
more than one enzyme conformer further complicates the kinetic models, Atkin et al argue that 
based on the biophysical data on conformational relaxation kinetics and the dynamic nature of 
CYP450 proteins, the simplest working kinetic model should include more than one P450 




While CYP450s were originally thought to be monomeric proteins, there is now evidence that 
CYP450s form homomeric and heteromeric complexes in the endoplasmic reticulum and that 
these interaction can modulate CYP450 function [112].  Both full length and N-terminal 
truncated recombinant CYP450s have been shown to form aggregates in solution to varying 
degrees, through a combination of hydrophobic and electrostatic interactions [112, 470, 522-
525]. CYP450 complex formation is likely to alter the enzyme conformation and access to 
binding sites and may be the reason for the presence of non-equilibrating CYP450 conformers 
[60].  Figure 7.2, taken from the review by Davydov and Halpert et al, illustrates how CYP450 
cooperativity may combine multiple substrate binding sites, effector modulated conformational 
changes and CYP450-CYP450 interactions.  
 









Figure 7.2 A model of CYP450 cooperativity based on the combination of multiple substrate binding, effector 
modulated conformational changes and CYP450-CYP450 interactions. The CYP450 oligomer consists of two 
enzymes in two different conformational states, one in a functional state able to bind substrate and one in a non-
functional state. The binding of an effecter molecule causes a rearrangement of the P450 oligomer converting the 
non-functional enzyme into a functional state. Figure from [60]. 
 
Atypical kinetic curves 
 
The allosteric effects discussed above result in substrate concentration versus velocity curves 
that deviate from the typical hyperbolic curve described by the Michaelis-Menten model. The 
most common atypical curves and corresponding Eadie- Hofstee plots are shown in Figure 7.3 
[63].  A biphasic curve indicates the presence of a second low affinity binding site or enzyme 
conformer. At low substrate concentrations, this curve appears hyperbolic but at high substrate 
concentration the curve increases linearly. A sigmoidal curve is typically a result of 
autoactivation: a substrate activates its own metabolism, either by binding to a second site within 
the active site or by binding to a separate allosteric site. Substrate inhibition or partial substrate 
inhibition, occurring when the velocity decreases at higher substrate concentrations, results in a 




convex shaped substrate concentration versus velocity curve and a Eadie-Hofstee plot with a 
hook in the upper quadrant.  
 
Figure 7.3 [Substrate] versus velocity graphs and their corresponding Eadie-Hofstee plots characteristic of 
hyperbolic, biphasic, sigmoidal and substrate inhibition kinetics. Figure from [63]. 
 
There are numerous examples of CYP3A4 and CYP2C9 substrates showing each of these 
atypical kinetic profiles in vitro: CYP3A4 metabolism of aflatoxin B1 (sigmoidal autoactivation) 
[526], naphthalene (biphasic) [61] and testosterone (substrate inhibition) [513]; CYP2C9 
metabolism of dapsone (sigmoidal autoactivation) [61], naproxen (biphasic) [61] and celecoxib 
(substrate inhibition) [513]. Many reports on atypical kinetics are however incongruent, 
suggesting that differences in experimental setup, including enzyme source and the presence or 
absence of cytochrome B5, can greatly affect the kinetic profile of a drug [511] e.g. piroxicam 
5′-hydroxylation shows substrate inhibition in purified baculovirus-CYP2C9 and liver 
microsomes but not in expressed CYP2C9 microsomes. 
Effects of SNPs on CYP450 kinetics 
 
Single amino acid substitutions can affect the Km and Vmax of CYP450s in a substrate dependent 
manner, as discussed for polymorphic variants in Chapter 4 (examples of the effects of 
polymorphic variation on kinetic parameters from the literature can be found in Appendix B 




Tables B1 - B9). There are also a number of studies showing that amino acid changes in 
CYP450s can affect the kinetic profile of a substrate [527].  
Aims and Objectives  
 
The aim of this Chapter was to test the kinetic activity of the panel of CYP3A4 and CYP2C9 
variant proteins in simple fluorescent-based assays, making use of the P450 shunt-pathway and 
thereby circumventing the need for membrane bound CYP450s or the reconstitution of CPR 
mediated CYP450 activity.  
 
The objectives were as follows: 
1. Test the activity of CYP3A4 and CYP2C9 protein samples using fluorescent substrates. 
2. Test the effect of glycerol on CYP3A4 and CYP2C9 kinetics. 
3. Determine suitable kinetic models to calculate the kinetic parameters for CYP3A4 and 
CYP2C9 turnover of fluorescent substrates.  
4. Determine the kinetic parameters for the panel of CYP3A4 and CYP2C9 variants to 
establish the effect of individual mutations on enzyme activity.  





7.2.1 Testing CYP450 catalytic activity using fluorescent substrates 
 
Fluorescent based activity assays were used to test the catalytic activity of recombinant CYP3A4 
and CYP2C9 proteins previously expressed in E.coli and partially purified by His-tag 
purification (Chapter 5). These N-terminal truncated proteins are referred to as ‘solution-phase 
CYP450s’ in this Chapter to distinguish them from membrane bound baculosomal CYP450s.   
 
Commercially available CYP450 Vivid® substrates can be oxidised at either one of two 
potential oxidation sites, yielding a highly fluorescent product and thus enabling the direct 
monitoring of substrate turnover (Figure 7.4).  The fluorescein- and resorufin-based substrates 
used to test CYP3A4 and CYP2C9 activity are shown in Figure 7.5 together with their 




Figure 7.5 Structures of resorufin- and fluorescein-based CYP3A4 and CYP2C9 Vivid substrates and their 
fluorescent products.  Sites of potential oxidation are indicated by an arrow.  
Figure 7.4 Schematic showing the cleavage of a 
Vivid substrate leading to a highly fluorescent 
product. (figure from www.b2b.invitrogen.com) 




To avoid the difficulties associated with reconstituting CYP450 activity from recombinant CPR 
and CYP3A4 proteins in solution, cumene hydroperoxide (CuOOH) (Figure 7.6) was used to 




Figure 7.7 Testing Vivid Red substrate turnover by solution-phase CYP3A4 and CYP2C9. 
100µl reactions consisted of 4µM Vivid substrate, varying concentrations of P450 (based on P450 concentration in 
His-tagged enriched samples measured by CO binding spectral assays) and 0.5mM CuOOH in 100mM potassium 
phosphate buffer, pH 7.4. The change in fluorescent units (RFU) was measured over time for the linear range of the 
reaction after the addition of CuOOH.  A) Turnover of BOMR by CYP3A4. Negative controls consisted of 1) 
substrate and CuOOH, no 3A4; 2) CuOOH and 80nM 3A4, no substrate; 3) substrate and 80nM 3A4, no CuOOH. 
B) Turnover of DBOMF by CYP3A4. Negative controls consisted of 1) substrate and CuOOH, no 3A4; 2) substrate 
and 35nM 3A4, no CuOOH. C) Turnover of OOMR by CYP2C9. Negative controls consisted of 1) substrate and 
CuOOH, no 3A4; 2) 500nM 2C9 and CuOOH, no substrate; 3) substrate and 500nM 2C9, no CuOOH. D) Turnover 
of BOMF by CYP2C9. Negative controls consisted of 1) substrate and CuOOH, no 2C9; 2) 500nM 2C9 and 
CuOOH, no substrate; 3) substrate and 500nM 2C9, no CuOOH.  
Figure 7.6 Structure of cumene hydroperoxide 
used to mediate CYP450 activity via the shunt 
pathway. 




Various concentrations of solution-phase P450 were tested for each substrate and negative 
controls were included to ensure activity was P450 dependent (Figure 7.7). The following 
negative controls were included: 1) substrate and CuOOH, no protein; 2) P450 and CuOOH, no 
substrate and 3) P450 and substrate, no CuOOH. While low levels of substrate turnover (< 16% 
of activity) was seen for some of the controls, particularly CYP3A4 substrate DBOMF, there 
was clear CYP450-depend substrate turnover for all four substrates. CYP3A4 showed more than 
20 fold higher CYP450-dependent turnover per nmol P450 for the fluorescein-based substrate 
DBOMF than for the resorufin-based substrate BOMR. CYP2C9 showed more than 4 fold 
higher CYP450-dependent turnover per nmol P450 for the resorufin-based substrate OOMR than 
for the fluorescein-based substrate BOMF.  
 
7.2.2 CYP3A4 kinetics 
 
CYP3A4 kinetic assays were carried out for both BOMR and DBOMF substrates using 
recombinant solution-phase CYP3A4 wild-type protein samples and CuOOH. Atypical CYP3A4 
kinetic profiles were observed for both substrates (Figure 7.8). The presence of 15% glycerol in 
the reaction mixture altered the kinetic profile and increased the activity at all substrate 
concentrations for both substrates. Note that the scales in Figure 7.7 and Figure 7.8 are different 
because Figure 7.7 shows the total velocity of the reaction whereas Figure 7.8 shows velocity per 
nmol P450.  
 
The presence of glycerol results in a more complex kinetic profile for the BOMR substrate, 
showing a decrease in velocity between 5 and 8 µM followed by a more gradual increase with 
increasing substrate concentrations (Figure 7.8 A). This kinetic profile closely resembles the 
non-hyperbolic profile observed previously observed in our laboratory for NADPH-CPR 
mediated turnover of BOMR by commercial baculosomal CYP3A4 proteins in the absence of 
glycerol (Figure 7.9) [473].   
 






Figure 7.8 Solution-phase CYP3A4 kinetics for the turnover of Vivid substrates in the presence and absence of 15% 
glycerol. 
 
Reactions were carried out in 100mM potassium phosphate buffer with and without 15% (v/v) glycerol and 0.5mM 
CuOOH was used to initiate the reaction, mediating CYP3A4 activity via the shunt pathway. The initial velocity 
(nmol fluorescent product formed/min/nmol P450) was plotted for each substrate concentration. Error bars represent 
standard deviations of 2 replicas.  A) CYP3A4 kinetics for the turnover of BOMR Vivid red substrate (0.25 - 24 
µM). A final concentration of 200nM CYP3A4 was used in each reaction.  B) CYP3A4 kinetics for the turnover of 
DBOMF Vivid green substrate (0.25 - 32 µM). A final concentration of 35nM CYP3A4 was used in each reaction. 








Figure 7.9 Baculosomal CYP3A4 turnover of BOMR Vivid Red substrate displaying a non-hyperbolic kinetic 
profile. (figure from [473]) 
 
In contrast, the presence of glycerol simplified the kinetics for the DBOMF substrate, resulting 
in a profile that resembles substrate inhibition (Figure 7.8 B).  The profile in the absence of 
glycerol is complex, showing two different peaks. This kinetic assay was repeated with more 
data points to confirm the presence of two peaks and to ensure that it was reproducible (Figure 
7.10). Once again two distinct peaks were visible at 4 µM and 16 µM DBOMF confirming the 




Figure 7.10 Solution-phase CYP3A4 kinetics for the turnover of DBOMF Vivid Green substrate in the absence of 
glycerol, repeated with addition data points. A final concentration of 35nM P450 in 100mM potassium phosphate 
was used for each reaction. 0.5mM CuOOH was used to mediate CYP3A4 activity via the shunt pathway and the 
initial velocity (nmol resorufin formed/min/nmol P450) was plotted for each substrate concentration.  Error bars 
represent standard deviations of 2 replicas. 





NADPH-CPR mediated baculosomal CYP3A4 kinetics for the turnover of DBOMF was carried 
out in the presence and absence of 15% glycerol for comparison (Figure 7.11). In contrast to 
solution-phase CYP3A4 wild-type protein, 15% glycerol did not appear to alter the kinetic 
profile of baculosomal CYP3A4 and decreased the velocity at all DBOMF substrate 
concentrations. CuOOH mediated baculosomal CYP3A4 kinetics in the absence of glycerol was 
also carried out; the kinetic profile and rate of substrate turnover was comparable to NADPH-




Figure 7.11 Baculosomal CYP3A4 kinetics for DBOMF (0.5-20 µM) in the presence and absence of 15% glycerol.  
The CYP3A4 baculosomal reagent also contained the reductase partner CPR, however the concentration is not 
known. A final concentration of 2nM CYP3A4 and 1mM NADPH in 100mM potassium phosphate buffer was used 
in each reaction.  Error bars represent standard deviation of 3 replicas.  
 
Fitting kinetic models to CYP3A4 data sets to determine kinetic parameters 
 
While the kinetic profiles for CYP3A4 turnover of BOMR and DBOMF substrates in the 
presence and absence of glycerol resemble Michaelis-Menten kinetics in the lower substrate 
concentration range, more complex models are required to describe the kinetics observed at 
higher substrate concentrations. Figure 7.12 shows a schematic of the Michaelis-Menten model 
and Figure 7.13 shows this model fitted to truncated CYP3A4 kinetic data sets (lower substrate 




concentration ranges only). Table 7.1 gives kinetic constants, Km and Vmax (= kcat) derived from 
the Michaelis-Menten model, as well as R2 values for curve fitting.   
 
 
Figure 7.12 Schematic of Michaelis-Menten kinetic model where E is an enzyme molecule, S is a substrate 
molecule, P is the product and kp is the rate constant. 
 
The Vmax for baculosomal CYP3A4 was much higher than for solution-phase CYP3A4 for both 
substrates (over 600 fold higher for BOMR and nearly 80 fold higher for DBOMF when 
comparing the kinetic constants in the absence of glycerol). The presence of 15% glycerol 
increased the Vmax by 2- and 3-fold for solution-phase CYP3A4 turnover of BOMR and DBOMF 
respectively but decreased the Vmax by 2-fold for baculosomal CYP3A4 turnover of DBOMF. 
The Km values were similar for solution-phase and baculosomal CYP3A4 samples and the 
presence of 15% glycerol did not have a significant effect on Km for either substrate.  
 
 
Table 7.1 A comparison of kinetics constants for truncated CYP3A4 kinetic data sets in the presence and 
absence of 15% glycerol calculated using the Michaelis-Menten kinetic model. 
Michaelis-Menten Kinetics Vmax  
(nmol/min/nmol P450) 
Km (µM) R2 
BOMR Vivid Red     
Solution-phase CYP3A4 - No Glycerol 0.0056 ± 0.0005 3.1 ± 0.5 0.979 
Solution-phase CYP3A4- 15% Glycerol 0.0096 ±  0.0009 3.8 ± 0.7 0.978 
Baculosomal CYP3A4 – no glycerol* 3.6  3.2  
DBOMF Vivid Green    
Solution-phase CYP3A4 - No Glycerol 0.075  ± 0.009   1.6  ± 0.4 0.929 
Solution-phase CYP3A4 - 15% Glycerol 0.24  ± 0.02 2.1 ± 0.4 0.959 
Baculosomal CYP3A4 – No glycerol 5.8 ± 0.4 1.5  ± 0.2 0.961 
Baculosomal CYP3A4 – 15% Glycerol 3.3 ± 0.1 1.2 ± 0.1 0.980 
 ± standard error.   * Data for ‘Baculosomal CYP3A4 – no glycerol’ is from [473]. 





Figure 7.13  Michaelis-Menten model fitted to the truncated CYP3A4 kinetic data sets for the turnover of Vivid 
substrates in the presence and absence of 15% glycerol using non-linear regression.  
A) Solution-phase CYP3A4 BOMR Vivid Red and (B) DBOMF Vivid Green kinetics, error bars represent standard 
deviations of 2 replicas. (C) Baculosomal CYP3A4 DBOMF Vivid Green, error bars represent standard deviations 
of 3 replicas.   




The next step was to find a kinetic model that could adequately explain the full kinetic data sets. 
This was however only possible for the turnover of BOMR in the absence of glycerol and the 
turnover of DBOMF in the presence of 15% glycerol as the other profiles were to complex.  
Biphasic CYP3A4 turnover of BOMR in the absence of glycerol 
 
The multisite biphasic kinetics model shown in Figure 7.14 has previously been used to describe 
CYP3A4 kinetic data and was fitted to the full data set for CYP3A4 turnover of BOMR in the 
absence of glycerol; the Michaelis-Menten model was used for comparison (Figure 7.15). It was 
difficult to determine the correct model from the Eadie-Hofstee plot of the data (Figure 7.15 B), 
however a comparison of the two fits in Prism using the F-test showed that the biphasic model 
was the preferred model for this data set.  
 
 
Figure 7.14 Scheme of biphasic kinetic model where E is an enzyme molecule, S is a substrate molecule and P is the 
product. The different rate constants are represented by k. 
 
The kinetic constants derived from each model and the R2 for the curve fitting are shown in 
Table 7.2. In the biphasic model, Km1 and Vmax1 are observed at low substrate concentrations and 
result from substrate binding to the low Km, low Vmax binding site. The substrate turnover by the 
second low affinity site (high Km), shown by the linear portion of the graph, is described by 
intrinsic clearance parameter (Clint), which is the ratio of Vmax2/Km2. It is difficult to estimate the 
actual values of Vmax and Km for the second binding site as saturation is not achieved and the 
linear part of the graph is formed by a combination of substrate turnover by both the high and 
low affinity site  [528]. The equation for the biphasic model can be found in the Methods, 
Section 7.4.4.  
 
The single site Michaelis-Menten model gives a higher Km and Vmax than the multisite biphasic 
model for the high affinity binding site, however the student t-test showed that the difference 




was not significant. The biphasic model converges back to the Michaelis-Menten model if there 
is no second binding site or if the second binding site contributes very little to substrate turnover.  
 
      
Figure 7.15  Graphs fitted to solution-phase CYP3A4 kinetic data for the turnover of BOMR Vivid Red in the 
absence of glycerol using non-linear regression. A) The biphasic model is shown by the solid line and the Michealis-
Menten model is shown by the dotted line. A comparison of the two fits in Prism using the F-test showed that the 
biphasic model was the preferred model for this data set.  B) Eadie-Hofstee plot of data showing V (nmol 
resorufin.min-1.nmol P450-1) versus V/[S] (nmol resorufin.min-1.nmol P450-1.µM BOMR-1). Error bars represent 
standard deviations of 2 replicas. 
 
 




Table 7.2  A comparison of kinetic constants calculated using Michaelis-Menten and biphasic kinetic models 
for CYP3A4 turnover of BOMR in the absence of glycerol  
Michaelis-Menten Model Biphasic Model 
Vmax 0.0051 ± 0.0002 nmol/min/nmol P450 Vmax1 0.0040 ± 0.0004 nmol/min/nmol P450 
Km (µM) 2.7 ± 0.4 µM Km1 (µM) 1.8 ± 0.4 µM 
R2 0.963 CLint (Vmax2/Km2) 0.00005  ±  0.00002  min-1µM-1 
  R2 0.971 
± standard error. A comparison of the two fits, in Prism using the F-test, showed that the biphasic model was the 
preferred model for this data set. The null hypothesis that the Michaelis-Menten kinetic model was the best fit was 
rejected, P value = 0.027.  
Substrate inhibition for CYP3A4 turnover of DBOMF in the presence of  15% glycerol 
 
The rate of DBOMF substrate turnover by solution-phase CYP3A4 decreased at higher substrate 
concentration suggesting that substrate inhibition was occurring. CYP450 substrate inhibition 
has been observed for a number of different substrates and various substrate inhibition models 
have been developed to describe the kinetic curves obtained [513, 518].  Three different models 
(Figure 7.16, Figure 7.17 and Figure 7.18), of varying complexity, were fitted to the kinetic data 
set to determine the model that best described the kinetics observed. The equations derived from 
these models, based on both the steady-state and rapid equilibrium assumptions that the rate of 
formation and decomposition of enzyme-substrate complexes are equal, can be found in the 
Methods, Section 7.4.4, Table 7.9.   
 
The first model, referred to here as the ‘substrate inhibition model’ (Figure 7.16), is a general 
model commonly used to describe the substrate inhibition observed for a range of enzymes 
[529]. This model assumes that at high substrate concentrations a second substrate molecule 
binds to the enzyme substrate complex rendering it unproductive and thereby decreasing 
substrate turnover.  
 
Figure 7.16  Substrate inhibition model, where E is an enzyme molecule, S is a substrate molecule and P is the 
product. The different rate constants are represented by k. 




The second model, derived by Lin et al in 2001 and referred to here as the ‘P450 substrate 
inhibition model 1’ (scheme shown in Figure 7.17), assumes that there are two binding site 
simultaneously available to bind substrate - one catalytic and one inhibitory - and that the sites 
interact in the presence of substrate. This causes a change in the binding constants for the 
catalytic site (Ks) and the inhibition site (KI) as well as the Vmax when a second substrate is 
bound. α and β are the factors by which the dissociation constants and Vmax change in the 
presence of a second bound substrate.   
 
 
Figure 7.17  P450 substrate inhibition kinetic model 1. 
E is an enzyme molecule, ES is an enzyme molecule with a substrate molecule bound to the catalytic binding site 
and SE is an enzyme molecule with a substrate molecule bound to the non-productive inhibitory site. SES is an 
enzyme with substrate molecule bound to both sites. kp is the rate at which product, P, is formed from the productive 
complex ES (ES → E + P). β is the factor by which the rate kp changes when there is also a substrate molecule 
bound at the inhibitory site (SES → SE + P).  Dissociation constants are defined as follows Ks = k-1/k-1; KI = k2/k-2; 
αKI = k3/k-3; αKs = k4/k-4. 
 
The third model,  derived by Schrag et al in 2002 and refered to here as ‘P450 substrate 
inhibition model 2’ (Figure 7.18), also has two binding sites similtaneously available to bind 
substrate but differs from the previous model in that the two sites do not interact, so the presence 
of one substrate molecule does not affect the binding constant of the second substrate molecule. 
Substrate inhibition results from the substrate molecules at the two different sites competing for 
the reactive oxygen; thus, while the binding constants are unaffected, the presence of a second 




substrate changes the rate constant and hence Vmax by a factor of α. The second site is also shown 
to be catalytically active in this model but results in the formation of a different product, P2.  
 
 
Figure 7.18  P450 substrate inhibition model 2 
E is an enzyme molecule, ES is an enzyme molecule with a substrate molecule bound to the catalytic binding site 1 
and SE is an enzyme molecule with a substrate molecule bound to the catalytic binding site 2. SES is an enzyme 
with a substrate molecule bound to both sites. kp1 is the rate at which the product of interest, P1, is formed from the 
productive complex ES (ES → E + P). α is the factor by which the rate kp1 changes when there is a substrate 
molecule bound at the other catalytic site (SES → SE + P1).  Dissociation constants are defined as follows Km1 = 
k1/k-1; Km2 = k2/k-2. 
 
Figure  7.19 shows the substrate inhibition model and the P450 substrate inhibition model fitted 
to the kinetic data set for the turnover of DBOMF by solution-phase CYP3A4 in the presence of 
15% glycerol. Figure 7.20 shows the same models fitted to the kinetic data set for the turnover of 
DBOMF by baculosomal CYP3A4 in the presence and absence of 15% glycerol. P450 substrate 
inhibition model 2 was also fitted to the data but cannot clearly be seen in this graph as it 
followed the same curve as the P450 substrate inhibition model 1. The Eadie-Hofstee plots for 
each data set are also included, showing a curve characteristic of substrate inhibition.  A 
comparison of the fits in prism using the F-test showed that the substrate inhibition model was 
the preferred model for the turnover of DBOMF by solution-phase CYP3A4 in the presence of 
15 % glycerol but that the P450 substrate inhibition model was the preferred model for the 
turnover of DBOMF by baculosomal CYP3A4 in the presence and absence of 15 % glycerol.  
 




Both models fit reasonably to all data sets and, while the more complex P450 substrate inhibition 
model is likely to describe CYP3A4 substrate inhibition more adequately, many combinations of 
solutions to the equation lead to curves that fit the data equally well. This is due to the high 
number of variables (Vmax, Ks, Ki, α and β) in the equation and leads to an ambiguous fit in Prism 
where kinetic parameters cannot be determined with any confidence.  
 
 
Figure  7.19  Graphs fitted to solution-phase CYP3A4 kinetic data for the turnover of DBOMF Vivid Green in the 
presence of 15% glycerol using non-linear regression. A) The substrate inhibition model is shown by the solid line 
and the P450 substrate inhibition model 1 is shown by the dotted line. A comparison of the two fits in Prism using 
the F-test showed that the substrate inhibition model was the preferred model for this data set.  B) Eadie-Hofstee 
plot of data showing V (nmol fluorescein.min-1.nmol P450-1) vs. V/[S] (nmol fluorescein.min-1.nmol P450-1.µM 
BOMR-1). Error bars represent standard deviations of 2 replicas. 






Figure 7.20 Graphs fitted to baculosomal CYP3A4 kinetic data for the turnover of DBOMF Vivid Green in the 
presence and absence of 15% glycerol using non-linear regression. A) The substrate inhibition model is shown by 
the solid line and the P450 substrate inhibition model 1 is shown by the dotted line. A comparison of the two fits in 
Prism using the F-test showed that the P450 substrate inhibition model 1 was the preferred model for this data set.  
B) Eadie-Hofstee plot of data showing V (nmol fluorescein.min-1.nmol P450-1) vs. V/[S] (nmol fluorescein.min-








The kinetic parameters obtained by fitting the substrate inhibition model to the three data sets are 
shown in Table 7.3. The Vmax (nmol fluorescein formed per min per nmol P450) was 
significantly lower (6 fold decrease) for solution-phase CYP3A4 turnover than for baculosomal 
CYP3A4 turnover in the presence of 15% glycerol. The presence of 15% glycerol decreased the 
Vmax for baculosomal CYP3A4 by ~ 2 fold. The Km for solution-phase CYP3A4 was higher than 
for baculosomal CYP3A4, however the difference between Km values was not statistically 
significant.  
 
Table 7.3  Kinetic constants calculated using the substrate inhibition model for CYP3A4 turnover of DBOMF  








Solution-phase  3A4 - 15 % Glycerol 0.6 ± 0.2 6 ± 3 3  ± 1 0.954 
Baculosomal 3A4 – No Glycerol 6.3 ± 0.4 1.7 ± 0.2 21 ± 4 0.952 
Baculosomal 3A4 – 15% Glycerol 3.8 ± 0.2 1.3 ± 0.2 19 ±  2 0.954 
A student t-test showed that Vmax values for the three data sets were significantly different (P value < 0.05) while Km 
values did not differ significantly from each other (P value > 0.05) 
 
7.2.3 CYP2C9 kinetics 
 
CYP2C9 kinetic assays were carried out for OOMR and BOMF substrates using solution-phase 
CYP2C9 wild-type protein samples and CuOOH. The CYP2C9 kinetic profiles observed for 
each substrate in the presence and absence of 15% glycerol are shown in Figure 7.21. The 
presence of glycerol in the reaction mixture increased the turnover rate of OOMR at all substrate 
concentrations and does not alter the shape of the kinetic profile. The presence of glycerol does 
not appear to affect the rate of turnover of BOMF at lower substrate concentrations but at high 











Figure 7.21  Solution-phase CYP2C9 kinetics for the turnover of Vivid substrates in the presence and absence of 
15% glycerol.  
 
Reactions were carried out in 100mM potassium phosphate buffer with and without 15% (v/v) glycerol and 0.5mM 
CuOOH was used to initiate the reaction, mediating CYP3A4 activity via the shunt pathway. The initial velocity 
(nmol fluorescent product formed/min/nmol P450) was plotted for each substrate concentration.  A) CYP2C9 
kinetics for the turnover of OOMR Vivid Red substrate (0.75 – 28.8 µM). A final concentration of 300 nM CYP3A4 
was used in each reaction. Error bars represent standard deviations of 3 replicas.   B) CYP2C9 kinetics for the 
turnover of BOMF Vivid Green substrate (0.25 - 32 µM). A final concentration of 500 nM CYP2C9 was used in 
each reaction. Error bars represent standard deviations of 2 replicas. 





Fitting kinetic models to CYP2C9 data sets to determine kinetic parameters 
 
Figure 7.22 shows the Michaelis-Menten model and the biphasic model fitted to solution-phase 
CYP2C9 kinetic data set for the turnover of OOMR substrate.  A comparison of the two fits in 
Prism using the F-test shows that the Michaelis-Menten model is the preferred model. The 
Eadie-Hofstee plot is linear – indicating Michaelis-Menten kinetics – except at very low 
substrate concentrations. This suggests that there is only one binding site for OOMR contributing 
to substrate turnover. The kinetic parameters determined using the Michaelis-Menten model are 
shown in Table 7.4.  
 
For solution-phase CYP2C9 turnover of BOMF, substrate inhibition appears to be occurring at 
higher BOMF substrate concentrations, however the substrate inhibition models discussed 
previously fit poorly to the full data set. For this reason the Michaelis-Menten model was fitted 
to the truncated data set (Figure 7.23) from which kinetic parameters were calculated (Table 7.4).  
Vmax and Km values were similar to that for the OOMR substrate. The presence of glycerol did 
not have a statistically significant effect on the Vmax or Km for the turnover of BOMF.  
 
 
Table 7.4 A comparison of kinetics constants for solution-phase CYP2C9 kinetic data sets in the presence and 
absence of 15% glycerol calculated using the Michaelis-Menten kinetic model. 
Michaelis-Menten Kinetics Vmax  
(nmol/min/nmol P450) 
Km (µM) R2 
OOMR Vivid Red – full data sets    
2C9 - No Glycerol 0.024 ± 0.001 7.5 ± 0.9 0.9604 
2C9 - 15% Glycerol 0.044 ± 0.001* 6.7 ± 0.5 0.9849 
BOMF Vivid Green – truncated data set    
2C9 - No Glycerol 0.0043 ± 0.0005 10 ± 2 0.9707 
2C9 - 15% Glycerol 0.0031 ± 0.0002   6 ± 1 0.9743 
 ± standard error. The student t-test showed that Vmax for the turnover of OOMR by CYP2C9 – 15% glycerol was 
significantly higher than CYP2C9 – no glycerol, P < 0.005 but there was no significant difference between the Km 
for the two data sets.  There is no significant difference between Vmax and Km parameters for the turnover of BOMF 
in the presence and absence of 15% glycerol.  
 






Figure 7.22  Graphs fitted to CYP2C9 kinetic data for the turnover of OOMR Vivid Red in the presence and absence 
of 15% glycerol using non-linear regression. A) The Michaelis-Menten model is shown by the solid line and 
biphasic model is shown by the dotted line. B) Eadie-Hofstee plot of data showing V (nmol resorufin.min-1.nmol 
P450-1) vs. V/[S] (nmol resorufin.min-1.nmol P450-1.µM OOMR-1). Error bars represent standard deviations of 3 
replicas. 
 









Figure 7.23 Graphs fitted to solution-phase CYP2C9 kinetic data for the turnover of BOMF Vivid Green in the 
presence and absence of 15% glycerol using non-linear regression. A) The Michaelis-Menten model fitted to the 
truncated data set. B) Eadie-Hofstee plot of the full data set showing V (nmol fluorescein.min-1.nmol P450-1) vs. 









7.2.4 Activity of CYP3A4 variants 
 
CYP3A4 kinetic assays were carried out for nine CYP3A4 variants, including the wild-type 
enzyme, using solution-phase CYP3A4 protein samples. The reactions were initiated with 
CuOOH as before.  DBOMF Vivid green substrate was chosen to test the activity of CYP3A4 
variants because wild-type CYP3A4 showed high turnover levels for DBOMF compared to the 
other Vivid substrates. 15% glycerol was included in all reactions as this gave a kinetic profile 
similar to that seen for baculosomal CYP3A4, increased enzyme activity and simplified the 
kinetic profile enabling the calculation of kinetic parameters based on the full data set using the 
substrate inhibition model.  
 
Figure 7.24 A shows the Michaelis-Menten model fitted to the truncated kinetic data set (0.75 – 
5.6 µM DBOMF) and Figure 7.24 B shows the substrate inhibition model fitted to the full kinetic 
data set (0.75 - 43.3 µM DBOMF) for each variant. The residual plots are also included to 
illustrate how well each model fits the data.  The residual is the distance of a data point from the 
fitted curve, with a point above the curve having a positive residual and a point below the curve 
having a negative residual. If the model fits the data well the residual data points should be 
randomly distributed close to the x-axis with no apparent trend in their distribution above and 
below the axis. The residual plot in panel A shows that, even for the truncated data set, the 
Michaelis-Menten model does not adequately explain the data as a clear trend is visible. 
Although there is still a trend in the residual plot in panel B, the points are more randomly 
distributed suggesting the substrate inhibition model is a better fit for the data. The Eadie-
Hofstee plots for the full data sets are shown in panel C.  
 
The kinetic parameters Vmax, Km, Vmax/Km and Ki calculated using each model are shown in Table 
7.5 together with the R2 value for curve fitting. A visual comparison of the Vmax, Km, Ki and 
Vmax/Km for the different variants and models is shown in Figure 7.25.  
 
CYP3A4 variants I223R and M445T showed a significant decrease in Vmax compared to wild-
type when calculated using either model. S222P also showed a decrease in Vmax but the decrease 
was only significant for the Michaelis-Menten model fitted to the truncated data set.  L373F and 
L293P both showed an increase in Vmax but this increase was once again only significant for the 
Michaelis-Menten model fitted to the truncated data set.     






Figure 7.24  Turnover of DBOMF Vivid Green by CYP3A4 polymorphic variants 
A final concentration of 50 nM P450, 0.5mM CuOOH and 15% glycerol in 100mM potassium phosphate buffer 
pH7.4 was used in each reaction.  The error bars represent the standard deviation of 3 replicas. A) Michaelis-Menten 
model fitted to the truncated CYP3A4 kinetic data sets; B) Substrate inhibition model fitted to the full CYP3A4 
kinetic data set. The residual plot for each fitted curve is also shown. C) Eadie-Hofstee plots for the full kinetic data 






The substrate inhibition model showed no significant difference in Km or Ki values for variants compared to wild-type.  S222P, I223R and M445T 
had significantly lower Km values when the Michaelis-Menten model was used on the truncated data set. S222P and I223R lie within substrate 
recognition sites so it is plausible that they may affect substrate binding.  The catalytic efficiency of the CYP3A4 variants was not significantly 
different to the wild-type protein when either of the kinetic models were used (Figure 7.25 D).   
 
Table 7.5  Kinetic constants for the turnover of DBOMF Vivid Green by CYP3A4 variants calculated using the Michaelis-Menten and substrate inhibition models 
CYP3A4 WT G56D K96E P218R S222P I223R L293P L373F M445T 
Michaelis-Menten 
         
     Vmax (nmol/min/nmol P450) 0.45 ± 0.04 0.43 ± 0.03 0.39 ± 0.03 0.58 ± 0.07 0.25 ± 0.02* 0.15 ± 0.01*** 0.68 ± 0.05*  0.67 ± 0.04* 0.20 ± 0.01** 
     Km (µM) 7 ± 1 4.3 ±  0.6 6.9 ±  0.9 6  ±  1 2.4 ±  0.3* 3.1 ±  0.3*** 5.2 ± 0.7 6.1 ±  0.6 2.8 ±  0.3* 
     Vmax/Km 0.07 ± 0.01 0.10 ± 0.01 0.057 ± 0.009 0.09 ± 0.02 0.11 ± 0.02 0.048 ± 0.005 0.13 ± 0.02 0.11 ± 0.01 0.07 ± 0.009 
     R 2 0.980 0.975 0.987 0.971 0.952 0.985 0.979 0.989 0.976 
Substrate inhibition 
         
     Vmax (nmol/min/nmol P450) 0.60 ± 0.08 0.8 ± 0.1 0.69 ±0.08 0.9 ± 0.1 0.39 ± 0.03 0.23 ± 0.01* 0.86 ± 0.09 0.64 ± 0.08 0.29 ± 0.02* 
     Km (µM) 9 ± 2 9  ± 2 13  ± 2 11  ± 2 4.3  ± 0.6 5.2  ± 0.5 7  ± 1 5  ± 1 4.4  ± 0.4 
     Vmax/Km (min-1µM-1) 0.07 ± 0.02 0.09 ± 0.02 0.05 ± 0.01 0.09 ± 0.02 0.09 ± 0.01 0.043 ± 0.005 0.13 ± 0.03 0.12 ± 0.03 0.066  ± 0.007 
     Ki (µM) 11 ± 2 7 ± 1 7 ± 1 9 ± 2 12 ± 2 11 ± 1 14 ± 3 21 ± 5 13 ± 1 
     R 2 0.978 0.985 0.992 0.981 0.973 0.988 0.977 0.957 0.986 
Notes: ± Standard error.  Student t-test was used to determine values significantly different from wild-type: * P < 0.05, ** P < 0.01, *** P < 0.005. 





Figure 7.25 A visual comparison of the A) 
Vmax , B) Km, C) Ki and  D) catalytic 
efficiency of different CYP3A4 variants for 
the turnover of DBOMF Vivid Green 
calculated using substrate inhibition model 
on the full data set and Michaelis-Menten  
model on the truncated data set. The error 
bars represent the 95% confidence intervals 
of the mean of 3 replicas. Student t-test was 
used to determine values significantly 
different from wild-type: * P < 0.05, ** P < 
0.01, *** P < 0.005 
 




7.2.5 Activity of CYP2C9 variants 
 
Kinetic assays were carried out for eight CYP2C9 polymorphic variant proteins, including the 
wild-type, using solution-phase CYP2C9 protein samples, OOMR Vivid red substrate and 
CuOOH to initiate the reactions as described above. OOMR was the substrate of choice because 
it showed typical Michaelis-Menten kinetics and high turnover when tested using wild-type 
CYP2C9. 15% glycerol was included in the reactions because it was shown to increase the rate 
of OOMR turnover.  
 
Figure 7.26 shows the Michaelis-Menten model fitted to the CYP2C9 variant kinetic data sets, 
together with the residual and Eadie-Hofstee plots for the data. When compared to the biphasic 
model (data not shown), the Michaelis-Menten model was the preferred model for all variants 
and residual plot shows a random distribution of data points around the x-axis indicating that the 
model adequately explains the data. This is also confirmed by the linear nature of the Eadie-
Hofstee plots.  
 
Figure 7.26  Turnover of OOMR Vivid Red by CYP2C9 variants. 250 nM P450, 0.5mM CuOOH and 15% glycerol 
(v/v) in 100mM potassium phosphate buffer pH7.4 was used in each reaction.  The error bars represent the standard 
deviation of 3 replicas A) Michaelis-Menten model fitted to the CYP2C9 kinetic data set for each variant. The 
residual plot of the data is shown on the right. B) Eadie-Hofstee plot of data showing V (nmol resorufin.min-1.nmol 
P450-1) versus V/[S] (nmol resorufin.min-1.nmol P450-1.µM OOMR-1). The error bars represent the standard 







Table 7.6  Kinetic constants for the turnover of OOMR Vivid green by CYP2C9 variants  
CYP2C9 WT V76M R132Q R150H Q214L P279T I359L I359T 
Michaelis-Menten 
        Vmax (nmol/min/nmol P450) 0.0264 ± 0.0005 0.0211 ± 0.0005*** 0.0283 ± 0.0007 0.0249 ± 0.0005 0.0136 ± 0.0003*** 0.0277 ± 0.0005 0.0177 ± 0.0003*** 0.0189 ± 0.0004*** 
Km (µM) 7.7 ± 0.4 3.4 ± 0.2*** 9.4 ± 0.5 6.0 ± 0.3* 6.8 ± 0.3 7.3 ± 0.3 5.2 ± 0.2*** 5.0 ± 0.3*** 
Vmax/Km 0.0034 ± 0.0002 0.0062 ± 0.0005** 0.0030 ± 0.0002 0.0041 ± 0.0002 0.0020 ± 0.0001*** 0.0038 ± 0.0002 0.0034 ± 0.0002 0.0037 ± 0.0003 
R 2 0.993 0.983 0.992 0.989 0.991 0.994 0.992 0.984 
± Standard error.  Student t-test was used to determine values significantly different from wild-type: * P < 0.05, ** P < 0.01, *** P < 0.005. 
 
 
The kinetic parameters Vmax, Km and Vmax/Km for each variant are shown in Table 7.6 together with the R2 values for curve fitting. A visual 
comparison of the Vmax, Km and Vmax/Km values are shown in Figure 7.27.  
 
Variants V76M, Q214L, I359L and I359T had significantly lower Vmax values than the wild-type. All four of these mutation were also found to 
have a significant effect on the thermal stability of the P450 form of the protein, with V76M, I359L and I359T found to be destabilising and 
Q214L found to be stabilising  (Chapter 6 Results). V76M, I359L and I359T, as well as R150H, also showed a significant decrease in Km 
compared to wild-type.  V76M showed ~ 2 fold increase in catalytic efficiency due to the increase in Km and Q214 showed a ~ 40% decrease in 
catalytic efficiency due to the decrease in velocity.  All other variants showed comparable catalytic efficiency to the wild-type enzyme.  





Figure 7.27  A visual comparison of the A) Vmax, B) Km, and C) catalytic efficiency of CYP2C9 variants for the 
turnover of OOMR Vivid Red calculated using the Michaelis-Menten model. The error bars represent the 95% 
confidence intervals of the mean of 3 replicas. Student t-test was used to determine values significantly different 
from wild-type: * P < 0.05, ** P < 0.01, *** P < 0.005. 





7.3.1 The effect of glycerol on Cytochrome P450s 
 
The inclusion of glycerol in the CYP450 assay mixes has a substantial effect on both the 
magnitude and shape of the kinetic profiles. Glycerol is well known for its protein stabilising 
properties and is commonly used in CYP450 storage buffers to preserve protein structure. The 
addition of sugars such as glycerol, sucrose and glucose to an aqueous solution containing 
proteins leads to the preferential hydration of the proteins’ and hence an increase in the proteins 
chemical potential [530-532]. This in turn makes any increase in protein surface area in contact 
with the solvent or the exposure of additional hydrophobic residues to the solvent even more 
energetically unfavourable than in water, thereby stabilising the folded native state of globular 
proteins.  
 
Glycerol also has other more specific effects on CYP450 proteins, with a number of studies 
showing that glycerol can affect the P450 spin state and inhibit P450 activity.  Headlam et al 
found that glycerol shifted the spin state equilibrium of CYP11A1 towards the low-spin state and 
inhibited CYP11A1 activity in a substrate dependent manner [533]. Based on this study the 
authors concluded: 1) osmotic stress exerted by glycerol at concentrations up to 20% caused 
water molecules to dissociate from the active site, decreasing the molecular volume of CYP11A1 
and causing a high-spin to low-spin shift; and 2) glycerol inhibited CYP450 activity by 
preventing the association of critical water molecules on substrate binding, the extent of 
inhibition depending on the size of the substrate and number of water molecules that usually 
associate with the CYP450 for the given substrate.  In contrast to CYP11A1, cytochrome 
P450cam showed a shift from low-spin to high-spin as a result of the dissociation of 19 water 
molecules in the presence of sucrose or stachyose [501]. The effect of osmotic pressure on the 
spin equilibrium thus appears to be isoform specific and probably depends on the hydration state 
of the active site for the low- and high- spin conformers.  
 
The addition of 20% glycerol increases the viscosity of water by 50% (West, 1978), however the 
viscosity of a liver microsomal membrane is about 2-fold higher than water (Feinstein 1978) so it 
seems unlikely that glycerol would have a significant influence on the movement of proteins 




within the membrane [534]. It has however been suggested that glycerol inhibits electron transfer 
between CPR and the CYP450 by decreasing the dielectric constant of the medium and 
promoting inhibitory electrostatic interactions between the redox partners [534].  
 
Perhaps more relevant to the work described here, glycerol can also affect CYP450 aggregate 
formation: a study showed that purified cytochrome CYP2B4 (P-450LM4) monodispersed into 
hexameric oligomers in 20% glycerol but had a tendency to from larger non-specific aggregates 
at lower glycerol concentration [119]. This hexameric form of CYP2B4 is thought to be the 
specific, naturally occurring quaternary structure.  Based on the thermostability assays on 
solution-phase CYP3A4 and CYP2C9 proteins described in Chapter 6, it seems reasonable to 
speculate that CYP3A4 and CYP2C9 may also form hexamers in solution: those assays were 
carried out in P450 storage buffer containing 20% glycerol and it is distinctly possible therefore 
that CYP3A4 and CYP2C9 form larger non-specific aggregates in the absence of glycerol, as 
seen for CYP2B4.  However further studies would be required to confirm this and are beyond the 
scope of the present Thesis. 
 
Based on the evidence from previous studies, it is clear that glycerol has a number of 
confounding effects of CYP450s that may vary according to the protein source and environment. 
This highlights the importance of considering the effects of glycerol when ascribing a kinetic 
model to the reactions as these effects may shed light on the molecular mechanisms underlying 
the observed atypical kinetics.  
 
7.3.2 CYP3A4 and CYP2C9 wild-type kinetics 
 
Enzyme activity was observed for CYP3A4 and CYP2C9 wild-type recombinant protein in 
solution using resorufin and fluorescein based fluorescent substrates in a simple 96 well plate 
assay format making use of the peroxide shunt pathway. Generally the Km values for all four 
substrates were comparable to literature values for kinetics assays using baculosomal CYP450s 
and an NADPH regenerating system. The kcat values for solution-phase CYP450 turnover of 
Vivid substrates however were substantially lower than those reported in the literature, 
regardless of the presence or absence of glycerol in the assays or the kinetic model fitted to the 
data (Table 7.7).   




Table 7.7 Comparing kinetic parameters for the turnover of Vivid substrates by CYP450 with those reported 
in the literature  
CYP450: Vivid 
substrate  
This work  Literature   
Solution * (+ 15% glycerol) Baculosomes * (no glycerol) Baculosomes †  
Km (µM) kcat (min-1) Km (µM) kcat (min-1) Km (µM) kcat (min-1) 
CYP3A4:BOMR 3.8 0.01 3.2 Ψ 3.6 Ψ 2.3 / 1.4 6.3 / 1.1 
CYP3A4:DBOMF 6 0.6 1.7 6.3 7.8 / na 8.6 / na 
CYP2C9:OOMR 6.7 0.04 - - 2.0 / 1.4 0.1 / 0.66 
CYP2C9:BOMF 6 0.003 - - 2.1 / 15 0.4/ 9 
* Best fit model to the full data set were used where possible. Kinetic parameters for BOMR and BOMF in the 
presence of 15% glycerol were determined using the Michaelis-Menten model on the truncated data sets as models 
did not fit well to full data sets.  
Ψ Baculosome kinetics for BOMR turnover were performed previously in the Blackburn laboratory where kinetic 
constants were obtained by fitting Michaelis-Menten model to truncated data set. [473]  
† Kinetic parameters reported by [535]/ [536]  
 
Analogous kinetic assays using the DBOMF substrate and commercially available baculosomal 
CYP3A4 preparations containing CPR gave much higher kcat’s, comparable to the literature, and 
the kinetic parameters were similar regardless of whether NADPH or CuOOH was used to drive 
the reaction. This suggests that the differences between the CuOOH driven peroxide shunt 
pathway and the NADPH-CPR dependent catalytic cycle do not account for the differences in 
activity between solution-phase CYP450s and membrane bound CYP450s. Differences in 
protein environment must therefore be responsible for the variation in activity and it may 
therefore be relevant that interaction with lipids and accessory proteins within the membrane 
stabilise the protein have been shown to modulate CYP450 activity [124].  
 
One possible explanation here is that the formation of oligomers or aggregates in solution – not 
formed in the membrane - may trap proteins in a closed, inactive conformation unable to bind 
larger substrates but still susceptible to reduction by dithionate and CO binding. If this were the 
case, the number of CYP450 molecules available to turnover substrate would be much less than 
predicted by CO P450 spectral assays and would lead to an underestimation of kcat. 
 
Solution-phase CYP3A4 displayed atypical kinetics profiles for both resorufin- and fluorescein-
based Vivid substrates that differed from the atypical profiles observed for baculosomal 
CYP3A4. Interestingly the inclusion of 15% glycerol in the reaction mixture gave kinetic 
profiles that closely resembled those obtained for baculosomal CYP3A4 and increased the rate of 




substrate turnover per molecule P450 at all substrate concentrations. It appears therefore that 
glycerol may mimic the membrane environment to some extent; this is likely a result of 
glycerol’s stabilising properties and its ability to affect the spin state of CYP450s via osmotic 
pressure.  Davydov et al have shown that a pressure-sensitive conformational heterogeneity 
exists in both CYP3A4 oligomers and monomers, revealing that a conformational equilibrium is 
inherent to the monomeric structure. The authors found that allosteric substrates [77] and the 
membrane environment [124] could shift the conformational equilibrium, stabilising the high-
spin state of the haem iron by reducing the accessibility of water into the active site. It therefore 
seems reasonable to propose here that, in a similar way to the membrane or an effector molecule, 
glycerol is shifting the conformational equilibrium towards the high-spin state by displacing 
water molecules from the active site, leading to kinetic profiles that resemble those seen for 
baculosomal CYP450s.  
 
Despite obtaining a similar shape kinetic curve and an increase in the rate of substrate turnover 
for solution-phase CYP3A4 in the presence of 15% glycerol, the kcat was still ~ 400 fold lower 
for CYP3A4 turnover of BOMR (calculated using the Michaelis-Menten model) and 10 fold 
lower for DBOMF (calculated using the substrate inhibition model) than that observed for 
baculosomal CYP3A4 in the absence of glycerol.  While the 10 fold difference for DBOMF may 
be attributed to effects of the membrane environment and/or the formation of 
oligomers/aggregates in solution (even in the presence of glycerol) it is not immediately apparent 
why there should be a 400 fold difference for the turnover of BOMR by CYP3A4; this apparent 
anomaly will be discussed further in Chapter 8.  
 
In contrast to CYP3A4 in solution, 15% glycerol inhibited the NADPH-CPR mediated 
baculosomal CYP3A4 turnover of DBOMF; reducing the kcat by 40%. Here, glycerol may inhibit 
CYP450 activity by inhibiting electron transfer by the CPR as described by Voznesensky et al 
but the effect of glycerol on CuOOH driven baculosomal CYP3A4 would need to be tested to 
determine whether glycerol primarily inhibits NADPH-CPR mediated baculosomal activity and 
this was deemed to be outside the scope of this Thesis.   
 
 




Proposed Kinetic model for CYP3A4 turnover of DBOMF  
 
The kinetic profile for the turnover of DBOMF in the absence of glycerol consists of two peaks 
resembling two overlapping substrate inhibition curves; one with a low Km and one with a higher 
Km (Figure 7.8 B). In the presence of 15% glycerol the kinetic profile has a single peak to which 
a single substrate inhibition curve with a low Km could be fitted (Figure  7.19 A). The model 
proposed here for the turnover of DBOMF by CYP3A4 thus assumes two enzyme conformers: 
one with a high binding affinity and one with a low binding affinity, each able to bind two 
molecules of DBOMF and with the binding of the second molecule resulting in enzyme 
inhibition (Figure 7.28 A). In the proposed model, the presence of glycerol stabilises the high 
affinity conformer, shifting the equilibrium and thereby increasing the velocity in the low 
concentrations range (Figure 7.28 B). By contrast, the high affinity conformer is dominant in the 
baculosomal protein preparations as it is stabilised by membrane interactions even in the absence 
of glycerol. The classic substrate inhibition model is shown for each conformer in Figure 7.28 
for simplicity but it is likely that the substrate inhibition may be more complex in reality, 
resembling something more like the P450 substrate inhibition model (Figure 7.17).  
 
                           
 
Figure 7.28 Kinetic model for the turnover of DBOMF by CYP3A4 in the absence (A) and presence of 15% 
glycerol (B). The high affinity CYP3A4 conformer (EH) and low affinity conformer (EL) are in equilibrium 
(equilibrium constant L) and can both bind two substrate molecules (S) with the binding of the second substrate 
leading to a non-productive enzyme species. The rates of product formation by EH and EL are given by rate constants 
kp1 and kp2 respectively.  
 




The Km values for both substrates were comparable to those observed for the NADPH-CPR 
mediated baculosomal CYP3A4 system and were not significantly affected by the presence of 
15% glycerol in the reactions mixtures using the Michaelis-Menten model fitted to the truncated 
data sets or the biphasic or substrate inhibition models fitted to the full data sets where 
applicable. This shows that glycerol is not affecting the binding affinity of the substrate to high 
affinity enzyme - as would be expected for the model described here - and supports the theory 
that baculosomal CYP3A4 is predominantly in a state comparable to the high affinity state 
observed for the solution-phase CYP3A4.   
Proposed Kinetic model for CYP3A4 turnover of BOMR  
 
An analogous explanation for the curves observed for the turnover of BOMR in the absence and 
presence of 15% glycerol is more complicated. The kinetic curve in the absence of glycerol 
shows biphasic kinetics (Figure 7.8 A). One again the presence of 15% glycerol increases the 
height of the initial hyperbolic part of the profile (Figure 7.8 A) and the Km values remain 
comparable for the Michaelis-Menten model fitted to the truncated data sets. The presence of 
glycerol causes a decrease in velocity after the initial hyperbolic part of the profile – resembling 
substrate inhibition - troughing around 8µM followed by a linear increase as seen for the 
baculosomal preparations.  
 
A curve described by the biphasic model (Figure 7.14) with two binding site is mathematically 
equivalent to a model consisting of two conformers: one with a high affinity binding site and one 
with a low affinity binding site (Figure 7.29). In this case, the hyperbolic section results from 
turnover from the high affinity site and the linear portion of the graph arises from a combination 
of turnover from both conformers.    
 
Similarly to the CYP3A4 model for DBOMF, the presence of glycerol shifts the equilibrium 
towards the high affinity conformer, which is then subject to substrate inhibition, making the 
presence of substrate inhibition more evident in the profile. The low affinity conformer does not 
show substrate inhibition or reach saturation in the substrate concentration range tested and 
hence the velocity increases linearly with BOMR concentration after the trough (Figure 7.8 A). 
 
   





Figure 7.29 Biphasic model based on the presence of two enzyme conformers. High affinity CYP3A4 conformer 
(EH) and low affinity conformer (EL) are in equilibrium (equilibrium constant L) and can both bind substrate 
molecule (S). The rates of product formation by EH and EL are given by rate constants kp1 and kp2 respectively.  
 
CYP2C9 turnover of OOMR and BOMF 
 
The turnover of OOMR by CYP2C9 followed Michaelis-Menten kinetics in the absence and 
presence of 15% glycerol. Glycerol increased the rate of substrate turnover while the Km 
remained unchanged at ~ 7µM.  
 
The rate of turnover of BOMF by CYP2C9 was very low and followed a profile that resembles 
the start of a substrate inhibition, but none of the models tested fitted adequately to the data. 
Glycerol did not have a significant effect on Km or Vmax when the Michaelis-Menten model was 
fitted to the truncated data set. The error bars were large owing to the very low changes in 
fluorescence with time; this assay would need to be repeated with a higher number of replicates 
and a larger range of substrate concentrations to determine whether substrate inhibition is truly 
occurring and to find a suitable model to fit the data.  
 
Glycerol had a less prominent effect on CYP2C9 activity than on CYP3A4 activity; CYP2C9 
was much more stable in solution than CYP3A4 and, while thermostability studies suggest that 
there are energetically distinct sub-populations of CYP2C9 in solution that may result from 
oligomers/aggregates (Chapter 6), there is less evidence in the literature for catalytically distinct 
CYP2C9 conformers in solution.  
7.3.3 Effect of CYP3A4 and CYP2C9 polymorphic variation on Vivid substrate turnover 
 
Kinetic assays for CYP3A4 and CYP2C9 polymorphic variants were carried out in the presence 
of glycerol because glycerol increased the rate of substrate turnover and gave kinetic profiles that 




more closely resembled profiles obtained for membrane bound CYP450s. Vmax in nmol product 
formed per min per nmol P450 (=kcat) was calculated based on the concentration of specific P450 
in the protein sample, as determined by carbon monoxide binding assays, ruling out any 
differences in activity resulting from different levels of expression or P450:P420 ratios.  
 
The kinetic profiles for all CYP3A4 variants showed substrate inhibition at higher substrate 
concentrations, as seen for the wild-type.  Since most literature reports comparing the kinetic 
parameters of CYP3A4 variants simply assume Michaelis-Menten kinetics, both the substrate 
inhibition model and the Michaelis-Menten models were fitted to the full and truncated data sets 
respectively in order to see how the choice of model affects the kinetic parameters and 
conclusions drawn from the data. 
CYP3A4 variants 
 
The substrate inhibition model gave the best fit to the data sets, but kinetic parameters calculated 
using this more complex model had larger confidence interval and hence fewer variants had a 
significantly different Vmax compared to the wild-type and none of the variants had a significantly 
different Km.   
 
CYP3A4 variants I223R maximum turnover rate of DBOMF was only 30% of the wild-type. 
I223R was found in breast cancer patients in 2009 [537]  but there are no studies reported to date 
that have tested the effect of this mutation on CYP450 drug metabolism. The side chain of this 
residue - falling within the F-G loop and SRS (2,3) - is orientated towards the active site and has 
been implemented in the gating of pw2b. Both in silico predictions by SDM and thermostability 
assays indicate that this mutation is destabilising. These results suggest that the I223R mutation 
may be linked to a poor metaboliser phenotype.    
 
The Vmax for the CYP3A4 variant M445T was 50% lower than the wild-type. M445T 
corresponds to allele CYP3A4*3 and was first identified in a Chinese population at a frequency 
of < 1% [538] and later found in Caucasian’s with a frequency of 4%, with Eastern Europeans 
having the highest frequency (10%) [539].  Met445 is positioned at the start of α-helix on the 
border of the cys pocket, just two residues away from the haem bound cysteine residue (Figure 
7.30). In silico predictions using SDM and thermostability assays both indicate that this mutation 




is destabilising. Furthermore this residue is solvent accessible and is predicted to form part of the 
P450:CPR interface, although the assay setup used here however excludes any changes in 
activity resulting from a mutational effect on CPR binding. It is interesting to note though that, 
since CPR binds to the proximal face of CYP450, this mutation alters interactions in this region 
(as seen in Figure 6.30) so it is likely that it will alter interactions between the redox partners in 
addition to destabilising CYP3A4. 
 
By contrast, other studies where CYP3A4 M445T was expressed in E.coli, quantified using CO 
spectral binding assays and reconstituted with CPR and lipids, reported no significant difference 
in turnover numbers for testosterone [539, 540] or chlorpyrifos at the single substrate 
concentrations tested [539]. Met445 does not lie within an SRS region so it would not 
automatically be expected to have substrate specific effects. One explanation for this apparent 
conflict in data may therefore be that the presence of lipids and CPR in their reconstituted 
reaction mixture had a stabilising effect on the protein, minimising the observed effect of the 
mutation. Notable though, the studies on testosterone and chlorpyrifos were not full kinetic 
studies so a comparison of their data with the effects of the M445T on catalytic efficiency rather 
than kcat may be more appropriate; this would render the results consistent as the catalytic 
efficiency of M445T determined was similar to the wild-type enzyme.      
 
 
Figure 7.30  Proximal view of CYP3A4 M445T model aligned to the wild-type structure 
The wild-type CYP3A4 pdb structure 2V0M is shown in grey. The M445T model was generated using the  program, 
ANDANTE. Wild-type residue Met445 is shown in cyan ball and sticks and the side chain of the variant residue 
Thr445 is shown in red ball and sticks.  Other side chain positions in the M445T model that deviate from the wild-
type structure can be seen in red. The haem group is coordinated to the cysteine residue, in yellow.   




S222P, L293P and L373F only showed significantly altered kinetic parameters when the 
Michaelis-Menten model was fitted to the truncated data set. All three variants had a higher 
affinity for the DBOMF substrate than the wild-type, reflected by significantly lower Km values. 
S222P also had a lower kcat whereas L293P and L373F had higher turnover numbers.  
 
Previous in vitro studies have shown that the S222P mutation causes a 15 – 70% decrease in Kcat 
values for the turnover of testosterone, midazolam and nifedipine [538, 541]. The effect of 
S222P on substrate affinity was reported to be substrate specific and resulted in the following 
changes to Km: 3-4 fold higher for nifedipine, 2 fold higher for midazolam and similar for 
testosterone.  Ser222 falls within the F’ helix and SRS (2, 3) and, although the side chain is not 
facing towards the active site in the crystal structure, this mutation effects substrate binding in a 
substrate specific manner. A proline residue is usually found at the end of an alpha helix and is 
known as a helix breaker; this S222P mutation is therefore likely to alter the conformation of the 
flexible F-G loop region.  In Chapter 6 it was proposed that this mutation may affect CYP450 
oligomer formation and, as discussed here, this could also lead to changes in kinetic parameters. 
 
L293P is a solvent exposed residue found near the start of the helix I, on the border of SRS 4. 
This mutation was predicted to be neutral by SDM and did not affect the thermostability of the 
enzyme. Previous in vitro studies either found that this variant had similar kinetic parameters to 
the wild-type enzyme [541, 542] or that it gave a 2 fold increase in turnover number compared to 
wild-type for the substrates tested [539].  This is similar to the results seen here for DBOMF 
turnover where the Vmax was about 50% higher but the difference was only significant for the 
Michaelis-Menten model fitted to the truncated data sets.  
 
L373F gave a four-fold increase in Km for midazolam metabolism and displayed an altered 
testosterone metabolite profile in an in vitro study using a bacterial expression system [540]. 
Leu373 is a haem contact and thermostability assays confirmed that mutating this residue to the 
larger phenalaline residue destabilises the P450 form of the protein (see Chapter 6, Figure 6.4 for 
a model of L373F aligned to the wild-type structure).  Surprisingly, despite being destabilising, 
this mutation did not have a significant effect on substrate binding or catalytic efficiency and 
showed a moderate but significant increase in Kcat for DBOMF turnover when the Michaelis-
Menten model was fitted to the truncated data set. 






CYP2C9 variants all followed Michealis-Menten kinetics for the turnover of OOMR, making 
data analysis more straight forward and giving much smaller confidence intervals for kinetic 
parameters. V76M, Q214L, I359L/T and R150H variants all showed altered CYP2C9 
metabolism.  
 
Despite decreasing the thermostability of CYP2C9 and leading to a moderate decrease in Kcat, 
V76M had an increased catalytic efficiency due to a two fold increase in binding affinity for the 
OOMR substrate. This was surprising as V76M does not fall within an SRS region. While this 
mutation was predicted to be neutral by SDM, it decreased the proportion of stable P450 in 
thermostability assays (Chapter 6).  Binding of a substrate to a less stable CYP450 may stabilise 
the structure, causing a larger decrease in free energy than binding to a more stable CYP450; 
consequently, the substrate would have a higher binding affinity for the less stable mutant 
enzyme.  The CYP2C9*23 allele responsible for the in V76M mutation was first identified in an 
European American population in 2005 [543] but there are no reports to date of the effects of this 
mutation on enzyme activity.  
 
Q214L did not alter the Km of CYP2C9 for OOMR but did decrease the kcat by two fold, leading 
to a significant decrease in catalytic efficiency. Q214L is a stabilising mutation - confirmed by 
both SDM predictions and thermostability assays - and despite falling within SRS (2, 3), it did 
not have a significant effect on substrate affinity. This confirms the premise that stabilising 
mutations can also be damaging: increased stability can lead to reduced conformational 
flexibility that is important for function.  CYP2C9*28 containing the Q214L mutation was found 
in Japanese subjects with an allele frequency of 0.002 [544]. In vitro studies using mammalian or 
insect cell expression systems found that Q214L decreases catalytic efficiency by between 45 to 
85% [544, 545] and a significant decrease in binding affinity was reported for two of the 
substrates tested, indicating that this residue plays a more important role in the binding of some 
substrates than others.  
 
I359L and I359T are the non-synonymous amino acid substitutions associated with CYP2C9*3 
and CYP2C9*4 alleles, respectively. I359L has long been associated with poor warfarin 
metabolism and patients with this polymorphism require lower warfarin doses as they are at 




higher risk of bleeding complications when using this anticoagulant [546]. I359L and I359T 
showed a similar decrease in Kcat and Km but no significant change to the catalytic efficiency for 
OOMR turnover. Ile359 falls within SRS 5 and a mutation at this position - to either leucine or 
threonine - greatly decreases the thermostability of the wild-type enzyme in solution (Chapter 6). 
Several in vitro studies, most of which are reports on I359L, show that mutations at this position 
leads to a large decrease in catalytic activity and an increase in Km for some but not all substrates 
tested [544, 547-553]. Figure 7.31 shows models of variants I359L and I359T aligned to the 
wild-type CYP2C9 structure. 
 
 
Figure 7.31 CYP2C9 I359L and I359T models aligned to the wild-type structure 
The wild-type CYP2C9 pdb structure 1R9O is shown in grey. The I359L and I359T models were generated using 
the modelling program, ANDANTE. Wild-type residue Ile359 is shown in cyan balls and sticks and the side chains 
of the variant residues Leu359 and Thr359 are shown in orange and red ball and sticks, respectively. Other side 
chain positions that deviate from the wild-type structure can be seen in orange (I359L) and red (I359T). The haem 
group is shown in black.  
 
The CYP2C9*8 R150H allele commonly occurs in African Americans and has been associated 
with decreased warfarin metabolism in in vivo studies [554]. An in vitro study also showed 
decrease phenytoin metabolism by this variant compared to the wild-type enzyme [555]. The 
only previous in vitro study that determined the full kinetic parameters of R150H found that this 
variant had improved affinity for CPR and a two fold lower Km, resulting in a two fold increase 
in catalytic efficiency for tolbumide metabolism [556].  While the kinetic assays in this Chapter 
did not account for any changes in enzyme activity resulting from changes in CPR affinity, a 




significant decrease in Km was also observed here for R150H. The kcat and catalytic efficiency 
were also higher compared to the wild-type enzyme, but the difference was not statistically 
significant. Interestingly R150H does not fall within any of the known functional regions of 
CYP2C9, was not predicted to be damaging by SDM and did not have an effect on the 
thermostability of the enzyme (Figure 7.32). Despite this, it appears to affect CYP2C9 function 
in vivo and in vitro.   
 
 
Figure 7.32 CYP2C9 R150H model aligned to the wild-type structure 
The wild-type CYP2C9 pdb structure 1R9O is shown in grey. The R150H variant model was generated using the 
modelling program, ANDANTE. Wild-type residue Arg150 is shown in cyan ball and sticks and the side chain of 
the variant residue His150  is shown in red ball and sticks.  Other side chain positions that deviate from the wild-




Solution phase P450 assays, making use of fluorescent substrates and CuOOH to drive catalysis, 
were used to test the effect of polymorphic variation on the kinetic activity of CYP450s and have 
provided new insights into the effect of mutations on CYP450 function. This solution-phase 
assay setup does however have the following disadvantages: 1) Human CYP450s in solution do 
not always behave in the same way as CYP450 immobilised within a membrane. This led to very 
low levels of metabolism for solution-phase CYP450s compared with baculosomal CYP450s; 2) 
The effect of mutations on CPR: P450 interactions cannot be accounted for in this assay format; 
3) The assays are labour intensive and require large amounts of reagents and expensive 




fluorescent substrates, making it difficult to test large panels of variants in parallel;  4) Vivid 
substrates, particularly DBOMF and OOMR, were unstable in aqueous solutions with significant 
auto-oxidation occurring over a 6 hour time period, making it essentially impossible to use the 
same working substrate solution to test all the variants, even if all the assays were carried out 
consecutively on the same day.  These limitations once again highlight the need for a robust, 
cost-effective, high-throughput platform to monitor CPR mediated CYP450 drug metabolism. 
    





7.4.1 Testing the activity of CYP3A4 and CYP2C9 using Vivid substrates  
 
CYP3A4 and CYP2C9 wild-type proteins were expressed in E.coli and purified                                                                                                                                                                                                                                                                                                                 
using by His Ni-TED columns and P450 levels in the partially purified samples were measured 
using CO P450 spectral assays as described in Chapter 5.  The CYP3A4 and CYP2C9 Vivid 
substrates (Invitrogen) listed in Table 7.8 were dissolved in 100% acetonitrile and the 2 mM 
stock solutions were stored at -20°C.  Fresh working stocks of Vivid substrates were made up in 
100 mM potassium phosphate buffer pH 7.4 before each assay. Enzymes-substrate premixes 
were prepared on ice, aliquoted into Nunc 96-well polypropylene microwell plates (Thermo 
Scientific, USA)  and equilibrated at room temperature. Reactions were initiated with cumene 
hydroperoxide (CuOOH, Sigma-Aldrich) and the plate was shaken on a plate vortex for ~10 s 
prior to starting readings. 100 µl reaction mixtures contained final concentrations of 4µM Vivid 
substrate, varying concentrations of P450 and 0.5 mM CuOOH in 100 mM potassium phosphate 
buffer, pH 7.4. The change in fluorescent units (RFU) was monitored continuously for 20 
minutes using a Varian Cary Eclipse fluorescence plate reader. Instrument setting for the 
different substrates are shown in Table 7.8. Negative controls consisted of the following: 
substrate and CuOOH, no P450; CuOOH and P450, no substrate; substrate and P450, no 
CuOOH. The change in fluorescent units (∆RFU) was plotted vs. time (min) and the initial 
velocity (∆RFU/min) was calculated for the linear part of the reaction (usually over the first 5 or 
10 minutes). Velocity was converted from ∆RFU/min to nM product formed/min using a 
standard curve generated from a fluorescein sodium salt (Sigma-Aldrich) or a resorufin sodium 
salt (Sigma-Aldrich) dilution series measured using the same instrument settings used in the 
assay.   
 
Table 7.8 Fluorescent plate reader settings used for CYP450 activity assays 
Vivid Substrate Product Ex/Em (nm) Slit width Ex/Em (nm) 
BOMR 3A4 red resorufin 530/585 10/10 
DBOMF 3A4 green fluorescein 485/530 10/10 
OOMR 2C9 red resorufin 530/585 10/10 
BOMF 2C9 green fluorescein 485/530 10/5 




7.4.2 CYP3A4 and CYP2C9 wild-type kinetic assays 
 
CYP3A4 and CYP2C9 kinetics assays for the turnover of Vivid substrates in the presence and 
absence of 15% glycerol were carried as above with the following amendments: 
Solution-phase CYP3A4 kinetics for the turnover of BOMR Vivid Red substrate 
Each 100µl reaction contained final concentrations of 0.25-24 µM BOMR substrate, 200 nM 
CYP3A4, 0.5mM CuOOH and 0% or 15% (v/v) glycerol in 100 mM potassium phosphate buffer 
pH 7.4. Assays were carried out in duplicate for each substrate concentrations and the average 
initial velocity and standard deviation was calculated over the first 5 min of the reactions.  
Solution-phase CYP3A4 kinetics for the turnover of DBOMF Vivid Green substrate 
Each 100µl reaction contained a final concentration of 0.25 - 32µM DBOMF substrate, 35 nM 
CYP3A4, 0.5 mM CuOOH and 0% or 15% (v/v) glycerol in 100 mM potassium phosphate 
buffer pH 7.4. Assays were carried out in duplicate and the average initial velocity and standard 
deviation was calculated over the first 5 min of the reactions. 
Baculosomal CYP3A4 kinetics for the turnover of DBOMF Vivid Green substrate 
NADPH-CPR mediated CYP3A4 kinetic assays were carried out using a commercial 
baculosomal reagent co-expressing CYP3A4 and CPR (Invitrogen). Fresh 30 mM NADPH 
(Sigma-Aldrich) stocks in 100 mM potassium phosphate buffer were made up and stored at 4°C 
for up to two weeks.   Reactions were initiated by the adding substrate-NADPH premixes to the 
baculosomal regent. Each 100 ul reaction contained a final concentration of 2 nM CYP3A4 (the 
concentration of CPR in the baculosomal reagent was not supplied by Invitrogen), 0.5 – 20 µM 
DBOMF, 1 mM NADPH and 0% or 15% (v/v) glycerol in 100mM potassium phosphate buffer. 
Assays were carried out in triplicate and the average initial velocity and standard deviation was 
calculated over the first 5 min of the reactions. 
Solution-phase CYP2C9 kinetics for the turnover of OOMR Vivid Red substrate 
Each 100 µl reaction contained final concentrations of 0.75-28.8 µM OOMR substrate, 250 nM 
CYP2C9, 0.5 mM CuOOH and 0% or 15% (v/v) glycerol in 100 mM potassium phosphate 
buffer pH 7.4. Assays were carried out in triplicate for each substrate concentrations and the 
average initial velocity and standard deviation was calculated over the first 5 min of the 
reactions.  




Solution-phase CYP2C9 kinetics for the turnover of BOMF Vivid Green substrate 
Each 100 µl reaction contained final concentrations of 0.25 - 24 µM BOMF substrate, 250 nM 
CYP2C9, 0.5 mM CuOOH and 0% or 15% (v/v) glycerol in 100mM potassium phosphate buffer 
pH 7.4. Assays were carried out in duplicate for each substrate concentrations and the average 
initial velocity and standard deviation was calculated over the first 8 min of the reactions. 
7.4.3 CYP3A4 and CYP2C9 variant kinetic assays 
 
Variant proteins were expressed in E.coli and purified using by His Ni-TED columns and P450 
levels in the partially purified samples were measured using CO P450 spectral assays as 
described in Chapter 5.  Variants and wild-type kinetic assays were all carried out on the same 
day, however separate 100 µM Vivid working solutions were made up from the same 2 mM 
Vivid stock in acetonitrile immediately before assaying each variant because both DBOMF and 
OOMR substrates were found to be unstable in aqueous solution, either as a result of 
autoxidation or precipitation.  Kinetics assays for the turnover of Vivid substrates were carried 
out as described in section 7.4.1 with the following amendments: 
CYP3A4 variant kinetic assays 
Each 100 µl reaction contained final concentrations of 0.75 -28.8 µM DBOMF substrate, 50 nM 
CYP3A4, 0.5 mM CuOOH and 15% (v/v) glycerol in 100 mM potassium phosphate buffer pH 
7.4. Assays were carried out in triplicate for each substrate concentrations and the average initial 
velocity and standard deviation was calculated over the first 5 min of the reactions. 
CYP2C9 variant kinetic assays 
Each 100 µl reaction contained final concentrations of 0.75 -28.8 µM OOMR substrate, 250 nM 
CYP2C9, 0.5 mM CuOOH and 15% (v/v) glycerol in 100mM potassium phosphate buffer pH 
7.4. Assays were carried out in triplicate for each substrate concentrations and the average initial 
velocity and standard deviation was calculated over the first 10 min of the reactions. 
7.4.4 Kinetic data analysis 
 
Graph-Pad Prism software (San Diego, USA) was used to fit various kinetic models to the data 
using non-linear regression.   Equations used for curve fitting to determine kinetic parameters for 
the different kinetic models are shown in Table 7.9.  Eadie-Hofstee graphs (velocity vs. 




velocity/substrate) were also plotted to give insight into which kinetic model was likely to fit the 
data best.   
 
Table 7.9  Equations representing the different kinetic models fitted to the kinetic data using nonlinear 
regression. 






(𝑉𝑚𝑎𝑥1  × [𝑆]) + (𝐶𝐿𝑖𝑛𝑡 × [𝑆]
2 )
𝐾𝑚1 + [𝑆]
  [61] 
Substrate Inhibition 𝑣 =  
𝑉𝑚𝑎𝑥 × [𝑆]
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8.1.1 Overview of protein microarray technology 
 
Protein microarrays are miniaturised assays for the high-throughput analysis of protein 
interactions and function. Based on the technology originally developed for DNA microarrays, 
protein microarrays are typically fabricated by depositing tiny droplets of protein sample, with 
volumes in the picolitre to nanolitre range, onto a chemically derivatised glass slide using a 
contact spotter or a non-contact microarrayer. The high-density in format principle allows 
thousands of different biomolecular interactions to be assayed in parallel, eradicating variation 
introduced from one experiment to the next and ensuring that all assays are essentially carried 
out under the same experimental conditions [558].  The low volumes and high throughput nature 
of these assays also make them both time and cost-effective, saving precious samples and 
expensive reagents.  
 
Protein microarrays can be categorised into two groups:  analytical microarrays and functional 
microarrays [559]. Analytical protein microarrays are routinely used to detect the presence and 
abundance of a target protein in a complex sample. Resembling miniaturised ELISA or sandwich 
assays, the capture molecules, typically antibodies, are arrayed onto the surface of a glass slide 
and used to probe a complex mixture of proteins (e.g. a cell lysate) [560].  Reverse-phase arrays, 
where the complex mixture of proteins is printed onto the slide surface and then probed using 
antibodies, are also used [561, 562].  
 
A pivotal study in 2000 showed that proteins could be immobilised onto a glass slide while 
retaining their native structures and biological functions [563]. This provided the foundation for 
the development of a diverse range of functional protein microarrays used to study protein‐
protein, protein‐lipid, protein‐nucleic acid, antibody‐antigen, protein‐carbohydrate, receptor‐
ligand and enzyme‐substrate interactions [564].   
 
Ensuring the protein remains correctly folded and functional after immobilisation is challenging 
and is affected by the choice of surface chemistry. Non-specific absorption onto the surface can 
denature proteins and interfere with protein structure and function.  The surface chemistry will 
also affect protein binding, the density and orientation of the protein and non-specific adsorption 




of macromolecules onto the surface. There are a variety of immobilisation strategies that make 
use of different slide surfaces. These include the following: random covalent attachment onto 
epoxy, aldehyde, NHS or carboxylic ester surfaces; adsorption onto polyvinylidene fluoride 
(PVDF), nitrocellulose or polystyrene surfaces; embedding of proteins within gel-coated 
surfaces; and affinity attachment of His-tagged proteins to nickel-coated surfaces or biotinylated 
proteins to streptavidin-coated surfaces [559, 565, 566].  Affinity attachment is advantageous as 
the orientation of the protein can be controlled (directed immobilisation), giving a homogeneous 
protein layer whilst potentially ensuring functional regions are accessible rather than buried in 
the surface  [567]. Keeping the proteins hydrated on the array surface is also important for 
retaining protein function whilst choice of binding buffer, slide wash and block steps as well as 
storage method for fabricated arrays will also affect the 3-D structure and functional-state of 
immobilised proteins [568]. Jonkheijm et al have reviewed microarray surface chemistry, protein 
attachment and the retention of protein function on surfaces in more detail [569].  
 
Protein microarray detection strategies include both label free and label-dependent methods 
[570]. Of these, fluorescence is the most common detection method used due to its stability and 
sensitivity, as well as the availability of fluorescent scanners and dyes commonly used for DNA 
microarrays. Other label-dependent methods include chemiluminescence, colorimetry and 
radioactivity. Label-free methods include surface plasmon resonance imaging, mass 
spectrometry and atomic force microscopy. While fluorescent-based assays are simple, 
conducive to multiplexing and have a high signal-to-noise ratio, label-free methods eradicate the 
possibility of labelling interfering with protein interactions as well as quantitation difficulties 
arising from differences in labelling efficiency between proteins.  
8.1.2 Enzyme activity arrays  
 
Protein microarrays capable of detecting and characterising enzyme activity generally make use 
of fluorescently-labelled activity-based probes (including mechanism-based suicide inhibitors 
and other low molecular weight fluorescent affinity labels (FALs)) to selectively label enzymes 
based on their activity and screen for suitable inhibitors [571-573]. By including time points and 
varying the concentrations of activity based probe and inhibitor applied to different sub-arrays, 
kinetic parameters and inhibition constants can be determined [572, 574]. The analyte solutions 
are typically applied to individual replica sub-arrays that are separated by teflon coatings or by a 




gasket with different chambers.  However, while this fluorescent-based inhibitor-based approach 
is able to screen a large number of protein samples for activity, it does not monitor substrate 
turnover directly, but is rather an activity-based binding assay. 
 
Drop-to-drop arrays, where one drop containing the enzyme is overlaid by drops containing the 
other reaction components (or vice versa) create an array where a completely separate reaction, 
with different analyte concentrations, can take place in each spot. Evaporation from the surface 
however becomes problematic at sub-nanolitre reaction volumes. Hydrophilic-in-hydrophobic 
micropatterned surfaces have been used to generate larger spots (30- 150nL) with high surface 
tension, reducing the effects of evaporation on kinetics [575]. This was, however, at the cost of 
the number of reactions per slide, reducing the high-throughput nature of the array. In another 
study, Sakakihara et al used a hydrophilic-in-hydrophobic micropatterned surface covered in a 
layer of oil to generate femtolitre droplets for single molecule enzymatic arrays [576].  
 
Microfluidic chips, made up of large arrays of nanolitre to femtolitre chambers etched into a 
surface (e.g. glass, polymer of silica) can be used to monitor enzyme-dependent substrate 
turnover. [577]. Here, fluid flow is tightly controlled, allowing the sequential addition of reaction 
components whilst the chambers reduce problems of evaporation as well as cross contamination 
between reactions. These arrays are extremely sensitive; for example, a recent study generated 
single molecule kinetics for the turnover of a resorufin-based fluorescent substrate by 
horseradish peroxidase using femtoliter-sized fused silica chambers [578]. The disadvantage is 
that this technology requires special apparatus for etching chambers into surfaces and loading 
samples.  
8.1.3 Human CYP450 enzyme microarrays 
 
Miniaturising CYP450 assays is challenging due to the instability of human CYP450 enzymes 
and the instability of the CYP450:CPR complex. This complex has a Kd = 0.05 µM [92] and 
electron transfer from the reductase has a Km = 0.2 µM [100] .   Early efforts to miniaturise 
CYP450 assays involved immobilising CYPs to electrodes made from graphite, glassy-carbon or 
gold, with the electrode serving as an electron source, eliminating the need for co-immobilisation 
of a reductase. This approach has been used to develop CYP450 biosensors to study the redox 
properties of CYP450s and to improve the electrochemical performance of CYP450s for 




technological and commercial applications [579, 580]. These approaches are however not readily 
amenable to high-throughput multiplexed assays and drug screening and there are some concerns 
about the timing of electron transfer from the electrode to the CYP450 affecting the reaction 
cycle.   
 
Specific and highly sensitive fluorescent CYP450 substrates have facilitated medium-throughput 
assays, with reaction volumes of 5 to 250 µl, in 96- 384- and 1536- well plates e.g. [581].  Lee et 
al described one of the first noteworthy CYP450 protein microarrays in which baculosomal 
CYP450 and CPR protein preparations, together with a NADPH regenerating system, were 
encapsulated in an alginate matrix in a nanolitre-scale microarray format and used for the cell-
based screening of drugs metabolised by CYP450s and their toxic metabolites [582]. In an 
extension of this work, alginate CYP450 microarrays were used for fluorescence-based kinetic 
and inhibition studies [381]. While these arrays were quantitative, they were not truly amenable 
to truly high-throughput studies due to the long gelation and aging times for enzyme 
encapsulation- required to stabilise proteins on the surface.  A 30% to 60% decrease in enzyme 
activity compared with solution phase assays was observed in these studies.  
 
In a more recent study, a highly miniaturised solution phase platform termed ‘luminometic sub-
nanoliter droplet-to-droplet array (LUMDA)’, with greatly reduced reaction volumes (picolitre 
range) and no requirement for enzyme encapsulation has been developed [382].  In a proof of 
principle study, this approach was used to monitor the inhibition of liposomes expressing 
CYP3A4 by the prototypical CYP3A4 inhibitors, erythromycin and ketoconazole, as well as two 
new structurally related inhibitors. The assay was luciferase-based, using a ‘pro-luciferin’ 
CYP3A4 substrate to couple enzyme activity to light emission. Droplets containing different 
reaction components were sequentially overlaid onto a silicon dioxide surface using piezoelectric 
inkjet printing followed by incubation and luminometric detection. All reaction components 
were printed in buffers containing 30% (v/v) glycerol; the inclusion of 30% glycerol was 
reported to eradicate evaporation and stabilise droplets during the assay procedure.  
 
Notably, the enzyme microarray approaches described above aim simply to miniaturise 
microsome or liposome-based CYP450 assays and do not immobilise the CYP or CPR proteins 
onto the surface; thus they are not true protein microarrays, as conventionally understood.   
 




8.1.4 The P450 Biochip 
 
The P450 Biochip, previously developed in the Blackburn laboratory by Dr Beeton-Kempen, is a 
fluorescence-based protein microarray platform developed to provide quantitative kinetic data 
for CYP450 drug metabolism [473]. This platform relies on the oriented co-immobilization of 
soluble recombinant CYP450 and it redox partner CPR onto a surface allowing functional 
interactions between these two partners in a membrane-, alginate- and lipid-free environment. 
The robotically printed arrays - with sub-nanolitre reaction volumes – in principle enable the 
high-throughput study of CYP450 metabolism since, with up to 1100 reactions per slide, many 
assays can be run in parallel.   
 
Figure 8.1 shows a schematic of BCCP-tagged CYP3A4 immobilised to a streptavidin-coated 
microarray surface. Commercially available hydrogel‐coated glass slides (Schott H-slides) were 
used for array fabrication. The hydrogel is made up of long chain polyethylene glycol (PEG) 
polymers covalently attached to the glass slide and functionalised with N‐hydroxysuccinimidyl 
ester (NHS) groups [583].  This “non-stick” PEG layer prevents non‐specific macromolecule 
adsorption onto the glass surface, whilst providing an aqueous-like surface environment that 
should help to stabilise specifically-immobilised proteins on the microarray.  
 
The slides were coated with streptavidin, allowing the oriented immobilisation of biotinylated 
recombinant proteins onto the surface via non-covalent biotin-streptavidin interactions. Due to 
the highly specific, essentially irreversible interaction between biotin and streptavidin (Kd = 10‐15 
M), unbound proteins can be washed off the slide without disrupting the bound proteins [584]. 
This allows the binding and purification of biotinylated CYP450 and CPR proteins from partially 
pure protein preparations or crude lysates in a single step [585, 586]. This directed 
immobilisation ensures that the CYP450 and CPR proteins are orientated away from the surface, 
whilst the PEG coating and flexible BCCP-linker allows the immobilised proteins some degree 
of movement, in principle facilitating interactions between neighbouring protein partners.   
 
In this P450 Biochip format, fluorescent CYP450 substrates together with the cofactor NADPH 
are overlaid over the spots of immobilised proteins and the increase in fluorescent signal is 
monitored with time. An advantage of this platform is that array printing and detection can be 




done using conventional DNA microarray technology (a contact printer with solid pins and a 
fluorescent laser scanner). 
 
Figure 8.1 Schematic of a biotinylated BCCP-tagged CYP450 protein immobilised to a streptavidin-coated slide 
surface.  
 
This platform was developed and optimised, by a previous student in the Blackburn laboratory, 
Dr Beeton-Kempen, using the same CYP3A4 wild-type and CPR constructs used in this Thesis 
and Biphasic kinetics, Km1 = 1.6 µM  and Vmax1 =  0.110 nM/min, were observed for the 
metabolism of BOMR (substrate concentrations 0.75 - 43.25 µM)  by CYP3A4 wild-type 
protein. These initial results were promising as the Km determined was comparable to literature 
reports for the turnover of BOMR as well as to solution-phase CuOOH assays performed in the 
same study (Km = 1.4 μM for substrate range 1 – 6 µM using the Michaelis-Menten model). The 
Km reported for the array platform is also in agreement with the more recent results in Chapter 7 




of this Thesis where biphasic kinetics for CuOOH mediated CYP3A4 turnover of BOMR with 
Km = 1.8 µM were observed for substrate range 0.75 - 43.25 µM.  
Problems with the P450 Biochip 
 
Despite the encouraging data obtained for turnover of the BOMR substrate by CYP3A4 on the 
prototype array surface, inhibition studies using the potent CYP3A4 inhibitor ketoconazole on 
this platform gave unexpected data [473]: while the reported Ki values for ketoconazole usually 
fall between 4 nM and 180 nM, depending on the substrate and assay condition [587], 
ketoconazole concentrations between 0.1 nM and 100 µM apparently did not inhibit BOMR 
turnover on the P450 Biochip array surface at all; inhibition was only eventually observed at 
ketoconazole concentrations greater than 100 µM. The mechanism of inhibition of CYP3A4 by   
ketoconazole is still unclear, with different studies reporting competitive, non-competitive and 
mixed-type CYP3A4 inhibition [587, 588]; even so, the inhibitory profile obtained on the array 
surface did not conform to any of the inhibitory models previously reported in the literature.  
15% (v/v) glycerol had been included in the array buffers to slow down evaporation and had 
been observed to be essential for substrate turnover on the array surface. Dr Beeton-Kempen thus 
concluded that glycerol may be interfering with ketoconazole inhibition (noting that glycerol is 
known to be able to bind the haem iron), raising questions as to whether glycerol was a suitable 
anti-evaporating agent [473].   
 
One shortfall of the P450 Biochip platform is the inability to control evaporation from the array 
surface: while glycerol prevents spots drying out completely and retains some water due to its 
hygroscopic nature, rapid evaporation must still occur from the ~ 10 nanolitre reaction droplets. 
Notably the array printing was performed within a printing chamber where the humidity and 
hence evaporation could be controlled but the slide was then by necessity removed from the 
chamber for scanning and scanned every 5 min over 30 to 60 min during which time the 
humidity was not controlled. Thus, the influence of evaporation on substrate concentration and 
hence on reaction rates was not accounted for in the prototype P450 Biochip development work. 
 
Interestingly, a study analysing single glycerol droplets in humid air streams showed that the 
glycerol droplets, with an average starting diameter of 10 µm, have  ~ 20% (v/v) water content at 
50% humidity after they reach equilibrium [589]; the time for a glycerol droplet to reach 




equilibrium was found to be in the order of 1 min. This is in agreement with the graphs of % 
relative humidity versus % glycerol at equilibrium reported in [590] showing that at 50% relative 
humidity the glycerol content is 80% (v/v) and a relative humidity greater than 90% is required 
to maintain  a water content of over 75% (v/v) at equilibrium.  
However, evaporation from the PEG-coated P450 array surface is obviously much more 
complicated than this since the 3-D surface itself is hydrated and water molecules, as well as 
reagent components can diffuse from the droplet into the bulk surface and vice versa until an 
equilibrium is reached. Furthermore, proteins and other reagents within the spots will also affect 
the water content at equilibrium, making it very difficult overall to estimate the true effective 
concentration of reaction components on this platform.   
 
Regardless of the true extent of evaporation, it seems reasonable to assume that printed droplets 
will have reached equilibrium on the array surface by the time they are place in the scanner and 
the first scan is performed. Consequently, the spot volume is likely to remain constant during the 
scanning period when the kinetic data is collected, but the droplet volume is likely to be 
significantly reduced, leading to an increase in substrate, glycerol, NADPH and salt 
concentrations.  
 
As evaporation was not prevented on the P450 biochip and the effects of evaporation on 
substrate concentration were not taken into account, it appears serendipitous that the Km for the 
turnover of BOMR Vivid substrate was comparable to the Km observed in the literature and 
CuOOH mediated solution-phase assays.  This Chapter aims to explore the anomalous 
ketoconazole inhibition results and the effect of glycerol and evaporation on substrate turnover 
on the array surface to ascertain whether the CYP450 Biochip is in fact suitable for testing the 
kinetic activity of multiple variant CYP450 proteins in parallel.  
8.1.5 Aims and objectives 
 
1. Test CPR activity in solution 
2. Test the effect of increasing glycerol and sucrose concentration on activity and 
ketoconazole inhibition 




3. Determine whether reliable kinetic parameters for NADPH CPR-dependent turnover of 
Vivid substrates by CYP3A4 and CYP2C9 polymorphic variants can be obtained on the 
P450 Biochip array surface.  






8.2.1 CPR activity 
 
Prior to any array work, the activity of the solution-phase N-terminal truncated CPR protein 
expressed in E.coli (Chapter 5) was tested by monitoring the NADPH-dependant reduction of 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to blue-formazan by CPR 
(Figure 8.2).  The formation of blue-formazan was measured spectrophotometrically by the 
increase in absorbance at 610nm.  
 
 
Figure 8.2  Reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to blue formazan  by 
CPR in the presence of NADPH (Figure from [591]) 
  
 
The His-tag purified recombinant CPR showed satisfactory activity, suitable for downstream 
CYP450 assays. MTT reduction by CPR followed Michaelis-Menten kinetics (Figure 8.3) with 
Km = 109  ± 15 µM  and kcat = 858 ± 43 min-1. The kcat was comparable to results obtained 
previously for the same protein construct, as well as for the rat full length CPR, while the Km was 
2 and 5 fold  higher respectively (Table 8.1).  





Figure 8.3  Michaelis-Menten model fitted to CPR kinetic data for the reduction of MTT in the presence of NADPH 
using non-linear regression. A concentration of ~20 nM CPR (partially purified protein, concentration estimated 
from protein gels) in 100mM potassium phosphate buffer pH 7.4 was used in each reaction and reactions were 
initiated by the addition of a NADPH regenerating system.  The formation of blue-formazan was monitored at 610 
nm for 30 s at varying MTT concentrations (0.1 - 500µM). 
  
Table 8.1  Kinetic constants for the reduction of MTT by CPR 
Protein construct kcat (min-1) Km (µM) Reference 
N-term truncated Human CPR 858 ± 43 109 ± 15 This work 
N-term truncated Human CPR 766 54 ± 5 [473] 
Rat full length CPR 1190 ± 40 20 ± 2 [591] 
Specific activity observed in this work for partially protein = 4.5 U/mg  
8.2.2 Testing the effect of glycerol on CYP450 activity and inhibition 
 
To explore the reason for the very weak CYP3A4 inhibition by ketoconazole in the expected 
concentration ranges on the P450 Biochip array surface observed in previous work, activity 
assays systematically testing the effect of increasing glycerol concentrations on CYP3A4 activity 
and ketoconazole inhibition in solution were carried out using CuOOH to drive the reaction. 
Sucrose was also tested as an alternative anti-evaporation agent. Assays were carried out using 
8µM DBOMF Vivid Green substrate and 100 nM ketoconazole.  
 
Solution-phase CYP3A4 activity increased with glycerol concentration, peaking at 24% glycerol 
with activity more than 2 fold higher than in the absence of glycerol, but then began to decrease 
again as glycerol concentrations increased further (Figure 8.4 A).  Activity was still higher in the 
presence of 60% glycerol than in the absence of glycerol; glycerol concentrations higher than 




60% were not tested due to the difficulty of accurately pipetting viscous liquids but if the 
observed trend continued, higher glycerol concentrations would presumably further reduce 
CYP3A4 activity. By contrast, CYP3A4 activity decreased gradually with increasing sucrose 
concentrations (Figure 8.4 B): activity in the presence of 60% sucrose was 52% lower than in the 
absence of sucrose.  
 
100 nM ketoconazole inhibited CYP3A4 activity by 70-80 % at lower glycerol concentrations, 
however ketoconazole’s potency as an inhibitor decreased at higher glycerol concentrations: 100 
nM ketoconazole showed only 40% inhibition in the presence of 60% glycerol. Increasing 
sucrose concentration did not have an effect on ketoconazole inhibition: 100 nM ketoconazole 




Figure 8.4 The effect of increasing glycerol and sucrose concentrations on CYP3A4 activity and ketoconazole 
inhibition.   
 
75 nM CYP3A4 and 8 µM DBOMF in 100 mM potassium phosphate buffer was used in each reaction and the 
reactions were initiated with 0.5 mM CuOOH. The increase in fluorescence was monitored over the first 5 min of 
the reaction, for which the reaction was linear. A and B show the rate of CYP3A4 turnover of DBOMF at each 
glycerol or sucrose concentration, in the absence and presence of 100 nM ketoconazole, as a percentage of CYP3A4 
turnover of DBOMF in the absence of glycerol/sucrose and inhibitor. C and D show the remaining CYP3A4 activity 
in the presence of 100nM ketoconazole as a percentage of the activity in the absence of ketoconazole at each 
glycerol or sucrose concentration.   
 




Based on these results, glycerol is more suitable than sucrose for preserving CYP3A4 enzyme 
activity whilst reducing evaporation rates and even at concentrations exceeding 60% glycerol 
(v/v) activity levels should be similar to the activity observed in the absence of glycerol. 
Glycerol is however problematic for inhibition studies as it clearly interferes with ketoconazole 
inhibition. By comparison, sucrose did not alter ketoconazole inhibition, but high concentrations 
resulted in much lower levels of CYP3A4 activity. 
8.2.3 CYP450 microarray assays: The importance of negative controls 
 
A microarray assay was set up to test the kinetic activity of the 7 CYP3A4 polymorphic variant 
proteins including the wild-type using the original protocol established by Dr Beeton-Kempen. 
Briefly, a solution containing a mixture of partially purified biotinylated CYP3A4 and CPR 
proteins was printed onto a streptavidin-coated array surface and left in the humidified printing 
chamber for an additional 30 minutes to allow proteins to bind. The slide was then blocked with 
BSA plus free biotin and washed to remove unbound proteins. The spots containing bound 
protein were overlaid with a mixture of BOMR substrate and NADPH in a second print round 
and the increase in fluorescence was monitored in each spot over time using a fluorescent 
scanner. 15% glycerol was included in the printing buffer for the first and second print rounds. 
Two controls, not previously performed, were included at each substrate concentration: a “CPR 
only control” (CYP3A4 was excluded from the first round of printing) and a “no protein control” 
(both CYP3A4 and CPR were excluded from the first round of printing).  The print layout is 
shown in the Methods, Section 8.4.3.  
 
The kinetic profiles for the turnover of BOMR on the array surface by wild-type CYP3A4 and 
the negative controls are shown in Figure 8.5 A. Unexpectedly, both the “CPR only” and “no 
protein” control showed kinetic profiles comparable to the kinetic profile observed for “CPR + 
CYP3A4” suggesting that the substrate turnover observed was protein independent.  Figure 8.5 B 
shows the results from identical assay repeated a few days later using fresh reagents. The 
magnitude and shape of the kinetic curves differed between the two assays, particularly at higher 
substrate concentrations, but again the kinetic profiles for the negative controls were comparable 
to the kinetics for CPR + CYP3A4. The data for the CYP3A4 variants was therefore not 
analysed as it was clear that the observed substrate turnover in these assays was not P450 
dependent.  




Additional controls at a single substrate concentration (5.7 µM) were also included on a separate 
section of the same slide on both occasions (Figure 8.5 C & D).  “No NADPH”, “no substrate” 
and “NADPH only” controls showed no significant increase in fluorescent signal with time, 
however the “BOMR + NADPH - no protein” control again showed a similar rate of substrate 




Figure 8.5 Turnover of BOMR substrate on microarray surface. 
A) & B) Kinetic profiles for the turnover of BOMR (0.5 – 43.3 µM) on the array surface for reactions containing 
3A4 and CPR and two negative controls: “CPR only” and “no protein”. Graphs A and B show results from two 
identical experiments carried out on different days. Reactions were carried out in 100mM potassium phosphate 
buffer pH 7.4, 15% glycerol and initiated with BOMR and 1mM NADPH. The linear reactions were monitored for 
40 min and velocities were calculated based on the average of 3 to 7 replicates.  C) & D) Additional controls 
included on a different section of the same slide as experiments in A and B, respectively: 1) 3A4 + CPR + 5.7 µM 
BOMR + 1mM NADPH; 2) 3A4 + CPR +  5.7 µM  BOMR, no NADPH;  3) 3A4 + CPR + NADPH, no substrate; 
4) 5.7 µM BOMR + 1mM NADPH, no protein; 5) 1mM NADPH only.  
 
Due to the high volumes of data produced in a single assay, signals from replicate spots were 
averaged at each time point and the averaged signal was used to plot RFU versus time graphs, 
rather than generating individual RFU versus time graphs for each spot and then averaging the 




rates. Consequently, error bars are not shown on the graph but rather the percentage median 
coefficient of variation (CV) calculated across all time points for each sample is used to show the 
experimental error associated with the data (Table 8.2 & Table 8.3).   
 
Table 8.2 Percentage median CVs calculated for the data shown in Fig 7.5 A and B 
  Assay A Assay B 
µM BOMR  3A4 + CPR CPR only No protein 3A4 + CPR CPR only No protein 
0.50 7.3 7.9 38.6 11.5 12.1 17.0 
0.75 5.6 3.8 22.4 20.5 20.2 47.0 
1.13 4.7 6.0 38.2 23.1 12.2 17.8 
1.69 8.1 6.7 38.4 12.3 4.0 22.5 
2.53 4.3 4.1 7.7 18.2 16.5 21.0 
3.80 3.4 2.5 6.3 15.8 6.9 22.0 
5.70 4.0 2.2 6.4 16.1 14.6 14.2 
8.54 3.3 3.3 5.0 17.0 9.8 21.6 
12.81 2.9 3.3 10.3 6.6 2.6 13.4 
19.22 3.1 4.0 6.2 3.7 11.5 11.6 
28.83 3.6 24.0 4.0 7.8 8.5 21.0 
43.25 2.8 5.9 6.8 15.0 3.9 31.0 
Average 4.4 6.1 15.9 14.0 10.2 21.7 
 
 
Table 8.3 Percentage median CVs calculated for the data shown in Figure 8.5 C and D 
 5.7 µM BOMR    Assay A Assay B 
Control 1 positive 2.8 9.5 
Control 2 no substrate 4.8 7.4 
Control 3 no NADPH 19.2 27.9 
Control 4 no protein na 13.6 
Control 5 NADPH only na 36.8 
 
The variations between replica spots in the first assay (Assay A) was very low for samples at all 
substrate concentrations (CV < 10%) with the exception of the “no protein” control in the low 
substrate concentration range where CV values were as high as 38%.  The variation between 
replica spots in the second assay (Assay B) was generally higher than the first assay and the “No 
protein” spots showed higher inter-spot variation than the other samples. Control samples, where 
very low or no increase in fluorescence was observed, also had higher CVs but this is expected 
due to a low signal to noise ratio.  
 




The CVs in both assays were calculated based on the following number of replicate spots: “3A4 
+ CPR”, 7 spots; “CPR only”, 3 spots; “No protein”; 6 spots. The “3A4 + CPR” and “CPR only” 
were printed consecutively in the same area of the sub-array with no wash steps in-between. The 
“No protein” spots were scattered throughout the sub-array with other samples and pin wash 
steps were carried out in between them (see Methods, Figure 8.15 for print layout). This suggests 
that the high CV values for “No protein spots” may result from the varied position/time of 
printing of the replicate spots within the sub-array.  
 
To confirm and investigate this apparent protein independent turnover on the array surface, 
another microarray assay, testing different combinations of reaction components, was carried 
out. Reaction components were printed onto two slides in parallel: Slide 1 was processed as 
usual with BSA in the blocking solution; whereas for Slide 2, BSA was excluded from blocking 
solution. The results from this assay confirmed that the BOMR substrate turnover on the slide - 
was NADPH dependent and protein independent (Figure 8.6). All combinations of reaction 
components containing both NADPH and substrate showed similar rates of substrate turnover 
that increased with increasing substrate concentration. While the trends were similar on both 
slides, the rate of substrate turnover was lower on slide 2.  
 
The median CVs for replicate reactions on slide 1 and 2 are shown in Table 8.4. The variation 
between replicate spots for slide 1 was satisfactory: all median CVs < 20% even at low substrate 
concentrations, the average median CV was ~7% and all median CVs > 10% were for samples 
that had ≥ 42 replicate spots. The variation between spots on slide 2 (no BSA in blocking step) 
was higher than for slide 1 (blocked with BSA): all median CVs were ≤ 35% and the average 
median CV was 13.4%.  The spots on slide 2 were printed immediately after the corresponding 
spot on slide 1 using the same pins and samples.  
 





Figure 8.6 NADPH dependent BOMR 
turnover on the microarray surface. The 
graphs shows the rate of resorufin 
formation on the array surface for 
different combinations of the reaction 
components at varying BOMR substrate 
concentrations (1.1 – 12.8 µM) on A) 
slide 1, with BSA in blocking solution 
and B) slide 2, without BSA in blocking 
solution. The reactions were carried out 
in 100mM potassium phosphate buffer 
pH 7.4, 15% glycerol and the linear 
reactions were monitored for 45min.  
Each bar represents the average of at 
least 6 replicate spots. C) Slide 1 
scanned at time 0 and after 45 min.  
 





Table 8.4 Percentage median CVs calculated for the data shown in Figure 8.6 A and B 
Reaction components No of replicates  











SLIDE 1 - with BSA blocking 
     
   CPR + NADPH 6 7.6 3.6 3.9 5.8 5.2 
   3A4 + NADPH 6 6.2 2.7 3.6 4.1 4.1 
   3A4 + CPR + NADPH 42 7.7 16.7 11.9 14.1 12.6 
   Buffer + NADPH 60 6.0 18.2 6.3 4.5 8.7 
   CPR - No NADPH 6 5.9 2.9 4.0 2.4 3.8 
   3A4 - No NADPH 6 6.5 4.1 3.6 3.3 4.4 
   3A4 + CPR - No NADPH 42 10.7 7.2 6.7 5.0 7.4 
   Buffer - No NADPH 60 9.5 7.4 7.8 5.3 7.5 
SLIDE 2 - no BSA blocking     
 
   CPR + NADPH 6 18.2 7.6 7.2 4.7 9.4 
   3A4 + NADPH 6 16.5 6.4 3.6 4.8 7.8 
   3A4 + CPR + NADPH 42 12.7 13.3 13.3 14.7 13.5 
   Buffer + NADPH 60 18.1 17.2 13.6 35.1 21.0 
   CPR - No NADPH 6 8.2 4.3 6.5 4.7 5.9 
   3A4 - No NADPH 6 10.8 4.5 8.2 4.9 7.1 
   3A4 + CPR - No NADPH 42 16.9 16.9 15.0 16.0 16.2 
   Buffer - No NADPH 60 31.6 23.8 30.1 20.8 26.6 
 
Variation between sub-arrays 
 
To determine the reproducibility of the array data across the slide surface, replicate spots at the 
same position in different sub-arrays printed by different pins at the same time were examined. 
The data for the “Buffer + NADPH” sample at each substrate concentration in Figure 8.6 above 
was an average of replicate spots from the same sub-array (sub-arrays 5 – 8). Six addition 
“Buffer + NADPH, no protein” spots were also printed in sub-arrays 1- 4. (See Methods, Figure 
8.16 for slide layout).  Figure 8.7 compares the rate of substrate turnover of “Buffer + NADPH, 
no protein” spots at varying substrate concentrations calculated from spots in row 10, sub-arrays 
1 to 4 and spots in row 10, sub-array 5 – 8 for slide 1 and slide 2.   






Figure 8.7 Inter-sub-array variability for the turnover of BOMR on the slide surface. P450 storage buffer only spots 
were printed in the first print round; spots were overlaid by 1mM NADPH and 1.1 -12.8 µM BOMR Vivid substrate 
in the second print round. Each bar represents the average of 6 replicate spots printed within the same row by the 
same pin. Panel A is data from slide 1; Panel B is data from slide 2. 
 
The variability between data in different sub-arrays was between 3 and 56 %.  Spots in sub-
arrays 5 to 8 showed higher turnover at almost all substrates concentrations on both slides and as 
seen previously, slide 2 generally showed higher variability than slide 1; other than this, there 
were no obvious trends.  
 




Variation within sub-arrays 
 
Variation between replicate spots within a sub-array was also examined (Figure 8.8). All spots in 
a sub-array are printed from the same well by the same pin, one after the other. There was a 1% 
to 45% difference in the rate of BOMR turnover between the rows within sub-arrays on slide 1; 
the largest variation was seen at the lower substrate concentrations while data at the highest 
substrate concentration showed very little variation. There was a 3% to 54% difference in the 
rate of BOMR turnover between rows within sub-arrays on slide 2 and high variation was seen at 
both high and low substrate concentrations.  The variability on both slides was generally the 
highest for rows furthest apart.   
 
Figure 8.8 Intra- sub-array variability for the turnover of BOMR on the array surface. P450 storage buffer only spots 
were printed in the first print round; spots were overlaid by 1mM NADPH and 1.1 -12.8 µM BOMR Vivid substrate 
in the second print round. Each row contained 6 replicate spots at each substrate concentration. All rows were 
printed by the same pin one after the other, starting with row 10.   No wash steps were included between replicate 
spots. Panel A is data from slide 1; Panel B is data from slide 2. 




8.2.4 Further testing of fluorescent substrates in solution 
 
Additional solution phase assays were performed in an attempt to gain insight into the protein-
independent turnover observed on the array surface and to test whether any NADPH-CPR 
mediated CYP450 activity could be observed in solution. The resorufin- and fluorescein-based 
CYP3A4 and CYP2C9 Vivid substrates were tested (Figure 8.9 A-D).  A positive control 
showing CuOOH mediated CYP3A4 or CYP2C9 activity was included for each substrate, as 
well as the following negative controls with and without NADPH: 1) No protein, 2) CPR only, 




Figure 8.9 Testing the turnover of CYP3A4 and CYP2C9 Vivid fluorescent substrates in solution  
 
Turnover of resorufin-based Vivid substrates BOMR (A) and OOMR (B) and the fluorescein-based Vivid substrates 
DBOMF (C) and BOMF (D) by different components in the CYP3A4 and CYP2C9 reaction setups. The blue bars in 
each graph represent “P450 + substrate + CuOOH”, serving as the positive control. The red bars in each graph 
represent reactions with NADPH as follows: “No protein + substrate + NADPH”, “P450 + CPR + substrate + 
NADPH”, “P450 only + substrate + NADPH” and “CPR only + substrate + NADPH’’. The green bars in each graph 
represent reaction without NADPH as follows: “No protein + substrate”, “P450 + CPR + substrate”, “P450 only + 
substrate” and “CPR only + substrate’’.5.7 µM Vivid substrate was used for each reaction and the total increase in 
fluorescence after 5 min was plotted. The concentrations of other components in the reactions, where applicable, 
were as follows: 250nM CYP3A4 (total protein concentration), 250nM CYP2C9 (total protein concentration), 
250nM CPR (total protein concentration), 0.5mM CuOOH and 1mM NADPH. The reactions were carried out in 
100mM potassium phosphate buffer, pH 7.4, 15% glycerol. The structure of each Vivid substrate is shown on the 
right of the graph.   




No protein independent substrate turnover above background was observed for any of the 
substrates. However, NADPH dependent CPR turnover of resorufin-based substrate BOMR, 
observed in the absence of CYP3A4 (CPR control), was four times higher than that observed for 
CuOOH mediated CYP3A4 turnover of BOMR (positive control). All negative controls for the 
other three substrates showed no or very low increases in fluorescence compared with the 
positive control.  
 
These results confirmed that the protein-independent turnover was specific to the microarray 
platform. Several other attempts were made to gain further insight into the substrate independent 
turnover occurring on the microarray surface. Analogous assays were performed in Nunc 
immobilizer streptavidin-coated 96 well plates with a PEG surface similar to the microarray 
slides. Elevated NADPH, glycerol and potassium phosphate concentrations (10 nM, ~60% and 
1M respectively) were tested in an attempt to mimic the effect of evaporation on the slide 
surface. The streptavidin-coated plates were also tested as an alternative platform for obtaining 
CPR mediated CYP3A4 activity using the less problematic DBOMF substrate.  No protein 
independent turnover or CPR dependent CYP3A4 turnover was observed in any of these assays 
(results not shown).  
 






The utility of a P450 Biochip for generating CYP450 kinetic data was previously exemplified 
using recombinant human wild-type CYP3A4 and CPR protein [473]. On the grounds that 
previous kinetic results looked promising despite concerns that glycerol may be interfering with 
enzyme inhibition, a series of experiments were carried out here aimed at improving the 
platform, with the goal of using it to obtain kinetic data for the panel of CYP3A4 and CYP2C9 
polymorphic variants. Based on the spectrophotometric assay monitoring the reduction of MTT 
by CPR and CuOOH mediated solution-phase CYP450 assays (Chapter 7), biotinylated BCCP-
tagged CPR and CYP3A4 proteins were shown to be catalytically active and thus deemed 
suitable for protein microarray work.   
Glycerol’s effect on CYP3A4 activity and inhibition: implications for the microarray platform 
 
Glycerol is routinely used in protein microarrays due to its hygroscopic nature, low volatility and 
protein stabilising properties. In particular, it is thought to maintain a solvated environment for 
proteins/peptides in small droplets on array surfaces and to act as a water mimic, capable of 
forming multiple hydrogen bonds.  
 
To gain insight into the possible effects of glycerol on the CYP450 Biochip, the effect of 
increasing glycerol concentrations on CYP3A4 activity and ketoconazole inhibition was tested 
using CuOOH mediated solution-phase assays in microwell plates - with 100 µl reaction 
volumes and a 5 min assay duration, evaporation was assumed to be negligible. Increasing 
glycerol concentrations between 0 and 24 % (v/v) lead to increased CYP3A4 activity and 
glycerol concentration in this lower range did not affect ketoconazole inhibition. At glycerol 
concentrations ≥ 36% (v/v), however, CYP3A4 activity began to decrease again and the potency 
of ketoconazole inhibition declined with increasing glycerol concentrations.  The increase in 
CYP3A4 activity observed at lower substrate concentrations is consistent with results in Chapter 
7.  
 
Interestingly, a report in the literature showed that glycerol causes CYP11A1 to shift towards the 
low spin state [533]. In the presence of sub-saturating glycerol concentrations (20% and 35%), a 




high-spin inducing substrate shifted the protein to a high-spin state but in the presence of 65% 
glycerol, the addition of high-spin inducing substrate did not cause a spin-shift. High glycerol 
concentration (> 35%) may reduce activity by affecting the structural flexibility of the enzyme 
and preventing water molecules crucial for catalytic activity from entering the active site. High 
viscosity may also have an effect on the diffusion rates.  
 
High glycerol concentrations have also been reported to reduce the binding affinity of 
ketoconazole in other related studies. Arrabito et al observed that ketoconazole had an IC50 more 
than 4 fold higher in the liposome-based LUMDA CYP3A4 array, where printing buffers 
contained 30% glycerol, than in microwell assays with no glycerol [382].  The authors claimed 
that 30% (v/v) glycerol keeps the water content in the spots constant and resolves evaporation 
issues. Using a stroboscopic imaging tool present in the inkjet printer they showed that final 
spots do not change shape or size for more than 8 hours. However while the spots in that study 
were stable after a glycerol:water equilibrium is reached, it seems inevitable that evaporation 
must have occurred extremely rapidly as the picolitre spots were printed; so while the glycerol 
content remained constant during the experiment, it is likely to be higher than expected (> 30%).  
If this is true, based on the results from this Chapter, the elevated glycerol concentration (> 30%) 
explains the reduced inhibitory effect of ketoconazole observed on the LUMDA-chip.   
 
The inclusion of sucrose as an alternative anti-evaporation agent did not have the same effect as 
glycerol on the activity of CYP3A4: increasing sucrose concentrations reduced CYP3A4 activity 
and had no effect on the potency of ketoconazole inhibition. Different osmolytes interact 
differently with proteins and water molecules due to varying properties such as size and polarity 
[592, 593]. Perhaps importantly here, while sucrose generally stabilises proteins more than 
glycerol, glycerol is a much smaller molecule and is able to access regions surrounding the 
protein that are inaccessible to sucrose.   
 
It appears that, in the case of the P450 Biochip, if evaporation was effectively controlled to 
ensure that glycerol concentration remains constant at < 30% (v/v), inclusion of glycerol in the 
array spotting buffer would be beneficial, stabilising the proteins and increasing activity without 
interfering with inhibition. Controlling or accounting for evaporation from the array surface, 
while keeping reaction volumes low to maintain a truly high-throughput assay format, is 
however by no means trivial. Overlaying immobilised proteins with substrate-NADPH mixes 




encapsulated in water-in-oil emulsions or using a hydrophilic-in-hydrophobic micropatterned 
surface covered in a layer of oil as described by Sakakihara et al may be possible solutions to 
this problem.  
NADPH-dependent, CYP450 and CPR-independent turnover on the microarray surface: Are 
Vivid CYP450 substrates suitable for use on the CYP450 microarray platform? 
 
Inclusion of a “no protein control” revealed that the resorufin-based CYP3A4 substrate, Vivid 
Red BOMR, was oxidised to its fluorescent product resorufin in the absence of CYP3A4 and 
CPR on the microarray surface. This reaction was found to be NADPH-dependent and specific to 
the microarray platform; there was no protein-independent turnover in the corresponding 
reactions in solution, even when reactions were carried out in streptavidin-derivatised PEG-
coated 96 well plates with elevated NADPH, glycerol and substrate concentrations.  
 
Subsequent microarray experiments, carried out by another student in the Blackburn lab, have 
also shown NADPH–dependent protein-independent turnover of resorufin-based CYP2C9 
substrate, OOMR [594], suggesting that resorufin-based substrates are incompatible with the 
microarray format. Unfortunately, the microarray scanner, optimised for DNA microarrays, only 
has two standard lasers λex = 532 nm and λex = 635 nm and a range of emission filters 
optimised for conventional dyes, Cy3 and Cy5. Consequently, the turnover of fluorescein-based 
substrates, DBOMF and BOMF, could not be monitored using the microarray scanner. Confocal 
laser scanning microscopy has a much wider range of excitation and emission wavelengths and 
offers an alternative method for monitoring substrate turnover.  This method of detection was 
however only conducive to endpoint assays due to practical limitations such as long scanning 
times (~20 min per scan) and the proximity of the confocal microscope to the microarray 
printing equipment. Preliminary hand-spotted arrays, monitored using confocal microscopy, 
tested the CPR mediated CYP3A4 turnover of DBOMF, CYP2C9 turnover of BOMF and 
CYP2D6 turnover of coumarin-based Vivid substrate EOMCC [594]. CPR mediated CYP3A4 
turnover of DBOMF showed promising results in this assay, however kinetic curves for CPR 
mediated CYP2C9 turnover of BOMF and CYP2D6 turnover of EOMCC had a similar or lower 
magnitude to the negative controls included in those assays [594].  
 
The instability of Vivid substrates in aqueous solution, mentioned in Chapter 7, may also be 
problematic for microarray assays. The time from dilution of substrates to the end of the assays 




is typically over 2 hours since it includes preparing and aliquoting samples into the 384 well 
sample plate for second round printing, printing the substrates (can take 20 min or longer 
depending on the complexity of the print pattern and number of pin wash steps) and scanning.  
Autoxidation of substrates over the duration of the assay may decrease the substrate 
concentration resulting in apparent elevated Km values.  
NADPH CPR-dependent turnover of BOMR 
 
Further testing of Vivid substrates in solution also revealed the NADPH-dependent, CYP3A4-
independent turnover of BOMR by CPR. This CPR dependent turnover was ~ 5 fold higher than 
the CuOOH mediated CYP3A4 turnover of BOMR and probably immediately explains the very 
high relative kcat observed for baculosomal NADPH-CPR mediated CYP3A4 turnover of BOMR 
(compared with CuOOH mediated CYP3A4 turnover of BOMR in solution; 400 fold difference 
between baculosomal and solution phase assays for BOMR) but not for the DBOMF substrate 
(only a 10 fold difference in kcats for DBOMF using the same enzyme preparations) observed in 
Chapter 7 (see discussion in Section 7.3.2). The concentration of CPR in the commercial 
baculosomal CYP3A4 reagent is not specified, but it is likely that a large proportion of the 
observed BOMR activity is in fact CPR-dependent rather than CYP3A4 dependent. Notably, 
there are no other reports of NADPH-CPR dependent turnover of BOMR to date, most likely 
because CPR and CYP3A4 are co-expressed in microsomal and baculosomal protein 
preparations making it difficult to perform a “CPR only” control.    
 
There are however studies reporting the NADPH dependent reduction of resorufin and 7-
alkoxyresorufins to colourless non-fluorescent compounds by CPR [595, 596] which revealed 
the redox cycling of resorufin in the presence of CPR: CPR catalyses the one-electron reduction 
of resorufin followed by either a second one-electron reduction or a one-electron oxidation by 
molecular oxygen.   
 
The results in this Chapter highlight the importance of the “CPR only” control and clearly show 
that BOMR is unsuitable for determining CPR-mediated CYP450 activity.  However, CPR did 
not turn over either of the fluorescein-based Vivid substrates, DBOMF or BOMF, or the other 
resorufin-based substrate OOMR.  
 




Possible mechanisms for CYP450-independent turnover of Vivid substrates 
 
An initial hypothesis to account for the NADPH-dependant, CYP450- and CPR-independent 
turnover of resorufin-based Vivid substrates on the microarray surface was that it was due either 
to catalysis by BSA (present on the surface as a blocking agent) [597, 598] or to iron(II)-
mediated GIF- or Fenton-type biomimetic chemistry (the possible iron source being from 
corrosion of the stainless steel pins used for printing); however, neither of these possibilities 
were supported by the subsequent controls that were run. A more likely hypothesis therefore is 
that transient, reversible reduction of BOMR by NADPH - generating a charged intermediate - 
enhances electrostatic interactions with the positively charged surface, thus promoting surface-
mediated general acid catalysis of the acetal group (Figure 8.10). The PEG-coated array surface 
is likely to be positively charged due to the known ability of PEG to coordinate divalent ions.  In 
support of this latter hypothesis, subsequent work from the Blackburn laboratory showed that 
reactions carried out on more strongly charged amine surfaces gave significantly higher rates of 
surface-dependent BOMR turnover than the PEG-coated surfaces [594]. However, further work 




Figure 8.10 Proposed mechanism for NADPH-dependent CYP450 and CPR-independent turnover of BOMR on the 
array surface.  A) NADPH transiently reduces the resorufin ring of BOMR yielding a negatively charged species. B) 
The negatively charged species associates with the positively charged surface promoting hydrolysis of the acetal 
linkage by general acid based catalysis leading to the formation (after re-oxidisation) of resorufin.  
 
To account for the NADPH-dependent turnover of BOMR by CPR observed in solution, it seems 
possible that either (1) BOMR binds into a vacant FAD binding site in CPR due to molecular 
mimicry of the aromatic heterocycles of the flavin moiety by BOMR (Figure 8.11), or (2) 
BOMR binds non-specifically in the cleft between the NADPH and FAD binding domains in 
CPR. Either way, it then seems plausible that substrate binding to CPR leads to reduction of the 
resorufin moiety by NADPH, followed by oxidation of the substrate side chain by a bound 




flavin, causing side chain cleavage and the formation (after re-oxidation) of resorufin. To 
account for why CPR metabolises BOMR but not the closely related OOMR substrate, at least 
two possibilities exist: (i) This may reflect fundamental chemical reactivity differences, since the 
benzylic position on BOMR is easier to oxidise than the corresponding position on OOMR 
(Figure 8.11); or (ii) This may reflect enzyme substrate specificity (perhaps BOMR has a higher 
affinity than OOMR for the FAD pocket or the cleft between the FAD and NADPH binding 
domains). Of these two possibilities, the explanation based on differences in chemical reactivity 
seems the more likely a priori, but further experiments would be needed to elucidate the precise 
mechanism of CPR-dependent substrate turnover observed here. 
 
 
Figure 8.11 Structures of FAD, OOMR and BOMR illustrating the similarity between the Flavin and resorufin rings. 
The flavin and resorufin rings are circled in red. The benzylic position in BOMR and the corresponding site of 
oxidation in OOMR are indicated by a blue arrow.  
Reproducibility across the microarray surface 
 
To maximise the number of reactions per slide while minimising printing times, replicate 
reactions are usually printed one after the other in the same area of the slide.  The reproducibility 
between replica reactions printed one after the other, in the same row by the same pin with no 
pin washing steps in between them, was satisfactory and generally showed median CVs < 15%.  
These median CVs were similar to CVs observed for replica spots in previous work on the P450 
Biochip [473]. Much higher variation occurred between replicate reactions further apart on the 
slide surface including both high intra- and inter-sub-array variation. This poor reproducibility 




would be problematic for testing CYP450 variants as it may lead to apparent differences in 
activity, which are in fact an artefact of printing.  
 
Previously, spot reproducibility across the entire slide surface was tested using biotinylated-Cy5-
BSA: after the fluorescent protein was printed across the entire slide surface, the slide was 
washed and scanned. CVs across the slide surface were satisfactory; however, importantly if 
spots are saturated with biotinylated protein during printing, this assay is in fact testing the 
variation in protein binding capacity across the surface and spot morphology rather than printing 
reproducibility, which becomes much more critical when substrates are printed onto the slide for 
kinetic studies. The CVs of a fluorescent standard printed across the whole slide, with the same 
pin and the same wash steps as the assay, would serve as a better measure of printing 
reproducibility in the future.   
Is the detection of CPR mediated CYP450 activity from co-immobilised proteins on array surface 
actually plausible?  
 
Surface characterisation of biotinylated CYP3A4 and CPR co-immobilised onto the streptavidin-
derivatised PEG-coated slide, carried out by a Master’s student in our laboratory, provided 
valuable information on the density of streptavidin on the surface and hence the protein binding 
capacity within each microarray spot [594]. Atomic force microscopy (AFM) topographical 
images revealed white spots 23 to 25 nm in diameter, corresponding to the expected size of 
several biotinylated CYP450/CPR proteins bound to a streptavidin tetramer.  There were an 
average of 200 streptavidin molecules per µm2 of slide surface and the distance between 
molecules was ~50 nm. Each droplet printed onto the slide had a volume of ~ 10 nl and a spot 
area of ~ 70 000 µm2. Consequently, there were about 14 million streptavidin molecules per 
reaction, providing ~ 56 million binding sites for biotinylated proteins to bind to (4 binding sites 
per streptavidin molecule). In the best case theoretical scenario, where 2 active P450 molecules 
and 2 active CPR molecules bind to each streptavidin molecule, the effective P450 concentration 
in each 10 nl spot would therefore be ~ 4 nM; in reality it is likely to be lower than this as 
catalytically inactive apo-protein and P420 protein present in the CYP3A4 protein samples will 
also bind to streptavidin.  
 
Based on an estimate of total CYP3A4 protein within the partly purified sample from a protein 
gel and P420:P450 ratios from CO spectral binding assays, P420 made up ~ 4% and apo protein 




~ 25 % of the total CYP3A4 protein in the sample and apo protein made up ~ 50 % of the 
CYP2C9 protein (Chapter 5). Taking this into account, 2- 3 nM is probably a more accurate 
estimate of the effective P450 concentration in each 10 nl spot.  If CYP3A4 forms oligomers in 
solution, as discussed in Chapters 6 and 7, it is likely that P450 also binds as oligomers to the 
streptavidin surface. This would serve to increase the protein concentration within each spot but 
would only increase substrate turnover if more than one P450 in each oligomer was in an active 
conformation and able to interact with CPR.  
 
Based on the CuOOH mediated solution-phase CYP3A4 assays for the turnover of DBOMF, a 2 
nM protein concentration on the array surface should result in a Vmax of between 0.5 and 1.2 
nM/min. This is well within the range of detection of the microarray scanner and should be 
above the background signal, provided there is no P450 independent substrate turnover. Indeed, 
work done in parallel has shown CuOOH mediated CYP3A4 and CYP2C9 activity for 
robotically printed arrays [594]. Based on kcat values from solution phase assays, the observed 
activity in these assays would require ~3.5 nM CYP3A4 and ~0.5 nM CYP2C9 protein in each 
reaction spot on the surface.   Keeping in mind that there is no CPR in these assays, this is well 
within the predicted binding capacity of the surface. 
 
Promising preliminary results have also shown CPR mediated CYP3A4 activity in hand spotted 
arrays, using the DBOMF substrate and confocal microscopy for detection [594]. The spot area 
and spot volume for hand spotted arrays is ~ 50 times that of robotically printed arrays, giving an 
effective working concentration similar to that of a printed array (hand-spotted droplets had a 
volume of 500 nl and yielded spots ~ 2 mm in diameter). Based on the corresponding solution 
phase activity assay, the observed activity in the hand-spotted array would require a ~ 10 nM 
CYP3A4 concentration in each reaction - while this is higher than the predicted 2 to 3 nM 
binding capacity it is still within an order of magnitude. 
 
Based on these experiments and calculations, it seems reasonable to conclude that the 
streptavidin-coated microarray surface has sufficient binding capacity to enable the detection of 
CPR-mediated CYP450 turnover in both hand-spotted and robotically printed arrays. The next 
question is therefore whether the proximity and relative orientation of CYP450 and CPR on the 
array surface allows for productive interactions, enabling electron transport between the redox 
partners.  




The cut-off distance generally used to identify interacting residues at the interface of two 
proteins is 4.5 Å [599-601]. This suggests that the CPR and CYP450 protein need to move to 
within at least 4.5 Å of each other to allow for the formation of the transient CPR:CYP450 
complex. A crude in silico model of the CYP3A4 and CPR constructs immobilised to a surface 
by the C‐terminal BCCP‐tags gave an optimal distance of 87 Å between biotinylated Lys122 
residues on each protein (Figure 8.12) [473]. However, the average distance between the edges 
of spots consisting of immobilised streptavidin molecules and bound CPR/CYP450 protein was 
500 Å according to AFM images, so it seems unlikely that electron transfer between proteins 
attached to separate streptavidin tetramers could occur without substantial changes in the 
orientation of the PEG polymers.  
 
 
Figure 8.12 In silico model of CYP3A4 and CPR immobilised to a surface via a C-terminal BCCP tag (Figure from 
[473]) 
 
Following on from this, at the surface densities of streptavidin complexes measured by AFM, the 
transient CPR:CYP450 complex required for electron transport is only likely to form from 
proteins bound to the same streptavidin molecule. Figure 8.13 shows the tetrameric structure of 
streptavidin, made up of two dimers, with a biotin molecule bound to each of the four subunits. 




The distance between the carboxyl groups of the biotin molecules bound to adjacent subunits is ~ 
20 Å for biotin molecules bound to different dimers (Figure 8.13 B) and ~ 30 Å for biotin 
molecules bound within the same dimer (Figure 8.13 C).  The carboxyl groups of biotin 
molecules bound to adjacent subunits in different dimers are facing towards each other, 
facilitating the interaction between proteins attached at these points. In contrast, the carboxyl 
groups of biotin molecules within the same dimer are facing away from each other and 
obstruction by the subunits may sterically hinder any interaction between proteins attached at 
these positions.  
 
 
Figure 8.13 A) Structure of a streptavidin tetramer with a biotin molecule bound to each of the four subunits, PDB 
structure 3RY2. The distance between the carboxyl groups of biotin molecules bound to adjacent sub-units is shown 
by a dashed line. B) Close up view of biotin molecules bound to subunits on separate dimers with carboxyl groups 
facing towards each other separated by a distance of 18.7 Å. C) Close up view of the distance between biotin 
molecules bound to subunits within a dimer with carboxyl groups facing away from each other separated by a 
distance of 30 Å.  
 
There is still debate around whether biotin binds to streptavidin cooperatively, with some studies 
suggesting cooperative binding and others suggesting non-cooperative binding [602-604]. A 
study by Gonzalez et al suggests that biotin binding causes structural cooperativity between 
subunits, without substantial changes to the binding affinity of the remaining binding sites [584]. 
There is also evidence that steric hindrance between biotinylated molecules can affect binding, 
leading to a decrease in the occupancy of biotin binding sites [605, 606]; this has led to the 
design of biotin homologs with longer spacer arms e.g. sulfo-NHS-LC-LC-biotin and NHS-
PEG12-biotin. The BCCP-tag has a diameter of 25 - 30 Å, so the binding of BCCP-tags with 
bulky proteins attached at the two adjacent biotin sites, 20 Å apart, may be unfavourable due to 
steric hindrance.  If this is the case, interaction between a CPR and CYP450 molecule bound to 




the same streptavidin molecule may not occur unless oligomer formation allows proteins bound 
to subunits within the same dimer to interact. It is interesting in this regard that the data of Nair, 
2014 suggests that CYP3A4, but not CYP2C9 or CYP2D6, can reconstitute activity with CPR on 
the array surface, possibly implying different oligomeric states of these CYP450s.  
 
Further experimental work is therefore required to determine the quaternary structure of CPR 
and CYP3A4 in solution as well as the ratio of bound biotinylated proteins to streptavidin. In 
addition, hand-spotted microarrays need to be repeated with more data points and further 
negative controls to confirm that the apparent CPR-dependent CYP3A4 turnover of DBOMF on 
the array surface is reproducible.  
Conclusion 
 
In summary, while the P450 microarray platform in principle offers an attractive alternative to 
time, reagent and labour intensive solution phase assays, there are in practice a number of issues 
that need to be addressed before this platform can be used to reliably test the effect of 
polymorphic variation on drug metabolism. In particular, before the CYP450 microarray 
platform can be used as a quantitative tool to obtain kinetic data for CPR-mediated CYP450 
activity a method is needed to prevent evaporation from the array surface, the relative orientation 
of CPR and CYP450 on the array surface need to be optimised, printing reproducibility needs to 
be improved and suitable CYP450 substrates and detection methods compatible with continuous 
assay measurements need to be established.   





8.4.1 Testing CPR activity 
 
The activity of the solution-phase N-terminal truncated CPR protein was tested using a 
continuous spectrophotometric assay based on the reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium Bromide (MTT) to blue-formazan [591].  1 ml reaction mixtures consisted 
of 20 nM CPR (concentration estimated from Bradford assays together with a protein gel of the 
solution-phase CPR protein preparations) and varying concentrations of MTT (0.1 -500 nM) in 
100mM potassium phosphate buffer pH 7.4. The reactions were carried out in disposable plastic 
cuvettes and initiated by the addition of a NADPH regenerating system (0.5 mM NADP+, 5 mM 
glucose 6‐phosphate and 0.5 U/ml glucose-6‐phosphate dehydrogenase final concentrations). 
The cuvettes were inverted several times, placed in a Varian Cary 50 UV Visible 
spectrophotometer (Varian, Australia) and the absorbance at 610 nm was monitored for 1 min to 
determine the rate of MTT reduction.   
8.4.2 Testing the effect of glycerol and sucrose concentrations on CYP3A4 DBOMF 
turnover and ketoconazole inhibition 
 
A 10 mM ketoconazole stock solution was prepared in 100% methanol and a serial dilution in 
100 mM potassium phosphate solution, pH 7.4 was performed to obtain a 1µM ketoconazole 
working stock solution. The ketoconazole solution became cloudy when it was diluted with 
buffer so the absorbance of the 10 µM stock in buffer was compared to a 10 µM stock in 100% 
methanol to account for any precipitation that occurred on dilution into an aqueous solution. The 
precipitation in the aqueous solution only decreased the expected concentration by 20%.   
 
Activity assays were carried out as described in Chapter 7 section 7.4.1 with the following 
amendments: Each 100 µl reaction contained final concentrations of 8µM DBOMF substrate, 
75nM CYP3A4, 0.5 mM CuOOH and 0% to 60% (v/v) glycerol or sucrose in 100 mM 
potassium phosphate buffer pH 7.4 and was carried out in the presence and absence of 100 nM 
ketoconazole. The linear reaction was monitored for 5 min.  




8.4.3 Preparing streptavidin-coated microarray slides 
Preparation of streptavidin solution 
 
 A vial of streptavidin lyophilisate (Prospec, Israel) was equilibrated to RT and dissolved in 1 X 
spotting buffer (100 mM KCl, 0.01% Triton X‐100, 25 mM HEPES pH 8.5) to a stock 
concentration of 10 mg/ml. The solution was mixed by vortexing for 30 min. This stock was 
diluted further in 1X spotting buffer to a working stock solution of 1 mg/ml. The working stock 
can be stored at -20°C and reused numerous times until the solution runs out.  The working stock 
solution was centrifuged before use to remove insoluble particles.  
Preparation of streptavidin-coated slides 
 
A sealed container of Nexterion H slides (Schott, Germany) was removed from -20°C storage 
and equilibrated at room temperature for 1 hour to minimise condensation. The following steps 
were performed with gentle shaking (20-40 rpm) on an orbital shaker to derivatise each slide: 
 
1) 1 hour derivatisation step in 1 mg/ml streptavidin solution 
2) 1 hour blocking step in ethanolamine solution (50 mM ethanolamine in 50 mM potassium 
phosphate buffer, pH 8.0) 
3) 3 ×  5min wash step in 100 mM potassium phosphate buffer, pH 8.0 
4) 5 min wash step in dH2O 
 
Each slide was placed in a 50ml tube dried by centrifugation at 1600 rpm for 5 min at room 
temperature. Slides were stored at -20°C in a sealed container.  
Preparation of Cy5-biotin-BSA 
 
A 10 mg/ml stock solution of BSA (Roche) in PBS pH 7.4 and a 35 mg/ml stock solution of 
(+)-Biotin N-hydroxysuccinimide (NHS) ester in DMSO were prepared. Biotin-NHS was added 
to a tube of BSA stock solution to give a final concentration of 1 mg/ml (i.e. 10 mg BSA to 1 mg 
Biotin) and the tube was wrapped in foil and incubated at RT for 4 h with gentle shaking. ~ 2 mg 
of biotinylated BSA (200 µl) was added to one vial of Cy5 mono-reactive dye (Amersham). The 
vial was vortexed thoroughly to dissolve the dye, wrapped in foil at incubated at RT for 1 h with 




vortexing every 10 min. The sample was added to SigmaSpin Post‐Reaction Purification 
Columns (Sigma Aldrich) to remove free Cy5 and biotin-NHS esters. The total protein in the 
sample was determined by a Bradford assay and the concentration of Cy5 in the sample was 
measured spectrophotometrically (A650, extinction coefficient 0.15 μM‐1.cm‐1).  The dye to 
protein (D/P) molar ratio was determined. A D/P ratio ≥ 2 indicated that the Cy5 labelling was 
sufficient for downstream applications.   
Testing the homogeneity of streptavidin coating across the slide surface 
 
Quality control tests were performed on the first and last slide from each batch of streptavidin-
coated slides.  The slides were equilibrated for 1 h at RT and then immersed in 10 ng/ml Cy5-
biotin-BSA in 1 × spotting buffer for 30 min at RT with gentle shaking. The slides were then 
washed for 3 × 5 min in PBST and 1× 5 min in dH2O, dried by centrifugation at 1600rpm for 5 
min at RT and scanned using the Tecan LS Series Laser Scanner (Tecan Group Ltd., 
Switzerland), λex = 532 nm. This scanner has two lasers;  λex = 532 nm (‘green’) and λex = 635 
nm (‘red’) optimised for Cy3 and Cy5 dyes respectively. There are a range of emission filters 
specific to each laser:  ~ 560 – 590 nm for the “green” dyes and 655 – 695 nm for the ‘red dyes’. 
Using GenePix Pro measuring tools the average fluorescence intensity and the standard deviation 
across the printing area of interest were calculated and used to determine the CV for each slide. 
A CV < 5% within the printing area on the quality control slides was required for downstream 
assays.  
8.4.4 CYP450 microarray assay 
Sample preparation for first and second print rounds  
 
All protein and substrate premixes were prepared on the day of printing; protein samples for the 
first round of printing were prepare in P450 storage buffer and BOMR substrate + NADPH 
premixes and resorufin standards for the second round of printing were prepared in 100mM 
potassium phosphate buffer pH 7.4, 15% (v/v) glycerol. Partially purified CPR and CYP3A4 
protein samples, previously expressed in E.coli (Chapter 5) were used for the microarray assays 
and protein concentrations within the samples were based on the total protein determined by 
Bradford assays rather than P450 content, following the protocol previously established by Dr 




Beeton-Kempen. 20 µl aliquots of each sample for the first and second print rounds were 
pipetted into the relevant wells of a 384‐well Genetix source plate (Genetix Ltd., UK). 
Microarray assay testing CYP3A4 variant activity  
 
The following samples were prepared for the first print round: 10 ng/µl Cy5-biotin BSA; 250 nM 
CPR and a 250 nM 3A4 + 250 nM CPR protein mix for each CYP3A4 protein (WT, K96E, 
P218R, S222P, I223R, L293P and M445T). The following samples were prepared for the second 
print round: a resorufin dilution (1-500 nM) series consisting of 10 standards; 1mM NADPH 
only and 5.7 µM BOMR only for the negative controls; and 12 NADPH-substrate premixes 
consisting of 0.50 – 43.2 µM BOMR and 1mM NADPH.    
 
Microarray assay testing different combination of reaction components to determine the 
components essential for BOMR turnover on the array surface 
 
The following protein samples were prepared for the first print round: 500 nM CPR; 500nM 
CYP3A4 wt; 250 nM 3A4 wt + 250 nM CPR. The following samples were prepared for the 
second print round: a resorufin dilution (1-500 nM) series consisting of 10 standards, 4 substrate 
premixes with and without NADPH (1.1 µM;  2.5 µM; 5.7 µM and 12.8 µM BOMR with and 
without 1mM NADPH)  
Print layouts  
 
16 sub-arrays (4 x 4) were printed onto each slide using 16, solid, flat‐tipped, 300 μm stainless 
steel Telechem pins. The position of the pins in the print head is shown in Figure 8.14 A.  Each 
sub-array consisted of 6 x 12 spots and all spots in each sub-array were printed by the same pin, 
one after the other. This means that the first spot in each sub-array are printed simultaneously.   
The 384-well plate must be set up accordingly to the position of the pins in the pin head. The 
visit numbers for the plate are shown in red and the visit number that is input into the printing 
pattern is based on the wells visited by the first row of pins (pins 1 to 4) e.g. the wells visited by 
pins for visit number 25 are shown in green in Figure 8.14 B. For identical sub-arrays across the 
slide, the same sample should be placed in all 16 wells visited simultaneously by the pin head.  
The slide layout for each assay is shown in Figure 8.15 and Figure 8.16. 




Printing parameters  
The slides were printed with a QArray2 robotic microarrayer (Genetix Ltd.). Print runs were 
carried out at 25°C and the humidity in the printing chamber was set to 50%. The inking time 
and stamp time were set to 500 ms and 0 ms respectively and the maximum stamps per ink was 
1. Three stamps per spot were used in the first print round and one stamps per spot for the second 




Figure 8.14  A) Position of pin in the pin head B) 384 well plate template where each block represents a well. Visit 
numbers are shown in red. The well visited by the 16 pins for visit number 25 are shown in green.  
Assay procedure  
A pack of slides were removed from -20°C storage and equilibrated at RT for 1 h before 
printing. Slides were then removed from the sealed package and dried by centrifugation at 1600 
rpm for 5 min at RT. The 384-well sample plate was loaded and the slide lined up on the print 
bed for the first print run. After the proteins were printed onto the slide, the slide was left on the 
print bed in the printing chamber for 30min to allow the proteins to bind to the surface. The slide 
was then placed in P450 blocking buffer (20 mM potassium phosphate pH 7.4, 0.2 mM EDTA, 
5% (v/v) glycerol, 100 μM biotin, 0.1 mg/ml BSA) on ice with gentle shaking for 15 min. The 
slide was washed for 3 x 5 min in P450 slide wash buffer (20 mM potassium phosphate pH 7.4, 
0.2mM EDTA, 5% (v/v) glycerol,), 5 min in dH2O and dried by centrifugation. The slide was 
then placed back in the same position on the print bed for the second print run where substrate 
premixes were overlaid over the protein spots.  Immediately after the print run ended, the slides 
were removed from the printing chamber placed in the scanner and scanned every 5 to 10 min 
for 45min at 175 PMT. Slides were scanned using the 532 nm excitation laser. Since resorufin 
has an emission wavelength of 585 nm, falling within the range of the emission filters supplied 
with the laser (560 -590 nm). 





Figure 8.15 Print layout for microarray assay testing CYP3A4 variant activity A) The 6x12 layout of protein samples within each sub-array for print round 1 (except sub-arrays 
15 and 16 where variant CYP3A4 spots are replace by P450 storage buffer only spots for ‘no protein’ negative controls). P450 storage buffer spots between each protein 
sample were included as no “protein controls” at each substrate concentration and as controls for protein carry over. B) The layout of substrate premixes and resorufin standards 
for print round 2. A different substrate concentration or control (BOMR premix) was used in each sub-array. C) The 4x4 sub-array layout on the slide; BOMR concentrations 
0.5 – 43.2 µM in sub-arrays 1 to 12 with additional controls in sub-arrays 13 to 16.  





Figure 8.16  Print layout for microarray assay testing CYP3A4 variant activity A) The 6x12 layout of protein samples within each sub-arrays 1 to 4 and 9 to12 for print round 1. 
All spots in sub-arrays 5 to 8 and 13 to16 were P450 storage buffer only.  B) The layout of substrate premixes and resorufin standards for print round 2. Resorufin standards 1 
to 10 were printed in the last two rows of sub-arrays 1 to 10 with 1nM resorufin in sub-array 1 and 500 nM resorufin in sub-array 10. C) The 4x4 sub-array layout on the slide; 






The fluorescent signal from the slides was captured using GenePix Pro 6.1.0.4 microarray 
software (Axon Instruments Inc., US). A circular feature finder with a diameter of 150 µm (for 
the first microarray assay) or 170 µm (for the second microarray assay) was used to define the 
spot sizes. The median background intensity for each spot was measured in the local area around 
the spot within 3 feature diameters from the centre of the spot excluding the first 6 pixels 
surrounding the spot. The median background intensity was subtracted from the median 
fluorescent signal for each spot. The corrected median fluorescent signal was averaged across 
replicate spots at each time point and the standard deviations were calculated. Velocity graphs 
were plotted using the averaged values and RFU/min was converted to nM/min using the 
resorufin standard curve (the standard curve was stable over the 45 min period of the assay). The 
median % CV across all time points was calculated for each reaction (median average standard 
deviation across all time points divided by the median average fluorescent signal across all time 
points).   
8.4.5 Testing fluorescent substrates in solution for NADPH-CPR mediated CYP450 
turnover 
 
The turnover of CYP3A4 Vivid substrates BOMR and DBOMF and CYP2C9 Vivid substrates 
BOMF and OOMR by different combination of reaction components was tested in 96 well plates 
Activity assays were carried out as described in Chapter 7 section 7.4.1 using partially purified 
protein samples. Protein concentrations were based on total protein as measured by Bradford 
assay. The following reactions were carried out for each substrate: 1) 5.7 µM Vivid substrate, 
1mM NADPH; 2)  5.7 µM Vivid substrate; 3)  250 nM CYP3A4 or CYP2C9, 250 nM CPR, 5.7 
µM Vivid substrate, 1mM NADPH; 4) 250 nM CYP3A4 or CYP2C9, 250 nM CPR, 5.7 µM 
Vivid substrate; 5) 250 nM CYP3A4 or CYP2C9, 5.7 µM Vivid substrate, 0.5 mM CuOOH; 6) 
250 nM CYP3A4 or CYP2C9, 5.7 µM Vivid substrate, 1mM NADPH; 7) 250 nM CYP3A4 or 
CYP2C9, 5.7 µM Vivid substrate; 8) 250nM CPR, 5.7 µM Vivid substrate, 1mM NADPH; 9)  
250nM CPR, 5.7 µM Vivid substrate.  All reactions were carried out in 100 mM potassium 











The aims of this Thesis were to develop in silico and in vitro approaches for determining the 
effect of non-synonymous mutations on CYP450 stability and function, with the intention of 
providing new cost effective ways to studying the effect of polymorphic variation on CYP450-
mediated drug metabolism in the pre-clinical stages of drug testing.  
 
An initial goal was to study CYP450 structure-functions relationships in silico, defining regions 
of the protein structure important for different aspects of CYP450 function. In collaboration with 
the group of Prof Chun Wei (University of Singapore), a new expanded mammalian CYP450 
substrate recognition site map was generated based on molecular interactions identified in ligand 
bound crystal structures and docking complexes.  In addition, using static crystal structures and 
the computational tools CAVER and Protein Interaction Calculator, this Thesis describes the 
identification of the largest set of tunnel-gating residues reported to date.   
 
Following this, a structural alignment of the 9 major human drug metabolising CYP450s was 
annotated with substrate recognition sites, gating residues, CPR contact residues (based on 
previous study from the Blackburn group), haem contact residues and conserved motifs, as well 
as the positions of 348 SNPs found in these enzymes.  While this alignment gives a good 
overview of the structure-function relationship in CYP450s, CYP450s are complex enzymes and 
the molecular mechanisms underlying oligomer formation and protein flexibility are still poorly 
understood and thus it is difficult to predict the effects of mutations on these latter aspects of 
enzyme function. In addition, substrate recognition site and gating residues are not necessarily 
important for the access and binding of all potential substrates and consequently mutations at 
these positions are likely to display substrate specific effects.   
 
The representative computational tool SDM was used to calculate the effect of each SNP on 
protein stability. While there is a selection of tools available for predicting deleterious mutations, 
they are not able to quantitatively predict the effect of mutations on ligand binding; as such, 
SDM was used to determine the effect of mutations on the stability of the apo protein structure 
only. These stability calculations were then combined with the functional analyses to take the 
effects of mutations on haem incorporation, ligand binding and CYP450-CPR complex 
formation into account. The resultant CYP450 SNP Map was then compared with experimental 
data to establish the main causes of altered drug metabolism observed for CYP450 variants in 





surprisingly good predictive capability, highlighting the value of combining detailed structure-
function analysis with protein stability data to predict the effect of mutations on enzyme activity. 
The data obtained should be useful to researchers and clinicians a like since it serves as a useful 
guide for selecting CYP450 variants for in vitro testing, for rationalising new in vitro and clinical 
data, and for predicting the effect of uncharacterised variants on drug metabolism. 
 
Following the in silico analysis, nine CYP3A4 and eight CYP2C9 variants including the wild-
types, were expressed in E.coli for in vitro testing.  The N-terminal membrane binding region 
was removed allowing for soluble expression in the cytosolic fraction and a His-tag and BCCP-
tag were included on the C-terminus of each construct for downstream purification and surface 
immobilisation. While soluble expression levels and P450:P420 ratios varied substantially 
between variant proteins, sufficient holoprotein P450 protein was obtained for downstream 
application for all 17 constructs.    
 
The data from thermostability assays suggests that CYP3A4 and CYP2C9 proteins exist as 
heterogeneous populations of distinct conformers in solutions and that single point mutations can 
shift the equilibrium between these conformers. In addition, these assays suggest that mutations 
may affect protein stability by disrupting haem binding or altering oligomer formation.  Further 
studies are, however, required to confirm that the observed conformation heterogeneity is a result 
of oligomer formation and to determine the quaternary structure of the CYP3A4 and CYP2C9 
constructs. Two thirds of the variants showed significantly altered thermostability compared to 
the corresponding wild-type protein and all variants predicted to alter protein function by 
stabilising or destabilising the apo-protein structure in silico were found to significantly alter the 
thermostability of the holoprotein in solution.  
 
CuOOH driven fluorescent-based kinetic assays revealed atypical kinetic profiles for both of the 
CYP3A4 substrates and one of the two CYP2C9 substrates tested. Various kinetic models 
involving a combination of kinetically distinct conformers and the binding of more than one 
substrate in the active site leading to substrate inhibition were proposed, but despite this, fitting 
curves to some of the data was not possible. Inclusion of 15% glycerol in the reaction mixtures 
generally increased the rate of substrate turnover and gave kinetic profiles that more closely 
resembled those observed for membrane bound proteins. The kinetic data obtained for CYP3A4 





and/or binding affinity for the substrates tested compared to the wild-type proteins and revealed 
two previously uncharacterised variants with altered function.  
One of the original aims of this work was to explore the use of a CYP450 protein microarray 
platform, previously developed in the Blackburn laboratory, to test the catalytic activity of the 
panel of CYP3A4 and CYP2C9 variants in parallel. Unfortunately, the results described in this 
Thesis epitomise the numerous challenges surrounding miniaturised high-throughput CYP450 
platforms and suggest that the platform, in its current form, cannot provide accurate data on 
CYP450 turnover.  While this Thesis appears to shed a more pessimistic light on the utility of the 
microarray platform than previously reported [473, 594], it raises important concerns about the 
reliability of the data generated that should be taken into account going forward.  The results 
reported here raise questions as to the theoretical feasibility of CPR-mediated CYP450 activity 
on the array surface and highlight the need to explore enzyme encapsulation techniques to 
prevent evaporation, as well as alternative substrates and/or metabolite detections techniques.  
 
Finally, this Thesis uncovers a previously unrecognised catalytic activity of CPR in efficiently 
turning over the commonly used BOMR Vivid Red CYP3A4 substrate and testable mechanisms 
to account for this apparently paradoxical redox activity (i.e. CPR is a reductase, yet product 







 Sequence alignments annotated with CYP450 ligand contacts Appendix A.
 
CYP2C4Rab             ---------------MDPVAGLVLGLCCLLLLS---------LWKQNSGRGKLPPGPTPFPIIG--------NILQ------IDVKDISKSLTKFSERYGPVFTVYLGM-KPTVVLHGYK 
CYP2C5Rab             ---------------MDPVVVLVLGLCCLLLLS---------IWKQNSGRGKLPPGPTPFPIIG--------NILQ------IDAKDISKSLTKFSECYGPVFTVYLGM-KPTVVLHGYE 
CYP2C9Hum             ---------------MDSLVVLVLCLSCLLLLS---------LWRQSSGRGKLPPGPTPLPVIG--------NILQ------IGIKDISKSLTNLSKVYGPVFTLYFGL-KPIVVLHGYE 
CYP2C19Hum            ---------------MDPFVVLVLCLSCLLLLS---------IWRQSSGRGKLPPGPTPLPVIG--------NILQ------IDIKDVSKSLTNLSKIYGPVFTLYFGL-ERMVVLHGYE 
CYP2C8Hum             ---------------MEPFVVLVLCLSFMLLFS---------LWRQSCRRRKLPPGPTPLPIIG--------NMLQ------IDVKDICKSFTNFSKVYGPVFTVYFGM-NPIVVFHGYE 
CYP2C2Rab             ---------------MDLVVVLGLCLSCLLLPS---------LWKQSHGGGKLPPGPTPFPILG--------NVLQ------LDFKDLSKSLTNLSKVYGPVFTVYLGM-KPTVVVHGYE 
CYP2C3Rab             ---------------MDLLIILGICLSCVVLLS---------LWKKTHGKGKLPPGPTPLPVVG--------NLLQ------LETKNINKSLSMLAKEYGSIFTLYFGM-KPAVVLYGYE 
CYP2C21Dog            ------------------FIVLVICLSCLISFF---------LWNQNRAKGKLPPGPTPLPIIG--------NILQ------INTKNVSKSLSKLAENYGPVFTVYFGM-KPTVVLYGYE 
CYP2E1Hum             ------------MSALGVTVALLVWAAFLLLVS---------MWRQVHSSWNLPPGPFPLPIIG--------NLFQ------LELKNIPKSFTRLAQRFGPVFTLYVGS-QRMVVMHGYK 
CYP2A4Mou             -----------MLTSGLLLVAAVAFLSVLVLMS---------VWKQRKLSGKLPPGPTPLPFVG--------NFLQ------LNTEQMYNSLMKISQRYGPVFTIYLGS-RRIVVLCGQE 
CYP2A5Mou             -----------MLTSGLLLVAAVAFLSVLVLMS---------VWKQRKLSGKLPPGPTPLPFIG--------NFLQ------LNTEQMYNSLMKISQRYGPVFTIYLGP-RRIVVLCGQE 
CYP2A6Hum             -----------MLASGMLLVALLVCLTVMVLMS---------VWQQRKSKGKLPPGPTPLPFIG--------NYLQ------LNTEQMYNSLMKISERYGPVFTIHLGP-RRVVVLCGHD 
CYP2A13Hum            -----------MLASGLLLVTLLACLTVMVLMS---------VWRQRKSRGKLPPGPTPLPFIG--------NYLQ------LNTEQMYNSLMKISERYGPVFTIHLGP-RRVVVLCGHD 
CYP2A1Rat             -----------MLDTGLLLVVILASLSVMLLVS---------LWQQ-KIRGRLPPGPTPLPFIG--------NYLQ------LNTKDVYSSITQLSERYGPVFTIHLGP-RRVVVLYGYD 
CYP2G1Rat             -----------MALGGAFSIFMTLCLSCLLILI---------AWKRTSRGGKLPPGPTPIPFLG--------NLLQ------VRIDATFQSFLKLQKKYGSVFTVYFGP-RPVVILCGHE 
CYP2B1Rat             -----------MEPT---ILLLLALLVGFLLLL---------VRGHPKSRGNFPPGPRPLPLLG--------NLLQ------LDRGGLLNSFMQLREKYGDVFTVHLGP-RPVVMLCGTD 
CYP2B2Rat             -----------MEPS---ILLLLALLVGFLLLL---------VRGHPKSRGNFPPGPRPLPLLG--------NLLQ------LDRGGLLNSFMQLREKYGDVFTVHLGP-RPVVMLCGTD 
CYP2B4Rab             -----------MEFS---LLLLLAFLAGLLLLL---------FRGHPKAHGRLPPGPSPLPVLG--------NLLQ------MDRKGLLRSFLRLREKYGDVFTVYLGS-RPVVVLCGTD 
CYP2B5Rab             -----------MEFS---LLLLLAFLAGLLLLL---------FRGHPKAHGRLPPGPPPLPVLG--------NLLQ------MDRKGLLRSFLRLREKYGDVFTVYLGS-RPVVVLCGTD 
CYP2B6Hum             -----------MELS---VLLFLALLTGLLLLL---------VQRHPNTHDRLPPGPRPLPLLG--------NLLQ------MDRRGLLKSFLRFREKYGDVFTVHLGP-RPVVMLCGVE 
CYP2B11Dog            -----------MELS---VLLLLALLTGLLLLM---------ARGHPKAYGHLPPGPRPLPILG--------NFLQ------MDRKGLLKSFLRLQEKYGDVFTVYLGP-RRTVMLCGID 
CYP2S1Hum             -----------MEATG-TWALLLALALLLLLTL---------ALSGTRARGHLPPGPTPLPLLG--------NLLQ------LRPGALYSGLMRLSKKYGPVFTIYLGPWRPVVVLVGQE 
CYP2F1Hum             -----------MDSISTAILLLLLALVCLLLTL------------SSRDKGKLPPGPRPLSILG--------NLLL------LCSQDMLTSLTKLSKEYGSMYTVHLGP-RRVVVLSGYQ 
CYP2T1Rat             ------------MVTCEATLLLLLILTLMLMSWGWL-----AHQARARMQKDLPPGPAPLPLLG--------NLLQ------LQSGHLDRVLMELSSRWGPVFTVWLGP-RPAVVLSGYA 
CYP2D1Rat             --------MELLNGTGLWSMAIFTVIFILLVDLMHR---------RHRWTSRYPPGPVPWPVLG--------NLLQ------VDLSNMPYSLYKLQHRYGDVFSLQKGW-KPMVIVNRLK 
CYP2D6Hum             -----------MGLEALVPLAVIVAIFLLLVDLMHR---------RQRWAARYPPGPLPLPGLG--------NLLH------VDFQNTPYCFDQLRRRFGDVFSLQLAW-TPVVVLNGLA 
CYP2J2Hum             ----------MLAAMGSLAAALWAVVHPRTLLLGTVAFLLAADFLKRRRPKNYPPGPWRLPFLG--------NFF--L----VDFEQSHLEVQLFVKKYGNLFSLELGD-ISAVLITGLP 
CYP2R1Hum             --------MWKLWRAEEGAAALGGALFLLLFALG------VRQLLKQRRPMGFPPGPPGLPFIG--------NIYSLA----ASSELPHVYMRKQSQVYGEIFSLDLGG-ISTVVLNGYD 
CYP2W1Hum             --------MALLLLLFLGLLGLWGLLCACAQDPS--------------PAARWPPGPRPLPLVG--------NLHL------LRLSQQDRSLMELSERYGPVFTVHLGR-QKTVVLTGFE 
CYP1A2Hum             ------MALSQSVPFSATELLLASAIFCLVFWVLKG------LRPRVPKGLKSPPEPWGWPLLG--------HVLT-------LGKNPHLALSRMSQRYGDVLQIRIGS-TPVLVLSRLD 
CYP3A4Hum             ---------MALIPDLAMETWLLLAVSLVLLYLYG-------THSHGLFKKLGIPGPTPLPFLG--------NILS-------YHKGFCMFDMECHKKYGKVWGFYDGQ-QPVLAITDPD 
CYP46A1Hum            --------MSPGLLLLGSAVLLAFGLCCTFVHR------------ARSRYEHIPGPPRPSFLLG--------HLPCFWKKDEVGGRVLQDVFLDWAKKYGPVVRVNVFH-KTSVIVTSPE 
CYP11A1Hum            ---------MLAKGLPPRSVLVKGCQTFLSAPREGLGRLRVPTGEGAGISTRSPRPFNEIPSPG---DNGWLNLYHFWR--ETGTHKVHLHHVQNFQKYGPIYREKLGN-VESVYVIDPE 
CYP19A1Hum            MVLEMLNPIHYNITSIVPEAMPAATMPVLLLTG-------LFLLVWNYEGTSSIPGPGYCMGIGPLI---SHG--------RFLWMGIGSACNYYNRVYGEFMRVWISG-EETLIISKSS 








CYP2C4Rab             AVKEALVDLGE-EFAGR---GHFPIAEKVNKGLGIVFT--NANTWKEMRRFSLMTLRNFGMGKRSI-------EDRVQEEARCLVEELRKTNA--LPCDPTFILGCAPCNVICSVILHNR 
CYP2C5Rab             AVKEALVDLGE-EFAGR---GSVPILEKVSKGLGIAFS--NAKTWKEMRRFSLMTLRNFGMGKRSI-------EDRIQEEARCLVEELRKTNA--SPCDPTFILGCAPCNVICSVIFHNR 
CYP2C9Hum             AVKEALIDLGE-EFSGR---GIFPLAERANRGFGIVFS--NGKKWKEIRRFSLMTLRNFGMGKRSI-------EDRVQEEARCLVEELRKTKA--SPCDPTFILGCAPCNVICSIIFHKR 
CYP2C19Hum            VVKEALIDLGE-EFSGR---GHFPLAERANRGFGIVFS--NGKRWKEIRRFSLMTLRNFGMGKRSI-------EDRVQEEARCLVEELRKTKA--SPCDPTFILGCAPCNVICSIIFQKR 
CYP2C8Hum             SVKEALIDNGE-EFSGR---GNSPISQRITKGLGIISS--NGKRWKEIRRFSLTTLRNFGMGKRSI-------EDRVQEEAHCLVEELRKTKA--SPCDPTFILGCAPCNVICSVVFQKR 
CYP2C2Rab             AVKEALVDLGH-ELSGR---SRFLVTAKLNKGFGVIFS--NGKRWTETRRFSLMTLRNFGMGKRSI-------EERVQEEAHCLVEELRKTNA--SPCDPTFILGAAPCNVICSVIFQNR 
CYP2C3Rab             TVKEALIDRGE-EFSGR---GIFPVFDRVTKGLGIVFS--SGEKWKETRRFSLTVLRNLGMGKKTI-------EERIQEEALCLIQALRKTNA--SPCDPTFLLFCVPCNVMCSVIFQNR 
CYP2C21Dog            AVKEALIDRSE-EFSGR---GHFPLLDWTIQGLGIVFS--NGEKWKQTRRFSLTVLRNMGMGKKTV-------EDRIQEEALYLVEALKKTNA--SPCDPTFLLGCAPCNVICSIIFQNR 
CYP2E1Hum             AVKEALLDYKD-EFSGR---GDLPAFH-AHRDRGIIFN--NGPTWKDIRRFSLTTLRNYGMGKQGN-------ESRIQREAHFLLEALRKTQG--QPFDPTFLIGCAPCNVIADILFRKH 
CYP2A4Mou             AVKEALVDQAE-EFSGR---GEQATFDWLFKGYGIAFS--SGERAKQLRSFSIATLRDFGVGKRGI-------EERIQEEAGFLIDSFRKTNG--AFIDPTFYLSRTVSNVISSIVFGDR 
CYP2A5Mou             AVKEALVDQAE-EFSGR---GEQATFDWLFKGYGVVFS--SGERAKQLRRFSIATLRDFGVGKRGI-------EERIQEEAGFLIDSFRKTNG--AFIDPTFYLSRTVSNVISSIVFGDR 
CYP2A6Hum             AVREALVDQAE-EFSGR---GEQATFDWVFKGYGVVFS--NGERAKQLRRFSIATLRDFGVGKRGI-------EERIQEEAGFLIDALRGTGG--ANIDPTFFLSRTVSNVISSIVFGDR 
CYP2A13Hum            AVKEALVDQAE-EFSGR---GEQATFDWLFKGYGVAFS--NGERAKQLRRFSIATLRGFGVGKRGI-------EERIQEEAGFLIDALRGTHG--ANIDPTFFLSRTVSNVISSIVFGDR 
CYP2A1Rat             AVKEALVDQAE-EFSGR---GEQATYNTLFKGYGVAFS--SGERAKQLRRLSIATLRDFGVGKRGV-------EERILEEAGYLIKMLQGTCG--APIDPTIYLSKTVSNVISSIVFGER 
CYP2G1Rat             AVKEALVDQAD-DFSGR---GEMPTLEKNFQGYGLALS--NGERWKILRRFSLTVLRNFGMGKRSI-------EERIQEEAGYLLEELHKVKG--APIDPTFYLSRTVSNVICSVVFGKR 
CYP2B1Rat             TIKEALVGQAE-DFSGR---GTIAVIEPIFKEYGVIFA--NGERWKALRRFSLATMRDFGMGKRSV-------EERIQEEAQCLVEELRKSQG--APLDPTFLFQCITANIICSIVFGER 
CYP2B2Rat             TIKEALVGQAE-DFSGR---GTIAVIEPIFKEYGVIFA--NGERWKALRRFSLATMRDFGMGKRSV-------EERIQEEAQCLVEELRKSQG--APLDPTFLFQCITANIICSIVFGER 
CYP2B4Rab             AIREALVDQAE-AFSGR---GKIAVVDPIFQGYGVIFA--NGERWRALRRFSLATMRDFGMGKRSV-------EERIQEEARCLVEELRKSKG--ALLDNTLLFHSITSNIICSIVFGKR 
CYP2B5Rab             AIREALVDQAE-AFSGR---GKIAVVDPIFQGYGVFFA--NGEHWRALRRFSLATMRDFGMGKRSV-------EERIQEEARCLVEELRKSKG--ALLDNTLLFHSVTSNIICSIVFGKR 
CYP2B6Hum             AIREALVDKAE-AFSGR---GKIAMVDPFFRGYGVIFA--NGNRWKVLRRFSVTTMRDFGMGKRSV-------EERIQEEAQCLIEELRKSKG--ALMDPTFLFQSITANIICSIVFGKR 
CYP2B11Dog            AIREALVDNAE-AFSGR---GKIAVVEPVFQGYGVVFA--NGERWKTLRRFSLATMRDFGMGKRSV-------EERIQEEAQCLVEELRKTEG--VLQDPTFFFHSMTANIICSIVFGKR 
CYP2S1Hum             AVREALGGQAE-EFSGR---GTVAMLEGTFDGHGVFFS--NGERWRQLRKFTMLALRDLGMGKREG-------EELIQAEARCLVETFQGTEG--RPFDPSLLLAQATSNVVCSLLFGLR 
CYP2F1Hum             AVKEALVDQGE-EFSGR---GDYPAFFNFTKGNGIAFS--SGDRWKVLRQFSIQILRNFGMGKRSI-------EERILEEGSFLLADVRKTEG--EPFDPTFVLSRSVSNIICSVLFGSR 
CYP2T1Rat             ALRDALVLQAD-AFSGP---RVHGCLRTLTHGNGIVFS--NGPALATLRTLHLNTEELR--GSSTI-------EERILEETACVLDEFQATMG--APFDPRRLLDNAVSNVICTVVFGKR 
CYP2D1Rat             AVQEVLVTHGE-DTADRPPVPIFKCLGVKPRSQGVILAS-YGPEWREQRRFSVSTLRTFGMGKKSL-------EEWVTKEAGHLCDAFTAQAG--QSINPKAMLNKALCNVIASLIFARR 
CYP2D6Hum             AVREALVTHGE-DTADRPPVPITQILGFGPRSQGVFLAR-YGPAWREQRRFSVSTLRNLGLGKKSL-------EQWVTEEAACLCAAFANHSG--RPFRPNGLLDKAVSNVIASLTCGRR 
CYP2J2Hum             LIKEALIHMDQ-NFGNRPVTPMREHI---FKKNGLIMS--SGQAWKEQRRFTLTALRNFGLGKKSL-------EERIQEEAQHLTEAIKEENG--QPFDPHFKINNAVSNIICSITFGER 
CYP2R1Hum             VVKECLVHQSE-IFADRPCLPLFMKM---TKMGGLLNSR-YGRGWVDHRRLAVNSFRYFGYGQKSF-------ESKILEETKFFNDAIETYKG--RPFDFKQLITNAVSNITNLIIFGER 
CYP2W1Hum             AVKEALAGPGQ-ELADRPPIAIFQLIQ---RGGGIFFS--SGARWRAARQFTVRALHSLGVGREPV-------ADKILQELKCLSGQLDGYRG--RPF-PLALLGWAPSNITFALLFGRR 
CYP1A2Hum             TIRQALVRQGD-DFKGR---PDLYTSTLITDGQSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELMAGPGHFDPYNQVVVSVANVIGAMCFGQH 
CYP3A4Hum             MIKTVLVKECYSVFTNR---RPFGPVGFMKSAISIAED----EEWKRLRSLLSPTFTSGKLKEMVP---------IIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVN 
CYP46A1Hum            SVKKFLMSTKY-NKDSKMYRALQTVFGERLFGQGLVSEC-NYERWHKQRRVIDLAFSRSSLVSLMET---------FNEKAEQLVEILEAKADGQTPVSMQDMLTYTAMDILAKAAFG-- 
CYP11A1Hum            DVALLFKSEGP-NPERFLIPPWVAYHQYYQRPIGVLLK--KSAAWKKDRVALNQEVMAPEATKNFLP----LLDAVSRDFVSVLHRRIKKAGSGNYSGDISDDLFRFAFESITNVIFGER 
CYP19A1Hum            SMFHIMKHNHYSSRFGS----KLGLQCIGMHEKGIIFNN-NPELWKTTRPFFMKALSGPGLVRMVT---------VCAESLKTHLDRLEEVTNESGYVDVLTLLRRVMLDTSNTLFLR-- 
CYP8A1Hum             YDAVVWEPRTRLDFHAY----AIFLMERIFDVQLPHYSP-SDEKARMKLTLLHRELQALTEAMYTN------LHAVLLGDATEAGSGWHEMGL--LDFSYSFLLRAGYLTLYGIEALPRT 















CYP2C4Rab             FDYKDEEFLKLMERLNENIRILSS----PWLQVYN----NFPALLDYFPGIHKTLLKNA-DYTKNFIMEKVKEHQKLLDVNNP-RDFIDCFLIKMEKENN---LEFTLGSLVIAVFDLFG 
CYP2C5Rab             FDYKDEEFLKLMESLNENVRILSS----PWLQVYN----NFPALLDYFPGIHKTLLKNA-DYIKNFIMEKVKEHQKLLDVNNP-RDFIDCFLIKMEQENN---LEFTLESLVIAVSDLFG 
CYP2C9Hum             FDYKDQQFLNLMEKLNENIKILSS----PWIQICN----NFSPIIDYFPGTHNKLLKNV-AFMKSYILEKVKEHQESMDMNNP-QDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFG 
CYP2C19Hum            FDYKDQQFLNLMEKLNENIRIVST----PWIQICN----NFPTIIDYFPGTHNKLLKNL-AFMESDILEKVKEHQESMDINNP-RDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLG 
CYP2C8Hum             FDYKDQNFLTLMKRFNENFRILNS----PWIQVCN----NFPLLIDCFPGTHNKVLKNV-ALTRSYIREKVKEHQASLDVNNP-RDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFV 
CYP2C2Rab             FDYTDQDFLSLMGKFNENFKILNS----PWVQFCN----CFPILFDYFPGSHRKAVKNI-FYVKNYITEQIKEHQKSLDINNP-RDFIDCFLIKMEQEKCNQQSEFTIENLLTTVSDVFM 
CYP2C3Rab             FDYDDEKFKTLIKYFHENFELLGT----PWIQLYN----IFP-ILHYLPGSHRQLFKNI-DGQIKFILEKVQEHQESLDSNNP-RDFVDHFLIKMEKEKHKKQSEFTMDNLITTIWDVFS 
CYP2C21Dog            FEYDDKDFLTLLEYFHENLLISST----SWIQLYN----AFPLLIHYLPGSHHVLFKNI-ANQFKFISEKIKEHEESLNFSNP-RDFIDYFLIKIEKEKHNKQSEFTMDNLIITIWDVFS 
CYP2E1Hum             FDYNDEKFLRLMYLFNENFHLLST----PWLQLYN----NFPSFLHYLPGSHRKVIKNV-AEVKEYVSERVKEHHQSLDPNCP-RDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFF 
CYP2A4Mou             FDYEDKEFLSLLRMMLGSLQFTAT----SMGQVYE----MFSSVMKHLPGPQQQAFKEL-QGLEDFITKKVEHNQRTLDPNSP-RDFIDSFLIRMLEEKKNPNTEFYMKNLVLTTLNLFF 
CYP2A5Mou             FDYEDKEFLSLLRMMLGSFQFTAT----SMGQLYE----MFSSVMKHLPGPQQQAFKEL-QGLEDFITKKVEHNQRTLDPNSP-RDFIDSFLIRMLEEKKNPNTEFYMKNLVLTTLNLFF 
CYP2A6Hum             FDYKDKEFLSLLRMMLGIFQFTST----STGQLYE----MFSSVMKHLPGPQQQAFQLL-QGLEDFIAKKVEHNQRTLDPNSP-RDFIDSFLIRMQEEEKNPNTEFYLKNLVMTTLNLFI 
CYP2A13Hum            FDYEDKEFLSLLRMMLGSFQFTAT----STGQLYE----MFSSVMKHLPGPQQQAFKEL-QGLEDFIAKKVEHNQRTLDPNSP-RDFIDSFLIRMQEEEKNPNTEFYLKNLVMTTLNLFF 
CYP2A1Rat             FDYEDTEFLSLLQMMGQMNRFAAS----PTGQLYD----MFHSVMKYLPGPQQQIIKVT-QKLEDFMIEKVRQNHSTLDPNSP-RNFIDSFLIRMQEE-KNGNSEFHMKNLVMTTLSLFF 
CYP2G1Rat             FDYEDQRFRSLMKMINESFVEMSM----PWAQLYD----MYWGVIQYFPGRHNRLYNLI-EELKDFIASRVKINEASFDPSNP-RDFIDCFLIKMYQDKSDPHSEFNLKNLVLTTLNLFF 
CYP2B1Rat             FDYTDRQFLRLLELFYRTFSLLSS----FSSQVFE----FFSGFLKYFPGAHRQISKNL-QEILDYIGHIVEKHRATLDPSAP-RDFIDTYLLRMEKEKSNHHTEFHHENLMISLLSLFF 
CYP2B2Rat             FDYTDRQFLRLLELFYRTFSLLSS----FSSQVFE----FFSGFLKYFPGAHRQISKNL-QEILDYIGHIVEKHRATLDPSAP-RDFIDTYLLRMEKEKSNHHTEFHHENLMISLLSLFF 
CYP2B4Rab             FDYKDPVFLRLLDLFFQSFSLISS----FSSQVFE----LFPGFLKHFPGTHRQIYRNL-QEINTFIGQSVEKHRATLDPSNP-RDFIDVYLLRMEKDKSDPSSEFHHQNLILTVLSLFF 
CYP2B5Rab             FDYKDPVFLRLLDLFFQSFSLISS----FSSQVFE----LFPGFLKHFPGTHRQIYRNL-QEINTFIGQTVEKHRATLDPSNP-RDFIDVYLLRMEKDKSDPSSEFHHRNLILTVLTLFF 
CYP2B6Hum             FHYQDQEFLKMLNLFYQTFSLISS----VFGQLFE----LFSGFLKYFPGAHRQVYKNL-QEINAYIGHSVEKHRETLDPSAP-KDLIDTYLLHMEKEKSNAHSEFSHQNLNLNTLSLFF 
CYP2B11Dog            FGYKDPEFLRLMNLFYVSFALISS----FSSQMFE----LFHSFLKYFPGTHRQVYNNL-QEIKAFIARMVEKHRETLDPSAP-RDFIDAYLIRMDKEKAEPSSEFHHRNLIDTALSLFF 
CYP2S1Hum             FSYEDKEFQAVVRAAGGTLLGVSS----QGGQTYE----MFSWFLRPLPGPHKQLLHHV-STLAAFTVRQVQQHQGNLDASGPARDLVDAFLLKMAQEEQNPGTEFTNKNMLMTVIYLLF 
CYP2F1Hum             FDYDDERLLTIIRLINDNFQIMSS----PWGELYDILDPRFPSLLDWVPGPHQRIFQNF-KCLRDLIAHSVHDHQAS----SP-RDFIQCFLTKMAEEKEDPLSHFHMDTLLMTTHNLLF 
CYP2T1Rat             YNYGDPEFLRLLDLFSDNFRIMSS----RWGETYN----MFPSFMDWIPGPHHRIFKNF-QELRLFISEQIQWHRQSRQTGEP-RDFIDCFLEQMDKEHQDPESHFQDETLVMTTHNLFF 
CYP2D1Rat             FEYEDPYLIRMVKLVEESLTEVSG----FIPEVLN----TFPALLRIP-GLADKVFQGQ-KTFMALLDNLLAENRTTWDPAQPPRNLTDAFLAEVEKAKGNPESSFNDENLRMVVVDLFT 
CYP2D6Hum             FEYDDPRFLRLLDLAQEGLKEESG----FLREVLN----AVPVLLHIP-ALAGKVLRFQ-KAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFS 
CYP2J2Hum             FEYQDSWFQQLLKLLDEVTYLEAS----KTCQLYN----VFPWIMKFLPGPHQTLFSNW-KKLKLFVSHMIDKHRKDWNPAET-RDFIDAYLKEMSKHTGNPTSSFHEENLICSTLDLFF 
CYP2R1Hum             FTYEDTDFQHMIELFSENVELAAS----ASVFLYN----AFPWIGILPFGKHQQLFRNA-AVVYDFLSRLIEKASVNRKPQLP-QHFVDAYLDEMDQGKNDPSSTFSKENLIFSVGELII 
CYP2W1Hum             FDYRDPVFVSLLGLIDEVMVLLGS----PGLQLFN----VYPWLGALL-QLHRPVLRKI-EEVRAILRTLLEARRPHVCPGDPVCSYVDALIQQGQG--DDPEGLFAEANAVACTLDMVM 
CYP1A2Hum             FPESSDEMLSLVKNTHEFVETASSGNPLDFFP-----------ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSV-RDITGALFKHSKKGPRASGNLIPQEKIVNLVNDIFG 
CYP3A4Hum             IDSLNNPQDPFVENTKKLLRFDFLD---PFFLSIT----VFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHR-VDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIF 
CYP46A1Hum            --METSMLLGAQKPLSQAVKLMLEG----ITASRN-------TLAKFLPGKRKQLREVR-ESIRFLRQVGRDWVQRRREALKRGEEVPADILTQILKAEEG---AQDDEGLLDNFVTFFI 
CYP11A1Hum            QGMLEEVVNPEAQRFIDAIYQMFH----TSVPMLN----LPPDLFRLFRTKTWKDHVAAWDVIFSKADIYTQNFYWELRQKGSVHHDYRGILYRLLGD-----SKMSFEDIKANVTEMLA 
CYP19A1Hum            IPLDESAIVVKIQGYFDAWQALLIK----------------PDIFFKISWLYKKYEKSV-KDLKDAIEVLIAEKRRRISTEEKLEECMDFATELILAEKRG---DLTRENVNQCILEMLI 
CYP8A1Hum             HESQAQDRVHSADVFHTFRQLDRL-------------------LPKLARGSLSVGDKDHMCSVKSRLWKLLSPARLARRAHRS--KWLESYLLHLEEMG------VSEEMQARALVLQLW 















CYP2C4Rab             AGTETTSTTLRYSLLLLLKHPEVAARVQEEIERVIGRHRSPCMQDRSH-------MPYTDAVIHEIQRFIDLLPTNLPHAVTRDVKFRN---YFIPKG-TDIITSLTSVLHDEKAFPNPK 
CYP2C5Rab             AGTETTSTTLRYSLLLLLKHPEVAARVQEEIERVIGRHRSPCMQDRSR-------MPYTDAVIHEIQRFIDLLPTNLPHAVTRDVRFRN---YFIPKG-TDIITSLTSVLHDEKAFPNPK 
CYP2C9Hum             AGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSH-------MPYTDAVVHEVQRYIDLLPTSLPHAVTCDIKFRN---YLIPKG-TTILISLTSVLHDNKEFPNPE 
CYP2C19Hum            AGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRGH-------MPYTDAVVHEVQRYIDLIPTSLPHAVTCDVKFRN---YLIPKG-TTILTSLTSVLHDNKEFPNPE 
CYP2C8Hum             AGTETTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSH-------MPYTDAVVHEIQRYSDLVPTGVPHAVTTDTKFRN---YLIPKG-TTIMALLTSVLHDDKEFPNPN 
CYP2C2Rab             AGTETTSTTLRYGLLLLMKHPEVIAKVQEEIERVIGRHRSPCMQDRSR-------MPYTDATVHEIQRYINLIPNNVPHTTICNLKFRN---YLIPKG-TDVLTSLSSVLHDDKEFPNPD 
CYP2C3Rab             AGTDTTSNTLKFALLLLLKHPEITAKVQEEIEHVIGRHRSPCMQDRTR-------MPYTDAVMHEIQRYVDLVPTTLPHAVTQDIEFNG---YLIPKG-TDIIPSLTSVLYDDKEFPNPE 
CYP2C21Dog            AGTETTSTTLRYGLLVLLKHPDVTAKVQEEIHRVVGRHRSPCMQDRSC-------MPYTDAVVHEIQRYIDLVPNNLPHSVTQDIKFRE---YLIPKG-TTILTSLTSVLHDEKGFPNPD 
CYP2E1Hum             AGTETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQE-------MPYMDAVVHEIQRFITLVPSNLPHEATRDTIFRG---YLIPKG-TVVVPTLDSVLYDNQEFPDPE 
CYP2A4Mou             AGTETVSTTLRYGFLLLMKYPDIEAKVHEEIDRVIGRNRQPKYEDRMK-------MPYTEAVIHEIQRFADLIPMGLARRVTKDTKFRD---FLLPKG-TEVFPMLGSVLKDPKFFSNPK 
CYP2A5Mou             AGTETVSTTLRYGFLLLMKHPDIEAKVHEEIDRVIGRNRQPKYEDRMK-------MPYTEAVIHEIQRFADMIPMGLARRVTKDTKFRD---FLLPKG-TEVFPMLGSVLKDPKFFSNPK 
CYP2A6Hum             GGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAK-------MPYMEAVIHEIQRFGDVIPMSLARRVKKDTKFRD---FFLPKG-TEVYPMLGSVLRDPSFFSNPQ 
CYP2A13Hum            AGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAK-------MPYTEAVIHEIQRFGDMLPMGLAHRVNKDTKFRD---FFLPKG-TEVFPMLGSVLRDPRFFSNPR 
CYP2A1Rat             AGSETVSSTLRYGFLLLMKHPDVEAKVHEEIEQVIGRNRQPQYEDHMK-------MPYTQAVINEIQRFSNLAPLGIPRRIIKNTTFRG---FFLPKA-TDVFPILGSLMTDPKFFPSPK 
CYP2G1Rat             AGTETVSSTLRYGFLLLMKYPEVEAKIHEEINQVIGTHRTPRVDDRAK-------MPYTDAVIHEIQRLTDIVPLGVPHNVIRDTHFRG---YFLPKG-TDVYPLIGSVLKDPKYFRYPE 
CYP2B1Rat             AGTETSSTTLRYGFLLMLKYPHVAEKVQKEIDQVIGSHRLPTLDDRSK-------MPYTDAVIHEIQRFSDLVPIGVPHRVTKDTMFRG---YLLPKN-TEVYPILSSALHDPQYFDHPD 
CYP2B2Rat             AGTETGSTTLRYGFLLMLKYPHVTEKVQKEIDQVIGSHRPPSLDDRTK-------MPYTDAVIHEIQRFADLAPIGLPHRVTKDTMFRG---YLLPKN-TEVYPILSSALHDPQYFDHPD 
CYP2B4Rab             AGTETTSTTLRYGFLLMLKYPHVTERVQKEIEQVIGSHRPPALDDRAK-------MPYTDAVIHEIQRLGDLIPFGVPHTVTKDTQFRG---YVIPKN-TEVFPVLSSALHDPRYFETPN 
CYP2B5Rab             AGTETTSTTLRYGFLLMLKYPHVTERVQKEIEQVIGSHRPPALDDRAK-------MPYTDAVIHEIQRLGDLVPFGAPHMVTKDTQFRG---YVIPKN-TEVFPVLSSALHDPRYFETPN 
CYP2B6Hum             AGTETTSTTLRYGFLLMLKYPHVAERVYREIEQVIGPHRPPELHDRAK-------MPYTEAVIYEIQRFSDLLPMGVPHIVTQHTSFRG---YIIPKD-TEVFLILSTALHDPHYFEKPD 
CYP2B11Dog            AGTETTSTTLRYGFLLMLKYPHIAERIYKEIDQVIGPHRLPSLDDRAK-------MPYTDAVIHEIQRFGDLLPIGVPHMVTKDICFRG---YIIPKG-TEVFPILHSALNDPHYFEKPD 
CYP2S1Hum             AGTMTVSTTVGYTLLLLMKYPHVQKWVREELNRELGAGQAPSLGDRTR-------LPYTDAVLHEAQRLLALVPMGIPRTLMRTTRFRG---YTLPQG-TEVFPLLGSILHDPNIFKHPE 
CYP2F1Hum             GGTKTVSTTLHHAFLALMKYPKVQARVQEEIDLVVGRARLPALKDRAA-------MPYTDAVIHEVQRFADIIPMNLPHRVTRDTAFRG---FLIPKG-TDVITLLNTVHYDPSQFLTPQ 
CYP2T1Rat             GGTETTSTTLRYGLLIMLKYPEVAAKVQEELDATVGRTRAPSLADRAH-------LPYTNAVLHEIQRFISVLPLGLPRALIRDVNLRN---HFLHKG-TFVIPLLVSAHRDPTQFKDPD 
CYP2D1Rat             AGMVTTATTLTWALLLMILYPDVQRRVQQEIDEVIGQVRCPEMTDQAH-------MPYTNAVIHEVQRFGDIAPLNLPRFTSCDIEVQD---FVIPKG-TTLIINLSSVLKDETVWEKPH 
CYP2D6Hum             AGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAH-------MPYTTAVIHEVQRFGDIVPLGVTHMTSRDIEVQG---FRIPKG-TTLITNLSSVLKDEAVWEKPF 
CYP2J2Hum             AGTETTSTTLRWALLYMALYPEIQEKVQAEIDRVIGQGQQPSTAARES-------MPYTNAVIHEVQRMGNIIPLNVPREVTVDTTLAG---YHLPKG-TMILTNLTALHRDPTEWATPD 
CYP2R1Hum             AGTETTTNVLRWAILFMALYPNIQGQVQKEIDLIMGPNGKPSWDDKCK-------MPYTEAVLHEVLRFCNIVPLGIFHATSEDAVVRG---YSIPKG-TTVITNLYSVHFDEKYWRDPE 
CYP2W1Hum             AGTETTSATLQWAALLMGRHPDVQGRVQEELDRVLGPGRTPRLEDQQA-------LPYTSAVLHEVQRFITLLPH-VPRCTAADTQLGG---FLLPKG-TPVIPLLTSVLLDETQWQTPG 
CYP1A2Hum             AGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLSDRPQ-------LPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNG---FYIPKK-CCVFVNQWQVNHDPELWEDPS 
CYP3A4Hum             AGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQ-------MEYLDMVVNETLRLFP-IAMRLERVCKKDVEING---MFIPKG-VVVMIPSYALHRDPKYWTEPE 
CYP46A1Hum            AGHETSANHLAFTVMELSRQPEIVARLQAEVDEVIGSKRYLDFEDLGR-------LQYLSQVLKESLRLYP-PAWGTFRLLEEETLIDG---VRVPGN-TPLLFSTYVMGRMDTYFEDPL 
CYP11A1Hum            GGVDTTSMTLQWHLYEMARNLKVQDMLRAEVLAARHQAQGDMATMLQL-------VPLLKASIKETLRLHP-ISVTLQRYLVNDLVLRD---YMIPAK-TLVQVAIYALGREPTFFFDPE 
CYP19A1Hum            AAPDTMSVSLFFMLFLIAKHPNVEEAIIKEIQTVIG-ERDIKIDDIQK-------LKVMENFIYESMRYQPVVDLVMRKALEDD-VIDG---YPVKKG-TNIILNIGRMHR-LEFFPKPN 
CYP8A1Hum             ATQGNMGPAAFWLLLFLLKNPEALAAVRGELESILWQAEQPVSQTTTLPQKVLDSTPVLDSVLSESLRLTAAPFITREVVVDLAMPMADGREFNLRRGDRLLLFPFLSPQRDPEIYTDPE 












CYP2C4Rab             VFDPGHFLDESGNFKKS---------DYFMPFSAGKRMCVGEGLARMELFLFLTSILQNFKLQSLVE-----PKDLDITAVVN-GFVSVPPSYQLCFIPI--------- 
CYP2C5Rab             VFDPGHFLDESGNFKKS---------DYFMPFSAGKRMCVGEGLARMELFLFLTSILQNFKLQSLVE-----PKDLDITAVVN-GFVSVPPSYQLCFIPI--------- 
CYP2C9Hum             MFDPHHFLDEGGNFKKS---------KYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVD-----PKNLDTTPVVN-GFASVPPFYQLCFIPV--------- 
CYP2C19Hum            MFDPRHFLDEGGNFKKS---------NYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLID-----PKDLDTTPVVN-GFASVPPFYQLCFIPV--------- 
CYP2C8Hum             IFDPGHFLDKNGNFKKS---------DYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDD-----LKNLNTTAVTK-GIVSLPPSYQICFIPV--------- 
CYP2C2Rab             RFDPGHFLDASGNFRKS---------DYFMPFSTGKRVCVGEALARMELFLFLTAILQNFTPKPLVN-----PNNVDENPFSS-GIVRVPPLYRVSFIPV--------- 
CYP2C3Rab             KFDPGHFLDESGNFKKS---------DYFMPFSAGKRACVGEGLARMELFLLLTTILQHFTLKPLVD-----PKDIDPTPLEN-GFVSVPPSYELCFVPV--------- 
CYP2C21Dog            QFDPGHFLDENGSFKKS---------DYFMAFSAGKRVCVGEGLARMELFLLLTNILQHFTLKPLVD-----PKDIDTTPIAN-GLGATPPSYKLCFVPV--------- 
CYP2E1Hum             KFKPEHFLNENGKFKYS---------DYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVD-----PKDIDLSPIHI-GFGCIPPRYKLCVIPRS-------- 
CYP2A4Mou             DFNPKHFLDDKGQFKKS---------DAFVPFSIGKRYCFGEGLARMELFLFLTNIMQNFHFKSTQA-----PQDIDVSPRLV-GFVTIPPTYTMSFLSR--------- 
CYP2A5Mou             DFNPKHFLDDKGQFKKN---------DAFVPFSIGKRYCFGEGLARMELFLFLTNIMQNFHFKSTQA-----PQDIDVSPRLV-GFATIPPTYTMSFLSR--------- 
CYP2A6Hum             DFNPQHFLNEKGQFKKS---------DAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSSQS-----PKDIDVSPKHV-GFATIPRNYTMSFLPR--------- 
CYP2A13Hum            DFNPQHFLDKKGQFKKS---------DAFVPFSIGKRYCFGEGLARMELFLFFTTIMQNFRFKSPQS-----PKDIDVSPKHV-GFATIPRNYTMSFLPR--------- 
CYP2A1Rat             DFDPQNFLDDKGQLKKN---------AAFLPFSTGKRFCLGDGLAKMELFLLLTTILQNFRFKFPMK-----LEDINESPKPL-GFTRIIPKYTMSFMPI--------- 
CYP2G1Rat             AFYPQHFLDEQGRFKKN---------DAFVAFSSGKRICVGEALARMELFLYFTSILQRFSLRSLVP-----PADIDIAHKIS-GFGNIPPTYELCFMAR--------- 
CYP2B1Rat             SFNPEHFLDANGALKKS---------EAFMPFSTGKRICLGEGIARNELFLFFTTILQNFSVSSHLA-----PKDIDLTPKES-GIGKIPPTYQICFSAR--------- 
CYP2B2Rat             TFNPEHFLDADGTLKKS---------EAFMPFSTGKRICLGEGIARNELFLFFTTILQNFSVSSHLA-----PKDIDLTPKES-GIAKIPPTYQICFSAR--------- 
CYP2B4Rab             TFNPGHFLDANGALKRN---------EGFMPFSLGKRICLGEGIARTELFLFFTTILQNFSIASPVP-----PEDIDLTPRES-GVGNVPPSYQIRFLAR--------- 
CYP2B5Rab             TFNPGHFLDADGALKRN---------EGFMPFSLGKRICLGEGIARTELFLFFTTILQNFSIASPVP-----PEDIDLTPRES-GVGNVPPSYQIRFLAR--------- 
CYP2B6Hum             AFNPDHFLDANGALKKT---------EAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSMASPVA-----PEDIDLTPQEC-GVGKIPPTYQIRFLPR--------- 
CYP2B11Dog            VFNPDHFLDANGALKKN---------EAFIPFSIGKRICLGEGIARMELFLFFTTILQNFSVASPMA-----PEDIDLTPQEI-GVGKLPPVYQISFLSRGGC------ 
CYP2S1Hum             EFNPDRFLDADGRFRKH---------EAFLPFSLGKRVCLGEGLAKAELFLFFTTILQAFSLESPCP-----PDTLSLKPTVS-GLFNIPPAFQLQVRPTDLHSTTQTR 
CYP2F1Hum             EFNPEHFLDANQSFKKS---------PAFMPFSAGRRLCLGELLARMELFLYLTAILQSFSLQPLGA-----PEDIDLTPLSS-GLGNLPRPFQLCLRPR--------- 
CYP2T1Rat             HFNPTNFLDDQGEFQNN---------DAFMPFAPGKRMCLGAGLARSEIFLFLTAILQKFSLLPVGS-----PADIDLTPQCT-GLGNVPPAFQLRLVAR--------- 
CYP2D1Rat             RFHPEHFLDAQGNFVKH---------EAFMPFSAGRRACLGEPLARMELFLFFTCLLQRFSFSVPVG-----QPRPSTHGFFA--FPVAPLPYQLCAVVREQGL----- 
CYP2D6Hum             RFHPEHFLDAQGHFVKP---------EAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTG-----QPRPSHHGVFA--FLVSPSPYELCAVPR--------- 
CYP2J2Hum             TFNPDHFLEN-GQFKKR---------EAFMPFSIGKRACLGEQLARTELFIFFTSLMQKFTFRPPN------NEKLSLKFRMG--ITISPVSHRLCAVPQV-------- 
CYP2R1Hum             VFHPERFLDSSGYFAKK---------EALVPFSLGRRHCLGEHLARMEMFLFFTALLQRFHLHFPH------ELVPDLKPRLG--MTLQPQPYLICAERR--------- 
CYP2W1Hum             QFNPGHFLDANGHFVKR---------EAFLPFSAGRRVCVGERLARTELFLLFAGLLQRYRLLPPPG-----VSPASLDTTPARAFTMRPRAQALCAVPRP-------- 
CYP1A2Hum             EFRPERFLTADGTAINKPLS------EKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLEFSVPP------GVKVDLTPIYG--LTMKHARCEHVQARRFSIN----- 
CYP3A4Hum             KFLPERFSKKNKDNIDP---------YIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKE-----TQIPLKLSLGG--LLQPEKPVVLKVESRDGTVSGA-- 
CYP46A1Hum            TFNPDRFGPGAPKPRFT-----------YFPFSLGHRSCIGQQFAQMEVKVVMAKLLQRLEFRLVPGQRFGLQEQATLKPLDPVLCTLRPRGWQPAPPPPPC------- 
CYP11A1Hum            NFDPTRWLSKDKNITYFR----------NLGFGWGVRQCLGRRIAELEMTIFLINMLENFRVEIQHLSDVGTTFNLILMPEKPISFTFWPFNQEATQQ----------- 
CYP19A1Hum            EFTLENFAKNVPYRYFQ-------------PFGFGPRGCAGKYIAMVMMKAILVTLLRRFHVKTLQG---QCVESIQKIHDLSLHPDETKNMLEMIFTPRNSDRCLEH- 
CYP8A1Hum             VFKYNRFLNPDGSEKKDFYKDGKRLKNYNMPWGAGHNHCLGRSYAVNSIKQFVFLVLVHLDLELINA-----DVEIPEFDLSRYGFGLMQPEHDVPVRYRIRP------ 
                       *   .:                        :. * . * *   *   :   .  ::    
 
Figure A1: Alignment of mammalian CYP450 isoforms showing ligands contacts identified in X-ray crystal structures of CYP450-ligand 
complexes. 
 
Ligand contacts highlighted here were identified in 43 different CYP450-ligand complexes deposited in the PDB before 2011. Residues are 
colour-coded based on the number of times they are involved in ligand contacts in different structures of the same isoform as follows: Yellow (1), 




CYP1A2Hum       ----------------------MALSQSVPFSATELLLASAIFCLVFWVLKG-LRPRVPKGLKSPPEPWGWPLLGHV-----------------------LTLG-KNPHLALSRMSQRYG  
CYP46A1Hum      ------------------------MSPGLLLLGSAVLLAFGLCCTFVHRARS-RYEHIPGPPRPSFLLGHLPCFWKK-----------------------DEVGGRVLQDVFLDWAKKYG  
CYP2A6Hum       ---------------------------MLASGMLLVALLVCLTVMVLMS----VWQQRKSKGKLPPGPTPLPFIGNY-----------------------LQLNTEQMYNSLMKISERYG  
CYP2B4Rab       ---------------------------MEFS---LLLLLAFLAGLLLLL----FRGHPKAHGRLPPGPSPLPVLGNL-----------------------LQMDRKGLLRSFLRLREKYG  
CYP2C5Rab       -------------------------------MDPVVVLVLGLCCLLLLS----IWKQNSGRGKLPPGPTPFPIIGNI-----------------------LQIDAKDISKSLTKFSECYG  
CYP2C8Hum       -------------------------------MEPFVVLVLCLSFMLLFS----LWRQSCRRRKLPPGPTPLPIIGNM-----------------------LQIDVKDICKSFTNFSKVYG  
CYP2C9Hum       -------------------------------MDSLVVLVLCLSCLLLLS----LWRQSSGRGKLPPGPTPLPVIGNI-----------------------LQIGIKDISKSLTNLSKVYG  
CYP2D6Hum       ---------------------MGLEALVPL-----AVIVAIFLLLVDLM-----HRRQRWAARYPPGPLPLPGLGNL-----------------------LHVDFQNTPYCFDQLRRRFG  
CYP2R1Hum       ----------------MWKLWRAEEGAAAL---GGALFLL-LFALGVRQ-----LLKQRRPMGFPPGPPGLPFIGNI---------------------YSLAASSELPHVYMRKQSQVYG  
CYP3A4Hum       -----------------------MALIPDLAMETWLLLAVSLVLLYLYG----THSHGLFKKLGIPGPTPLPFLGNI------------------------LSYHKGFCMFDMECHKKYG  
                                                         .                              . .                                            :  
  
 
CYP1A2Hum       DVLQIRIGS-TPVLVLSRLDTIRQALVRQG-DDFKGRPDLYTSTLITDGQSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELMAGPGHFDPYNQ  
CYP46A1Hum      PVVRVNVFH-KTSVIVTSPESVKKFLMS---TKYNKDSKMYRALQTVFGERLFG---QGLVSECNYERWHKQRRVIDLAFS--RSSLVSLMETFNEKAEQLVEILEAKADGQTPVSMQDM  
CYP2A6Hum       PVFTIHLGP-RRVVVLCGHDAVREALVDQA-EEFSGRGEQATFDWVF--------KGYGVVFS-NGERAKQLRRFSIATLRDFGVGKRGIEERIQEEAGFLIDALRGTG--GANIDPTFF  
CYP2B4Rab       DVFTVYLGS-RPVVVLCGTDAIREALVDQA-EAFSGRGKIAVVDPIF--------QGYGVIFA-NGERWRALRRFSLATMRDFGMGKRSVEERIQEEARCLVEELRKSK--GALLDNTLL  
CYP2C5Rab       PVFTVYLGM-KPTVVLHGYEAVKEALVDLG-EEFAGRGSVPILEKVS--------KGLGIAFS-NAKTWKEMRRFSLMTLRNFGMGKRSIEDRIQEEARCLVEELRKTN--ASPCDPTFI  
CYP2C8Hum       PVFTVYFGM-NPIVVFHGYESVKEALIDNG-EEFSGRGNSPISQRIT--------KGLGIISS-NGKRWKEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTK--ASPCDPTFI  
CYP2C9Hum       PVFTLYFGL-KPIVVLHGYEAVKEALIDLG-EEFSGRGIFPLAERAN--------RGFGIVFS-NGKKWKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTK--ASPCDPTFI  
CYP2D6Hum       DVFSLQLAW-TPVVVLNGLAAVREALVTHG-EDTADRPPVPITQILGFG-----PRSQGVFLARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHS--GRPFRPNGL  
CYP2R1Hum       EIFSLDLGG-ISTVVLNGYDVVKECLVHQS-EIFADRPCLPLFMKM--------TKMGGLLNSRYGRGWVDHRRLAVNSFRYFGYGQKSFESKILEETKFFNDAIETYK--GRPFDFKQL  
CYP3A4Hum       KVWGFYDGQ-QPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMK----------SAISIA-EDEEWKRLR--SLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDV  




CYP1A2Hum       VVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP--------ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKN---SVRDITGALFKHSKK-GPRASG  
CYP46A1Hum      LTYTAMDILAKAAFG----METSMLLGAQKPLSQAVKLMLEGITASRNT--------LAKFLPG---KRKQLREVRESIRFLRQVGRDWVQRRRE---ALKRGEEVPADILTQ-ILKAEE  
CYP2A6Hum       LSRTVSNVISSIVFGDRFDYKDKEFLSLLRMMLGIFQF-TSTSTGQLYE----MFSSVMKHLPGPQQQAFQLLQGLEDF-IAKKVEHNQRTLDPN---SPRDFIDSFLIRMQE-EEKNPN  
CYP2B4Rab       FHSITSNIICSIVFGKRFDYKDPVFLRLLDLFFQSFSL-ISSFSSQVFE----LFPGFLKHFPGTHRQIYRNLQEINTF-IGQSVEKHRATLDPS---NPRDFIDVYLLRMEK-DKSDPS  
CYP2C5Rab       LGCAPCNVICSVIFHNRFDYKDEEFLKLMESLNENVRI-LSSPWLQVYN----NFPALLDYFPGIHKTLLKNADYIKNF-IMEKVKEHQKLLDVN---NPRDFIDCFLIKMEQ-ENN---  
CYP2C8Hum       LGCAPCNVICSVVFQKRFDYKDQNFLTLMKRFNENFRI-LNSPWIQVCN----NFPLLIDCFPGTHNKVLKNVALTRSY-IREKVKEHQASLDVN---NPRDFIDCFLIKMEQ-EKDNQK  
CYP2C9Hum       LGCAPCNVICSIIFHKRFDYKDQQFLNLMEKLNENIKI-LSSPWIQICN----NFSPIIDYFPGTHNKLLKNVAFMKSY-ILEKVKEHQESMDMN---NPQDFIDCFLMKMEK-EKHNQP  
CYP2D6Hum       LDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKE-ESGFLREVLN----AVPVLLHIP-ALAGKVLRFQKAFLTQ-LDELLTEHRMTWDPAQ--PPRDLTEAFLAEMEK-AKGNPE  
CYP2R1Hum       ITNAVSNITNLIIFGERFTYEDTDFQHMIELFSENVEL-AASASVFLYN----AFPWIGILPFGKHQQLFRNAAVVYDF-LSRLIEKASVNRKPQL--P-QHFVDAYLDEMDQ-GKNDPS  
CYP3A4Hum       FGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSIT----VFPFLIPILEVLNICVFP--REVTNF-LRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNS-KETESH  













CYP1A2Hum       NLIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLSDRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPE  
CYP46A1Hum      GAQDDEGLLDNFVTFFIAGHETSANHLAFTVMELSRQPEIVARLQAEVDEVIGSKRYLDFEDLGRLQYLSQVLKESLRLYP-PAWGTFRLLEEETLIDGVRVPGNTPLLFSTYVMGRMDT  
CYP2A6Hum       TEFYLKNLVMTTLNLFIGGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAKMPYMEAVIHEIQRFGDVIPMSLARRVKKDTKFRDFFLPKGTEVYPMLGSVLRDPS  
CYP2B4Rab       SEFHHQNLILTVLSLFFAGTETTSTTLRYGFLLMLKYPHVTERVQKEIEQVIGSHRPPALDDRAKMPYTDAVIHEIQRLGDLIPFGVPHTVTKDTQFRGYVIPKNTEVFPVLSSALHDPR  
CYP2C5Rab       LEFTLESLVIAVSDLFGAGTETTSTTLRYSLLLLLKHPEVAARVQEEIERVIGRHRSPCMQDRSRMPYTDAVIHEIQRFIDLLPTNLPHAVTRDVRFRNYFIPKGTDIITSLTSVLHDEK  
CYP2C8Hum       SEFNIENLVGTVADLFVAGTETTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSDLVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDK  
CYP2C9Hum       SEFTIESLENTAVDLFGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYIDLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNK  
CYP2D6Hum       SSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEA  
CYP2R1Hum       STFSKENLIFSVGELIIAGTETTTNVLRWAILFMALYPNIQGQVQKEIDLIMGPNGKPSWDDKCKMPYTEAVLHEVLRFCNIVPLGIFHATSEDAVVRGYSIPKGTTVITNLYSVHFDEK  
CYP3A4Hum       KALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFP-IAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPK  




CYP1A2Hum       LWEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLEFSVP---PGVKVDLTPIYGLTMKHARCEHVQARRFSIN------   
CYP46A1Hum      YFEDPLTFNPDRFGPGAPKPR-----FTYFPFSLGHRSCIGQQFAQMEVKVVMAKLLQRLEFRLV---PGQRFGLQEQATLKPLDPVLCTLRPRGWQPAPPPPPC  
CYP2A6Hum       FFSNPQDFNPQHFLNEKGQFKK---SDAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSS--QSPKDIDVSPKHVGFATIPRNYTMSFLPR---------  
CYP2B4Rab       YFETPNTFNPGHFLDANGALKR---NEGFMPFSLGKRICLGEGIARTELFLFFTTILQNFSIASP--VPPEDIDLTPRESGVGNVPPSYQIRFLAR---------  
CYP2C5Rab       AFPNPKVFDPGHFLDESGNFKK---SDYFMPFSAGKRMCVGEGLARMELFLFLTSILQNFKLQSL--VEPKDLDITAVVNGFVSVPPSYQLCFIPI---------  
CYP2C8Hum       EFPNPNIFDPGHFLDKNGNFKK---SDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSV--DDLKNLNTTAVTKGIVSLPPSYQICFIPV---------  
CYP2C9Hum       EFPNPEMFDPHHFLDEGGNFKK---SKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSL--VDPKNLDTTPVVNGFASVPPFYQLCFIPV---------  
CYP2D6Hum       VWEKPFRFHPEHFLDAQGHFVK---PEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPT---GQPRPSHHGVFAFLVSPSPYELCAVPR---------  
CYP2R1Hum       YWRDPEVFHPERFLDSSGYFAK---KEALVPFSLGRRHCLGEHLARMEMFLFFTALLQRFHLHFP----HELVPDLKPRLGMTLQPQPYLICAERR---------  
CYP3A4Hum       YWTEPEKFLPERFSKKNKDNID---PYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPC---KETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGA--  
                 :  *  * * .*                  *. * * * *  :*  :: : .   :*                                 :                
  
  
Figure A2: Alignment of mammalian CYP450 isoforms showing ligands contacts identified in docking CYP450-ligand complexes. 
 
Residues are colour-coded based on the frequency with which they interact with ligands in docking complexes. Yellow (less than 20 % of 










 CYP450 SNP tables Appendix B.












































n/a n/a          unknown 





n/a n/a          unknown 

















Phenacetin  >0.04    









         unknown 
L65P -54 0.4 3.6 α-helix A undefined -4.8 
damagin
g 
         unknown 
G73R 113.3 61.1 46.6 
end of helix 
A 
undefined 1.8 neutral          unknown 




7-ERF similar 0.90 0.72 0.76 [608] 
 
neutral 
Phenacetin  similar    
D104N 3.0 14.2 32.8 
loop btwn 





         unknown 
L111F 23.2 17.4 11.7 
loop btwn 
helix B & 





F125I -23.2 11.4 4.5 B-C loop SRS1 -0.9 neutral          unknown 
R138H -20.2 79.0 68.1 α-helix C 
CPR contact 
/SRS1 
-0.6 neutral          unknown 




7-ERF similar 0.53* 0.31 0.59 [608] 
 
decreased 
activity Phenacetin similar    
M180V -22.9 20.5 25.1 α-helix D undefined -0.9 neutral          unknown 
F186L1 -23.2 6.7 26.8 
loop btwn 
helix D & E 




7-ERF 0.28 0.27* 0.06* 0.20* [608] 
 
decreased 
activity Phenacetin  0.125    
F205V -49.9 0.0 7.7 
end of helix 
E 












7-ERF similar 1.55* 0.78 0.41 [608] 
 
decreased 
activity Phenacetin similar    
R281W 54.4 85.2 80.1 
loop btwn 
helix G & 
H 
undefined -0.2 neutral          unknown 










7-ERF similar 1.03 0.94 0.90 [608] 
 
neutral 




92.3 B-sheet 2 undefined -4.6 
damagin
g 
         unknown 
I314V1 -26.7 5.2 8.3 α-helix I 
haem 
contact/SRS 4 
-1.0 neutral          unknown 









MelQx  1.22 1.67 1.40 
IQ  1.29 2.00 1.60 
PhIP  0.87 2.64 3.00 
GluP-1  3.25 2.60 0.90 
Phenacetin  0.72 0.60 0.90 




helix J & K g 














Phenacetin ND    
I386F1 23.2 14.8 27.7 
loop btwn 













MelQx  1.70 3.33 2.00 
IQ  1.76 0.50 0.30 
PhIP  4.80 1.82 0.40 
GluP-1  4.00 2.80 0.70 
Phenacetin  12.80 1.73 0.10 
T395M1 46.8 43.7 53.0 B-sheet 41 undefined -1.0 neutral          unknown 




undefined -1.0 neutral          unknown 









MelQx  0.74 1.41 1.90 
IQ  1.05 1.43 1.40 
PhIP  13.20 2.36 2.50 
GluP-1  2.75 2.60 1.00 
Phenacetin  2.48 0.80 0.30 






E.coli ND ND      [317] inactive 
F432S1 -100.9 0.0 3.5 310 helix meander -5.3 
damagin
g 
         unknown 
D436N1 3.0 82.5 
102.
5 
loop btwn  
310 helix 
and helix L 
undefined -0.8 neutral          unknown 
T438I1 50.6 68.2 87.8 
loop btwn  
310 helix 
and helix L 
undefined -0.8 neutral 
Chinese 
hamster V79  
similar  




Phenacetin  similar    














Phenacetin  >0.04    
 
R457W 54.4 44.0 46.8 
loop btwn  
310 helix 




-0.4 neutral          unknown 
Q478H -9.4 19.5 45.2 
end of helix 
L 
undefined 0.3 neutral E.coli similar similar 7-ERF    0.90 [609] neutral 






undefined -1.6 neutral          unknown 
R510Q1 -29.6 69.5 86.2 B-sheet 52 undefined -0.3 neutral          unknown 
I514V -26.7 n/a n/a 
truncated 
C-terminal  
undefined n/a n/a          unknown 
 
Substrate abbreviations 
7-ERF 7-ethoxyresorufin   
Phenacetin  N-(4-Ethoxyphenyl)acetamide 




GluP-1 2-amino-6-methyldipyrido[1,2-a :3`,2`-d]imidazole 
 
 
1 SNPs found in the Human Cytochrome P450 (CYP) Allele Nomenclature Database, http://www.cypalleles.ki.se/. 
2 RSA refers to the relative solvent accessibility as calculated by SDM. 
3 Relative holoprotein levels refers to the P450:P420 ratio (usually determined by a carbon monoxide difference spectra) relative to wild-type enzyme. 
4 Relative activity refers to the activity relative to wild-type enzyme where full kinetics is not available and turnover has only been measured for a limited number of substrate 
concentrations.  
ND refers to protein levels, activity or kinetic parameters that were not detectable and the asterisk (*) indicates data reported to be significantly different from the wild-type enzyme. 





Table B2: CYP2A6 SNP table  
 
SNP 






































G5R 1 113.3 n/a n/a 
truncated 
N-terminal 
undefined n/a n/a n/a          unknown 





n/a n/a n/a          unknown 
S29N1 25.1 n/a n/a 
truncated 
N-terminal 
halting signal n/a n/a n/a          unknown 






Nicotine  1.61 0.98 0.59* [610] 
decreased 
activity 
F118L1  -23.2 7.2 4.3 B-C loop 
SRS1/gating 
residue 
-0.4 0.2 neutral In vivo    similar    [611] unknown 
G121R 113.3 84.0 75.4 
start of 
helix C 
SRS1 2.7 0.0 
damagin
g 
         unknown 




-0.9 0.7 neutral insect  similar ND Coumarin   5.36 0.10 0.02 [612] inactive 







         unknown 
S131A1  -0.4 0.3 0.1 α-helix C SRS1 2.9 0.0 
damagin
g 




E151K 30.2 61.6 72.4 α-helix D undefined -1.1 0.0 neutral          unknown 
D158E1  27.3 77.9 63.3 α-helix D undefined 1.5 0.1 neutral          unknown 
L160H1  -13.5 0.2 0.3 α-helix D undefined -1.9 0.1 neutral 
HepG2   ND 
Coumarin  
 
ND    [613] 
inactive 
In vivo   Coumarin ND    [310] 
L160I1  0.0 0.2 0.8 α-helix D undefined -0.4 0.0 neutral          unknown 
D169E 27.3 55.3 71.8 
loop btwn 
helix D&E 
undefined -1.0 0.1 neutral          unknown 
K194E1 -30.2 95.7 88.4 
loop btwn 
helix E&F 
undefined -0.4 0.0 neutral E.coli  similar similar  Coumarin  2.10* 1.80* 0.85 [614] neutral 
R203S1 -84.4 62.2 55.2 α-helix F SRS(2,3) -1.2 0.0 neutral 
E.coli similar  
Coumarin same    
[615] 
 neutral 
Nicotine same 1.26 0.93 0.73 
E.coli  similar similar  Coumarin  0.99 1.05 1.05 [614] 
R203C1 -64.9 62.2 


















1.33 0.25 0.19 
In vivo   Nicotine 
Decrease
d (0.6) 
   
S224P1 23.7 24.5 12.8 α-helix G' SRS(2,3) 1.6 0.4 neutral E.coli  
decreased 
(0.62) 




Coumarin  1.71 0.97 0.59 
Q239K 24.8 79.6 74.0 α-helix G SRS(2,3) -0.1 0.0 neutral          unknown 
R257C -64.9 72.4 92.6 
End of α-
helix G 
undefined -4.6 2.4 
damagin
g 




T258K 52.5 67.8 70.1 
loop btwn 
helix G & 
H 
undefined 0.7 0.2 neutral          unknown 
R265Q -29.6 44.9 80.6 
loop btwn 
helix G & 
H 
undefined -0.6 0.9 neutral          unknown 
E279Q 5.4 74.4 75.2 
loop btwn 
helix H & I 
undefined -0.1 0.3 neutral          unknown 
V292M 22.9 9.3 24.4 α-helix I SRS4 0.7 0.0 neutral          unknown 
T294S -27.1 0.1 0.5 α-helix I SRS4 -1.0 0.5 neutral          unknown 







         unknown 
R311C -64.9 7.4 22.5 α-helix I SRS4 9.8 0.7 
damagin
g 
         unknown 
Y351H1 -40.4 15.3 34.9 α-helix K undefined -1.4 0.7 
neutral 
(7/10) 
         unknown 
V365M1 22.9 10.7 5.1 
loop btwn 
helix K & 
B-sheet 31 
SRS5 1.5 0.3 neutral 
E.coli   




Nicotine   0.98 0.40* 0.40* 
In vivo   Nicotine 
decrease
d 
   
E.coli similar  










 Nicotine  0.47* 0.68 0.14* [610] 





Y392F1 -82.5 7.4 6.5 B-sheet 32 undefined 1.3 0.1 neutral E.coli  similar 




Nicotine   1.41* 1.24* 0.88 
Tegafur  2.33* 0.84* 0.36* 
Q409R 29.6 81.7 96.3 
loop btwn 
B-sheet 32 
& helix K' 
meander 0.0 0.0 neutral          unknown 
N418S -25.1 50.9 57.1 
loop btwn 
B-sheet 32 
& helix K' 
undefined 1.2 0.1 neutral          unknown 
N418D1 -3.0 50.9 58.3 
loop btwn 
B-sheet 32 
& helix K' 








& helix K' 
undefined 0.2 0.0 neutral E.coli similar similar Coumarin     1.06 [609] neutral 
G435R 113.3 18.3 6.1 
loop btwn  





-1.3 0.6 neutral          unknown 
N438Y1 79.5 38.1 45.2 
loop btwn  








E.coli decreased  Nicotine  
decrease
d  
1.41 0.92 0.63* [610] 
decreased 
activity 
I471T1 -50.6 1.7 13.0 
btwn B-
sheet 51 & 
52 












Nicotine     ND 
E.coli  similar 
Coumarin   2.5* 0.21* 0.08* 
[313] Nicotine   0.57* 0.17* 0.28* 
Tegafur  3.33* 0.27* 0.08* 








   
[617, 
618] 
K476R1 4.8 32.5 42.1 
btwn B-
sheet 51 & 
52 
SRS6 1.3 0.6 neutral 
E.coli  similar similar Coumarin  1.54* 1.41 0.91  
decreased 
activity? In vivo   Nicotine 
decrease
d 
   [611] 
G479V1 79.9 2.0 0.9 
btwn B-
sheet 51 &  
52 






very low ND Coumarin    ND [619] inactive 
R485L1 54.0 44.8 34.7 
btwn B-
sheet 51 & 
52 
SRS6 1.3 0.1 neutral 
In vivo   Coumarin similar    
[617] neutral  






1 SNPs found in the Human Cytochrome P450 (CYP) Allele Nomenclature Database, http://www.cypalleles.ki.se/. 
2 RSA refers to the relative solvent accessibility as calculated by SDM. 
3 SD refers to the standard deviation of the SDM score across different crystal structures of the same isoform. 
4 Relative holoprotein levels refers to the P450:P420 ratio (usually determined by a carbon monoxide difference spectra) relative to wild-type enzyme. 
5 Relative activity refers to the activity relative to wild-type enzyme where full kinetics is not available and turnover has only been measured for a limited number of substrate 
concentrations.  
ND refers to protein levels, activity or kinetic parameters that were not detectable and the asterisk (*) indicates data reported to be significantly different from the wild-type enzyme. 
































n levels  
Relative 
holoprotei





















n/a           unknown 







COS-1 similar  7-EFC similar 1.14 0.89 0.78 
[620
] 
neutral COS-7   





 similar similar similar 
Selegiline 
Dep 
 similar similar similar 





similar increased similar 
[621
] 




undefined n/a  
COS-1 1.2 similar 
Bupropio
n 
 0.73 0.74 1.02 
[622
] 
neutral COS-7   





 similar similar similar 
Selegiline 
Dep 
 similar similar similar 
COS-7   
Artemethe
r 
similar similar similar similar 
[621
] 







COS-7   





 similar similar similar 
Selegiline 
Dep 
 similar similar similar 
COS-7   
Artemethe
r 
similar similar similar similar 
[621
] 







COS-1 1.2 similar 
Bupropio
n 
 0.73 0.74 1.02 
[622
] 
neutral COS-7   





 similar similar similar 
Selegiline 
Dep 
 similar similar similar 
COS-7   
Artemethe
r 
similar similar similar similar 
[621
] 
















COS-7   





 ND ND ND 
Selegiline 
Dep 
 ND ND ND 





ND ND ND  







 ND ND ND 
[623
] inactive 










 ND ND ND 
COS-7   
Artemethe
r 
 ND ND ND 
[621
] 





undefined 0.6 neutral 
COS-1 ND ND 
Bupropio
n 
 ND ND ND 
[623
] 
inactive COS-7   





 ND ND ND 
Selegiline 
Dep 
 ND ND ND 
COS-7   
Artemethe
r 
ND ND ND ND 
[621
] 
















COS-7   





 similar similar decreased 
Selegiline 
Dep 
 similar similar similar 





similar decreased similar 
[621
] 
P167A1 -24.1 1.3 2.8 
start of 
helix E 
undefined 0.3 neutral          unknown 









COS-1 0.03  
Bupropio
n 











   0.95 




1 g Selegiline 
Dem 




 similar similar similar 
COS-7   
Artemethe
r 
similar similar similar similar 
[621
] 
I182M -3.8 6.6 11.7 α-helix E undefined -0.3 neutral          unknown 
V183I 26.7 1.6 2.7 α-helix F undefined -0.1 neutral          unknown 
M198T
1 
-46.8 34.6 32.8 α-helix E SRS(2, 3) -2.7 
damagin
g 
COS-7   






 ND ND ND 
Selegiline 
Dep 
 similar  similar similar 





similar decreased similar 
[621
] 
Y226H -40.4 77.1 73.2 F-G loop SRS(2, 3) 0.6 neutral          unknown 















undefined 0.0 neutral 













 similar   
Selegiline 
Dep 
 similar   




undefined -0.4 neutral 
COS-1 similar  7-EFC 
increase
d 









& H Selegiline 
Dem 




 similar similar similar 






   





similar increased similar 
[621
] 
N289K 54.5 40.3 40.6 
start of 
helix I 
SRS4 1.3 neutral          unknown 






-1.7 neutral          unknown 
I328T1 -50.6 0.3 0.0 α-helix J undefined -3.9 
damagin
g 
COS-1 ND ND 
Bupropio
n 












   0.50 
[622
] 
COS-7   





 ND ND ND 
Selegiline 
Dep 
 ND ND ND 
COS-7   
Artemethe
r 
ND ND ND ND 
[621
] 
HEK293 very low  
Bupropio
n 
    [624
] 
Yeast very low   similar similar similar  





helix J & 
J’ 









   0.78 



















COS-7   





 ND ND ND 
Selegiline 
Dep 
 ND ND ND 
COS-7   
Artemethe
r 
very low ND ND ND 
[621
] 




K’& 3 10 
helix 
undefined -1.3 neutral          unknown 
T423N -2.0 23.4 28.5 
loop 
btwn 3 10 
helix & 
α-helix L 
undefined -0.4 neutral          unknown 
P428T1 3.4 10.0 15.1 
loop 






COS-1 13.2  
Bupropio
n 












   0.50 
[622
] 
COS-7   











 ND ND ND 
COS-7   
Artemethe
r  





-22.9 2.3 4.6 
 Β-sheet 
51 
undefined -0.5 neutral 
COS-7   






 similar similar similar 
Selegiline 
Dep 
 similar similar similar 
COS-7   
Artemethe
r 





51.0 1.5 0.7 
loop bwn  
Β- sheet 
51 & 52 
SRS6 0.5 neutral 
COS-7   






 ND ND ND 
Selegiline 
Dep 
 ND ND ND 
COS-7   
Artemethe
r 
ND ND ND ND 
[621
] 
Q485L1 22.9 56.4 43.6 
loop bwn  
Β-sheet 
51 & 52 
undefined -1.7 neutral 
COS-7   






 similar similar similar 
Selegiline 
Dep 
 similar similar similar 
COS-7   
Artemethe
r 
similar similar similar similar 
[621
] 
R487C1 -64.9 42.5 12.6 






COS-1 similar  7-EFC 
small 
increase 




COS-7   





 similar similar similar 





COS-7   
Artemethe
r 





7-EFC 7-ethoxy-4-trifluoromethylcoumarin O-deethylaton 
Selegiline Dem selegiline N-demethylation 
Selegiline Dep selegiline N-depropagylation 
Artemether Artemether demethylation 
Bupropion Bupropion hydroxylation 
 
1 SNPs found in the Human Cytochrome P450 (CYP) Allele Nomenclature Database, http://www.cypalleles.ki.se/. 
2 RSA refers to the relative solvent accessibility as calculated by SDM. 
3 Relative holoprotein levels refers to the P450:P420 ratio (usually determined by a carbon monoxide difference spectra) relative to wild-type enzyme. 
4 Relative Activity refers to the activity relative to wild-type enzyme where full kinetics is not available and turnover has only been measured for a limited number of substrate 
concentrations.  
ND refers to protein levels, activity or kinetic parameters that were not detectable and the asterisk (*) indicates data reported to be significantly different from the wild-type enzyme. 













 Table B4: CYP2C8 SNP table  
 
SNP 





















n levels  
Relative 
holoprotei
























n/a n/a n/a              unknown 
A82S 0.4 0.2 3.0 
α-helix 
B 
undefined -3.2 0.1 
damagin
g 






















Yeast    similar    
[626
] 





undefined -11.5 0.0 
damagin
g 










undefined 1.5 0.4 neutral COS-1 similar  
Paclitax
el 




V181I 26.7 0.3 3.8 
α-helix 
E 





































F-G loop SRS(2,3) 0.2 0.1 neutral Yeast similar similar 
Paclitax
el 






























I244V -26.7 0.9 1.3 
α-helix 
G 










undefined 0.5 0.6 neutral COS-1 similar  
Paclitax
el 






-3.8 0.1 0.4 
α-helix 
H 
undefined -0.4 0.0 neutral 



























undefined 0.2 0.1 neutral 
E.coli   
Paclitax
el 








0.9    
Yeast    
decrease
d 






























-1.1 0.8 neutral COS-1 similar same 
Paclitax
el 









undefined -5.2 0.0 
damagin
g 














































































undefined -3.0 0.0 
damagin
g 
         unknown 
 
Substrate abbreviations 
Paclitaxel paclitaxel 6á-hydroxylation 
Arachidonic Acid (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid (various metabolites) 
 
Notes 
1 SNPs found in the Human Cytochrome P450 (CYP) Allele Nomenclature Database, http://www.cypalleles.ki.se/. 
2 RSA refers to the relative solvent accessibility as calculated by SDM. 
3 SD refers to the standard deviation of the SDM score across different crystal structures of the same isoform. 
4 Relative holoprotein levels refers to the P450:P420 ratio (usually determined by a carbon monoxide difference spectra) relative to wild-type enzyme. 
5 Relative activity refers to the activity relative to wild-type enzyme where full kinetics is not available and turnover has only been measured for a limited number of substrate 
concentrations.  
The asterisk (*) indicates data reported to be significantly different from the wild-type enzyme. (Note that some studies provide quantitative data without indicating whether 







Table B5: CYP2C9 SNP table  
 
SNP 























on levels  
Relative 
holoprote













on wt mut 





undefined n/a n/a n/a          unknown 







n/a n/a n/a          unknown 







n/a n/a n/a E.coli   
Tolbutami
de  











n/a n/a n/a          unknown 














SRS1'b -4.3 0.6 
damagin
g 




11 & 12 
V76M1 22.9 0.1  1.8 
Β-sheet 
12 









CPR contact -2.5 1.1 
damagin
g (2/3) 
COS-7 decrease  
Lornoxica
m  





COS-7   
Tolbutami
de  
decrease 11.0 similar 0.01 [553
] 




Diclofenac  3.89* 0.19* 0.05* 
[545
] 
Lorsartan  2.46* 0.06* 0.03* 
Glimepirid
e 













































-0.2 0.0 neutral          unknown 
T130R
1 
57.3 3.7  4.4 
α-helix 
C 
SRS1 -2.1 0.7 
damagin
g 












Insect similar similar 
Diclofenac  1.72* 0.42* 0.24* 
[545
] 
Lorsartan  1.34 0.05* 0.04* 
Glimepirid
e 








































1.11 0.01* 0.01* 
R144C
1 
-64.9 0.8  16.8 
α-helix 
D 
undefined -11.5 0.0 
damagin
g 













   
HepG2   
(S)-
warfarin 




HepG2   
Tolbutami
de 
similar    
   
(S)-




similar decrease decrease 
[636
] Diclofenac   similar decrease decrease 
Lauric 
acid  
 similar decrease decrease 
Insect   
(S)-
warfarin  
 1.0 0.7 0.7 [549
] 
Phenytoin  1.0 0.7 0.7 
Yeast   
Diclofenac   0.7 0.4 0.6 [550
] Losartan  0.8 0.5 0.6 
Insect   
Lornoxica
m  
 1.1 1.2 1.1 
[637
] 











undefined -2.6 4.0 
damagin
g (1/3) 









undefined -0.6 0.0 neutral E.coli   
Tolbutami










































-0.6 0.0 neutral          unknown 
Q214L
1 














Insect similar similar 
Diclofenac  4.06* 1.11 0.27* 
[545
] 
Lorsartan  1.81* 0.23* 0.13* 
Glimepirid
e 









undefined -0.1 0.0 neutral E.coli   
Tolbutami
de   












undefined -4.0 0.3 
damagin
g 
E.coli   
Tolbutami
de   













undefined 1.1 1.3 
neutral 
(2/3) 










groove/SRS4 (2/3) de  d ] activity 
I327T1 -50.6 2.7  3.9 
α-helix 
J 
undefined -3.9 1.3 
damagin
g 












undefined -0.3 0.0 neutral Insect similar similar 
Diclofenac  0.88 0.86 0.94 
[633
] 
















undefined -2.2 0.0 
damagin
g 





Invivo   Phenytoin  decrease    
[555
] 
E.coli  decrease  
Tolbutami
de  
 3.0 0.8 0.3 
[556
] 





undefined 0.9 0.0 neutral          unknown 
E354K
1 
30.2 0  2.3 
α-helix 
K 



















SRS5 -6.8 1.5 
damagin
g 
         unknown 
I359L1 0.0 1.7  2.2 
end α-
helix K 
SRS5 0.2 0.0 neutral 
Yeast   
Tolbutami
de  







 increase large decrease 
large 
decrease 
Yeast similar  
(S)-
Warfarin 






Diclofenac  3.2* 0.9 0.3* 
Piroxicam  1.5 0.05* 0.02* 
Phenytoin  2.0* 0.08* 0.04* 
Tenoxica
m 
 3.2* 0.13* 0.04* 
Mefenami
c acid 
 4.9* 0.3* 0.06* 
Tolbutami
de 
 11.5* 1.1 0.1* 
Insect   
(S)-
Warfarin 
 5.0 0.2 0.04 [549
] 
Phenytoin  4.0 0.2 0.06 
Yeast   
Diclofenac  3.2 1.0 0.3 [550
] Losartan   1.4 0.12 0.1 
Yeast   Diclofenac  8.3 1.4 0.2 
[551
] 




 5.0 0.14 0.04 
[552
]    Diclofenac  3.5 0.4 0.1 
   
Lauric 
Acid 
 3.7 0.2 0.05 
COS-7 decrease  
Lornoxica
m 
 1.3 0.34* 0.28* 
[631
] 
Insect similar similar 
Diclofenac  2.94* 1.11 0.37* 
[545
] 
Losartan  0.88 0.20* 0.23* 
Glimepirid
e 
 0.72 0.13* 0.20* 
I359T1 -50.6 1.7  4.7 
end α-
helix K 
SRS-5 -3.9 0.0 
damagin
g 













Warfarin ] activity 
Diclofenac   4.6 0.9 0.2 
Lauric 
acid  
 2.8 0.3 0.1 
In vivo   Losartan  decrease    
[638
] 




















SRS5 -0.9 1.0 neutral E.coli   
Tolbutami
de  
















undefined 1.2 0.0 neutral E.coli ND ND 
Tolbutami
de  










meander -4.1 0.0 
damagin
g 
         unknown 
L447F 23.2 0.9  1.2 
α-helix 
L 
undefined -0.8 0.0 neutral          unknown 
L447T -50.6 0.9 4.1 
α-helix 
L 
undefined -3.5 3.3 
damagin
g 






9.4 8.4  7.06 
α-helix 
L 
undefined 1.4 0.3 neutral E.coli   
Tolbutami
de  














SRS6 -3.5 3.3 
damagin
g (2/3) 











SRS-6 0.6 0.5 neutral 





Insect similar similar 
Diclofenac 
 





 0.69 0.01* 0.01* 
Glimepirid
e 








undefined 1.7 0.5 neutral   decrease 
Tolbutami
de  
























































1 SNPs found in the Human Cytochrome P450 (CYP) Allele Nomenclature Database, http://www.cypalleles.ki.se/. 
2 RSA refers to the relative solvent accessibility as calculated by SDM. 
3 SD refers to the standard deviation of the SDM score across different crystal structures of the same isoform. 
4 Relative holoprotein levels refers to the P450:P420 ratio (usually determined by a carbon monoxide difference spectra) relative to wild-type enzyme. 
5 Relative activity refers to the activity relative to wild-type enzyme where full kinetics is not available and turnover has only been measured for a limited number of substrate 
concentrations.  
ND refers to protein levels, activity or kinetic parameters that were not detectable and the asterisk (*) indicates data reported to be significantly different from the wild-type enzyme. 











































n levels  
Relative 
holoprotei













n wt mut 




undefined n/a n/a          unknown 







n/a n/a Yeast similar  similar  
S-
Mephenytoin 
 0.99 1.17 1.2 [316
] 
neutral Omeprazole  0.79 1.01 1.28 
CEC  1.00 1.41 1.48 
[315
] 








Yeast similar similar? 
S-
Mephenytoin 
 1.25 1.41* 1.15 [316
] 
neutral    Omeprazole  1.25 1.03 0.81 










SRS1'a -2.0 neutral 
Yeast   
S-
Mephenytoin 















 3.00* 1.78* 0.60 [316
] 
Omeprazole  2.70* 1.20 0.44* 














Yeast similar similar 
S-
Mephenytoin 
 0.71 0.70 0.95 [316
] 
neutral Omeprazole  0.67 0.51 0.75 












CPR contact 2.2 
damagin
g 












0.0 neutral Yeast similar similar 
S-
Mephenytoin 
 0.60* 0.71 1.26 [316
] substrate 
specific 
Omeprazole  1.61* 0.87 0.53 














0.4 neutral          unknown 
W120R
1 






















   
Yeast similar similar 
S-
Mephenytoin 
 N.D. N.D. N.D. [316
] 
Omeprazole  N.D. N.D. N.D. 










SRS1 1.4 neutral Yeast similar similar 
S-
Mephenytoin 

























E.coli   
S-
Mephenytoin 
 N.D. N.D. ND [460
] 
inactive 
Tolbutimide  N.D. N.D. ND 
Yeast similar similar 
S-
Mephenytoin 
 N.D. N.D. N.D. [316
] 
Omeprazole  N.D. N.D. N.D. 








         unknown 





undefined 0.2 neutral 
E.coli   
S-
Mephenytoin 





Yeast similar similar 
S-
Mephenytoin 
 1.90* 0.77 0.39* [316
] 
Omeprazole  1.92* 0.78 0.44* 










undefined -0.6 neutral 
E.coli   
S-
Mephenytoin 




Yeast similar similar 
S-
Mephenytoin 
 1.01 1.13 1.12 [316
] 
Omeprazole  0.91 1.05 1.13 















Yeast similar similar 
S-
Mephenytoin 
 1.57* 0.19* 0.12* [316
] decreased 
activity 
Omeprazole  1.23 0.20* 0.16* 










undefined 1.0 neutral Yeast similar similar 
S-
Mephenytoin 







Omeprazole  1.21 0.76 0.63 
CEC  1.27 0.98 0.76 
[315
] 
A173V 51.4 0.0 0.0 
α-helix 
E 
undefined -0.2 neutral          unknown 
N176S -25.1 0.0 1.1 
α-helix 
E 




















Yeast similar? similar? 
S-
Mephenytoin 












SRS(2,3) 0.6 neutral 
E.coli   
S-
Mephenytoin 
















2.94* 0.62* 0.18* 
Yeast similar similar 
S-
Mephenytoin 
 2.10* 0.34* 0.16* [316
] 
Omeprazole  1.95* 0.69 0.34* 














undefined -0.3 neutral E.coli similar? similar 
S-
Mephenytoin 




























undefined -1.4 neutral          unknown 

























α-helix J undefined -0.6 neutral 
Yeast   
S-
Mephenytoin 




Yeast   Omeprazole  1.14 0.75 0.67 
[641
] 
Yeast similar similar 
S-
Mephenytoin 
 2.40* 1.29 0.53 [644
] 
Omeprazole  1.11 0.97 0.88 











undefined -0.4 neutral Yeast similar similar 
S-
Mephenytoin 














undefined -0.3 neutral          unknown 




























Omeprazole  1.44* 0.52* 0.36* 
V374I1 26.7 8.6 3.7 
B-sheet 
41 
undefined 0.8 neutral          unknown 
V394M
1 
22.9 0.0 0.4 
 α-helix 
K' 
undefined -0.1 neutral E.coli similar? similar 
S-
Mephenytoin 
 1.09 1.05 0.95 [643
] 
neutral 


























meander -0.3 neutral 
E.coli   
S-
Mephenytoin 




Yeast similar similar 
S-
Mephenytoin 
 1.12 1.06 0.96 [316
] 
Omeprazole  0.90 0.98 1.04 





















E.coli   
S-
mephenytoin 
ND    [645
] 
inactive 
tolbutamide ND    
Yeast similar ND 
S-
Mephenytoin 
 N.D. N.D. N.D. 
[316
] 





























Omeprazole  0.77 0.21* 0.27* 
CEC  1.36 0.51 0.37* 
[315
] 





   
[646
] 
F448L1 -36.7 0.0 0.2 
α-helix 
L 














S-Mephenytoin S-mephenytoin 4'-hydroxylation 
Omeprazole Omeprazole 5'-hydroxylation 
Tolbutimide Tolbutamide hydroxylation 
Mephobarbital Mephobarbital 4′-hydroxylation 
Notes 
1 SNPs found in the Human Cytochrome P450 (CYP) Allele Nomenclature Database, http://www.cypalleles.ki.se/. 
2 RSA refers to the relative solvent accessibility as calculated by SDM. 
3 Relative holoprotein levels refers to the P450:P420 ratio (usually determined by a carbon monoxide difference spectra) relative to wild-type enzyme. 
4 Relative activity refers to the activity relative to wild-type enzyme where full kinetics is not available and turnover has only been measured for a limited number of substrate 
concentrations.  
ND refers to protein levels, activity or kinetic parameters that were not detectable and the asterisk (*) indicates data reported to be significantly different from the wild-type enzyme. 
































n levels  
Relative 
holoprotei













n wt mut 






n/a n/a          unknown 






n/a n/a          unknown 




halting signal n/a n/a          unknown 




halting signal n/a n/a          unknown 




halting signal n/a n/a          unknown 










         unknown 





n/a n/a          unknown 
R62W1 54.4 22.4 55.8 
α-helix 
A 




A85V1 51.4 63.0 68.4 
α-helix 
B 
undefined -1.6 neutral          unknown 
A90V1 51.4 0.8 0.8 
α-helix 
B 
undefined -0.2 neutral COS-7 similar  
Bufuralol similar 0.91 1.62 1.84 [647
] 
neutral 
DXM similar    
L91M1 -3.8 1.5 3.1 
α-helix 
B 
CPR contact -0.8 neutral          unknown 





CPR contact -1.2 neutral          unknown 
V104A
1 






         unknown 
V104M
1 
22.9 3.2 2.5 
B-C 
loop 
SRS1 -0.6 neutral          unknown 














Yeast similar similar 
Bufuralol  similar similar similar 
codeine  increased similar 
decrease
d 






         unknown 
I109V1 -26.7 7.6 3.1 
α-helix 
B' 
SRS1 -0.4 neutral          unknown 
V119M
1 





1.0 neutral          unknown 






-0.4 neutral          unknown 






         unknown 














         unknown 
V136I1 26.7 58.6 38.9 
α-helix 
C 
CPR contact 0.6 neutral          unknown 
Q151E1 -5.4 74.1 61.6 
α-helix 
D 
undefined 0.4 neutral          unknown 






         unknown 






         unknown 
E155K1 30.2 49.6 64.4 
α-helix 
D 
undefined -1.0 neutral          unknown 
E156A1 -49.8 1.9 4.7 
α-helix 
D 












   
N166D
1 




undefined 0.0 neutral          unknown 





undefined 0.2 neutral          unknown 





undefined -0.3 neutral          unknown 




















         unknown 








         unknown 




undefined -1.1 neutral          unknown 
G212E 78.3 0.0 0.0 
α-helix 
F 
SRS(2,3) 0.6 neutral          unknown 



















         unknown 







         unknown 
E278K1 30.2 32.0 19.7 
α-helix 
H 
undefined -0.9 neutral          unknown 
M279K 5.7 18.6 30.3 
α-helix 
H 
undefined -0.3 neutral          unknown 





undefined 0.7 neutral          unknown 
L295V -26.7 0.9 5.3 α-helix I SRS1 -1.4 neutral          unknown 




g decreased ] 
I297L1 0 4.5 9.7 α-helix I SRS1 0.2 neutral Insect   
DXM  1.13 6.55* 5.76* [649
] 
substrate 
specific Codeine  2.87* 1.57 0.57 
A300G -28.5 5.5 4.6 α-helix I SRS1 -4.2 
damagin
g 
         unknown 
D301N 3 20.9 23.7 α-helix I SRS1 0.6 neutral          unknown 
S311L 77.7 5.5 2.2 α-helix I SRS1 2.7 
damagin
g 
         unknown 












Insect similar ND Bufuralol ND    
[651
] 
R329L -6.7 74.1 74.6 
α-helix 
J 
undefined -0.2 neutral          unknown 
R330P -60.7 63.4 25.5 
α-helix 
J 
undefined -1.8 neutral          unknown 
E334A1 -49.8 19.6 28.2 
α-helix 
J 
undefined -0.5 neutral          unknown 
V338M
1 




undefined 1.0 neutral          unknown 








         unknown 






         unknown 






























   Codeine  2.05 3.00* 1.46 








0.4 neutral          unknown 











         unknown 









0.0 neutral          unknown 
E383K1 30.2 62.0 76.5 
Β-sheet 
41 
undefined -1.2 neutral          unknown 
K404Q
1 






undefined -0.2 neutral          unknown 





















DXM  2.42* 0.86 0.35* 
[649
] Codeine similar 0.84 1.20 1.43 




E418Q1 5.4 56.8 46.1 310 helix meander -0.6 neutral          unknown 








         unknown 





undefined -0.9 neutral          unknown 








1.5 neutral          unknown 














COS-1  ND 
Propafenon
e 













-1.0 neutral          unknown 











         unknown 
A449D
1 
22.5 19.3 12.5 
α-helix 
L 
haem contact -0.5 neutral          unknown 


















undefined -0.3 neutral          unknown 





SRS6 0.2 neutral          unknown 
H478Y
1 





SRS6 1.5 neutral          unknown 
G479A
1 





SRS6 1.3 neutral          unknown 





SRS6 -0.2 neutral          unknown 





SRS6 0.5 neutral          unknown 





SRS6 -0.8 neutral          unknown 
S486T1 27.1 51.4 48.1 
Β-sheet 
52 











Bufuralol similar 1.26 1.38 1.07 [647
] DXM similar    
 
Substrate abbreviations 
Sparteine Sparteine 2-oxidase/Sparteine 5-oxidase 
Bufuralol  Bufuralol 1'-hydroxylation 
DXM Dextromethorphan O-demethylation 
Codeine Codeine O-demethylation 




1 SNPs found in the Human Cytochrome P450 (CYP) Allele Nomenclature Database, http://www.cypalleles.ki.se/. 
2 RSA refers to the relative solvent accessibility as calculated by SDM. 
3 Relative holoprotein levels refers to the P450:P420 ratio (usually determined by a carbon monoxide difference spectra) relative to wild-type enzyme. 
4 Relative activity refers to the activity relative to wild-type enzyme where full kinetics is not available and turnover has only been measured for a limited number of substrate 
concentrations.  
ND refers to protein levels, activity or kinetic parameters that were not detectable and the asterisk (*) indicates data reported to be significantly different from the wild-type enzyme. . 











Table B8: CYP2E1 SNP table  
 
SNP 























n levels  
Relative 
holoprotei















n wt mut 
V72L 26.7 7.5 2.7 
B-sheet 
11 
SRS1'b -0.4 0.3 neutral          unknown 


























































         unknown 
G173S 28.9 4.9 6.7 
α-helix 
E 
undefined 0.6 0.5 neutral          unknown 
A175T 27.5 0.2 0.4 
α-helix 
E 
undefined -2.8 0.3 
damagin
g 
         unknown 




E a-stoid ne  ] 
COS-1   
Chloroxazo
ne  
similar similar similar 
[654
] 








SRS(2,3) 0.4 1.2 neutral          unknown 





SRS4 1.5 0.6 neutral          unknown 





undefined 0.2 0.1 neutral          unknown 







SRS5 1.9 0.0 neutral          unknown 






31 & 41 
CPR 
contact 
0.2 0.0 neutral          unknown 
V389I1 26.7 0.2 0.9 
Β-sheet 
32 
undefined -0.3 0.0 neutral 
COS-1  similar  
Chloroxazo
ne  




COS-1   
Chloroxazo
ne 
 similar similar similar 
[654
] 













         unknown 
V396L 26.7 2.4 0.0 
α-helix 
K' 































51 & 52 
SRS6 -1.3 0.3 neutral          unknown 
Substrate abbreviations 
Chlorzoxazone Chlorzoxazone 6-hydroxylation 
Nitrophenol  Nitrophenol 2-hydroxylation 
 
Notes 
1 SNPs found in the Human Cytochrome P450 (CYP) Allele Nomenclature Database, http://www.cypalleles.ki.se/. 
2 RSA refers to the relative solvent accessibility as calculated by SDM. 
3 SD refers to the standard deviation of the SDM score across different crystal structures of the same isoform. 
4 Relative holoprotein levels refers to the P450:P420 ratio (usually determined by a carbon monoxide difference spectra) relative to wild-type enzyme. 














Table B9: CYP3A4 SNP table  
 
SNP 






















n levels  
Relative 
holoprotei













on wt mut 
















halting signal -3.1 2.5 
damagin
g (5/7) 









SRS1'a -2.3 1.6 
damagin
g (4/7) 
E.coli similar  
Testostero
ne 





E.coli similar  
Testostero
ne 
 2.10 0.77 0.37 
[541
] Midazolam  1.59 0.60 0.38 








undefined -5.5 1.4 
damagin
g 








CPR contact -0.3 0.4 neutral          unknown 





-1.1 0.4 neutral In vivo   Cortisol  
decrease
? 










































undefined 0.9 0.3 neutral          unknown 





undefined -0.3 0.0 neutral E.coli similar  
Testostero
ne  













undefined 0.2 0.2 neutal E.coli similar  
Testostero
ne  






-49.9 0.7 4.6 
α-helix 
E 
undefined -1.4 0.0 neutral          unknown 

















E.coli similar  
Testostero
ne 
 3.75 0.33 0.09 
[541
] Midazolam  3.61 0.33 0.09 
Nifedipine  5.94 0.40 0.07 




undefined -1.6 0.3 neutral          unknown 


















































SRS(2,3) 1.3 0.0 neutral In vivo   Cortisol  
decrease
? 








1 3 F' Testostero
ne  
 1.46 0.84 0.58 
] activity 
E.coli similar  
Testostero
ne 
 1.32 0.40 0.30 
[541
] Midazolam  1.90 0.33 0.17 
Nifedipine  3.43 0.36 0.10 
















SRS(2,3) 2.7 0.4 
damagin
g 






start  of  
helix I 
start of SRS4 -0.5 0.1 neutral 
HepG2 similar  
Testostero
ne  
















   
   
Testostero
ne 
 0.85 0.75 0.88 
[541
] Midazolam  0.95 0.80 0.84 














         unknown 
M318I 3.8 0.0 0.1 
α-helix 
I 
undefined -0.5 0.0 neutral          unknown 
Y319C
1 
-85.1 9.7 8.9 
α-helix 
I 
undefined -7.0 1.9 
damagin
g 








CPR contact -0.7 1.0 neutral          unknown 





















 HepG2 decrease  
Testostero
ne 













0.0 0.0 neutral E.coli same  
Testostero
ne  



















meander 2.3 0.3 
damagin
g (5/7) 




P416L1 54.0 5.2 4.2 
start of 
310 helix 
meander 3.9 0.2 
damagin
g 









undefined -2.9 0.7 
damagin
g 














CPR contact -2.6 0.3 
damagin
g 
E.coli similar  
Testostero
ne 

























CPR contact 0.0 0.1 neutral          unknown 
F463C -81.4 0.1 5.2 
start of  
β-sheet 
51 
undefined -8.1 0.0 
damagin
g 


































SRS6 -8.7 2.3 
damagin
g 




Testosterone Testosterone – 6β hydroxylation 
Cortisol Cortisol 6β- hydroxylation 
Nifedipine Nifedipine oxidation 




1 SNPs found in the Human Cytochrome P450 (CYP) Allele Nomenclature Database, http://www.cypalleles.ki.se/. 
2 RSA refers to the relative solvent accessibility as calculated by SDM. 
3 SD refers to the standard deviation of the SDM score across different crystal structures of the same isoform. 
4 Relative holoprotein levels refers to the P450:P420 ratio (usually determined by a carbon monoxide difference spectra) relative to wild-type enzyme. 
5 Relative activity refers to the activity relative to wild-type enzyme where full kinetics is not available and turnover has only been measured for a limited number of substrate 
concentrations.  
ND refers to protein levels, activity or kinetic parameters that were not detectable and the asterisk (*) indicates data reported to be significantly different from the wild-type enzyme. . 






 Expression construct sequences Appendix C.
The DNA sequences for N-terminal truncated CYP3A4, CYP2C9 and CYP3A4 cloned into the 
pBJW102.2 parent expression vector are shown below. The start and stop codons are underlined 
and the coding region is shown in bold with sequences coding for the CYP3A4/CYP2C9/CPR in 
red,  BCCP-tag in blue, His-tag in green and the G-S linkers in yellow. Position of SNPs for 
variants expressed in this study are boxed in black with the nucleotide substitution and 
corresponding amino acid substitution shown in the right margin. The translated protein 
sequences, with the position of variants indicated, are also provided 
C-terminal tagged CYP3A4 expression construct 
   1 CTCGAGAAAT CATAAAAAAT TTATTTGCTT TGTGAGCGGA TAACAATTAT AATAGATTCA  
  61 ATTGTGAGCG GATAACAATT TCACACAGAA TTCATTAAAG AGGAGAAATT AACTATGGCA  
 121 CTTACGGCCT ATGGAACCCA TTCACATGGA CTTTTTAAGA AGCTTGGAAT TCCAGGGCCC  
 181 ACACCTCTGC CTTTTTTGGG AAATATTTTG TCCTACCATA AGGGCTTTTG TATGTTTGAC  
 241 ATGGAATGTC ATAAAAAGTA TGGAAAAGTG TGGGGCTTTT ATGATGGTCA ACAGCCTGTG  
 301 CTGGCTATCA CAGATCCTGA CATGATCAAA ACAGTGCTAG TGAAAGAATG TTATTCTGTC  
 361 TTCACAAACC GGAGGCCTTT TGGTCCAGTG GGATTTATGA AAAGTGCCAT CTCTATAGCT  
 421 GAGGATGAAG AATGGAAGAG ATTACGATCA TTGCTGTCTC CAACCTTCAC CAGTGGAAAA  
 481 CTCAAGGAGA TGGTCCCTAT CATTGCCCAG TATGGAGATG TGTTGGTGAG AAATCTGAGG  
 541 CGGGAAGCAG AGACAGGCAA GCCTGTCACC TTGAAAGACA TCTTTGGGGC CTACAGCATG  
 601 GATGTGATCA CTAGCACATC ATTTGGAGTG AACATCGACT CTCTCAACAA TCCACAAGAC  
 661 CCCTTTGTGG AAAACACCAA GAAGCTTTTA AGATTTGATT TTTTGGATCC ATTCTTTCTC  
 721 TCAATAACAG TCTTTCCATT CCTCATCCCA ATTCTTGAAG TATTAAATAT CTGTGTGTTT  
 781 CCAAGGGAAG TTACAAATTT TTTAAGAAAA TCTATAAAAA GGATGAAAGA AAGTCGCCTC  
 841 GAAGATACAC AAAAGCACCG AGTGGATTTC CTTCAGCTGA TGATTGACTC TCAGAATTCA  
 901 AAAGAAACTG AGTCCCACAA AGCTCTGTCC GATCTGGAGC TCGTGGCCCA ATCAATTATC  
 961 TTTATTTTTG CTGGCTATGA AACCACGAGC AGTGTTCTCT CCTTCATTAT GTATGAACTG  
1021 GCCACTCACC CTGATGTCCA GCAGAAACTG CAGGAGGAAA TTGATGCAGT TTTACCCAAT  
1081 AAGGCACCAC CCACCTATGA TACTGTGCTA CAGATGGAGT ATCTTGACAT GGTGGTGAAT  
1141 GAAACGCTCA GATTATTCCC AATTGCTATG AGACTTGAGA GGGTCTGCAA AAAAGATGTT  
1201 GAGATCAATG GGATGTTCAT TCCCAAAGGG GTGGTGGTGA TGATTCCAAG CTATGCTCTT  
1261 CACCGTGACC CAAAGTACTG GACAGAGCCT GAGAAGTTCC TCCCTGAAAG ATTCAGCAAG  
1321 AAGAACAAGG ACAACATAGA TCCTTACATA TACACACCCT TTGGAAGTGG ACCCAGAAAC  
1381 TGCATTGGTA TGAGGTTTGC TCTCATGAAC ATGAAACTTG CTCTAATCAG AGTCCTTCAG  
1441 AACTTCTCCT TCAAACCTTG TAAAGAAACA CAGATCCCCC TGAAATTAAG CTTAGGAGGA  
1501 CTTCTTCAAC CAGAAAAACC CGTTGTTCTA AAGGTTGAGT CAAGGGATGG CACCGTAAGT  
1561 GGAGCCGGGG GTGGCAGCGG TTCTGGCGCA GCAGCGGAAA TCAGTGGTCA CATCGTACGT  
1621 TCCCCGATGG TTGGTACTTT CTACCGCACC CCAAGCCCGG ACGCAAAAGC GTTCATCGAA  
1681 GTGGGTCAGA AAGTCAACGT GGGCGATACC CTGTGCATCG TTGAAGCCAT GAAAATGATG  
1741 AACCAGATCG AAGCGGACAA ATCCGGTACC GTGAAAGCAA TTCTGGTCGA AAGTGGACAA  
1801 CCGGTAGAAT TTGACGAGCC GCTGGTCGTC ATCGAGGGTG GCAGCGGTTC TGGCCACCAT  
1861 CACCATCACC ATAAGCTTAA TTAGCTGAGC TTGGACTCCT GTTGATAGAT CCAGTAATGA  
1921 CCTCAGAACT CCATCTGGAT TTGTTCAGAA CGCTCGGTTG CCGCCGGGCG TTTTTTATTG  
1981 GTGAGAATCC AAGCTAGCTT GGCGAGATTT TCAGGAGCTA AGGAAGCTAA AATGGAGAAA  
2041 AAAATCACTG GATATACCAC CGTTGATATA TCCCAATGGC ATCGTAAAGA ACATTTTGAG  
2101 GCATTTCAGT CAGTTGCTCA ATGTACCTAT AACCAGACCG TTCAGCTGGA TATTACGGCC  
2161 TTTTTAAAGA CCGTAAAGAA AAATAAGCAC AAGTTTTATC CGGCCTTTAT TCACATTCTT  
2221 GCCCGCCTGA TGAATGCTCA TCCGGAATTT CGTATGGCAA TGAAAGACGG TGAGCTGGTG  
2281 ATATGGGATA GTGTTCACCC TTGTTACACC GTTTTCCATG AGCAAACTGA AACGTTTTCA  
2341 TCGCTCTGGA GTGAATACCA CGACGATTTC CGGCAGTTTC TACACATATA TTCGCAAGAT  
2401 GTGGCGTGTT ACGGTGAAAA CCTGGCCTAT TTCCCTAAAG GGTTTATTGA GAATATGTTT  
G>A   G56D 
 
 C>G   P218R  T>C   S222P 
  
 C>T   L373F  
 
A>G   K96E 
 
 
T>G   I223R 
 
 T>C   L293P  




2461 TTCGTCTCAG CCAATCCCTG GGTGAGTTTC ACCAGTTTTG ATTTAAACGT GGCCAATATG  
2521 GACAACTTCT TCGCCCCCGT TTTCACCATG GGCAAATATT ATACGCAAGG CGACAAGGTG  
2581 CTGATGCCGC TGGCGATTCA GGTTCATCAT GCCGTTTGTG ATGGCTTCCA TGTCGGCAGA  
2641 ATGCTTAATG AATTACAACA GTACTGCGAT GAGTGGCAGG GCGGGGCGTA ATTTTTTTAA  
2701 GGCAGTTATT GGTGCCCTTA AACGCCTGGG GTAATGACTC TCTAGCTTGA GGCATCAAAT  
2761 AAAACGAAAG GCTCAGTCGA AAGACTGGGC CTTTCGTTTT ATCTGTTGTT TGTCGGTGAA  
2821 CGCTCTCCTG AGTAGGACAA ATCCGCCCTC TAGATTACGT GCAGTCGATG ATAAGCTGTC  
2881 AAACATGAGA ATTGTGCCTA ATGAGTGAGC TAACTTACAT TAATTGCGTT GCGCTCACTG  
2941 CCCGCTTTCC AGTCGGGAAA CCTGTCGTGC CAGCTGCATT AATGAATCGG CCAACGCGCG  
3001 GGGAGAGGCG GTTTGCGTAT TGGGCGCCAG GGTGGTTTTT CTTTTCACCA GTGAGACGGG  
3061 CAACAGCTGA TTGCCCTTCA CCGCCTGGCC CTGAGAGAGT TGCAGCAAGC GGTCCACGCT  
3121 GGTTTGCCCC AGCAGGCGAA AATCCTGTTT GATGGTGGTT AACGGCGGGA TATAACATGA  
3181 GCTGTCTTCG GTATCGTCGT ATCCCACTAC CGAGATATCC GCACCAACGC GCAGCCCGGA  
3241 CTCGGTAATG GCGCGCATTG CGCCCAGCGC CATCTGATCG TTGGCAACCA GCATCGCAGT  
3301 GGGAACGATG CCCTCATTCA GCATTTGCAT GGTTTGTTGA AAACCGGACA TGGCACTCCA  
3361 GTCGCCTTCC CGTTCCGCTA TCGGCTGAAT TTGATTGCGA GTGAGATATT TATGCCAGCC  
3421 AGCCAGACGC AGACGCGCCG AGACAGAACT TAATGGGCCC GCTAACAGCG CGATTTGCTG  
3481 GTGACCCAAT GCGACCAGAT GCTCCACGCC CAGTCGCGTA CCGTCTTCAT GGGAGAAAAT  
3541 AATACTGTTG ATGGGTGTCT GGTCAGAGAC ATCAAGAAAT AACGCCGGAA CATTAGTGCA  
3601 GGCAGCTTCC ACAGCAATGG CATCCTGGTC ATCCAGCGGA TAGTTAATGA TCAGCCCACT  
3661 GACGCGTTGC GCGAGAAGAT TGTGCACCGC CGCTTTACAG GCTTCGACGC CGCTTCGTTC  
3721 TACCATCGAC ACCACCACGC TGGCACCCAG TTGATCGGCG CGAGATTTAA TCGCCGCGAC  
3781 AATTTGCGAC GGCGCGTGCA GGGCCAGACT GGAGGTGGCA ACGCCAATCA GCAACGACTG  
3841 TTTGCCCGCC AGTTGTTGTG CCACGCGGTT GGGAATGTAA TTCAGCTCCG CCATCGCCGC  
3901 TTCCACTTTT TCCCGCGTTT TCGCAGAAAC GTGGCTGGCC TGGTTCACCA CGCGGGAAAC  
3961 GGTCTGATAA GAGACACCGG CATACTCTGC GACATCGTAT AACGTTACTG GTTTCACATT  
4021 CACCACCCTG AATTGACTCT CTTCCGGGCG CTATCATGCC ATACCGCGAA AGGTTTTGCA  
4081 CCATTCGATG GTGTCGGAAT TTCGGGCAGC GTTGGGTCCT GGCCACGGGT GCGCATGATC  
4141 TAGAGCTGCC TCGCGCGTTT CGGTGATGAC GGTGAAAACC TCTGACACAT GCAGCTCCCG  
4201 GAGACGGTCA CAGCTTGTCT GTAAGCGGAT GCCGGGAGCA GACAAGCCCG TCAGGGCGCG  
4261 TCAGCGGGTG TTGGCGGGTG TCGGGGCGCA GCCATGACCC AGTCACGTAG CGATAGCGGA  
4321 GTGTATACTG GCTTAACTAT GCGGCATCAG AGCAGATTGT ACTGAGAGTG CACCATATGC  
4381 GGTGTGAAAT ACCGCACAGA TGCGTAAGGA GAAAATACCG CATCAGGCGC TCTTCCGCTT  
4441 CCTCGCTCAC TGACTCGCTG CGCTCGGTCG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT  
4501 CAAAGGCGGT AATACGGTTA TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG  
4561 CAAAAGGCCA GCAAAAGGCC AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTTCCATA  
4621 GGCTCCGCCC CCCTGACGAG CATCACAAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC  
4681 CGACAGGACT ATAAAGATAC CAGGCGTTTC CCCCTGGAAG CTCCCTCGTG CGCTCTCCTG  
4741 TTCCGACCCT GCCGCTTACC GGATACCTGT CCGCCTTTCT CCCTTCGGGA AGCGTGGCGC  
4801 TTTCTCATAG CTCACGCTGT AGGTATCTCA GTTCGGTGTA GGTCGTTCGC TCCAAGCTGG  
4861 GCTGTGTGCA CGAACCCCCC GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC  
4921 TTGAGTCCAA CCCGGTAAGA CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA  
4981 TTAGCAGAGC GAGGTATGTA GGCGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG  
5041 GCTACACTAG AAGGACAGTA TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA  
5101 AAAGAGTTGG TAGCTCTTGA TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTG  
5161 TTTGCAAGCA GCAGATTACG CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT  
5221 CTACGGGGTC TGACGCTCAG TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT  
5281 TATCAAAAAG GATCTTCACC TAGATCCTTT TAAATTAAAA ATGAAGTTTT AAATCAATCT  
5341 AAAGTATATA TGAGTAAACT TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA  
5401 TCTCAGCGAT CTGTCTATTT CGTTCATCCA TAGTTGCCTG ACTCCCCGTC GTGTAGATAA  
5461 CTACGATACG GGAGGGCTTA CCATCTGGCC CCAGTGCTGC AATGATACCG CGAGACCCAC  
5521 GCTCACCGGC TCCAGATTTA TCAGCAATAA ACCAGCCAGC CGGAAGGGCC GAGCGCAGAA  
5581 GTGGTCCTGC AACTTTATCC GCCTCCATCC AGTCTATTAA TTGTTGCCGG GAAGCTAGAG  
5641 TAAGTAGTTC GCCAGTTAAT AGTTTGCGCA ACGTTGTTGC CATTGCTACA GGCATCGTGG  
5701 TGTCACGCTC GTCGTTTGGT ATGGCTTCAT TCAGCTCCGG TTCCCAACGA TCAAGGCGAG  
5761 TTACATGATC CCCCATGTTG TGCAAAAAAG CGGTTAGCTC CTTCGGTCCT CCGATCGTTG  
5821 TCAGAAGTAA GTTGGCCGCA GTGTTATCAC TCATGGTTAT GGCAGCACTG CATAATTCTC  
5881 TTACTGTCAT GCCATCCGTA AGATGCTTTT CTGTGACTGG TGAGTACTCA ACCAAGTCAT  
5941 TCTGAGAATA GTGTATGCGG CGACCGAGTT GCTCTTGCCC GGCGTCAATA CGGGATAATA  




6061 AACTCTCAAG GATCTTACCG CTGTTGAGAT CCAGTTCGAT GTAACCCACT CGTGCACCCA  
6121 ACTGATCTTC AGCATCTTTT ACTTTCACCA GCGTTTCTGG GTGAGCAAAA ACAGGAAGGC  
6181 AAAATGCCGC AAAAAAGGGA ATAAGGGCGA CACGGAAATG TTGAATACTC ATACTCTTCC  
6241 TTTTTCAATA TTATTGAAGC ATTTATCAGG GTTATTGTCT CATGAGCGGA TACATATTTG  
6301 AATGTATTTA GAAAAATAAA CAAATAGGGG TTCCGCGCAC ATTTCCCCGA AAAGTGCCAC  
6361 CTGACGTCTA AGAAACCATT ATTATCATGA CATTAACCTA TAAAAATAGG CGTATCACGA  
6421 GGCCCTTTCG TCTTCAC  
C-terminal tagged CYP2C9 expression construct 
   1 CTCGAGAAAT CATAAAAAAT TTATTTGCTT TGTGAGCGGA TAACAATTAT AATAGATTCA  
  61 ATTGTGAGCG GATAACAATT TCACACAGAA TTCATTAAAG AGGAGAAATT AACTATGGCA  
 121 CTTACGGCCC TCCCTCCTGG CCCCACTCCT CTCCCAGTGA TTGGAAATAT CCTACAGATA  
 181 GGTATTAAGG ACATCAGCAA ATCCTTAACC AATCTCTCAA AGGTCTATGG CCCTGTGTTC  
 241 ACTCTGTATT TTGGCCTGAA ACCCATAGTG GTGCTGCATG GATATGAAGC AGTGAAGGAA  
 301 GCCCTGATTG ATCTTGGAGA GGAGTTTTCT GGAAGAGGCA TTTTCCCACT GGCTGAAAGA  
 361 GCTAACAGAG GATTTGGAAT TGTTTTCAGC AATGGAAAGA AATGGAAGGA GATCCGGCGT  
 421 TTCTCCCTCA TGACGCTGCG GAATTTTGGG ATGGGGAAGA GGAGCATTGA GGACCGTGTT  
 481 CAAGAGGAAG CCCGCTGCCT TGTGGAGGAG TTGAGAAAAA CCAAGGCCTC ACCCTGTGAT  
 541 CCCACTTTCA TCCTGGGCTG TGCTCCCTGC AATGTGATCT GCTCCATTAT TTTCCATAAA  
 601 CGTTTTGATT ATAAAGATCA GCAATTTCTT AACTTAATGG AAAAGTTGAA TGAAAACATC  
 661 AAGATTTTGA GCAGCCCCTG GATCCAGATC TGCAATAATT TTTCTCCTAT CATTGATTAC  
 721 TTCCCGGGAA CTCACAACAA ATTACTTAAA AACGTTGCTT TTATGAAAAG TTATATTTTG  
 781 GAAAAAGTAA AAGAACACCA AGAATCAATG GACATGAACA ACCCTCAGGA CTTTATTGAT  
 841 TGCTTCCTGA TGAAAATGGA GAAGGAAAAG CACAACCAAC CATCTGAATT TACTATTGAA  
 901 AGCTTGGAAA ACACTGCAGT TGACTTGTTT GGAGCTGGGA CAGAGACGAC AAGCACAACC  
 961 CTGAGATATG CTCTCCTTCT CCTGCTGAAG CACCCAGAGG TCACAGCTAA AGTCCAGGAA  
1021 GAGATTGAAC GTGTGATTGG CAGAAACCGG AGCCCCTGCA TGCAAGACAG GAGCCACATG  
1081 CCCTACACAG ATGCTGTGGT GCACGAGGTC CAGAGATACA TTGACCTTCT CCCCACCAGC  
1141 CTGCCCCATG CAGTGACCTG TGACATTAAA TTCAGAAACT ATCTCATTCC CAAGGGCACA  
1201 ACCATATTAA TTTCCCTGAC TTCTGTGCTA CATGACAACA AAGAATTTCC CAACCCAGAG  
1261 ATGTTTGACC CTCATCACTT TCTGGATGAA GGTGGCAATT TTAAGAAAAG TAAATACTTC  
1321 ATGCCTTTCT CAGCAGGAAA ACGGATTTGT GTGGGAGAAG CCCTGGCCGG CATGGAGCTG  
1381 TTTTTATTCC TGACCTCCAT TTTACAGAAC TTTAACCTGA AATCTCTGGT TGACCCAAAG  
1441 AACCTTGACA CCACTCCAGT TGTCAATGGA TTTGCCTCTG TGCCGCCCTT CTACCAGCTG  
1501 TGCTTCATTC CTGTCGGGGG TGGCAGCGGT TCTGGCGCAG CAGCGGAAAT CAGTGGTCAC  
1561 ATCGTACGTT CCCCGATGGT TGGTACTTTC TACCGCACCC CAAGCCCGGA CGCAAAAGCG  
1621 TTCATCGAAG TGGGTCAGAA AGTCAACGTG GGCGATACCC TGTGCATCGT TGAAGCCATG  
1681 AAAATGATGA ACCAGATCGA AGCGGACAAA TCCGGTACCG TGAAAGCAAT TCTGGTCGAA  
1741 AGTGGACAAC CGGTAGAATT TGACGAGCCG CTGGTCGTCA TCGAGGGTGG CAGCGGTTCT  
1801 GGCCACCATC ACCATCACCA TAAGCTTAAT TAGCTGAGCT TGGACTCCTG TTGATAGATC  
1861 CAGTAATGAC CTCAGAACTC CATCTGGATT TGTTCAGAAC GCTCGGTTGC CGCCGGGCGT  
1921 TTTTTATTGG TGAGAATCCA AGCTAGCTTG GCGAGATTTT CAGGAGCTAA GGAAGCTAAA  
1981 ATGGAGAAAA AAATCACTGG ATATACCACC GTTGATATAT CCCAATGGCA TCGTAAAGAA  
2041 CATTTTGAGG CATTTCAGTC AGTTGCTCAA TGTACCTATA ACCAGACCGT TCAGCTGGAT  
2101 ATTACGGCCT TTTTAAAGAC CGTAAAGAAA AATAAGCACA AGTTTTATCC GGCCTTTATT  
2161 CACATTCTTG CCCGCCTGAT GAATGCTCAT CCGGAATTTC GTATGGCAAT GAAAGACGGT  
2221 GAGCTGGTGA TATGGGATAG TGTTCACCCT TGTTACACCG TTTTCCATGA GCAAACTGAA  
2281 ACGTTTTCAT CGCTCTGGAG TGAATACCAC GACGATTTCC GGCAGTTTCT ACACATATAT  
2341 TCGCAAGATG TGGCGTGTTA CGGTGAAAAC CTGGCCTATT TCCCTAAAGG GTTTATTGAG  
2401 AATATGTTTT TCGTCTCAGC CAATCCCTGG GTGAGTTTCA CCAGTTTTGA TTTAAACGTG  
2461 GCCAATATGG ACAACTTCTT CGCCCCCGTT TTCACCATGG GCAAATATTA TACGCAAGGC  
2521 GACAAGGTGC TGATGCCGCT GGCGATTCAG GTTCATCATG CCGTTTGTGA TGGCTTCCAT  
2581 GTCGGCAGAA TGCTTAATGA ATTACAACAG TACTGCGATG AGTGGCAGGG CGGGGCGTAA  
2641 TTTTTTTAAG GCAGTTATTG GTGCCCTTAA ACGCCTGGGG TAATGACTCT CTAGCTTGAG  
2701 GCATCAAATA AAACGAAAGG CTCAGTCGAA AGACTGGGCC TTTCGTTTTA TCTGTTGTTT  
2761 GTCGGTGAAC GCTCTCCTGA GTAGGACAAA TCCGCCCTCT AGATTACGTG CAGTCGATGA  
2821 TAAGCTGTCA AACATGAGAA TTGTGCCTAA TGAGTGAGCT AACTTACATT AATTGCGTTG  
2881 CGCTCACTGC CCGCTTTCCA GTCGGGAAAC CTGTCGTGCC AGCTGCATTA ATGAATCGGC  







G>A   V76M 
G>A  R132Q 
G>A  R150H 
A>T  Q214L 
C>A P297T 
A>C  I359L 




3001 TGAGACGGGC AACAGCTGAT TGCCCTTCAC CGCCTGGCCC TGAGAGAGTT GCAGCAAGCG  
3061 GTCCACGCTG GTTTGCCCCA GCAGGCGAAA ATCCTGTTTG ATGGTGGTTA ACGGCGGGAT  
3121 ATAACATGAG CTGTCTTCGG TATCGTCGTA TCCCACTACC GAGATATCCG CACCAACGCG  
3181 CAGCCCGGAC TCGGTAATGG CGCGCATTGC GCCCAGCGCC ATCTGATCGT TGGCAACCAG  
3241 CATCGCAGTG GGAACGATGC CCTCATTCAG CATTTGCATG GTTTGTTGAA AACCGGACAT  
3301 GGCACTCCAG TCGCCTTCCC GTTCCGCTAT CGGCTGAATT TGATTGCGAG TGAGATATTT  
3361 ATGCCAGCCA GCCAGACGCA GACGCGCCGA GACAGAACTT AATGGGCCCG CTAACAGCGC  
3421 GATTTGCTGG TGACCCAATG CGACCAGATG CTCCACGCCC AGTCGCGTAC CGTCTTCATG  
3481 GGAGAAAATA ATACTGTTGA TGGGTGTCTG GTCAGAGACA TCAAGAAATA ACGCCGGAAC  
3541 ATTAGTGCAG GCAGCTTCCA CAGCAATGGC ATCCTGGTCA TCCAGCGGAT AGTTAATGAT  
3601 CAGCCCACTG ACGCGTTGCG CGAGAAGATT GTGCACCGCC GCTTTACAGG CTTCGACGCC  
3661 GCTTCGTTCT ACCATCGACA CCACCACGCT GGCACCCAGT TGATCGGCGC GAGATTTAAT  
3721 CGCCGCGACA ATTTGCGACG GCGCGTGCAG GGCCAGACTG GAGGTGGCAA CGCCAATCAG  
3781 CAACGACTGT TTGCCCGCCA GTTGTTGTGC CACGCGGTTG GGAATGTAAT TCAGCTCCGC  
3841 CATCGCCGCT TCCACTTTTT CCCGCGTTTT CGCAGAAACG TGGCTGGCCT GGTTCACCAC  
3901 GCGGGAAACG GTCTGATAAG AGACACCGGC ATACTCTGCG ACATCGTATA ACGTTACTGG  
3961 TTTCACATTC ACCACCCTGA ATTGACTCTC TTCCGGGCGC TATCATGCCA TACCGCGAAA  
4021 GGTTTTGCAC CATTCGATGG TGTCGGAATT TCGGGCAGCG TTGGGTCCTG GCCACGGGTG  
4081 CGCATGATCT AGAGCTGCCT CGCGCGTTTC GGTGATGACG GTGAAAACCT CTGACACATG  
4141 CAGCTCCCGG AGACGGTCAC AGCTTGTCTG TAAGCGGATG CCGGGAGCAG ACAAGCCCGT  
4201 CAGGGCGCGT CAGCGGGTGT TGGCGGGTGT CGGGGCGCAG CCATGACCCA GTCACGTAGC  
4261 GATAGCGGAG TGTATACTGG CTTAACTATG CGGCATCAGA GCAGATTGTA CTGAGAGTGC  
4321 ACCATATGCG GTGTGAAATA CCGCACAGAT GCGTAAGGAG AAAATACCGC ATCAGGCGCT  
4381 CTTCCGCTTC CTCGCTCACT GACTCGCTGC GCTCGGTCGT TCGGCTGCGG CGAGCGGTAT  
4441 CAGCTCACTC AAAGGCGGTA ATACGGTTAT CCACAGAATC AGGGGATAAC GCAGGAAAGA  
4501 ACATGTGAGC AAAAGGCCAG CAAAAGGCCA GGAACCGTAA AAAGGCCGCG TTGCTGGCGT  
4561 TTTTCCATAG GCTCCGCCCC CCTGACGAGC ATCACAAAAA TCGACGCTCA AGTCAGAGGT  
4621 GGCGAAACCC GACAGGACTA TAAAGATACC AGGCGTTTCC CCCTGGAAGC TCCCTCGTGC  
4681 GCTCTCCTGT TCCGACCCTG CCGCTTACCG GATACCTGTC CGCCTTTCTC CCTTCGGGAA  
4741 GCGTGGCGCT TTCTCATAGC TCACGCTGTA GGTATCTCAG TTCGGTGTAG GTCGTTCGCT  
4801 CCAAGCTGGG CTGTGTGCAC GAACCCCCCG TTCAGCCCGA CCGCTGCGCC TTATCCGGTA  
4861 ACTATCGTCT TGAGTCCAAC CCGGTAAGAC ACGACTTATC GCCACTGGCA GCAGCCACTG  
4921 GTAACAGGAT TAGCAGAGCG AGGTATGTAG GCGGTGCTAC AGAGTTCTTG AAGTGGTGGC  
4981 CTAACTACGG CTACACTAGA AGGACAGTAT TTGGTATCTG CGCTCTGCTG AAGCCAGTTA  
5041 CCTTCGGAAA AAGAGTTGGT AGCTCTTGAT CCGGCAAACA AACCACCGCT GGTAGCGGTG  
5101 GTTTTTTTGT TTGCAAGCAG CAGATTACGC GCAGAAAAAA AGGATCTCAA GAAGATCCTT  
5161 TGATCTTTTC TACGGGGTCT GACGCTCAGT GGAACGAAAA CTCACGTTAA GGGATTTTGG  
5221 TCATGAGATT ATCAAAAAGG ATCTTCACCT AGATCCTTTT AAATTAAAAA TGAAGTTTTA  
5281 AATCAATCTA AAGTATATAT GAGTAAACTT GGTCTGACAG TTACCAATGC TTAATCAGTG  
5341 AGGCACCTAT CTCAGCGATC TGTCTATTTC GTTCATCCAT AGTTGCCTGA CTCCCCGTCG  
5401 TGTAGATAAC TACGATACGG GAGGGCTTAC CATCTGGCCC CAGTGCTGCA ATGATACCGC  
5461 GAGACCCACG CTCACCGGCT CCAGATTTAT CAGCAATAAA CCAGCCAGCC GGAAGGGCCG  
5521 AGCGCAGAAG TGGTCCTGCA ACTTTATCCG CCTCCATCCA GTCTATTAAT TGTTGCCGGG  
5581 AAGCTAGAGT AAGTAGTTCG CCAGTTAATA GTTTGCGCAA CGTTGTTGCC ATTGCTACAG  
5641 GCATCGTGGT GTCACGCTCG TCGTTTGGTA TGGCTTCATT CAGCTCCGGT TCCCAACGAT  
5701 CAAGGCGAGT TACATGATCC CCCATGTTGT GCAAAAAAGC GGTTAGCTCC TTCGGTCCTC  
5761 CGATCGTTGT CAGAAGTAAG TTGGCCGCAG TGTTATCACT CATGGTTATG GCAGCACTGC  
5821 ATAATTCTCT TACTGTCATG CCATCCGTAA GATGCTTTTC TGTGACTGGT GAGTACTCAA  
5881 CCAAGTCATT CTGAGAATAG TGTATGCGGC GACCGAGTTG CTCTTGCCCG GCGTCAATAC  
5941 GGGATAATAC CGCGCCACAT AGCAGAACTT TAAAAGTGCT CATCATTGGA AAACGTTCTT  
6001 CGGGGCGAAA ACTCTCAAGG ATCTTACCGC TGTTGAGATC CAGTTCGATG TAACCCACTC  
6061 GTGCACCCAA CTGATCTTCA GCATCTTTTA CTTTCACCAG CGTTTCTGGG TGAGCAAAAA  
6121 CAGGAAGGCA AAATGCCGCA AAAAAGGGAA TAAGGGCGAC ACGGAAATGT TGAATACTCA  
6181 TACTCTTCCT TTTTCAATAT TATTGAAGCA TTTATCAGGG TTATTGTCTC ATGAGCGGAT  
6241 ACATATTTGA ATGTATTTAG AAAAATAAAC AAATAGGGGT TCCGCGCACA TTTCCCCGAA  
6301 AAGTGCCACC TGACGTCTAA GAAACCATTA TTATCATGAC ATTAACCTAT AAAAATAGGC  






C-terminal tagged CPR expression construct 
    1 CTCGAGAAAT CATAAAAAAT TTATTTGCTT TGTGAGCGGA TAACAATTAT AATAGATTCA  
   61 ATTGTGAGCG GATAACAATT TCACACAGAA TTCATTAAAG AGGAGAAATT AACTATGGCA  
  121 CTTACGGCCT TCAGAAAGAA AAAAGAAGAA GTCCCCGAGT TCACCAAAAT TCAGACATTG  
  181 ACCTCCTCTG TCAGAGAGAG CAGCTTTGTG GAAAAGATGA AGAAAACGGG GAGGAACATC  
  241 ATCGTGTTCT ACGGCTCCCA GACGGGGACT GCAGAGGAGT TTGCCAACCG CCTGTCCAAG  
  301 GACGCCCACC GCTACGGGAT GCGAGGCATG TCAGCGGACC CTGAGGAGTA TGACCTGGCC  
  361 GACCTGAGCA GCCTGCCAGA GATCGACAAC GCCCTGGTGG TTTTCTGCAT GGCCACCTAC  
  421 GGTGAGGGAG ACCCCACCGA CAATGCCCAG GACTTCTACG ACTGGCTGCA GGAGACAGAC  
  481 GTGGATCTCT CTGGGGTCAA GTTCGCGGTG TTTGGTCTTG GGAACAAGAC CTACGAGCAC  
  541 TTCAATGCCA TGGGCAAGTA CGTGGACAAG CGGCTGGAGC AGCTCGGCGC CCAGCGCATC  
  601 TTTGAGCTGG GGTTGGGCGA CGACGATGGG AACTTGGAGG AGGACTTCAT CACCTGGCGA  
  661 GAGCAGTTCT GGCCGGCCGT GTGTGAACAC TTTGGGGTGG AAGCCACTGG CGAGGAGTCC  
  721 AGCATTCGCC AGTACGAGCT TGTGGTCCAC ACCGACATAG ATGCGGCCAA GGTGTACATG  
  781 GGGGAGATGG GCCGGCTGAA GAGCTACGAG AACCAGAAGC CCCCCTTTGA TGCCAAGAAT  
  841 CCGTTCCTGG CTGCAGTCAC CACCAACCGG AAGCTGAACC AGGGAACCGA GCGCCACCTC  
  901 ATGCACCTGG AATTGGACAT CTCGGACTCC AAAATCAGGT ATGAATCTGG GGACCACGTG  
  961 GCTGTGTACC CAGCCAACGA CTCTGCTCTC GTCAACCAGC TGGGCAAAAT CCTGGGTGCC  
 1021 GACCTGGACG TCGTCATGTC CCTGAACAAC CTGGATGAGG AGTCCAACAA GAAGCACCCA  
 1081 TTCCCGTGCC CTACGTCCTA CCGCACGGCC CTCACCTACT ACCTGGACAT CACCAACCCG  
 1141 CCGCGTACCA ACGTGCTGTA CGAGCTGGCG CAGTACGCCT CGGAGCCCTC GGAGCAGGAG  
 1201 CTGCTGCGCA AGATGGCCTC CTCCTCCGGC GAGGGCAAGG AGCTGTACCT GAGCTGGGTG  
 1261 GTGGAGGCCC GGAGGCACAT CCTGGCCATC CTGCAGGACT GCCCGTCCCT GCGGCCCCCC  
 1321 ATCGACCACC TGTGTGAGCT GCTGCCGCGC CTGCAGGCCC GCTACTACTC CATCGCCTCA  
 1381 TCCTCCAAGG TCCACCCCAA CTCTGTGCAC ATCTGTGCGG TGGTTGTGGA GTACGAGACC  
 1441 AAGGCCGGCC GCATCAACAA GGGCGTGGCC ACCAACTGGC TGCGGGCCAA GGAGCCTGCC  
 1501 GGGGAGAACG GCGGCCGTGC GCTGGTGCCC ATGTTCGTGC GCAAGTCCCA GTTCCGCCTG  
 1561 CCCTTCAAGG CCACCACGCC TGTCATCATG GTGGGCCCCG GCACCGGGGT GGCACCCTTC  
 1621 ATAGGCTTCA TCCAGGAGCG GGCCTGGCTG CGACAGCAGG GCAAGGAGGT GGGGGAGACG  
 1681 CTGCTGTACT ACGGCTGCCG CCGCTCGGAT GAGGACTACC TGTACCGGGA GGAGCTGGCG  
 1741 CAGTTCCACA GGGACGGTGC GCTCACCCAG CTCAACGTGG CCTTCTCCCG GGAGCAGTCC  
 1801 CACAAGGTCT ACGTCCAGCA CCTGCTAAAG CAAGACCGAG AGCACCTGTG GAAGTTGATC  
 1861 GAAGGCGGTG CCCACATCTA CGTCTGTGGG GATGCACGGA ACATGGCCAG GGATGTGCAG  
 1921 AACACCTTCT ACGACATCGT GGCTGAGCTC GGGGCCATGG AGCACGCGCA GGCGGTGGAC  
 1981 TACATCAAGA AACTGATGAC CAAGGGCCGC TACTCCCTGG ACGTGTGGAG CGGGGGTGGC  
 2041 AGCGGTTCTG GCGCAGCAGC GGAAATCAGT GGTCACATCG TACGTTCCCC GATGGTTGGT  
 2101 ACTTTCTACC GCACCCCAAG CCCGGACGCA AAAGCGTTCA TCGAAGTGGG TCAGAAAGTC  
 2161 AACGTGGGCG ATACCCTGTG CATCGTTGAA GCCATGAAAA TGATGAACCA GATCGAAGCG  
 2221 GACAAATCCG GTACCGTGAA AGCAATTCTG GTCGAAAGTG GACAACCGGT AGAATTTGAC  
 2281 GAGCCGCTGG TCGTCATCGA GGGTGGCAGC GGTTCTGGCC ACCATCACCA TCACCATAAG  
 2341 CTTAATTAGC TGAGCTTGGA CTCCTGTTGA TAGATCCAGT AATGACCTCA GAACTCCATC  
 2401 TGGATTTGTT CAGAACGCTC GGTTGCCGCC GGGCGTTTTT TATTGGTGAG AATCCAAGCT  
 2461 AGCTTGGCGA GATTTTCAGG AGCTAAGGAA GCTAAAATGG AGAAAAAAAT CACTGGATAT  
 2521 ACCACCGTTG ATATATCCCA ATGGCATCGT AAAGAACATT TTGAGGCATT TCAGTCAGTT  
 2581 GCTCAATGTA CCTATAACCA GACCGTTCAG CTGGATATTA CGGCCTTTTT AAAGACCGTA  
 2641 AAGAAAAATA AGCACAAGTT TTATCCGGCC TTTATTCACA TTCTTGCCCG CCTGATGAAT  
 2701 GCTCATCCGG AATTTCGTAT GGCAATGAAA GACGGTGAGC TGGTGATATG GGATAGTGTT  
 2761 CACCCTTGTT ACACCGTTTT CCATGAGCAA ACTGAAACGT TTTCATCGCT CTGGAGTGAA  
 2821 TACCACGACG ATTTCCGGCA GTTTCTACAC ATATATTCGC AAGATGTGGC GTGTTACGGT  
 2881 GAAAACCTGG CCTATTTCCC TAAAGGGTTT ATTGAGAATA TGTTTTTCGT CTCAGCCAAT  
 2941 CCCTGGGTGA GTTTCACCAG TTTTGATTTA AACGTGGCCA ATATGGACAA CTTCTTCGCC  
 3001 CCCGTTTTCA CCATGGGCAA ATATTATACG CAAGGCGACA AGGTGCTGAT GCCGCTGGCG  
 3061 ATTCAGGTTC ATCATGCCGT TTGTGATGGC TTCCATGTCG GCAGAATGCT TAATGAATTA  
 3121 CAACAGTACT GCGATGAGTG GCAGGGCGGG GCGTAATTTT TTTAAGGCAG TTATTGGTGC  
 3181 CCTTAAACGC CTGGGGTAAT GACTCTCTAG CTTGAGGCAT CAAATAAAAC GAAAGGCTCA  
 3241 GTCGAAAGAC TGGGCCTTTC GTTTTATCTG TTGTTTGTCG GTGAACGCTC TCCTGAGTAG  
 3301 GACAAATCCG CCCTCTAGAT TACGTGCAGT CGATGATAAG CTGTCAAACA TGAGAATTGT  
 3361 GCCTAATGAG TGAGCTAACT TACATTAATT GCGTTGCGCT CACTGCCCGC TTTCCAGTCG  




 3481 CGTATTGGGC GCCAGGGTGG TTTTTCTTTT CACCAGTGAG ACGGGCAACA GCTGATTGCC  
 3541 CTTCACCGCC TGGCCCTGAG AGAGTTGCAG CAAGCGGTCC ACGCTGGTTT GCCCCAGCAG  
 3601 GCGAAAATCC TGTTTGATGG TGGTTAACGG CGGGATATAA CATGAGCTGT CTTCGGTATC  
 3661 GTCGTATCCC ACTACCGAGA TATCCGCACC AACGCGCAGC CCGGACTCGG TAATGGCGCG  
 3721 CATTGCGCCC AGCGCCATCT GATCGTTGGC AACCAGCATC GCAGTGGGAA CGATGCCCTC  
 3781 ATTCAGCATT TGCATGGTTT GTTGAAAACC GGACATGGCA CTCCAGTCGC CTTCCCGTTC  
 3841 CGCTATCGGC TGAATTTGAT TGCGAGTGAG ATATTTATGC CAGCCAGCCA GACGCAGACG  
 3901 CGCCGAGACA GAACTTAATG GGCCCGCTAA CAGCGCGATT TGCTGGTGAC CCAATGCGAC  
 3961 CAGATGCTCC ACGCCCAGTC GCGTACCGTC TTCATGGGAG AAAATAATAC TGTTGATGGG  
 4021 TGTCTGGTCA GAGACATCAA GAAATAACGC CGGAACATTA GTGCAGGCAG CTTCCACAGC  
 4081 AATGGCATCC TGGTCATCCA GCGGATAGTT AATGATCAGC CCACTGACGC GTTGCGCGAG  
 4141 AAGATTGTGC ACCGCCGCTT TACAGGCTTC GACGCCGCTT CGTTCTACCA TCGACACCAC  
 4201 CACGCTGGCA CCCAGTTGAT CGGCGCGAGA TTTAATCGCC GCGACAATTT GCGACGGCGC  
 4261 GTGCAGGGCC AGACTGGAGG TGGCAACGCC AATCAGCAAC GACTGTTTGC CCGCCAGTTG  
 4321 TTGTGCCACG CGGTTGGGAA TGTAATTCAG CTCCGCCATC GCCGCTTCCA CTTTTTCCCG  
 4381 CGTTTTCGCA GAAACGTGGC TGGCCTGGTT CACCACGCGG GAAACGGTCT GATAAGAGAC  
 4441 ACCGGCATAC TCTGCGACAT CGTATAACGT TACTGGTTTC ACATTCACCA CCCTGAATTG  
 4501 ACTCTCTTCC GGGCGCTATC ATGCCATACC GCGAAAGGTT TTGCACCATT CGATGGTGTC  
 4561 GGAATTTCGG GCAGCGTTGG GTCCTGGCCA CGGGTGCGCA TGATCTAGAG CTGCCTCGCG  
 4621 CGTTTCGGTG ATGACGGTGA AAACCTCTGA CACATGCAGC TCCCGGAGAC GGTCACAGCT  
 4681 TGTCTGTAAG CGGATGCCGG GAGCAGACAA GCCCGTCAGG GCGCGTCAGC GGGTGTTGGC  
 4741 GGGTGTCGGG GCGCAGCCAT GACCCAGTCA CGTAGCGATA GCGGAGTGTA TACTGGCTTA  
 4801 ACTATGCGGC ATCAGAGCAG ATTGTACTGA GAGTGCACCA TATGCGGTGT GAAATACCGC  
 4861 ACAGATGCGT AAGGAGAAAA TACCGCATCA GGCGCTCTTC CGCTTCCTCG CTCACTGACT  
 4921 CGCTGCGCTC GGTCGTTCGG CTGCGGCGAG CGGTATCAGC TCACTCAAAG GCGGTAATAC  
 4981 GGTTATCCAC AGAATCAGGG GATAACGCAG GAAAGAACAT GTGAGCAAAA GGCCAGCAAA  
 5041 AGGCCAGGAA CCGTAAAAAG GCCGCGTTGC TGGCGTTTTT CCATAGGCTC CGCCCCCCTG  
 5101 ACGAGCATCA CAAAAATCGA CGCTCAAGTC AGAGGTGGCG AAACCCGACA GGACTATAAA  
 5161 GATACCAGGC GTTTCCCCCT GGAAGCTCCC TCGTGCGCTC TCCTGTTCCG ACCCTGCCGC  
 5221 TTACCGGATA CCTGTCCGCC TTTCTCCCTT CGGGAAGCGT GGCGCTTTCT CATAGCTCAC  
 5281 GCTGTAGGTA TCTCAGTTCG GTGTAGGTCG TTCGCTCCAA GCTGGGCTGT GTGCACGAAC  
 5341 CCCCCGTTCA GCCCGACCGC TGCGCCTTAT CCGGTAACTA TCGTCTTGAG TCCAACCCGG  
 5401 TAAGACACGA CTTATCGCCA CTGGCAGCAG CCACTGGTAA CAGGATTAGC AGAGCGAGGT  
 5461 ATGTAGGCGG TGCTACAGAG TTCTTGAAGT GGTGGCCTAA CTACGGCTAC ACTAGAAGGA  
 5521 CAGTATTTGG TATCTGCGCT CTGCTGAAGC CAGTTACCTT CGGAAAAAGA GTTGGTAGCT  
 5581 CTTGATCCGG CAAACAAACC ACCGCTGGTA GCGGTGGTTT TTTTGTTTGC AAGCAGCAGA  
 5641 TTACGCGCAG AAAAAAAGGA TCTCAAGAAG ATCCTTTGAT CTTTTCTACG GGGTCTGACG  
 5701 CTCAGTGGAA CGAAAACTCA CGTTAAGGGA TTTTGGTCAT GAGATTATCA AAAAGGATCT  
 5761 TCACCTAGAT CCTTTTAAAT TAAAAATGAA GTTTTAAATC AATCTAAAGT ATATATGAGT  
 5821 AAACTTGGTC TGACAGTTAC CAATGCTTAA TCAGTGAGGC ACCTATCTCA GCGATCTGTC  
 5881 TATTTCGTTC ATCCATAGTT GCCTGACTCC CCGTCGTGTA GATAACTACG ATACGGGAGG  
 5941 GCTTACCATC TGGCCCCAGT GCTGCAATGA TACCGCGAGA CCCACGCTCA CCGGCTCCAG  
 6001 ATTTATCAGC AATAAACCAG CCAGCCGGAA GGGCCGAGCG CAGAAGTGGT CCTGCAACTT  
 6061 TATCCGCCTC CATCCAGTCT ATTAATTGTT GCCGGGAAGC TAGAGTAAGT AGTTCGCCAG  
 6121 TTAATAGTTT GCGCAACGTT GTTGCCATTG CTACAGGCAT CGTGGTGTCA CGCTCGTCGT  
 6181 TTGGTATGGC TTCATTCAGC TCCGGTTCCC AACGATCAAG GCGAGTTACA TGATCCCCCA  
 6241 TGTTGTGCAA AAAAGCGGTT AGCTCCTTCG GTCCTCCGAT CGTTGTCAGA AGTAAGTTGG  
 6301 CCGCAGTGTT ATCACTCATG GTTATGGCAG CACTGCATAA TTCTCTTACT GTCATGCCAT  
 6361 CCGTAAGATG CTTTTCTGTG ACTGGTGAGT ACTCAACCAA GTCATTCTGA GAATAGTGTA  
 6421 TGCGGCGACC GAGTTGCTCT TGCCCGGCGT CAATACGGGA TAATACCGCG CCACATAGCA  
 6481 GAACTTTAAA AGTGCTCATC ATTGGAAAAC GTTCTTCGGG GCGAAAACTC TCAAGGATCT  
 6541 TACCGCTGTT GAGATCCAGT TCGATGTAAC CCACTCGTGC ACCCAACTGA TCTTCAGCAT  
 6601 CTTTTACTTT CACCAGCGTT TCTGGGTGAG CAAAAACAGG AAGGCAAAAT GCCGCAAAAA  
 6661 AGGGAATAAG GGCGACACGG AAATGTTGAA TACTCATACT CTTCCTTTTT CAATATTATT  
 6721 GAAGCATTTA TCAGGGTTAT TGTCTCATGA GCGGATACAT ATTTGAATGT ATTTAGAAAA  
 6781 ATAAACAAAT AGGGGTTCCG CGCACATTTC CCCGAAAAGT GCCACCTGAC GTCTAAGAAA  
 6841 CCATTATTAT CATGACATTA ACCTATAAAA ATAGGCGTAT CACGAGGCCC TTTCGTCTTC  






CYP3A4 recombinant protein sequence 
   1 MALTAYGTHS HGLFKKLGIP GPTPLPFLGN ILSYHKGFCM FDMECHKKYG KVWGFYDGQQ  
 61 PVLAITDPDM IKTVLVKECY SVFTNRRPFG PVGFMKSAIS IAEDEEWKRL RSLLSPTFTS  
121 GKLKEMVPII AQYGDVLVRN LRREAETGKP VTLKDIFGAY SMDVITSTSF GVNIDSLNNP  
181 QDPFVENTKK LLRFDFLDPF FLSITVFPFL IPILEVLNIC VFPREVTNFL RKSIKRMKES  
241 RLEDTQKHRV DFLQLMIDSQ NSKETESHKA LSDLELVAQS IIFIFAGYET TSSVLSFIMY  
301 ELATHPDVQQ KLQEEIDAVL PNKAPPTYDT VLQMEYLDMV VNETLRLFPI AMRLERVCKK  
361 DVEINGMFIP KGVVVMIPSY ALHRDPKYWT EPEKFLPERF SKKNKDNIDP YIYTPFGSGP  
421 RNCIGMRFAL MNMKLALIRV LQNFSFKPCK ETQIPLKLSL GGLLQPEKPV VLKVESRDGT  
481 VSGAGGGSGS GAAAEISGHI VRSPMVGTFY RTPSPDAKAF IEVGQKVNVG DTLCIVEAMK  
541 MMNQIEADKS GTVKAILVES GQPVEFDEPL VVIEGGSGSG HHHHHHKLN*  
 CYP2C9 recombinant protein sequence 
   1 MALTALPPGP TPLPVIGNIL QIGIKDISKS LTNLSKVYGP VFTLYFGLKP IVVLHGYEAV  
  61 KEALIDLGEE FSGRGIFPLA ERANRGFGIV FSNGKKWKEI RRFSLMTLRN FGMGKRSIED  
 121 RVQEEARCLV EELRKTKASP CDPTFILGCA PCNVICSIIF HKRFDYKDQQ FLNLMEKLNE  
 181 NIKILSSPWI QICNNFSPII DYFPGTHNKL LKNVAFMKSY ILEKVKEHQE SMDMNNPQDF  
 241 IDCFLMKMEK EKHNQPSEFT IESLENTAVD LFGAGTETTS TTLRYALLLL LKHPEVTAKV  
 301 QEEIERVIGR NRSPCMQDRS HMPYTDAVVH EVQRYIDLLP TSLPHAVTCD IKFRNYLIPK  
 361 GTTILISLTS VLHDNKEFPN PEMFDPHHFL DEGGNFKKSK YFMPFSAGKR ICVGEALAGM  
 421 ELFLFLTSIL QNFNLKSLVD PKNLDTTPVV NGFASVPPFY QLCFIPVGGG SGSGAAAEIS  
 481 GHIVRSPMVG TFYRTPSPDA KAFIEVGQKV NVGDTLCIVE AMKMMNQIEA DKSGTVKAIL  
 541 VESGQPVEFD EPLVVIEGGS GSGHHHHHHK LN*  
CPR recombinant protein sequence 
  1 MALTAFRKKK EEVPEFTKIQ TLTSSVRESS FVEKMKKTGR NIIVFYGSQT GTAEEFANRL  
 61 SKDAHRYGMR GMSADPEEYD LADLSSLPEI DNALVVFCMA TYGEGDPTDN AQDFYDWLQE  
121 TDVDLSGVKF AVFGLGNKTY EHFNAMGKYV DKRLEQLGAQ RIFELGLGDD DGNLEEDFIT  
181 WREQFWPAVC EHFGVEATGE ESSIRQYELV VHTDIDAAKV YMGEMGRLKS YENQKPPFDA  
241 KNPFLAAVTT NRKLNQGTER HLMHLELDIS DSKIRYESGD HVAVYPANDS ALVNQLGKIL  
301 GADLDVVMSL NNLDEESNKK HPFPCPTSYR TALTYYLDIT NPPRTNVLYE LAQYASEPSE  
361 QELLRKMASS SGEGKELYLS WVVEARRHIL AILQDCPSLR PPIDHLCELL PRLQARYYSI  
421 ASSSKVHPNS VHICAVVVEY ETKAGRINKG VATNWLRAKE PAGENGGRAL VPMFVRKSQF  
481 RLPFKATTPV IMVGPGTGVA PFIGFIQERA WLRQQGKEVG ETLLYYGCRR SDEDYLYREE  
541 LAQFHRDGAL TQLNVAFSRE QSHKVYVQHL LKQDREHLWK LIEGGAHIYV CGDARNMARD  
601 VQNTFYDIVA ELGAMEHAQA VDYIKKLMTK GRYSLDVWSG GGSGSGAAAE ISGHIVRSPM  
661 VGTFYRTPSP DAKAFIEVGQ KVNVGDTLCI VEAMKMMNQI EADKSGTVKA ILVESGQPVE  
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Abstract: The original map of mammalian cytochrome P450 (CYP450) residues involved in substrate recognition was prepared for the 
CYP2 family by Gotoh in 1992 by manual alignment of mammalian CYP450 residues with substrate recognition site (SRS) residues 
manually delimited from a bacterial cytochrome P450-substrate complex. Using modern structural bioinformatics tools, we have identi-
fied CYP450-ligand interactions in mammalian complexes to create a “X-ray structures” SRS map. In a parallel approach, we have built 
a “docking” SRS map by successful docking of 868 known substrates of 10 mammalian CYP450 isoforms and analysis of contacts made 
in docking solutions. We subsequently combined these maps to create a unified description of SRSs. The new map largely agrees with the 
original map by Gotoh with the six original SRS regions appearing in similar locations along the CYP450 sequence as in Gotoh’s map. 
However, important differences also occur: Two new SRS regions appear before SRS1 and we have assigned them as SRS1’a and 
SRS1’b; SRS1 is much bigger in our map than in Gotoh’s (49 aligned positions versus 28); & SRS2 and SRS3 are co-joined in our map 
to give a single large SRS region (60 aligned positions) we have designated as SRS(2,3), in contrast to the 9 and 10 aligned positions in-
dividually covered by SRS2 and SRS3 respectively in Gotoh’s original map. These differences result in the SRS zone covering 33 % of 
the mammalian CYP450 sequence in our map as opposed to 16 % in Gotoh’s map. 
Keywords: Cytochrome P450, contact residues, docking complex, Gotoh’s map, site of metabolism, substrate recognition site. 
INTRODUCTION 
 The Cytochromes P450 (CYP450, EC 1.14.14.1) are a super-
family of heme-thiolate monooxygenases that catalyze the oxida-
tion of a wide variety of hydrophobic endogenous and xenobiotic 
substrates [1] and CYP450 homologs have been identified from all 
lineages of life including eukaryotes and bacteria [2] and viruses 
[3]. CYP450 genes have been organised into families and sub-
families on the basis of sequence identity – members of the same 
family share more than 40 % amino acid identity whereas members 
of the same sub-family share more than 55 % amino acid identity 
[4]. The nomenclature system for CYP450 genes and proteins is as 
follows: the abbreviation ‘CYP’, followed by an Arabic numeral 
indicating the gene family, a capital Roman letter indicating the 
sub-family and another Arabic numeral for the individual gene [4]. 
 Enzymes in CYP450 family 1 through 3 are the major xenobi-
otic metabolizing enzymes in mammals and are characterized by 
broad substrate specificities [5, 6] – for example, a search of the 
PubChem database shows that CYP3A4 has ~ 400 known xenobi-
otic substrates, CYP2D6 has ~ 210, CYP2C9 has ~ 160, CYP1A2 
has ~ 65, CYP2A6 has ~ 30, CYP2B4 has ~ 10 and CYP2C5 has ~ 
5. This evolutionary strategy has allowed few catalysts to han-
dle/process relatively large numbers of exogenous molecules en-
countered by mammals. Notably, whilst the substrate specificities 
of these xenobiotic metabolizing CYP450 enzymes partially over-
lap, they are also distinguishable from each other [5, 7, 8]. 
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 An important goal in CYP450 research has been the elucidation 
of the molecular mechanisms underlying the broad specificities of 
the mammalian xenobiotic metabolizing CYP450 systems and an 
important step towards this is the identification of parts of the 
CYP450 protein that are involved in the recognition/binding of 
substrates [5, 7]. A comprehensive delimitation of mammalian sub-
strate recognition site (SRS) amino acid residues was carried out by 
Gotoh [5], who inferred a map of SRSs in mammalian CYP450 
proteins by performing group-to-group alignment (the modern day 
equivalent of profile-profile alignment) of a group of mammalian 
CYP450 sequences to a group of bacterial CYP450 sequences that 
included Pseudomonas putida CYP450 101A (also known as 
P450cam); CYP450 101A was the only CYP whose substrate-
binding residues were known at the time – these had been deter-
mined by X-ray crystallography of a substrate-bound form [2, 5]. 
 Gotoh’s work stimulated experimental studies that sought to 
investigate the existence of the SRSs he had predicted in mammal-
ian CYP450. Generally, the strategy employed in these studies has 
involved identification of amino acid differences that lie within 
Gotoh’s SRSs and that are principally responsible for characteristic 
functional differences between closely-related enzymes [7]. Such 
amino acids have been identified on the basis of either functional 
inter-conversions achieved by inter-changing specific residues be-
tween closely-related enzymes or by studying the functional proper-
ties of chimeras of closely-related enzymes [7-9]. Examples of 
these studies include work from Halpert’s laboratory which pro-
vided support for the existence in CYP2B1 of five out the six SRSs 
predicted by Gotoh – the only exception being SRS3 [10, 11]. 
Halpert’s laboratory also provided evidence for the existence in 
CYP3A4 of SRS2 [12], SRS1 [13] & SRS5 [14] and provided 
agreement between substrate recognition studies with CYP450 
family 2 and family 3 enzymes [9], whilst Conley et al. provided 
evidence for the existence of SRS1 in porcine aromatase cyto-
chrome P450 (P450arom) [15]. Together, these works have vali-
dated Gotoh’s prediction of the six SRSs and have established that 
these regions are involved in substrate-binding and contribute to the 
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differences in substrate specificities observed between isoforms 
[14, 15]. 
 However, other experimental studies have identified amino acid 
differences which lie outside Gotoh’s SRSs but which are also ap-
parently responsible for characteristic functional differences be-
tween closely-related CYP450 enzymes [7, 8, 16, 17]. Whilst al-
most all of the residues identified by analysis of closely-related 
CYP450 isoforms as being critical for substrate specificity are lo-
cated in or near SRSs [7], the identification of residues outside 
Gotoh’s SRSs that influence substrate specificity suggests that there 
is scope to re-evaluate and extend Gotoh’s original SRS map. For 
example, von Weymarn et al. showed that substitution of the amino 
acid triplet Ser407, Asn417 and Ala419 (all lying between SRS5 
and SRS6) protects CYP2B1 against mechanism-based inactivation 
by acetylenic compounds [16]; Biagini et al. showed that the non-
SRS residues Val4 (occurs before SRS1) and Phe187 (occurs closer 
to SRS2, between SRS1 and SRS2) have a role in testosterone hy-
droxylation by CYP2C11 [17]; He et al. showed that the non-SRS 
residues His120 (occurs just C-terminal to SRS1) and Pro221 (oc-
curs between SRS2 and SRS3) have a role in progesterone hy-
droxylation by CYP2B5 [7]; & Ibeanu et al. showed that the non-
SRS residues Pro220 and Thr221 (both lying in the F-G loop be-
tween SRS2 and SRS3) are important determinants of the omepra-
zole hydroxylase activity of CYP2C19 [8]. 
 Gotoh’s SRS map undoubtedly provided a good framework for 
researchers to contextualise their experimental results. We note 
however that the strategy of studying characteristic functional dif-
ferences between closely-related CYP450 enzymes had been used 
prior to Gotoh’s work to delimit specificity determining residue 
positions in CYP450 sequences. For example, Aoyama et al. 
showed that CYP2B1 positions Leu58 and Ile114 modulate the 
stereo- and regio-specificity of steroid hydroxylation by the enzyme 
[18]; of these, Ile114 lies within Gotoh’s SRS1 but Leu58 occurs 
before SRS1 in Gotoh’s map. Linberg & Negishi showed that posi-
tions 117, 209 and 365 in mouse P450coh (now called CYP2A5) 
modulate substrate specificity [19, 20]; of these, residue 117 lies in 
Gotoh’s SRS1, residue 209 lies in Gotoh’s SRS2 and residue 365 
lies in Gotoh’s SRS5. Kedzie et al. showed that CYP2B1 position 
478 modulates androstenedione 16-beta hydroxylase activity [21]; 
this residue lies in Gotoh’s SRS6.  
 Mechanism-based inhibitors were also used to delimit substrate 
recognition sites prior to Gotoh’s work. For example, using mecha-
nism based inhibitors Yun et al. discovered that CYP1A2 positions 
175-184 (peptide FQELMAAVGR) and 67-78 (peptide 
L(S)QQYGDVLQIR) include substrate recognition/binding regions 
[22]; of these, residues 175-184 comprise a non-SRS region lying 
between Gotoh’s SRS1 and SRS2, whilst residues 67-78 comprise a 
non-SRS region occurring before Gotoh’s SRS1. More recently, 
methods using mechanism-based inhibitors have continued to yield 
insights into substrate recognition in CYP450, an example being the 
work of Lin et al. which demonstrated the role of the CYP2B1 resi-
due Thr205 in androgen 16-beta hydroxylation activity [23]; this 
residue lies within Gotoh’s SRS2. 
 A sizeable number of mammalian structures have been depos-
ited into the RCSB Protein Data Bank (www.pdb.org) since Gotoh 
published his map – in 2011 there are around 40 substrate/inhibitor-
bound mammalian CYP450 structures and around 10 sub-
strate/inhibitor-free structures. Examples of substrate-bound struc-
tures include: CYP2C5 in complex with the drug Diclofenac [24]; 
CYP2C9 in complex with the anti-coagulant Warfarin [25]; 
CYP2E1 in complex with fatty-acid substrate analogs [26]; 
CYP2R1 in complex with vitamin D3 [27]; CYP2A6 in complex 
with Methoxsalen and with Coumarin [28]; CYP1A2 in complex 
with alpha-naphthoflavone [29]; CYP3A4 in complex with Me-
tyrapone and Progesterone [25]; human brain CYP46A1 in complex 
with cholesterol substrate [30]; human placental aromatase 
(CYP19A1) in complex with Androstenedione [31]; human Prosta-
cyclin synthase (CYP8A1) in complex with the inhibitor Minoxidil 
[32]; and rat CYP24A1 docked with 1 ,25-dihydroxyvitamin D3 
[33]. 
 Furthermore, since publication of Gotoh’s SRS map, numerous 
structural bioinformatics tools which enable the precise delimitation 
of interactions between protein and ligand in protein-ligand com-
plexes have been developed. These tools include the program Lig-
plot - which delimits hydrophobic and hydrogen-bond interactions 
between protein amino acid side chains and the bound ligand [34] - 
and Zamora’s energetics functions/molecular interaction fields 
which calculate ligand-protein interaction energies [35]. Powerful 
docking tools such as FlexX, Gold, Glide etc have also been devel-
oped which can be used for example to generate in silico CYP450-
substrate complexes that can then be evaluated on the basis of con-
siderations of the likely site-of-metabolism [36]. The site of me-
tabolism may be experimentally determined or can today be pre-
dicted using powerful programs such as Metasite [37-39]. Further-
more, molecular dynamics tools and systems have also been devel-
oped specifically for CYP450s that can be applied to elucidate the 
roles of different parts of CYP450 molecules (especially the F-G 
loop) in substrate recognition [40-42].  
 Gotoh’s SRS map continues to be a highly relevant tool in 
CYP450 research today. For example, it can be used to guide priori-
tisation of mutants when studying the effect of clinically-relevant 
CYP450 polymorphic variation on drug metabolism or on adverse 
drug reactions using reconstituted recombinant protein systems. In 
addition, when the importance of the different positions within SRS 
regions as determinants of CYP450 substrate specificity is scored, 
say, by using the frequency with which they are used in CYP450-
ligand complexes, such a map can be used to inform protein engi-
neering studies of CYP450 substrate specificity. However, the de-
velopment of such a quantitative position-scored SRS map has to be 
preceded, among other things, by the definition of as complete an 
SRS map as possible. In the present work, we have therefore ap-
plied a range of new computational tools to the wealth of new struc-
tural data with the goal of creating a more complete mammalian 
CYP450 substrate recognition site map which can, amongst others, 
explain aspects of the substrate specificity data that did not other-
wise accord with Gotoh’s original SRSs.  
MATERIALS AND METHODS 
Structures and Sequences 
 Structures of ligand-bound mammalian CYP450 proteins were 
retrieved from the RCSB Protein Data Bank [43]. The structure 
PDB codes are as follows. CYP1A2 (Homo sapiens): 2HI4. 
CYP2A6 (Homo sapiens): 3EBS, 1Z11, 2FDU, 2FDV, 2FDW and 
2FDY. CYP2A13 (Homo sapiens): 2P85. CYP2B4 (Oryctolagus 
cuniculus): 2Q6N, 2BDM, 1SUO, 3KW4 and 3ME6. CYP2B6 
(Homo sapiens): 3IBD. CYP2C5 (Oryctolagus cuniculus): 1N6B 
and 1NR6. CYP2C8 (Homo sapiens): 2NNJ, 2NNI, 2NNH and 
2VN0. CYP2C9 (Homo sapiens): 1OG5 and 1R9O. CYP2E1 
(Homo sapiens): 3GPH, 3KOH, 3LC4, 3E4E and 3E6I. CYP2R1 
(Homo sapiens): 3C6G, 3DL9 and 3CZH. CYP3A4 (Homo 
sapiens): 1W0F, 1W0G, 2J0D, 2V0M and 3NXU. CYP46A1 
(Homo sapiens): 2Q9F, 3MDM, 3MDR, 3MDT and 3MDV. 
CYP19A1 (Homo sapiens): 3EQM. CYP8A1 (Homo sapiens): 
3B6H. CYP11A1 (Homo sapiens): 3NA0. We note that 3EBS is a 
structure of the I208S/I300F/G301A/S369G mutant of CYP2A6 
bound to the drug phenacetin. We also note that 1NR6 is a structure 
of the N202H/R206E/I207L/S209G/S210T mutant of CYP2C5 
bound to the drug diclofenac. 
 Sequences were retrieved from the Universal Protein Resource 
Knowledgebase (UniProtKB/Swiss-Prot) database via the European 
Bioinformatics Institute website [44]. The accession numbers were 
according to the UniProtKB database unless otherwise stated. The 
sequence accession numbers used herein are as follows. CYP1A2: 
P05177 (Homo sapiens), CYP2A6: P11509 (Homo sapiens), 
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CYP2A13: Q16696 (Homo sapiens), CYP2B4: P00178 (Orycto-
lagus cuniculus), CYP2B6: P20813 (Homo sapiens), CYP2C5: 
P00179 (Oryctolagus cuniculus), CYP2C8: P10632 (Homo 
sapiens), CYP2C9: P11712 (Homo sapiens), CYP2E1: P05181 
(Homo sapiens), CYP2R1: Q6VVX0 (Homo sapiens), CYP3A4: 
P08684 (Homo sapiens), CYP46A1: Q9Y6A2 (Homo sapiens), 
CYP19A1: P11511 (Homo sapiens), CYP8A1: Q16647 (Homo 
sapiens) and CYP11A1: P05108 (Homo sapiens). 
 This study includes complexes of substrate- and inhibitor-
bound CYP450s. Substrate complexes are included only if the sub-
strate presents a known site of metabolism, or one predicted by 
MetaSite (see below), within 5 Å of the heme iron. Similarly, in-
hibitor complexes are included only if the inhibitor presents a lone 
pair of electrons (most commonly via an inhibitor nitrogen atom) 
within 5 Å of the heme iron. Using these criteria, the following 
exclusions were made: (CYP3A4, 2V0M, KLN 1501), (CYP2C8, 
2NNH, REA 502), (CYP2C8, 2NNH, PLM 503), (CYP2C8, 2NNI, 
PLM 502), (CYP2C8, 2NNJ, PLM 502), (CYP8A1, 3B6H, BOG 
701), (CYP2B4, 2BDM, TMI 502) and (CYP2B4, 2BDM, TMI 
503). 
Delimitation of Protein-ligand Interactions 
 The program LIGPLOT [34] was used in default mode to de-
limit interactions between the ligand and the protein in X-ray crys-
tal structure complexes used in this study and in docking complexes 
generated in this study. LIGPLOT delimits and reports amino acid 
residues that make hydrophobic interactions and hydrogen-bond 
interactions with the bound ligand. In order to confirm that the de-
limitations made using LIGPLOT were consistent with those made 
using other related methods, we also used Zamora’s molecular in-
teraction fields (MIFs) [35] to delimit amino acid residues that in-
teract with ligand in a limited number of X-ray protein-ligand com-
plexes; in this quality control exercise, only amino acids whose 
MIF-calculated interaction energies with the ligand were   
-1 kcal/mol were regarded as “contact residues”. Through this exer-
cise, we quickly established that Zamora’s MIF were delimiting 
exactly the same set of residues as LIGPLOT in the considered 
structures, confirming that LIGPLOT’s delimitations can be trusted. 
Given that Zamora’s MIFs appeared to provide no additional de-
limitations over LIGPLOT, for simplicity we thereafter only used 
LIGPLOT in all subsequent work. 
Sequence Alignments 
 CYP450 protein sequences were aligned using the program 
ClustalW (default parameters) [45-47]. The quality of the multiple 
sequence alignments was assessed using various cues that included: 
(i) successful alignment of the heme iron-binding cysteine residue, 
(ii) successful alignment of secondary structure elements such as 
the I, F and G helices and (iii) similarity with Gotoh’s alignment of 
CYP2 family proteins and bacterial CYPs [5]. 
The CYP Substrate Space: Molecular Descriptors 
 A list of known substrates for CYP1A2, CYP2A6, CYP2B4, 
CYP2C5, CYP2C8, CYP2C9, CYP2D6, CYP2R1, CYP3A4 and 
CYP46A1 was compiled from primary literature, Micromedex, 
RCSB Protein Data Bank and other online databases and resources. 
Online resources that were used include the twelve sources listed as 
references [43, 48-58]. Chemical structures for these substrates 
were obtained from PubChem database and were processed using 
the “Standardize Molecule”, “Strip Salts”, and “Add Hydrogens” 
modules of Pipeline Pilot Student Edition v6.1.5. [59]. PaDEL-
Descriptor v2.4 [60] was then used to compute the PubChem fin-
gerprints [61] for the substrates. A principal component analysis 
(PCA) plot of the substrates using the PubChem fingerprints was 
performed using SIMCA-P+ v12.0.1 [62] to show the distribution 
of the substrates in the chemical space. 
 
Prediction of Sites of Metabolism Using MetaSite 
 MetaSite is a program designed to compute and rank the likely 
structure of metabolites formed by CYP-mediated primary metabo-
lism [37]. To do this, MetaSite calculates two sets of descriptors, 
one for the CYP enzyme and one for the potential substrate, respec-
tively representing the chemical fingerprint of the enzyme and the 
substrate. The set of descriptors used to characterize the CYP en-
zyme is based on GRID flexible molecular interaction fields 
(GRID-MIFs). Using the 3D structure of a given compound, Meta-
Site then automatically calculates charges and reactivities, pharma-
cophoric recognition, descriptor handling, and similarity. Validation 
of the method has shown that the primary site of metabolism is 
found in the top three MetaSite predictions in more than 85% of 
cases.  
 In our work, SMILES strings for CYP450 ligands were pre-
pared from PDB files of the entities using Open Babel [63]. PDB 
files of ligands were extracted from PDB files of CYP450-ligand 
complexes. Sites of metabolism were predicted by MetaSite using 
default parameters in both CYP450 isoform-specific predictions 
and in organ-specific (e.g. liver) predictions. 
Generation of a SRS Map Based on X-ray Structures: the  
“X-ray Structures” SRS Map 
 CYP450 protein-ligand contacts were delimited using the pro-
gram LIGPLOT [34] as described above. This identified, for a 
given CYP450-ligand complex, the CYP450 amino acid residues 
making hydrophobic and/or H-bond interactions with the ligand. 
The protein sequences of the CYP450 isoforms whose complexes 
with ligands had been analysed using LIGPLOT were retrieved 
from the UniProtKB database and aligned using ClustalW as de-
scribed above. The alignment included sequences of other mammal-
ian CYP450 isoforms of interest whose structures in complex with 
ligands have not yet been determined. The CYP450 contact resi-
dues identified using LIGPLOT were annotated on the multiple 
sequence alignment to generate a contact map (simply an alignment 
of sequences where contact residues and frequency of contact in 
structures of the same CYP450 isoform is indicated) as follows: (a) 
The structures for a given CYP450 isoform were grouped and ana-
lysed using LIGPLOT to identify contact residues; (b) continuous 
sequence sub-strings of about 15 amino acid residues were defined 
that include the residues delimited by LIGPLOT as interaction resi-
dues. This step facilitates the identification of contact residues on 
the sequence of the appropriate isoform in the multiple sequence 
alignment; (c) the contact residues for each isoform in the multiple 
sequence alignment were identified using the sub-strings and 
shaded using the following colour scheme: (i) yellow if the use of 
that residue position in ligand contacts has been observed only once 
in the LIGPLOT contact maps for the CYP450 isoform under con-
sideration, (ii) blue if observed twice, (iii) turquoise if observed 
thrice, (iv) green if observed four times, (v) red if observed five 
times and (vi) dark red if observed six times. N.B. The highest 
number of structures collected for the individual CYP450 isoforms 
in this study was six. The resultant contact map is shown in Fig. S1 
of the Supplementary Materials. An implicit assumption here is that 
whenever a residue position in a given CYP450 isoform is delim-
ited as an interaction/contact residue using LIGPLOT, all residues 
that are evolutionarily equivalent to that residue position in other 
CYP450 isoforms are also contact residues. Evolutionarily equiva-
lent residue positions are in the same column of a multiple sequence 
alignment and these are residue positions that descend from the 
same sequence position in an ancestral sequence [64]. Hence, the 
delimitation of a contact residue in a multiple sequence alignment 
automatically delimits a “contact column” of residues – namely the 
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 We generated a SRS map from the contact map as follows: (a) 
SRSs were assembled as blocks of “contact columns” which are 
within three amino acid residues of each other. The use of three 
amino acids is arbitrary and is inspired by Gotoh’s use of the same 
value in delimiting the precise boundaries for his SRSs [5]; (b) the 
precise N-terminal and C-terminal boundaries of the SRSs are de-
limited by calculating column positions that are three amino acid 
residues away (counting to the left for the N-terminal boundary and 
to the right for the C-terminal boundary, the third amino acid posi-
tion is included in the SRS) from the outer-most “contact columns” 
in the SRS assembled so far. The farthest column position among 
the several options that can sometimes be calculated for a SRS is 
taken as the boundary of the SRS. 
Generation of CYP450-ligand Complexes by Docking 
 Structures of CYP1A2 (2HI4), CYP2A6 (1Z10), CYP2B4 
(2Q6N), CYP2C5 (1NR6), CYP2C8 (2VN0), CYP2C9 (1R9O), 
CYP2D6 (2F9Q), CYP2R1 (3CZH), CYP3A4 (2V0M) and 
CYP46A1 (2Q9F) were retrieved from the RCSB Protein Data 
Bank. These structures were prepared for docking using AutoDock 
Vina [65] by (a) removing multiple copies of the CYP450 isozyme, 
(b) removing water molecules, (c) removing buffer molecules, (d) 
removing bound substrate, (e) addition of hydrogen atoms, and (f) 
converting pdb file to pdbqt format using AutoDockTools [66].  
 The docking space in each CYP450 isozyme was defined using 
a grid box whose size was determined by requiring that the grid box 
accommodates the largest substrate from a comprehensive list of 
substrates of the CYP450 isoform.  
 In general, in the absence of precedence in the literature, it is 
essential before docking of the ligands begins to determine if the 
docking software, here AutoDock Vina, is suitable for docking 
ligands in the active site of the enzyme system in question, here 
CYP450. It is also essential to identify the general set of parameters 
that permit accurate docking for a given docking system – i.e. it is 
essential to calibrate the docking system. In that light, a re-docking 
study was performed in which substrates whose structures bound to 
CYP450 isoforms are known were re-docked into the structure of 
the appropriate CYP450 isozyme using AutoDock Vina. RMSD 
values - representing the structural difference between docking 
complexes and X-ray structure complexes - were calculated for the 
substrate in each substrate-CYP450 isoform combination. Note that 
the CYP450 protein structure in each re-docking study was identi-
cal to that in the relevant X-ray complex since it was regarded as a 
rigid object during docking. 
 All RMSD values for the structural difference between the sub-
strate in docking- and X-ray complexes in the re-docking study 
were less than 2 Å. Wang et al. [67] have previously reported a 
comparative evaluation of 11 scoring functions for molecular dock-
ing and used a 2 Å value to compare the similarity of outputs from 
the different docking software. It is therefore reasonable to con-
clude that substrates in the re-docking complexes generated here 
had similar orientations to substrates in the relevant X-ray struc-
tures, indicating that AutoDock Vina run under default parameters 
can provide a suitable platform for the docking of ligands into 
CYP450 proteins. We therefore proceeded to generate CYP450-
ligand complexes for delimiting the docking SRS map by applying 
AutoDock Vina (default conditions) onto the remaining substrates 
for each of the CYP450 isoforms. PaDEL-ADV v1.7 [68] was used 
to automate the docking of substrates into CYP450 active sites 
using the AutoDock Vina software. 
 We generated a maximum of 9 docking modes for each sub-
strate (note that some substrates had less than 9 docking modes 
because the software could not find additional unique binding 
modes). Due to the large number of docking modes generated (ap-
proximately 7000), visual inspection of the docking modes of the 
substrates was generally not done. Docking modes for a few sub-
strates were however visualized randomly for quality control pur-
poses. In addition, the docking modes of some substrates with high 
binding energy (near to -1 kcal/mol) were also visualized to check 
for errors in their chemical representation. In carrying out such 
visualization, we were only concerned about the correct chemical 
and structural representation of the substrates and did not in general 
examine the docking modes to explain why the compound was a 
substrate; this was only done for glibenclamide and vardenafil as 
the docking complexes of these two suggested that SRS2 and SRS3 
are co-joined. 
Generation of a SRS Map Based on Docking Complexes: the 
“Docking” SRS Map 
 An in-house version of PaDEL-ADV (v1.7) [68] was used to 
automate both the AutoDock Vina [65] docking process and the 
LIGPLOT [34] identification of protein-ligand contacts in com-
plexes generated using AutoDock Vina. In this regard, the internal 
workings of PaDEL-ADV are briefly as follows. PaDEL-ADV 
starts by reading a directory containing substrate files. For each 
substrate, the structure file was converted into a PDB file using The 
Chemistry Development Kit [69]. The PDB file was subsequently 
converted to pdbqt format using the “prepare_ligand4.py” python 
script provided by AutoDockTools [66]. Following that, AutoDock 
Vina was used to dock the substrate into the active site of the ap-
propriate CYP450 protein. Individual binding modes were then 
extracted from the output pdbqt file using the “vina_split” program 
of AutoDock Vina. These pdbqt files were then converted to PDB 
files using the “pdbqt_to_pdb.py” python script [66]. LIGPLOT 
was then applied to the PDB files of the individual binding modes 
to identify protein-ligand contacts for all the poses of each sub-
strate. Information about these protein-ligand contacts for all the 
substrates of a CYP450 protein was then consolidated into a pro-
tein-ligand contact matrix where each row represents a pose of a 
substrate and each column represents a protein residue that is con-
tacted by substrate. This protein-ligand contact matrix was used 
directly to delimit the SRS docking map. The protein-ligand contact 
matrix used here was processed to remove those poses with a com-
puted ligand binding free energy greater than -1 kcal/mol and those 
poses in which the atoms of the substrate are more than 5 Å away 
from the heme iron.  
 The remaining poses were then used to generate a contact map 
and then a SRS map using procedures such as those used for the X-
ray structures SRS map. The docking complexes contacts map is 
shown in Fig. S2 of the Supplementary Materials. 
 The 5 Å distance cut-off was chosen because it is a commonly 
accepted upper limit for the distance between the site of metabolism 
and the heme iron at a specific committed stage in the CYP450 
catalytic cycle. The -1 kcal/mol cut-off used was strictly speaking 
an arbitrary value and was chosen to include as many of the known 
substrates for a given enzyme in the analysis as possible without 
introducing too many incorrect poses [Note that since all scoring 
functions aim to reproduce the Gibbs free energy of binding, any 
cut-off must be < 0 kcal/mol in order for the binding to be favor-
able]. Thus for example, in CYP2C9 there are 6 known substrates, 
the lowest energy of which was -1.1 kcal/mol; if we had set a lower 
cut-off (e.g. -2 kcal/mol), we would exclude these known substrates 
from analysis, whereas if we had used a higher cut-off (e.g. -0.1 
kcal/mol), we would have risked including poses that may be incor-
rect. 
Assessment of SRS Map Completeness: Calculation of the Cov-
erage of the CYP450 Substrate Space Achieved by Ligands in 
X-ray Structures 
 Our objective here was to determine the coverage of the 
CYP450 substrate space achieved by the ligands that we used to 
delineate the X-ray structures SRS map. Calculation of this cover-
age gives us a ligand-based measure of the likely extent of com-
pleteness of the X-ray structures SRS map. For example, a map 
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derived from contacts made by a higher percentage of ligands in the 
CYP450 substrate space is naturally expected to yield a more com-
plete description of SRSs than a map derived from a smaller per-
centage of ligands. The ligand-based measure of SRS map com-
pleteness can then be compared with other measures of complete-
ness such as the projection of SRSs onto the CYP450 fold (vide 
infra). Our strategy for achieving a calculation of this coverage was 
to divide the CYP450 substrate space calculated above into clusters 
of similar molecules and to calculate the percentage of these clus-
ters that contain at least one molecule from the set used to delimit 
the X-ray structures SRS map. This percentage value was taken as a 
quantitative measure of the coverage of the CYP450 substrate space 
achieved by the ligands used to delineate the X-ray structures SRS 
map. We used k-means clustering to divide-up the CYP450 sub-
strate space into clusters. 
 K-means clustering [70, 71] is an unsupervised, heuristic 
method of cluster analysis which aims to partition n observations 
into k clusters, in which each observation belongs to the cluster 
with the nearest mean, the aim being to find the centres of natural 
clusters in the data using an iterative refinement approach. Using 
this method, we clustered all the molecules in the CYP450 substrate 
space into structurally-related chemical families. We performed the 
k-means clustering as follows: Centroids for k clusters were defined 
using k randomly selected ligands; Each ligand was then assigned 
to the cluster with a centroid nearest to it. The positions of the cen-
troids were then recalculated and the ligands re-assigned to the 
clusters. The recalculation of the centroids and reassignment of the 
ligands continued until the centroid positions became stable. In this 
study, the software RapidMiner [72] was used to perform the k-
means clustering. 
 An important challenge when performing k-means clustering is 
the choice of the optimum value of k – the number of clusters. In 
this study, we devised a simple strategy to guide the selection of k 
for the k -means clustering. In this strategy, we defined four chemi-
cal types/families into which some molecules in the CYP450 sub-
strate space could be easily assigned manually on the basis of struc-
tural similarity, the idea being to use these four chemical families as 
“markers” in the evolution of the clusters. The four chemical fami-
lies chosen were: dihydropyridines; selective serotonin reuptake 
inhibitors; beta-blockers; & benzodiazepines. The satisfactory as-
signment of molecules from these four families into clusters of 
closely-related members was taken to be indicative of equally satis-
factory evolution of clusters in all parts of the CYP450 substrate 
space. There are 48 molecules that belong to the families described 
above and the distribution of these 48 chemical entities across clus-
ters was followed during the course of the clustering procedure. 
Hence in our strategy for selection of the optimum k-value (i.e. 
termination of the clustering algorithm), the clustering of the 48 
molecules from the four chemical families described above was 
followed in the clusters that were generated by RapidMiner as the 
value of k was increased during the course of k-means clustering; 
manually assessment was used to establish the extent of similarity 
within clusters containing at least one molecule from the 48 marker 
molecules. Our strategy therefore achieved the definition of algo-
rithm/search termination criteria by simply assessing some of the k-
means clusters’ verisimilitude to a pre-defined and manually-
ascribed notion of chemical similarity that had been applied to a 
small part of the CYP450 substrate chemical space. Achievement of 
satisfactory clustering of the 48 marker molecules (a small part of 
the CYP450 substrate space, 48/868 ~ 6 %) was taken to be indica-
tive of equally satisfactory clustering in all other parts of the 
CYP450 substrate space. We note that a major source of the dis-
parities between PubChem fingerprints (used here to calculate the 
co-ordinates of the CYP450 substrates in chemical space) and our 
visual assignment of the 48 marker molecules on the basis of struc-
tural similarity is that PubChem fingerprints place greater direct 
emphasis on electronic structure similarity and less emphasis on 
structural similarity while the opposite is true in the case of our 
visual assignments.  
Assessment of SRS Map Completeness: Projection of the SRSs 
Delimited in the Final Unified Map Onto the CYP450 Fold 
 The CYP2C9 structure 1OG2 (chain A) was chosen as a repre-
sentative mammalian CYP450 fold because the structure does not 
have gaps in between its N-term end (sequence position Pro30) and 
its C-term end (Val490). This absence of gaps in the CYP2C9 
structure allows visual assessment of the completeness of the uni-
fied SRS map by identification of parts of the CYP450 fold that are 
proximal to and unscreened from the catalytic centre and which 
either have or have not been assigned as SRS zones. For this pur-
pose, CYP2C9 SRS boundaries were extracted from the final uni-
fied SRS map and applied onto the CYP2C9 structure 1OG2. 
RESULTS 
Generation of a SRS Map Based on X-ray Structures: the  
“X-ray Structures” SRS Map 
 Figure 1 shows a comparison between the X-ray structures map 
and Gotoh’s map.  Contact residues in CYP450-ligand complexes 
have been projected onto an alignment of CYP2C9, CYP2B4 and 
CYP3A4 and the X-ray structures map delimited as described in 
Materials and Methods. 
The CYP450 Substrate Space: Molecular Descriptors Assess-
ment of SRS Map Completeness 
 Figure 2 shows the distribution of known CYP450 substrates/ 
ligands in chemical descriptor space (see Materials and Methods for 
further details).  The plot allows comparative visualization of the 
chemical spread of the ligands in CYP450-ligand complexes. 
Calculation of the Coverage of the CYP450 Substrate Space 
Achieved by Ligands in X-ray Structures 
 We have found that the automatically-assigned clusters that 
contain the 48 “marker” chemical entities (belonging to the four 
chemical families defined above) bear the greatest agreement with 
manually-assigned chemical similarity at the k -value of 86. Hence 
the percentage spread of the CYP450 substrate space achieved by 
the ligands that we used to delineate the X-ray structures SRS map 
was calculated at k = 86. To determine the coverage of the ligands 
that were used to delineate the X-ray structures SRS map, each 
ligand was assigned to the cluster with a centroid nearest to it. The 
percentage coverage of these ligands was then computed by divid-
ing the total number of clusters that are occupied by these ligands 
(22) by the total number of clusters (86), revealing that the cover-
age of ‘total known’ CYP450 substrate space by the ligands that 
were used to delineate the X-ray structures SRS map is 26%. Con-
sidered in isolation, this result suggests that the coverage of the 
CYP450 substrate space achieved by the ligands from X-ray struc-
tures alone is low. In turn, this suggests that the completeness of the 
SRS map delimited from the X-ray structures may also be low and 
therefore that X-ray structures of more diverse CYP450-ligand 
complexes need to be observed before high SRS map completeness 
could be attained. 
Generation of a SRS Map Based on Docking: the “Docking” 
SRS Map 
 The overall statistics of the substrates and CYP450 isoforms 
used in the docking experiments are provided in Table 1 below. The 
relevant sections of the docking SRS map are shown in Fig. S3 in 
the Supplementary Materials. 
Are the Newly-delimited SRS Substantive? 
 We have performed structural analysis to assess the likelihood 
that the newly delimited SRS zones constitute substantive SRSs -  
 




















































Fig. (1). Comparison of the X-ray structures SRS map delimited here and Gotoh’s SRS map Contact residues in CYP450-ligand complexes have been projected 
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The newly defined X-ray structures SRS map is illustrated here using sections from an alignment of CYP2C9, CYP2B4 and CYP3A4. The complete set of 
sequences and contacts, from which the SRS map was delimited, is shown in Fig.S1 of Supplementary Materials. SRS regions delimited in this work are boxed 
in green while those delimited by Gotoh are boxed in yellow. Contact residues identified in crystal structures are shown in red characters. Secondary structure 
assignment is shown below the sequence (black rectangular boxes represent - helices and black arrows represent -sheets). Panel [A] shows the newly-
identified SRS zones designated as SRS1’a and SRS1’b. Panel [B] shows SRS1. Panel [C] shows another newly-identified SRS zone designated as SRS1’c. 
Panel [D] shows close proximity between SRS2 and SRS3 and Panel [E, F] and [G] show SRS4, SRS5 and SRS6, respectively. The positions of CYP2C9 and 

















Fig. (2). Comparative analysis of the chemical diversity of ligands from CYP450-ligand complexes used in this study 
This plot shows the distribution of human CYP450 substrates in chemical space using PubChem fingerprints as chemical descriptors. Structures of chemical 
entities were sourced, chemical descriptors calculated and principal component analysis performed as described in Materials and Methods. The known sub-
strates for CYP1A2, CYP2A6, CYP2B4, CYP2C5, CYP2C8, CYP2C9, CYP2D6, CYP2R1, CYP3A4 and CYP46A1 are represented by triangles: Ligands 
used in this study to delineate the X-ray structures SRS map (i.e. ligands bound to X-ray structures) are represented by red triangles and all other known ligands 
are represented by green triangles, illustrating the coverage of CYP450 substrate space achieved by the ligands in X-ray structures.  
 
Table 1. Statistics of Substrates and CYP450 Isoforms Used to Generate the Docking SRS Map 
CYP450 No. of Known Substrates No. of Substrates Used to Generate Contact Map
a 
% Substrates Used to Generate Contact Map 
1A2 65 61 93.8 
46A1 11 11 100.0 
2A6 33 26 78.8 
2B4 12 12 100.0 
2C5 5 5 100.0 
2C8 28 27 96.4 
2C9 156 152 97.4 
2D6 212 186 87.7 
2R1 2 2 100.0 
3A4 401 386 96.3 
aSubstrates that, (1) are more than 5Å from hem, (2) have greater than -1kcal/mol binding affinity with CYP450 protein, (3) are unable to be docked using AutoDock Vina, were 
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i.e. to assess if they are stand-alone SRSs that are distinct from each 
other (where relevant) as well as from the known ones. 
 We carried out a qualitative assessment of the likelihood of 
each newly-delimited SRS zone constituting a stand-alone SRS by 
searching for structural elements that are removed and/or screened 
from the active site and are interposed between the newly-delimited 
SRS zone and other SRS zones (newly-delimited and/or previously-
defined). Such intervening regions achieve the separation of SRS 
zones by non-SRS zones and their presence supports the conclusion 
that the newly-delimited SRS zone is substantive and stand-alone. 
Structural Analysis of Newly-delimited SRS Regions: SRS1’c 
 Figure 3 shows the relationship between SRS1 and the newly-

















Fig. (3). The relationship between SRS1 and SRS1’c on the CYP450 fold 
CYP2B4 protein is shown in green, the heme group is shown in turquoise 
and bifonazole is shown in orange (PDB structure 2BDM). SRS1 residues 
are shown in blue (CYP2B4 residues 92-118 inclusive) and X-ray structures 
SRS map boundaries delimited herein have been used for SRS1. SRS1’c is 
shown in red (residues 125-135 inclusive). SRS1’c residues Ser128 and 
Met132 are shown respectively in grey and magenta and sticks have also 
been rendered for these two residues. The delimitation of SRS1’c in the X-
ray structures SRS map is based upon the observed contacts between the 
bifonazole ligand and CYP2B4 Ser128 and CYP2B4 Met132 in the struc-
ture 2BDM. The residues that lie between SRS1 and SRS1’c are shown in 
yellow (residues 119-124 inclusive). The structural model was rendered in 
pymol (www.pymol.org).  
 
 SRS1 and SRS1’c are quite proximal and there are no structural 
elements between SRS1 and SRS1’c that would obviously obstruct 
interaction between the residues that intervene between SRS1 and 
SRS1’c and the substrate. The intervening residues are Glu119-
Leu124 inclusive along the CYP2B4 sequence. It is conceivable 
that the intervening residues (shown in yellow in Fig. 4) may in fact 
be SRS residues, thereby giving a much bigger SRS1 than previ-
ously delimited. We therefore analysed the results of docking 
twelve CYP2B4 substrates into the CYP2B4 structure 2BDM (the 
structure rendered in Fig. 3) to explore the possible involvement of 
SRS1-SRS1’c intervening residues (rendered in yellow) in substrate 
binding. The following are the PubChem codes of the CYP2B4 
substrates used in this study: 2341 = Benzphetamine, 4116 = 
Methoxyflurane, 6009 = Aminopyrine, 6013 = Testosterone, 6115 
= Aniline, 7095 = Biphenyl, 7485 = p-nitroanisole, 35703 = 7-
ethoxycoumarin, 107683 = 7-pentoxyresorufin, 114982 = 7-
benzyloxyresorufin, 130779 = 7-ethoxy-4-trifluoromethylcoumarin 
and 5359271 = Ethylmorphine. 
 Contacts between CYP2B4 substrates and SRS1-SRS1’c inter-
vening residues are summarized in Table 2 below. 
 The results in Table 2 show involvement of SRS1-SRS1’c in-
tervening residues in substrate contact. This suggests that SRS1 
extends from Ala92 to Phe135 along the CYP2B4 sequence (the 
blue, yellow and red sections in Fig. 3). In the final SRS map de-
limited here, SRS1’c is therefore not given as a stand-alone SRS 
region but is fused to SRS1. 
Structural Analysis of Newly-delimited SRS Regions: SRS1’a 
and SRS1’b 
 Figure 4 shows the relationship between SRS1 and the newly-
delimited SRS regions - SRS1’a and SRS1’b. 
 SRS1’a and SRS1’b are separated from SRS1 and from each 
other by structural elements that include residues that are far re-
moved from the CYP450 active site and whose interaction with 
bound ligand is screened by other residues (see Fig. 4). Hence 
SRS1’a and SRS1’b are truly distinct from SRS1 and from each 
other as SRS regions (i.e. they do not form a single continuous SRS 
zone). Furthermore, SRS1, SRS1’a and SRS1’b appear as distinct 
SRS contacts zones in the large-scale docking study upon which the 
delimitation of the docking SRS map is based (see Figs. S2 and S3). 
By way of example, the large scale docking study includes the 
CYP46A1 structure 2Q9F and the CYP3A4 structure 2V0M; The 
X-ray structure hydrophobic contact between CYP3A4 Phe57 and 
ketoconazole that results in the delimitation of SRS1’a is also ob-
served in docking complexes of the CYP3A4 structure 2V0M and 
gives rise to a standalone SRS1’a in the docking SRS map (see 
Figs. S2 and S3); Furthermore, the X-ray structure contacts between 
CYP46A1 Phe80 (hydrophobic) and CYP46A1 His81 (hydrogen-
bond) and Cholesterol-3-sulphate which result in the delimitation of 
SRS1’b are also observed in docking complexes of the CYP46A1 
structure 2Q9F and give rise to a stand-alone SRS1’b (see Figs. S2 
and S3). Hence the view arising from structural analysis that 
SRS1’a, SRS1’b and SRS1 are distinct SRS zones is directly sup-
ported by their emergence as separate zones in the docking SRS 
map.  
Structural Analysis of Newly-delimited SRS Regions: the Over-
lap of SRS2 and SRS3 
 The overlap between Gotoh’s SRS2 and SRS3 in the docking 
SRS map (Fig. S3, Panel D) as opposed to their close proximity in 
the X-ray structures SRS map (Fig. S3, Panel D and Fig. 1, panel 
D) is due to the contacts involving Tyr225 and His230 identified in 
CYP2C9 docking complexes. Tyr225 makes contact with ligand 
110634 (Vardenafil) and His230 makes contact with ligand 3488 
(Glibenclamide) and 110634 (Vardenafil). Tyr225 accounts for 2 % 
of the total number of contacts delimited in CYP2C9 docking com-
plexes in this study while His230 accounts for 4.6 %. 
 We evaluated the docking complexes that give ligand contacts 
with residues Tyr225 and His230 by analysing the agreement be-
tween the experimentally validated and/or MetaSite-predicted sites 
of metabolism of the ligand and the sites of metabolism suggested 
by the pose of the docked ligand in the CYP2C9 active site. The 
sites of metabolism (experimental and predicted) for Glibenclamide 
and Vardenafil are shown in Fig. S4 in the Supplementary Materi-
als.  
 Glibenclamide (also known as Glyburide) is a second genera-
tion sulfonylurea used for treatment of type II and gestational dia-
betes mellitus [73-76]. It targets ATP-dependent ion channels [77, 
78] and is mainly metabolised by CYP2C9, CYP2C19 and 
CYP3A4 in the human liver [74]. Experimentally-verified sites of 
metabolism in the Glibenclamide cyclo-hexyl moiety (indicated by 
arrows (5), (6a) and (7a) in Fig. S4, Panel A) have been identified 
in various publications [76]. Experimentally-verified sites of me-
tabolism in the Glibenclamide ethyl bridge moiety (indicated by 
arrows (1) and (4) in Fig. S4, Panel A) have also been identified 
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[76]. The active-site orientation of Glibenclamide in the highest-
scoring (and only) docking complex/solution from which the con-
tact between Glibenclamide and CYP2C9 His230 was delimited is 
shown in Fig. S5 in the Supplementary Materials. It can be seen 
that the Glibenclamide molecule presents the cyclo-hexyl moiety 
towards the heme iron in the catalytic centre. This docking solution 
is in accord with the known metabolites of Glibenclamide. 
 Vardenafil is a potent and selective inhibitor of cyclic GMP-
specific phosphodiesterase type 5 (PDE5) found in smooth muscle 
cells that line blood vessels – especially in the corpus cavernosum 
of the penis. Vardenafil is used for the treatment of erectile dys-
function [79-81]. Vardenafil is predominantly metabolised by he-
patic CYP3A4 and to a lesser extent by CYP3A5 and CYP2C iso-
forms [79]. Although the main Vardenafil metabolite is N-
desethylvardenafil (Vardenafil with the ethyl group removed from 
the piperazine moiety by hydrolysis) [80, 81], there is evidence for 
the existence of hydroxylated metabolites [81]. 
 The three docking solutions for the docking of Vardenafil into 
the CYP2C9 active site have generally the same orientation in 
which a predicted site of metabolism (site (5) in Fig. S4 Panels C & 
D) comes close to the catalytic heme iron. Vardenafil makes contact 
with the residue Tyr225 in each of these three complexes; the orien-
tation of Vardenafil in the lowest-energy (highest ranking) docking 
complex is shown in Fig. S6 in the Supplementary Materials. These 
three docking solutions are in accord with the predicted metabolites 
of Vardenafil. 
The Unified SRS Map: Set Union of the X-ray Structures and 
Docking SRS Maps 
 The SRS zones of the X-ray structures SRS map and the dock-
ing SRS map are added together in set-theoretic fashion to give the 
unified SRS map shown in Fig. 5 below. The unified map also in-
corporates results from structural analyses of SRS zones delimited 
in the X-ray structures map such as the amalgamation of SRS1’c 
and SRS1 to give a large SRS1 zone. 
 The SRS boundaries shown pictorially in Fig. 5 above are given 
along the CYP450 sequence for CYP2C9 isoform (SRS boundaries 
are also given in Table 3). A version of the unified SRS map that 
includes more CYP450 sequences is shown in Fig. S11 in the Sup-
plementary Materials.  
Assessment of SRS Map Completeness: Projection of the SRSs 
Delimited in the Final Unified Map Onto the CYP450 Fold 
 The SRSs in the final unified map shown in Fig. 5 above were 
projected onto the CYP2C9 structure 1OG2.pdb as described in the 
Materials and Methods section above. The projections are shown in 












Fig. (4). The relationship between SRS1, SRS1’a and SRS1’b on the CYP450 fold. 
CYP3A4 protein is shown in green, the heme group is shown in turquoise and ketoconazole is shown in orange (PDB structure 2V0M). SRS1 residues are 
shown in magenta (CYP3A4 residues 99-125 inclusive) and X-ray structures SRS map boundaries delimited herein have been used for SRS1. SRS1’a residues 
are shown in red (residues 54-60 inclusive) and SRS1’b residues are shown in blue (residues 74-81 inclusive). The residues that lie between SRS1’a residues 
and SRS1’b residues are shown in yellow (residues 61-73 inclusive). The structural model was rendered in pymol (www.pymol.org).  
Table 2. Summary of Contacts Between CYP2B4 Substrates and SRS1-SRS1’c Intervening Residues 
CYP2B4 Residue List of Substrates Making Contact with Residue Percentage of Substrates Making Contact with Residue 
Trp121 2341, 6009, 6013, 7485, 107683, 114982 and 5359271 7/12 = 58.3 % 
Leu124 2341, 6009, 35703, 107683, 114982, 130779 and 5359271 7/12 = 58.3 % 
Arg125 2341, 6009, 107683, 114982 and 130779 5/12 = 41.7 % 
 















































Fig. (5). The unified SRS map: set union of the X-ray structures and docking SRS maps 
The final SRS map is built by taking the N term-most limit and the C term-most limit for each SRS in the comparison between the X-ray structures SRS map 
and the docking SRS map. Regions of the CYP2C9 sequence that fall in the final SRS zones 1'a to 6 are shown in panels [A] – [F]. SRS zones are boxed in red 
and secondary structures are shown below the sequence (black rectangular boxes represent - helices and black arrows represent -sheets). Based on visual 
inspection of the CYP2C9 1OG2 crystal structure, SRS residues with side chains facing towards the active site are shown in bold face while those pointing 
away are shown in plain font. Panel [A] shows SRS1'a and SRS1'b; panel [B] shows the extended SRS1 which results from combining SRS1 in Fig. 1 and 
SRS1'c; panel [C] shows the co-joining of SRS2 and SRS3 regions given as SRS(2,3); and panels [D], [E] and [F] show SRS4, SRS5 and SRS6, respectively. 
Numbering of sequence positions is according to the CYP2C9 sequence. 
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Table 3. SRS Boundaries in CYP2B4, CYP2C9 and CYP3A4 
CYP450 Isoform SRS Boundary Positions (Boundary Residues are Part of SRSs) 
CYP2B4 (SRS1’a: L43-S54), (SRS1’b: T67-V75), (SRS1: E93-F135), 
(SRS(2,3): F195-I245), (SRS4: Q286-R308), (SRS5: R358-V371) and 
(SRS6: P465-S483). That is 171/491 = 35 % of CYP2B4 residues are SRS residues. 
CYP2C9 (SRS1’a: I37-S53), (SRS1’b: T66-I74), (SRS1: E92-F134), 
(SRS(2,3): F194-I244), (SRS4: E285-R307), (SRS5: R357-V370) and 
(SRS6: P464-F482). That is 176/490 = 36 % of CYP2C9 residues are SRS residues. 
CYP3A4 (SRS1’a: I50-F60), (SRS1’b: G73-V81), (SRS1: Y99-G140), 
(SRS(2,3): Q200-S252), (SRS4: L293-S315), (SRS5: R365-C377) and 
(SRS6: T471-P488). That is 169/503 = 34 % of CYP3A4 residues are SRS residues. 
The percentage of SRS residue positions in the alignment of Fig.S11 (Supplementary Materials) is 197/589 = 33 %. Note that aligned sequences have, by definition, the same length 




















 A B 
Fig. (6). Projection of SRS zones in the final unified map onto the CYP450 fold 
SRS boundaries along the CYP2C9 sequence (given in Table 3 above) were applied onto the CYP2C9 structure 1OG2. The colour codes for the SRSs are as 
follows: SRS1’a is in red, SRS1’b is in blue, SRS1 is in yellow, SRS(2,3) is in magenta, SRS4 is in orange, SRS5 is in hot-pink and SRS6 is in grey. The heme 
group is shown in turquoise. Parts of the CYP450 structure that have not been assigned to SRSs are in green. Panel (A) shows a “side-view” (relative to the 
heme group) and Panel (B) shows a “top view” (relative to the heme group). The structural model was rendered in pymol (www.pymol.org).  
 
 Projection of SRSs delimited in the final unified map onto the 
mammalian CYP450 fold (as typified by the CYP2C9 structure 
1OG2) reveals that the majority of regions on the mammalian 
CYP450 fold that are proximal to the active site and that are not 
screened from the active site by other CYP450 structural elements 
are assigned as SRS zones. This suggests that the SRS map delim-
ited herein is highly complete. Projection of SRSs onto the CYP450 
fold provides a more direct and therefore more reliable measure for 
assessing the completeness of the SRS map than the ligand-based 
measure. Thus, conclusions drawn from observing the distribution 
of SRSs on the CYP450 fold override and out-weigh those inferred 
from the ligand-based chemical diversity measure. We therefore 
conclude that the new SRS map delimited herein is highly com-
plete. 
Review of the Explanatory Power of the New Map: Filling the 
Gaps in Gotoh’s Map 
 We have assessed the explanatory power of the new unified 
map delimited herein by reviewing studies in the literature where 
residues, falling outside the SRS regions in Gotoh’s map, have been 
shown through experiment to play a role in the determination of the 
substrate specificity of CYP450 isoforms. We are interested to see 
if the role of these ‘non-Gotoh-SRS’ residues in the determination 
of CYP450 substrate specificity can be explained by the reassign-
ment of these residues to SRS zones in our map. The 11 cases we 
identified in the literature are reported in Table 4, some of which 
have already been discussed in the Introduction (vide supra). We 
found that in five out of eleven of these cases, residues previously 
identified as non-Gotoh-SRS residues, now lie within SRS zones in 
our new map. 
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 The most well-known family of non-SRS regions that influence 
substrate specificity lie between Gotoh’s SRS2 and SRS3, as illus-
trated in cases numbered 1, 2 and 3 in Table 4. It is clear that our 
map resolves these cases since it combines SRS2 & SRS3 as well 
as the intervening sequence into a single SRS region.  
 
 He et al. (case no 4, Table 4) previously identified the non-
Gotoh-SRS residue CYP2B5 His120 as an important determinant of 
CYP2B5 progesterone hydroxylation activity [7]. This role of this 
residue in substrate specificity can be explained by the assignment 
of CYP2B5 His120 to the enlarged SRS1 in our new map. 
 
Table 4. Review of the Explanatory Power of the New Map 
Study Number: 
Reference 
Isoform: Residue(s) Description of Findings in Study Position in Gotoh's Map Position in New Map 
a1: [8] CYP2C19: Pro220 Important determinant of omeprazole hy-
droxylase activity.  
Occurs between Gotoh's 
SRS1 and SRS2 (F-G 
loop) 
SRS(2,3) 
a2: [8] CYP2C19: Thr221 Important determinant of omeprazole hy-
droxylase activity.  
Occurs between Gotoh's 
SRS1 and SRS2 (F-G 
loop) 
SRS(2,3) 
a3: [7] CYP2B5: Pro221 Important determinant of progesterone 
hydroxylation activity.  
Occurs between Gotoh's 
SRS2 and SRS3 (F-G 
loop) 
SRS(2,3) 
a4: [7] CYP2B5: His120 Important determinant of progesterone 
hydroxylation activity.  
C-term of Gotoh's SRS1 SRS1 
a5: [22] CYP1A2: residues 67-
78 
(L(S)QQYGDVLQIR) 
Using mechanism-based inhibitors, this 
study identifies a stretch of rat CYP1A2 
residues that includes residues involved in 
substrate recognition region.  
N-term of Gotoh's SRS1 Occurs between SRS1’a and 
SRS1’b. Residues 67-78 
(shown in bold) fall within 
SRS1'b  
6: [22] CYP1A2: residues 
175-184 (FQEL-
MAAVGR) 
Identified as a substrate recognition region 
using mechanism-based inhibitors.  
Occurs between Gotoh's 
SRS1 and SRS2 
Non-SRS residues occurring 
mid-way between SRS1 and 
SRS(2,3) 
7: [9] CYP3A12: Thr187 Using chimeric enzymes and site-directed 
mutagenesis, this study identifies Thr187 as 
one of three residue positions responsible 
for differences in steroid hydroxylation 
between canine CYP3A12 and CYP3A26.  
Occurs between Gotoh's 
SRS1 and SRS2  
Non-SRS residue occurring 
closer to SRS(2,3) in the space 
between SRS1 and SRS(2,3) 
8: [17] CYP2C11: Phe187 In this study, site-directed mutagenesis on 
allelic variants in the Gun and Wistar rats 
identified Phe187 as an important residue 
for steroid hydroxylation 
Occurs between Gotoh's 
SRS1 and SRS2 
Non-SRS residue between 
SRS1 and SRS(2,3) 
9: [17] CYP2C11: Val4 In this study, site-directed mutagenesis on 
allelic variants in the Gun and Wistar rats 
identified Val4 as an important residue for 
steroid hydroxylation.  
Occurs in the hydrophobic 
transmembrane domain 
Non-SRS residue in hydropho-







Chimeric constructs and site directed 
mutagenesis studies show that substitution 
of these three residues in CYP2B1 protects 
the enzyme against inactivation by two 
acetylenic mechanism-based inhibitors.  
Occur between SRS5 and 
SRS6 
Non-SRS residues occurring 
between SRS5 and SRS6 
11: [18] CYP2B1: Leu58 CYP2B1 variant L58F, I114F affects the 
metabolism of testosterone, eliminating the 
production of 16 beta-hydroxylated me-
tabolites but having no effect on the pro-
duction of 6 alpha-hydroxylated and 17 
keto metabolites.  
C-term of Gotoh's SRS1 Non-SRS residue between 
SRS1’a and SRS1’b (4th resi-
due after of SRS1’a) 
a Case numbers shown in bold type denote CYP450 non-SRS residue positions (Gotoh’s map) that have been experimentally shown to influence substrate specificity and whose role 
in determining substrate specificity we have successfully explained in this study by their re-assignment to SRS zones in our unified map. 
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 A fascinating case that highlights the explanatory power of our 
new map is provided by the work of Yun et al. [22] (case no. 5, 
Table 4) who used mechanism-based inhibitors to suggest that rat 
CYP1A2 positions 67-78 [L(S)QQYGDVLQIR] were involved in 
substrate recognition. Our work reveals that the three last residues 
of this peptide [“QIR”] lie within CYP1A2 SRS1’b in our new 
map, consistent with the experimental results of Yun et al. 
 In the remaining 6 cases our new map does not offer an imme-
diate explanation for the role of these non-SRS residues in substrate 
specificity, as discussed briefly below. 
 Rat CYP1A2 positions 175-184 (FQELMAAVGR) identified 
by Yun et al. [22] (case no. 6, Table 4) lie almost mid-way between 
the enlarged SRS1 and SRS(2,3) in our new map. The homologous 
residues in CYP2C9 (residues 156-163; “LRKTKASP”) are surface 
residues that are distal to the active-site and that are extensively 
screened from the active-site by other parts of the CYP2C9 struc-
ture (Fig. S7). It is therefore difficult to speculate on a mechanism 
by which these residues could gain access to the active site and it 
seems possible instead that they have been mis-identified as sub-
strate recognition regions in the previous work. 
 Fraser et al. identified canine CYP3A12 Thr187 as an important 
determinant in CYP3A12-catalysed steroid hydroxylation [9] (Case 
no. 7, Table 4). Examination of the homologous residue positions in 
structures of CYP3A4 (Thr187) and CYP2C9 (Asn176) reveals that 
this residue is screened from the active site by the I-helix and that it 
either lies just on the plane of the heme co-factor in some CYP 
structures (e.g. in the CYP3A4 structure 1TQN) or quite beneath 
the plane of the heme co-factor in others (e.g. in the CYP2C9 struc-
ture 1R9O; Fig. S8). It is difficult to assess the likelihood of sub-
strate access/contact of this position solely from static structures.  
 Biagini et al. (case no. 8, Table 4) showed that the non-SRS 
residue CYP2C11 Phe187 is an important determinant of CYP2C11 
testosterone hydroxylation [17]. This residue lies 6 amino acids 
upstream of SRS(2,3) in our new map and lies in the same struc-
tural neighbourhood as CYP3A12 Thr187 (case no. 7, Table 4), but 
we note that these positions in CYP2C11 and CYP3A12 are infact 
not homologues of each other. Examination of the position of the 
homologous residue to CYP3A12 Thr187 in the CYP2C9 structure 
(Phe187) shows that it is screened from the active site by the I-helix 
and that it lies quite above the plane of the heme co-factor and in 
close proximity to SRS(2,3) (Fig. S9). It is therefore attractive to 
speculate that Biagini’s data indicates a truer limit of SRS(2,3) than 
has been possible to delimit with the methods used in this study.  
 Biagini et al. also identified rat CYP2C11 Val4 as an important 
determinant in CYP2C11-catalysed steroid hydroxylation [17] (case 
no. 9, Table 4). Early sequence positions such as CYP2C11 Val4 lie 
in the hydrophobic CYP450 membrane anchor polypeptide and do 
not form part of the CYP450 catalytic domain. As such, this residue 
position probably influences enzyme performance by mechanisms 
outside the scope of those we are studying here. 
 The role of CYP2B1 residues Ser407, Asn417 and Ala419 (case 
no. 10, Table 4) in providing protection against mechanism-based 
inactivation by acetylenic inhibitors [62] cannot be explained by 
our new SRS map. However, we note that Asn417 and Ala419 lie 
in the range of residues CYP2B1 Phe413-Ile435, a segment that 
immediately precedes the strictly conserved Cys436 which forms 
an obligate thiolate with the heme, suggesting possible alternative 
explanations for the experimental observations based on chemical 
modification of Cys436 by the acetylenic inhibitors. 
 Finally, we note that the involvement of rat CYP2B1 Leu58 in 
modulating CYP2B1 testosterone hydroxylation activity [66] (Case 
number 11, Table 4) cannot be explained by way of re-assignment 
to our unified SRS zones since it lies 4 residue after the C-terminal 
boundary of SRS1’a in CYP2B1. 
 
DISCUSSION 
 Taking advantage of the wealth of new CYP450 structural data 
and new computational tools that have become available over the 
last 10 years, we have created an expanded, unified Substrate Rec-
ognition Site map for mammalian Cytochrome P450s. To do this, 
we collected 43 structures of mammalian CYP450-ligand com-
plexes and used the program Ligplot [34] to identify contact resi-
dues in a suitable subset of those structures. From this, we created 
an ‘X-ray structures’ SRS map by projecting the identified contact 
residues onto an alignment of sequences of mammalian CYP450s 
(Fig. 1). In a parallel approach we generated plausible CYP450-
ligand complexes by docking known CYP450 substrates into struc-
tures of CYP450 isoforms using the program AutoDock Vina [65]. 
In analysing the docking modes, we used arbitrary cut-offs to ex-
clude those where the computed binding free energy was too low (> 
-1 kcal/mol) or where no atom of the ligand was within 5 Å from 
the heme iron. In considering these cut-offs, we note that, given the 
very high energy of the iron (IV) oxo species generated during the 
catalytic cycle, once a compound has bound and is in close-enough 
proximity to the iron (IV) oxo species, the chemical question be-
comes which atom will be oxidized - which is probably controlled 
as much by precise available local conformations as it is by bond 
energies in the substrate. We did not attempt to further evaluate in 
this work why each compound was a substrate, but from this in 
silico study, we created a ‘docking’ SRS map by projecting contact 
residues onto an alignment of sequences of mammalian CYP450s 
(Fig. S3). The X-ray structures SRS map and the docking SRS map 
largely agreed with each other and importantly include the main 
features in Gotoh’s original SRS map, but equally importantly they 
also exhibit new features that were absent in Gotoh’s map. Features 
in common with Gotoh’s map included the appearance of Gotoh’s 
six original SRS regions in the same locations as they appear in 
Gotoh’s map.  
 We subsequently combined our docking- and X-ray structures 
SRS maps to obtain the new, unified SRS map described in this 
work (Fig. 5). Important differences between the new map delim-
ited herein and the old map by Gotoh include the following: (i) two 
new regions appear before SRS1 in our map – we have designated 
the new regions as SRS1’a and SRS1’b; (ii) SRS1 is much wider in 
our map than in Gotoh’s – it covers 49 aligned-sequence positions 
in our map versus 28 aligned-sequence positions in Gotoh’s map; 
(iii) SRS2 and SRS3 are co-joined in our map to give a single large 
SRS region which we have designated as SRS(2,3) to maintain 
consistency with Gotoh’s numbering. SRS2 covers 9 aligned-
sequence positions in Gotoh’s map while SRS3 covers 10 positions 
whereas our newly-designated SRS(2,3) covers 60 aligned-
sequence positions; (iv) SRS4 in our map has a C-terminal exten-
sion of 3 aligned-sequence positions relative to SRS4 in Gotoh’s 
map; (v) SRS5 in our map has a N-terminal extension of 2 aligned-
sequence positions and a C-terminal extension of 1 aligned-
sequence position relative to SRS5 in Gotoh’s map; & (vi) SRS6 in 
our map has a N-terminal extension of 7 aligned-sequence positions 
and a C-terminal extension of 2 aligned-sequence positions relative 
to SRS6 in Gotoh’s map. 
 Our work shows that in mammalian CYP450, Gotoh’s SRS2 
and SRS3 are in fact, one continuous SRS region [SRS (2,3)]. This 
is consistent with the observation that the conformation of the F-G 
loop - which lies between Gotoh’s SRS2 and SRS3 - is highly vari-
able in X-ray structures of mammalian CYP450 isoforms and is 
able to adopt conformations that are more proximal to (and un-
screened from) the active site than is possible in many bacterial 
CYP450s (including, notably, structures of CYP101A – the tem-
plate in Gotoh’s delimitations). For example, in the CYP2C9 struc-
ture 1OG2 the F-G loop is almost completely folded into two small 
helices that are connected by a short loop that allows a bent connec- 
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tion between the two small helices. In that same structure the F-
helix and the G-helix are completely folded in helical conformation. 
Furthermore, the F-helix, F-G loop and G-helix in 1OG2 closely 
associate with each other and with the other secondary structure 
elements of the CYP450 protein to form a “lid” above the active 
site cleft. This configuration brings the large F-G loop close enough 
to the active site to make it likely that it participates in substrate 
recognition. Similarly, in the CYP3A4 structures 1TQN, 1W0F and 
2V0M, the F-helix is partially unwound and part of the F-G loop is 
folded into a helix separated from the G-helix by a “loop part” of 
the F-G loop. Again, the F-helix, F-G loop and G-helix form close 
associations with each other and with the other secondary structure 
elements of the CYP450 protein and form a “lid” above the active 
site cleft. This configuration of unscreened proximity to the active 
site suggests that the mammalian F-G loop could be involved in 
substrate recognition, as suggested by our unified SRS map. 
 An important difference between mammalian and bacterial F-G 
loops is that F-G loops are generally much smaller in bacterial 
CYP450 than in mammalian CYP450: They typically comprise ~ 
21 amino acids in mammalian CYP450 (see CYP2C9 structure 
1R9O, Ser209-Thr229 inclusive for example) but typically com-
prise only ~ 8 amino acids in bacterial CYP450 (see CYP101A 
structure 3CPP, Thr185-Thr192 inclusive for example), as has been 
noted previously [82]. We also observe, however, that in a subset of 
bacterial CYP450 structures - importantly, including the one used 
by Gotoh to delimit his mammalian SRSs (structure 3CPP) - the F-
G loop is folded away from the rest of the protein and forms a hoop 
that lies in a plane almost perpendicular to the plane defined by the 
F-helix and the first half of the G-helix, as shown in Fig. S10. As a 
result of this configuration, Gotoh’s approach of identifying resi-
dues within 10 Å of any atom of the bound camphor substrate in 
structure 3CPP as SRS residues had the effect of excluding F-G 
residues Asp188-Thr192, giving rise to the separation between 
SRS2 and SRS3 calculated in bacterial structures that was subse-
quently transferred (erroneously) to mammalian CYP450s in Go-
toh’s map. We note that the inclusion of Asp188-Thr192 as SRS 
residues would have required Gotoh to set the maximum distance 
threshold for interaction at 18 Å, well beyond the commonly-
accepted thresholds for interaction (interaction distance cut-offs are 
typically less than 10 Å [34, 83, 84]). 
 An interesting prediction of our unified map is that 33 % of the 
CYP450 sequence is involved in substrate contact (c.f. Gotoh’s 
figure of 16 %), suggesting that the overall spread of SRS regions 
had previously been substantially underestimated. This observation 
naturally leads to the questions “how complete is the description of 
SRS regions in the new map” and “how can we assess the degree of 
completeness”? Projection of the SRS regions delimited in our map 
onto the CYP450 fold (Fig. 6) reveals that the majority of locations 
on the CYP450 fold that are unobstructed from and are proximal to 
the catalytic heme iron have been included as SRS regions in our 
new unified map. This suggests that the new map given here repre-
sents a high degree of completeness in the description of CYP450 
SRS regions. An important caveat here though is that it is well ap-
preciated that docking algorithms are not particularly good at accu-
rately predicting the energetics of different possible ligand binding 
modes, plus even programs such as MetaSite make prediction of 
multiple likely oxidation sites on a given substrate but do 
not necessarily get these in the right order compared to experimen-
tal observations. Taken together, it is possible that our docking 
studies will therefore tend to implicate a wider range of residues as 
part of SRSs than are actually involved through side chain-substrate 
interactions. In this regard, we note that many residues in our uni-
fied SRSs are facing outwards from the CYP450 active site (see 
Fig. 5 for examples); whilst this does not automatically preclude 
their involvement in substrate binding as main chain atoms can also 
participate, it may mean that, in the context of substrate recognition, 
such residues are more permissive to mutation. Further experimen-
tation will be required to explore this. 
 In calculating that the coverage achieved by the X-ray structure 
ligands is only 26 % of CYP450 substrate space, it is interesting to 
note that the X-ray- and docking SRS maps determined here are in 
close agreement, with both identifying for example the new SRSs 
1’a, 1’b and 1’c, the notable exceptions being that the co-joining of 
SRS1 & SRS1’c and of SRSs 2 & 3 were only identified in the 
latter. Thus, despite the apparently substantially incomplete repre-
sentation of the chemical types that constitute the CYP450 substrate 
space, the limited set of X-ray structures currently available seem-
ingly already give a reasonably complete picture of how mammal-
ian CYP450s recognise their substrates. In other words, it appears 
that most parts of the complete SRS zone on the CYP450 fold are 
sampled by a relatively small number of ligands, which in turn 
suggests that it may not be necessary to observe a large number of 
CYP450-ligand complexes (for example, > 50 % of the CYP450 
substrate universe) in order to achieve the definition of a highly 
complete SRS map. It is worth emphasising of course that the dock-
ing studies performed here have played a critical role, both in con-
firming the usage of and extending the span of SRSs identified in 
the X-ray map, as well as in verifying the existence and usage of, 
for example, SRS(2,3) in a range of CYP450s for which there are 
currently no appropriate ligand-bound X-ray structures. 
 We have re-examined the 11 cases we identified in the literature 
of non-Gotoh-SRSs that are apparently involved in determining 
substrate recognition (Table 4) and found that our new unified SRS 
map provides direct and ready explanation for 5 of these 11 cases. 
Of the remaining 6 cases, one involves surface residues that are 
distal to and extensively screened from the active site, another lies 
completely outside the catalytic domain in the N-terminal hydro-
phobic membrane anchor peptide, two more are screened from the 
active site by the I-helix, and a further one is in proximity to the 
cysteine that forms the obligate heme thiolate. It seems likely there-
fore that in at least 5 of the 6 cases that remain unexplained by our 
unified SRS-map, the origin of their effect infact lies in longer-
range, ‘second sphere’ cooperative effects rather than in direct in-
teraction with substrate molecules. Thus, our new, unified SRS map 
has neatly accounted for each of the literature examples of non-
Gotoh-SRS regions that could plausibly directly contact substrates, 
thereby immediately demonstrating the utility of our expanded, 
unified SRS map. 
 Further development of our new SRS maps by scoring the indi-
vidual positions in SRS zones according to how frequently their use 
has been observed in X-ray crystal structures and/or in docking 
complexes will provide a useful resource in studies that seek to 
modulate CYP450 specificity by mutagenesis; such “scored posi-
tion” maps - of which Fig. S2 is a preliminary example - would for 
example inform future structure-activity studies on CYP450s by 
providing ranked lists of specificity-determining residues to be 
targeted by mutagenesis. 
 In considering other future possible uses of our expanded, uni-
fied SRS map, it is interesting to reflect on the fact that the human 
CYP450 enzymes that are involved in primary drug metabolism are 
known to be highly polymorphic in the population, with the distri-
bution of polymorphisms varying between ethnic groups [85, 86]. 
The impact of the vast majority of such polymorphic variations in 
human CYP450 genes on the metabolism of new and existing drugs 
- as well as on adverse drug-drug reactions - remains poorly under-
stood today, but clear individual examples exist in the literature. 
For example, CYP2C9 has over 35 non-synonymous single nucleo-
tide polymorphisms (SNPs) [www.cypalleles.ki.se] distributed 
throughout the protein sequence (Fig. 1) and the effect of individual 
CYP2C9 variant alleles on warfarin dose requirement has been 
documented, with patients with R144C and I359L mutations having  
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considerably lower warfarin clearance rates [87-89]. Interestingly, 
site-directed mutagenesis studies have shown that single amino acid 
changes in CYP450s can affect not only rates of reaction, but also 
substrate specificity, enantioselectivity and regioselectivity of oxi-
dation [90-92]. We therefore anticipate that our new, unified SRS 
map may help in gaining a better understanding of structure-
function relationships in CYP450s, as an important step towards 
predicting the effects of SNPs on drug metabolism and on adverse 
drug reactions; indeed, we note that that numerous SNPs in just 
CYP2C9, CYP2B4 and CYP3A4 lie within our new, expanded 
SRSs (Fig. 5), suggesting a potential direct influence of such SNPs 
on substrate recognition.  
ABBREVIATIONS 
SRS = Substrate recognition site 
CYP450 = Cytochrome P450 
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Differential tunnel-opening patterns were established in static structures of mammalian CYP450 isoforms
and subsequently applied to identify tunnel-intersecting residues. The identified tunnel-intersecting
residues permitted the subsequent construction of gating models via the identification of
intra-protein interactions. We define 28 two-state gating models and 37 singlet gating-residue models.
Our results reveal the preponderance of aromatic gating residues in CYP3A4 and CYP2A6, whereas we find
a preponderance of polar/charged residues in CYP2C5. In CYP2C8 there is balanced presence of polar/
charged and hydrophobic aliphatic residues in gating models, whilst in CYP2C9 there is balanced presence
of all residue-types. These patterns suggest fast evolutionary dynamics for gating residues and we find that
the average rate of evolution of gating residues in CYP2C5, CYP2C8, CYP2C9 and CYP2A6 is significantly
faster than the average rate of evolution of the entire sequence.
Our study identifies 67% of calculable gating models identified in the literature by molecular dynamics
approaches and 92% of residues appearing in literature models appear in our models. However, only 6% of
the models identified in this work had been previously-described in the literature. This suggests that our
study has defined the most comprehensive list yet of tunnel-gating models in mammalian CYP450 and in
doing so have created a benchmark for molecular dynamics approaches to the ligand-tunnelling problem
in CYP450.
 2010 Elsevier Inc. All rights reserved.1. Introduction
The Cytochromes P450 (CYP450, EC 1.14.14.1) are a super-
family of hemoprotein monooxygenases that catalyse the oxidation
of hydrophobic endogenous and xenobiotic substrates (Bridges
et al., 1998). CYP4501 homologs have been sequenced from all
lineages of life – including eukaryotes and bacteria (Werck-Reichhart
and Feyereisen, 2000; Zawaira et al., 2008). Furthermore, a viral
CYP450 from the giant virus Acanthamoeba polyphaga has recently
been characterized (Lamb et al., 2009).
The crystal structures of CYP450 determined so far show the
same overall fold in which the active site is buried in the core of
the protein (Hasemann et al., 1995; Sansen et al., 2007; Schoch
et al., 2004; Wester et al., 2004; Yano et al., 2004). In some of these
crystal structures, such as that of 6-deoxyerythronolide-bound
CYP450eryF (CYP107A1, PDB code 1OXA; (Cupp-Vickery andll rights reserved.
ernher & Beit Building North,
ctious Disease and Molecular
f Cape Town, Anzio Road,
awaira).
D, random expulsion molec-Poulos, 1995)), the active site is completely cut-off from the bulk
solvent. That is, the protein surface is not accessible from the active
site and there are absolutely no access routes that would permit
molecules of at least the size of water molecules, represented as
spherical probes of radius 1.4 Å in calculations, to access the active
site (Wade et al., 2004). Such structures have been denoted as
‘‘closed” structures (Wade et al., 2004) and are consistent with
the CYP450 catalytic cycle requirement of complete isolation of
the active site from the bulk solvent in order to prevent uncoupling
reactions and to ensure reaction specificity.
In other crystal structures tunnels wide enough to accommo-
date only molecules at most the size of water molecules, connect
the buried active site to the protein surface (Wade et al., 2004).
In still other crystal structures, large tunnels from the active site
to the protein surface that are sterically accessible for typical size
substrate molecules have been delimited. Such crystal structures
have been denoted as ‘‘wide-open” (Wade et al., 2004) and include
a structure of substrate-free CYP55A1 (PDB code 1ROM; (Park
et al., 1997a,b)) and a structure of substrate-free CYP450BM-3
(PDB code 2HPD; (Boddupalli et al., 1992; Fulco, 1991)). In these
‘‘wide-open” crystal structures, sterically accessible access routes
have been delimited in distinct parts of the CYP450 structure/fold
(Wade et al., 2004).
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the CYP450 active site to the bulk solvent has driven the emer-
gence of an entire field of CYP450 research in which it is sought
to elucidate how reactants (substrate, protons, oxygen) enter and
how products (metabolites, water) exit the active site of CYP450
(Schleinkofer et al., 2005; Wade et al., 2004); a number of putative
active-site access channels have been proposed, based on use of
various theoretical approaches, as exemplified below.
Standard molecular dynamics (MD) approaches and extensions
thereof, such as random expulsion molecular dynamics (REMD)
and steered molecular dynamics (SMD) have been used in long-
standing efforts to solve the CYP450 active-site access puzzle
(Ludemann et al., 1997, 2000a,b; Schleinkofer et al., 2005; Wade
et al., 2004, 2005; Winn et al., 2002). Pathways delimited from
the MD approaches are supported by results from other indepen-
dent theoretical approaches such as thermal motion pathway
(TMP) analysis (Ludemann et al., 1997) and adiabatic mapping
(Ludemann et al., 2000b).
Channels in several CYP450 isoforms accessible to spherical
probes the size of water molecules have been found using MD ap-
proaches and have been named as pathway (pw) pw1, pw2 and
pw3 (Ludemann et al., 1997, 2000a,b; Wade et al., 2004, 2005; Winn
et al., 2002). These pathways are delimited by the secondary
structure elements lining them at their exit points from the
CYP450 structure. The pathway pw2 has been further sub-divided
into the sub-types pw2a, pw2b, pw2c, pw2d and pw2e on the basis
of REMD ligand egress trajectories (Schleinkofer et al., 2005). A
ligand following pw1 from the active site exits close to the heme
plane, passes under the I helix and egresses between the C/C0 and
H or L helices – close to the G–H loop and b2 strand (Wade et al.,
2004). The subclasses of pw2 share proximity with the B–C loop/B0
helix (Schleinkofer et al., 2005). Pw2a exits the CYP450 structure be-
tween the F–G loop, B–C loop/B0 helix/BB0 loop and the b1 strand
(Wade et al., 2004). Pw2b exits between the B/B0 loop and the b1
and b3 strands whilst pw2c exits between the G and I helices and
the B0 helix/B–C loop. Pw2d exits between the N-terminus and heli-
ces a and A whilst pw2e exits through the B–C loop. Pw3 exits be-
tween the F and G helices or at the EF loop (Wade et al., 2004). In
addition, a number of CYP450 crystal structures have a small chan-
nel from the active site to the protein surface that has been referred
to as the ‘‘solvent channel”, abbreviated as channel S, which exits be-
tween the F, E and I helices and the b4 strand (Haines et al., 2001;
Wade et al., 2004). Channel S is thought to be important in conveying
and controlling proton access to the CYP450 active site (Wade et al.,
2004). The relative positions of these tunnels are illustrated in
Fig. S2. A water channel, named channel W, has also been identified
which exits the CYP450 structure at the base of the B–C loop near the
C-terminus of the B-helix (Cojocaru et al., 2007).
Cojocaru and co-workers applied the computational geometry
tool, CAVER (Petrek et al., 2006), to conduct the largest survey
to-date of the distribution and pattern of tunnels in static
CYP450 structures (Cojocaru et al., 2007). In that study two new
pathway families (pw4 and pw5) and two further pw2 subfamilies
(pw2f and pw2ac) were identified (Cojocaru et al., 2007). This work
showed that the computational geometry algorithm, CAVER, ap-
plied on static structures of CYP450s recapitulates largely the same
spectrum of access routes as that from molecular dynamics simu-
lations. Hence it has been possible to assign tunnels calculated
using CAVER to the tunnel systems calculated using REMD ap-
proaches. It is known that CAVER can give a number of possible
tunnels emanating from the same user-defined starting point but
terminating at different CAVER-calculated exit points on the pro-
tein surface. This occurs owing to the fact that several choices for
tunnel-exit points may exist in the calculations of the CAVER algo-
rithm. The CAVER algorithm divides three-dimensional space into
a grid and calculations are based on grid-points. An envelope (con-vex hull) is calculated around the protein molecule and grid points
that fall on this envelope are assigned as possible exit-points for
tunnels. Hence, when several such points fall in the same space
as a REMD tunnel, several ‘‘variants” of that REMD tunnel will ap-
pear in CAVER calculations (Cojocaru et al., 2007; Petrek et al.,
2006). In principle, only one ‘‘variant” need be considered and
the greatest priority is given to the widest tunnel that bears the
greatest verisimilitude to the associated REMD tunnel. In cases
where it is not straightforward to assign the CAVER-calculated tun-
nel that bears the greatest verisimilitude to REMD tunnels all the
candidates may be assigned as ‘‘variants” of that REMD tunnel.
Gating residues have been identified for some of the pathways in
CYP3A4 and CYP2C5 using MD approaches. Fishelovitch and
co-workers identified the following CYP3A4 gating residue pairs in
SMD simulations of both Temazepam (TMZ) and Testosterone-
6OH (TST-OH): pw2a, F57-F215; pw2b, F108-F220; pw2c,
F108-F241; pw3, F213-F241 and S, R212-L482. However, SMD
simulations in the same study identified different pw2e-gating res-
idues for TMZ and TST-OH: F108-I120 and R105-S119, respectively
(Fishelovitch et al., 2009). In CYP2C5 REMD simulations that used
progesterone and 21-hydroxy-progesterone as substrate, Schle-
inkofer and co-workers identified K241-V106 as a pw2c gating
residue pair (Schleinkofer et al., 2005). Interestingly, the SMD simu-
lations on CYP3A4 suggest that certain residues play a role in gating
more than one tunnel [e.g. F108 (pw2b, pw2c & pw2e) and F241
(pw2c and pw3)] and interact with different residues in doing so
(e.g. F108-F220 vs F108-F241 vs F108-I120). It is also interesting that
some of the SMD-predicted gating residues apparently vary in a sub-
strate-dependent manner.
Taken together, these observations suggest that the picture of
tunnel-gating residues in cytochrome P450 enzymes is far from
complete and that further analysis using different approaches is
warranted. We have therefore built a strategy for the identification
of tunnel-gating residues based on the assumption that amino-acid
side chain motions are the main mechanism by which CYP450
molecules open or close ligand access tunnels. Usefully, a constant
characteristic of the SMD-predicted gating residues is that the gat-
ing interactions that close the tunnel of interest are present in the
start configuration of the MD simulation and always appear to per-
sist throughout the course of the MD simulation, their eventual
breakage accompanying the escape of the ligand from the protein
(Fishelovitch et al., 2009; Schleinkofer et al., 2005). Hence it is
plausible that additional tunnel-gating residues which can be iden-
tified from static structures by other approaches may also be ex-
pected to make interactions that show the same trends.
Our strategy begins with the use of the computational geometry
tool, CAVER, to perform a focused and detailed analysis of the dis-
tribution of tunnels in static CYP3A4, CYP2C5, CYP2C8, CYP2C9 and
CYP2A6 structures with the view of building ‘‘tunnel-open”/‘‘tun-
nel-closed” CYP450 structure pairs for as many of the known
(putative) pathways as possible. These ‘‘tunnel-open”/‘‘tunnel-
closed” pairs are subsequently used to identify amino-acids whose
side chains obstruct a given REMD tunnel of interest by searching
for side chains in the ‘‘tunnel-closed” structure that intersect with
the REMD tunnel of interest calculated in the ‘‘tunnel-open” struc-
ture. The ‘‘tunnel-open” and ‘‘tunnel-closed” structures are aligned
to facilitate delimitation of the amino-acids whose side chains
intersect the tunnel of interest. Gating interactions are subse-
quently delimited by tracking-down intra-protein interactions
made by the tunnel-intersecting residues. These interactions form
part of the two-state models described in this work when delimi-
tations are performed using structures of the same CYP450 iso-
form. In our strict regime for delimitation of two-state gating
models, we stipulate that tunnel-closure interactions occur exclu-
sively in the ‘‘tunnel-closed” structure and tunnel-opening interac-
tions occur exclusively in the ‘‘tunnel-open” structure. When
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different CYP450 isoforms, only the tunnel-intersecting residue
may be delimited but not interactions that occur exclusively in
either the ‘‘tunnel-open” or ‘‘tunnel-closed” structure. The gating
models we derive in this case are termed singlet gating models
to denote that, unlike in the primary description of a two-state gat-
ing model where two interacting amino acids and the tunnel they
obstruct are specified, here only one amino acid and the tunnel it
intersects are specified.
Since our goal is to define as many ‘‘tunnel-open”/‘‘tunnel-
closed” pairs as possible that are based on CAVER-calculated tun-
nels which bear the greatest verisimilitude to REMD tunnels, it is
necessary to optimise the trade-off between the cut-off gorge
widths for the CAVER-calculated tunnels that are to be included
in the study versus the verisimilitude of the included tunnels to
REMD tunnels. We note that in the optimisation process, for any gi-
ven gorge width cut-off, the assignment of CAVER-calculated tun-
nels to REMD tunnels (i.e. tunnel verisimilitude – done visually in
this work) would be more subjective than the assignment of the
number of ‘‘tunnel-open”/‘‘tunnel-closed” pairs. We also note as
a reminder that CAVER should not be expected, within the frame-
works of the CYP450 ligand-tunnelling problem, to calculate tun-
nels of large gorge widths – typically taken as P2.8 Å i.e. large
enough for at least water molecules to pass through. Hence verisi-
militude to REMD tunnels is an important criterion and guide
within the context of the CYP450 ligand-tunnelling problem. In
addition to the assumption described above that amino-acid side
chains play a paramount role in the gating of tunnels, we also as-
sume that the CAVER-calculated tunnels that we subsequently as-
sign to REMD tunnels are sufficiently related to REMD tunnels
enough to allow the accurate extraction of further information
about REMD tunnels – such as gating models.
Two-state gating models (where they can be built) offer the
most parsimonious rationalisation for differential tunnel-opening
patterns in static structures. We have explored the relationship be-
tween gating models identified in this work and gating models
identified in MD approaches described in the literature. Further-
more, the large survey of gating residues presented herein has per-
mitted analysis of the side chain chemical types, rate of evolution
and divergence and conservation of the tunnel-intersecting gating
residues and the gating interaction networks they make in CYP450.2. Materials and methods
2.1. Structures and sequences
Structures were retrieved from the RCSB Protein Data Bank
(www.pdb.org). The structure PDB codes are as follows. CYP3A4
(Homo sapiens): 1TQN, 1W0F, 2J0D and 2V0M. CYP2C5 (Oryctolagus
cuniculus): 1DT6, 1N6B and 1NR6. CYP2C8 (Homo sapiens): 1PQ2,
2NNH, 2NNI, 2NNJ and 2VN0. CYP2C9 (Homo sapiens): 1OG2, 1OG5
and 1R90. CYP2A6 (Homo sapiens): 1Z10, 1Z11, 2FDU, 2FDV, 2FDY,
2FDWand 2PG5. Sequences were retrieved from the Universal Protein
Resource Knowledgebase (UniProtKB/Swiss-Prot) database via the
European Bioinformatics Institute website (http://www.ebi.ac.uk).
The accession numbers were according to the UniProtKB database un-
less otherwise stated. The sequence accession numbers used herein
are as follows. CYP2C5: P00179 (Oryctolagus cuniculus), CYP2C8:
P10632 (Homo sapiens), CYP2C9: P11712 (Homo sapiens), CYP2A6:
P11509 (Homo sapiens) and CYP3A4: P08684 (Homo sapiens).2.2. Calculation of tunnels using CAVER
Tunnels were searched in each of the CYP450 structures using
the program CAVER (Petrek et al., 2006). CAVER is a computationalgeometry tool that uses the Dijkstra algorithm to calculate the
shortest low-cost accessible path from a user-defined starting
point located within the interior of the protein to the bulk solvent.
Several accessible routes may be returned and in such situations
CAVER returns a ranked/prioritised list of possible accessible
routes. CAVER gives greatest priority to the access route with the
widest gorge width irrespective of the length of the route. Further-
more, when two access channels have the same gorge width, the
shorter channel has greater priority (personal communication, Petr
Benes, CAVER support) (Petrek et al., 2006). We used the heme Iron
(heme Fe) in CYP450 structures as the starting-point in tunnel
searches. The heme Fe co-ordinates were read directly from PDB
files. Water molecules were ignored in the searches.
For a given CYP450 structure, the determination of the variation
of the number of ‘‘tunnel-open”/‘‘tunnel-closed” pairs with the
gorge width cut-off began with issuing a request to CAVER for a large
number of tunnels – typically 60. The number of ‘‘tunnel-open”/
‘‘tunnel-closed” pairs was recorded as the gorge width of accepted
tunnels (accepted as being significant and therefore included in
the study) was increased from 0.7 Å to 3.3 Å (inclusive) in steps of
0.1 Å. Qualitative notes about the overall similarity of accepted tun-
nels to REMD tunnels were also made to assist in the assignment of
the verisimilitude of the CAVER-calculated tunnels to REMD tunnels
at given gorge width cut-offs. At cut-offs 6 1 Å, the majority of
accepted tunnels were not akin to the previously-defined REMD
tunnels. The maximum number of ‘‘tunnel-open”/‘‘tunnel-closed”
pairs, calculated at each point as the gorge-width cut-off is incre-
mented in steps of 0.1 Å from 0.7 to 3.3 Å (inclusive) in each
CYP450 structure, was found to be 4. There was no differential
tunnel-opening in all CYP450 structures outside the gorge width
cut-off range [0.7–3.3 Å]. We also found that a gorge width cut-off
of 1.4 Å allowed the best balance of factors (verisimilitude versus
number of differential pairs) in the majority of the CYP450 struc-
tures that were analysed and was subsequently applied in all tunnel
calculations in this study.
2.3. Structure alignments
Structure visualisations and alignments were done using the
program Pymol (www.pymol.org). Structure alignments of
CYP450 catalytic domains were evaluated by applying a panel of
visual criteria such as the simultaneous achievement of stacking
of heme co-factors in parallel planes with less than 3 Å distance
separation between corresponding atoms and complete superim-
position of I-helices. General good alignment of F and G helices
was also considered in accepting or rejecting alignments of struc-
tures. The Root Mean Square Deviation (RMSD) of the alignments
was also considered. Protein sequences were aligned using the pro-
gram ClustalW (default parameters) (Jeanmougin et al., 1998;
Thompson et al., 1994, 1997).
2.4. Delimitation of two-state gating models
Two-state gating models here are delimited from different
structures of the same CYP450 isoform. The search for two-state
gating models begins with the identification of tunnel-open/tun-
nel-closed pairs of structures for a given tunnel and a given
CYP450 isoform. These pairs are identified from profiles calculated
using CAVER (Petrek et al., 2006) as described above. Tunnel-open/
tunnel-closed pairs are aligned using Pymol (www.pymol.org) and
only the tunnel of interest is displayed. Amino-acid side-chains
from the tunnel-closed structure that intersect the tunnel in the
tunnel-open structure are manually identified by searching along
the tunnel from the tunnel’s start-point at the heme Iron (Fe) to
the tunnel’s end-point at the protein surface. This manual search
usually identifies only one residue whose side-chain intersects
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tunnel-intersecting residue are subsequently identified using the
Protein Interaction Calculator (PIC) server (default parameters)
(Tina et al., 2007). This delimitation of residues interacting with
the tunnel-intersecting residue is done independently for the ‘‘tun-
nel-open” and the ‘‘tunnel-closed” structures.
The interactions delimited in the tunnel-closed structure using
PIC have to satisfy the requirement that they are absent in the tun-
nel-open structure in order to constitute ‘‘tunnel-closure” interac-
tions in a two-state gating model. Similarly, interactions delimited
in the tunnel-open structure using PIC have to satisfy the require-
ment that they are absent in the tunnel-closed structure in order
to constitute ‘‘tunnel-opening” interactions in a two-state gating
model. Hence interactions common to both ‘‘tunnel-open” and ‘‘tun-
nel-closed” structures are omitted from our strict two-state gating
models. We note that such two-state gating models offer a detailed
maximum parsimony mechanistic explanation for the differential
channel-opening patterns in structures of a given CYP450 isoform.
The description of a given two-state gating model includes a
3-tuple, (Aa1, Aa2, pw), where Aa1 is the manually-delimited ami-
no acid whose side-chain intersects the REMD tunnel pw and Aa2
is an amino acid delimited to be involved in a non-covalent inter-
action (e.g. hydrophobic, ionic, main chain–main chain H-bond
etc.) with the manually-delimited amino acid Aa1. These 3-tuples
are reported directly in Table 2 and Table S2.
2.5. Delimitation of singlet gating models from structures of different
CYP450 isoforms
In close analogy to the delimitation of two-state gating-models,
the delimitation of singlet gating models in this approach beginsTable 1
CAVER-calculated tunnels in CYP3A4 structures.
CYP450: PDB code CAVER tunnel number REMD equivalent an
pw2a pw2b




CYP3A4: 1W0F 1 
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Tunnels calculated in a structure of a given CYP450 isoform are numbered sequ
the REMD pathway to which the numbered CAVER-calculated tunnel is assigned
For example, four significant tunnels are calculated in the CYP3A4 structure 1TQ
tunnel has a gorge width of 2.330 Å. The REMD pathways pw1 and pw2d were
a This is a variant of the solvent channel (S) that is positioned forward more
b This is a variant of the solvent channel (S) that is positioned backwards –
c1 This tunnel is probably an artefact of the gap created by the missing residue
canonical pw2a and can therefore be assigned as pw2a. However, others have
c2 This tunnel is probably an artefact of the gap created by the missing residue
of the canonical tunnel S and pw2a. Unlike the canonical S it does not bend ove
this tunnel is therefore not trivial and is not attempted here.
d This is probably the true pw2a tunnel in 2J0D as it is closest to the b1 stra
e This tunnel is probably an artefact of the gap created by the missing residue
of the canonical tunnel S and pw2a. Unlike the canonical S it does not bend ove
this tunnel is therefore not trivial and is not attempted here.
f This variant of the solvent channel (S) in 2J0D is more proximal to the F hwith the alignment of structures of different CYP450 isoforms with
differential tunnel-opening patterns for a given tunnel of interest.
Tunnel-open/tunnel-closed pairs of different CYP450 isoforms are
aligned using Pymol (www.pymol.org) and only the tunnel of
interest is displayed. Amino-acid side-chains from the tunnel-
closed structure that intersect the tunnel in the tunnel-open struc-
ture are manually identified by searching along the tunnel from the
tunnel’s start-point at the heme Iron (Fe) to the tunnel’s end-point
at the protein surface. This manual search usually identifies only
one residue whose side-chain intersects with the tunnel of interest.
The description of a gating-residue model includes a 2-tuple
(Aa1, pw) where Aa1 is the manually-delimited amino acid whose
side-chain intersects the REMD tunnel pw. We do not directly re-
port 3-tuple models here as there is no simple way of delimiting
interactions that occur exclusively in tunnel-open or tunnel-closed
structures. However, it is possible to assemble possible 3-tuple gat-
ing-residue models from these results by appending to the 2-tuple
models (Aa1, pw), residues delimited to be in direct interaction
with Aa1. These residues are described in the comments column
of Table 3 and Table S3.2.6. Calculation of intra-protein interactions
For a given tunnel-intersecting residue identified manually as
described above, the intra-protein interaction partners in main
chain-main chain, main chain-side chain, side chain-side chain,
hydrophobic aliphatic, ionic and hydrophobic aromatic interac-
tions are identified using Protein Interaction Calculator Server
(PIC) (Tina et al., 2007). Default parameters are used unless other-
wise stated.d tunnel gorge width



















entially in Arabic numerals. The cross sign () is placed under the name of
. The gorge width of the numbered tunnel is also reported in the same row.
N and the first tunnel (No. 1) is assigned to the REMD pathway pw2b. This
not observed.
towards the F–G loop.
farther removed from the F–G loop.
s (214–218 inclusive) in 2J0D. It lies in close proximity to the space of the
assigned it as pw2f (Cojocaru et al., 2007).
s (214 – 218 inclusive) in 2J0D. This tunnel lies midway between the space
r the I-helix nor does it encroach towards the b4 strand. The assignment of
nd and is not adjacent to the missing part of the F–G loop.
s (214 – 218 inclusive) in 2J0D. This tunnel lies midway between the space
r the I-helix nor does it encroach towards the b4 strand. The assignment of
elix than the variants in 1TQN.
Table 2
Two-state gating models in CYP3A4.
Model number Structures: open/closed Tunnel-closing interaction Gated tunnel
1 1TQN/2V0M (CYP3A4) Arg 212-Glu 308 S
Comment: see comments in model number 2 below
2 1TQN/2V0M (CYP3A4) Arg 212-Asp 214 S
Comment: the Arg 212-Glu 308 ionic interaction, the Arg 212 O-Asp 214 OD2 main chain-side chain interaction and the Arg 212 O-Asp 214N main
chain–main chain interaction that close tunnel S in 2V0M are absent in 1TQN as determined by Protein Interaction Calculator. Instead, the
interactions are replaced by: (a) Arg 212NH1-Phe 304 O (carbonyl oxygen) interaction. This main chain (Phe 304 O)-side chain (Arg 212 NH1)
interaction stretches the Arg 212 side-chain downwards parallel to channel S. This interaction is accompanied by greater unwinding of the F helix
in 1TQN. (b) Side interaction between the N nitrogen of Arg 212 and the OE2 oxygen of Glu 308. This main chain (Arg 212 N)-side chain (Glu 308
OE2) interaction co-operates with the interaction in (a) to position the Arg 212 side-chain parallel to channel S
3 1TQN/2V0M (CYP3A4) Leu 482-Ile 369 S
Comments: see comments in model number 4 below
4 1TQN/2V0M (CYP3A4) Leu 482-Phe 304 S
Comments: the Leu 482-Ile 369 and Leu 482-Phe 304 hydrophobic aliphatic interactions that closes tunnel S in 2V0M are absent in 1TQN as
determined by Protein Interaction Calculator. Instead, Leu 482 makes hydrophobic contact with Met 371 in 1TQN. The Leu 482 O-Gln 484N main
chain–main chain interaction is present in both 1TQN and 2V0M and is not listed as an interaction specific for either tunnel closure or opening
5 2V0M/1W0F (CYP3A4) Phe 213-Phe 108 pw3
Comment: see comments in model number 9 below
6 2V0M/1W0F (CYP3A4) Phe 213-Phe 215 pw3
Comments: see comments in model number 9 below
7 2V0M/1W0F (CYP3A4) Phe 213-Phe 241 pw3
Comments: see comments in model number 9 below
8 2V0M/1W0F (CYP3A4) Phe 213-Phe 304 pw3
Comments: see comments in model number 9 below
9 2V0M/1W0F (CYP3A4) Phe 213-Val 240 pw3
Comments: the Phe 213-Phe 108, Phe 213-Phe 215, Phe 213-Phe 241 and Phe 213-Phe 304 hydrophobic aromatic interactions and the Phe 213-Val
240 hydrophobic interaction that close tunnel pw3 in 1W0F are absent in 2V0M as determined by Protein Interaction Calculator. Instead, they are
replaced in 2V0M by the Phe 213-Leu 211 hydrophobic interaction and the Phe 213N-Leu 211 O main chain–main chain interaction. We note that
the Phe 213-Phe 220 interaction is present in both 2V0M and 1W0F
10 2V0M/1TQN (CYP3A4) Phe 215-Phe 108 pw2a
Comments: see comments in model number 12 below
11 2V0M/1TQN (CYP3A4) Phe 215-Phe 213 pw2a
Comments: see comments in model number 12 below
12 2V0M/1TQN (CYP3A4) Phe 215-Phe 220 pw2a
Comments: the Phe 215-Phe 108, Phe 215-Phe 213 and Phe 215-Phe 220 hydrophobic aromatic interactions that close tunnel pw2a in 1TQN are absent
in 2V0M as determined by Protein Interaction Calculator. Instead, Phe 215 makes hydrophobic interactions with Leu 216 and with Leu 479 in 2V0M
The two-state gating models we delimited in CYP3A4 structures are numbered in Arabic numerals. The tunnel-open/tunnel-closed pairs of CYP3A4
structures were constructed using the profiles in Table 1 above. Each of the numbered models corresponds to a manually-delimited residue whose side-
chain intersects the tunnel of interest (listed in the fourth column from the right) and the intra-protein interactions it makes. The manually-delimited
tunnel-intersecting residue in each model is shown underlined and in boldface.
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delimited in the literature by molecular dynamics approaches
Gating models delimited by MD (for a given tunnel) were col-
lated from the literature and tabulated. The tabulated literature
gating models were analysed to establish the extent of agreement
and overlap with gating models identified in this work using vari-
ous simple metrics/measures. Gating model information is given in
the literature in the form of 3-tuples (Aa1, Aa2, pw). Several met-
rics were devised to compare 3-tuples identified in this work with
those reported in the literature. The first metric, Q1, expresses the
percentage of all literature gating 3-tuples (identified by molecular
dynamics approaches) that have also been identified in this work.
In the calculation of the second metric, Q2, the set of literature
3-tuples is trimmed to include only those 3-tuples that include
pathways for which it has been possible to delimit gating residues
for a given CYP450 isoform using our approach described herein.
Q2 is calculated in the same manner as Q1 over this trimmed/lim-
ited set of literature 3-tuples. We also calculate P1, the percentage
of 3-tuples models identified in this work that have been previ-
ously described in the literature. For purposes of calculation of
P1, the 2-tuple models delimited in this work are converted to
3-tuples by assuming that only one 3-tuple model arises from a
given 2-tuple. This ‘‘pessimistic” model effectively gives thesmallest possible number of 3-tuple gating-residue models since
all the interactions involving the tunnel-intersecting residue Aa1
in the 2-tuple models may be realised as exclusively tunnel-clo-
sure interactions (these interactions are listed in the comments
section of Table 3 and Table S3).
2.8. Analysis of gating models
Tunnel-intersecting residues in the gating models delimited as
described above were classified according to side chain chemical
type as hydrophobic aromatic (Phe, Trp, Tyr), Polar/Charged (Arg,
Lys, Glu, Asp, Thr, Gln, Asn, Ser, His, Cys) or hydrophobic aliphatic
(Leu, Ile, Val, Met, Pro). Glycine (no side-chain) and Alanine
(amphipathic) were not considered as residues that fall in any of
these three classes and therefore would not have contributed to
counts of residues had they been delimited as tunnel-intersecting
residues. The abovementioned assignment of amino-acid residues
as hydrophobic aromatic, polar/charged or hydrophobic aliphatic
was along the lines discussed by Valdar for conservation analysis
(Valdar, 2002). The distribution of side chain chemical-types occur-
ring as tunnel-intersecting residues in each of CYP2C5, CYP2C8,
CYP2C9 and CYP2A6 was determined by calculating the percentage
of tunnel-intersecting residues that are hydrophobic aromatic, po-
lar/charged or hydrophobic aliphatic.
Table 3
Singlet gating models in CYP3A4.
Model number Structures: open/closed Gating residue Gated tunnel Maximum number of 3-tuple models
1 1DT6 (CYP2C5)/1TQN (CYP3A4) CYP3A4 Phe113 pw2c (8)
Comments: Phe 113 makes hydrophobic contacts with the following residues in 1TQN: Met 114, Leu 293, Val 296, Ala 297 and Ile 300
Phe 113 also makes the following main chain–main chain interactions in 1TQN: Phe 113N-Val 111 O, Phe 113 O-Lys 115N and Phe 113 O-Ser 116N
Finally Phe 113 makes a Phe 113 O-Ser 116 OG main chain-side chain interaction.
2 1DT6 (CYP2C5)/1TQN (CYP3A4) CYP3A4 Phe 241 pw2c (11)
Comments: Phe 241 makes hydrophobic aromatic interactions with the following residues in 1TQN: Phe 108, Phe 213 and Phe 304
Phe 241 makes the following hydrophobic interactions in 1TQN: Val 111, Met 114, Ile 120, Pro 242, Ile 300 and Ile 301. Phe 241 also makes Phe
241N-Cys 239 O and Phe 241 O-Arg 243N main chain–main chain interactions in 1TQN
Furthermore, Phe 241 makes Phe 241N-Cys 239 SG and Phe 241 O-Cys 239 SG main chain-side chain interactions in 1TQN
3 2FDV (CYP2A6)/2V0M(CYP3A4) CYP3A4 Trp 126 W (10)
Comments: Trp 126 makes aromatic hydrophobic contact with Tyr 99. Trp 126 makes hydrophobic contact with Ile 118, Ala 121 and Pro 439. Trp
126N makes main chain–main chain interactions with Glu 122 O, Asp 123 O and Glu 124 O. Trp 126 O makes main chain–main chain interactions
with Arg 128N, Leu 129N and Arg 130N
4 2FDV (CYP2A6)/2V0M(CYP3A4) Lys 127 W (4)
Comments: Lys 127N makes main chain–main chain interactions with Asp 123 O and Glu 124 O
Lys 127 O makes main chain–main chain interactions Arg 130N and Ser 131N
Lys 127 O makes main chain–side chain interactions with Ser 131 OG
The singlet gating models we delimited in CYP3A4 structures are numbered in Arabic numerals. The tunnel-open/tunnel-closed pairs of CYP structures
were constructed using the profiles in Table 1 above. Each of the numbered models corresponds to a manually-delimited residue whose side-chain
intersects the tunnel of interest (listed in the fourth column) and the intra-protein interactions it makes. Unlike in the two-state models defined in Table 2
and Table S2, interactions in the ‘‘tunnel-open” mode cannot be defined here. Furthermore, unlike in the two-state models, the interactions of tunnel-
intersecting residues occurring exclusively in the tunnel-open structure or tunnel-closed structure cannot be labelled here. The manually-delimited
tunnel-intersecting residue in each model is shown underlined and in boldface. The singlet gating models are given here as the 2-tuples (Aa1, pw) where
Aa1 is the manually-delimited tunnel-intersecting residue that intersects tunnel pw. The number in parentheses ( ) in the column ‘‘Maximum number of 3-
tuple models” gives the maximum number of 3-tuple gating-reside models (Aa1, Aa2, pw) that can be generated by pairing the residue Aa2 delimited to
interact with the tunnel-intersecting residue Aa1. Residues of type Aa2 are listed in the ‘‘comments” section of Table 3 for a given residue Aa1.
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ing residues in CYP2C5, CYP2C8, CYP2C9 and CYP2A6. The se-
quences of CYP2C5, CYP2C8, CYP2C9 and CYP2A6 were aligned
using the software ClustaW (default parameters) (Jeanmougin
et al., 1998; Thompson et al., 1994, 1997) and the alignment was
used to calculate a tree using the program PROML in the PHYLIP
suite of programs (version 3.69, default parameters, http://evolu-
tion.genetics.washington.edu/phylip.html). The PROML-calculated
tree and the ClustalW-calculated alignment were used as input
in the program Rate4Site (Pupko et al., 2002) (version 2.01 for
windows, default parameters) to calculate the relative rates of
evolution of all the sequence positions in the alignment of
CYP2C5, CYP2C8, CYP2C9 and CYP2A6. The average rate of evolu-
tion of the tunnel-intersecting residues in each of the isoforms
CYP2C5, CYP2C8, CYP2C9 and CYP2A6 was calculated as the arith-
metic average of the rates of evolution of the corresponding
positions in the ClustalW-calculated alignment. The statistical sig-
nificance of the difference between the average rate of evolution
of the entire sequence and the average rate of evolution of the
tunnel-intersecting residue was calculated for each of CYP2C5,
CYP2C8, CYP2C9 and CYP2A6 using the Student’s t-test at the
5% level of statistical significance. Here the null hypothesis that
the average rate of evolution of the entire sequence is the same
as the average rate of evolution of the tunnel-intersecting resi-
dues was tested against the alternative hypothesis that the aver-
age rate of evolution of the entire sequence is less than the
average rate of evolution of the tunnel-intersecting residues in
each of CYP2C5, CYP2C8, CYP2C9 and CYP2A6. Student’s t-test cal-
culations were performed using functions in Microsoft Excel
spreadsheets.
Finally, we annotated an alignment of PDB-extracted sequences
of CYP2C5, CYP2C8, CYP2C9 and CYP2A6 to show the relationship
between conserved positions in the CYP2 family, CYP secondary
structure elements, Gotoh’s substrate recognition sites (Gotoh,
1992), the residues delimited in the two-state gating models of this
work and the tunnel-intersecting residues in the gating models
delimited herein.3. Results
3.1. Calculation of tunnels using CAVER
The distribution of tunnels calculated in CYP3A4 structures
using CAVER is shown in Table 1. The distribution of tunnels in
CYP2C5, CYP2C8, CYP2C9 and CYP2A6 structures is shown in
Table S1.3.2. Delimitation of two-state gating models
A list of the two-state gating models that we delimited in
CYP3A4 is given in Table 2. Two-state models delimited in CYP2C5,
CYP2C8 and CYP2C9 are given in Table S2. Furthermore, an exam-
ple of the manual delimitation of a tunnel-intersecting residue is
shown in Fig. 1 below for the case of the CYP3A4 tunnel-open/tun-
nel closed pair 1TQN/2V0M (see Table 1 above). This example con-
siders the opening and closure of tunnel S. Analysis of this pair of
structures, after calculation of tunnels in 1TQN and subsequent
alignment to 2V0M, identifies Arginine 212 as the 2V0M residue
whose side-chain intersects 1TQN tunnel S.3.3. A note on the gating of pw2b
The tunnel pw2b is open in all the four structures of CYP3A4
considered in this study (the structures 1 W0E and 1 W0G give
the same tunnel pattern as 1 W0F). As such it is not possible to de-
fine tunnel-open/tunnel-close pairs of structures for this tunnel.
However, we have identified a conserved network of interactions
present in all four CYP3A4 structures that restricts the space avail-
able to the pw2b tunnel as it extends from the active-site to the pro-
tein surface. We speculate that this space restriction then allows
the swinging motions of side chains of gating residues (candidates
are residues such as Phe 220 and Phe 219) to efficiently shut-down
or open pw2b. In the absence of this network of space-restricting
residues, several combinations of gating residues or large protein
Fig. 1. The manual delimitation of the tunnel-intersecting residue in a two-state gating model for tunnel S in CYP3A4. Panel (A) shows the alignment of the CYP3A4 structures
1TQN and 2V0M without any CAVER-calculated tunnels shown. Panel (B) shows the same alignment of 1TQN and 2V0M in the same orientation but with the CAVER-
calculated tunnel S shown in purple. In both panels (A) and (B), 1TQN is shown in green, 2V0M in grey, the heme group in turquoise, Arg 212 in 2V0M is shown in blue and Arg
212 in 1TQN is shown in red. Panel (B) shows that Arg 212 in 2V0M intersects the CAVER-calculated tunnel S in 1TQN. The two structures were aligned using Pymol. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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protein surface the tunnel pw2b can exit-from. This network of
interactions comprises the following pairs of ionic interactions:
Arg 106-Asp 76, Arg 106-Glu 374, Arg 372-Asp 76 and Arg
372-Glu 374.
3.4. Delimitation of singlet gating models from structures of different
CYP450 isoforms
A list of the singlet gating models that we delimited is given in
Table 3 and in Table S3. Furthermore, an example of the manual
delimitation of the gating residue whose side-chain intersects a
tunnel is shown in Fig. 2 below for the case of 1DT6.pdb (CYP2C5)Fig. 2. Conserved network of interactions that restricts the space available for
tunnel pw2b exit on the CYP450 protein surface. Tunnel pw2b calculated in the
CYP3A4 structure 1TQN using CAVER is shown in purple. The amino-acid residues
that constitute the conserved networks of interacting residues that are thought to
restrict the space available for tunnel pw2b are: Arg 106 (in red), Asp 76 (in blue),
Arg 372 (in green) and Glu 374 (in yellow). Arg 106 makes ionic contact with Asp 76
and with Glu 374. Arg 372 makes ionic contact with Asp 76 and with Glu 374. The
aligned CYP3A4 structures are as follows: 1TQN (in grey), 1W0F (in salmon), 2J0D
(in orange) and 2V0M (in cyan). The heme group is rendered in hot-pink. (For
interpretation of the references to colour in this figure legend, the reader is referred
to the web version of this article.)and 1TQN.pdb (CYP3A4) which comprise a pw2c tunnel-open/tun-
nel-closed pair of structures. The pathway pw2c is open in 1DT6
and closed in 1TQN. Analysis of this pair of structures, after calcu-
lation of tunnels in 1DT6 and subsequent alignment to 1TQN, iden-
tifies Phe 113 and Phe 241 as 1TQN.pdb residues whose side chains
intersect tunnel pw2c in 1DT6.pdb.
3.5. Comparison of gating models delimited in this work with those
delimited in the literature by molecular dynamics approaches
Gating models delimited by molecular dynamics approaches in
the literature are shown in Table 4 below. The percentage of all
literature gating model 3-tuples that have also been identified in
this work (defined as Q1 in Section 2) is calculated by comparing
Tables 2 and 3, S2 and S3 with Table 4 as: 4/9 = 44%. As noted
above, gating models for pw2b and pw2e cannot be deduced for
the CYP3A4 isoform using our approach because pw2b and pw2e
are open in all the CYP3A4 structures. After excluding pw2b and
pw2e gating models from the set of literature gating models in
Table 4, six gating models remain (model 3, 5 and 6 are omitted
in Table 4). Therefore a more objective measure of the percentage
of literature gating model 3-tuples (limited set) that have also been
identified in this work (defined as Q2 in Section 2) is re-calculated
as: 4/6 = 67%. We also note that 11/12 = 92% of residues that ap-
pear in the limited set of literature molecular dynamics gating
models (i.e. the set that excludes gating residues for CYP3A4 tunnel
pw2b and pw2e) have also appeared in the models delimited in
this work – matched here to the same tunnel as in the literature
(Fig. 3).
A total of 65 gating models have been identified in this work (28
two-state gating models plus 37 singlet gating models) across
CYP3A4, CYP2C5, CYP2C8, CYP2C9 and CYP2A6; 4 of these are in
common with those identified by molecular dynamics in the
literature (across CYP3A4 (Fishelovitch et al., 2009) and CYP2C5
(Schleinkofer et al., 2005)), hence the percentage of gating models
identified in this work which are also described in the MD
literature (defined as P1 in Section 2) is calculated as 4/65 = 6%.
We have identified a total of 27 gating models for CYP3A4 and
CYP2C5 (16 two-state models plus 11 singlet gating models).
Hence P1 is calculated across the same spread of CYP isoforms as
4/27 = 15%.
Table 4
Gating models identified from molecular dynamics studies in the literature.
Model number Gating residues Tunnel Comments Reference
CYP2C5
1 K241-V106 pw2c Breakage of the Val 106 O-K 241 NZ main chain-side chain H-bond was found
to be a pre-requisite for pw2c channel opening in REMD and MD simulations
Schleinkofer et al. (2005)
CYP3A4
2 F57-F215 pw2a This gating model was identified from SMD simulations
using temazepam and testosterone-6OH as products
Fishelovitch et al. (2009)
CYP3A4
3 F108-F220 pw2b This gating model was identified from SMD simulations
using temazepam and testosterone-6OH as products
Fishelovitch et al. (2009)
CYP3A4
4 F108-F241 pw2c This gating model was identified from SMD simulations
using temazepam and testosterone-6OH as products
Fishelovitch et al. (2009)
CYP3A4
5 F108-I120 pw2e This gating model was identified from SMD
simulations using temazepam as product
Fishelovitch et al. (2009)
CYP3A4
6 R105-S119 pw2e This gating model was identified from SMD
simulations using testosterone-6OH as product
Fishelovitch et al. (2009)
CYP3A4
7 F213-F241 pw3 This gating model was identified from SMD
simulations using temazepam as product
Fishelovitch et al. (2009)
CYP3A4
8 F213-V240 pw3 This gating model was identified from SMD
simulations using testosterone-6OH as product
Fishelovitch et al. (2009)
CYP3A4
9 R212-L482 S This gating model was identified from SMD
simulations using temazepam and testosterone-6OH as products
Fishelovitch et al. (2009)
Amino-acid residues and tunnels that constitute a literature molecular dynamics gating model (specified as a 3-tuple of two amino acids and the REMD tunnel they gate)
which has also been identified here are underlined.
Gating model residues from literature molecular dynamics gating models that have also appeared in the gating models delimited here, matched here to the same tunnel as in
the literature but not to the same amino acid interaction partner, are shown in bold type.
Fig. 3. The manual delimitation of tunnel-intersecting residues in a singlet gating model for tunnel pw2c in CYP3A4. Panel (A) shows the alignment of the CYP3A4 structure
1TQN and the CYP2C5 structure 1DT6 without any CAVER-calculated tunnels shown. Panel (B) shows the same alignment of 1TQN and 1DT6 in the same orientation but with
the CAVER-calculated tunnel pw2c shown in purple. The tunnel pw2c is open in the structure 1DT6. In both panels (A) and (B), 1TQN is shown in yellow, 1DT6 in green, the
heme group in turquoise, CYP3A4 Phe 113 in 1TQN is shown in blue and CYP3A4 Phe 241 in 1TQN is shown in red. Panel (B) shows that Phe 113 and Phe 241 in 1TQN intersect
the CAVER-calculated tunnel pw2c in 1DT6. The two structures were aligned using Pymol. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
Table 5
The distribution of amino-acid side chain-types occurring as tunnel-intersecting





CYP3A4 11/16 = 68.75 3/16 = 18.75 2/16 = 12.5
CYP2C5 2/11 = 18.18 6/11 = 54.55 3/11 = 27.27
CYP2C8 2/14 = 14.29 6/14 = 42.86 6/14 = 42.86
CYP2C9 5/13 = 38.46 4/13 = 30.77 4/13 = 30.77
CYP2A6 6/11 = 54.55 2/11 = 18.18 3/11 = 27.27
For each CYP isoform, the side chain chemical-type with the highest percentage of
tunnel-intersecting residues binned into it is underlined (and shown in boldface if it
accounts for 50% or more of the tunnel-intersecting residues).
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Tunnel-intersecting residues in the gating models listed in
Tables 2 and 3, S2 and S3 were classified according to side chain
chemical types as described in Section 2. The distribution of side
chain chemical-types occurring as tunnel-intersecting residues is
reported in Table 5 below.
The levels of sequence similarity within the CYP2C sub-family
and the different usage of amino-acid side chain chemical types
in the CYP2 family and within the CYP2C sub-family highlighted
in Table 5 suggest that the rate of evolution of the tunnel-gating
residue positions is faster than average rate of evolution of the
entire sequence for a given CYP450 isoform. We proceeded to
Table 6
The statistical significance of the average rate of evolution of tunnel-intersecting
residues in CYP2 isoforms in this study.







The null hypothesis that the average rate of evolution of the entire sequence
(1.0055) is the same as the average rate of evolution of the tunnel-intersecting
residues was tested against the alternative hypothesis that the average rate of
evolution of the tunnel-intersecting residues is greater than the average rate of
evolution of the entire sequence (1.0055) in each of CYP2C5, CYP2C8, CYP2C9 and
CYP2A6. Student’s t-test calculations were performed using functions in Microsoft
Excel spreadsheets. The null hypothesis is rejected in favour of the alternative
hypothesis at the 5% level for each of CYP2C5, CYP2C8, CYP2C9 and CYP2A6.
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sequences.
The average relative rate of evolution of all sequence positions
in the alignment of CYP2C5, CYP2C8, CYP2C9 and CYP2A6 was
calculated as 1.0055. The average relative rate of evolution of the
tunnel-intersecting residues in CYP2C5, CYP2C8, CYP2C9 and
CYP2A6 and the associated p-values calculated from Student t-test
are reported in Table 6.
Fig. S1 shows the annotated alignment of PDB file-derived
sequences of CYP2C5, CYP2C8, CYP2C9 and CYP2A6 showing the
relationship between conserved positions in the CYP2 family, CYP
secondary structure elements, Gotoh’s substrate recognition sites
(Gotoh, 1992), the residues delimited in the two-state gating mod-
els of this work and the tunnel-intersecting residues in the singlet
gating models delimited herein. The CYP2C5 sequence was ex-
tracted from the PDB file 1N6B, CYP2C8 from 2NNH, CYP2C9 from
1R9O and CYP2A6 from 2FDV.
4. Discussion
We have used the computational geometry tool, CAVER (Petrek
et al., 2006), to calculate the distribution of tunnels in CYP2C5,
CYP2C8, CYP2C9, CYP2A6 and CYP3A4 structures. In this work,
we have accepted as significant, only those tunnels with a gorge
width of 1.4 Å. This cut-off was determined from a thresholding
exercise designed to strike an optimal balance between the num-
ber of ‘‘tunnel-open”/‘‘tunnel-closed” pairs generated for subse-
quent analysis and the verisimilitude the CAVER-calculated
tunnels bear to REMD tunnels. It has largely been possible to assign
the CAVER-calculated tunnels to REMD pathways. The assignments
to pw2b, pw2c, pw2e, pw3 and W have been straightforward for all
the significant CAVER-calculated tunnels in this work. On the other
hand, there are cases where it has not been clear if assignment of
CAVER-calculated tunnels to pw2a would be more appropriate
than assignment to tunnel S and vice versa. An extreme example
of this is tunnel number 2 in the CYP3A4 structure 2J0D (see Table
1), which falls midway in the space between tunnel S and tunnel
pw2a; we have therefore not assigned it to any REMD tunnel in
this work. It is also noted that a number of CAVER-calculated tun-
nels may be assigned to the same REMD pathway as explained in
the Introduction.
The distribution of tunnels in Tables 1 and S1 was subsequently
used to select tunnel-open/tunnel-closed pairs of structures for
calculation of two-state gating models and singlet gating models.
We have deduced two-state gating models (reported in Table 2
and Table S2) from tunnel-open/tunnel-closed structures of the
same CYP450 isoform and singlet gating models (reported in Table
3 and Table S3) from tunnel-open/tunnel-closed structures ofdifferent CYP450 isoforms. It is not always possible to successfully
deduce gating models from tunnel-open/tunnel-closed pairs iden-
tified from Table 1 and Table S1. The most common reason for fail-
ure has been substantial intersections of main chain atoms of the
tunnel-closed structure with the tunnel of interest calculated in
the tunnel-open structure after alignment of the tunnel-open and
tunnel-closed structures. This occurrence causes a breakdown in
our approach since we assume for the purposes of this work that
tunnel closure is solely due to obstructions by side-chains (i.e.
we use side chain motions to explain the tunnel patterns in
CYP450 structures). In this manner, pw2e gating residues in
CYP2A6 cannot be deduced from our analysis of the pw2e tun-
nel-open CYP2C9 structure 1R9O and the pw2e tunnel-closed
CYP2A6 structure 2FDV because residues 105 to 107 inclusive in
2FDV clash with the CAVER-calculated pw2e tunnel in 1R9O after
alignment in Pymol. Similarly, the delimitation of pw2b-gating res-
idues from the tunnel-open/tunnel-closed pair of structures 2NNH/
2FDV (CYP2C8/CYP2A6) is not possible because CYP2A6 residues
Glu 103 to Ala 105 inclusive clash with the CAVER-calculated
pw2b tunnel in 2NNH after alignment of 2NNH and 2FDV in Pymol.
It is obvious that singlet gating models and two-state gating
models cannot be defined for a given REMD tunnel if that tunnel
is open in all structures of a given CYP450 isoform. For that reason,
our approach cannot delimit singlet gating models and two-state
gating models for pw2b and pw2e in CYP3A4 as these tunnels
are open in all the CYP3A4 structures. This has been taken into ac-
count in the definition of Q2, a metric that expresses the percent-
age of literature molecular dynamics 3-tuple gating models that
have also been identified on this work. In the calculation of Q2,
the three models in the literature (models 3, 5 and 6 in Table 4)
have been omitted to leave a total of 6 MD models in the literature
set. This limited set is expected to achieve a more unbiased assess-
ment of the overlap between models delimited herein and those
described in the literature.
The value of Q2 is calculated over the limited set of literature MD
3-tuple gating-residue models as 67%. This highlights the high de-
gree of coverage of literature gating models by the set of models
identified in our work. The singlet gating models identified in this
work are reported as 2-tuple models (see Table 3 and Table S3)
whilst on the other hand MD gating models in the literature are re-
ported as 3-tuples. In order to calculate P1, the percentage of singlet
gating models identified in this work that have also been identified
in the literature, it is necessary to define a model for the extraction
of 3-tuples from the 2-tuple models listed in Table 3 and Table S3.
Such a model would then permit the comparison of like objects in
the calculation of P1. We have chosen a ‘pessimistic’ model for
the extraction of 3-tuples that assumes that only one 3-tuple model
can be generated from each of the 2-tuple models listed in Table 3
and Table S3. That is, of the all the amino-acid residues making
interactions with the tunnel-intersecting residue as listed in the
‘comments’ section of Table 3 and Table S3, only one residue makes
interactions that occur exclusively in the tunnel-closed structure.
These 3-tuple models would be generated by pairing a given
tunnel-intersecting residue with a residue delimited to be involved
in an interaction of sorts with the tunnel-intersecting residue.
Alternatively, it is possible to base calculations on an ‘‘optimistic”
model that generates 3-tuples from all the residues delimited to
interact with a given tunnel-intersecting residue. That is, here it is
assumed that all of the interactions involving the tunnel-
intersecting residue listed in the ‘‘comments” section of Table 3
and Table S3 occur exclusively in the tunnel-closed structure. Using
this pessimistic model, we describe 61 new potential gating residue
pairs for cytochrome P450 enzymes, as well as independently
re-finding the majority (4 out of 6) of such gating residue pairs pre-
viously described in the literature. One trivial explanation for the
large number of new gating models found here is that we have
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than previously analysed. However, even if we just consider
CYP3A4, we found 16 gating models in this work, of which only 4
had previously been described in the literature. The statistic P1 is
calculated as 4/65 = 4% across the entire set of CYP450 isoforms
analysed here and as 4/27 = 15% across the same spread of
CYP450 isoforms as in the literature (CYP3A4 & CYP2C5). This
suggests that the body of new gating models described for the first
time here will be of significant value in the further study of
ligand-tunnelling problems in CYP450s; it also suggests that the
combination of tools such as CAVER and Protein Interaction Calcu-
lator (PIC) might provide a simple, rapid and comprehensive alter-
native to complex MD simulations as a means to explore tunnels
and tunnel gating in other classes of protein.
It is interesting to note that for those literature CYP450 gating res-
idue pairs which we did not re-find directly in this work, in each case
we did find the same pair of individual residues, but predict that they
instead interact directly with different partners. Indeed, in general
we find multiple potential gating interactions for each individual
gating residue, suggesting either that previous MD simulations have
been remarkably adept at choosing between different potential
interactors, or that the picture is more complex than first thought.
Further evidence of such potential complexity arises from the obser-
vation that our work has identified clusters of aromatic gating resi-
dues which might provide a mechanism for coordinated opening/
closing of different tunnels; we have recently initiated correlated
motion analyses to investigate this possibility further, results of
which will be presented elsewhere. The high value of the statistic
Q2 (67%) and the fact that 11/12 = 92% of residues that appear in
the limited set of literature molecular dynamics gating models (i.e.
the set that excludes gating residues for CYP3A4 tunnel pw2b and
pw2e) have also appeared in the models delimited in this work,
underscores the utility of the two major assumptions we have made
in the development of a frame-work for the identification of gating
models: that amino-acid side chains play a paramount role in the
gating of tunnels and that the CAVER-calculated tunnels that we
subsequently assign to REMD tunnels are sufficiently related to
REMD tunnels and relevant enough to allow the accurate extraction
of gating models.
In addition, through this work we have identified a network of io-
nic interactions present in all the CYP3A4 structures that restricts
the space of the CYP3A4 surface available for exit of the pw2b tun-
nel. The pairs of ionic interactions that make-up the interaction net-
work are as follows: Arg 106-Asp 76, Arg 106-Glu374, Arg 372-Asp
76 and Arg 372-Glu374. We speculate that this space-restricting
network of interactions may operate together with proximal bulky
residues such as Phe 220 to create an effective pw2b gating system.
Fishelovitch and co-workers have found that the ionic interactions
Asp 76-Arg 106 and Asp 76-Arg 372 are highly stable and remain
unperturbed during product exit in SMD simulations (Fishelovitch
et al., 2009). This is in harmony with the notion that the ionic inter-
actions are a component of a wider pw2b-gating mechanism in
which they specifically serve to restrict the exit space available to
pw2b on the CYP3A4 surface. We have not managed to delimit
pw2b-gating residues in this work as pw2b is open in all CYP3A4
structures. However, Phe 220 is proximal to CAVER-calculated
pw2b tunnels in all the four CYP3A4 structures and side chain rota-
mers of Phe 220 that intersect pw2b can readily be selected from
rotamer databases (data not shown). It is therefore plausible that
the swinging motions of the Phe 220 side chain form the basis for
gating of the space-restricted pw2b tunnel. We also note that Fishe-
lovitch and co-workers identified Phe 220 as a pw2b gating-residue
(3-tuple model is (Phe 220, Phe 108, pw2b)) in SMD simulations
(Fishelovitch et al., 2009).
A survey of the gating models delimited in this work reveals
that the most conserved gating model is the gating of tunnel Wby a tunnel-intersecting Tryptophan residue whose position on
the CYP450 fold is also conserved; this residue is Trp 126 in
CYP3A4, Trp 120 in CYP2C5, Trp 120 in CYP2C8 and Trp 120
CYP2C9. Interestingly, the gating of tunnel W by Trp 126/Trp 120
is the only gating model that is conserved between the CYP2 and
CYP3 families. It is also the only gating model in the CYP2C sub-
family where the tunnel-intersecting residue is absolutely con-
served both in residue position and in residue identity. There are
tunnel-intersecting residue positions and residue types that show
a reasonable degree of conservation in the CYP2C sub-family, nota-
bly those involved in the gating of pw3: in CYP2C5 these residues
are Leu 207, Ile 229 and Leu 233; in CYP2C8 these residues are Ile
207, Leu 208, Thr 229 and Val 233; and in CYP2C9 these residues
are Ile 207, Leu 208, Thr 229 and Tyr 225. It can be seen that the
sequence positions 207 and 229 are involved in gating in all the
CYP2C isoforms considered here; not surprisingly, there is greater
conservation of pw3-intersecting residues between CYP2C8 and
CYP2C9 – Ile 207, Leu 208 and Thr 229 intersect pw3 in both –
in accord with the close sequence resemblance of CYP2C8 and
CYP2C9 (78% identity). The gating models of tunnel pw2c are an-
other class of models that show interesting features including a
fairly high degree of conservation in position and residue identity
of the tunnel-intersecting residue: In CYP2C5 the pw2c-intersect-
ing residue Lys 241 is located on the G-helix, interacting with Val
106, a residue located on the BC-loop/B0 helix; and in CYP2C8 the
pw2c-intersecting residue is Arg 241, interacting with the I-helix
(N-term) residue Glu 285. Hence in CYP2C5 and CYP2C8, the posi-
tion 241 is a conserved tunnel-intersecting position where a basic
amino-acid side-chain intersects pw2c. However, an interesting
charge switch occurs in CYP2C9 whereby the tunnel-intersecting
residue is Arg 108 – a residue located on the BC-loop/B0-helix.
Furthermore, CYP2C9 Arg 108 interacts with, among others (see
Table S2), Asp 293 – a residue located in the N-terminal region of
the I-helix.
The analysis of amino acid chemical types (summarized in Table
5) of the entire set of tunnel-intersecting residues (listed in
Tables 2 and 3, S2 and S3) reveals a number of interesting trends.
Table 5 reveals a strong presence of hydrophobic aromatic tunnel-
intersecting residues in CYP3A4. Here hydrophobic aromatic side
chains account for 68.75% of the tunnel-intersecting residues in
CYP3A4 gating models. In contrast to the situation in CYP3A4, in
CYP2C5 there is a more predominant presence (54.55%, Table 5) of
polar/charged tunnel-intersecting residues in the gating models,
whilst in CYP2C8 there is equal presence of polar/charged (42.86%,
Table 5) and hydrophobic aliphatic (42.86%, Table 5) tunnel-
intersecting residues in the gating models. The combined
percentage presence of polar/charged and hydrophobic aliphatic
residues (85.72%) is much greater than the percentage presence of
hydrophobic aromatic residues in the CYP2C8 gating models
(14.29%). Unlike in CYP3A4, CYP2C5 and CYP2C8, in CYP2C9 gating
models there is a more equitable presence of hydrophobic aromatic
(38.46%), polar/charged (30.77%) and hydrophobic aliphatic
(30.77%) tunnel-intersecting residues with a slight bias for hydro-
phobic aromatic residues. Finally, in CYP2A6, like in CYP3A4, there
is a predominant presence (54.55%) of hydrophobic aromatic tun-
nel-intersecting residues. It is interesting to note that CYP2A6 is
more akin to CYP3A4 than it is to other CYP2 isoforms studied here
(CYP2C5, CYP2C8 and CYP2C9) in its use of hydrophobic aromatic
tunnel-intersecting residues. It is clear from Table 5 that there is very
different usage of amino-acid side chain chemical types in the CYP2
family and within the CYP2C sub-family. Given the levels of se-
quence similarity within the CYP2C sub-family and given the differ-
ent usage of side chain chemical types of tunnel-intersecting
residues, we expected that the rate of evolution of the tunnel-inter-
secting residues would be greater than the rate of evolution of the
entire sequence in each of the CYP2 isoforms considered in this
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residues was found to be significantly faster than the average rate of
evolution of the entire sequence for each of CYP2C5, CYP2C8,
CYP2C9 and CYP2A6 (see Table 6). In keeping with the relatively fast
evolutionary dynamics of tunnel-intersecting residues, the tunnel-
intersecting residue positions are not among the most conserved
positions in sequence alignments (see Fig. S1).
We previously built a model for the interaction between mam-
malian CYP450 and P450-oxidoreductase (POR) proteins (Zawaira
et al., 2010). The following CYP2B4 residues are special in the mod-
el because they have been experimentally-delimited by others as
interfacial residues: R85, M137, E143, K384, K421, R422, K433
and R443. Analysis of the corresponding residues in CYP2A6;
R88, V140, E146, K387, K424, K425, K436 and R446, respectively,
CYP2C5; K84, M136, E142, K380, K417, K418, K429 and R439,
respectively, CYP2C8; K84, M136, E142, K383, K420, K421, K432
and R442, respectively, and CYP2C9; K84, M136, E142, K383,
K420, K421, K432 and G442, reveals a very high degree of conser-
vation of these residues – unlike the much lower conservation of
tunnel-gating residues. Current models for the evolution of protein
function assert that the rate of evolution increases from the cata-
lytic site (centre of chemical function) to the protein core (struc-
tural core), to surface regulation regions such as protein–protein
recognition sites and to ordinary surface sites (Valencia, 2005).
On the basis of the conservation patterns described above, we cast
tunnel-gating residues into this hierarchical evolution model by
placing them between surface regulation regions and ordinary
surface sites. When cast in this manner, this gives rise to the view
that the evolution of viable gating interactions occurs more spon-
taneously within the CYP450 protein than the co-evolution of
interactions between CYP450 and POR that support functional
CYP450-POR recognition. In turn, the co-evolution of interactions
that support functional CYP450-POR recognition is assumed to be
more spontaneous than the evolution of the structural core of
CYP450. Indeed, the average relative rate of evolution of the above-
mentioned eight interfacial positions in CYP2A6, CYP2C5, CYP2C8
and CYP2C9 is much lower than that of the tunnel-gating positions
(0.6488625 versus the values in Table 6). One could speculate that
the higher rate of evolution of gating residues is permitted because
viable gating residue networks may arise at several points along
the tunnel hence, unlike surface regulation sites such as protein–
protein binding sites, many permutations can be attempted faster
until a viable one is attained. However, we note that residues that
line these tunnels are probably constrained in their evolution by
selection against combinations that may cause local structure col-
lapse or any other irreversible alteration of tunnels.
Finally, the amino acid residue interaction patterns delimited
in this work suggests the presence of clusters of residues in
CYP450 isoforms which we hypothesise to form regulatory net-
works through which the enzyme achieves co-ordinated tunnel
gating for the multiple tunnels in CYP450. We are currently
investigating these clusters using correlated motions analysis
and preliminary data strongly supports the hypothesis that the
clusters comprise a regulatory network. This work will be re-
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Combining In Silico Protein Stability Calculations with Structure-Function Relation-
ships to Explore the Effect of Polymorphic Variation on Cytochrome P450 Drug  
Metabolism 
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Abstract: We carried out an in silico structural analysis of 348 non-synonymous single nucleotide polymorphisms, found across nine of 
the major human drug metabolising cytochrome P450 isoforms, to determine the effects of mutations on enzyme structure and function. 
Previous functional studies in our group have delineated regions of the cytochrome P450 structure important for substrate recognition, 
substrate and product access and egress from the active site and interaction with the cytochrome P450 reductase. Here we combine the in-
formation from those studies with new in silico calculations on the effect of mutations on protein stability and we compare our results to 
experimental data in order to establish the likely causes of altered drug metabolism observed for cytochrome P450 variants in functional 
assays to date, in the process creating a cytochrome P450 polymorphic variant map. 
Using the computational tool Site Directed Mutator we predicted destabilising mutations that result in altered enzyme function in vitro 
with a specificity of 83%. We found that 75% of all cytochrome P450 mutations that show altered activity in vitro are either predicted to 
be destabilising to protein structure or are found within regions predicted to be important for catalytic activity. Furthermore, we found 
that 70% of the mutations that showed similar activity to the wild-type enzyme in in vitro studies lie outside of functional regions impor-
tant for catalytic activity and are predicted to have no effect on protein stability. Our resultant cytochrome P450 polymorphic variant map 
should therefore find utility in predicting the likely functional effect of uncharacterised variants on drug metabolism.  
Keywords: Cytochrome P450, drug metabolism, protein stability, polymorphic variation, single nucleotide polymorphisms (SNPs).  
INTRODUCTION 
 Cytochrome P450s (CYP450s), a large functionally diverse 
superfamily of haem-thiolate enzymes found across all lineages of 
life [1], are responsible for the metabolism of a wide range of struc-
turally diverse endogenous and exogenous compounds. CYP450s 
are most well known for their important role in phase I drug me-
tabolism, oxidising 70-80% of pharmaceutical drugs [2, 3], with 
substrate oxidation being achieved by the insertion of an active 
oxygen molecule, derived from molecular oxygen, into the sub-
strate.  
 Camphor-metabolising CYP101 (P450cam) from Pseudomonas 
putida was the first CYP450 to have its crystal structure solved [4] 
and extensive studies on this enzyme, combined with other subse-
quently solved bacterial CYP450 structures, provided the initial 
framework for our understanding of structure-function relationships 
in CYP450 enzymes. CYP450s have a globular three-dimensional 
fold typically made up of six -strands and thirteen -helices sur-
rounding a large buried hydrophobic active site [5]. Today there are 
over 500 CYP450 structures available in the Protein Data Bank 
(PDB), including over 100 mammalian structures. As predicted by 
Hasemann and co-workers [6], despite very low sequence identities, 
the CYP450 fold is highly conserved in eukaryote structures. The 
haem-binding region is the most structurally conserved, apart from 
local differences in the I-helix. A number of key conserved struc-
tural features have been described including the conserved ERR 
triad [6], the I-helix catalytic groove [5, 7, 8] and the hydro- 
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phobic Cys-pocket or the B-bulge surrounding the catalytic cysteine 
residue that coordinates to the haem ion. By comparison the sub-
strate binding region is a more variable and flexible region. Whilst 
all prokaryotic CYP450s are soluble and located in the cytosol, 
most eukaryotic CYP450s are bound to endoplasmic reticulum 
membrane by an N-terminal anchor and are known as microsomal 
CYP450s; hydrophobic regions in the F and G helices are also 
thought to facilitate membrane binding. Similarities and differences 
found across different CYP450 structures have been discussed in 
detail in a number of recent reviews [9-11].  
 Most CYP450 crystal structures are in a “closed” conformation 
with the active site completely cut-off from the bulk solvent but 
some structures show “open” or “wide-open” conformations [12, 
13], suggesting that CYP450s undergo considerable conformational 
changes to allow substrate/products and water molecules in and out 
of the active site. A number of approaches, including thermal mo-
tion pathway analysis [14], adiabatic mapping [15], molecular dy-
namics [14, 16-22] and computational geometry tools [23-28] have 
been used in an attempt to understand CYP450 flexibility, differen-
tial tunnel opening and gating patterns observed in these enzymes. 
These independent methods are in general agreement and several 
pathways found in distinct parts of the CYP450 fold have been 
identified as putative substrate access and solvent tunnels; however 
the gating patterns observed for these tunnels are not necessarily 
conserved between isoforms, perhaps suggesting fast evolutionary 
dynamics [25].  
 Substrate recognition sites (SRS) are of particular interest in the 
CYP450 field because drug metabolizing mammalian CYP450s are 
highly promiscuous enzymes that are able to metabolise a wide 
range of diverse substrates, yet are still able to maintain a degree of 
specificity. An updated SRS map based on CYP450-ligand interac-
tions in mammalian crystal complexes and docking studies has 
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recently been described [29] that identifies a number of new SRS 
regions not predicted in Gotoh’s original SRS map [30].  
 During the catalytic cycle, mammalian microsomal CYP450s 
source electrons from their redox partner NADPH dependent 
CYP450 reductase (CPR), which forms a transient complex with 
CYP450 during electron transfer [31]. CPR is made up of four do-
mains: FMN-binding, connecting, FAD-binding and NADPH-
binding. A number of studies have contributed to elucidating the 
CYP450-CPR interface and have identified clusters of basic resi-
dues on the proximal surface of CYP450s that interact with exposed 
acidic clusters on the CPR FNM domain surface [32-37].  
 The human genome encodes 57 different CYP450 enzymes but 
the majority of human drug metabolism can be attributed to a small 
number of highly polymorphic isoforms, namely CYP1A2 (5%), 
CYP2A6 (2%), CYP2B6 (2-4%), CYP2C8 (1%), CYP2C9 (10%), 
CYP2C19 (5%), CYP2D6 (20-30%), CYP2E1(2-4%) and CYP3A4 
(40-45%) [38], where the number in brackets indicates the percent-
age of drug metabolism carried out by each isoform. The distribu-
tion of this polymorphic variation differs between ethnic groups and 
has been shown to affect drug response [39]. Single nucleotide 
polymorphisms (SNPs) occur both in the coding and non-coding 
regions of these genes, resulting in effects on CYP450 expression 
as well as function [38, 40]. Phenotypic effects of non-synonymous 
polymorphisms have been shown to be substrate specific in a num-
ber of cases [41-44] making prediction of the effect of polymor-
phisms on drug metabolism difficult. Importantly though, structural 
stability, haem binding, substrate access and recognition, as well as 
interactions with CPR, are all aspects of CYP450 function that can 
be directly affected by changes in the amino acid sequence.  
 In vitro approaches have been used to measure the effect of 
non-synonymous polymorphic variation on CYP450 structure and 
function and a variety of expression systems such as bacteria, yeast, 
insect cells and mammalian cells are now commonly used to ex-
press stable CYP450 enzymes with similar catalytic properties to 
human liver microsomes. Recombinant expression systems for 
individual CYP450 enzymes have enabled site-directed mutagene-
sis studies to investigate the effect of SNPs on protein function. 
CYP450-holoprotein levels are routinely obtained from carbon 
monoxide difference spectra [45] allowing the quantification of 
total haem incorporation and differentiating between correctly 
folded holoprotein (P450) and misfolded holoprotein (P420). In 
vitro screening techniques have been developed to monitor CYP450 
substrate turnover, including radiometric, fluorogenic and chroma-
tography/mass spectrometry based activity assays [46-48]; and 
miniaturised high throughput platforms have begun to make 
CYP450 activity assays more time and cost effective [49-51]. A 
high throughput screening platform has been used recently to assay 
18 CYP2C19 variants against 10 different drugs [43]; however few 
such studies have been reported to date and as a result, the effect of 
non-synonymous mutations on drug metabolism remains poorly 
understood experimentally for all except a limited set of mutations 
and substrates.  
 The sheer number of CYP450 polymorphisms, combined with 
the many diverse potential drugs, highlights the need for improved 
in silico prediction tools and experimental approaches for determin-
ing the effects of single amino acid substitutions in CYP450 en-
zymes on drug metabolism. Here we analyse the impact of poly-
morphic variation on enzyme stability and function in mammalian 
CYP450 drug metabolising enzymes: We use representative in 
silico modeling tools to predict the qualitative effect of mutations 
on protein stability; We then combine the resulting data with previ-
ous in silico analyses of conserved structural features, SRS regions, 
CPR contacts and tunnel gating residues to create a unified CYP450 
SNP map; and finally we use this CYP450 SNP map to correlate 
the location of individual mutations with their experimentally ob-
served impact on CYP450 function. 
METHODS 
Crystal Structures 
 Structures of human CYP450 proteins and rat CYP2B4 were 
retrieved from the RCSB Protein Data Bank [52]. The PDB codes 
for the structures used in this study are as follows. CYP1A2: 2HI4. 
CYP2A6: 1Z10, 1Z11, 2FDU, 2FDV, 2FDW, 2FDY, 2PG5, 2PG6, 
2PG7, 3EBS. CYP2B6: 3IBD. CYP2C8: 1PQ2, 2NNH, 2NNI, 
2NNJ, 2VN0. CYP2C9: 1OG2, 1OG5, 1R9O. CYP2C19: 4GQS. 
CYP2D6: 2F9Q. CYP2E1: 3E6I, 3E4E, 3GPH, 3KOH, 3LC4. 
CYP3A4: 1TQN, 1W0E, 1W0F, 1W0G, 2J0D, 2V0M, 3NXU. 
CYP2B4 (rat):2BDM. Only chain A was used for structures that 
have more than one CYP450 chain in the asymmetric unit.  
Non-synonymous Single Nucleotide Polymorphisms  
 Non-synonymous single nucleotide polymorphisms (SNPs) 
were sourced from the Human Cytochrome P450 Allele Nomencla-
ture Committee home page [53] and NCBI dbSNP [54] for isoforms 
CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
CYP2D6, CYP2E1 and CYP3A4. 
Comparative Modeling of Polymorphisms Using ANDANTE 
 Polymorphisms were modelled using ANDANTE, a program 
that makes use of environmental substitution tables (ESSTs) to 
reduce the side chain rotamer search space during comparative 
modeling of single amino acid mutations [55]. A Python script was 
written to run ANDANTE in batch mode. Mutant structures were 
generated for each SNP using all the available PDB crystal struc-
tures for the respective isoform. ANDANTE was run using the 
default parameters and the “- local” option which attempts to mini-
mise all rotamer clashes in the local area that result from the muta-
tion. Note that ANDANTE does not take co-factors or ligands into 
account when modeling side chain positions. All mutant structures 
for each SNP were visualised and compared to the original template 
crystal structures using PyMOL [56]. 
Predicting the Effect of Polymorphisms on Protein Stability Using 
SDM 
 Site directed mutator (SDM) [57], a statistical potential energy 
function first developed by Topham et al [58], was used as a repre-
sentative in silico tool to predict the effect of each SNP on protein 
stability. SDM uses environment-specific substitution frequencies 
within homologous protein families to calculate a stability score. 
The environment specific substitution tables (ESSTs) provide in-
formation on the amino acids local structural environment and the 
probability of it being substituted by another amino acid. The algo-
rithm uses these ESSTs to calculate a stability score, which predicts 
the difference in free energy between a wild-type and mutant pro-
tein, by analogy to a reversible folding-unfolding thermodynamic 
cycle. 
 SDM input: SDM requires a wild-type and mutant structure 
(which has only one single amino acid substitution) in PDB format 
as input. The mutant structures built using ANDANTE, together 
with their template structures, were used as input for the mutant and 
wild-type structures respectively.  
 SDM output: SDM output gives details of the local structural 
environment of the wild-type and mutant residue which includes 
secondary structure prediction and percentage solvent accessibility. 
SDM also outputs a pseudo G score or stability score and a pre-
diction of disease association. Negative scores suggest that the mu-
tation is destabilising and positive scores indicate a stabilising ef-
fect. A cut-off of 2 kcal.mol-1 had previously been used to indicate 
that a mutation is damaging to the protein structure. Both stabilising 
and destabilising mutations that reach this cut-off were therefore 
categorised as damaging mutations whilst mutation with scores 
between -2 and 2 kcal.mol-1 are classified as neutral. It must be 
noted that like ANDANTE, SDM does not consider co-factors or 
ligands when calculating solvent accessibility or stability scores. 
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 SDM was run on all ANDANTE derived mutant structures. If 
ANDANTE generated more than one structure for the same SNP, 
an average SDM score and standard deviation were calculated. In 
subsequent analysis, we used the output from SDM in a qualitative 
manner, describing mutations as damaging or neutral and made no 
further specific use of the absolute numerical SDM score.  
Generating an Annotated Structural Alignment 
 A multiple CYP450 structural alignment was generated includ-
ing one representative structure for each isoform using the program 
Baton (D.Burke, unpublished data and [59]). The PDB codes for 
representative structures were as follows CYP1A2: 2HI4, CYP2A6: 
2FDV, CYP2B6: 3IBD, CYP2C8: 1PQ2, CYP2C9: 1R9O, 
CYP2C19: 4GQS, CYP2E1: 3E4E, CYP2D6: 2F9Q, CYP3A4: 
1TQN. 
 The program JOY [60] was used to annotate the protein se-
quence alignment with 3D structural features. Here is a brief de-
scription of the structural features represented by JOY. 
 Solvent accessibility is measured using the program PSA which 
implements the algorithm developed by Lee and Richards (1971). A 
relative solvent accessibility (RSA) is calculated by comparing an 
extended conformation of a residue to the residue conformation in 
question. The default cut-off setting of 7% RSA was used. This 
classifies residues with less than 7% RSA as inaccessible and resi-
dues of >7% as accessible. In the Joy format, buried residues are 
displayed in upper case and accessible residues in lower case. 
 Secondary structure assignment is calculated using the program 
SSTRUC (D.K.Smith, unpublished). In the JOY format, residues 
forming , 310 and  helices, and  strands are displayed in different 
colours. The default consensus secondary structure definition was 
used which means a consensus secondary structure is assigned, 
underneath the alignment, if more than 70% of the residues at that 
position are in a particular conformational state. -helices A – L 
and -sheets 1-5 are labelled below the alignment according to 
CYP450 nomenclature of Poulos and co-workers [5]. 
 Main chain dihedral angles are also calculated by SSTRUC. 
Residues with a positive main chain  angle are shown in italics. 
 Hydrogen bonding within a structure is calculated using the 
program HBOND (J.Overington, unpublished), which calculates the 
associated energy and angles for interactions between heavy atom 
donor and acceptor pairs. JOY uses a lenient distant cut-off of 3.5Å 
for hydrogen bonds. The hydrogen bond data is split into three 
classes: 1) side chain to main chain amide; 2) side chain to main 
chain carbonyl; 3) side chain to other side chain. Residues whose 
side chain is bonded to a main chain amide are denoted in bold 
face. Residues that are underlined indicate that their side chain is 
hydrogen bonded to a main chain carbonyl. Residues whose side 
chain is hydrogen bonded to another side chain are not displayed in 
the JOY format used here. 
Defining CYP450 Functional Regions 
 The structural alignment was further annotated with known 
functional regions. If residues did not fall within any of these re-
gions then their functional region was classified as undefined. 
Functional regions can overlap so one residue may fall within more 
than one functional region. The definitions of functional regions are 
as follows. 
Conserved Motifs 
 The hydrophobic signal-anchor sequence, usually preceded by 
an acidic amino acid residue that targets the protein to the endo-
plasmic reticulum, is the 20-25 amino acid stretch near the N-
terminus [61]. The halting-signal refers to the basic residues found 
between the signal-anchor sequence and the proline-rich motif, 
which ensure the correct orientation of the protein in the membrane 
[61]. The first two functional regions are truncated in the crystal 
structures and therefore do not appear in the structural alignment. 
The proline rich motif is defined as the N-terminal sequence motif 
PPGPXPXPXXGN, which has been shown to be important for 
protein folding rather than catalytic activity [62-64]. The conserved 
consensus motif (G/A)GX(D/E)T, located in the middle of the I-
helix, has been labelled the I-helix catalytic groove. This region 
plays an important role in proton transport [7, 8] and is responsible 
for the formation of the oxygen binding pocket [5]. The K-helix 
core stabilising motif is the invariant EXXR motif within the K-
helix that interacts with the meander region [6]. The meander is 
found between the K’-helix and the L-helix and is highly conserved 
in structure despite the lack of any secondary structure formation. 
The absolutely conserved Asp and Arg residues in the core stabilis-
ing motif interact with an Arg/His residue in the meander region, 
forming a set of salt bridges known as the ERR triad. The Cys-
pocket refers to the sequence motif FXXGXXXCXG that forms a 
-bulge around the absolutely conserved catalytic Cys residue. 
Haem Contacts 
 Haem-residue interactions were identified using the protein-
ligand interaction database CREDO [65]. CREDO assigns each 
contact residues to an interaction type based on the geometry and 
distance thresholds using criteria adapted from Marcou and Rognan 
[66]. Residues interacting with the haem group were identified in 
all the available PDB structures for each isoform, combined and 
mapped onto the representative structure in the sequence alignment. 
This was done to account for any differences in the haem binding 
regions for structures of the same isoform due to conformational 
changes. 
SRS Regions 
 SRS regions were assigned based on the recently described 
mammalian CYP450 expanded and unified substrate recognition 
map [29]. This map was created by identifying interacting residues 
in mammalian crystal structure complexes as well as interacting 
residues observed in docking studies.  
Cytochrome P450 Reductase (CPR) Contacts 
 CPR contacts were assigned based on the recent model for in-
teractions between CYP2B4 and FMN domain of rat CYP450 re-
ductase [37]. This model was built using the bacterial redox com-
plex structure (CYP102: 1BVY, chain A) as a template and was 
used to identify the key residues involved in ionic interactions at the 
interface. All CYP2B4–P450-oxidoreductase interfacial residues 
calculated from the 1BVY.pdb-derived structural model at 6Å dis-
tance cut-off were mapped onto the human CYP450 representative 
structures via structural alignment. Residues forming part of ionic 
charge clusters where further categorised as ionic charge cluster 
residues to distinguish them from the other CPR contact residues at 
the interface. 
Gating Residues 
 Tunnel-gating residues were assigned based on residues previ-
ously identified as tunnel-gating residues in the literature [19, 25]. 
Our group recently identified residues involved in putative gating 
models responsible for the differential tunnel-opening patterns seen 
in static structures of mammalian CYP450 [25]. (CYP2A6: F107, 
F111, F118, M205, L241, Q242, Q245, M293; CYP2C8: N99, 
S114, W120, R125, F205, I207, L208, N209, T229, V233, R241, 
E285, E300, V362, P367, M388, I476; CYP2C9: I99, A103, R108, 
F110, G111, F114, W120, I207, L208, Y225, T229, D293, F476; 
CYP3A4: F108, F113, W126, K127, R212, F213, D214, F215, 
F220, V240, F241, F304, E308, I369, L482.) Previous studies had 
used steered molecular dynamics simulations to identify residues 
serving as gate keepers to substrate/product tunnels in CYP3A4 
enzymes [19]. (CYP3A4: F57, R105, F108, S119, I120, R212, 
F213, F215, F220, V240, F241, L482.)  
 Furthermore, solvent explicit molecular dynamics have previ-
ously been used to identify an aqueduct gating mechanism that is 
regulated by binding of the CYP450 reductase [67]. (CYP3A4: 
R375) As R375 is highly conserved in CYP450 is has been sug-
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gested that this could be a general aqueduct gating mechanism. All 
residues at this position in the alignment have been defined as aq-
ueduct gating residues. (CYP1A2: H388, CYP2A6: R372, 
CYP2B6: H369, CYP2C8: H368, CYP2C9: H368, CYP2C19: 
H368, CYP2D6: H376, CYP2E1: H370, CYP3A4: R375)  
Experimental Data Collection 
 Available experimental data on protein expression, holoprotein 
levels, enzyme activity and kinetics (Km, Vmax and Vmax/Km) was 
gathered from the literature and tabulated for each SNP. (Table S1-
S9 in the Supplementary Materials). Due to the wide range of data 
types and the great diversity in methodology all data was expressed 
as a fraction (variant data/ wild-type data) measured in the same 
experiment. If the difference between wild-type and variant data 
was reported to be statistically significant, it is indicated in Tables 
S1-S9 with an asterisks (some studies provide quantitative data 
without statistical evidence). If no quantitative data was available 
then data was expressed qualitatively as similar to wild-type “simi-
lar”, significantly lower than wild-type “decreased”, significantly 
higher than wild-type “increased” or not detectable “ND”. All in 
vivo data was recorded qualitatively. If more than one non-
synonymous SNP coexist in one allele and have therefore been 
tested as a double or triple mutant (as is common for CYP2D6), 
data was included only if it is clear which SNP is dominant in the 
resulting phenotype.  
Classifying SNPs Based on Experimental Data 
 After careful analysis of all available data, SNPs were classified 
into six groups based primarily on the in vitro experimental evi-
dence. In vivo data was however, considered if it was the only data 
available. “Inactive” refers to mutations that resulted in pro-
tein/holoprotein levels that are not detectable or activity that is less 
than 2% of wild-type activity for all expression systems and sub-
strates tested. “Decreased activity” refers to SNPs that resulted in 
significantly decreased expression levels, haem incorporation or 
altered kinetic parameters, leading to impaired enzyme function. 
“Increased activity” refers to mutants that show significant in-
creases in activity. “Substrate specific” refers to mutants that show 
more than 50% difference in mutant/wild-type activity ratios for 
different substrates. “Neutral” refers to mutants that show similar 
holoprotein levels and activity to that of the wild-type enzyme. 
“Unknown” refers to SNPs that have not yet been tested in vitro or 
for which the experimental data is inadequate or contradictory. 
RESULTS 
 The effect of 348 individual CYP450 mutations on protein sta-
bility was calculated using the tool SDM [57]. Pseudo G scores - 
together with predicted effect on stability – and structural informa-
tion, including the relative solvent accessibility (RSA) of the wild-
type and mutant residue, the secondary structure location and the 
functional region within which the mutation falls, is recorded for 
each of these CYP450 variants in Tables S1-S9 (Supplementary 
Materials). A visual representation of CYP450 secondary structure 
elements, functional regions and positions of SNPs is shown for 
CYP3A4 in (Fig. 1).  
Experimental Data 
 Experimental activity data was available for 38% of the SNPs 
analysed in this study (Fig. 2); these data are collated in Tables S1-
S9 (Supplementary Materials). 17% of these SNPs are categorised 
as inactive, 34% of SNPs lead to decreased activity and 11% dis-
played substrate specific effects on activity. It must be noted though 
that only a small percentage of SNPs have been tested on more than 
one substrate in the same in vitro experiment, so it is possible that 
some SNPs that currently fall within the neutral or decreased activ-
ity category, based on available data, would show substrate specific 
effects if tested on a broader range of different substrates. CYP3A4 
L293P and CYP2C9 R150H were the only SNPs reported to give 
increased activity in vitro. The remaining 37% of SNPs tested 
showed no significant effect on enzyme expression or active. Table 
1 lists the SNPs that could be classified based on experimental data, 
complete with their secondary structure, functional region location, 
their predicted effect on protein stability, and their classification 



















Fig. (1). CYP450 Structural overview 
CYP3A4, PDB structure 1TQN, is shown in grey with the haem group in black. Secondary structure elements, -helices and -strands are labelled using the 
nomenclature of Poulos and co-workers [5]. Positions of polymorphic variants found in CYP3A4 are indicated in red. (A) Distal face view showing the position 
of the halting signal (yellow), the proline-rich motif (magnenta), the I-helix catalytic groove (blue), the core stabilising motif, the meander stabilised by the 
ERR triad (orange) and the cys-pocket (cyan). (B) Side view showing the position of the SRS regions (cyan), the gating residues (magnenta), the haem contacts 
(green) and the CPR interface (yellow) on the proximal face of the protein.  
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Table 1. Structural Information and Protein Stability Predictions for SNPs that could be Classified According to their Effect on En-
zyme Activity Based on Experimental Data Collected from the Literature.  
STRUCTURAL INFORMATION PROTEIN STABILITY 
 SNP 










P42R loop btwn N-term & helix A proline rich motif -0.3 neutral inactive 
T83M B-sheet12 SRS1'b 0.1 neutral neutral 
E168Q -helix D undefined 0.0 neutral decreased activity 
F186L loop btwn Helix D & E undefined -1.0 neutral decreased activity 
S212C loop btwn helix E & F undefined -1.9 neutral decreased activity 
G299A B-sheet 2 undefined -5.2 damaging neutral 
D348N -helix J undefined 0.8 neutral substrate specific 
R377Q -helix K ERR triad/core stabilising motif -1.1 neutral inactive 
I386F loop btwn helix K & B-sheet 31 haem contact/SRS5 0.1 neutral substrate specific 
C406Y B-sheet 32 undefined 0.0 neutral substrate specific 
R431W 310 helix ERR triad/meander 2.3 damaging inactive 
T438I loop btwn 310 helix & helix L undefined -0.8 neutral neutral 
R456H loop btwn 310 helix & helix L 
Cys pocket/haem contact/CPR contact 
(charge cluster residue) 
-1.5 neutral inactive 
Q478H end of helix L undefined 0.3 neutral neutral 
CYP2A6 
V110L  -helix B' SRS1 0.3 neutral decreased activity 
R128Q  -helix C haem contact/CPR contact -0.9 neutral inactive 
L160H  -helix D undefined -1.9 neutral inactive 
K194E loop btwn helix E & F undefined -0.4 neutral neutral 
R203S -helix F SRS(2,3) -1.2 neutral neutral 
R203C -helix F SRS(2,3) -7.2 damaging decreased activity 
S224P -helix G' SRS(2,3) 1.6 neutral decreased activity 
V365M loop btwn helix K & B-sheet 31 SRS5 1.5 neutral substrate specific 
Y392F B-sheet 32 undefined 1.3 neutral substrate specific 
E419D loop btwn B-sheet 32 & helix K' undefined 0.2 neutral neutral 
N438Y loop btwn 310 helix & helix L Cys-pocket/CPR contact 2.1 damaging decreased activity 
I471T btwn B-sheet 51 & 52 SRS6 -2.3 damaging substrate specific 
K476R btwn B-sheet 51 & 52 SRS6 1.3 neutral decreased activity 
G479V btwn B-sheet 51 & 52 SRS6 2.1 damaging inactive 





750    Current Drug Metabolism, 2013, Vol. 14, No. 7 Arendse et al. 
(Table 1) Contd…. 
 
STRUCTURAL INFORMATION PROTEIN STABILITY 
SNP 










R22C Truncated N-terminal halting signal n/a n/a neutral 
T26S Truncated N-terminal undefined n/a n/a neutral 
D28G Truncated N-terminal undefined n/a n/a neutral 
R29T Truncated N-terminal halting signal n/a n/a neutral 
M46V loop btwn N-term & helix A SRS1'a -1.8 neutral inactive 
G99E B-C loop SRS1 -1.0 neutral inactive 
K139E loop btwn helix C & D undefined 0.6 neutral inactive 
R140Q loop btwn helix C & D undefined 0.4 neutral decreased activity 
T168I start of helix E undefined 3.4 damaging decreased activity 
Q172H -helix E undefined 2.4 damaging neutral 
M198T -helix E SRS(2, 3) -2.7 damaging substrate specific 
S259R loop btwn helix G & H undefined 0.0 neutral neutral 
K262R loop btwn helix G & H undefined -0.4 neutral substrate specific 
I328T -helix J undefined -3.9 damaging inactive 
R336C loop btwn helix J & J’ undefined -3.0 damaging decreased activity 
I391N loop btwn B-sheet 32& helix K’ undefined -4.6 damaging inactive 
P428T loop btwn 3 10 helix & helix L haem contact -1.2 neutral inactive 
M459V  -sheet 51 undefined -0.5 neutral neutral 
G476D loop bwn -sheet 51 & 52 SRS6 0.5 neutral inactive 
Q485L loop bwn -sheet 51 & 52 undefined -1.7 neutral neutral 
R487C  Start of -sheet 52 undefined -3.6 damaging neutral 
CYP2C8 
R139K loop btwn helix C & D undefined -1.4 neutral neutral 
G171S -helix E undefined 1.5 neutral neutral 
R186G loop btwn helix E & F undefined -4.6 damaging inactive 
I223M F-G loop SRS(2,3) 0.2 neutral neutral 
A238P -helix G SRS(2,3) -2.2 damaging decreased activity 
K247R -helix G undefined 0.5 neutral neutral 
I264M -helix H undefined -0.4 neutral decreased activity  
I269F -helix H undefined 0.2 neutral decreased activity 
K383N loop btwn B-sheet 42 & 32 CPR contact -1.1 neutral neutral 
K399R loop btwn helix K' & 310 helix undefined -0.4 neutral decreased activity 
P404A loop btwn helix K' & 310 helix meander 1.2 neutral decreased activity 
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L19I truncated N-terminal signal-anchor sequence n/a n/a neutral 
L90P loop btwn helix B & C CPR contact -2.5 damaging  decreased activity 
R125H -helix C CPR contact/SRS1 -0.6 neutral decreased activity 
T130R -helix C SRS1 -2.1 damaging decreased activity 
R132Q loop btwn helix C & D 
CPR contact (charge cluster resi-
due)/SRS2 
-0.2 neutral decreased activity 
R144C -helix D undefined -11.5 damaging decreased activity 
R150H -helix D undefined -0.6 neutral increased activity 
R150L -helix D undefined -0.2 neutral neutral 
Q214L -helix F' (F-G loop) SRS(2,3) 3.2 damaging  decreased activity 
H251R -helix G undefined -0.1 neutral neutral 
E272G -helix H undefined -4.0 damaging neutral  
P279T loop btwn helix H & I undefined 1.1 neutral  neutral 
T299A centre of -helix I catalytic groove/SRS4 1.9 neutral  decreased activity 
R335Q loop btwn helix J & J' undefined -0.3 neutral neutral 
R335W loop btwn helix J & J' undefined -2.2 damaging decreased activity 
E354K -helix K ERR triad / core stabilizing motif -4.0 damaging inactive 
I359L end -helix K SRS5 0.2 neutral decreased activity 
I359T end -helix K SRS-5 -3.9 damaging decreased activity 
D360E loop btwn helix K & B-sheet 31 SRS-5 -1.3 neutral decreased activity 
P382S loop btwn B-sheet 42 & 32 SRS5 -0.9 neutral neutral 
D397A loop btwn helix K’ & 310 helix undefined 1.2 neutral inactive 
Q454H -helix L undefined 1.4 neutral neutral 
A477T loop btwn B-sheet 51 & 52 SRS-6 0.6 neutral decreased activity 
P489S end of B-sheet 52 undefined 1.7 neutral neutral 
CYP2C19 
L17P truncated N-terminal signal-anchor sequence n/a n/a neutral 
I19L truncated N-terminal signal-anchor sequence n/a n/a neutral 
S51G -helix A SRS1'a -2.0 neutral decreased activity 
M74T B-sheet 12 SRS1'b -2.7 damaging neutral 
E92D loop btwn helix B & B' CPR contact/SRS1 0.0 neutral substrate specific 
W120R -helix C haem contact/SRS1 -2.7 damaging decreased activity 
E122A -helix C SRS1 1.4 neutral substrate specific 
R132Q loop btwn helix C & D 
CPR contact (charge cluster resi-
due)/SRS1  
0.4 neutral inactive 
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R144H -helix D undefined 0.2 neutral decreased activity 
R150H -helix D undefined -0.6 neutral neutral 
A161P loop btwn helix D & E undefined -10.5 damaging decreased activity 
F168L  -helix E undefined 1.0 neutral neutral 
W212C -helix F' SRS(2,3) -2.1 damaging decreased activity 
P227L F-G loop SRS(2,3) 0.6 neutral decreased activity 
D256N loop btwn helix G & H undefined -0.3 neutral decreased activity 
R329H -helix J undefined -0.6 neutral neutral 
I331V1 
(WT 1.B) 
loop btwn helix J & J' undefined -0.4 neutral neutral 
D360N loop btwn helix K & B-sheet 31 SRS5 1.5 neutral decreased activity  
V394M  -helix K' undefined -0.1 neutral neutral 
R410C 3 10 helix meander -0.3 neutral neutral 
R433W loop btwn 3 10 helix & helix L 
Cys-pocket/haem contact/CPR contact 
(charge cluster residue) 
0.4 neutral inactive 
R442C -helix L CPR contact (charge cluster residue) -10.0 damaging decreased activity 
CYP2D6 
A90V -helix B undefined -0.2 neutral neutral 
T107I -helix B' SRS1 4.2 damaging substrate specific 
E156A -helix D undefined 0.42 neutral decreased activity 
R296C -helix I SRS1 -8.8 damaging neutral 
I297L -helix I SRS1 0.2 neutral substrate specific 
H324P loop btwn helix H & I undefined -4.6 damaging inactive 
I369T loop btwn helix K & B-sheet 31 Haem contact/SRS5 -3.2 damaging substrate specific 
E410K loop btwn -helix K’ & 310 helix undefined 0.4 neutral substrate specific 
R441C loop btwn 310 helix & helix L 
Cys-pocket/haem contact/CPR contact 
(charge cluster residue) 
-10.4 damaging inactive 
S486T -sheet 52 SRS6 0.7 neutral neutral 
CYP2E1 
R76H B-sheet 12 SRS1'b 0.8 neutral decreased activity 
V179I -helix E undefined -0.1 neutral neutral 
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G56D btwn N-term & -helix A SRS1'a -2.3 damaging  decreased activity 
R130Q -helix D haem contact/CPR contact/SRS1 -1.4 neutral inactive 
V170I loop btwn helix D & E undefined -0.3 neutral neutral 
D174H -helix E undefined 0.2 neutral neutral 
T185S -helix E undefined -1.4 neutral decreased activity 
F189S loop btwn helix E & F undefined -5.2 damaging decreased activity 
S222P -helix F' SRS(2,3) -0.9 neutral decreased activity 
L293P loop btwn helix H & I undefined -0.5 neutral increased activity 
T363M -helix K core-stabilising motif 2.1 damaging decreased activity 
L373F start of B-sheet 31 haem contact/SRS5 0.0 neutral decreased activity 
P416L start of 310 helix meander 3.9 damaging inactive 
M445T start of -helix L CPR contact -2.6 damaging neutral 

















Fig. (2). SNPs categorised according to available experimental data. 
 
 The number of SNPs per isoform, classified into 6 categories on 
the basis of available experimental data, is shown in Table 2. To 
date, CYP2B6 and CYP2C19 polymorphic variants have been the 
most thoroughly characterised, the largest contribution for CYP2B6 
variant data coming from a study by Watanabe et al, who investi-
gated the effect of 26 variant CYP2B6 alleles, expressed in COS-7 
cells, on 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) and se-
legiline metabolism [68]. There is in vitro data for 24 out of the 39 
CYP2C19 SNPs and 20 of these were tested by Wang et al who 
reported expression levels, P420:P450 holoprotein levels and ki-
netic data for 3 different substrates and 10 inhibitors using high 
through-put activity assays [43, 69]. The functional data available 
for individual CYP2D6 SNPs is the most incomplete and as a re-
sult, we were able to classify only 12% of the SNPs found in 
CYP2D6. CYP2D6 shows the highest levels of polymorphic varia-
tion and although there is a large amount of clinical data available, 
as well as data from several in vitro studies, most CYP2D6 alleles 
contain multiple SNPs in the coding and/or non-coding regions of 
the gene, which makes it difficult to determine the contribution of 
individual mutations to the observed phenotype.  
The CYP450 SNP Map 
 A multiple structural alignment, including a representative 
structure for each of the nine isoforms, is shown in (Fig. 3). This 
alignment has been annotated with structural features using the 
program JOY [60]. Secondary structure assignment and regions 
important for the enzyme’s structural integrity and function are 
indicated as described in Methods. The positions of SNPs are 

































































































Fig. (3). The CYP450 SNP map consists of a multiple structural alignment, including a representative structure for each of the nine drug metabolising CYP450 
isoforms.  
The alignment is annotated with the following structural features according to the JOY format: Solvent inaccessible/buried residues (upper case), Solvent ac-
cessible (lower case), Positive  (italics), Hydrogen bond to main chain amide (bold), Hydrogen bond to main chain carbonyl (underlined), -helix (red), -
sheet (blue), 310-helix (dark red).  
Secondary structures are named according to the nomenclature of Poulos et al [5]. The positions of conserved motifs are also indicated below the alignment.  
Functional regions as described in materials and methods are indicated as follows: SRS regions (boxed in grey), haem contacts (shaded in green), CPR contacts 
(shaded in yellow- light yellow for residues within 6Å of interface and bright yellow for charge cluster residues), gating residues (boxed in blue) and aqueduct 
gating residues (boxed in dashed-blue). 
The positions of known SNPs are highlighted according to their classifications based on experimental data available in the literature. Inactive (red), decreased 
activity (orange), substrate specific (magenta), increased activity (bright green), neutral (blue) and unknown (grey). If more than one SNP can occur at the same 
residue position then the position is highlighted according to the SNP that shows the most drastic effect on enzyme function.  
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Table 2. Summary of Experimental Data for Drug Metabolising CYP450 Isoforms 
Experimental Data CYP1A2 CYP2A6 CYP2B6 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP2E1 CYP3A4 Total 
inactive 4 3 7 1 2 2 2 0 2 23 
decreased activity  3 5 3 5 12 9 1 1 6 45 
substrate specific 3 3 2 0 0 2 4 0 0 14 
increased activity  0 0 0 0 1 0 0 0 1 2 
neutral 4 4 9 5 9 9 3 2 4 49 
unknown 24 26 10 8 21 17 71 15 23 215
Total SNPs  38 41 31 19 45 39 81 18 36 348
 
highlighted according to their assignment based on available ex-
perimental data. The alignment does not give information on the 
mutant residue type but this information can be found in the Tables 
S1-S9 in the Supplementary Materials. If more than one SNP oc-
curs at the same position, the wild-type residue is highlighted ac-
cording to the mutant residue type that has the greatest known ef-
fect on enzyme function.  
 Approximately half the SNPs analysed fell within ordered sec-
ondary structure regions (helices A-L or -sheets 1-5), while the 
other half occurred in loop/disordered regions. Ordered helices and 
-strands make up about 50% of the CYP450 structure, indicating 
that the SNPs are evenly spread across the protein structure (Table 
S10 in the Supplementary Materials). 
Effect of SNPs on Protein Stability 
 SDM predicted 28% of the SNPs analysed to be damaging mu-
tations that are likely to result in a functionally impaired enzyme 
(Fig. 4). The majority of these mutations are predicted as damaging 
due to destabilising effects (- G scores) however 6% of the SNPs 
are predicted as damaging due to a stabilising effect (+ G scores); 
the literature rationalisation on positive G scores as damaging is 
based on the premise that mutations that are highly stabilising may 
reduce conformational flexibility that is important for function [70-
73]. 64% of the SNPs were predicted to be neutral by SDM. SDM 
could not be used to predict the effect of the remaining 8% of the 
SNPs on stability as these mutations lie within the N-terminal do-
main, which is truncated or disordered in crystal structures. Here 
we have considered such mutations as being neutral since they are 
unlikely to affect the stability of the catalytic domain and since in 
vitro studies have shown that the N-terminal membrane anchor 
region is not important for enzyme activity [74]. A detailed sum-
mary of the SDM data obtained for SNPs found in each isoform can 
be found in Table S11 in the Supplementary Material.  
Correlation Between Stability Predictions and Experimental 
Data 
 The correlation between SDM results and experimental data is 
shown in Figure 5, from which it can be seen that of the 38 CYP450 
SNPs for which there is experimental data and which were pre-
dicted to be damaging by SDM, 31 showed altered activity in the 
experimental data, giving a positive predictor value (PPV) of 82% 
for SDM here. Conversely, of the 84 SNPs in our dataset that 
showed altered activity experimentally, SDM predicted that 31 
would be damaging, meaning that used on its own, SDM has a sen-
sitivity (i.e. the percentage of correctly classified true positives) of 
37% in analysis of CYP450 SNPs. Finally, of the 42 SNPs classi-
fied as neutral based on experimental data and which could be ana-
lysed by SDM, 35 were predicted to have no significant effect on 
protein stability, meaning that used on its own, SDM has a specific-
ity (i.e. the percentage of correctly classified true negatives) of 83% 












Fig. (4). Proportion of SNPs predicted to be damaging to protein structure 
 
Effect of SNPs on Function 
 According to our analysis, 54% of the CYP450 sequence space 
forms part of one or more functional regions (Fig. 6): The seven 
conserved motifs cover ~13% of the CYP450 sequence space; just 
over 5% of CYP450 residues form haem contacts; ~8% form the 
CPR interface; & SRS’s are the largest functional regions, covering 
one third of the sequence space. Gating residues have been identi-
fied only in four of the nine isoforms so they currently only make 
up an average of 0.5% of the CYP450 sequence. 
 Figure 6 also shows the percentage of SNPs falling within each 
functional region. Based on the percentage sequence space covered 
by each functional region, SNPs are evenly spread throughout all 
functional regions, including the conserved motifs, with 52% of 
SNPs falling within one or more defined regions and the other 48% 
falling within undefined functional regions. A breakdown of the 
number of SNPs falling within each functional region for each iso-
form is given in Table S12 in the Supplementary Material. 
Correlation Between Functional Region Analysis and 
Experimental Data 
 The correlation between the functional region location of SNPs 
and experimental data is shown in Figure 7, from which it can be 
seen that of the 64 CYP450 SNPs for which there is experimental 
data and which fall in functional regions important for catalytic 
activity (and which are therefore potentially damaging), 53 showed 
altered activity in the experimental data, giving a positive predictor 
value of 83% for this functional region analysis. Conversely, of the 
84 SNPs in our dataset that showed altered activity experimentally, 
53 fall in functional regions important for catalytic activity (and are 
therefore potentially damaging), giving a sensitivity of 63%. Fi-
nally, of the 49 SNPs classified as neutral based on experimental 
data, 38 were found to fall within undefined regions or regions that 
are not important for catalytic activity (and are therefore less likely 
to be damaging), giving a specificity of 78%. 
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 Table 3 shows the number of SNPs occurring in each functional 
region as classified according to experimental data. Where a SNP 
occurs in more than one region, it was assigned to the functional 
region that corresponds best with the observed experimental data. 
For example if a mutation occurs at the position of a haem contact 
and it falls within a SRS region but the experimental data shows 
that no holoprotein could be detected for this variant then this SNP 
is assigned to the haem contact region instead of the SRS region. If 
it is unclear which functional region best fits the data then the SNP 
is assigned to both regions thus explaining the differences in the 
absolute numbers in Figure 7 and Table 3. The numbers in brackets 
indicates the number of these SNPs predicted to be damaging by 
SDM.  
 Five SNPs within the N-terminal signal anchor sequence and 
halting signal have been functionally characterised in vitro and all 
of them were classified as neutral according to experimental data. 
N-terminal regions play a role in membrane binding but mutations 
in these regions are not expected to have an effect on protein fold-
ing or catalytic activity. The majority of the other neutral SNPs 
(67%) occurred within undefined regions, while 16% occurred 
within SRS regions.  
 Of the 13 mutations falling within the other conserved motifs - 
namely the proline rich motif, the I-helix catalytic groove, the Cys-
pocket, the core stabilising motif and the meander region – 12 re-
sulted in an inactive protein or a protein with decreased activity. 
Three of these inactive SNPs fell within the ERR triad. 
 Approximately 82% of SNPs falling within SRS regions had 
some effect on protein function with the majority causing decreased 
activity. Experimental data showed that 31 SNPs falling within 
undefined functional regions had an effect on enzyme activity, of 
which 10 were predicted to be damaging by SDM.  
 The correlation between the experimental data and the com-
bined SDM stability- and functional analysis predictions is shown 
in Figure 8, from which it can be seen that of the 78 CYP450 SNPs 
for which there is experimental data and which fall in functional 
regions important for catalytic activity and/or are predicted to be 
damaging by SDM, 63 showed altered activity in the experimental 
data, giving a positive predictor value of 81% for this combined 
analysis. Conversely, of the 84 SNPs in our dataset that showed 
altered activity experimentally, 63 fall in functional regions impor-
tant for catalytic activity and/or are predicted to be damaging by 















Fig. (5). Correlation between SDM stability predictions and experimental data.  
The y-axis shows the percentages of SNPs predicted to be damaging to protein structure (dark grey columns), those predicted to be neutral (medium grey 
columns) and those that fell within truncated regions of the structure that could not be analysed by SDM (light grey columns) for (A) each experimentally 
classified group and (B) for a combination of all groups showing altered enzyme function vs. those classified as neutral, as shown along the x-axis. The num-










Fig. (6). Percentage of SNPs falling within each functional region and the percentage sequence space covered by each functional region, illustrating that SNPs 
are spread evenly across functional regions. 
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nally, of the 49 SNPs classified as neutral based on experimental 
data, 34 were found to fall within undefined regions or regions that 
are not important for catalytic activity and are predicted to have no 
effect on stability, giving a specificity of 69% for this combined 
analysis.  
DISCUSSION 
 Previous functional studies in our group have delineated regions 
of the cytochrome P450 structure important for substrate recogni-
tion [29], substrate and product access and egress from the active 
site [25] and interaction with the cytochrome P450 reductase [37]. 
Here we have combined the information from those studies with 
new in silico calculations on the effect of polymorphic variations in 
the major human drug metabolising CYP450 enzymes on protein 
stability and have compared our results to experimental data in 
order to establish the likely causes of altered drug metabolism ob-
served for cytochrome P450 variants in functional assays to date. In 
the process, we have created a cytochrome P450 polymorphic vari-
ant map (Fig. 3), which gives an overview of the location of known 
CYP450 polymorphic variation in relation to important structural 
and functional regions, whilst detailed SNP tables (Tables S1-S9) 
provide information on the structural environments of each variant 
residue, the predicted effect of the mutation on protein stability and 
a summary of the available in vitro data for each SNP.  
 A number of in silico tools are available that aim to distinguish 
between disease associated mutations and benign mutations based 
on the residues position relative to functional sites, protein stability 
calculations or a combination of both. Using the tools PolyPhen 
(http://genetics.bwh.harvard.edu/pph) and SIFT (http://blocks.fhcrc. 
org/sift/SIFT.html), Wang et al previously predicted that 39-43% of 
the human CYP450 SNPs they analysed would have an impact on 
protein function [75] and, correlation with known experimental data 
suggested a PPV of 70%. Other CYP450 studies have used a com-








Fig. (7). Correlation between functional analysis and experimental data. 
The y-axis shows the percentages of SNPs falling within functional regions important for catalytic activity (dark grey) vs. those falling within undefined func-
tional regions or regions that do not affect catalytic activity (light grey) for (A) each experimentally classified group and for (B) a combination of all groups 
showing altered enzyme function vs. those classified as neutral, as shown along the x-axis. The numbers of SNPs accounting for these percentages are shown 
within the columns. Note that functional regions important for catalytic activity include all defined regions excluding the N-terminal signal- anchor motif and 
halting signal. 
Table 3. Correlation between Experimental Data and Functional Region Localisation of SNPs 
Functional Region Inactive Decreased activity  Substrate specific Increased activity  Neutral 
signal anchor sequence 0 (0) 0 (0) 0 (0) 0 (0) 3 (n/a) 
halting signal 0 (0) 0 (0) 0 (0) 0 (0) 2 (n/a) 
proline rich motif 1 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
I-helix catalytic groove 0 (0) 1 (0) 0 (0) 0 (0) 0 (0) 
cys-pocket 3 (1) 1 (1) 0 (0) 0 (0) 0 (0) 
core stabilizing motif  2 (1) 1 (1) 0 (0) 0 (0) 0 (0) 
meander 2 (2) 1 (0)  0 (0) 0 (0) 1 (0) 
ERR-Triad 3 (2)  0 (0) 0 (0) 0 (0) 0 (0) 
haem contact 6 (1) 2 (1) 0 (0) 0 (0) 0 (0) 
CPR contact 1 (0)  5 (3) 0 (0) 0 (0) 2 (1) 
SRS 5 (1) 23 (8) 9 (4) 0 (0) 8 (2) 
gating residue 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
undefined 7 (4) 17 (6) 5 (0) 2 (0) 33 (4) 
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the binding pocket and ligand interactions for small sets of SNPs 
[76-78]. However, whilst tools such as PolyPhen take the positions 
of some functional sites into account, quantitatively predicting the 
effect of mutations on ligand and co-factor binding is still a huge 
challenge for computational biology as accurate calculations are 
very computationally intensive, limiting their use for large interac-
tions surfaces.  
 In the present study we aimed to break down the analysis of 
possible functional effects of SNPs into different components, ena-
bling us to distinguish between mutations affecting stability and 
those lying within functional regions of the enzyme; in turn this 
enabling us to more precisely predict the molecular mechanisms 
underlying changes in enzyme activity caused by different CYP450 
SNPs. There are a number of in silico tools which aim to predict the 
effect of single point mutations on protein stability, based on meth-
ods such as physical effective energy functions [79-81], empirical 
potential energy functions [82, 83], statistical potential energy func-
tions [58, 84, 85] and machine learning [86-89]. Of these, physical 
potential energy functions are likely to be the most accurate but are 
generally computationally expensive and time consuming whilst 
machine learning methods and empirical potential energy functions 
use experimental data to fit their function and generally suffer from 
over fitting the function to the training data set. Here, we therefore 
chose to use Site Directed Mutator (SDM) as a representative tool 
to predict the effect of mutations on the stability of the apoprotein, 
enabling us to distinguish between mutations affecting the inherent 
stability of the protein fold as appose to those at functional sites 
important for haem or substrate binding. SDM - which is a statisti-
cal potential energy function - provides a quick high-throughput 
method for calculating the effect of single point mutations on pro-
tein stability and performs comparably or better to a number of 
other published methods [90]. SDM is not based on prior knowl-
edge of the mutant’s thermodynamic measurements and has been 
found to demonstrate better sensitivity in predicting stabilizing 
mutations than other methods [57]. Importantly for our purposes, 
SDM focuses solely on predicting effects of mutations on protein 
stability ( G), ignoring effects on functional regions such a ligand 
contacts. Interestingly, we found that when SDM was used in isola-
tion, we observed a PPV of 82%, apparently immediately exceeding 
the performance of PolyPhen or SIFT for CYP450 enzymes. 
 By way of illustration of our approach, CYP2C19*5, corre-
sponding to the single amino acid substitution R433W, has been 
identified as a defective allele that contributes to the s-mephenytoin 
poor metaboliser phenotype in Caucasian and Oriental populations 
[91]. In vitro functional assays have shown that expression levels in 
yeast are similar to the wild-type but that P450 holoprotein is not 
detected [43]. Figure 9 shows a model of the CYP2C19 polymor-
phic variant R433W aligned to the wild-type structure. Arg433 is a 
buried residue with a relative solvent accessibility of 5.3%. When 
this residue is mutated to a tryptophan the side chain volume in-
creases by 54.4 Å3 while the relative solvent accessibility changes 
from 2% to 17%. The G SDM score for this mutation is 0.4 
kcal.mol-1, which indicates that this mutation is neutral and does not 
have a significant effect on the stability of the apoprotein. However, 
Arg433 is part of the Cys-pocket or -bulge, which is a highly con-
served region important for haem binding. Based on the protein-
ligand interaction data for CYP2C19, Arg433 is a haem contact resi-
due that interacts through its 5-guanidino group with the haem 
propionate via a salt bridge. Mutating this residue to a tryptophan 
disrupts this interaction and the increase in volume and the position 
of the side chain may plausibly result in a steric clash between tryp-
tophan and the haem group, providing a possible explanation for the 
lack of holoprotein observed in vitro.  
 Reliable in silico prediction of the effect of SNP variants on 
CYP450 protein function remains a challenging endeavour today. 
In the present study, using a representative, computationally-light in 
silico tool in isolation to predict the effects of individual SNPs on 
the stability of the CYP450 apoproteins, we were able to demon-
strate an encouraging specificity of 83% and a positive predictor 
value of 82% for our predictions when compared to available ex-
perimental data, but a sensitivity of only 37% for CYP450 SNPs 
(Fig. 5, Table 4), suggesting that altered CYP450 activity is only 










Fig. (8). Correlation between experimental data and the combined SDM stability- and functional analysis predictions. 
The y-axis shows the percentage of SNPs found in functional regions important for catalytic activity or predicted by SDM to be damaging to the structure 
(dark grey) vs. those found in undefined functional region and predicted to have no effect on stability (light grey) (A) for each experimentally classified group 
and (B) for combination of all groups showing altered enzyme function vs. those classified as neutral. The numbers of SNPs accounting for these percentages 
are shown within the columns. Note that functional regions important for catalytic activity include all defined regions excluding the N-terminal signal- anchor 
motif and halting signal. 













Fig. (9). CYP2C19 R433W model aligned to the wild-type structure. 
The CYP2C19 R433W model (red) generated by ANDANTE is aligned to 
the wild type CYP2C19 pdb structure 4GQS (grey). Wild-type residue Arg 
433 is shown interacting with the haem group. 
 
ment with studies by Blundell et al who have shown that although 
changes in protein stability can be relatively accurately predicted in 
silico, these predictions alone are not sufficient to enable accurate 
large-scale classification of benign and disruptive single amino acid 
substitutions [57, 90, 92]. However, by combining the SDM predic-
tions on effect of each SNP on protein stability with an analysis of 
whether or not the relevant SNP fell within a known functional 
region important for catalysis, we were able to significantly im-
prove the sensitivity of our predictions to 75%, whilst still retaining 
very good positive predictor and specificity values (Table 4). In 
more detail, our combined ‘SDM plus functional region analysis’ 
approach enabled us to account for 87% of the SNPs resulting in 
very low or inactive enzyme activity; 76% of the SNPs resulting in 
decreased activity and 64% of the SNPs resulting in substrate spe-
cific affects in vitro (Fig. 8).  
Table 4. Summary performance of SDM and functional re-






SDM alone 37 83 82 
Functional region 
analysis alone 
63 78 83 
SDM plus functional 
region analysis 
75 69 81 
 
 Although we have annotated our alignment in Figure 3 with the 
known CYP450 functional regions, CYP450 function is by no 
means completely understood. Information about residues impor-
tant for conformational change, oligomerisation and interactions 
with effector molecules is still limited. Investigating further muta-
tions that show altered in vitro activity but do not affect protein 
stability and lie outside known functional regions may shed light on 
hinge regions and peripheral or allosteric binding sites important for 
conformational change and substrate access in CYP450s. In this 
context, it is interesting that our analyses reveal that 5 out of the 14 
SNPs that show altered substrate specific in vitro activity, together 
with both SNPs that showed increased in vitro activity, lie within 
currently undefined functional regions of CYP450 structure (Table 
3). For example, CYP2C19 variant D256N shows similar expres-
sion and holoprotein levels to the wild type enzyme but shows sub-
strate specific changes in Km and reduced Vmax [93]; Asp
256 lies in 
the loop region between helices G and H (Fig. 10). This G/H loop 
has shown high conformation variability in MD studies on mam-
malian CYP450 structures [18, 94] and we therefore speculate that 
Asp256 may form part of a hinge region important for conforma-












Fig. (10). CYP2C19 D256N model aligned to the wild-type structure. 
The CYP2C19 D256N model (red) generated by ANDANTE is aligned to 
the wild type CYP2C19 pdb structure 4GQS (grey). Asp256 and Asn256 are 
shown as sticks. 
 
 A significant limitation in our analysis on damaging SNPs is the 
quality, availability and variability of experimental data found in 
the literature. In particular, heterogonous expression system, total 
protein quantification, methods for generating kinetic data, as well 
as kinetic models for data analysis, vary between studies and can all 
profoundly influence results, as recently reviewed by Hiratsuka 
[95]. For example, most CYP450 substrate turnover is still analysed 
today using Michaelis-Menten kinetics, yet it is well documented 
that some CYP450 isoforms such as CYP3A4 show atypical kinet-
ics due to multiple binding sites, substrate inhibition, allosteric 
regulation or multiple active forms of the enzyme. Depending on 
the model to which the experimental data was fitted, substantially 
different kinetic parameters might be reported for any given system, 
complicating quantitative comparisons between different studies on 
mammalian CYP450 SNPs.  
 The sum of the defined functional regions drawn together in our 
CYP450 SNP Map make up over half of the protein, whilst the 
substrate recognition regions cover ~33% of the sequence space, 
reflecting the broad substrate specificities of mammalian CYP450s. 
It is important to recognise therefore that not all mutations in these 
functional regions will affect enzyme activity for all possible sub-
strates. It is also important to note that certain residues within SRS 
regions have side chains facing away from the active site (see for 
example Fig. 5 in reference [29]); some of these residues make 
contact with the substrate via main chain interactions rather than 
side chain interactions and mutation of such residues might directly 
affect ligand interactions (and hence enzyme function) as a result 
either of altered positioning of main chain atoms relative to the 
bound ligand within the active site, or alternatively by directly af-
fecting protein stability. In other instances, such residues with side 
chains facing away from the active site do not obviously make main 
chain contacts to the ligand; here mutational effects on enzyme 
function are more likely to be manifested through either direct ef-
fects on protein stability or through co-operative conformational 
changes that indirectly perturb the active site. By way of example 
of this latter type, CYP2A6 variant R203S, lying within the F helix 
and SRS(2,3), shows similar activity to the wild type enzyme in in 
vitro studies; the side chain of Arg203 faces away from the active 
site (Fig. 11) and SDM predicts that mutation of Arginine 203 to 
Serine will not be damaging, consistent with experimental data. By 
contrast, variant R203C does show reduced activity in vitro; this 
mutation is predicted to be highly destabilising by SDM and is 
likely to affect substrate binding by disrupting the F helix. It could  
 

















Fig. (11). CYP2A6 model showing the position of R203. 
CYP2A6, PDB structure 1Z10 chain A, is shown in grey, the haem group in 
red and a coumarin substrate molecule bound within the active site shown in 
green. R203 is shown in blue. 
 
be argued that such residues that make neither side chain nor main 
chain contacts to the ligand in known CYP450 structures should be 
excluded from the annotated functional regions in our CYP450 SNP 
Map. However, we have chosen to leave these residues annotated as 
part of the substrate recognition site regions here for consistency 
with the existing literature on CYP450s [29, 30]; we also note that 
as further CYP450 structures are determined, the precise position-
ing of equivalent residues relative to bound ligands may change, 
again arguing for their retention as part of the SRS regions at this 
point. 
 Inclusion of SDM data in our CYP450 SNP Map has proved 
useful in extending predictions of the likely consequence of muta-
tion on CYP450 function, including those variants that fall within 
known functional regions. Importantly, most SNPs analysed in this 
study have only been tested to date for one or a small subset of 
substrates so it is plausible that more SNPs lying within SRS re-
gions will show altered metabolism or substrate specific effects 
when tested on a larger panel of drugs. Our study therefore provides 
a useful rationalisation of CYP450 structure-function relationships 
by combining both in silico and experimental data into a unified 
CYP450 SNP Map that has surprisingly good predictive capability 
(judged by the sensitivity and specificity data presented here) and 
which should therefore find utility in predicting the likely effects of 
uncharacterised CYP450 variants on drug metabolism. 
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